Novel Vaccination Strategies

Novel Vaccination Strategies Edited by Stefan H. E. Kaufmann

Related Titles J. Hacker, J. Heesemann

Molecular Infection Biology: Interactions Between Microorganisms and Cells 2002 ISBN 0-471-17846-2

M. Schleef

Plasmids for Therapie and Vaccination 2001 ISBN 3-527-30269-7

K. J. Syrjänen, S. M. Syrjänen

Papillomavirus Infections in Human Pathology 2000 ISBN 0-471-97168-5

G. Stuhler, P. Walden

Cancer Immune Therapy Current and Future Strategies 2002 ISBN 3-527-30441-X

J. N. Zuckerman

Principles and Practice of Travel Medicine 2002 ISBN 0-471-49079-2

Novel Vaccination Strategies Edited by Stefan H. E. Kaufmann

Editor : Prof. Dr. Stefan H. E. Kaufmann Max-Planck-Institute for Infection Biology Department of Immunology Schumannstraûe 21/22 10117 Berlin Germany

& This book was carefully produced. Never-

theless, authors, editor and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for British Library Cataloguing-in-Publication Data : A catalogue record for this book is available from the British Library. Bibliographic information published by Die Deutsche Bibliothek Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at .  Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2004 All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law. Printed in the Federal Republic of Germany Printed on acid-free paper Composition ProSatz Unger, Weinheim Printing betz-druck gmbh, Darmstadt Bookbinding Litges & Dopf Buchbinderei GmbH, Heppenheim ISBN

3-527-30523-8

V

Contents Colour Plates

XXXIII

Part I 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8

Part II 2

2.1 2.2 2.2.1 2.2.2 2.2.2.1 2.2.2.2 2.2.3 2.3 2.3.1

Challenges for the Vaccine Developer, including Correlates of Protection Gustav J. V. Nossal Introduction 3 Mechanisms of Protection within the Immune System 4 Protection against Viruses 5 HIV/AIDS as an Example of a Persisting Virus 8 Protection against Extracellular Bacteria 9 Protection against Intracellular Bacteria 11 Protection against Parasites 12 Conclusions 14 References 15

3

Vaccination and Immune Response Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses 19 Stefan Ehlers and Silvia Bulfone-Paus Introduction 19 Activation of Innate Immunity: Sensing the Enemy 20 Pathogen-associated Molecular Patterns 21 Host Cellular Sensors 24 Dendritic Cells 24 Mast Cells 25 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors 26 Translating Innate Immune Activation into Regulatory Circuits: Molecular Pathways Shaping Adaptive Immunity 27 TLR-initiated Signaling Cascades 27

VI

Contents

2.3.2 2.3.2.1 2.3.2.2 2.3.3 2.3.3.1 2.3.3.2 2.4

Molecules Involved in Recruiting Effector Cells 28 Defensins 28 Chemokines 30 Molecules Involved in T and B Cell Differentiation 31 Th1-inducing Cytokines 32 Th2-inducing Cytokines 35 Implications for Vaccine Development 36 References 38

3

Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination 51 James M. Brewer and Kevin G. J. Pollock Introduction 51 The Two-Signal Model of Adjuvant-induced Immune Activation 53 Th1 and Th2 Induction by Vaccine Adjuvants 56 Antigen Dose Effects 57 The Three-signal Model of Adjuvant-induced Immune Activation 58 Th2 Induction by Adjuvants 61 Differential Activation of DCs 63 Inappropriate Th1/Th2 Responses to Vaccines 64 Human Th2 vaccines 65 Human Th1 Vaccines 65 Conclusion 66 References 67

3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11

4 4.1 4.2 4.3 4.3.1 4.3.2 4.3.3 4.3.4 4.3.5 4.4 4.4.1 4.4.2 4.4.3 4.4.4 4.5 4.5.1 4.5.2 4.6

Memory 73 Alexander Ploss and Eric G. Pamer Introduction 73 Characteristics of Memory Cells 74 CD8+ T Cell Memory 75 Phenotyping Memory CD8+ T Cells 75 Enhanced Responsiveness of Memory CD8+ T cells: Potential Mechanisms 76 Generation of Memory CD8+ T Cells 76 Maintaining CD8+ T Cell Memory 78 Models of CD8+ T cell Memory Generation 79 CD4+ T Cell Memory 82 Differentiation of Effector and Memory CD4+ T Cells 82 Phenotype of Memory CD4+ T Cells 83 Memory Generation and Maintenance 83 Trafficking of Memory CD4+ T Cells 84 B cell Memory 84 Generation of B Cell Memory 84 Maintenance of B Cell Memory 85 Conclusions 86

Contents

Acknowledgements 86 References 86 5

5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8

T Cell-based Vaccines 89 Katharina M. Huster, Kristen M. Kerksiek, and Dirk H. Busch Summary 89 Introduction 89 Ex-vivo Detection of Antigen-specific T Cells 91 In-vivo Kinetics of Antigen-specific T Cell Responses 95 Effector Function and Subtypes of Effector T Cells 97 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition 99 Functional Heterogeneity of T Cell Memory 101 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination 103 Concluding Remarks 106 References 107

Part III

Adjuvants

6

Microbial Adjuvants 115 Klaus Heeg, Stefan Zimmermann, and Alexander Dalpke Introduction 115 Microbial Danger Signals 117 Toxins (CT and LT) 117 Toll-like Receptor-dependent Microbial Adjuvants 118 Lipopolysaccharide and Lipid A Derivatives 118 Peptidoglycan and Lipoteichoic Acid 119 Other Microbial Components (Lipopeptides, Flagellin) 119 Bacterial DNA 119 Toll-like Receptor-dependent Synthetic Compounds 121 Synthetic CpG DNA 121 Other Synthetic TLR ligands 123 Low Molecular Weight TLR Agonists 124 Conclusion 125 References 126

6.1 6.2 6.2.1 6.2.2 6.2.2.1 6.2.2.2 6.2.2.3 6.2.2.4 6.2.3 6.2.3.1 6.2.3.2 6.2.3.3 6.3

7 7.1 7.2 7.2.1 7.2.2 7.2.3

Host-derived Adjuvants 129 Norbert Hilf, Markus Radsak, and Hansjörg Schild Introduction 129 Heat Shock Proteins in Immunology 130 General Remarks 130 Heat Shock Proteins Are Immunogenic 131 Heat Shock Proteins Bind Peptides 131

VII

VIII

Contents

7.2.4 7.2.5 7.2.6 7.2.7 7.2.8 7.2.9 7.3 7.4

Receptor-mediated Uptake of HSPs 133 Cross-presentation Pathways for HSP–Peptide Complexes 135 Danger Signals – The Importance of the Second Signal 137 Heat Shock Proteins as Danger Signals 137 Heat Shock Proteins as Endogenous Adjuvants 139 Clinical Use of Heat Shock Proteins 140 Cytokines as Adjuvants 141 Concluding Remarks 142 References 142

8

Microparticles as vaccine adjuvants and delivery systems 147 Derek T. O’Hagan and Manmohan Singh Introduction 147 The Role of Adjuvants in Vaccine Development 148 Immunostimulatory Adjuvants 150 MPL 150 CpG 150 QS21 150 Cytokines 151 Particulate Vaccine Delivery Systems 151 Lipid-based Particles as Adjuvants 152 The Adjuvant Effect of Synthetic Particles 153 Uptake of Microparticles into APC 153 Microparticles as Adjuvants for Antibody Induction 153 The Induction of Cell-mediated Immunity with Microparticles 155 Microparticles as Delivery Systems for DNA Vaccines 155 Microparticles as Delivery Systems for Adjuvants 157 Microparticles as Single-dose Vaccines 157 Alternative Particulate Delivery Systems 159 Alternative Routes of Immunization 159 Mucosal Immunization with Microparticles 160 Microparticles as Delivery Systems for Mucosal Adjuvants 160 Adjuvant for Therapeutic Vaccines 162 Future Developments in Vaccine Adjuvants 162 Acknowledgments 163 References 163

8.1 8.2 8.3 8.3.1 8.3.2 8.3.3 8.3.4 8.4 8.4.1 8.4.2 8.4.3 8.4.4 8.4.5 8.4.6 8.4.7 8.4.8 8.4.9 8.5 8.5.1 8.5.2 8.6 8.7

9

9.1 9.2 9.2.1 9.2.1.1

Liposomes and ISCOMs 173 Gideon Kersten, Debbie Drane, Martin Pearse, Wim Jiskoot, and Alan Coulter Introduction 173 Liposomes and Related Structures 176 Composition, Characteristics, and Preparation Methods of Liposomes 176 Composition and Characteristics of Liposomes 176

Contents

9.2.1.2 9.2.2 9.2.2.1 9.2.2.2 9.2.2.3 9.2.3 9.3 9.3.1 9.3.1.1 9.3.1.2 9.3.1.3 9.3.2 9.3.2.1

9.3.2.2 9.3.3 9.3.3.1 9.3.3.2 9.4

10

Liposomes 176 Transfersomes 176 Niosomes 177 Virosomes 177 Proteosomes and Outer Membrane Vesicles 178 Archaeosomes 179 Cochleates 179 Preparation Methods of Liposomes 179 Mechanisms of Action of Liposomes 180 Protection, Stabilization, and Mimicry 181 Targeting 182 Enhanced or Controlled Processing 182 Liposome Performance and Products 183 ISCOMs 184 Composition, Characteristics, and Preparation Methods of ISCOMs 184 Composition 184 Characteristics of ISCOMs 185 Preparation of ISCOMs 186 Immunology and Mode of Action of ISCOM Vaccines 187 Immune Responses to ISCOM Vaccines 187 Parenteral Immunization of Mice 187 Parenteral Immunization of Nonhuman Primates 188 Mucosal Immunization 189 Effective Immunization with ISCOM Vaccines in the Presence of Preexisting Antibody 189 Mode of Action of ISCOM Vaccines 189 Performance and Products 191 Protection Afforded by ISCOM Vaccines in Animal Models 191 Human Clinical Trials with ISCOMs 191 Perspectives 193 References 194

Virosomal Technology and Mucosal Adjuvants 197 Jean-François Viret, Christian Moser, Faiza Rharbaoui, Ian C. Metcalfe, and Carlos A. Guzmán 10.1 Overview 197 10.2 Mucosal Adjuvants 200 10.2.1 Introduction 200 10.2.2 Families of Mucosal Adjuvants 200 10.2.3 Administration Strategies 204 10.2.3.1 Direct Admixing of Antigen and Adjuvants 204 10.2.3.2 Covalent Linkage of the Adjuvant and Antigen or Adjuvant Incorporation into other Mucosal Delivery Systems 205 10.2.3.3 Adjuvant in Prime–Boost Vaccination Strategies 205 10.2.4 Interaction of Mucosal Adjuvants with the Innate Immune System 206

IX

X

Contents

10.2.5 10.3 10.3.1 10.3.2 10.3.2.1 10.3.2.2 10.3.2.3 10.3.2.4 10.3.3 10.3.4

Conclusion 207 Virosomal Technology 208 Introduction 208 Adjuvant Properties of Virosomes 209 Virosome Structure and Immunopotentiation 209 Depot Effect 210 The Pivotal Role of Fusion-active Virosomal Hemagglutinin 210 Effect of Pre-existing Immunity to Influenza Virus 211 Validation of the Virosomal Vaccine Concept 212 Conclusion 213 References 214

Part IV

Classical and Novel Vaccination Strategies : A Comparison

11

Classical Bacterial Vaccines 221 Thomas Ebensen, Claudia Link, and Carlos A. Guzmán Bacterial Vaccines: Introductory Remarks 221 Inactivated Vaccines 223 Methods of Inactivation 223 Advantages and Limitations of Inactivated Vaccines 223 Live Vaccines 224 Attenuation 225 Advantages and Limitations of Live Bacterial Vaccines 225 Vaccines for Human Bacterial Diseases 226 Anthrax (Bacillus anthracis) 226 Cholera (Vibrio cholerae) 227 Enterotoxigenic Escherichia coli 228 Plague (Yersinia pestis) 229 Shigellosis (Shigella species) 229 Tuberculosis (Mycobacterium tuberculosis) 230 Typhoid Fever (Salmonella enterica serovar Typhi) 231 Tularemia (Francisella tularensis) 232 Whooping cough (Bordetella pertussis) 232 Veterinary Bacterial Vaccines 233 Infections Caused by Bordetella and Pasteurella Species 234 Brucellosis (Brucella spp.) 235 Porcine Pleuropneumonia (Actinobacillus pleuropneumoniae) 237 Diseases Caused by Mycoplasma spp. 237 Salmonellosis in Animals 238 Leptospirosis (Leptospira spp.) 239 Other Commercially Relevant Animal Diseases 239 Conclusions 240 Acknowledgements 240 References 240

11.1 11.2 11.2.1 11.2.2 11.3 11.3.1 11.3.2 11.4 11.4.1 11.4.2 11.4.3 11.4.4 11.4.5 11.4.6 11.4.7 11.4.8 11.4.9 11.5 11.5.1 11.5.2 11.5.3 11.5.4 11.5.5 11.5.6 11.5.7 11.6

Contents

12 12.1 12.2 12.3 12.3.1 12.3.2 12.3.2.1 12.3.2.2 12.3.2.3 12.4 12.4.1 12.4.2 12.4.2.1 12.4.2.2 12.4.2.3 12.4.2.4 12.4.2.5 12.4.3 12.4.4

13 13.1 13.2 13.2.1 13.2.2 13.3 13.4 13.4.1 13.4.2 13.5 13.5.1 13.5.2 13.5.3 13.6 13.7 13.7.1 13.7.2 13.7.3 13.7.4 13.8

Subunit Vaccines and Toxoids 243 Maria Lattanzi, Giuseppe Del Giudice, and Rino Rappuoli Introduction 243 Toxoids 243 Subunit Vaccines: Conventional Vaccinology Approach 244 Polysaccharide Vaccines 244 Recombinant DNA Technology for Subunit Vaccines 245 HBV Vaccine 246 Acellular Pertussis Vaccine 246 Lyme Disease Vaccine 247 The Future of Subunit Vaccine Development: The Genomic Approach 248 When Theory Becomes Reality: The MenB Example 248 Further Applications of the Genomic Approach to Vaccine Development 253 Streptococcus pneumoniae 253 Staphylococcus aureus 254 Porphyromonas gingivalis 254 Streptococcus agalactiae 254 Chlamydia pneumoniae 255 The Genomic Approach to Parasite Vaccines 255 The Genomic Approach to Viral Vaccines 256 References 258 Engineering Virus Vectors for Subunit Vaccines Joseph Patrick Nkolola and Tomas Hanke Introduction 265 Adenoviruses 266 Replication Incompetent Adenoviruses 266 Replication-selective Adenoviruses 267 Adeno-associated Viruses 269 Poxviruses 269 Mammalian Poxviruses 271 Avipoxvirus Vectors 272 Herpes Simplex Viruses 272 Recombinant HSV Vectors 273 Amplicon Vectors 273 Disabled Infectious Single-cycle HSV 275 Retroviruses 275 Alphaviruses 276 Full-length Infectious Clones 277 RNA Replicons 277 DNA Plasmid Replicons 277 Particle-based Replicons 279 Polioviruses 279

265

XI

XII

Contents

Rhabdovirus Vectors 281 Heterologous Prime–Boost Vaccination Strategies 282 Cell Lines Acceptable for Growing Human Recombinant Subunit Vaccines 282 13.11.1 History and General Characteristics of the Cell Line 283 13.11.2 The Cell Bank System 283 13.11.3 Quality Control Testing 283 13.12 Conclusion 284 References 284 13.9 13.10 13.11

14

14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8

15

15.1 15.2 15.3 15.3.1 15.3.2 15.3.3 15.4 15.5

16

16.1 16.2

Update on antiviral DNA vaccine research (2000– 2003) 289 Daniel Franke, Jovan Pavlovic, Tillmann S. Utesch, Max von Kleist, Jan Schultz, Guenter Dollenmaier, and Karin Moelling Summary 289 Effect of Antiviral DNA Vaccines in Mice 289 Effect of Antiviral DNA Vaccines in Larger Species 301 Genetic Adjuvants 302 CTL-Epitope Immunization 303 Targeting DNA Vaccines to Cellular Compartments or the Cell Surface 304 DNA for Chimeric Antigens 304 DNA-prime–Protein/Viral-boost Immunization 305 Age-dependent Effectiveness of DNA Vaccines 306 References 307 Live Recombinant Bacterial Vaccines 319 Simon Clare and Gordon Dougan Summary 319 Introduction 319 Early Efforts to Generate Recombinant Live Bacterial Vaccines 322 Clinical Studies Involving the Development of Live Recombinant Vaccines 325 Live Recombinant Salmonella Vaccines 325 Live Cholera Vaccines 328 Live Shigella Vaccines 329 Expression of Heterologous Antigens in Live Bacterial Vectors 330 The Future 333 Acknowledgements 334 References 334 Mucosal Vaccination 343 Wieslawa Olszewska and Peter J. M. Openshaw Summary 343 Introduction 343 Goals of Mucosal Vaccination 344

Contents

16.3 16.3.1 16.3.2 16.3.3 16.3.4 16.3.5 16.4 16.4.1 16.4.1.1

16.4.1.2 16.4.1.3 16.4.2 16.4.2.1 16.4.2.2 16.4.2.3 16.4.2.4 16.4.2.5 16.4.2.6 16.4.2.7 16.5 16.5.1 16.6 16.7

17

17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.7.1 17.7.2 17.7.3 17.8

Benefits of Mucosal Vaccination 345 Main Features of the Common Mucosal Immune System 345 Distinctive Characteristics of Mucosal Immunity 346 Multivalent Mucosal Vaccines 347 Edible Vaccines 347 Overcoming Preexisting Immunity or Tolerance 348 Challenges for Mucosal Immunization 349 Mucosal Delivery Systems 349 Live Bacterial Vectors 349 Commensal Flora as Expression Vectors 349 Pathogens as Expression Vectors 349 Virosomes 350 Mucosal DNA Vaccines 350 Mucosal Adjuvants 351 Biodegradable Polymeric Particles 351 Bacterial Toxins 351 CpG Oligodinucleotides 352 Cytokines and Chemokines 353 Saponins 353 Immune Stimulating Complexes (ISCOMS) 353 MF59 355 Vaccination via the Respiratory Tract 355 Applications of Nasal Vaccination 355 Oral Vaccines 357 Conclusions 357 Acknowledgements 357 Reference List 359 Passive Vaccination and Antidotes : A Novel Strategy for Generation of Wide-spectrum Protective Antibodies 365 Antonio Cassone and Luciano Polonelli Introduction and Definitions 365 Emergence of New Agents of Disease 367 Passive Vaccination and Antidotes: Advantages and Disadvantages 368 Passive Vaccination: Implementation and Obstacles 370 A Novel Strategy for Passive Vaccination: Concept and Relevance of Killer Antibodies 371 Fungi and Fungal Infections 372 A Novel Approach to Passive Vaccination through the Merging of Killer Phenomenon and Idiotypic Network 373 The Killer Phenomenon 373 Antibodies and the Idiotypic Network 374 Yeast Killer Toxin Anti-idiotypes 375 Microbicidal IdAb: Consequences and Extensions 377

XIII

XIV

Contents

17.9 17.10 17.11

18 18.1 18.2 18.2.1 18.2.2 18.2.3 18.3 18.3.1 18.3.2 18.3.3 18.4 18.4.1 18.4.1.1 18.4.1.2 18.4.2 18.4.2.1 18.4.2.2 18.4.2.3 18.4.2.4 18.4.3 18.4.3.1 18.4.3.2 18.5 18.5.1 18.5.2 18.5.3 18.6

19

19.1 19.2 19.2.1

Passive Vaccination with Single-chain Variable-fragment Antibodies Carried or Secreted by a Mucosal Live Bacterial Vector 378 Antibody Peptide Fragments as Wide-spectrum Anti-infectives 380 Conclusions and Perspectives 382 Acknowledgements 383 References 383 Plant-based Oral Vaccines 387 Kan Wang, Rachel Chikwamba, and Joan Cunnick Introduction 387 Mucosal Immunization 387 Vaccination Strategies for Infectious Diseases 388 Mucosal Immunization vs. Parenteral Immunization 389 Mucosal Immunization and Adjuvants 390 Plant-derived Edible Vaccines 391 Advantages of the Plant-based System 391 Transient and Stable Systems for Production of Plant-derived Proteins 392 Choice of Plants and Plant Tissues 393 Plant-expression Systems for Antigen Production 394 Transcriptional Level 396 Choice of Promoters 396 Transcriptional Gene Silencing 396 Post-transcriptional Level 397 Introns 397 mRNA Stability and 3´ Terminator 397 An Optimal Start Context and 5´-end Enhancer for Translation 398 Codon Usage 398 Post-translational Level and Beyond 399 Targeting and Retention Signals 399 Stability of Gene Expression and Transmission of the Transgene 400 Maize as Production and Delivery System 400 Antigen Production in Endosperm Tissue of Maize Seed 402 Antigen Production in Embryo (Germ) Tissue of Maize Seed 403 Pharmaceutical Crop Production and Containment 405 Concluding Remarks 406 References 407 Virus-like Particles : Combining Innate and Adaptive Immunity for Effective Vaccination 415 Martin F. Bachmann and Gary T. Jennings Summary 415 Immunology of Vaccines 415 Immunology of VLPs 416 B Cell Responses 416

Contents

19.2.2 19.3 19.4 19.4.1 19.4.2 19.4.3 19.5 19.5.1 19.5.2 19.5.3 19.5.4

T Cell Responses 417 VLPs as Viral Vaccines 419 VLPs as Carriers of B and/or T Cell Epitopes 420 Fused Epitopes 420 Coupled Epitopes 422 Targeting Self Molecules by using VLPs 424 Clinical Development 425 Hepatitis B Virus VLP Vaccine 425 Human Papilloma VLP Vaccines 426 Norwalk Virus VLP Vaccines 428 VLPs Presenting Foreign Epitopes 429 References 430

Part V

Vaccines for Specific Targets

20

Helicobacter pylori 435 Paolo Ruggiero, Rino Rappuoli, and Giuseppe Del Giudice Introduction 435 Epidemiology of H. pylori Infection 436 H. pylori-related Diseases 436 H. pylori Antigens Relevant in Virulence and Pathogenesis 437 Eradication of H. pylori: the Pros and Cons 439 Current Therapies against H. pylori: Efficacy and Limits 439 Why Develop a Vaccine against H. pylori 440 Animal Models of H. pylori Infection 441 Mice and Other Rodents 441 Ferrets 442 Gnotobiotic Piglets 442 Monkeys 443 Dogs 443 The feasibility of Vaccination in Animal Models 443 The Mechanisms of Protective Immunity against H. pylori 444 Vaccination against H. pylori in Humans 446 Vaccination with Purified Recombinant Urease 446 Salmonella-vectored Urease 447 Inactivated Whole-cell Vaccines 448 Parenteral Multi-component Vaccines 449 Conclusions 450 References 451

20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.8.1 20.8.2 20.8.3 20.8.4 20.8.5 20.9 20.10 20.11 20.11.1 20.11.2 20.11.3 20.11.4 20.12

21 21.1 21.2

Novel Vaccination Strategies against Tuberculosis 463 Stefan H. E. Kaufmann Introduction 463 Mechanisms underlying Infection and Immunity 464

XV

XVI

Contents

21.3 21.4 21.5 21.5.1 21.5.2 21.5.3 21.6

Rational Vaccine Design: Basic Considerations 469 Protective Antigens and Knockout Targets 469 The Major Strategies: Subunit, Attenuated, and Combination Vaccines 471 Subunit Vaccines 471 Attenuated Vaccines 472 Combination Vaccines 474 Concluding Remarks 474 Acknowledgements 474 References 475

22

Rationale for Malaria Vaccine Development 479 Allan Saul,Victor Nussenzweig, and Ruth S. Nussenzweig 22.1 Introduction 479 22.2 Preerythrocytic Vaccines 481 22.2.1 Rationale for Vaccines that Elicit Antibody-mediated Protection 481 22.2.2 Rationale for Vaccines that Elicit Cell-mediated Immunity 482 22.2.3 Human Vaccine Trials 485 22.3 Asexual Stage Vaccines 488 22.3.1 Red Cell Surface Antigens 490 22.3.2 Antigens Eliciting Antibody-dependent Cellular Inhibition 491 22.3.3 Antitoxin Vaccines 492 22.3.4 Antibody-independent Mechanisms 493 22.4 Mosquito-stage Vaccines 494 22.4.1 Targets of Transmission-blocking Vaccines 495 22.4.1.1 The 6-Cys Malaria Gamete Surface Antigens 495 22.4.1.2 The P25 and P28 EGF Domain Zygote, Ookinete, and Oocyst Antigens 496 22.4.1.3 Chitinase 497 22.5 Conclusion 497 References 498 23

23.1 23.2 23.3 23.3.1 23.3.2 23.3.3 23.3.4 23.4 23.5 23.6 23.6.1

Vaccine for Specific Targets : HIV 505 R. Kay, Edmund G.-T. Wee, and Andrew J. McMichael Introduction 505 Antibody Vaccines 506 The T Cell Response 509 CTL-inducing Vaccines 510 Studies in Humans 511 CD4+ T Cell Help 512 The Dynamics of the CD8+ T Cell Response 513 Innate Immunity 513 Mucosal Immunity 515 Vaccine Design 516 Attenuated and Killed Vaccines 516

Contents

23.6.2 23.6.2.1 23.6.2.2 23.6.2.3 23.6.2.4 23.6.2.5 23.6.3 23.6.4 23.6.5 23.7

Subunit Vaccines 517 DNA 517 Viral and Bacterial Vectors 517 Delivery: Prime–Boost Regimen 517 Whole Protein-based or Epitope-based Vaccines 518 Clades 518 Measurement of CTL Responses 520 Phase 1 and 2 Trials 521 Phase 3 Trials 521 Conclusion 522 Acknowledgements 522 References 522

24

Vaccines against Bioterror Agents 529 Karen L. Elkins, Drusilla L. Burns, Michael P. Schmitt, and Jerry P. Weir Introduction and Overview 529 Vaccination against Smallpox 531 Vaccination against Viral Hemorrhagic Fevers 532 Vaccination against Anthrax 533 Vaccination against Plague 536 Vaccination against Tularemia 538 Vaccination against Botulinum Toxin 540 Vaccination against Category B and C Pathogens 542 Vaccine Development and Regulation for ‘Low-incidence’ Pathogens, including Bioterror Pathogens and Emerging Diseases 542 Perspectives 543 Acknowledgements 544 References 544

24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 24.10

Part VI

Vaccines in the Real World: Safety, Cost Efficiency and Impact of Vaccination

25

Imperfect Vaccines and the Evolution of Pathogen Virulence Paul W. Ewald Introduction 549 Virulence-antigen Vaccines against Bacteria 551 Corynebacterium diphtheriae 551 Bordetella pertussis 553 Hemophilus influenzae 555 Virulence-antigen Vaccines against Viruses 556 Circumventing Social Barriers to Vaccination 558 A Call for Field Experiments 559 References 560

25.1 25.2 25.2.1 25.2.2 25.2.3 25.3 25.4 25.5

549

XVII

XVIII

Contents

26 26.1 26.2 26.3 26.3.1 26.3.2 26.3.3 26.3.4 26.3.5 26.3.6 26.3.7 26.4 26.4.1 26.4.2 26.4.3 26.4.4 26.4.5 26.4.6 26.4.7 26.4.8 26.4.9 26.4.10 26.4.11 26.4.12 26.5 26.5.1 26.5.2 26.5.3 26.6 26.6.1 26.6.2 26.7

26.7.1 26.7.2 26.7.2.1 26.7.2.2 26.7.2.3 26.7.3 26.7.3.1 26.7.3.2 26.7.3.3 26.7.3.4

Cost-Effectiveness of Vaccinations 567 Thomas D. Szucs Introduction 567 Differences between Vaccines and Medicines 570 Analytic Methods 570 Elements of an Economic Evaluation 570 The Input 570 Direct Medical Costs 571 Direct Nonmedical Costs 571 Indirect Costs 572 The Output: Consequences and Outcomes 573 Economic Evaluation Methodology 573 Cost-of-Illness Studies 574 Cost-minimization Analyses 574 Cost–Benefit Analyses 575 Cost-effectiveness Analyses 575 Cost–Utility Analyses 576 The Importance of the Perspective 576 The Use of Models 577 Why Discounting? 578 Dealing with Uncertainty 578 Target Populations 578 The Timing of Economic Studies 579 Collecting Economic Data during a Clinical Trial 580 Post-marketing Studies and Pharmacoeconomics 580 Areas of Controversy 581 Measuring Indirect Costs 581 Externalities 582 Methodologic Quality 582 Challenges of the Future 583 Limitations and Ethical Issues 584 Strategic Outlook for the Vaccine Industry 584 Case Study for Illustration and Education: Economic Evaluation of Vaccination of Children Against Hepatitis A and Hepatitis B in Germany 585 Objective 585 Methodology 585 Determination of Costs 585 Determination of Effectiveness 586 Determination of Cost-effectiveness 586 Results 586 Costs 586 Effectiveness 586 Cost-effectiveness 587 Which Strategy Saves the Most Money? 589

Contents

26.7.3.5 Which Strategy is the Most Effective in Terms of Disease Prevention? 589 26.7.4 Discussion 590 26.7.4.1 Limitations of the Study 591 References 592 27 27.1 27.2 27.3 27.3.1 27.3.1.1 27.3.1.2 27.3.1.3 27.3.1.4 27.3.1.5 27.3.1.6 27.3.2 27.3.3 27.3.3.1

27.3.3.2

27.3.3.3 27.4 27.4.1 27.4.2 27.4.3 27.4.4 27.5

Index

Immunological Safety of Vaccines: Facts, Hypotheses and Allegations 595 Michel Goldman and Paul-Henri Lambert Introduction 595 Recognized Adverse Effects of Vaccines: a Brief Overview 596 Autoimmunity Triggered by Infection or Immunization: an Increasing Concern 598 Mechanisms of Autoimmunity Induction 598 Molecular Mimicry 598 Enhanced Presentation of Self-antigens 599 Bystander Activation 599 Polyclonal B Cell Activation 599 Antibodies 599 Regulatory T Cells 600 Autoimmune Pathology in the Course of Infectious Diseases 600 The Risk of Vaccine-associated Autoimmunity 601 Vaccine-attributable Autoimmune Diseases 601 Guillain–Barré Syndrome and Influenza Vaccine 601 Measles–Mumps–Rubella Vaccine and Thrombocytopenia 602 Vaccine-related Allegations of Autoimmune Adverse Effects 602 Hepatitis B and Multiple Sclerosis 602 Vaccination and Diabetes 603 New-generation Vaccines and Autoimmunity: Approaches to Early Risk Assessment 604 Other Unsubstantiated Allegations 605 Measles–Mumps–Rubella Vaccine and Autism 606 Thiomersal and Neurological Disorders 606 Aluminum and Macrophagic Myofasciitis 606 Multiple Vaccinations and Allergies 607 Concluding Remarks 607 References 607 613

XIX

XXI

Novel Vaccination Strategies “We are not only responsible for what we do – but also for what we do not do.” Voltaire

Preface

Of last year’s 56 million instances of premature death, almost 17 million were due to infectious diseases. This translates into one dead individual every two seconds. Annual instances of death caused by each of the two leading infections, AIDS and tuberculosis, exceed the mortalities caused by injuries, diabetes, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, breast cancer, and rheumatic diseases together. Similarly, almost 40 % of all life-years lost by disability are due to infectious diseases; this is more than all losses due to injuries, neuropsychiatric disorders, cardiovascular diseases, and cancer that follow in these dreadful statistics. Yet, there is another side to the picture, and that is that we have an extraordinarily effective measure for prevention of infectious diseases at hand. These are vaccines, which annually save more than 8 million lives, which translates into one person saved every 5 seconds. Vaccination is not only effective but it is also the most cost-efficient measure in medicine. Unfortunately, 2 to 3 million additional lives are currently being lost due to the fact that already-existing vaccines are not being made available to everybody. Wherever broadscale vaccination programs have been implemented, their success rates are remarkable. Incidences of measles, polio, rubella, mumps, pertussis, and diphtheria have all been dramatically reduced in countries where broadscale vaccination programs exist. The vaccines against these diseases were developed mostly by trial and error, and therefore could only be successful for pathogens that cause disease in a direct way. Pathogens that use more tricky strategies and subvert, impair, or misdirect the host immune response cannot be prevented by such a strategy. The next generation of vaccines has to be designed in a rational way, on the basis of our increasing knowledge of immunology and molecular genetics at the interface between pathogen and host. Fortunately, basic sciences have advanced dramatically during the past decade, and we now have available the genomic blueprints of all major pathogens as well as of the human host and the most-favored experimental animal model, the mouse.

XXII

Preface

It is the goal of this book, “Novel Vaccination Strategies”, to benefit from recent achievements in basic research for the rational design of novel vaccination strategies against diseases that have thus far evaded successful control. In addition, it includes a kind of retrospective review of vaccine examples that have already demonstrated their great efficacy, so that we can learn from these experiences. The immune system is the target of all vaccination strategies and, hence, a great part of this book tries to decipher the immune mechanisms underlying control of the plethora of infectious agents. It is generally accepted that the acquired immune response, which accounts for specificity and memory, is the ultimate target of vaccination. Yet, the acquired immune response often fails to directly attack pathogens, and rather does so by activating innate immune mechanisms. Hence, the innate immune response is under the stringent control of the acquired immune response. More recently, we have also learnt that the acquired immune response is not activated by pathogens directly, but rather through mediation of the innate immune system. The innate immune response senses invading pathogens or vaccines and then instructs the acquired immune system to develop the most appropriate response against the homologous pathogen. Unfortunately, many pathogens have developed tricks to deviate host responses from the default direction. Here lies a major Achilles’ heel of the immune system and also a chance for rational vaccine design. For many infections that cannot be controlled by vaccines thus far, it will be important to induce an immune response that is better than the one stimulated by natural infection. Much can be expected from novel adjuvants capable of stimulating the most adequate immune response for a given pathogen. Adjuvants will be required particularly for subunit vaccines, whether they be based on naked DNA, on protein, or on carbohydrate antigens. The right formulation comprising both the protective antigen and the appropriate adjuvant will define the success of a future subunit vaccine. Yet, it is likely that for certain diseases, subunit vaccines comprising only a few specific antigens will be insufficient. In these cases viable vaccines will be required, and the choice of the most appropriate recombinant vaccine carrier will be equally difficult. The list of nature's scourges is headed by the ‘big three‘, that is, AIDS, tuberculosis, and malaria, which represent major challenges for rational vaccine design. Therefore, specific chapters are devoted to vaccine development against these diseases, as well as to vaccination strategies against Helicobacter pylori, which is responsible not only for gastric ulcers but also for certain forms of stomach cancer. Moreover, a chapter on vaccines against bioterror agents has been included, since we have become aware of the dreadful possibilities infectious agents offer to those who want to pervert our increasing knowledge about infectious diseases. We have to be aware that we live in a world that has been populated by microorganisms for more than 3 billion years, while the beginning of mankind dates back only 5 million years. Hence, it would be unreasonable to think that we can conquer all microbes successfully. Rather, we have to accept that the survival strategies of most microbes, which are based on a combination of rapid replication and rapid change, are highly successful and that our current knowledge may not be sufficient for designing vaccines against the most devious pathogens. Moreover, the undesired

Preface

possibility needs to be considered that novel, more hazardous strains may evolve under the pressure of imperfect vaccines. By design, this book focuses on the scientific basis of rational vaccine design. This is not, however, meant to underestimate the importance of subsequent development, safety assessment, and clinical trials. Two chapters have been included that deal with two important aspects downstream of vaccine research: safety assessment and costefficiency aspects of vaccination. It has become clear that the complete process of vaccine development is most successful as a close interaction between basic research, mostly done at public academic institutions, and development, best done by private industry. Unfortunately, vaccine development is not always high on the list of interests of industry. After all, the major goal of a successful vaccine is eradication of the targeted disease. Consequently, the most successful vaccine will concomitantly eradicate its own market. Moreover, many vaccines are needed for diseases that are most prevalent in countries that have the least financial resources. As a consequence, the return on investment for some vaccines may be too low to attract industry partners. On the other hand, public health systems would receive a profound return on investment. This has been proven impressively by the vaccines currently available. For every dollar that is spent on vaccination against measles, mumps, rubella, diphtheria, pertussis, or tetanus the public hand saves $10 to $20. Vaccination against childhood tuberculosis, tetanus, polio, measles, and hepatitis B prolongs healthy life by one year for a cost of $10 to $40. It is obvious that, not only the protected individual, but also the general public benefits enormously from vaccination. Currently available vaccines have proven their great cost-efficiency and success in an impressive way. Their availability has been made possible by efforts dating back several decades. Recent achievements in basic research have now laid a new foundation for rational design of novel vaccines, and the general public will benefit from such vaccines in future decades, provided appropriate efforts are undertaken now. Stefan H. E. Kaufmann

Berlin, August 2003

Acknowledgements

I thank the contributors of this book for sharing their insights into vaccine research, Yvonne Bennett for her excellent secretarial help, and Andreas Sendtko and PriscaMaryla Henheik, the publishing editors of Wiley-VCH, for their continuous efforts.

XXIII

XXV

List of Contributors Martin F. Bachmann Cytos Biotechnology AG Wagistr. 25 8952 Zürich-Schlieren, Switzerland James M. Brewer Division of Immunology, Infection and Inflammation University of Glasgow, Western Infirmary Glasgow, G11 6NT, Scotland Silvia Bulfone-Paus Research Center Borstel, Center for Medicine and Biosciences Dept. of Immunology and Cell Biology Parkallee 22 23845 Borstel Germany Drusilla L. Burns Division of Bacterial, Parasitic, and Allergenic Products Center for Biologics Evaluation and Research 1401 Rockville Pike, HFM 431 Rockville, MD 20852, USA

Dirk Hans Busch Institute for Medical Microbiology, Immunology, and Hygiene Technical University Munich Trogerstr. 9 81675 Munich, Germany Antonio Cassone Department of Infectious, Parasitic and Immune-Mediated Diseases Istituto Superiore di Sanit™ Viale Regina Elena, 299 00161 Rome, Italy Rachel Chikwamba Plant Biology Department Arizona State University Tempe, AZ 85287, USA Simon Clare Centre for Molecular Microbiology and Infection Department of Biological Sciences Imperial College London Exhibition Road London SW7 2AZ, UK

XXVI

List of Contributors

Alan Coulter Pharmaceutical R&D CSL Limited 45 Poplar Road Parkville,VIC., 3052 Australia

Debbie Drane Pharmaceutical R&D CSL Limited 45 Poplar Road Parkville,VIC., 3052 Australia

Joan Cunnick Department of Microbiology Iowa State University Ames, IA 50011 USA

Thomas Ebensen Vaccine Research Group GBF-German Research Centre for Biotechnology Division of Microbiology Mascheroder Weg 1 38124 Braunschweig Germany

Alexander Dalpke Institute of Medical Microbiology and Hygiene Philipps University Marburg Pilgrimstein 2 35037 Marburg Germany Giuseppe Del Giudice IRIS Research Center, Chiron Srl Via Fiorentina 1 53100 Siena Italy Guenter Dollenmaier Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Gordon Dougan Centre for Molecular Microbiology and Infection Department of Biological Sciences Imperial College London Exhibition Road London SW7 2AZ UK

Stefan Ehlers Research Center Borstel, Center for Medicine and Biosciences Division of Molecular Infection Biology Parkallee 22 23845 Borstel Germany Karen L. Elkins Division of Bacterial, Parasitic, and Allergenic Products Center for Biologics Evaluation and Research 1401 Rockville Pike, HFM 431 Rockville, MD 20852 USA Paul W. Ewald Department of Biology University of Louisville Louisville, KY 40292 USA Daniel Franke Institute of Medical Virology University of Zurich 8028 Zurich Switzerland

List of Contributors

Michel Goldman Department of Pathology and Pediatrics Geneva University 1 Rue Michel Servet Genè ve 27 Switzerland Carlos A. Guzmán Vaccine Research Group GBF-German Research Centre for Biotechnology Division of Microbiology Mascheroder Weg 1 38124 Braunschweig Germany Tomas Hanke Medical Research Council Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford, The John Radcliffe Hospital Headley Way Oxford OX3 9DS UK Klaus Heeg Institute of Medical Microbiology and Hygiene Philipps University Marburg Pilgrimstein 2 35037 Marburg Germany Norbert Hilf Institute for Cell Biology Department of Immunology University of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany

Katharina M. Huster Institute for Medical Microbiology, Immunology, and Hygiene Technical University Munich Trogerstr. 9 81675 Munich Germany Gary T. Jennings Cytos Biotechnology AG Wagistr. 25 8952 Zürich-Schlieren Switzerland Wim Jiskoot Utrecht Institute for Pharmaceutical Sciences Department of Pharmaceutics P.O. Box 80.082 3508 TB Utrecht The Netherlands Stefan H. E. Kaufmann Max Planck Institute for Infection Biology Department of Immunology Schumannstraûe 21–22 10117 Berlin Germany R. Kay Medical Research Council Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford The John Radcliffe Hospital Headley Way Oxford OX3 9DS UK

XXVII

XXVIII

List of Contributors

Kristen M. Kerksiek Institute for Immunology Ludwig Maximilian University Trogerstr. 9 81675 Munich, Germany Gideon Kersten Product and Process Development Netherlands Vaccine Institute Antonie van Leeuwenhoeklaan 11 3720 BA Bilthoven The Netherlands Paul-Henri Lambert Department of Pathology and Pediatrics Geneva University 1 Rue Michel Servet Genève 27 Switzerland Maria Lattanzi IRIS Research Center Chiron Srl Via Fiorentina 1 53100 Siena Italy Claudia Link Vaccine Research Group GBF-German Research Centre for Biotechnology Division of Microbiology Mascheroder Weg 1 38124 Braunschweig Germany

Andrew J. McMichael Medical Research Council Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford, The John Radcliffe Hospital Headley Way Oxford OX3 9DS UK Ian C. Metcalfe Berna Biotech Ltd Rehhagstrasse 79 3018, Bern Switzerland Karin Mölling Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Christian Moser Berna Biotech Ltd Rehhagstrasse 79 3018, Bern Switzerland Joseph Patrick Nkolola Medical Research Council Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford, The John Radcliffe Hospital Headley Way Oxford OX3 9DS UK

List of Contributors

Gustav J. V. Nossal Department of Pathology The University of Melbourne Victoria 3010 Australia Ruth S. Nussenzweig Department of Medical and Molecular Parasitology New York University School of Medicine New York, NY 10016 USA Victor Nussenzweig Department of Pathology New York University School of Medicine New York, NY 10016 USA Derek T. O'Hagan Chiron Vaccines Chiron Corp. 4560 Horton St. Emeryville, CA 94608 USA Wieslawa Olszewska Department of Respiratory Medicine National Heart and Lung Institute Imperial College London UK Peter J. M. Openshaw Department of Respiratory Medicine National Heart and Lung Institute Imperial College London UK

Eric G. Pamer Infectious Diseases Service Department of Medicine and Laboratory of Antimicrobial Immunity Immunology Program, Sloan-Kettering Institute Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 USA Jovan Pavlovic Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Martin Pearse Pharmaceutical R & D CSL Limited 45 Poplar Road Parkville,VIC., 3052 Australia Alexander Ploss Infectious Diseases Service Department of Medicine and Laboratory of Antimicrobial Immunity Immunology Program, Sloan-Kettering Institute Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 USA and Weill Graduate School of Medical Sciences Cornell University New York, NY 10021, USA

XXIX

XXX

List of Contributors

Kevin G. J. Pollock Scottish Centre for Infection and Environmental Health Clifton House Glasgow, G3 7LN Scotland

Allan Saul National Institutes of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 USA

Luciano Polonelli Microbiology Section Department of Pathology and Laboratory Medicine University of Parma Parma Italy

Hansjörg Schild Institute for Cell Biology Department of Immunology University of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany

Markus Radsak Institute for Cell Biology Department of Immunology University of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany

Michael P. Schmitt Division of Bacterial, Parasitic, and Allergenic Products Center for Biologics Evaluation and Research 1401 Rockville Pike, HFM 431 Rockville, MD 20852 USA

Rino Rappuoli IRIS Research Center Chiron Srl Via Fiorentina 1 53100 Siena, Italy Faiza Rharbaoui Vaccine Research Group GBF-German Research Centre for Biotechnology Division of Microbiology Mascheroder Weg 1 38124 Braunschweig Germany Paolo Ruggiero IRIS Research Center Chiron Srl Via Fiorentina 1 53100 Siena Italy

Jan Schultz Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Manmohan Singh Chiron Vaccines Chiron Corp. 4560 Horton St. Emeryville, CA 94608 USA Thomas D. Szucs Hirslanden Research Seefeldstrasse 214 8008 Zurich Switzerland

List of Contributors

Tillmann S. Utesch Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Jean-François Viret Berna Biotech Ltd Rehhagstrasse 79 3018, Bern Switzerland Max von Kleist Institute of Medical Virology University of Zurich 8028 Zurich Switzerland Kan Wang Department of Agronomy Iowa State University Ames, IA 50011 USA

E. G.-T. Wee Medical Research Council Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford, The John Radcliffe Hospital Headley Way Oxford OX3 9DS UK Jerry P. Weir Division of Viral Products Center for Biologics Evaluation and Research 1401 Rockville Pike, HFM 431 Rockville, MD 20852 USA Stefan Zimmermann Institute of Medical Microbiology and Hygiene Philipps University Marburg Pilgrimstein 2 35037 Marburg Germany

XXXI

XXXIII

Colour Plates

Fig. 4.1 Models of programmed memory T cell generation. T lymphocytes may commit to becoming long-term memory T cells at different times during the course of activation. We propose three distinct models for programmed memory T cell development. Model A suggests that differentiation of memory T cells is a gradual process, with naï ve T cells first differentiating into effector T cells and then, stochastically, further differentiating into memory T cells. Model B suggests that brief exposure to antigen results in two distinct effector T cell populations, one committed to long-term memory development, and the other to apoptotic death. Model C, on the other hand, proposes that naï ve T cells differ in their potential to differentiate into memory T cells.

Colour Plates

Fig. 7.1 The current model for the physiological role of HSPs in cross-priming. During the course of, for example, a viral infection, pathogen-derived proteins are produced by the infected host cell. Due to the usual protein turnover, viral peptide fragments are generated by the proteasome and may be presented on MHC class I molecules. HSPs are associated with such peptides in vivo. If the virus causes necrotic death of the infected cells, the HSP–peptide complexes are released and can be taken up by APCs in a receptor-mediated fashion via CD91 and LOX-1. The APC can represent the HSP-ligated viral peptides on its MHC class I molecules, thereby enabling its recognition by naive CD8+ T cells. Moreover , released HSP activates APCs via TLR4 and TLR2, resulting in the up-regulation of costimulatory molecules and in the secretion of various proinflammatory cytokines and chemokines. This second signal enables the priming of the naive CD8+ T cells, triggering their development into effector cytotoxic T cells (CTLs). These cells are now able to kill virus-infected cells without further costimulatory signals.

XXXV

XXXVI

Colour Plates

Fig. 13.2 Generation of rAAV vaccines. A Life cycle of wild-type AAV. Latency is established after AAV infection of the target cells, which may involve genome integration. AAV virions are rescued after subsequent infection with helper virus, which provides the sequences needed for viral replication in trans. B Production of rAAV vaccines. Permissive cells are cotransfected with a plasmid containing the transcription unit (blue) flanked by the AAV ITRs (green) and plasmid containing the AAV genome without the ITRs. Subsequent infection of these cells with a helper adenovirus enables rescue of rAAV virions, following the packaging of the ITR-containing plasmid, along with helper virus. Helper and rAAV virions can then be separated after heating at 56 °C by centrifugation on a cesium chloride gradient. Adapted from [3].

Colour Plates

Fig. 13.3 Generation of recombinant herpes simplex viruses (HSV) and HSV-derived amplicons. A Recombinant HSV vectors. HSV genomic DNA is cotransfected into permissive cells along with a plasmid containing the transcription unit (red) inserted in fragment of HSV genome (gray). During mitosis, homologous recombination occurs between the HSV genome sequences within the plasmid and HSV DNA. Both wild-type and recombined viral genomes are packaged into a mixed virus particle population, from which the recombinant viruses are isolated by plaque purification. B Amplicon-derived HSV vectors. The amplicon plasmid con-

taining the transcription unit (red) and the viral cleavage and packaging site is cotransfected into permissive cells together with a helper virus genome, which contains all the regulatory and structural genes needed for viral growth, including the HSV host shutoff protein, but is defective in packaging. Immediately after transfection, the amplicon plasmid undergoes DNA replication driven by helper proteins, which results in the generation of head-to-tail plasmid concatemers. These concatemers are then cleaved into genome unit-length molecules and packaged into virus particles, which after concentration are ready for use. Adapted from [35].

XXXVII

XXXVIII

Colour Plates

Fig. 15.1 Patterns of intestinal colonization displayed by enteric pathogens. Distinct enteric pathogens exhibit different modes of pathogenicity after interaction with the gut. This diagram illustrates the typical types of enteric infection and the level of the gut tissue associated with infection in a healthy human. EPEC enteropathogenic E. coli; ETEC enterotoxigenic E. coli.

Fig. 15.2 Interaction of Salmonella enterica with immune cells shown by confocal microscopy. A. anti- Salmonella B. anti-LAMP-1 C. Merged image. Provided by Dr Liljana Petrovska, Imperial College London.

Colour Plates

Fig. 16.1 Schematic representation of cells involved in immune reactions after mucosal challenge. APC, antigen-presenting cell; M, microfold epithelial cell; T, T cell; B, B cell; RBC, red blood cell.

Fig. 16.2 Goals of mucosal immunization. Successful mucosal immunization may induce humoral and cellular immune responses. Possible roles of both are shown. M, microfold epithelial cell; HEV, high endothelial venule; APC, antigen-presenting cell; the 1 symbol indicates possible sites of immune intervention.

XXXIX

XL

Colour Plates

Fig. 16.3 Challenges for mucosal vaccination: schematic representation of key issues in mucosal vaccine development.

Fig. 21.1 Schematic depiction of mechanisms underlying immunity to tuberculosis. Upper left and middle: major steps from infection to induction of immune response ; middle and lower left: granuloma formation and breakdown; right: major T cell populations involved in protective immunity; upper right: effector mechanisms in activated macrophages.

Colour Plates

Fig. 21.2 Cross-priming as a major pathway of antigen presentation in tuberculosis.

Fig. 23.2 On the surface of the HIV virion, env forms a trimeric complex of gp120–gp41 dimers. The conserved surfaces facilitate the formation of a trimer. The binding of gp120 to CD4 on the T cell induces a conformational change, which exposes the coreceptor binding site. Schematic diagram reproduced with kind permission of Dr. Sattentau [8].

XLI

XLII

Colour Plates Fig. 23.3 Schematic diagram of the likely arrangement of the HIV-1 gp120 glycoproteins in a trimeric complex. The view is from the target cell membrane. The CD4 binding pockets are indicated by black arrows, the approximate locations of the 2G12 epitopes are indicated by blue spots, and the conserved chemokine-receptor-binding regions are in red. Areas in green indicate the more variable glycosylated surfaces of gp120.

Fig. 23.4 Proposed dynamics of the T cell response to virus-specific T cells. Rare antigen-specific naïve CD8+ T cells are stimulated to divide rapidly. The frequency of effector cells (light blue) is much higher than that of those that can divide in vitro (dark blue). Persisting HIV antigen maintains the expanded T cells at a high level; without antigen these cells die by apoptosis. The population of T cells that is capable of dividing further (dark blue) maintains long-term memory and is likely to continually generate the expanded effectors.

Part I

3

1 Challenges for the Vaccine Developer, including Correlates of Protection G. J. V. Nossal

1.1 Introduction

For four reasons, a book on novel vaccination strategies is particularly timely. First, the stunning advances in basic biology, and particularly in genomics, have opened up new vistas in vaccinology and have introduced a much more solid underpinning of science into a field characterized by a fair degree of empiricism. Second, the devastating impact of the HIV/AIDS pandemic has alerted the world to the imperative need for a vaccine to contain it and, as a side effect, has permitted greater publicity for other major communicable disease killers, such as tuberculosis and malaria. Third, humanitarian issues, such as immunizing all the world's children and not only the children of the rich, have taken on a new urgency after September 11, 2001. As Varmus has argued, ‘to a very great, if not measurable extent, terrorism is a manifestation of anger and resentment about the world’s inequalities’ [1]. Fourth, the quite extraordinary generosity of the Bill and Melinda Gates Foundation has permitted highly significant new sums of money to flow into vaccine research and, through the Global Alliance for Vaccines and Immunization, has raised the prospect that new and improved vaccines might promptly reach those in greatest need of them [2]. That being said, the would-be inventor of new or improved vaccines still faces formidable challenges. The expensive applied research, development work, and clinical trials that are required following the academic research phase are usually the province of industry, which has an understandable requirement to be profitable. Where the vaccine is one chiefly of interest to developing countries, novel strategies of funding and/or execution may be necessary. For example, the Gates Foundation-funded African meningitis program seeking to combat epidemics caused by Neisseria meningitidis has engaged a vaccine manufacturer in India, with its much lower labor costs, to develop a carbohydrate–protein conjugate vaccine, with the help of two manufacturers in industrialized countries with some of the raw materials and of technology transfer. Another very real challenge is the fact that most existing licensed vaccines have been developed using antibody levels generated as the key guide. Now vaccines are required where T cell immunity is essential. The correlation between measured T

4

1 Challenges for the Vaccine Developer, including Correlates of Protection

cell reactivities and durable protection is frequently much more dubious. Moreover, unfortunately, animal models, particularly rodent ones, have been poor predictors of clinical efficacy. It is therefore important to explore all the mechanisms of protection that the immune system provides and to gradually build up a combinatorial image of what elements contribute to a vaccine that really works. Of course, all the correlative arguments in the world do not bypass the need for phased clinical trials. Part of the challenge will be to learn the correlates of protection from such trial results.

1.2 Mechanisms of Protection within the Immune System

The mechanisms of protection are conventionally divided into innate or primitive and adaptive or acquired, but as later chapters show, these systems are far from unrelated. Indeed, it is valuable to think of bodily defense as a complex, highly integrated series of interacting cellular and molecular processes, some depending on evolutionarily primitive recognition processes and others being much more specific and highly evolved. Moreover, because the most recent system, that which depends on the somatic generation of B and T cell repertoires, evolved in the presence of earlier systems, it is natural that functionally new processes should be ‘grafted onto’ what went before. Thus it comes as no surprise that antibodies serve their function with a high dependence on the complement system or on phagocytosis. So long as this is recognized, it is legitimate to set out the key elements of the innate and the adaptive systems. The innate immune system is evolutionarily as old as multicellular life itself, namely about two thousand million years, but its central molecular features have only recently been elucidated [3]. Table 1.1 summarizes its key elements. Probably the most important newer finding is that of the Toll-like receptors for pathogen products of various sorts. These evolutionarily old receptors form a link between the innate immune system and the adaptive system, as is fully discussed in another chapter 2. Table 1.2 deals with the more familiar mammalian adaptive immune system, which consists of a multiplicity of components. So the question is ‘Which element is the most important in protecting the host against infection?’ because that is what the vaccine developer should monitor as research on a new vaccine progresses. The matter is not simple, because various elements collaborate in vanquishing infections. Physicians have known for nearly a century that the crisis in lobar pneumonia that precedes recovery signifies a sufficiently high concentration of opsonic antibody to allow lung macrophages to engulf the invading bacteria. Without either the antibody or the macrophage, the patient would die. Yet it is clearly impractical for the researcher to seek to correlate every element of Table 1.2 with the degree of protection afforded by a vaccine. A further complexity is the fact that what leads to recovery from infection may not be identical to what is required to prevent infection or reinfection. In influenza, for example, cytotoxic T cells are probably the most important element limiting viral spread and thus speeding recovery, but antibodies in respiratory tract mucosal fluid are probably key to preventing an attack. Given these influences, it is not surprising that correlates of protection is a field that has not progressed very far.

1.3 Protection against Viruses Tab. 1.1 Some key elements of the innate defense system. . Cilia . Enzymes in mucous secretions, e. g., lysozyme . Repair mechanisms of damaged anatomical barriers, e. g. the clotting cascade or growth factor and chemokine release . Defensins . The complement cascade . Non-immunoglobulin opsonins, e. g., collectins such as mannose-binding protein or C-reactive protein, lectins, fibronectin, etc. . Recognition receptors on dendritic cells, macrophages, NK cells, and mast cells including Tolllike receptors, scavenger receptors, or integrin . Phagocytosis by polymorphonuclear leukocytes, monocytes, or macrophages . Cytokines, including interferons a, b, g and tumor necrosis factor

Tab. 1.2 Some key elements of the adaptive immune system. . B lymphocytes, their precursors and progeny, and their products – 8 different classes of antibody . T lymphocytes with a/b receptors, their precursors and progeny, their lymphokine products, and specifically CD4+ regulatory (suppressor) T cells; CD8+ cytotoxic and cytokine secretory cells; and CD1-specific CD4+ or double negative NK-1 T cells . T lymphocytes with g/d receptors, their various subsets, and their lymphokine products . Other atypical T cells . Fc receptors of various types on monocytes, macrophages, immature dendritic cells, B cells, polymorphonuclear leukocytes, NK cells, mast cells, and platelets, as well as soluble Fc receptors

The most convenient way of discussing present understanding is to deal separately with viral, bacterial, and parasitic pathogens.

1.3 Protection against Viruses

Virus infections can be relatively localized, e. g., to the respiratory or alimentary tracts (a more challenging situation for the induction of protective immunity) or they may spread systemically first via the lymph and then through the blood, where opportunities for engaging the major sites of immune induction are plentiful. Virus infections may be acute and followed either by death or by complete viral elimination; they may set up a latent infection, going underground in particular cells, only to reemerge sporadically and unpredictably, as with herpes viruses; or they can set up a chronic infection as in hepatitis B or C. Knowing the respective life histories of the viruses is important to devising appropriate vaccine research strategies. The innate immune system offers a substantial defense against viruses. In particular, the type 1 interferons, a and b, damp viral replication and thus limit their spread. NK cells become activated and, through cytotoxic activity, kill virus-infected cells. The

5

6

1 Challenges for the Vaccine Developer, including Correlates of Protection

innate immune system also provides a variety of other potent cytokines. Macrophages have antiviral functions but can also harbor viruses and aid their spread. Adaptive immune responses come in somewhat later and usually involve both antibodies and T cells. The general rule is that antibody, with its capacity to recognize structures on the surface of a virus, plays the main role in neutralizing free virus, whereas T cells, recognizing viral peptides processed intracellularly and presented on cell surfaces, have virus-infected cells as their target. In both pathways, it is important to delineate which viral antigens are the most important. As far as antibody formation is concerned, the key molecules are those that the virus uses to gain entry into the host cell. Covering these up with antibody prevents the initiation of infection, and such antibodies are known as neutralizing antibodies. Surface glycoproteins or outer capsid proteins are the most critical viral antigens that induce neutralizing antibody. Viruses having a lipid envelope need not only to attach but also to fuse with the host cell membrane. Often, a separate fusion protein exists, which is also a neutralization target. Newly formed viruses need to be released from the infected cell. With influenza virus, for example, release is achieved via a specific molecule, neuraminidase. Although not as important as antibodies to hemagglutinin, which binds the influenza virus to the cell, antineuraminidase antibodies also participate in protection. Ancillary to these highly specific antibodies are many other antibodies that recognize the virus surface and act in an opsonic manner. Finally, antibodies to any surface structure on a virus-infected cell can lead to that cell being killed by antibody-dependent cellular cytotoxicity or by complement-dependent lysis, aiding control of infection. At the same time, many antibodies are formed to internal virus components that are irrelevant to protection. In some instances, the process of viral entry is more complex, requiring two receptors. The classical case is HIV, where the gp 120 envelope protein binds to CD4 and, subsequent to this binding, an allosteric change allows the binding of another part of gp 120 to a coreceptor, namely CCR5 or CXCR4, which are members of the chemokine receptor family. It is believed that then a further conformational change leads to insertion of a hydrophobic amino-terminal fusion peptide of gp 41 into the target cell membrane. Cross-linking via gp 41 finally results in membrane fusion and viral entry. The newly and briefly exposed antigenic determinants of gp 120, which bind to the coreceptor, appear to be more conserved than the CD4-binding epitopes and may constitute attractive vaccine candidates [4]. The T cell side of antiviral defense is entirely different. Here, any viral protein, be it surface-located, internal, or indeed nonstructural, may be presented on the surface of an infected cell or of an antigen-presenting cell that has engulfed an infected cell or portions of it. Although classically, peptides from a cell in which virus is growing are presented by MHC class I molecules, and peptides derived by endo- or phagocytosis are presented by class II molecules, there are now numerous examples of cross-presentation. Conventionally, we think of CD8+ cytotoxic T cells recognizing peptides presented by class I as the chief protectors for vanquishing a virus infection. However, the CD4+ T cells recognizing peptides presented by class II are also hugely important. They act as helpers for the production of high-affinity antibody. They also provide help for the activation of CD8+ T cells, produce cytokines with antiviral activity, and recruit phagocytic cells.

1.3 Protection against Viruses

In some ways, therefore, the vaccine researcher seeking to develop a vaccine for a disease in which T cell immunity is paramount for protection suffers from an embarrassment of riches. In looking to see if a putative vaccine has engendered a T cell response, it is truly difficult to choose among the different viral proteins, so often ‘cocktails’ are used, rendering the test less precise than it might have been. Furthermore, it is difficult to know whether to go with whole viral proteins or with known T cell epitopes from a given protein. If the latter, the investigator must face the polymorphism of the human population for both class I and class II HLA molecules and either run the test with a variety of T cell peptides or choose to learn from only a given MHC haplotype. In infections that relapse (like herpes) or that persist (like HIV), the vaccine developer has to do better than nature, which is of course quite a challenge. Success may depend on a T cell response more precise and/or more intense than that accompanying the infection. For cytopathic viruses that kill or heal, leaving protective immunity, the correlate of protection is straightforward, being neutralizing antibody. Often, a combination of animal experimentation and clinical seroepidemiology has given good information on the actual levels or titers of antibody required for protection. These then guide choice of antigen dose in the vaccine and the number of injections required. To a degree, they also dictate how often booster doses are required, as in smallpox or yellow fever, although in practice protection may well last longer than threshold serum antibody levels, presumably because of very rapid memory responses should the virus gain reentry. Memory responses obviously take a few days to become manifest, since lymphocyte multiplication and differentiation are required. They are therefore most effective in systemic infections where the pathogen takes a few days to move from the point of entry via the skin or mucus membrane into the lymph, tissues, and blood. They are less effective in purely localized mucosal infections. Things are a little more complex in a disease like influenza, which starts in respiratory epithelium but becomes more serious as it spreads more deeply. Further, in this disease the key antigens and particularly the hemagglutinin exhibit very high mutation rates. Here minor changes due to an accumulation of point mutations, and known as antigenic drift, are dealt with by a clever, arduous global process, where vaccine manufacturers, guided by World Health Organization collaborating centers, include in the vaccine the most recent circulating variants, with susceptible people being counseled to have yearly boosters. On the other hand, when genetic reassortment occurs between different viral strains, frequently a wild human virus and an influenza virus of an animal such as a pig or a chicken, preexisting immunity is frequently lacking and a pandemic can sweep the globe. These are known as shift variants. It appears that major pandemics have occurred about three times a century over the past three centuries or so. Should we be looking to correlate protection with IgA present in respiratory mucus or intestinal fluids for respiratory or intestinal infections, respectively? From a practical point of view this has not proven to be necessary, because measuring serum (mainly IgG) antibody seems to do the job. Important as IgA is, we must remember that significant quantities of IgG enter these fluids as a transudate.

7

8

1 Challenges for the Vaccine Developer, including Correlates of Protection

Should we be measuring virus-specific T cell levels? For the ‘kill or cure’ diseases, the undoubtedly helpful T cell responses engendered by vaccines are really a bonus, and it has not proven necessary to document their numbers or persistence. As we shall see below, the situation is quite different for diseases such as HIV/AIDS or hepatitis B or C. There is a major difference between viruses that are mainly confined to body surfaces and those that become systemically disseminated. The former induce mainly mucosal immunity, which is much shorter-lived than systemic immunity. The same is true for mucosal vaccines, which tend to cause a shorter duration of protection. Still, in ‘real life’, significant serum antibody is also present and acts as a guide for the vaccine developer.

1.4 HIV/AIDS as an Example of a Persisting Virus

Many of the dilemmas facing the researcher seeking correlates of protection in a chronic virus infection are illustrated by the HIV/AIDS situation. Great early disappointment followed the realization that monomeric gp 120 protein given with adjuvant to human volunteers elicited antibodies that could neutralize laboratory-passaged HIV strains but not fresh primary isolates from patients [5]. Given the prominence of antibodies to the V3 loop and the extreme mutability of the envelope protein in this region, this really should not have been too surprising. But it is far too early to suggest that antibodies will never act protectively. Appropriate antibodies may, in times represent a useful correlate marker. We now possess a much better picture of the events that occur when HIV docks with the CD4+ cell and finally enters it [6]. When gp 120 engages CD4, a stable conformational change occurs which exposes a binding site for a coreceptor, usually CCR5 or CXCR4. This site is highly conserved, as also is the actual docking site for CD4 within the gp 120 molecule. Both sites are in recessed pockets on the inner core of the gp 120 molecule. After both CD4 and the coreceptor have engaged, the noncovalently linked gp 41 molecule changes conformation to reveal a hydrophobic fusion domain allowing viral entry into the host cell. Moreover, the gp 120–gp 41 dimers exist on the virus surface in triplets constituting a viral spike. Additional epitopes may be generated as a result of this trimerization, and what one wants is high-avidity binding to the trimer. It is not easy to elicit antibodies to these conserved elements, but some human subjects with HIV do manage to generate antibodies capable of neutralizing a broad diversity of HIV isolates. Perhaps the most informative approach has been the study of human monoclonal antibodies with this capacity [7]. The structure of one of these, b12, has been resolved to 2.7 Å and possesses a finger-like projection, which is the third hypervariable region of the heavy chain, which pokes into the recessed CD4 binding site of gp 120. Another (2G12), surprisingly, is directed against oligomannose epitopes clustered on one face of gp 120, raising the possibility of a carbohydrate vaccine. Such examples, and the clear proof that passive antibodies can protect against chimeric simian–human immunodeficiency virus (SHIV) challenge, offer the hope

1.5 Protection against Extracellular Bacteria

that eventually immunogens will be generated that are capable of eliciting antibodies with the right characteristics. This being said, overwhelmingly the most effort is being directed at vaccine approaches capable of inducing CD8+ cytotoxic T cell immunity. These are described in detail in another chapter 5. What is the evidence that HIV-specific cytotoxic T cells will be protective? The accumulation of evidence is impressive [4]. It began with the demonstration that human CD8+ T cells can suppress virus replication in autologous CD4+ T cells in vivo [8], which was soon followed by the observation that the appearance of large numbers of specific cytotoxic cells during primary infection with HIV correlated in time with a substantial fall in virus load. In the SHIV model, vaccines that elicit high CTL levels work, at least to some extent. In the opposite direction, when CD8 T cells are depleted, monkeys develop very high levels of viraemia. Further, clinical nonprogressors with long-maintained low viral loads have high CTL levels [9], as do those heavily HIV-exposed sex workers who remain uninfected [10]. In the absence of absolute proof, most investigators would rank specific cytotoxic T cells as the best surrogate marker for efficacy. At the same time, CD4+ cells should not be forgotten [11]. Although the exact mechanism is unknown, CD4+ cells are helpers for CD8+ T cell development. Of course, they are required for high-affinity antibody responses as well. Patients with low viraemia tend to have high CD4+ T cell proliferative responses to HIV antigens. Thus, it is probable that a good vaccine would induce both specific CD4+ and CD8+ responses (Table 1.3).

Tab. 1.3 Possiblecorrelates of protection in HIV/AIDS. Surrogate marker

Comments

Serum antibody

Best against actual conserved docking epitopes of virus; hard to generate. Some value against other epitopes, but mutability of virus is a problem.

Antibody in vaginal or rectal mucus

Hard to measure routinely.

CD8+ cytotoxic T cells

Which antigens and which epitopes to use for precision of measurement? Will tetramer staining prove helpful eventually?

CD4+ helper T cells

Which antigens? Which subtype?

Combination of all the above

Best hope in the long term.

1.5 Protection against Extracellular Bacteria

Strategies of host defense are different for bacteria that live extracellularly, for which antibodies are the chief agents of control, versus bacteria adapted to intracellular per-

9

10

1 Challenges for the Vaccine Developer, including Correlates of Protection

sistence, where T cells are key. With the former type, bacteria that remain localized, e. g., Staphylococcus aureus causing impetigo or boils, are less susceptible to conquest by antibody than bacteria that invade the body, e. g., Streptococcus pneumoniae causing pneumonia, meningitis, or septicaemia. The exotoxins, which some bacteria manufacture to aid tissue destruction, allowing them to get a foothold in the host, are very important targets of immune attack. Suitably treated either chemically (to create a toxoid) or genetically (to create a nontoxic but antigenically similar analogue), such molecules become very effective vaccines. Typical examples include Clostridium tetani and Corynebacterium diphtheriae, in which the relevant toxoids are among the most effective vaccines in common use. Other bacteria, such as Clostridium perfringens or Bacillus anthracis make more than one exotoxin. For some species, such as Bordetella pertussis, it is preferable to give a combination acellular vaccine, containing not only toxoided pertussis toxin but also other molecules that contribute to virulence, such as filamentous hemagglutinin, pertactin, or fimbrial proteins. In all these examples, antibody levels give the best correlate of protection. This is not to say that T cells do not play any part in defense, but simply that, in a practical sense, measuring the appropriate antibody is the best guide for the vaccine developer. Another important group of antigens that evoke protective antibodies are the capsular polysaccharides of the bacterial cell wall. Unfortunately for the vaccine developer, genetic polymorphism in these carbohydrate epitopes, even within a single bacterial species, is common. An extreme example is Streptococcus pneumoniae, in which over 90 serologically distinct capsular polysaccharides exist, and over 20 of these serotypes are important in human disease. Furthermore, when these carbohydrate antigens are used as vaccines, they prove to be suboptimal in several ways. Infants under 1.5 years old respond poorly or not at all. Beyond this age, both children and adults mount an antibody response without T cell help, which is generally of low affinity and results in poor B cell memory. Nevertheless, a 23-valent carbohydrate-based vaccine has proven helpful in elderly individuals. A major breakthrough occurred when researchers realized that this type of vaccine could be much improved by conjugating the carbohydrate moieties to a protein carrier such as diphtheria toxoid or mutated toxin. The protein carrier provides T cell help, allowing earlier responses, affinity maturation, and good memory. The first practical fruits of this approach were vaccines against Haemophilus influenzae serogroup B, or Hib [12, 13]. There are six capsular serotypes of H. influenzae, a to f, capable of causing human disease; fortunately, serotype b is overwhelmingly the most important. When the Hib conjugate vaccine was widely deployed in industrialized countries, it was surprisingly effective and Hib meningitis was virtually eliminated – partly because nasopharyngeal carriage rates were greatly reduced and ‘herd immunity’ became manifest. Once again, for the development of this vaccine, antibodies were the obvious correlate of protection. Exactly the same principles have been applied to a pneumococcal conjugate vaccine, where it has not proven possible to include 23 serotypes, but 7-valent, 9-valent, and 11-valent vaccines have been developed by various manufacturers. The serious pathogen Neisseria meningitidis serogroup C has also yielded to this approach. A re-

1.6 Protection against Intracellular Bacteria

cent widespread deployment of this vaccine has reduced the incidence of meningococcal C meningitis in the United Kingdom by over 80 % and of deaths by > 90 % [14]. In Sub-Saharan Africa, vicious epidemics of meningococcal A meningitis sweep across the continent every few years. A carbohydrate vaccine is moderately effective in outbreak control, but the World Health Organization in conjunction with the Program for Appropriate Technology In Health (PATH) has an ambitious goal of developing and deploying a meningococcal A conjugate vaccine to be given to everyone under 21, as well as to be included in routine infant immunization. Another example of interesting research on conjugates is Salmonella typhi, for which the carbohydrate Vi antigen delivered parenterally is somewhat protective, but hopes are high that Vi-protein conjugate vaccines will work better. Much work is being directed at beating the polymorphism problem by seeking antigens that (1) are exposed at the bacterial cell surface; (2) exhibit limited or no polymorphism; (3) are important determinants of virulence; and (4) do not cross-react significantly with ‘self ’ antigens. Genome mining in those instances where the DNA sequence of the relevant bacterium has been determined is playing a major role in this research. Entirely different approaches to immunization have met with some success in diseases caused by gastrointestinal-tract pathogens. First, there is the possibility of introducing killed whole bacteria or important virulence antigens in conjunction with a mucosal adjuvant. A vaccine based on whole killed Vibrio cholerae together with purified B subunit of the cholera toxin (CTB) is licensed in some countries. Experimental oral molecular vaccines work in animal models of Helicobacter pylori disease [15]. Second, extensive investigation of live attenuated bacteria, also given orally, shows some promise. At the moment, the only licensed version of such a vaccine is the Ty21 a strain of Salmonella typhi. Serum antibodies do not represent a particularly reliable correlate of protection in these diseases, and much of the developmental research has relied on protection of volunteers against challenge administration of the relevant pathogen. Unfortunately, this is not always a good predictor of the results of phase III clinical trials.

1.6 Protection against Intracellular Bacteria

Intracellular bacteria have evolved mechanisms to foil the usually very efficient phagosome–lysosome system of macrophages and other cells and have learnt to live most of their lives either inside a phagocytic vacuole or, having learnt to escape the phagosome, within the cytoplasm of the host cell. In these hidden locations, they are protected from serum antibody, but because peptides derived from them are expressed on the surface of the infected cell, infections can be controlled by T cell immunity. It was established over a century ago that immunity to extracellular bacteria can be passively transmitted via serum [16], but it was also soon established that this did not occur with certain infections, e. g., tuberculosis. Nevertheless, solid immunity to intracellular bacteria does exist, and which can be transferred from immune to naï ve ani-

11

12

1 Challenges for the Vaccine Developer, including Correlates of Protection

mals via lymphocyte cells [17] (which were soon shown to be T cells). Long before the difference between T and B cells was understood, a skin test to establish T cell immunity (delayed-type hypersensitivity) had been developed and widely used. The diseases caused by intracellular bacteria include some of the greatest scourges of humanity, such as tuberculosis, leprosy, and trachoma. Tuberculosis has taken on even greater significance since the HIV/AIDS pandemic, because infections that may have been well controlled flare up when T cell function wanes. The HIV/AIDS pandemic has also put the spotlight on intracellular bacteria such as Mycobacterium avium, which are relatively harmless unless T cell immunity fails. In general, infections by intracellular bacteria are chronic, and much of the pathology is associated with the immune response, e. g., granuloma formation. Usually immunity is not sterilizing, and the balance between bacterial persistence and T cell protection is somewhat labile. Both CD4+ and CD8+ T cells contribute to defense against intracellular bacteria [18], the CD8+ T cell being activated because bacteria escape into the cytosol, or because of antigens that escape, or because of cross-presentation. Various sorts of unconventional T cells also contribute to defense against intracellular bacteria. Because Stefan Kaufmann is one of the world experts in this field, please refer to his chapter 21 on tuberculosis for a discussion of this subject. Will delayed-type hypersensitivity skin tests or in-vitro measurements of T cell function be helpful to the vaccine developer in the search for, e. g., a more satisfactory vaccine against tuberculosis? Certainly, but they are not perfect correlates of protection. A person may yield a florid, highly positive Mantoux test while experiencing a flare-up and wide dissemination of tuberculosis. A negative test in a tuberculosis sufferer is in general a sign of poor prognosis (especially before the antibiotic era) but need not always be so. So the investigator also depends on the inherent plausibility of the antigen(s) chosen and on its efficacy in the most credible animal model available. Because of the chronic nature of the infections concerned, clinical testing of vaccines emerging from basic research is particularly arduous. However, adjuvant formulations and vaccination strategies (e. g., ‘prime–boost’ protocols) capable of eliciting strong CD4+ Th1 and CD8+ cytotoxic T cell responses are now available and should herald success in the long term.

1.7 Protection against Parasites

It is difficult to be dogmatic about correlates of protection in parasitic diseases, for the simple reason that there is no single licensed vaccine against any human parasitic disease. To this must be added the fact that most parasitic diseases do not themselves lead to solid immunity, Leishmania major being an exception when causing tropical sores. Nevertheless, a great deal of work has been done on animal models. I summarize here what is known about three important parasitic diseases: malaria, schistosomiasis, and leishmaniasis. Malaria is the most prevalent vector-borne disease in the world. It is caused by protozoa of 4 different species of Plasmodium, the most fatal of which is P. falciparum.

1.7 Protection against Parasites

Clearly this organism has developed powerful mechanisms to evade the host immune response, including an incredible degree of antigenic variation. Because of the chapter 22 dealing specifically with malaria, I will only mention that vaccine approaches are being directed at 4 distinct stages in the parasite's life cycle (Table 1.4). The mosquito injects a mobile sporozoite that exhibits a major circumsporozoite antigen. Antibodies to it or portions of it can block invasion of liver cells and be partially protective [19]. When the sporozoite reaches the liver cell, it develops into a shizont containing 10 000 to 30 000 merozoites. As a result, the hepatocyte presents on its surface peptides (T cell epitopes) from a number of preerythrocytic stage proteins. A CD8+ T cell attack on injected liver cells could materially decrease the total number of merozoites formed and thus be partially protective. Here, T cell immunity could correlate with protection. When the liver schizont ruptures, merozoites are released and invade erythrocytes to begin the blood stage of the cycle. A large number of merozoite surface antigens are being investigated as putative vaccine candidates, alone or, more usually, in various combinations. Here, antibody would be the effective agent. Finally, during the erythrocytic cycle, sexual stages known as gametocytes are formed. They exhibit some strong antigens, antibodies against which can inhibit sexual maturation within the mosquito after it takes a blood meal. It could well turn out that an eventual definitive malaria vaccine will contain antigens acting against all four stages. A further, more controversial, possibility is to try to neutralize a toxin, glycophosphatidylinositol, of malarial origin. An oligosaccharide from this glycan has been Tab. 1.4 Vaccine candidates from various stages of Plasmodium falciparum Stage

Antigen(s)

Desired response

Comments

Sporozoite

The major circumporozoite protein.

High affinity antibody

The most advanced vaccine candidate. Nature of adjuvant has been critical.

Liver cell schizont Various T cell epitopes, guided in part by elution of peptides from infected cells.

CD8+ cytotoxic cells

Research is most advanced for P. vivax. A promising, rather new area.

Merozoite

Proteins prominent on the surface. Proteins from internal organelles needed for invasion of erythrocytes.

High affinity antibody

An intense, competetive field. Many antigens nearing the clinic. Combinations also being tested.

Gametocytes

Antigens from surface.

High affinity antibody

The ‘unselfish’ vaccine. Does not help recipient directly but, widely used, would impair transmission.

Malarial toxin

GPI and oligosaccharides Neutralizing antibodies there from (see text).

Would be combined with other antigens.

13

14

1 Challenges for the Vaccine Developer, including Correlates of Protection

synthesized, conjugated to a protein carrier, and used as a vaccine. It materially reduces pathology and mortality in a murine model [20]. Again, antibodies would be the correlate of protection here. Most investigators now hold the view that a final malaria vaccine should induce both T cell and B cell immunity. Schistosomiasis is the most prevalent human parasitic disease caused by a metazoan parasite. It is caused by five different species of Schistosoma, of which the most important are S. mansoni, S. hematobium, and S. japonicum. The most advanced vaccine candidate is the molecule Sm28GST [21]. Mice immunized with it consistently show reduced worm burden, impaired female worm fecundity, and low egg viability. Clinical trials are now ongoing. Evidence suggests that Th2-type CD4+ T cells correlate with protection, promoting IgE formation via IL-4 and eosinophilia via IL-5, but the matter is not straightforward because the ova of schistosomes evoke a Th2 response that aids granuloma formation and subsequent pathology. Similarly, Th1 responses induced by a radiation-attenuated S. mansoni vaccine can be protective in animals, but T cells from severely diseased humans often secrete Th1 cytokines, suggesting an involvement in pathogenesis [22]. The line between protective immunity and immunopathology is thus clearly a fine one. Immunological interest in leishmaniasis was first aroused by the realization that tropical sores, once they eventually healed, resulted in immunity to reinfection. Interest was increased by the clear-cut finding that, in a murine model, Th1 type CD4+ T cell responses cure lesions, but Th2 type immunity leads to progressive lesions and death [23]. The promastigotes of the parasite live inside macrophages. Here the Th1 cytokines, particularly IFN-g, appear to be able to activate macrophages to kill the parasites. When the infected macrophage eventually ruptures, it releases amastigotes, which have to find another macrophage to infect. Amastigote antigens can be thought of as similar to merozoite antigens; thus, antibodies could theoretically play a role here. However, the experimental evidence that immunity to leishmaniasis is T cell dependent is so voluminous that I put this notion foward with some reluctance.

1.8 Conclusions

It is perhaps a blessing that the by now quite substantial number of investigators who have been seeking to invent new and improved vaccines have not been deterred by the considerable difficulties that need to be faced after the preclinical research has reached its conclusion. I have covered a good many examples in which the correlates of protection are straightforward – substantial levels of high affinity antibodies to one or more important bacterial or viral antigens. We have seen examples in which strong experimental evidence suggests that what is needed is a substantial T cell attack, Th1 in some instances, CD8+ cytotoxic T cells in others, or perhaps both. This leaves several disease problems for which we simply do not know what the correlates of protection will be.

References

As already noted, vaccine research has always been a combination of fine basic science and enlightened empiricism. From that viewpoint, putative vaccines will simply have to be taken one by one, readied for clinical evaluation when experimental efficacy is convincing and the disease burden sufficient, and studied in humans, with the field trials probably providing the best correlates of protection. It is a grand challenge, particularly now that the position of the less privileged on our globe has been articulated and addressed. I hope that this necessarily cursory overview chapter has whetted your appetite for the many in-depth contributions in the remainder of this book.

References 1. H. E. Varmus, Lancet, 2002, Suppl. 360, s.1–s.4. 2. G. J. V. Nossal, Nat. Immunol., 2000, 1, 5–8. 3. B. Beutler, The Immunologist, 2000, 8, 123–130. 4. N. L. Letvin, D. H. Barouch, D. C. Montefiori, Annu. Rev. Immunol., 2002, 20, 73–99. 5. J. R. Mascola, S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse et al., J. Infect. Dis., 1996, 173, 340–348. 6. R. Wyatt, J. Sodroski, Science, 1998, 280, 1184–1188. 7. M. Moulard, S. K. Phogat,Y. Shu, A. F. Labrijn, X. Xiao, J. M. Binley, M. Y. Zhang, I. A. Sidorov, C. C. Broder, J. Robinson et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 6913–6918. 8. C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, Science, 1986, 234, 1563–1566. 9. L. Musey, J. Hughes, T. Schacker, T. Shea, L. Corey, M. J. McElraith, N. Engl. J. Med., 1997, 337, 1267–1274. 10. S. Rowland-Jones, J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabaly, A. Gallimore, T. Corrah et al., Nature Med., 1995, 1, 59–64. 11. A. J. McMichael, S. L. RowlandJones, Nature, 2001, 410, 980–987. 12. P. Anderson, Infect. Immun., 1983, 39, 233–238.

13. R. Schneerson, J. B. Robbins, C. Chu, A. Sutton, G. Schiffman,W. F. Vann, Prog. Allergy, 1983, 33, 144–158. 14. E. Miller, D. Salisbury, M. Ramsay, Vaccine, 2002, 20, S58–S67. 15. G. Del Giudice, A. Covacci, J. L. Telford, C. Montecucco, R. Rappuoli, Annu. Rev. Immunol., 2001, 19, 523– 563. 16. E. A. von Behring, S. Kitasato, Deutsche Med Wochenschr, 1890, 16, 1113–1114. 17. G. B. Mackaness, J. Exp. Med., 1962, 116, 381–406. 18. S. H. E. Kaufmann, E. Hug, U. VÄth, I. Müller, Infect. Immun., 1985, 48, 263–266. 19. K. A. Bojang, P. J. M. Milligan, M. Pinder, L. Vigneron, A. Alloueche, K. E. Kester, W. R. Ballou, D. J. Conway, W. H. H. Reece, P. Gothard et al., Lancet, 2001, 358, 1927–1934. 20. L. Schofield, M. Hewitt , K. Evans, M. A. Siomos, P. Seeberger, Nature, 2002, 418, 785–789. 21. A. Capron, Parasitol. Today, 1998, 14, 379–384. 22. J. K. Mwatha, G. Kimani, T. Kamau, G. G. Mbugua, J. H. Ouma, J. Mumo, A. J. Fulford, F. M. Jones, A. E. Butterworth, M. B. Roberts et al. J. Immunol., 1998, 160, 1992–1999. 23. R. M. Locksley, J. A. Louis, Curr. Opin. Immunol., 1992, 4, 413–418.

15

Part II Vaccination and Immune Response

19

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses Stefan Ehlers and Silvia Bulfone-Paus

2.1 Introduction

A generally accepted view of adaptive immunity and, in particular, effector T cell development and function distinguishes between type 1 and type 2 responses [1]. Infection with bacteria, viruses, and fungi or stimulation of innate immune cells with components thereof, induces type 1 immunity, mediated by T helper 1 (Th1) or T cytolytic 1 (Tc1) cells. In this context, type-1 cytokines (i. e., IL-2, IL-12, IL-15, IFN-g, IFN-a, and IFN-b) are particularly involved in cell-mediated immunity to intracellular microbes. In contrast, infections by extracellular pathogens and multicellular parasites or exposure to allergens induce type 2 responses. Type-2 cytokines (i. e., IL4, IL-5, IL-6, IL-10, and IL-13) play a crucial role in promoting humoral immunity and/or immune deviation to a nonprotective response (tolerance) [2]. More than 98 % of multicellular animal species cannot produce an adaptive immune response to a pathogen [3]. Immunological memory is thus a privilege of a few vertebrate hosts, and its primary purpose is to sterilize primary infection and provide resistance to reinfection with pathogens. However, during the time it takes for clonal expansion of antigen receptor-bearing lymphocytes to occur, the primordial system of innate defense takes care of the host. Individual functions of innate immune cells are not only involved in mitigating the damaging insults of microbial or tumor growth, but are also critical in directing the differentiation processes that, after antigen encounter, ultimately lead to T and B effector cells. Full-fledged adaptive immunity, in turn, is the result of cells of the adaptive immune system calling upon cells of the innate immune system, either to provide professional phagocytes to engulf and destroy pathogens (type 1 immunity) or to release toxic mediators so as to establish environments that are inhospitable to helminth or arthropod invaders (type 2 immunity). As a consequence, the innate and adaptive immune systems should be viewed as two interdependent parts of a single integrated immune system. Several novel vaccination strategies strive to exploit innate pathways of immune activation to manipulate, at will, quantitative and qualitative aspects of the acquired immune response. The purposes of this chapter are (1) to delineate some of the me-

20

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

chanisms that trigger the activation of innate immune cells during infection and (2) to describe the mediators and dissect the major molecular pathways regulating the differentiation of effector functions of adaptive immunity, while (3) highlighting implications for the development of novel vaccination strategies.

2.2 Activation of Innate Immunity: Sensing the Enemy

Innate defenses are primarily aimed at recognizing foreign structures and eliminating them. Since infectious pathogens have often evolved to subvert these mechanisms, specialized cells of the innate immune system are also capable of presenting digested antigen to T cells in a context and environment appropriate for optimal effector cell development. Activation of innate immunity to provide this context may be conceptually divided into two stages (Figure 2.1): (1) a phase of antigen sensing during which a combination of surface receptors detects the presence of non-self structures on invading microorganisms (‘detection phase’) and (2) a phase of translating this sensory information into a language understood by the cells of the adaptive immune system, e. g., chemokines and cytokines (‘transmission phase’) [4].

Fig. 2.1 Overall view of innate immunity shaping adaptive immune responses. Cells of the innate immune system (DC = dendritic cells; MC = mast cells) detect the presenceof foreign structures, such as pathogen-associated molecular patterns, by surfaceexpressed pattern-recognition receptors,and translate this sensory input into a language (cytokines, chemokines) understood by cells of the adaptive immune system, skewing the response to either T helper 1 (Th1)/T cytolytic 1 (Tc1) or Th2/Tc2-type immunity.

2.2 Activation of Innate Immunity: Sensing the Enemy

2.2.1 Pathogen-associated Molecular Patterns

The costimulatory signals required for differentiation of adaptive immune responses are exclusively turned on when cells of the innate defense system interact with pathogen-associated molecular patterns (PAMPs, i. e., highly conserved structures that are necessary for the survival of microorganisms). Many pattern-recognition receptors primarily serve the purpose of enhancing phagocytosis. For example, the macrophage mannose receptor (recognizing terminal mannose and fucose residues on microbial cell walls) or the macrophage scavenger receptor (recognizing polyanionic ligands such as double stranded RNA, lipopolysaccharide, and lipoteichoic acid) are mainly involved in clearing pathogens from the site of invasion [5, 6]. Discrimination between different classes of microorganisms, however, is afforded by the Toll-like receptors 1 through 9 [7, 8]. Since PAMPs have multiple effects on the signals generated by cells of the innate immune system and may therefore be useful as natural adjuvants in driving adaptive responses, they are described here in detail (Table 2.1).

Tab. 2.1 Recognition of pathogen structures via surface receptors on innate immune cells. Pattern-recognition receptors on innate immune cells

Pathogen-associated molecular patterns or similar insults

TLR1/TLR2

Triacylated lipopeptides

TLR2

Lipoproteins, lipoteichoic acid, glycolipids, modulin, arabinose-capped lipoarabinomannan, GPI-anchored molecules from parasites

TLR2/TLR6

Diacylated lipopeptides, zymosan

TLR3

Double-stranded RNA

TLR4

Lipopolysaccharides

TLR5

Flagellin

TLR7 and TLR8

Imidazoquinoline Derivatives

TLR9

Unmethylated CpG-motif oligonucleotides

Complement receptors

Activated components of complement coating microbial surface

Scavenger receptors

Polyanionic compounds, e. g., lipoteichoic acid, double-stranded RNA, lipopolysaccharide

Mannose–fucose receptor

Terminal mannose and fucose on microbial glycoproteins/ glycolipids

CD14

Monomeric lipopolysaccharides

CD48

Fimbrial protein FimH on enterobacteria

CD91

Heat-shock proteins 70, 90, gp 96; calreticulin

IgE/FceR-crosslink

Parasitic lectins

unknown

Allergens

21

22

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

Peptidoglycan (PG) is a component of all bacterial cells. PG chains consist of alternating b-MurNAc(1 ? 4)GlcNAc disaccharide units linked via b-(1 ? 4) glycosidic bonds [9]. Peptide sidechains, which are attached to the carboxyl group of muramic acid residues, are primarily composed of five amino acids (L-Ala-D-Glu-X-D-Ala-DAla, where X stands for L-Lys or diaminopimelic acid). Certain variations both in peptide and glycan structure exist [10], depending on the microorganism. PG was reported to stimulate macrophages and DCs via TLR2 [11]. A core constituent of PG, muramyl dipeptide (MurNAc-L-Ala-D-isoGln), however, is not recognized by TLR2, but does activate cells via the intracellular sensor protein NOD2 [12]. Lipopeptides and lipoproteins are components of both Gram-positive and Gram-negative cell walls and may be viewed as functional substituents of PG. A 19-kDa lipoprotein derived from M. tuberculosis activates cells via TLR2 [13]. Mycoplasma macrophage-activating lipopeptide-2 (MALP-2) requires the cooperation of TLR2 and TLR6 to initiate proinflammatory responses, whereas certain bacterial lipopeptides require dimerization of TLR2 with TLR1 [14–16]. Since MALP-2 is diacylated, and bacterial lipopeptides are triacylated, distinct structural requirements seem to dictate the dimerization partner for TLR2 [17]. Lipoteichoic acid (LTA) is an amphiphilic, negatively charged glycolipid found in most Gram-positive bacteria. Appropriate purification of LTA from Staphylococcus aureus, or chemical synthesis of LTA, have revealed LTA to be a potent and exclusive TLR2 stimulus [18]. Structural requirements include a lipid anchor and d-Ala substituents, as l-Ala derivatives reduce the activity by a factor of 100 [19]. Lipopolysaccharide (LPS) is a major component of the outer membrane of Gram-negative bacteria and is composed of polysaccharides attached to a lipid portion (lipoid A). Lipoid A is responsible for all biological activities ascribed to LPS, and the spatial conformation of lipoid A – in part determined by the number and length of acyl chains – determines biological activity on a given cell type [20, 21]. LPS recognition by TLR4 requires several accessory molecules. LPS is first bound to the LPS-binding protein LBP, which transfers LPS monomers to CD14 [22]. Exactly how CD14 facilitates LPS recognition is unclear, as is the exact role of MD-2, another component of the LPS-recognition complex [23]. Ultimately, LPS interacts with TLR4 and initiates both MyD88-dependent and -independent intracellular signaling cascades [24]. Some forms of LPS (e. g., from Porphyromonas gingivitidis or Leptospira interrogans) seem to be recognized by TLR2 [25, 26]. The structural requirements for this interaction are not clear, other than that this recognition is greatly enhanced in the presence of TLR1. Flagellin is the protein subunit of bacterial flagella. It is recognized by TLR5, possibly via highly conserved N- and C-terminal ends that form its hydrophobic core [27, 28]. TLR5 is expressed on the basolateral, but not the apical, surface of epithelium. Therefore, flagellin of invading pathogens, but not commensal bacteria, induces intestinal epithelial cells to mount an inflammatory response [29]. Unmethylated CpG DNA motifs are prevalent in bacterial but not vertebrate genomic DNA and are recognized by host cells bearing TLR9 [30]. TLR9 is not on the cell surface but is present in vesicles that fuse with lysosomes [31]. Some CpG motifs are very powerful activators of NK cells and induce IFN-a production by DC2 cells; other motifs are potent B cell activators, triggering cell cycle progression and antibody secretion

2.2 Activation of Innate Immunity: Sensing the Enemy

[32]. Nonspecific activation of innate responses afforded by CpG can increase resistance in animal models of intracellular infection and sepsis [33]. The ability of CpG to act as a potent adjuvant was confirmed in studies using both model antigens such as hen egg lysozyme or ovalbumin, as well as tumor antigens and antigens from infectious agents, including hepatitis B, HIV, and influenza virus or Leishmania major [32, 34, 35]. In fact, CpG is a stronger Th1-like adjuvant for inducing B and T cell responses than the gold standard, Freund’s complete adjuvant, as measured by its ability to drive the differentiation of cytolytic Tcells and IFN-g secreting cells [36]. We should note that optimal CpG motifs for activation differ between human beings and mice [37, 38]. Lipoarabinomannans (LAMs) are lipoglycans restricted to the genus Mycobacterium. The carbohydrate backbone is comprised of a D-mannan core and a D-arabinan domain. At its reducing end, the mannan core is terminated by a glycosyl-phosphatidylinositol anchor, and the arabinan domain is capped by either mannosyl (ManLAM) or phosphoinositide residues (PILAM) [39]. PILAMs prevalent in rapidly growing mycobacterial species (M. smegmatis) activate mammalian cells in a TLR2-dependent manner to secrete TNF and IL-12. In contrast, ManLAM is not an agonist for TLR2 [40, 41]. A small mycobacterial glycolipid, phosphatidyliositol dimannoside (PIM) also activates cells in a TLR2-dependent manner [42]. Double-stranded RNA (dsRNA) is produced by most viruses during their infectious cycle. DsRNA induces protein kinase R activation via TLR3 [43]. TLR3 is expressed predominantly on myeloid DCs, making them the prime targets for initiating innate responses against viruses [44]. TLR3-deficient mice also show a reduced response to the viral RNA mimic polyinosine-polycytidylic acid (poly I:C) [43]. Glycosylphosphatidylinositol-anchored molecules (GPI) are the predominant antigens present on the plasma membrane of protozoa such as Trypanosoma cruzi and Plasmodium falciparum [45]. GPI from T. cruzi are recognized by TLR2 and potently induce nitric oxide, TNF, and IL-12 in murine macrophages [46]. The PI moiety is mostly composed of unsaturated fatty acids, which are essential for optimal biological activity [47]. FimH is a subunit protein of type 1 fimbrial adhesins present in many enterobacterial species, e. g., Escherichia coli and Salmonella enterica. It can bind directly to a GPI-anchored receptor present also on the surface of mast cells (CD48). Ligation of CD48 by FimH-expressing bacteria results in bacterial uptake into caveolar chambers, promotes bacterial survival inside the cytosol, and has been linked to the release of inflammatory mediators by mast cells [48]. Heat shock proteins (HSPs) are released from necrotic cells during tissue injury or lysis of infected cells and can form stable complexes with peptides. Some of them, e. g., HSP60, can be recognized by TLR4 [49]; others, e. g., gp96, HSP90, and HSP70, interact with antigen-presenting cells via a common receptor, CD91 [50]. HSP-chaperoned peptides enter the macrophage/dendritic cells through CD91 and are processed and presented by the MHC class I and MHC class II molecules, resulting in stimulation of CD4 and CD8 T cells. HSP-DC interaction through CD91 leads to maturation of DCs and secretion of an array of proinflammatory cytokines [51]. Immunization of mammals with HSP-peptide complexes elicits potent responses against the HSP-chaperoned peptides [52].

23

24

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

Parasite-derived glycans and lectins, e. g., from Schistosoma mansoni eggs or filarial nematodes, trigger responses by TLR-independent mechanisms and are known for their potent induction of Th2 responses [53, 54]. One well characterized lectin from S. mansoni eggs, termed IPSE, leads to cross-linking of IgE on basophils which release IL-4 and IL-13, thus driving a strong Th2 response [55, 56]. All currently known PAMPs are derived from prokaryotic, fungal, viral, or protozoan pathogens, and which receptors are required for recognition of ‘patterns’ expressed by multicellular eukaryotic parasites or allergens is still unknown. Whether as-yet undefined molecular patterns are at all necessary to skew adaptive immunity towards a type 2 pattern after encounter with these different types of insults remains to be determined. It is possible that a different type of signal, such as the absence of PAMPs – similar to the lack of self-MHC I for NK-cell activation – is a stimulus in itself for triggering type 2 immunity [57]. 2.2.2 Host Cellular Sensors

At the immunological level, innate defenses rely mostly on granulocytes, mast cells (MC), macrophages, dendritic cells (DC), natural killer (NK), NKT, and gdT cells. These cells serve as a bridge between PAMPs and the antigen-specific cells of adaptive immunity, translating the sensory input of pattern-recognition receptors into soluble mediators that communicate with T and B cells via specific cytokine/chemokine receptors. Although many cell types contribute in various ways to linking innate and adaptive responses, we shall focus in this chapter – for the purpose of clarity, and because the two prototypic immune responses (type 1 and type 2) are regulated differently by them – on the two pivotally involved cell types, DCs and MCs. 2.2.2.1 Dendritic Cells The key cell type, and indeed the most potent type of any antigen-presenting cell, which is able both to sense a foreign insult and to orchestrate the cells of the adaptive immune system, is the dendritic cell [58]. Like other cell types within the immune system, immature (im) DCs are continuously produced from hematopoietic stem cells within the bone marrow. FLT-3 ligand and, to a lesser extent, granulocytemacrophage colony-stimulating-factor (GM-CSF) are the key growth and differentiation factors in vivo [59]. Immature DCs have long been considered ‘sentinels’ of the immune system, since they are specialized, relatively long-lived phagocytic cells, which are resident in most tissues, where they survey the local environment for pathogens [60]. Pattern-recognition receptors, in particular TLRs, allow DCs to recognize microbial antigens and mature into highly effective antigen-presenting cells, undergoing changes that enable them to activate pathogen-specific lymphocytes that they encounter in the lymph nodes [24]. Maturing DCs lose the ability to take up and process antigen, but they up-regulate surface expression of MHC class I and II, as well as of costimulatory and adhesion molecules such as CD86, CD80, CD40, and CD54. Mature DCs express proinflam-

2.2 Activation of Innate Immunity: Sensing the Enemy

matory cytokines like IL-6, IL-12, IL-18, IL-23, and IL-27 and are able to detect the expression of cytokines by infected cells, thus integrating different signals of danger. Another consequence of imDC stimulation is the up-regulation of CCR7 expression and down-regulation of CCR5 expression, which allows DCs to migrate to regional lymph nodes [61]. There, mature DCs prime naive T cells and, depending on the predominating maturation signals, differentially induce Th1 versus Th2 development [62]. Bacterial CpG DNA, double-stranded viral RNA, LPS, as well as CD40 ligand and IFN-g induce immature DCs to produce IL-12 and promote Th1 immune responses. In contrast, anti-inflammatory molecules such as IL-10, TGF-b, corticosteroids, and prostaglandin E2 promote Th2 or regulatory T cell immune responses [63]. The ability of DCs to prime greatly diverse immune responses is the result of different DC subsets and their unlimited plasticity [63]. In addition to immature DCs, stem cells also give rise to two types of DC precursors (pre-DCs) – monocytes (preDC1) and plasmacytoid cells (pre-DC2) – during hematopoiesis [58, 63]. Functionally, immature DCs and pre-DCs differ since pre-DCs are more directly involved in innate immunity against microbes. Pre-DC1 phagocytose and kill various bacteria and fungi, and pre-DC2s play a major role in the early antiviral innate immune response by producing large amounts of IFN-ab upon viral infection [58, 63, 64]. Therefore, these cells were also called ‘natural interferon-producing cells’ (NIPCs). Unlike other innate immune cells, such as neutrophils, eosinophils, and basophils, which die after performing their functions, pre-DC1 and pre-DC2 differentiate into DCs. When placed in culture with GM-CSF and IL-4, or after bacterial uptake, pre-DC1 differentiate into immature myeloid DCs. Upon CD40 ligand-induced activation, DC1 produce large amounts of IL-12 and prime Th1 and cytotoxic T cell immune responses. In contrast, pre-DC2 differentiate into immature DC2 in the presence of IL-3 or CD40 ligand, and mature DC2 primarily induce Th2 immune responses [65, 66]. Interestingly, when immature DC2 cells become infected by a virus, they take on the typical morphology of mature DCs and up-regulate costimulatory molecules, but acquire the distinct ability to differentiate naïve CD4+ T cells into producers of IFN-g and IL-10 [67, 68]. 2.2.2.2 Mast Cells Mast cells (MC) are derived from CD34+ stem cells. They initiate their differentiation in the bone marrow under the influence of stem cell factor and interleukin-3. Their final maturation takes place in connective tissues [69]. Within minutes following activation, mast cells extrude granule-associated substances such as histamine. Within hours, mast cell activation is followed by de novo synthesis of numerous cytokines (TNF-a, interleukins 1–10, IL-12, IL-13, IL-15, IL16, IL-18, IL-25, and GM-CSF) and chemokines (CCL2–5, CCL8, CCL11, IL-8) [70, 71]. Mast cells are long-lived and therefore able to respond repeatedly to the same stimulus [72]. In addition to their well-established central role in the pathogenesis of allergic disorders, MCs are now also appreciated as key effector cells in the induction of protective immune responses to bacteria [72–74]. This notion is supported by several inde-

25

26

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

pendent lines of evidence. MCs are found at the portals of entry of many infectious agents, i. e., within mucosal surfaces of the gastrointestinal and respiratory tracts, or in the skin close to peripheral nerves and often associated with blood vessels [75, 76]. MCs are equipped with a large variety and number of receptors to detect bacteria or signs of bacterial infection, including Toll-like receptors (TLRs), CD48, and complement receptors [77–80]. Furthermore, genetically MC-deficient animals, such as KitW/KitW-v mice, exhibit insufficient host defense responses in various models of bacterial infection, e. g., in cecal ligation and puncture-induced acute septic peritonitis [73, 81]. Finally, protection from bacterial infections in mice can be improved by enhancing MC numbers and/or function [82, 83]. Mast cells may exert many different effects on inflammatory processes: (1) in early stages, mast cells can be activated via TLRs in the peripheral tissues through interaction with microbes; (2) the release of cytokines, such as IL-4 and IL-13, may influence DC maturation, and as a consequence, biases T cell differentiation to a Th2/Tc2 phenotype; (3) mast cell-derived chemokines may recruit distinct subsets of inflammatory cells to the site, amplifying a predominantly type-2 response; and (4) activated mast cells can migrate to secondary lymphoid organs, where they can directly influence the development of T cell immune responses via the release of cytokines and the expression of costimulatory molecules [84, 85]. 2.2.3 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors

NKT cells are a subset of T cells that express a heavily-biased T cell receptor repertoire as well as the NK cell receptor CD161 and are deficient in immunological memory. In contrast to conventional T cells, NKT cells recognize glycolipid antigens presented by the nonpolymorphic MHC class I-like molecule CD1 d [86]. Although they are not strictly necessary for the generation of a polarized Th cell response, they can modulate the latter by secreting large amounts of IL-4, IL-10, IL-13, as well as IFN-g or TNF upon T cell receptor engagement [87, 88]. A glycosphingolipid originally isolated from the sea sponge Agelas mauritianus, a-galactosylceramide (a-GalCer), is a potent inducer of NKT activity [89]. Optimal stimulation of NKT cells requires direct contact between NKT cells and DC through CD40–CD40–ligand interactions and IL-12 production by DC [90]. Most studies indicate that a-GalCer enhances Th2 polarization, but Th1 differentiation may also be affected. In vivo activation of NKTcells with a-GalCer ameliorates the diseases caused by Cryptococcus neoformans or encephalomyocarditis virus and inhibits development of the intrahepatocytic stages of Plasmodium yoelii and Plasmodium berghei in mice [91–93]. a-GalCer potentiates protective immune responses induced by malaria vaccines [94].

2.3 Translating Innate Immune Activation into Regulatory Circuits

2.3 Translating Innate Immune Activation into Regulatory Circuits : Molecular Pathways Shaping Adaptive Immunity 2.3.1 TLR-initiated Signaling Cascades

Upon recognition of their cognate ligands, TLRs induce the expression of a variety of host defense genes. These include inflammatory cytokines and chemokines, antimicrobial peptides, costimulatory molecules, MHC molecules, and other effectors necessary to arm the host cells against the invading microorganism and to prime adaptive immunity. After ligation of TLRs, receptor dimerization occurs, triggering recruitment of the adapter MyD88 to the receptor complex. Association of the TIR (Toll/IL-1R) domain of MyD88 with the TIR part of TLRs facilitates association of the death domain of MyD88 with the IL-1R-associated kinase (IRAK) [95, 96]. IRAK then autophosphorylates, dissociates from the receptor complex, and interacts with TNF-receptor-associated factor 6 (TRAF6) [97]. TRAF6 leads to activation of MAP kinases and, by recruiting ECSIT (evolutionarily conserved signaling intermediate in Toll pathways), activates AP-1 and NF-kB [98, 99]. In MyD88-deficient mice, all TLR-9-initiated signals are abolished [100]. In contrast, TLR4-initiated signals in these mice are transduced by a different adaptor pathway (TIRAP), leading to up-regulation of some costimulatory molecules on DCs, but not to the induction of IL-12 [101]. In addition, IFN-inducible protein 10 (IP-10, CXCL-10) is induced even in MyD88-deficient macrophages in response to LPS [102]. Since IRF-3 is required for IP-10 gene transcription, it is likely that IRF-3 activation contributes to MyD88-independent pathways of TLR-mediated cell activation. Further regulatory mechanisms and signaling pathways downstream of TLRs exist, such as the Rac1–PI3K–AKT pathway activated by TLR2 [103]. Much remains to be learnt concerning the bifurcation of intracellular pathways that differentially determine type 1 vs. type 2 cytokine secretion during infection. In a mycobacterial infection model, TNF production was predominantly ERK-dependent, but independent of p38 MAP kinase activation, whereas IL-10 secretion was predominantly p-38-dependent, but independent of ERK signaling [104]. The use of small molecules as inhibitors of these putatively divergent pathways is an attractive novel option to selectively skew adaptive immune responses. At present, there is little evidence that specific TLRs differentially induce Th1 vs. Th2 responses. However, certain subsets of DCs respond differently to different PAMPs because they express different TLRs. Thus, plasmacytoid DCs express TLR7 and TLR9, whereas myeloid DCs express many of the remaining TLRs, in particular TLR3, but not TLR7 and TLR9 [105–107]. This may provide a means of fine-tuning the adaptive response by targeting only certain specialized DCs. TLR2-dependent activation of mast cells was reported to preferentially induce TNF, IL-4, IL-5, IL-6, and IL-13, whereas TLR4 ligation led to TNF, IL-1b, IL-6, and IL-13, but not IL-4 or IL-5 secretion. In the same study, TLR2-mediated mast cell activation led to degranulation, but TLR4-mediated activation did not [108].

27

28

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

All MyD88-dependent signals favor Th1 responses. In the absence of MyD88, no Th1 differentiation occurs, whereas Th2 development is unaffected by MyD88 deficiency [109]. It is unclear whether Th2 differentiation is determined by specific, asyet unknown intracellular signals, or whether it is simply the default pathway. Surprisingly, human patients with a complete, recessive IRAK-4 deficiency seemed to suffer only from pyogenic bacterial infections, but were apparently resistant to other ubiquitous microorganisms such as Mycobacterium avium, the latter being clinically highly relevant in patients with hereditary defects in the IL-12/IFN-g signaling pathways [110, 111]. The fact that significant protective immunity against common pathogens is afforded even in the absence of critical receptors and/or major signaling pathways indicates that there is substantial plasticity and room for compensatory mechanisms in immune cell activation [110, 112]. 2.3.2 Molecules Involved in Recruiting Effector Cells

Correct and efficient priming of adaptive responses, and indeed, the overall type of immunity itself, heavily depend on the rapid recruitment of professional antigenpresenting cells together with T and B lymphocytes. Thus, molecules coordinating cellular movement from the blood stream into either inflammatory sites or sites of antigen presentation, such as lymph nodes, play a critical role in directing the priming process (Figure 2.2). Conversely, differential regulation of surface receptors capable of detecting gradients of chemoattractants is a crucial factor determining the cellular environment in which priming of immune responses takes place [113]. 2.3.2.1 Defensins Defensins are 2–6-kDa, cationic, microbicidal peptides that are classified, on the basis of their size and pattern of disulfide bonding, into a, b, and y (extant only in primates) categories. a-Defensins are particularly abundant in neutrophils, whereas b-defensins are more often produced by epithelial cells lining for instance the skin, the lung, and the genitourinary tract [114]. Defensins are produced constitutively or in response to microbial products. Defensins can kill or inactivate a wide spectrum of bacteria, fungi, or viruses by disrupting the microbial membrane [115, 116]. However, defensins are not only direct effector molecules of innate antimicrobial immunity. They can also enhance phagocytosis [117, 118], induce the activation and degranulation of mast cells [119, 120], and stimulate bronchial epithelial cells to augment IL-8 production [121]. In this way, defensins are involved in recruiting and activating neutrophils into inflammatory sites. Because some defensins can enhance TNF and IL-1 production – while reducing IL-10 secretion – in monocytes, they may play a role in amplifying the local inflammatory response [122]. Human neutrophil-derived a-defensins 1 (HNP1) and HNP2 are chemotactic for human monocytes and T cells [123, 124]. They are selectively chemotactic for resting CD4/CD45RA and CD8 T cells, whereas human b-defensin 2 (hBD2) is chemotactic for immature DCs and CD45RO memory T cells by interacting with human CCR6 [125, 126]. HBD3 and hBD4 are also chemotactic for monocytes via an as yet unidenti-

2.3 Translating Innate Immune Activation into Regulatory Circuits

Fig. 2.2 Major chemokine pathways linking innate and adaptive immune responses. Cells of the innate immune system, triggered by structures on microbes, release chemokines, thereby recruiting different type of cells during the initial phase of the immune response. Type 1 responses are dominated by cells bearing CCR5 and CXCR3 (underlined) and are further amplified by IFN-g derived from NK and Th1 cells up-regulating expression of CXCR3binding chemokines. Type 2 responses are dominated by cells bearing CCR3 (italics) and are further modulated by IL-4 and IL13 derived from Th2 cells and mast cells. DC (dendritic cell), MC (mast cell), imDC (immature dendritic cell), MF (macrophage), NK (natural killer cell), PMN (polymorphonuclear granulocyte), eos (eosinophil granulocyte), baso (basophil granulocyte), EndC (endothelial cell), EpC (epithelial cell), PAMP (pathogen-associated molecular patterns).

fied receptor [127, 128]. Defensins may also be involved in the maturation of immature DCs either directly or indirectly, by inducing the production of TNF and IL-1 [116]. Defensins therefore appear to be important potentiators of T cell priming. Indeed, a mixture of HNP1–3, when administered intranasally simultaneously with ovalbumin into C57BL/6 mice, enhanced the production of OVA-specific serum IgG antibody and the generation of IFNg, IL-5, IL-6, and IL-10 secreting OVA-specific CD4+ T cells [129]. Intraperitoneal injection of HNP1–3, together with keyhole limpet hemocyanin or B-cell lymphoma idiotype Ag, into mice not only augmented the levels of Ag-specific IgG, but also enhanced the resistance of immunized mice to tumor challenge [130]. In addition, when murine (m) mBD2 and mBD3 were used in a DNA vaccine approach together with B cell lymphoma epitopes, mice generated potent humoral immune responses and developed antitumor immunity [131].

29

30

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

2.3.2.2 Chemokines Chemokines are a superfamily of small heparin-binding cytokines that induce directed migration of various types of leukocytes through interaction with a group of seven transmembrane G protein-coupled receptors [132]. TLR activation induces the release of chemokines from tissue macrophages and resident DCs. For example, both TLR2 and TLR4 ligation result in the expression of CCL3, CCL4, and CCL5. TLR2 signaling, however, preferentially leads to secretion of IL-8, while TLR4 signaling leads to CXCL10 production [133]. IL-8 recruits neutrophils to the site of chemokine production, whereas CXCL10 guides activated T cells into infected tissues. Thus, the discrimination of the pathogen by TLRs and the subsequent production of a distinct subset of chemokines is one of the earliest points at which the immune system tailors its response to specific pathogens. CCL3 and CCL4 are also crucial for the initial influx of CCR5+ NK cells into infected tissues, as demonstrated in murine models of cytomegalovirus and Toxoplasma gondii infection [134, 135]. These NK cells represent an important early source of IFN-g, providing an environment favorable for Th1 differentiation. IFN-g in turn induces the expression of the chemokines CXCL9, CXCL10, and CXCL11, instigating the recruitment of activated CXCR3+ T cells and NK cells into the tissue and amplifying the protective response [136]. CXCL10 may also be induced in the absence of IFN-g, after TLR ligation, and is also important for the initial influx of CXCR3+ NK cells and T cells. In terms of modulating humoral immunity, CCL3 treatment stimulated strong antigen-specific serum IgG and IGM responses, and CCL4 administration promoted higher serum IgA and IgE responses, as well as higher titers of antigen-specific mucosal secretory IgA levels in mice. These chemokines may therefore differentially enhance serum and mucosal humoral immune responses [137]. ImDCs express several chemokine receptors, including CCR1, CCR5, and CCR6 [138, 139]. These are important for recruiting imDCs in response to early pathogeninduced release of CCL3, CCL4, and CCL20 and for keeping them in the tissue. After TLR-mediated activation, however, DCs down-modulate the expression of these chemokine receptors and up-regulate the expression of CCR7, allowing them to respond to CCL19 and CCL21 expressed in lymphatic tissues [61]. This serves as a stimulus for DCs to leave the tissue and ultimately migrate into the T cell-rich regions of lymph nodes, where priming of T cells occurs. Generally speaking, Th1-dominated responses are associated with the recruitment of CCR5- or CXCR3- bearing cells, whereas Th2-dominated responses are more closely dependent on the influx of CCR3-expressing cells [140]. Mast cell granule-derived serine proteases also play a major role in recruiting cells to the site of infection [141]. Chymase, a serine protease found in human mast cells, induces monocyte and neutrophil migration directly [142]. Murine mast cell protease-6, also known as tryptase, induces neutrophil extravasation indirectly by enhancing endothelial cell IL-8 production [143]. In addition, histamine is a major mediator synthesized by mast cells. Vasodilation and inflammation are among the prime consequences of it being released from the granules in which it is stored. Histamine promotes the expression of Th2 polarizing (e. g., IL-6 and IL-10) cytokines from hu-

2.3 Translating Innate Immune Activation into Regulatory Circuits

man lung macrophages [144]. Histamine also inhibits IL-12 production and augments IL-10 secretion of maturing monocyte-derived DC, resulting in a change from Th1 to Th2 in their T cell-polarizing function [145]. In addition, activated human plasmacytoid DCs respond to histamine by a marked down-regulation of IFN-a and TNF [146]. Most importantly, mast cell granules contain preformed TNF, which is a major mediator of neutrophil influx into sites of mast cell activation. Upon appropriate stimulation, mast cells are also capable of releasing – without degranulation – CCL20, a potent chemoattractant for imDC and T cells [147]. 2.3.3 Molecules Involved in T and B Cell Differentiation

Cytokines provide the most direct link between innate and adaptive immunity, because they regulate the communication between dendritic cells, lymphocytes, and other host cells in the course of an immune response [148, 149]. The local milieu of cytokines determines the commitment of T cells to a Th1/Tc1 or Th2/Tc2 type, as well as the immunoglobulin class switch in B cells, and drives the overall immune response towards either tolerance or immunity (Figure 2.3).

Fig. 2.3 Major cytokine pathways linking innate and adaptive immune responses. Cells of the immune system, triggered by structures on microbes, release cytokines that skew T cell development into a Th1/Tc1 or a Th2/Tc2 pathway. Feedback loops involving IFN-g (type 1 immunity) or IL-10, TGF-b, IL-4, and IL-13 (type 2 immunity) are indicated. DC (dendritic cell), MC (mast cell), Treg (regulatory, CD4+CD25+ T cell), Tmem (memory T cell).

31

32

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

2.3.3.1 Th1-inducing Cytokines Type I interferons (IFNs) were among the first cytokines identified, originally because of their antiviral activity and their effects on the cells of the innate response. IFNs have recently been shown to play an important role in connecting innate and adaptive immunity by acting on T cells and dendritic cells [4]. The term IFN-a/b defines a large group of closely related cytokines, which exert their activity by binding to a common receptor, the IFN-ab receptor. These cytokines include IFN-a, -b, -d, -t, -o and -k [150]. Although virtually any cell type can express IFN-a/b following viral infection, NIPCs produce 200–1000 times more IFN than other blood cells after microbial infection or after stimulation with bacterial components such as LPS and bacterial DNA [66, 151, 152]. IFN-a/b produced by NIPCs and macrophages can enhance the efficiency of the innate immune response by activating natural killer and other host reactive cells. Type I IFNs provide important signals for the differentiation and activation of DCs. In particular, IFN-a/b promotes the rapid differentiation of GM-CSF-treated human monocytes into DCs with enhanced T cell stimulatory capacity [4, 153]. Importantly, IFN-a/b plus GM-CSF-matured DCs induced a potent primary antibody response when pulsed with antigen and injected into SCID mice reconstituted with autologous peripheral blood lymphocytes [154]. In addition, IFN-a/b treatment of imDCs induces phenotypic and functional maturation of these cells, as shown by their expression of DC markers and their migratory response to chemokines [155]. The effects of IFN-a/b on DC maturation imply that they can exert an adjuvant activity. Indeed, experiments in mice revealed that (1) type I IFNs are extremely potent adjuvants when injected into immuncompetent mice with a reference antigen, (2) IFNs act directly on DCs, and (3) the natural adjuvant activity associated with infectious agents is mediated by IFN-a/b [149]. Interferon-gamma (IFN-g) is a potent activator of the antimicrobial functions of phagocytes and plays an important role in resistance to many pathogenic bacteria, fungi, and intracellular parasites [156]. It is mainly produced by Th1 cells and natural killer cells, but other T cell subsets such as NKT cells, CD8+ T cells, and gdT cells are also capable of secreting IFN-g. Furthermore, macrophages, dendritic cells, and B cells are able to produce IFN-g when appropriately stimulated [157]. Both type I and type II interferons activate natural killer (NK) cells to kill virus-infected cells and release cytokines. Interleukin-18 (IL-18) is a proinflammatory cytokine that belongs to the IL-1 cytokine family, due to its structure, receptor family, and signal transduction pathways [158, 159]. Similar to IL-1b, IL-18 is synthesized as a precursor requiring caspase-1 for cleavage into an active IL-18 molecule. Produced mainly by antigen-presenting cells, it induces the production of Th1 cytokines, e. g., IFN-g, and enhances cellmediated cytotoxicity in the presence of IL-12 [160, 161]. Interestingly, IL-18 in the absence of IL-12 induces the production of Th2-related cytokines from T and NK cells and basophils/mast cells. Therefore, IL-18 should be seen as a cytokine that enhances innate immunity and both Th1- and Th2-driven immune responses [162]. Interleukin-15 (IL-15) and IL-2 both utilize the IL-2Rb and the IL-2Rg chain as receptor structures; therefore, the two cytokines induce similar biological activities,

2.3 Translating Innate Immune Activation into Regulatory Circuits

such as stimulating NK, T, and B cells to proliferate, secrete cytokines, become cytotoxic, or produce antibodies [163]. Nevertheless, there are major differences between these two cytokines in terms of their cellular origins and the mechanisms controlling their synthesis and secretion. In contrast to the predominantly T cell-restricted expression of IL-2 transcripts, wide-spread constitutive expression of IL-15 mRNA occurs in a variety of tissues, including placenta, skeletal muscle, kidney, lung, heart, fibroblasts, epithelial cells, and activated monocytes. However, IL-15 protein is produced by only a limited number of cells, such as activated macrophages and epithelial cells [163]. Findings obtained from gene-targeted mice deficient in individual components of the IL-2/IL-15 system demonstrate distinct roles of IL-15 and IL-2 for the activation of the innate immune system [164, 165]. IL-15 is of pivotal importance for maintaining NK cell homeostasis, for promoting the differentiation of gdT cells, and for inducing CD8+ memory T cells [163]. IL-15 also promotes monocyte differentiation into Langerhans' cells [166]. Furthermore, some of the effects induced by IFN-a on the differentiation and/or activation of DCs seem to be mediated by IL-15, which is produced by DCs in response to IFN-a [167, 168]. In addition, IL-15 is a potent inhibitor of apoptosis [169–171]. Phagocytosis and chemokine production of neutrophils are strongly enhanced by IL-15 [172–174]Ë and expression of IL-15 in macrophages is upregulated in response to numerous signals that trigger innate immune responses, such as LPS, mycobacteria, or Toxoplasma gondii [175]. Most importantly, exogenous IL-15 improves host defense against and/or clearance of Salmonella [176], Plasmodium falciparum [177], and Cryptococcus neoformans [178]. Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine formed of a 35-kDa light chain (p35) and a 40-kDa heavy chain (p40), which is produced mainly by DCs and phagocytes (monocytes/macrophages and neutrophils) in response to pathogens during infection [179–181]. In synergy with TNF and IL-18, IL-12 can induce the production of large amounts of IFN-g by NK cells, a crucial event in the early phase of the innate immune response [182, 183]. IL-12 acts not only on NK cells, but also on NKT cells and T cells, inducing proliferation, cytotoxic activity, and the differentiation of Th1 cells [182]. T cells and NK cells, in turn, enhance the production of IL-12 through IFN-g giving rise to positive feedback during Th1 immune responses. Surprisingly, both IL-4 and IL-13 are also potent IL-12 inducers [184]. Recent data argue against an absolute requirement of IL-12 for Th1 responses, since two new members of the family of IL-12p40 related heterodimeric cytokines, IL-23 and IL-27, are also involved in the maturation of Th1 responses [185, 186]. Interleukin-23 (IL-23) is a heterodimer, comprising IL-12p40 and the recently cloned IL-23-specific p19 subunit, that binds to a receptor complex composed of the IL-12Rb1 subunit and a private IL-23R [183, 185]. IL-12 and IL-23 both promote cellular immunity by inducing IFN-g production and proliferative responses in target cells. IL-23, which is produced predominantly by macrophages and dendritic cells, differs from IL-12 in the T cell subsets that it targets. Whereas IL-12 acts on naïve and effector CD4+ T cells, IL-23 preferentially acts on memory CD4+ T cells. Recent studies of IL-23 receptor expression and IL-23 overexpression in transgenic mice re-

33

34

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

vealed that IL-23 plays a crucial role in autoimmune inflammation in the brain by a direct effect on macrophage function [187]. Interleukin-27 (IL-27) is a newly discovered heterodimeric cytokine that consists of an IL-12p40-related protein, EBI-3 (Epstein–Barr virus-induced gene 3), and p28, an IL-12p35-related polypeptide [183, 186]. IL-27 is a strong inducer of IFN-g production, particularly in synergy with IL-12 and IL-18. Mice deficient for EBI-3 have markedly decreased numbers of invariant NKT cells, which, in addition, produce significantly less IL-4 and IFN-g than normal mice [87]. Thus, EBI-3 also plays a critical regulatory role in the induction of Th2-type immune responses. IL-27 is produced by activated antigen-presenting cells and is mostly involved in the Th1 commitment of naive CD4+ T cells, mediated by IL-27R-dependent up-regulation of the major signal-transducing IL-12Rb2 chain [188]. In contrast, IL-23 (like IL-15) is critically important for the maintenance of immunological memory [183, 186], since IL-23R is expressed on memory, but not on naïve T cells [185, 189]. Interleukin-6 (IL-6) is a potent differentiation factor for B and T cells. IL-6 produced upon TLR ligation in DCs is a necessary requirement for T cell activation whenever CD4+CD25 regulatory T cells are present [190]. Indeed, IL-6-deficient mice were severely compromised in their induction of OVA-specific immune responses as long as CD4+CD25+ cells were present, but not when the latter were removed. Therefore, innate immune recognition by TLRs seems to control the activation of adaptive immune responses by at least two distinct mechanisms: the induction of costimulatory molecules on DCs and the production of IL-6, which renders pathogen-specific T cells refractory to the suppressive activity of CD4+CD25+ regulatory T cells. Since release of suppression is necessary for efficient T cell priming during vaccination, IL-6 is an attractive candidate for an immunopotentiating adjuvant. Indeed, when recombinant human IL-6 was used as an adjuvant in a subunit vaccine against tuberculosis consisting of the culture filtrate proteins of Mycobacterium tuberculosis emulsified in the adjuvant dimethyl-dioctadecylammonium bromide, an increased Th1 response characterized by enhanced IFN-g production and cell proliferation was observed [191]. Moreover, a specific local IgA response to heterologous antigen was increased in the lungs of mice when genes for murine IL-6 were coexpressed in recombinant vaccinia virus and inoculated intranasally [148]. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is by far the hematopoietic growth factor most widely used to augment immune responses [192]. It was initially defined as a survival and growth factor for hematopoietic progenitor cells and as a differentiation and activating factor for granulocytic and monocytic cells [193–195]. GM-CSF plays a crucial role in vitro for the differentiation of dendritic cells from precursor cells from bone marrow and peripheral blood [196]. GM-CSF is secreted by several different cell types, including fibroblasts, endothelial cells, and smooth muscle cells, after stimulation by proinflammatory cytokines such as IL-1 and TNF-a [197, 198]. LPS stimulates GM-CSF secretion from monocytes or macrophages, which could further potentiate the cellular response to LPS. It has been known since the early 1970s that endotoxin administration to mice raises the serum levels of GM-CSF [199]. The injection of GM-CSF into mice leads to increased numbers of neutrophils and cycling peritoneal macrophages [200]. It was

2.3 Translating Innate Immune Activation into Regulatory Circuits

therefore proposed that GM-CSF blockade may have some antiinflammatory effects and be employed for host protection. The immunomodulatory effects, which include the activation and augmentation of many of the functions of neutrophils, monocytes, macrophages, and dendritic cells, make this cytokine a candidate for a natural vaccine adjuvant [201, 202]. Indeed, the use of soluble GM-CSF (fusion protein), as well as gene-transduced, plasmid DNA, in vaccination-based therapies has proven to be relevant for the induction of cellular as well as humoral immune responses [203–205] therefore enhancing host defenses against a broad spectrum of invading organisms. 2.3.3.2 Th2-inducing Cytokines Interleukin-4 (IL-4) is one of a number of cytokines produced by activated mast cells and plays a predominant role in many immune and inflammatory reactions. Two biological activities have been defined in detail: IL-4 induces selective IgG1 and IgE isotype switching in B cells and promotes the differentiation of naïve CD4 T cells into a subset of T helper cells that express IL-4 as well as IL-5, IL-10, and IL-13 [206]. These cytokines and Ig isotypes are hallmarks of a Th2 response and play a protective role in immunity to extracellular pathogens [2]. Interleukin-13 (IL-13) belongs to the Th2 cytokine family and is structurally related to IL-4, belonging to the same a-helix protein family [207, 208]. The production of IL-4 and IL-13 is restricted to activated T lymphocytes (in particular, Th2 cells), mast cells, basophils, natural killer cells, and dendritic cells [208, 209]. Both cytokines are functionally active on a wide variety of cell types such as macrophages, NK cells, eosinophils, and mast cells. IL-4 and IL-13 act synergistically to promote DC maturation induced by bacterial products or proinflammatory mediators (such as TNF or CD40 ligand), as evaluated by up-regulation of MHC class II and costimulatory molecules [210]. Both cytokines show important immunosuppressive and antiinflammatory activities, which include the inhibition of proinflammatory cytokines (like IL-1, IL-6, IL-10, IL-12, and TNF-a) and chemokines (like IL-8, CCL3–5, and CCL11). In mice, a coordinate regulatory sequence element, situated in the intergenic region between the genes for IL-4 and IL-13, is critical for the optimal expression of type 2 cytokines. Mice deficient in this regulator had normal IL-4 producing mast cells, but their capacity to develop Th2 cells was completely absent in vitro and in vivo [211]. Initially, IL-13 was thought to be functionally redundant with IL-4 as a predominant antiinflammatory factor secreted during type-2 T cell responses. However, IL-13 possesses several additional properties that distinguish it from IL-4 [212]; for example, IL-13 plays a key protective role in the expulsion of helminths from the gut and, unlike IL-4, is the major contributor to granulomatous pathology in schistosomiasis [213, 214]. Therapeutic administration of IL-13 inhibitors to mice successfully prevents allergic responses and Schistosoma egg-induced lung pathology [215]. Agonist IL-13-treatment of mice, by inducing mastocytosis, eosinophilia, IgE synthesis, and mucus production, protects against ectoparasites and gastrointestinal worms and suppresses inflammation induced by Th1 cytokines [216]. Future studies are required to understand if this scenario holds true in humans.

35

36

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

Interleukin-10 (IL-10) was initially described as a mouse Th2 cell product, but is now known to be produced by a wide range of cell types, including T cells, B cells, keratinocytes, monocytes/macrophages, and dendritic cells. It activates B lymphocytes and NK cells and has an inhibitory effect on T cell and macrophage activation [217]. IL-10 reduces the production of proinflammatory cytokines such as TNF-a, IL-1, IL-6, IL-12, IFN-g, and GM-CSF, but also of chemokines like IL-8 and CCL3. Furthermore, IL-10 down-regulates the production of molecules important in triggering specific immunity such as MHC class II and costimulatory molecules, e.g., CD86, thereby inhibiting antigen-presenting cell maturation [218]. Some bacterial pathogens, like mycobacteria, Bordetella pertussis, or Yersinia enterocolitica, have developed mechanisms for modulating cytokine production by host cells. These bacteria can induce the production of antiinflammtory cytokines, such as IL-10 and TGF-b, which dampen the immune response [219–221]. These immunosuppressive cytokines may also contribute to the generation of so-called regulatory T cells which down-regulate immune activation. It is noteworthy that IL-10 also is a potent stimulator of NK cell activity [222]. Cytotoxic lysis of infected cells may contribute to the clearance of pathogens and facilitate antigen acquisition from dead cells for cross-priming by activated dendritic cells, providing a link between the innate and the adaptive immune responses [223, 224]. The transforming growth factor (TGF)-b family comprises three closely related cytokines with potent immunoregulatory proteins that affect the process of inflammation and repair both positively and negatively [225]. TGF-b regulates processes such as angiogenesis, chemotaxis, fibroblast proliferation, and the controlled synthesis and degradation of matrix proteins, e. g., collagen and fibronectin [226]. Many cell types express TGF-b constitutively and produce more when stimulated. These include macrophages, T and B cells, platelets, and fibroblasts. Importantly, TGF-b is also produced by regulatory T cells, which down-modulate the function of Th1 and other immune cells. TGF-b inhibits immune functions of T and B cells by reducing TNF-a and IL-1 production in peripheral blood monocytes and directly inhibits DC maturation. In a model of murine malaria, low amounts of active TGF-b production by splenic mononuclear cells were associated with a lethal outcome, and anti-TGF-b treatment transformed a normal resolving infection into a lethal one characterized by a hyperproduction of proinflammatory cytokines [227].

2.4 Implications for Vaccine Development

Inactivated pathogens and highly purified recombinant proteins or peptides without adjuvants do not elicit efficient Th cell responses. Some novel chemical adjuvants (such as ISCOMS or SBAS4) can enhance antigen-specific T cell responses, but the magnitude is often still not sufficient [228, 229]. Therefore, it is imperative to optimize strategies that will enhance antigen presentation by inducing a favorable costimulatory milieu. Biological adjuvants do this by activating TLRs.

2.4 Implications for Vaccine Development

Live carrier vaccines in particular have the advantage of bringing a variety of strongly activating PAMPs with them. For example, the widely used tuberculosis vaccine strain, Mycobacterium bovis BCG, is a powerful inducer of T cell responses because it contains PG, LAM, lipoproteins, lipopeptides, and CpG motifs as TLR agonists, and because it can persist for some time within antigen-presenting cells, providing long-lasting T cell priming [230]. However, the particular combination of PAMPs in a given bacterial strain may also favor some undesired responses because of a significant cross-regulation of PAMPs interacting simultaneously with different pattern recognition receptors. For instance, ligation of the mannose receptor (with ManLAM, present on certain mycobacterial strains) at the same time as stimulation of TLRs (e. g., TLR4 with LPS) reduces the production of IL-12 in DCs compared to DCs stimulated with the TLR agonist only [231]. This may effectively diminish the adjuvant Th1-inducing potency of, for example, a BCG carrier vaccine. Similar mechanisms may be operative in other bacterial carrier systems, although the precise ligands and receptors involved are probably different. As a consequence, the combination of highly purified recombinant molecules (PAMPs, chemokines, and cytokines) may prove to be superior to bacterial vaccine strains, because their individual dosage and composition can be modified to fit the particular requirements of the vaccinee. In a rational approach, an optimal adjuvant should attract professional antigenpresenting cells, and this may be best achieved by mimicking the damage signals normally provided by microbial components. Thus, modified – i. e., detoxified – forms of LPS, lipopeptides, dsRNA, or CpG DNA will induce an array of chemokines, and empirical studies are now needed to precisely determine the composition of the ‘cocktail’ necessary to recruit a defined set of inflammatory cells (e. g., only imDC but no neutrophils). Adjuvants should then facilitate the entry of antigens inside the cell, e. g., by enhancing the expression of CD14, scavenger receptors, mannose receptor, etc. An optimal adjuvant should also provide signals leading to both DC maturation and T cell costimulation. Depending on the type of immune response desired, the adjuvant should induce a heavily biased cytokine environment, directing either Th1 or Th2 development. Again, a mixture of chemokines and/or cytokines, together with selected and partially modified PAMPs, may best accomplish this. The current challenge is to identify the distinct signaling pathways operative in inducing this biased repertoire of cytokines and to provide exactly the right quantity and quality of stimuli to achieve the desired skewing of adaptive responses [232]. Because many chemokines and cytokines are pleiotropic, significant interference and cross-regulation events may lead to side-effects and less-than-expected performance of such adjuvant cocktails, and thorough in vivo investigation of their safety and efficacy is needed before they can be used in humans. Finally, it is possible that no mixture of vectors or adjuvants can provide all the stimuli in the correct combination necessary to elicit optimal cellular responses. Therefore, prime–boost scenarios using different presenting/adjuvant strategies with the same antigen consecutively, may result in the strongest elicitation of antibody, lymphoproliferative, and cytotoxic T cell responses [233]. In this way, vaccination protocols would make use of the full armamentarium that the innate immune system itself deploys to shape an optimal adaptive immune response.

37

38

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

References 1. Street NE, Mosmann TR, Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 1991, 5, 171–177. 2. Swain SL, Bradley LM, Croft M, Tonkonogy S, Atkins G, Weinberg AD, Duncan DD, Hedrick SM, Dutton RW, Huston G, Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol. Rev. 1991, 123, 115– 144. 3. Parish CR, O’Neill ER, Dependence of the adaptive immune response on innate immunity: some questions answered but new paradoxes emerge. Immunol. Cell Biol. 1997, 75, 523–527. 4. Le Bon A, Tough DF, Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 2002, 14, 432–436. 5. Fraser IP, Koziel H, Ezekowitz RA, The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin. Immunol. 1998, 10, 363–372. 6. Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J, Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. 2000, 191, 147–156. 7. Medzhitov R, Janeway C, Jr., The Toll receptor family and microbial recognition. Trends Microbiol. 2000, 8, 452–456. 8. Medzhitov R, Janeway C, Jr., Innate immune recognition: mechanisms and pathways. Immunol. Rev. 2000, 173, 89– 97. 9. Dmitriev BA, Ehlers S, Rietschel ET, Layered murein revisited: a fundamentally new concept of bacterial cell wall structure, biogenesis and function. Med. Microbiol. Immunol. (Berlin) 1999, 187, 173–181. 10. Schleifer KH, Kandler O, Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 1972, 36, 407–477. 11. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Take-

12.

13.

14.

15.

16.

17.

18.

da K, Akira S, Differential roles of TLR2 and TLR4 in recognition of gramnegative and gram-positive bacterial cell wall components. Immunity 1999, 11, 443–451. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G, Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J. Biol. Chem. 2003, 278, 5509–5512. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, Akira S, Norgard MV, Belisle JT, Godowski PJ, Bloom BR, Modlin RL, Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 2001, 291, 1544–1547. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A, The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA 2000, 97, 13766–13771. Underhill DM, Ozinsky A, Smith KD, Aderem A, Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Natl. Acad. Sci. USA 1999, 96, 14459– 14463. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S, Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 2001, 13, 933–940. Takeda K, Takeuchi O, Akira S, Recognition of lipopeptides by Toll-like receptors. J. Endotoxin. Res. 2002, 8, 459– 463. Morath S, Stadelmaier A, Geyer A, Schmidt RR, Hartung T, Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 2002, 195, 1635– 1640.

References 19. Deininger S, Stadelmaier A,Von Aulock S, Morath S, Schmidt RR, Hartung T, Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J. Immunol. 2003, 170, 4134– 4138. 20. Alexander C, Rietschel ET, Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res . 2001, 7, 167–202. 21. Seydel U, Schromm AB, Blunck R, Brandenburg K, Chemical structure, molecular conformation, and bioactivity of endotoxins. Chem. Immunol. 2000, 74, 5–24. 22. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC, CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249, 1431–1433. 23. Schromm AB, Lien E, Henneke P, Chow JC,Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT, Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J. Exp. Med. 2001, 194, 79–88. 24. Takeda K, Kaisho T, Akira S, Toll-like receptors. Annu. Rev.Immunol. 2003, 21, 335–376. 25. Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint G, I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, Underhill DM, Kirschning CJ,Wagner H, Aderem A, Tobias PS, Ulevitch RJ, Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2001, 2, 346–352. 26. Hirschfeld M,Weis JJ, Toshchakov V, Salkowski CA, Cody MJ,Ward DC, Qureshi N, Michalek SM,Vogel SN, Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 2001, 69, 1477– 1482. 27. Hayashi F, Smith KD, Ozinsky A, Hawn TR,Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A, The innate immune response to bacterial flagellin is mediated

28.

29.

30.

31.

32.

33.

34.

35.

36.

by Toll-like receptor 5. Nature 2001, 410, 1099–1103. Samatey FA, Imada K, Nagashima S, Vonderviszt F, Kumasaka T, Yamamoto M, Namba K, Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature 2001, 410, 331–337. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL, Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 2001, 167, 1882–1885. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S, A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB,Wagner H, CpGDNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 1998, 17, 6230–6240. Ashkar AA, Rosenthal KL, Toll-like receptor 9, CpG DNA and innate immunity. Curr. Mol. Med. 2002, 2, 545– 556. Wagner H, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 2002, 5, 62–69. Rhee EG, Mendez S, Shah JA,Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA,Vaccination with heatkilled leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J. Exp. Med. 2002, 195, 1565–1573. Kojima Y, Xin KQ, Ooki T, Hamajima K, Oikawa T, Shinoda K, Ozaki T, Hoshino Y, Jounai N, Nakazawa M, Klinman D, Okuda K, Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002, 20, 2857–2865. Krieg AM, CpG DNA: a novel immu-

39

40

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

37.

38. 39.

40.

41.

42.

43.

44.

45.

nomodulator. Trends Microbiol. 1999, 7, 64–65. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB, Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 2001, 98, 9237–9242. Krieg AM, Now I know my CpGs. Trends Microbiol. 2001, 9, 249–252. Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, Puzo G, Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. Microbes. Infect. 2002, 4, 945–953. Means TK,Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ, Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 1999, 163, 3920– 3927. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT,Vogel SN, Fenton MJ, Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J. Immunol. 2001, 166, 4074–4082. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ, Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukoc. Biol . 2001, 69, 1036–1044. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001, 413, 732–738. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P, Mantovani A, Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 2000, 164, 5998–6004. Almeida IC, Gazzinelli RT, Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and func-

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

tional analyses. J. Leukoc. Biol. 2001, 70, 467–477. Campos MA, Almeida IC, Takeuchi O, Akira S,Valente EP, Procopio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT, Activation of Tolllike receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. Immunol. 2001, 167, 416–423. Almeida IC, Camargo MM, Procopio DO, Silva LS, Mehlert A, Travassos LR, Gazzinelli RT, Ferguson MA, Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents. EMBO J. 2000, 19, 1476–1485. Malaviya R, Georges A, Regulation of mast cell-mediated innate immunity during early response to bacterial infection. Clin. Rev. Allergy Immunol. 2002, 22, 189–204. Ohashi K, Burkart V, Flohe S, Kolb H, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol. 2000, 164, 558–561. Binder RJ, Han DK, Srivastava PK, CD91: a receptor for heat shock protein gp96. Nat. Immunol. 2000, 1, 151–155. Binder RJ, Anderson KM, Basu S, Srivastava PK, Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol. 2000, 165, 6029–6035. Srivastava P, Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2002, 2, 185–194. Ehigiator HN, Stadnyk AW, Lee TD, Extract of Nippostrongylus brasiliensis stimulates polyclonal type-2 immunoglobulin response by inducing de novo class switch. Infect. Immun. 2000, 68, 4913–4922. Whelan M, Harnett MM, Houston KM, Patel V, Harnett W, Rigley KP, A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J. Immunol. 2000, 164, 6453–6460. Schramm G, Falcone FH, Gronow A, Haisch K, Mamat U, Doenhoff MJ, Oliveira G, Galle J, Dahinden CA, Haas H, Molecular characterization of an interleukin-4-inducing factor from

References

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

Schistosoma mansoni eggs. J. Biol. Chem. 2003, 278, 18384–18392. Okano M, Satoskar AR, Nishizaki K, Harn DA, Jr., Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response. J. Immunol. 2001, 167, 442–450. Barton GM, Medzhitov R, Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 2002, 270, 81–92. Liu YJ, Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001, 106, 259–262. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C, Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 2001, 22, 41–47. Banchereau J, Steinman RM, Dendritic cells and the control of immunity. Nature 1998, 392, 245–252. Sallusto F, Lanzavecchia A, Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 2000, 177, 134–140. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML, T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 1999, 20, 561–567. Liu YJ, Kanzler H, Soumelis V, Gilliet M, Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2001, 2, 585–589. Liu YJ, Kadowaki N, Rissoan MC, Soumelis V, T cell activation and polarization by DC1 and DC2. Curr. Top. Microbiol. Immunol. 2000, 251, 149–159. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ, The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 1997, 185, 1101–1111. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M, Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5, 919–923.

67. Kadowaki N, Antonenko S, Lau JY, Liu YJ, Natural interferon alpha/betaproducing cells link innate and adaptive immunity. J. Exp. Med. 2000, 192, 219– 226. 68. Cella M, Facchetti F, Lanzavecchia A, Colonna M, Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 2000, 1, 305– 310. 69. Rodewald HR, Dessing M, Dvorak AM, Galli SJ, Identification of a committed precursor for the mast cell lineage. Science 1996, 271, 818–822. 70. Kobayashi H, Ishizuka T, Okayama Y, Human mast cells and basophils as sources of cytokines. Clin. Exp. Allergy 2000, 30, 1205–1212. 71. Marshall JS, King CA, McCurdy JD, Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr. Pharm. Des. 2003, 9, 11–24. 72. Feger F,Varadaradjalou S, Gao Z, Abraham SN, Arock M, The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol. 2002, 23, 151–158. 73. Echtenacher B, Mannel DN, Hultner L, Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996, 381, 75–77. 74. Galli SJ, Maurer M, Lantz CS, Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 1999, 11, 53–59. 75. Henz BM, Maurer M, Lippert U, Worm M, Babina M, Mast cells as initiators of immunity and host defense. Exp. Dermatol. 2001, 10, 1–10. 76. Weber A, Knop J, Maurer M, Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br. J. Dermatol. 2003, 148, 224– 228. 77. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H, Protective roles of mast cells against enterobacterial infection are mediated by Tolllike receptor 4. J. Immuno l. 2001, 167, 2250–2256. 78. Shin JS, Gao Z, Abraham SN, Involvement of cellular caveolae in bacterial entry into mast cells. Science 2000, 289, 785–788.

41

42

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses 79. Prodeus AP, Zhou X, Maurer M, Galli SJ, Carroll MC, Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 1997, 390, 172–175. 80. Gommerman JL, Oh DY, Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC, A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J. Immunol. 2000, 165, 6915– 6921. 81. Malaviya R, Ikeda T, Ross E, Abraham SN, Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996, 381, 77–80. 82. Maurer M, Echtenacher B, Hultner L, Kollias G, Mannel DN, Langley KE, Galli SJ, The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 1998, 188, 2343–2348. 83. Bone-Larson CL, Hogaboam CM, Steinhauser ML, Oliveira SH, Lukacs NW, Strieter RM, Kunkel SL, Novel protective effects of stem cell factor in a murine model of acute septic peritonitis: dependence on MCP-1. Am. J. Pathol. 2000, 157, 1177–1186. 84. Friend DS, Gurish MF, Austen KF, Hunt J, Stevens RL, Senescent jejunal mast cells and eosinophils in the mouse preferentially translocate to the spleen and draining lymph node, respectively, during the recovery phase of helminth infection. J. Immunol. 2000, 165, 344–352. 85. Karulin AY, Hesse MD,Yip HC, Lehmann PV, Indirect IL-4 pathway in type 1 immunity. J. Immunol. 2002, 168, 545–553. 86. Bendelac A, Rivera MN, Park SH, Roark JH, Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 1997, 15, 535–562. 87. Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J, Wirtz S, Glickman J, Bailey D, Yoshida M, Galle PR, Kronenberg M, Birkenbach M, Blumberg RS, Disruption of T helper 2-immune responses in Epstein–Barr virus-induced

88.

89.

90.

91.

92.

93.

94.

gene 3-deficient mice. Proc. Natl. Acad. Sci. USA 2002, 99, 16951–16956. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG, NKT cells: facts, functions and fallacies. Immunol. Today 2000, 21, 573–583. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M, CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278, 1626–1629. Kitamura H, Iwakabe K,Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K,Van Kaer L, Kawano T, Taniguchi M, Nishimura T, The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 1999, 189, 1121–1128. Exley MA, Bigley NJ, Cheng O, Tahir SM, Smiley ST, Carter QL, Stills HF, Grusby MJ, Koezuka Y, Taniguchi M, Balk SP, CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukoc. Biol. 2001, 69, 713–718. Kawakami K, Kinjo Y,Yara S, Koguchi Y, Uezu K, Nakayama T, Taniguchi M, Saito A, Activation of Valpha14(+) natural killer T cells by alphagalactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 2001, 69, 213–220. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, BrunaRomero O, Nakayama T, Taniguchi M, Bendelac A,Van Kaer L, Koezuka Y, Tsuji M, Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 2000, 97, 8461–8466. Gonzalez-Aseguinolaza G,Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M, Natural killer T cell ligand al-

References

95.

96.

97.

98.

99.

100.

101.

102.

103.

104.

pha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 2002, 195, 617– 624. Muzio M, Ni J, Feng P, Dixit VM, IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278, 1612– 1615. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997, 7, 837–847. Cao Z, Henzel WJ, Gao X, IRAK: a kinase associated with the interleukin-1 receptor. Science 1996, 271, 1128–1131. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ, TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412, 346–351. Kopp E, Medzhitov R, Carothers J, Xiao C, Douglas I, Janeway CA, Ghosh S, ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev. 1999, 13, 2059–2071. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S, Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11, 115–122. Horng T, Barton GM, Medzhitov R, TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol. 2001, 2, 835–841. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S, Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharideinducible genes. J. Immunol. 2001, 167, 5887–5894. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG, Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat. Immunol. 2000, 1, 533–540. Reiling N, Blumenthal A, Flad HD, Ernst M, Ehlers S, Mycobacteria-induced tnf-alpha and il-10 formation by human macrophages is differentially regulated at the level of mitogen-acti-

105.

106.

107.

108.

109.

110.

111.

112.

vated protein kinase activity. J. Immunol. 2001, 167, 3339–3345. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ, Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194, 863–869. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A, Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31, 3388–3393. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G, Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31, 2154–2163. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H, Differential responses of mast cell Tolllike receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest. 2002, 109, 1351–1359. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R, Tolllike receptors control activation of adaptive immune responses. Nat. Immunol. 2001, 2, 947–950. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J,Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al Ghonaium A, Al Rayes H, Al Jumaah S, Al Hajjar S, Al Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, GougerotPocidalo MA, Ozinsky A, Casanova JL, Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299, 2076–2079. Dorman SE, Holland SM, Interferongamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000, 11, 321–333. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ,

43

44

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

Goyert S, Ehlers S, Cutting edge: Tolllike receptor (TLR)2- and TLR4mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J. Immunol. 2002, 169, 3480–3484. Murdoch C, Finn A, Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000, 95, 3032–3043. Lehrer RI, Ganz T, Defensins of vertebrate animals. Curr. Opin. Immunol. 2002, 14, 96–102. Raj PA, Dentino AR, Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol. Lett. 2002, 206, 9–18. Yang D, Biragyn A, Kwak LW, Oppenheim JJ, Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002, 23, 291–296. Ichinose M, Asai M, Imai K, Sawada M, Enhancement of phagocytosis by corticostatin I (CSI) in cultured mouse peritoneal macrophages. Immunopharmacology 1996, 35, 103–109. Fleischmann J, Selsted ME, Lehrer RI, Opsonic activity of MCP-1 and MCP-2, cationic peptides from rabbit alveolar macrophages. Diagn. Microbiol. Infect. Dis. 1985, 3, 233–242. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A, Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J. Immunol. 1999, 163, 947–953. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I, Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol. 2001, 31, 1066–1075. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS, Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J. Leukoc. Biol. 1997, 62, 217–226. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN, Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human

123.

124.

125.

126.

127.

128.

129.

monocytes and adhesion molecule expression in endothelial cells. Eur. Cytokine Netw. 2000, 11, 257–266. Territo MC, Ganz T, Selsted ME, Lehrer R, Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 1989, 84, 2017– 2020. Chertov O, Michiel DF, Xu L, Wang JM, Tani K, Murphy WJ, Longo DL, Taub DD, Oppenheim JJ, Identification of defensin-1, defensin-2, and CAP37/ azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 1996, 271, 2935–2940. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM,Wang JM, Howard OM, Oppenheim JJ, Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286, 525–528. Yang D, Chen Q, Chertov O, Oppenheim JJ, Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 2000, 68, 9–14. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R, Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity: its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001, 306, 257–264. Garcia JR, Krause A, Schulz S, Rodriguez-Jimenez FJ, Kluver E, Adermann K, Forssmann U, FrimpongBoateng A, Bals R, Forssmann WG, Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 2001, 15, 1819–1821. Lillard JW, Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR, Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA 1999, 96, 651–656.

References 130. Tani K, Murphy WJ, Chertov O, Salcedo R, Koh CY, Utsunomiya I, Funakoshi S, Asai O, Herrmann SH, Wang JM, Kwak LW, Oppenheim JJ, Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 2000, 12, 691–700. 131. Biragyn A, Surenhu M,Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW, Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 2001, 167, 6644–6653. 132. Yoshie O, Imai T, Nomiyama H, Chemokines in immunity. Adv. Immunol. 2001, 78, 57–110. 133. Re F, Strominger JL, Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 2001, 276, 37692–37699. 134. Salazar-Mather TP, Orange JS, Biron CA, Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J. Exp. Med. 1998, 187, 1–14. 135. Aliberti J, Reis e Sousa, Schito M, Hieny S,Wells T, Huffnagle GB, Sher A, CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat. Immunol. 2000, 1, 83–87. 136. Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD, Luster AD, IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000, 12, 483–494. 137. Lillard JW, Jr., Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR, MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 2003, 101, 807–814. 138. Sozzani S, Allavena P,Vecchi A, Mantovani A, The role of chemokines

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

in the regulation of dendritic cell trafficking. J. Leukoc. Biol. 1999, 66, 1–9. Sozzani S, Allavena P,Vecchi A, Mantovani A, Chemokines and dendritic cell traffic. J. Clin. Immunol. 2000, 20, 151–160. Luster AD, The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 2002, 14, 129– 135. Marone G, Galli SJ, Kitamura Y, Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends Immunol. 2002, 23, 425–427. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, Cui P, Sone S, Chymase is a potent chemoattractant for human monocytes and neutrophils. J. Leukoc. Biol. 2000, 67, 585–589. Huang C, De Sanctis GT, O’Brien PJ, Mizgerd JP, Friend DS, Drazen JM, Brass LF, Stevens RL, Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J. Biol. Chem. 2001, 276, 26276–26284. Marone G, Gentile M, Petraroli A, De Rosa N, Triggiani M, Histamineinduced activation of human lung macrophages. Int. Arch. Allergy Immunol. 2001, 124, 249–252. Mazzoni A,Young HA, Spitzer JH, Visintin A, Segal DM, Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 2001, 108, 1865–1873. Mazzoni A, Leifer CA, Mullen GE, Kennedy MN, Klinman DM, Segal DM, Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells. J. Immunol. 2003, 170, 2269–2273. Lin TJ, Maher LH, Gomi K, McCurdy JD, Garduno R, Marshall JS, Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa. Infect. Immun. 2003, 71, 365–373. Banyer JL, Hamilton NH, Ramshaw IA, Ramsay AJ, Cytokines in innate and

45

46

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

adaptive immunity. Rev.Immunogenet. 2000, 2, 359–373. Belardelli F, Ferrantini M, Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002, 23, 201–208. Roberts RM, Liu L, Guo Q, Leaman D, Bixby J, The evolution of the type I interferons. J. Interferon Cytokine Res. 1998, 18, 805–816. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ, The nature of the principal type 1 interferonproducing cells in human blood. Science 1999, 284, 1835–1837. Asselin-Paturel C, Boonstra A, Dalod M, Durand I,Yessaad N, Dezutter-Dambuyant C,Vicari A, O'Garra A, Biron C, Briere F, Trinchieri G, Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2001, 2, 1144–1150. Biron CA, Interferons alpha and beta as immune regulators: a new look. Immunity 2001, 14, 661–664. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F, Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 2000, 191, 1777–1788. Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F, Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001, 98, 3022–3029. Shtrichman R, Samuel CE, The role of gamma interferon in antimicrobial immunity. Curr. Opin. Microbiol. 2001, 4, 251–259. Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S, IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001, 22, 556–560. Sims JE, IL-1 and IL-18 receptors, and

159.

160.

161.

162.

163.

164.

165.

166.

167.

their extended family. Curr. Opin. Immunol. 2002, 14, 117–122. Gracie JA, Robertson SE, McInnes IB, Interleukin-18. J. Leukoc. Biol. 2003, 73, 213–224. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378, 88–91. Okamura H, Tsutsui H, Kashiwamura S,Yoshimoto T, Nakanishi K, Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. 1998, 70, 281– 312. Nakanishi K,Yoshimoto T, Tsutsui H, Okamura H, Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001, 12, 53–72. Fehniger TA, Caligiuri MA, Interleukin 15: biology and relevance to human disease. Blood 2001, 97, 14–32. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A, IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9, 669–676. Kennedy MK, Glaccum M, Brown SN, Butz EA,Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ, Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191, 771–780. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J, Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 2001, 194, 1013–1020. Mattei F, Schiavoni G, Belardelli F, Tough DF, IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell ac-

References

168.

169.

170.

171.

172.

173.

174.

175.

176.

tivation. J. Immunol. 2001, 167, 1179– 1187. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G, CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 2003, 170, 3468–3477. Bulfone-PauS S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, Krause H, Kunzendorf U, Interleukin-15 protects from lethal apoptosis in vivo. Nat. Med. 1997, 3, 1124–1128. Bulfone-PauS S, Bulanova E, Pohl T, Budagian V, Durkop H, Ruckert R, Kunzendorf U, Paus R, Krause H, Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J. 1999, 13, 1575– 1585. Bulanova E, Budagian V, Pohl T, Krause H, Durkop H, Paus R, Bulfone-PauS S, The IL-15R alpha chain signals through association with Syk in human B cells. J. Immunol. 2001, 167, 6292–6302. Girard D, Paquet ME, Paquin R, Beaulieu AD, Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood 1996, 88, 3176–3184. Cassatella MA, McDonald PP, Interleukin-15 and its impact on neutrophil function. Curr. Opin. Hematol. 2000, 7, 174–177. Musso T, Calosso L, Zucca M, Millesimo M, Puliti M, Bulfone-PauS S, Merlino C, Savoia D, Cavallo R, Ponzi AN, Badolato R, Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells. Infect. Immun. 1998, 66, 2640– 2647. Doherty TM, Seder RA, Sher A, Induction and regulation of IL-15 expression in murine macrophages. J. Immunol. 1996, 156, 735–741. Nishimura H, Hiromatsu K, Kobayashi N, Grabstein KH, Paxton R, Su-

177.

178.

179.

180.

181.

182.

183.

184.

gamura K, Bluestone JA,Yoshikai Y, IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection. J. Immunol. 1996, 156, 663–669. Elloso MM, Wallace M, Manning DD, Weidanz WP, The effects of interleukin-15 on human gammadelta T cell responses to Plasmodium falciparum in vitro. Immunol. Lett. 1998, 64, 125–132. Mody CH, Spurrell JC,Wood CJ, Interleukin-15 induces antimicrobial activity after release by Cryptococcus neoformans-stimulated monocytes. J. Infect. Dis. 1998, 178, 803–814. Macatonia SE, Hosken NA, Litton M,Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O’Garra A, Dendritic cells produce IL–12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 1995, 154, 5071– 5079. Reis e Sousa, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher A, In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 1997, 186, 1819–1829. Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Briere F, Trinchieri G, Biron CA, Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J. Exp. Med. 2002, 195, 517–528. Trinchieri G, Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3, 133–146. Brombacher F, Kastelein RA, Alber G, Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003, 24, 207–212. D’Andrea A, Ma X, Aste-Amezaga M, Paganin C, Trinchieri G, Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12

47

48

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

185.

186.

187.

188.

189.

and tumor necrosis factor alpha production. J. Exp. Med. 1995, 181, 537– 546. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B,Vega F,Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13, 715–725. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal MR, Rennick D, Kastelein RA, IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16, 779– 790. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD, Interleukin-23 rather than interleukin12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421, 744–748. Takeda A, Hamano S,Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A,Yoshida H, Cutting edge: role of IL-27/WSX-1 signaling for induction of T-Bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 2003, 170, 4886–4890. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP,Vega F, To W, Wagner J, O’Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal MR, Moore KW, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 2002, 168, 5699–5708.

190. Pasare C, Medzhitov R, Toll pathwaydependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299, 1033–1036. 191. Leal IS, Florido M, Andersen P, Appelberg R, Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine. Immunology 2001, 103, 375–381. 192. Hamilton JA, GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002, 23, 403–408. 193. Burgess AW, Metcalf D, The nature and action of granulocyte-macrophage colony stimulating factors. Blood 1980, 56, 947–958. 194. Handman E, Burgess AW, Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J. Immunol. 1979, 122, 1134–1137. 195. Gamble JR, Elliott MJ, Jaipargas E, Lopez AF,Vadas MA, Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA 1989, 86, 7169–7173. 196. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor. J. Exp. Med. 1992, 176, 1693–1702. 197. Zucali JR, Dinarello CA, Oblon DJ, Gross MA, Anderson L, Weiner RS, Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J. Clin. Invest. 1986, 77, 1857– 1863. 198. Leizer T, Cebon J, Layton JE, Hamilton JA, Cytokine regulation of colonystimulating factor production in cultured human synovial fibroblasts. I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990, 76, 1989–1996. 199. Sheridan JW, Metcalf D, Studies on the bone marrow colony stimulating factor (CSF): relation of tissue CSF to serum CSF. J. Cell Physiol 1972, 80, 129–140.

References 200. Metcalf D, Begley CG, Williamson DJ, Nice EC, De Lamarter J, Mermod JJ, Thatcher D, Schmidt A, Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp. Hematol. 1987, 15, 1–9. 201. Armitage JO, Emerging applications of recombinant human granulocytemacrophage colony-stimulating factor. Blood 1998, 92, 4491–4508. 202. Warren TL,Weiner GJ, Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. 2000, 7, 168–173. 203. Lu H, Xing Z, Brunham RC, GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J. Immunol. 2002, 169, 6324–6331. 204. Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL, Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 2001, 75, 12128–12140. 205. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E, A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/ neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine 1999, 17, 1239–1250. 206. Mosmann TR, Coffman RL, Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 1989, 46, 111–147. 207. Brombacher F, The role of interleukin13 in infectious diseases and allergy. Bioessays 2000, 22, 646–656. 208. Wynn TA, IL-13 effector functions. Annu. Rev. Immunol. 2003, 21, 425–456. 209. Hoshino T, Winkler-Pickett RT, Mason AT, Ortaldo JR,Young HA, IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. J. Immunol. 1999, 162, 51–59. 210. Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, Gessner A, Differential functions of IL-4 receptor types I and II for

211.

212.

213.

214.

215.

216.

217.

218.

219.

220.

dendritic cell maturation and IL-12 production and their dependency on GMCSF. J. Immunol. 2002, 169, 3574–3580. Mohrs M, Blankespoor CM, Wang ZE, Loots GG, Afzal V, Hadeiba H, Shinkai K, Rubin EM, Locksley RM, Deletion of a coordinate regulator of type 2 cytokine expression in mice. Nat. Immunol. 2001, 2, 842–847. Brubaker JO, Montaner LJ, Role of interleukin-13 in innate and adaptive immunity. Cell Mol. Biol. (Noisy-legrand) 2001, 47, 637–651. Bancroft AJ, McKenzie AN, Grencis RK, A critical role for IL-13 in resistance to intestinal nematode infection. J. Immunol. 1998, 160, 3453–3461. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA, IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J. Immunol. 1999, 162, 920– 930. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA, An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 1999, 104, 777–785. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK, Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent. Eur. J. Immunol. 2000, 30, 2083–2091. Moore KW, de Waal MR, Coffman RL, O’Garra A, Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F, Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 2000, 1, 311–316. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, Bowen G, Rook G, Walker C, Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory Tcells. Nat. Med. 2002, 8, 625–629. McGuirk P, McCann C, Mills KH, Pathogen-specific T regulatory 1 cells

49

50

2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses

221.

222.

223.

224.

225.

induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 2002, 195, 221– 231. Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J,Yersinia V-antigen exploits Tolllike receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. 2002, 196, 1017–1024. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J,Wang XY, Catino JJ, King I, Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 1996, 184, 579– 584. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G,Trinchieri G, Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195, 327–333. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM, The dual role of IL-10. Trends Immunol. 2003, 24, 36–43. Moustakas A, Pardali K, Gaal A, Heldin CH, Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol. Lett. 2002, 82, 85–91.

226. Govinden R, Bhoola KD, Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol. Ther. 2003, 98, 257–265. 227. Omer FM, Kurtzhals JA, Riley EM, Maintaining the immunological balance in parasitic infections: a role for TGF-beta? Parasitol. Today 2000, 16, 18– 23. 228. Cox JC, Coulter AR, Adjuvants: a classification and review of their modes of action. Vaccine 1997, 15, 248–256. 229. Moingeon P, Haensler J, Lindberg A, Towards the rational design of Th1 adjuvants. Vaccine 2001, 19, 4363–4372. 230. Hess J, Schaible U, Raupach B, Kaufmann SH, Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv. Immunol. 2000, 75, 1–88. 231. Nigou J, Zelle-Rieser C, Gilleron M, Thurnher M, Puzo G, Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. 2001, 166, 7477–7485. 232. Moingeon P, Strategies for designing vaccines eliciting Th1 responses in humans. J. Biotechnol. 2002, 98, 189–198. 233. Ramshaw IA, Ramsay AJ, The primeboost strategy: exciting prospects for improved vaccination. Immunol. Today 2000, 21, 163–165.

51

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination James M. Brewer and Kevin G. J. Pollock

3.1 Introduction

Currently, no effective vaccines are available against diseases such as HIV [1], malaria [2], and tuberculosis [3]. Although drug treatments have been developed, these conditions continue to cause substantial morbidity and mortality worldwide, mainly because the treatments are expensive and typically of long duration. These factors combine to reduce patient compliance and, in the absence of drug monitoring, they lead to low effectiveness and may even result in multi-drug resistance. Clearly, an effective vaccine against any of these diseases would make a considerable contribution to world health. The development of vaccines has mainly focused on the identification of antigens that elicit the appropriate specific immune response to generate immunity. With increasing progress in vaccine research, this process has become increasingly refined, moving from whole organisms to extracts, toxoids, or single proteins isolated from pathogens or expressed by recombinant DNA techniques. With progress in our understanding of the structures of the T and B lymphocyte antigen receptors and their ligands, this research has ultimately moved to the smallest unit of antigen capable of eliciting adaptive immunity, the T or B cell epitope. The drive behind this increasing refinement has been the promise of vaccines with increased effectiveness, improved safety profiles, and greater ease of manufacture. However, one unwanted side effect as the refinement of these vaccines improved was a concomitant reduction of their immunogenicity. In experimental situations, this lack of immunogenicity can be easily remedied by formulation of the antigen with a vaccine adjuvant. Adjuvants have been defined as ‘agents that act nonspecifically to increase the specific immune response or responses to an antigen’ [4]. Essentially this means that adjuvants can act to increase the specific immune response to an administered antigen and should also act with a wide range of antigens. Janeway also called adjuvants ‘the immunologist’s dirty little secret' in recognition of the fact that, although a great deal of effort has gone into the design of vaccine antigens, the study of adjuvants has been largely empirical, and the mechanisms of how they exert their activity are far less studied or understood

52

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination Tab. 3.1 Examples of Th1/Th2 induction by vaccine adjuvants . Arrows indicate adjuvant-induced changes in Th1/Th2 associated responses. Adjuvant

Antigen

Mouse strain

Subset

Criteria

Reference

FCA

OVA

129/Sv x C57BL/6) F2 BALB/c

Th1

: IFNg ; IL-5 : IFNg ; IL-5

[9]

OVA

Th1

[10]

Lipid A derivatives (MPL)

Leishmanial Ag (LeIF)

BALB/c

Th1

: IFNg ; IL-4

[11]

E. coli LT

Tetanus toxin epitope

BALB/c

Th1

: IFNg

[12]

ISCOMs

OVA

Th1

: IL-12 : IFNg : IgG2a : IFNg

[13]

HSV-2 Ag

BALB/c C57BL/6 BALB/c

OVA

BALB/c

Th1

[15]

HSV-2 Ag

BALB/c

Th1

: IgG2a : IFNg : IgG2a : IFNg

Alum/IL-12

HIV gp120

BALB/c

Th1

: IgG2a : IFNg

[16]

CpG

Tumor peptide Autoantigen (PDC)

Syngeneic B6 SJL/J

Th1 Th1

: IFN g : IFN g ; IL-4

[17] [18]

Microparticles

Mucin peptide

C57BL/6

Th1

[19]

M. tuberculosis 38 kDa Ag

C57BL/6

Th1

: IFN g ; IL-4 : IFN g

OVA

Th2

: IL-5 ; IFN g : IL-4 : IgE

[9]

OVA

(129/Sv x C57BL/6) F2 BALB/c

Influenza

BALB/c

Th2

[22]

HSV Ag

BALB/c

Th2

: IL-5 : IL-6 : IL-4 : IL-5

Cholera Toxin

OVA

BALB/c

Th2

: IL-4 ; IFN g

[24]

L3

Diphtheria Toxoid

Outbred NMRI Th2 mice

: IgG1 ; IgG2a

[25]

NISV

Alum

MF-59

Th1

Th2

[14]

[14]

[20]

[21]

[23]

3.2 The Two-Signal Model of Adjuvant-induced Immune Activation

[5]. One of the confounding issues in investigating the mechanisms of action of vaccine adjuvants has been the diverse range of unrelated substances that have adjuvant activity (Table 3.1). These include oil emulsions, natural and synthetic surfactants, mineral gels, bacterial derivatives, and some completely esoteric substances such as breadcrumbs and tapioca [6–8]. Trying to devise a unifying theory to explain this phenomenon is clearly not an easy task.

3.2 The Two-Signal Model of Adjuvant-induced Immune Activation

Induction of antigen-specific responses to protein antigens requires the activation of T helper cells. The signaling requirements for this activation have been described based on two distinct signals that are generated in the T cell and induced by APCs (Figure 3.1). Signal 1 is the cognate signal delivered to T cells by peptide/ MHC class II complexes on the surface of APCs [26]. As mentioned above, this interaction, which engenders antigen specificity on the APC-T cell interaction, has occupied a great deal of vaccine development activity. However, Signal 1 is usually inadequate for effective vaccination without the presence of a second signal, Signal 2 [26, 27]. Several studies have demonstrated that Signal 2 is induced in T cells by costimulatory molecules or cytokines expressed by APCs and is essential for T cell activation leading to immunity. In the absence of effective provision of Signal 2, T cells enter a state of functional hyporesponsiveness or anergy [27]. In terms of vaccine development, it appears that both whole organisms and adjuvants can program APCs to express costimulatory molecules to induce Signal 2 in T cells [28]. Although this model may explain the lack of immunogenicity of peptide vaccines,

Anergy

Antigen Signal 1 Signal 2 Adjuvant

APC

Activation

T cell

Fig. 3.1 A two-signal model of T cell activation. Signal 1 is provided through the interaction between the TcR with cognate peptide presented in the context of MHC molecules. Provision of Signal 1 alone results in induction of specific hyporesponsiveness or anergy in T cells [27]. A second costimulatory signal can act together with Signal 1, resulting in T cell activation. Both Signals 1 and 2 are stimulated in T cells through interaction with APCs. Although treatment of DCs with antigen alone may only be able to provide stimulus for Signal 1, the addition of an adjuvant may activate APCs, increasing the provision of both signals resulting in T cell activation [28].

53

54

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

it fails to explain how vaccine adjuvants or whole organisms can actually program the ability to induce Signal 2. Several in vitro and in vivo studies have demonstrated that dendritic cells (DCs) are the most effective APC population in inducing activation and proliferation of naïve T cells. DCs are strategically situated in diverse tissues such as the epidermis and gastrointestinal mucosa, where the potential for invasion by pathogens is high [29, 30]. Advances in the culture and isolation of DCs have enhanced our understanding of their biology and demonstrated the existence of subsets of DCs, some of which represent discrete stages of differentiation [31, 32], while others belong to distinct lineages [33, 34]. Nonlymphoid DCs found in tissues are specialized for high antigen capture [35, 36]. However, for optimal T cell activation, these cells must be activated, to allow migration to T cell areas of lymph nodes and to acquire increased antigen presentation and costimulatory activity [29, 30]. The term ‘Signal 0’ has been coined to describe the activation event in DCs, and several endogenous ligands have been described that can stimulate Signal 0 [37], including proinflammatory cytokines and T cell-derived signals [29]. However, several exogenous agents also activate DCs [29, 38]. Significantly, many of these exogenous agents with the capacity to activate DCs also possess adjuvant activity [39, 40], raising the possibility that adjuvants may have a common function in activating DCs. A mechanism whereby exogenous agents could activate the immune system was proposed by Janeway [5]. He hypothesized that a series of pathogen-associated molecular patterns (PAMPs) were recognized by a set of, at the time, uncharacterized pattern-recognition receptors (PRRs). Further investigations have indeed revealed a set of evolutionarily conserved motifs expressed by some bacteria and viruses that are recognized by members of a series of mammalian receptors, called toll-like receptors (TLRs) [38, 41]. These highly conserved receptors are expressed on DCs and macrophages and mediate DC activation upon encountering the appropriate microbial stimulation (Figure 3.2). However, given that TLRs are germline encoded, one of the major arguments against PRR-PAMP interactions regulating the decision by the immune system to activate is the potentially huge number of pathogen-derived ligands that would need to be recognized [42]. Clearly, most of this research has been performed in relation to how the immune system responds to invasion by pathogens, where an evolutionary pressure exists to allow the immune system to recognize infectious non-self. If the set of ligands recognized by TLRs were to be expanded to include all adjuvants, ranging from inorganic salts to synthetic particles to plant glycosides, the range of receptors required would be unfeasibly enormous. Unsurprisingly, given the lack of any evolutionary pressure, results suggest that such an innate recognition system does not apply to nonmicrobial adjuvants [43, 44]. However, this does raise the issue of how DCs are activated in response to these adjuvants. Given the massive heterogeneity of agents with adjuvant activity, it seems more likely that adjuvants may stimulate the production of endogenously synthesized factors, which could then stimulate the activation of DCs. One of the common activities of adjuvants is the ability, in varying degrees, to stimulate local inflammation at the injection site. Indeed, it was formerly thought that the induction of local reactions

3.2 The Two-Signal Model of Adjuvant-induced Immune Activation

flagellin TLR5

LPS

CpG Mature DC TLR9 T

TLR4 Signal 0 TLR3 dsRNA

T

TLR2

proteolipids

Immature DC

Tissue

T

Lymph Node

Fig. 3.2 Recognition of PAMPs by PRRs. Direct activation of DCs has been observed with a number of microbial products (PAMPs) that are thought to act by directly binding pattern-recognition receptors (PRRs) expressed on DCs [5]. Many PAMPs have adjuvant activity, presumably as a result of this interaction [39]. Receptors for a number of PAMPs have been defined as belonging to the Toll-like receptor (TLR) family. Ligation of TLRs generates a hypothetical activation signal, Signal 0, in immature DCs, resulting in changes in endocytosis, migration, presentation, and costimulation associated with mature DCs.

following vaccination is essential for the induction of an effective immune response [45]. More recently, studies have demonstrated that necrotic cells possess ‘natural’ adjuvant activity through the ability to activate DCs. Thus, it is possible that the induction of local tissue injury and cellular necrosis observed following the administration of adjuvants might consequently induce DC activation [42]. This would tend to support a ‘danger’-based system of immune recognition of adjuvants that induce local inflammation. Significantly, one prediction from this model would be an inability to separate the degree of tissue damage induced by an adjuvant from the magnitude of the immune response it can produce. Such a relationship would clearly have significant implications for the development of safe and effective vaccine adjuvants [7]. However, several previous studies have attempted, with success, in separating adjuvant activity from toxicity, indicating that this relationship is more complex than predicted from the danger model [46–48]. Interestingly, studies with the oil emulsion adjuvant, MF-59 in vivo have demonstrated that macrophages rather than DCs are the main cell type involved in clearance of the oil depot in the tissue. However, further analysis of MF-59 induced reactions demonstrated that in the paracortical T cell areas of the draining lymph node, DCs were the predominant cell type carrying adjuvant [49]. The authors proposed that, following uptake, adjuvant-induced macrophage death was responsible for the transfer of antigen from macrophages to DCs in vivo [50]. This suggests that, rather than causing gross tissue toxicity, the ability of some adjuvants to activate immune responses may be related to their ability to

55

56

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

induce cell death in specific types of cells, such as macrophages, involved in their removal.

3.3 Th1 and Th2 Induction by Vaccine Adjuvants

Aluminum compounds were originally identified as adjuvants over 70 years ago [51] and for much of this time they were unique in their widespread application to human vaccines. This was generally in the form of vaccines adsorbed to either preformed aluminum oxyhydroxide, more commonly known as aluminum hydroxide, or aluminum hydroxyphosphate (aluminum phosphate) gels, in order to overcome problems with the heterogeneity of protein aluminate precipitates [52]. The application of these adjuvants, collectively referred to here as alum, has been largely limited to certain bacterial and viral vaccines where protection against infection is known to be dependent on the generation of neutralizing antibodies [53]. When used appropriately, alum gels have enjoyed a good safety profile, which is undoubtedly the major factor in ensuring their continued use. However, alum is unlikely to fulfill the adjuvant requirements of many modern vaccines, due to the restricted range of immune responses induced by this adjuvant. Early studies demonstrated that, although alum adjuvants are very effective in promoting the expansion of humoral immune responses, including IgE production [54], they fail to stimulate cell mediated immune (CMI) responses such as delayed type hypersensitivity (DTH) [55]. More recently, the control of cellular and humoral immune responses has been attributed to mutually antagonistic subsets of CD4+ T helper (Th) lymphocytes referred to as Th1 and Th2 cells, respectively [56, 57]. Subsequent studies have demonstrated that, although alum can stimulate Th2 type responses and the production of cytokines such as IL-4 and IL-5 as well as B cell production of IgG1 and IgE, it fails to stimulate Th1 responses such as IFN g production and B cell IgG2 a secretion [6, 58]. This poses a significant problem to the continued development of vaccines, particularly given that the effectiveness of vaccines against the three diseases causing most global mortality – HIV, tuberculosis and malaria – are entirely or partially dependent on the generation of Th1 type immunity [1–3, 59]. In experimental situations, this problem can be overcome by employing one of the wide range of experimental adjuvants, in particular Freund’s complete adjuvant (FCA; [60]), that are known to induce antigen-specific Th1 responses (Table 3.1). However, the use of FCA causes inflammation, induration, or necrosis with disseminated granulomas being reported in the lungs, liver, kidneys, heart, lymph nodes, and skeletal muscles of rabbits or rats after s.c. or i.v. injection [61]. Therefore, for use in humans, adjuvants such as FCA are unacceptably toxic, inducing chronic granuloma formation and tissue destruction. In fact, if FCA is accidentally injected into humans, the affected area often has to be surgically removed to prevent longterm abscesses that result. Clearly, the lack of a clinically applicable adjuvant that induces Th1 responses poses a significant obstacle to the effective clinical application of vaccines against these diseases. Many of the developmental adjuvants listed in

3.4 Antigen Dose Effects

Table 3.1 have aimed to fulfill this role, although as yet none of them has succeeded. One reason underlying this lack of success is our poor understanding of what features of an adjuvant can lead to preferential Th1 or Th2 induction. Clearly understanding these mechanisms would facilitate the rational development of new and more effective adjuvants.

3.4 Antigen Dose Effects

Several studies have indicated that adjuvants may function by targeting antigen to APCs. This is particularly true of particulate adjuvant formulations that have been shown to engender quantitatively more effective uptake of antigen by phagocytic APCs than comparable levels of soluble antigens [62–64]. Although macrophages have been widely used as APCs in these models, recently particulate antigen has also been demonstrated to have a similar effect on DCs [44]. Furthermore, the increase in antigen internalization observed is reflected in the levels of peptide/MHC complexes detected on the surface of these cells, thus effectively increasing the dose of antigen administered [44, 64]. Antigen dose has been demonstrated to have significant effects of the generation of Th1 versus Th2 responses to antigens [65]. Historically, high doses of allergen have been used for immunotherapy and more recently, they have been associated with the preferential induction of Th1 cytokine production by CD4+ T cells from allergic donors [66]. In contrast, in vitro incubation with lower doses of antigen has been associated with Th2 responses [66]. In vitro studies with TcR transgenic CD4+ cells have also demonstrated similar effects of high and low antigen doses on the polarization of naïve T cells [67, 68]. However, other studies have demonstrated that ‘very’ high doses of antigens return the polarizing effect towards Th2 responses [68, 69]. The effect of antigen dose on Th cell cytokine production has been proposed to be mediated through alteration of the density of T cell epitopes on antigen-presenting cells that subsequently influence the magnitude of Signal 1 supplied to T cells [68]. From these studies it would then be hypothesized that low Signal 1 intensity may lead to Th2 responses, whereas high intensity signals may lead to Th1 responses. Similarly, studies with altered peptide ligands have shown that peptides that are weak T cell ligands stimulate Th2 type responses compared with strong T cell ligands [68]. These studies then indicate that particulate antigens or allergens would alter the effective dose of antigen administered and perhaps the subsequent Th1/Th2 response. Indeed many studies have associated the administration of particulate antigens with Th1 induction (Table 3.1). For example, HayGlass and colleagues [63] demonstrated that high molecular weight glutaraldehyde-polymerized ovalbumin (OVA) induces a strong Th1-like response in vivo in contrast to equivalent doses of soluble antigen alone that induced neither a Th1 or Th2 biased response. However, without a clearly defined dose and response pattern for all antigens, the generality of this mechanism in controlling Th1 and Th2 responses in vivo clearly remains ques-

57

58

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

tionable. Significantly, it has been observed that the form of the antigen used in these studies is an important issue, because dose–response effects for soluble versus particulate antigens are quite distinct [68].

3.5 The Three-signal Model of Adjuvant-induced Immune Activation

Much of what we understand about the regulation of Th1 and Th2 responses has been derived from studies in vitro. These studies have clearly demonstrated the overriding effects of exogenous cytokines, in particular IL-12 and IL-4, in the preferential generation of Th1 and Th2 cells, respectively, from monospecific precursor cells [56, 57, 70]. Further analyses of the role of APC-derived cytokines in T cell activation have identified a third requirement, Signal 3, for optimal activation of CD4 or CD8 cells. This third signal is associated with the presence of proinflammatory cytokines such as TNF, IL-1 and IL-12 produced by APCs [71, 72]. Significantly, these cytokines have been implicated in regulating the phenotype of developing T cell responses. Therefore, as well as being involved in optimal T cell activation, Signal 3 has been suggested to act as a polarizing signal in regulating the development of Th1 or Th2 responses (Figure 3.3) [37]. In vitro studies have demonstrated that the proinflammatory cytokine IL-6 is associated with stimulating the preferential expansion of Th2 cells. This appears to be mediated first by signaling via a suppressor of cytokine signaling, (SOCS)-1, to inhibit IFNg production and therefore Th1 differentiation, and second, by activating nuclear factor of activated T cells (NFAT), leading to production of IL-4 by naï ve T cells and selective differentiation into Th2 cells [73]. However, in vivo studies with knockout mice do not support this role for IL-6 in Th2 induction. IL-6 deficient mice produced increased Th2 (IL-4, IL-5, and IL-10) and Th1 (IFNg) cytokine responses to antigens prepared in alum compared with wild-type mice, suggesting that IL-6 acted

Activation

Antigen Signal 1 Signal 2 Signal 3

Adjuvant

Th1 or Th2? APC

T cell

Fig. 3.3 A three-signal model of T cell activation. In addition to Signals 1 and 2, Signal 3 has been proposedto regulate the differentiation of T cells into Th1 and Th2 phenotypes. As with the other signals, this signal is probably induced in T cells through interactions with APCs [37]. Environmental instruction, for example by adjuvants, may determine the ability of APCs to direct T cell differentiation.

3.5 The Three-signal Model of Adjuvant-induced Immune Activation

to inhibit cytokine responses generally [74]. Similarly, La Flamme and colleagues found that the Th2 response associated with injection of eggs from Schistosoma mansoni was similar in wild-type or IL-6-deficient mice [75]. Furthermore, although IL-6deficient mice injected with antigen in FCA had unaltered Th1 responses, Th2 responses were increased, suggesting that, in a Th1 polarizing condition, IL-6 may actually act to inhibit Th2 induction [74]. The role of IL-1 and TNF in polarizing Th1 and Th2 responses also remains unclear. Early studies demonstrated that IL-1 had differential effects on cloned Th1 and Th2 cells, with only Th2 clones expressing IL-1R and requiring IL-1 as a growth factor [76]. Similarly, antigen-specific T cell proliferation by lymph node cells isolated from mice primed in vivo with antigen prepared in alum but not FCA could be inhibited by IL-1-neutralising antibodies [58]. In vivo studies have demonstrated that, although both IL-1 and TNF have limited adjuvant activity, they do not appear to cause clear polarization of the resulting T helper cell response [77]. Similarly, immunization of IL-1RI knockout mice with KLH precipitated with alum supplemented with Corynebacterium parvum in FCA did not result in significant changes in the Th1/Th2 response compared with wild-type mice [78]. Previous studies demonstrated that TNFR1-deficient mice have normal Th1/Th2 profiles in response to immunization with antigen prepared in alum. However, following immunization with the same antigen prepared in FCA, TNFR1-deficient mice had greatly increased Th1 responses compared with wild-type mice, suggesting that TNF may regulate adjuvant-induced Th1 but not Th2 responses via TNFR1-mediated signaling [74]. Of the proinflammatory cytokines capable of delivering signal 3 to T cells, only IL-12 has a clear effect on polarization of the developing T cell response both in vitro and in vivo [79]. IL-12 is produced by DCs macrophages and B lymphocytes and stimulates production of several cytokines, in particular, IFNg from both T and NK cells, thus driving Th1 development [80]. Early studies demonstrated that administration of exogenous IL-12 had adjuvant activity in several models, including vaccination against Leishmania infection, where Th1 induction is essential for resistance [81]. One mechanistic explanation for this observation involves the previously described ability of IL-4 to down-regulate IL-12 receptor b2 chain (IL-12R b2) expression on T cells, therefore inhibiting the signaling pathway leading to Th1 induction [82]. Studies have shown that the effects of IL-4 on IL-12Rb2 expression can be inhibited during the early stages (before 24 h) of the developing immune responses by IL-12 itself [83, 84] (Figure 3.4). IL-12 plays an important role in the activity of many vaccine adjuvants. Studies in knockout mice demonstrate that IL-12 mediates Th1 induction by FCA [85], although some residual IL-12-independent IFN g production was noted in these mice. Similarly, both ISCOM and NISV adjuvant activity is dependent on IL-12 [13, 86]. In contrast, the activity of the mucosal adjuvant CT has been shown to be independent of IL-12 [87], although this may be due to the adjuvant activity of CT being largely mediated through Th2 cells [88]. Determining how IL-12 maintains Th1 cells and consequently cell-mediated immunity will provide new insights into controlling the immune response and thus may influence the design of new vaccines and immunotherapies.

59

60

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

A.

IL-12Rβ β2

-

IL-12Rβ β1

IL-12Rβ β1

ThP γc

IL-12

IL-12Rβ β2

IL-12Rβ β1

ThP γc

ThP

Th2

IL-4

IL-4

IL-4Rα α

IL-4

B.

IL-12Rβ β1

IL-4Rα α

IL-4

IL-12

IL-12Rβ β2

-

IL-12Rβ β1

IL-12Rβ β2

IL-12Rβ β1

IFNγγ

ThP

γc

Th1

IFNγγ

IL-4Rα α

IL-4

Fig. 3.4 Regulation of IL-12R expression by IL-4, IL-12, and IFNg. A. IL-4 rapidly down-regulates IL-12Rb2 on naive T helper cells (ThP), rendering them unresponsive to further IL-12 effects and ultimately resulting in Th2 generation [82]. B. Early exposure to IL-12 can inhibit the effects of IL-4 on IL-12Rb2 expression, allowing IL-12 effects to override, resulting in Th1 development [83]. Endogenous or exogenous IFN g further inhibits the effect of IL-4 and facilitates polarization to Th1[82].

As mentioned above, APC activation, including proinflammatory cytokine production in response to pathogen-associated molecules, is predominantly regulated by direct recognition via TLRs [38, 41, 89]. Signaling through TLRs is mediated through a common intracellular domain on the TLR, similar to that found in the IL-1 receptor, called a TIR domain. Signaling via this pathway involves the adaptor protein MyD88 and results in activation of NF-kB transcription factors and MAP kinases. Interestingly, microarray analysis indicates that the same core set of NF-kBdependent genes are activated in DCs by diverse pathogens such as influenza, E. coli, and Candida albicans and, significantly, their components such as dsRNA, LPS, and mannan had similar effects to whole pathogens [38, 90]. Activation of NFkB then acts to induce the production of proinflammatory cytokines such as IL-1, TNF and IL-12. The general tendency of proinflammatory cytokines to promote Th1 induction may reflect the differing transcription requirements for the production of Th1 and Th2 signature cytokines. In Th1 cells, IFN g production has been shown to be regulated by both NFAT and NF-kB transcription factors [70]. In contrast, NF- kB signaling does not appear to be associated with Th2 cell IL-4 production, although studies have shown that IL-1-induced NF- kB activation can facilitate the proliferation of Th2 cells [91]. It therefore appears that signaling through TLRs

3.6 Th2 Induction by Adjuvants

would result in a Th1 biased response either directly or via induction of proinflammatory cytokine production by APCs. This hypothesis has been tested in MyD88deficient mice, which fail to signal through their TLRs. In these mice, Th1 induction by FCA is significantly reduced, while Th2 responses to antigen prepared in alum is unaffected in comparison with wild-type mice [43]. Again, this reinforces the position made above, that, although it makes sense for the immune response to have evolved to recognize pathogen-associated motifs, it makes no sense to suggest that it would recognize an inorganic mineral gel. However, it still begs the question, ‘How are Th2 responses induced?’

3.6 Th2 Induction by Adjuvants

As mentioned above, much of what we understand regarding the regulation of the induction of Th2 responses has been derived in vitro. These studies have demonstrated the central role played by IL-4 in controlling Th2 responses [56] and have revealed the transcriptional events leading to induction of Th2 cells from monospecific precursors in considerable detail [57, 70]. Despite the detail with which we understand Th2 differentiation in vitro, it is less clear how these events occur in tissues – this is mainly due to the far greater level of complexity of the developing immune system in vivo. This is a particular problem in Th2 responses, since the major source of IL-4 in vivo is Th2 cells themselves, which produce IL-4 as part of an autocrine growth loop [56]. This anomaly has piqued interest in identifying a population of cells that could act as ‘prime movers’ to produce an initial source of IL-4 to subsequently support Th2 responses. As described above, the development of mice with disrupted cytokine genes has made a significant contribution to the study of factors involved in regulation of Th1 and Th2 immune responses in vivo [57]. Although some studies have been largely confirmatory, for example, those on the role of IL-12 in Th1 cell differentiation [85], clear evidence to confirm the role of IL-4 in induction of Th2 responses in vivo has been less forthcoming. For example, disruption of IL-4 or IL-4 mediated signaling has been shown to result in a reduced ability to produce Th2-type responses upon infection with Leishmania major or Nippostrongylus brasiliensis [92, 93]. By extrapolation from these studies, we may anticipate that alum may have no, or reduced, adjuvant activity in IL-4-deficient mice. However, alum not only continues to have effective adjuvant activity in these mice, but it also induces Th2 cells producing IL-5 at similar levels as in wild-type mice [9]. Similarly, mice immunized with rabbit anti-mouse IgD develop normal IL-4-producing Th2 cells in the absence of IL-4 signaling [94]. The Th2 response induced by alum in the absence of IL-4 could be due to compensatory effects of IL-13, which shares a common signaling pathway with IL-4 via binding to IL-4Ra chain and subsequent phosphorylation of signal transducer and activator of transcription (Stat) 6 [95–97]. However, results in Stat 6 or IL-4Ra deficient mice demonstrated that alum could induce levels of antigen-specific IL-4 and IL-5 production that were at least equivalent to those found in wild-type mice [21]. Although

61

62

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

these results clearly indicate that alum can stimulate Th2 development independently of either IL-4 or IL-13, it remains unclear how Th2 responses to a variety of stimuli, including alum adjuvants, can be induced in vivo. Interestingly, although Th2 cytokine responses were normal in IL-4Ra and Stat 6 deficient mice these studies clearly showed that alum could induce Th1 responses under these circumstances [21]. This suggests that, in normal immunocompetent animals, alum-induced IL-4, rather than inducing Th2 associated responses, primarily functions to inhibit the development of Th1-type responses. A likely mechanism for this inhibition, involving IL-4-mediated down-regulation of IL-12Rb2 expression and consequently IL-12 mediated signaling, is described above (Figure 3.4). Significantly, previous studies have shown that coadsorption of IL-12 on alum gel elicits a switch in the alum-induced response from Th2 to Th1 [16, 98]. This suggests that adsorption of IL-12 onto alum not only acts to positively promote Th1 responses, but can also counteract the actions of IL-4 in inhibiting Th1 induction, presumably through IL-12 inhibition of IL-4 mediated IL-12Rb2 down-regulation (Figure 3.4). Indeed, the studies in IL-4 and IL-4 signaling knockout mice suggest that the latter mechanism may be more important in inducing Th1 responses. These observations illustrate that adjuvants such as alum that are currently in use have the potential to be improved and consequently, that understanding the mechanism of action of alum would facilitate the rational design of new, safe adjuvants. The studies described above also imply that looking for an early source of IL-4 in vivo, although not relevant to the induction of Th2 responses, is clearly important in the inhibition of Th1 induction. Several sources of early IL-4 production have been proposed, including cells of the adaptive and innate immune responses. These include, gdT cells, NK1.1+CD4+ T cells, NK1.1-CD4+ T cells, eosinophils, and cells of the mast cell/basophil lineage (reviewed in [56]). Therefore, it is possible that adjuvants in general, and alum in particular, may be able to influence the Th1/Th2 balance of an immune response through effects on any of these cell populations. In fact, histological analysis of injection sites after administration of antigen prepared in adjuvant has revealed that, unlike Freund’s adjuvant which induces a predominantly macrophage infiltrate, the antigen depot induced by alum adjuvant contains significant levels of eosinophils as well as macrophages [99]. However, it is not clear from studies of adjuvants or pathogen infection models, exactly how cellular events at the site of injection can regulate the development of T cell responses in the local lymph nodes. Obstacles to these effects are, first, that cytokines have generally very short effector ranges in vivo [100], and second, that unlike memory or effector T cells that are already Th1/ Th2 committed, naïve T cells lack the ability to migrate into tissues [101]. In this context it is significant that CCR2-deficient mice, which fail to recruit monocytes to the site of M. tuberculosis infection, are incapable of mounting a Th1 response in vivo [102]. This suggests that cells migrating to the site of infection, under the stimulus of CCR2 signaling, may be able to carry information to the draining lymph nodes to instruct the developing T cell response – a event that has been called an ‘innate bridge’ [102]. After injection of alum, it is therefore possible that the cells that could be affected by and respond to early IL-4 production may not necessarily be T cells themselves but an intermediary cell acting as an innate bridge [37] (Figure 3.5).

3.7 Differential Activation of DCs

Th1

IL-12

IL-12 Th1 inducing stimuli

ThP DC1 CD40-CD40L

IL-10

IL-10

ThP Th2 inducing stimuli

DC2 CD40-CD40L

Tissue

Th2 Lymph Node

Fig. 3.5 Environmental conditioning of DCs and recall in the lymph node. How environmental conditions in the periphery are communicated to the lymph node to regulate T cell development remains unclear, although it is highly likely that DCs play a significant role. Studies have demonstrated that Th1- or Th2-inducing stimuli can induce DCs to produce distinct cytokine profiles and may result in the DCs being conditioned to become Th1-inducing (DC1) or Th2-inducing (DC2) [37, 89]. It has subsequently been proposed that in the lymph node, away from these environmental conditions, DCs recall their experience by reproducing DC1 or DC2 cytokine profiles upon stimulation via CD40-CD40L interactions with T cells [107].

3.7 Differential Activation of DCs

DCs are highly likely to be involved in forming an innate bridge through their recognition of exogenous agents in tissues and subsequent migration to lymph nodes to activate naïve T cells. For DCs to fulfill this role, their differentiation from common precursors into Th1- or Th2-inducing APCs would have to show plasticity [37, 89]. Although several studies have isolated Th1-inducing (DC1) and Th2-inducing DCs (DC2) from lymphoid tissue ex vivo, these cells appear to belong to distinct lineages rather than arise from a common precursor [33, 34]. Nevertheless, further studies have demonstrated that endogenous agents such as IL-12 and/or IFNg can program precursor cells to differentiate into DC1 [32, 103, 104], whereas treatment with IL-4 [103], IL-10 [105], or PgE2 [104] can cause differentiation into DC2. Significantly, exogenous microbial stimuli have also been demonstrated to polarize DCs into DC1 or DC2 [106]. This differential activation of DCs depends on the

63

64

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

microbial stimulus to induce production of either IL-12 (DC1) or IL-10 (DC2) by the DC [107]. DC1-inducing stimuli include a variety of agents that are known TLR ligands [38, 106]. Similarly, many microbial agents have been defined that induce maturation towards DC2. These include ES-62 produced by the filarial nematode Acanthocheilonema viteae [31], soluble egg antigen (SEA) from Schistosoma mansoni, Cholera toxin [106], and heat-killed yeasts [107]. However, in contrast to DC1-inducing stimuli, receptors for these microbial agents have not been clearly defined. This has led speculation that DC2-inducing receptors do not exist and that perhaps induction of Th2 responses occurs due to other mechanisms entirely independent of conventional PAMP/PRR interactions [38]. More recently, this proposal has been challenged by the observation that a lyso-phosphatidylserine unique to S. mansoni eggs and adult worms can interact with TLR2, resulting in Th2 polarization [108]. One temporal limitation of the ‘innate bridge’ concept is that, after encounter with exogenous agents in the periphery, the stimulus to produce polarizing cytokines is lost during transit into the lymphatics. One solution to this problem was suggested by the group of Reis e Sousa, who propose that the experience of interactions with pathogens in the periphery is recalled by DC in the draining lymph node after CD40CD154 interactions with T cells. This interaction causes the DC to secrete high levels of IL-12 or IL-10, depending on the experience of the DC in the periphery (Figure 3.5) [107]. These results suggest a model in which all DCs, irrespective of subset, can behave as flexible APCs. Further studies in this area should therefore allow the rational manipulation of DCs to induce appropriate Th cell responses by using existing or new adjuvants.

3.8 Inappropriate Th1/Th2 Responses to Vaccines

Modulation of the immune response for protection against infectious organisms has resulted in unintentional disease exacerbation, most notably in clinical trials of a pediatric RSV vaccine in the 1960s [109]. However, in murine models with parasite pathogens such as Schistosoma and Leishmania, the consequences of inappropriate Th1 or Th2 induction have been apparent. Th1 polarization with SEA from S. mansoni emulsified in FCA produced a vigorous Th1-mediated inflammatory response, but this resulted in unforeseen exacerbation of immunopathology compared with immunization with SEA alone and ultimately resulted in death [110]. Similarly, in Leishmania infection, where it has been recognized that Th1 responses are protective and Th2 responses exacerbate disease, only use of appropriate Th1-inducing adjuvants can lead to protection [93, 111]. One of the most effective adjuvants for Th1 induction in this model is IL-12 [98]; however, it is clear that IL-12 may also participate in a severe inflammatory response, resulting in unwanted tissue damage [112]. Thus, caution should be exercised when attempting to design vaccines, which must be protective as well as safe.

3.10 Human Th1 Vaccines

3.9 Human Th2 vaccines

To a large extent, the development of new-generation Th2 vaccines has focused on improving the safety, efficacy, and public acceptability of existing vaccines. MF-59 stimulates potent Th2 responses to a variety of vaccine antigens, with concomitant production of IL-4 and IL-5 [23]. Furthermore, this adjuvant has been combined with subunit influenza antigens and is a more effective adjuvant than alum [113]. Importantly, the addition of MF-59 to subunit influenza vaccines significantly enhances the immune response in elderly patients without causing clinically important changes in the safety profile of the influenza vaccine [113, 114]. As a result of this impressive safety profile, MF-59 has also recently been clinically tested in pediatric vaccines [115]. Other adjuvants used for Th2 potentiation in clinical trials include chitosan, which stimulates mucosal immunity to a formulation of the nontoxic mutant of diphtheria toxin, with subsequent enhancement of local and systemic antibody after nasal challenge [116]. Nevertheless, alum remains the main adjuvant approved for human use. Furthermore, the rational application of immunomodulators to adjuvants such as alum that are in current clinical use suggests potential strategies to generate more effective Th2 [117] or indeed Th1 [16] responses.

3.10 Human Th1 Vaccines

Few vaccines induce effective Th1 responses in humans. Those vaccines that do, for example, BCG [118] and whole cell pertussis vaccines [119], have been associated with local or systemic toxicity. Due to its ability to induce Th1 responses and its continued use in humans, BCG vaccines have been exploited as vaccine carriers, for example, in HIV/AIDS, tuberculosis, and malaria vaccines [120]. This approach uses recombinant BCG expressing the vaccine to generate immunity as part of the immune response to the organism. A simpler approach has been to incorporate BCG as an adjuvant as part of the vaccine [121]. However, although this approach appears to be capable of inducing Leishmania-specific Th1 responses, the duration of these responses was limited and the vaccine failed to protect volunteers [121]. This suggests that providing long-term Th1 immunity may require antigen persistence together with a persisting Th1 stimulus such as IL-12 [122]. However, as mentioned above, administration of IL-12 to humans is not without problems in itself, as clinical trials in cancer immunotherapy have shown [123]. Nevertheless, research into various TLR ligands continues to suggest novel adjuvants for Th1 responses that may find use in human vaccines. For example, bacterial lipoproteins (BLPs) such as the 19 kDa secreted lipoprotein from M. tuberculosis and synthetic lipopeptides comprising the active portion of these ligands are effective adjuvants in vitro [124]. These compounds appear to work via TLR2 on APCs to induce costimulatory molecule expression and inflammatory cytokine secretion [124]. Sig-

65

66

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

nificantly, BLPs have been found to be safe in human trials, although they were unable to stimulate sufficient HIV-specific immunity in a therapeutic vaccine trial [125]. Nevertheless, further clinical trials have demonstrated that the ability of BLPs to stimulate Th1 responses can be enhanced by the addition of alum and QS21 as coadjuvants [126]. As with IL-12, an unwanted consequence of the adjuvant activity of TLR ligands may be the resulting immunopathology that could occur, although the clinical data above argue against this. However, as with other Th1 adjuvants, questions of efficacy remain and the transition from laboratory to clinical vaccination remains elusive. Nevertheless, recent insights into immune mechanisms will continue to pave the way for more rational design of Th1 adjuvants.

3.11 Conclusion

There is clearly a major demand for vaccines capable of eliciting strong Th1-type, cellular immune responses for effective vaccination against, amongst other diseases, HIV/AIDS, tuberculosis, and malaria. Although vaccines based on live, attenuated pathogens will continue to have an impact in the future of vaccination, regulatory conditions dictate that most vaccines will preferably be based on nonliving or even nonreplicating vaccines. Furthermore, the increasing prevalence of immunosuppressed individuals makes the use of live vaccines less likely, due to their potential virulence. For nonliving vaccines to be effective inducers of Th1 responses, formulation with an adjuvant is essential. The types of adjuvant that induce potent Th1 responses are likely to be intimately connected with the induction of inflammatory responses, with consequent safety concerns. Furthermore, the maintenance of Th1 immunity may require persistence of inflammation, as has been seen in Leishmania vaccines, which raises further safety implications. It is possible that environmental exposure to infectious agents after vaccination could provide this long-term stimulus, although not if the complete eradication of these diseases is an objective. Clearly, the demand for new, safe, and effective Th1-stimulating adjuvants has never been so central to successful vaccination. Continuing to explore the immunological mechanisms that regulate Th1 immunity is the only possible route to identifying potential candidates to fulfill this demand in a rational and informed fashion.

References

References 1. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002, 2, 283–291. 2. Moorthy V, Hill AVS. Malaria vaccines. Br Med Bull 2002, 62, 59–72. 3. Young DB, Stewart GR. Tuberculosis vaccines. Br Med Bull 2002, 62, 73–86. 4. Rosen FS, Steiner LA, Unanue ER. Dictionary of Immunology. Macmillan, London, 1989. 5. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symposia on Quantitative Biology 1989, 54, 1–13. 6. Brewer JM, Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines, Cellular and Molecular Therapy 1997, 3, 233–246 7. Gupta RK, Relyveld EH, Lindblad EB, et al. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293–306. 8. Woodard LF. Surface chemistry and classification of vaccine adjuvants and vehicles, in Bacterial Vaccines, ed. A Mizraki, Alan R. Liss, New York 1990, 281–306. 9. Brewer JM, Conacher M, Satoskar A, et al. In interleukin-4 deficient mice, alum not only generates T helper-1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper-2 cytokine production. Eur J Immunol 1996, 26, 2062–2066. 10. Maletto B, Ropolo A, Moron V, Pistoresi-Palencia MC. CpG–DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J Leukoc Biol 2002, 72, 447–454. 11. Skeiky YA, Coler RN, Brannon M, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111 f.) formulated in MPL adjuvant. Vaccine 2002, 20, 3292–3303. 12. Beignon AS, Briand JP, Rappuoli R, et al. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma inter-

13.

14.

15.

16.

17.

18.

19.

20.

21.

feron after coapplication onto bare skin. Infect Immun 2002, 70, 3012–3019. Smith RE, Donachie AM, Grdic D, et al. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J Immunol 1999, 162, 5536–5546. Mohamedi SA, Brewer JM, Alexander J, et al. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Vaccine 2000, 18, 2083– 2094. Brewer JM, Roberts CW, Conacher M, et al. An adjuvant formulation which preferentially induces Th1 cytokine and CD8+ cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production. Vaccine Res 1996, 5, 77–89. Jankovic D, Caspar P, Zweig M, et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol 1997, 159, 2409–2417. Stern BV, Boehm BO, Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFNgamma-dependent CD4 cell immunity. J Immunol 2002, 168, 6099–6105. Jones DE, Palmer JM, Burt AD, et al. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology 2002, 36, 679–686. Newman KD, Samuel J, Kwon G. Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release 1998, 54, 49–59. Venkataprasad N, Coombes AG, Singh M, et al. Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 1999, 17, 1814–1819. Brewer JM, Conacher M, Mohrs M, et al. Aluminium hydroxide adjuvant initiates strong antigen specific Th2 responses in the absence of IL-4 or IL-13

67

68

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

mediated signalling. J Immunol 1999, 163, 6448–6454. Valensi JPM, Carlson JR,Van NGA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994, 153, 4029–4039. Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998, 16, 1822–1827. Boyaka PN, Ohmura M, Fujihashi K, et al. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J Immunol 2003, 170, 454– 462. Schroder U, Svenson SB. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/ fatty acid lipid suspensions as adjuvants. Vaccine 1999, 17, 2096–2103. Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Ann Rev Immunol 1983, 1, 143–173. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989, 7, 481–511. Khoruts A, Mondino A, Pape KA, et al. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 1998, 187, 225–236. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Ann Rev Immunol 2000, 18, 767– 811. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392, 245–252. Whelan M, Harnett MM, Houston KM, et al. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J Immunol 2000, 164, 6453–6460.

32. Maldonado L, Pez R, Maliszewski C, et al. Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(–) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 2001, 167, 4345–4350. 33. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283, 1183–1186. 34. Bottomly K. T cells and dendritic cells get intimate. Science 1999, 283, 1124– 1125. 35. Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including Bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 1993, 178, 479–488. 36. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med 1995, 182, 283–288. 37. Kalinski P, Hilkens CM,Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999, 20, 561–567. 38. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002, 14, 380–383. 39. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589, 1–13. 40. Bendelac A, Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 2002, 195, 19F–23. 41. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002, 20, 197–216. 42. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5, 1249–1255. 43. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2, 947–950. 44. Sun H, Pollock KG, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003, 21, 849–855. 45. WHO: Immunological Adjuvants.

References

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

56.

57.

58.

WHO Technical Report, Series 595 World Health Organisation, Geneva 1976. Bennett B, Check IJ, Olsen MR, Hunter RL. A comparison of commercially available adjuvants for use in research. J Immunol Meth 1992, 153, 31–40. Warren HS,Vogel FR, Chedid LA. Current status of immunological adjuvants. Ann Rev Immunol 1986, 4, 369– 388. Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993, 187, 430–446. Dupuis M, Murphy TJ, Higgins D, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998, 186, 18–27. Dupuis M, Denis-Mize K, LaBarbara A, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 2001, 31, 2910–2918. Glenny AT, Pope CG,Waddington H, Wallace U. Immunological notes. XXIII. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926, 29, 38–39. White JL, Hem SL. Characterization of aluminium-containing adjuvants. Dev Biol (Basel) 2000, 103, 217–228. Lindblad EB. Aluminium adjuvants, in The theory and Practical Application of Adjuvants, ed DES Stewart-Tull, John Wiley & Sons, Chichester 1994, 21–36. Hamaoka T, Katz DH, Bloch KJ, Benacerraf B. Hapten specific IgE antibody responses in mice. 1. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. J Exp Med 1973, 138, 306–311. Bomford R. The comparative selectivity of adjuvants for humoral and cell mediated immunity. Clin Exp Immunol 1980, 39, 435–441. O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8, 275–283. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2, 933–944. Grun JL, Maurer PH. Different T

59.

60.

61.

62.

63.

64.

65.

66.

67.

68.

helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses. Cell Immunol 1989, 121, 134–145. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406, 793– 798. Freund J, Casals J, Hosmaer EP. Sensitisation and antibody formation after injection of tubercule bacilli and paraffin oil. Proc Soc Exp Biol Med 1937, 37, 509–513. Holmdahl R, Lorentzen JC, Lu S, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 2001, 184, 184–202. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998, 16, 1025– 1031. Yang X, Gieni RS, Mosmann TR, HayGlass KT. Chemically modified antigen preferentially elicits induction of Th1like cytokine synthesis patterns in vivo. J Exp Med 1993, 178, 349–353. Dal Monte PR, Szoka FC, Jr. Effect of liposome encapsulation on antigen presentation in vitro: comparison of presentation by peritoneal macrophages and B cell tumors. J Immunol 1989, 142, 1437–1443. Parish CR, Liew FY. Immune response to chemically modified flagellin. III. Enhanced cell mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med 1972, 135, 298–311. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen presenting cell type. J Exp Med 1995, 181, 1081–1089. Constant S, Pfeiffer C, Woodard A, et al. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med 1995, 182, 1591–1596. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses:

69

70

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

the alternative approaches. Ann Rev Immunol 1997, 15, 297–322. Hosken NA, Shibuya K, Heath AW, et al. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor–alphabeta– transgenic model. J Exp Med 1995, 182, 1579–1584. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Ann Rev Immunol 2000, 18, 451–494. Vieira PL, Kalinski P, Wierenga EA, et al. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol 1998, 161, 5245–5251. Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999, 162, 3256–3262. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002, 39, 531–536. Brewer JM, Conacher M, Gaffney M, et al. Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of alum and Freund’s adjuvant. Immunol 1998, 93, 41–48. La Flamme AC, Pearce EJ. The absence of IL-6 does not affect Th2 Cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses. J Immunol 1999, 162, 5829–5837. Weaver CT, Unanue ER. The costimulatory function of antigen presenting cells. Immunol Today 1990, 11, 49–55. Schijns V, Claassen I,Vermeulen AA, et al. Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-alpha, interleukin-1alpha, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine. J Gen Virol 1994, 75, 55–63. Satoskar AR, Okano M, Connaughton S, et al. Enhanced Th2-like responses in IL-1 type 1 receptor-deficient mice. Eur J Immunol 1998, 28, 2066– 2074.

79. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995, 13, 251–276. 80. Scott P. IL-12: Initiation cytokine for cell-mediated immunity. Science 1993, 260, 496–497. 81. Afonso LCC, Scharton TM,Vieira LQ, et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263, 235–237. 82. Gollob JA, Kawasaki H, Ritz J. Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol 1997, 27, 647– 652. 83. Ouyang W, Ranganath SH,Weindel K, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4independent mechanism. Immunity 1998, 9, 745–755. 84. Himmelrich H, Parra-Lopez C, Tacchini-Cottier F, et al. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major downregulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12. J Immunol 1998, 161, 6156–6163. 85. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996, 4, 471–481. 86. Brewer JM, Tetley L, Richmond J, et al. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J Immunol 1998, 161, 4000–4007. 87. Grdic D, Smith R, Donachie A, et al. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur J Immunol 1999, 29, 1774– 1784. 88. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997, 148, 504–520. 89. Reis e Sousa C. Dendritic cells as sen-

References

90.

91.

92.

93.

94.

95.

96.

97.

98.

99.

100.

sors of infection. Immunity 2001, 14, 495–498. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001, 294, 870–875. Lederer JA, Liou JS, Kim S, et al. Regulation of NF-kappa B activation in T helper 1 and T helper 2 cells. J Immunol 1996, 156, 56–63. Kopf M, Le Gros G, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993, 362, 245–248. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002, 2, 845–858. Morris SC, Coffman RL, Finkelman FD. In vivo IL-4 responses to anti-IgD antibody are MHC class II dependent and beta 2-microglobulin independent and develop normally in the absence of IL-4 priming of T cells. J Immunol 1998, 160, 3299–3304. Hilton DJ, Zhang JG, Metcalf D, et al. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996, 93, 497–501. Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996, 17, 108–110. Hou J, Schindler U, Henzel WJ, et al. An interleukin-4-induced transcription factor: IL-4 Stat. Science 1994, 265, 1701–1706. Kenney RT, Sacks DL, Sypek JP, et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163, 4481–4488. Walls RS. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen dependent mechanisms. Proc Soc Exp Biol Med 1977, 156, 431– 435. Francis K, Palsson BO. Effective intercellular communication distances are determined by the relative time constants for cyto/chemokine secretion

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

and diffusion. Proc Natl Acad Sci USA 1997, 94, 12258–12262. Melchers F, Rolink AG, Schaniel C. The role of chemokines in regulating cell migration during humoral immune responses. Cell 1999, 99, 351–354. Peters W, Scott HM, Chambers HF, et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2001, 98, 7958–7963. Sato M, Iwakabe K, Kimura S, Nishimura T. Functional skewing of bone marrow derived dendritic cells by Th1 or Th2 inducing cytokines. Immunol Lett 1999, 67, 63–68. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000, 164, 4507–4512. De Smedt T,Van Mechelen M, De Becker G, et al. Effect of interleukin10 on dendritic cell maturation and function. Eur J Immunol 1997, 27, 1229–1235. de Jong EC,Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cellpromoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002, 168, 1704–1709. Edwards AD, Manickasingham SP, Sporri R, et al. Microbial recognition via toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002, 169, 3652–3660. van der Kleij D, Latz E, Brouwers JFHM, et al. A novel host–parasite lipid cross-talk: schistosomal lyso-phosphatidyl serine activates toll-like receptor 2 and affects immune polarisation. J Biol Chem 2002, 277, 48122–48129. Hussell T, Humphreys IR. Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol 2002, 130, 359–362. Rutitzky LI, Hernandez HJ, Stadecker MJ. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection.

71

72

3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination

111.

112. 113.

114.

115.

116.

117.

118.

Proc Natl Acad Sci USA 2001, 98, 13243–13248. Russell DG, Alexander J. Effective immunisation against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988, 140, 1274–1279. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995, 270, 908. Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999, 17, 1075–1081. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19, 2673–2680. Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002, 21, 133–138. Mills KHG, Cosgrove C, McNeela EA, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. Infect Immun 2003, 71, 726– 732. Near KA, Stowers AW, Jankovic D, Kaslow DC. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect Immun 2002, 70, 692–701. Sander B, Skansen-Saphir U, Damm O, et al. Sequential production

119. 120.

121.

122.

123.

124.

125.

126.

of Th1 and Th2 cytokines in response to live bacillus Calmette-Guerin. Immunol 1995, 86, 512–518. Mills KH. Immunity to Bordetella pertussis. Microbes Infect 2001, 3, 655–677. Letvin NL, Bloom BR, Hoffman SL. Prospects for vaccines to protect against AIDS, tuberculosis, and malaria. JAMA 2001, 285, 606–611. Sharifi I, FeKri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351, 1540–1543. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998, 4, 1409–1415. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3, 409–417. Sieling PA, Chung W, Duong BT, et al. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 2003, 170, 194–200. Seth A,Yasutomi Y, Jacoby H, et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 2000, 16, 337–343. Nardin EH, Oliveira GA, CalvoCalle JM, et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 2000, 182, 1486–1496.

73

4 Memory Alexander Ploss and Eric G. Pamer

4.1 Introduction

Immunologic memory, manifested as specific resistance to a second encounter with a pathogen, has been appreciated for more than 2000 years. In his book The History of the Peleponnesian War, Thucydides describes how a plague – the true pathogen is unknown – swept through Athens in 431 BCE [1]. Thucydides made several observations on the plague, including the fact that those who survived an infection were ‘never attacked twice – never at least fatally’. In other words, the few individuals surviving a first episode of plague did not develop disease when similar epidemics recurred. Although many similar examples of immunity following survival of infection were appreciated over the millennia, intentional exploitation of the mammalian immune system to prevent disease is a relatively recent activity. Between 1718 and 1721, Lady Mary Wortley Montagu, the wife of the British Ambassador to Constantinople, described in her letters a local practice among the Turks for preventing smallpox [2]. Turkish women infected healthy individuals intravenously with a small inoculum of matter collected from smallpox lesions, which caused a mild form of the disease, but rendered the person immune to severe smallpox. Almost 80 years later, in 1796, the British physician Edward Jenner reported successful protection of humans against smallpox infection by vaccination with cowpox virus [3]. Vaccination, a term derived from vacca (Latin for cow), became widespread upon confirmation of Jenner's results [4]. Nearly a century later, Louis Pasteur, while attempting to demonstrate the bacterial cause of chicken cholera, discovered that bacteria grown in culture lose their virulence but maintain the ability to elicit protective immunity. His discovery that chickens immunized with attenuated bacteria developed only mild disease but became resistant to infection with fully virulent bacteria of the same species validated Jenner's concept of immunization [5]. Thus, in the late 19th century, immunization with attenuated vaccines was developed for a number of diseases and applied in Europe and America. However, many vaccines, particularly those focusing on syphilis, tuberculosis, and salmonellosis, were unsuccessful. Neither Pasteur nor Robert Koch, who outlined

74

4 Memory

the parameters required to characterize an infectious disease [6], could explain mechanisms of infectious disease and immune defense. Groundbreaking work by Emil von Behring and Shibasaburo Kitasato led to the discovery of antibodies, opening the field of ‘humoral’ immunity. Serum transfer from animals infected with diphtheria into healthy animals and subsequent infection with the pathogen made recipient animals resistant to the normally lethal inoculum. This method of conferring ‘passive immunity’ provided the first real opportunity to define immune mechanisms. The nature of the antitoxin antibody was recognized by von Behring and Kitasato to be diphtheria-specific, because it could not confer protection to any other disease [7]. The intense focus on serum-mediated immunity relegated the demonstration by Metchnikoff of cell-mediated antimicrobial defense to the back burner, and it took many decades for this aspect of protective immunity to gain a position at center stage [8]. Indeed, a series of seminal papers by Murphy, including experiments demonstrating the ‘role of lymphoid tissue in the resistance to experimental tuberculosis in mice’ [9], remained widely unrecognized [10]. Not until the 1940s did Medawar and Gibson redirect attention to cell-mediated inflammatory processes [11]. Medawar and Gibson observed that skin graft rejection correlates with cellular infiltration [12, 13]. The pioneering experiments of Landsteiner and Chase showed that resistance to tuberculosis could be established by passive transfer of mononuclear cells [14, 15]. Additional studies by Mackaness and colleagues demonstrated the critical role of cellular immunity in certain bacterial infections [16]. Subsequently, Gowans demonstrated that adaptive immunity is mediated by recirculating, long-lived lymphocytes [17, 18]. The thymic origin of these lymphocytes, which were therefore termed T cells, was recognized, and they were shown to play a central role in mediating resistance to intracellular pathogens [19, 20]. The role of CD4+ and CD8+ T lymphocyte subsets in adoptive protection against intracellular infection was elucidated shortly thereafter [21–23]. Both CD4+ and CD8+ T cells provide long-term protective immunity against infections, and much has been learned in the last decade about T cellmediated immunity. This chapter reviews our current understanding of immunologic memory, focusing on more recent advances.

4.2 Characteristics of Memory Cells

Memory T and B lymphocytes mediate long-term protective immunity to infectious pathogens. A characteristic feature of memory cells is their long-term survival in the absence of reexposure to the pathogen. Additional characteristics of memory T cells are their increased frequency and enhanced responsiveness to antigen. Thus, upon reexposure to antigen following secondary infection, memory cells expand more rapidly and vigorously and acquire effector functions faster than naïve T cells [24–26]. Indeed, lower concentrations of antigen [27] and less costimulation [28] are required for memory T cell activation. The physiologic basis for these hallmarks of immune memory has become clearer in recent years.

4.3 CD8+ T Cell Memory

4.3 CD8+ T Cell Memory 4.3.1 Phenotyping Memory CD8+ T Cells

Memory T cell subsets are commonly distinguished from naïve cells on the basis of surface marker expression. A number of surface molecules associated with memory and naïve CD8+ T cells are involved in cell adhesion and chemotaxis, consistent with distinct trafficking of different T cell populations. The expression of the adhesion molecules CD44 and CD62L has been used to define memory cells. Although CD44lo and CD62Lhi are naive cells, they become CD44hi and CD62Llo upon activation. To make matters more complicated, however, CD62L is reexpressed on a fraction of memory cells, and expression of CD44 varies among different mouse strains [29]. Recent studies have demonstrated that memory CD8+ T cells can be divided into effector memory (CD62Llow CCR7-) and central memory (CD62Lhi CCR7+) populations, on the basis of L-selectin (CD62L) and CC-chemokine receptor 7 (CCR7) expression [30, 31]. The expression of tyrosine phosphatase CD45 isoforms is also used to distinguish between T cell differentiation stages. The CD45RB isoform is generally detected on naive cells, but memory cells express the CD45RA and CD45RO isoforms. However, because CD45 isoform expression on memory versus naïve T cells is complex and can change with nonspecific activation and cytokine treatment, CD45 is a relatively unreliable marker for memory T cell definition [32]. The IL-2 receptor a chain (CD25) and CD69 are rapidly expressed by T cells upon encountering cognate antigen, but their expression is not sustained on memory T cells. Some memory T cells, however, express the IL-2 receptor b beta chain (CD122), a component common to both IL-2 and IL-15 receptors, the latter cytokine being essential for memory CD8+ T cell maintenance [33, 34]. Ly-6C has also been used as a marker to distinguish effector from memory T cells. Low and intermediate expression of this marker is characteristic of effector T cells, but it is highly expressed on memory T cells [27, 35–37]. More recently, classification of human virus-specific T cells into naïve, effector, and memory cells on the basis of CD27 and CD28 expression was described [38]. Human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and hepatitis C virus (HCV) specific T cells, although similar during primary infection, give rise to distinct memory T cell populations during chronic infection, which are characterized by differential expression of various surface antigens and effector molecules. Naïve CD8+ T cells have CD27+ CD28+ and express CCR7. Early and intermediate effector T cells downregulate CD28, CCR7, and CD45RA and express cytotoxic factors such as perforin, granzyme A, and GMP-17 (a marker for cytotoxic granules and lysosomes). Memory cells appear to lose the CD28, CD27, and CCR7 markers and maintain CD45 expression at low levels. They exhibit a greater cytotoxic potential than nonprimed cells, and their telomeres are shortened. In this study, T cell populations responding to persistent viral infections were more diverse

75

76

4 Memory

than expected. EBV and HCV promoted the development of early effector memory T cells, but HIV induced intermediate and CMV induced terminally differentiated memory T cells. In aggregate, recent studies demonstrate the remarkable diversity within memory T cell populations and illustrate the importance of integrating phenotypic and functional characteristics when assessing memory T cells. 4.3.2 Enhanced Responsiveness of Memory CD8 + T cells: Potential Mechanisms

Enhanced sensitivity of memory T cells for cognate antigen likely results at least in part from more rapid signal transduction. Priming of naïve T cells leads to association of the tyrosine kinase Lck with the CD8 coreceptor, thereby enhancing TCR signaling. The association between Lck and CD8 is maintained in memory cells and contributes to the lower stringency for activation of effector and memory cells [39]. Additional qualitative differences have been reported further downstream in the signaling cascade, involving the mitogen-activated protein (MAP) kinases ERK1 and 2 (extracellular signal-regulated kinase), which activate transcription factors essential for T cell activation. In contrast to naïve T cells, memory cells show an increased ability to phosphorylate ERK1 and ERK2, thereby accelerating signal propagation [40]. In addition to enhancing the rate of T cell activation, regulation of signaling molecules can also influence activation-induced differentiation of memory cells. For example, transgenic mice expressing a partially calcium-independent mutant of the calcium/calmodulin kinase II (CaMKII) gB show an increase in the number of T cells in secondary lymphoid organs with a memory phenotype, suggesting that this kinase is important for the development of memory [41]. Lymphocyte differentiation is associated with programmed alterations in gene expression, which is largely regulated by structural changes in chromatin [42]. Distinct gene expression profiles have been reported for memory cells [40]. For example, mRNA levels for several cytokines including RANTES [43], interferon-g (IFN-g), and cytotoxic molecules such as perforin and granzyme B [44–48] are elevated in memory T cells. Transcripts for these genes are rapidly translated in memory T cells following TCR stimulation, circumventing the time required for transcriptional activation. 4.3.3 Generation of Memory CD8+ T Cells

Studies of CD8+ T cell memory have been greatly facilitated by the increasing spectrum of mice with targeted genetic deletions. For example, mice deficient in CD27, a member of the TRAF-linked tumor necrosis factor (TNF) receptor family that plays a costimulatory role during T cell priming, have a markedly diminished virus-specific memory CD8+ T cell response [49]. On the other hand, mice lacking the CD28 costimulatory molecule, although deprived of CD86-mediated helper signals, mount nearly normal memory CD8+ T cell responses in response to lymphocytic choriomeningitis virus (LCMV) or Listeria monocytogenes infection [50, 51], supporting the

4.3 CD8+ T Cell Memory

notion that the costimulatory networks contain built-in redundancies that can compensate for the absence of CD28. However, costimulatory requirements for memory T cell generation can vary significantly, because different pathogens create distinct inflammatory milieus. For example, induction of long-term immunity to influenza virus infection, in contrast to LCMV and Listeria monocytogenes infection, requires CD28 signaling [52]. 4-1BB, a TNF receptor family member, is another costimulatory molecule that has an impact on memory T cell formation. Mice lacking 4-1BB ligand have diminished late expansion of virus-specific effector and memory CD8+ T cells, suggesting that 4-1BB signals play a role in sustaining T cell activation and memory generation [53, 54]. TNFR-associated factor 2 (TRAF2) is an adapter protein, which associates with the cytoplasmic tail of several TNF receptor family members including CD27, CD40, OX40, and 4-1BB and thereby links signals to downstream pathways. Hence, the absence of TRAF2 is likely to abrogate signaling through multiple costimulatory pathways. However, studies using dominant negative forms of TRAF2 demonstrated that in, response to influenza virus infection, only secondary CD4+ and CD8+ T cell expansion is decreased, while the primary expansion is not affected [55]. Cytokines are also implicated in the generation of antigen-specific memory T cells. Infection of IL-15- or IL-15Ra-deficient mice with LCMV generates a potent primary response, but the memory pool decreases gradually over time, leading to impaired secondary CD8+ T cell expansion [56]. This demonstrates differential IL-15 requirements for naïve and memory CD8+ T cells [33]. In the absence of IL-15 signaling, the memory response is also diminished following vesicular stomatitis virus (VSV) infection; however, the primary CD8+ T cell expansion also appeared to be impaired [57]. These studies suggest that in some circumstances IL-15 may play a role in the generation of memory CD8 T cells. CD4+ T cells have also been implicated in the generation of CD8+ T cell memory; however, their importance varies with the type of infection. In the setting of LCMV infection, CD4+ T cells are not necessary for primary CD8+ T cell responses, but they are indispensable for long term CD8+ T cell memory [58]. Remarkably, CD4+ T cells contribute to CD8+ T cell memory at the time of initial priming, because activation of memory CD8+ T cells occurs independently of CD4+ T cell help. In contrast to what occurs during viral infections, generation of memory CD8+ T cells during bacterial infections is less dependent on CD4+ T cells. For example, although mice lacking the class II transactivator (CIITA) have diminished numbers of CD4+ T cells, they generate memory CD8+ T cells following infection with Listeria monocytogenes [59]. Consistent with this result, CD4+ T cell-depleted, CD4-/-, and MHC class II-/mice infected with Listeria monocytogenes mount protective recall responses following secondary challenge [60]. An important mechanism by which CD4+ T cells provide help to CD8+ T cell is through CD40-CD154 interactions [61, 62]. Antigen-presenting cells (APCs) were originally thought to be the mediators for these signals [63]. Recent data demonstrates, however, that activated CD8+ T cells that express CD40 may receive direct help for CD4+ T cells expressing CD154 [64]. Administration of agonistic anti-CD40 monoclonal antibodies greatly enhances the protective potential of adoptively trans-

77

78

4 Memory

ferred L. monocytogenes-specific CD8 T cells, providing further support for the role of CD40 in memory T cell generation and/or maintenance [65]. Signals transmitted from CD4+ T cells are not uniformly stimulatory. In recent years, CD4+ CD25+ T regulatory cells have been implicated in the control of autoimmunity [66]. During infection with Listeria monocytogenes, CD4+ CD25+ T regulatory cells can suppress memory CD8+ T cell expansion [67]. Thus, CD4+ T cells play both positive and negative roles in the control of CD8+ T cell memory. Primary infection with L. monocytogenes induces memory T cells specific for multiple distinct peptides. CD8+ T cells restricted by the nonclassical MHC class Ib molecule H2-M3 and specific for N-formyl methionine peptides expand more rapidly than MHC class Ia-restricted CD8+ T cells during a primary infection. However, the memory responses of H2-M3- versus MHC class Ia-restricted T cells are dramatically different. H2-M3-restricted memory T cells express activation markers upon reencountering antigen [68] but do not proliferate, but MHC class Ia-restricted T cells undergo explosive expansion [69]. The underlying mechanism for this disparity remains unclear but may reflect differences in thymic selection of these two CD8+ T cell types [70]. 4.3.4 Maintaining CD8+ T Cell Memory

Most infections are eliminated by the mammalian host, yet memory T cells persist afterwards for many years. Determining the mechanisms that enable long-term memory T cell persistence in the absence of antigen has been a great challenge. Pioneering studies with adoptively transferred, antigen-specific memory T cells demonstrated the ability of these cells to survive in MHC-deficient mice [71, 72]. These observations provide strong evidence that, once the differentiation program is initiated, memory CD8+ T cells can persist in the absence of antigen. However, immunological T cell memory that is maintained without MHC contact may become functionally impaired. For example, memory CD4+ T cells specific for the male (HY) antigen show defective responses upon rechallenge and also alter their surface phenotype expression if they are kept in MHC deficient hosts [73]. If maintenance of memory T cells is MHC- and antigen-independent, what regulates their persistence? Recent studies have demonstrated that IL-15 is crucial for invivo maintenance of memory CD8+ T cells [74]. Both primary and memory CD8+ T cell expansion is diminished in IL-15- or IL-15-receptor-deficient mice [57], and maintenance of memory T cell populations following immunization is markedly attenuated in the absence of IL-15 signaling [33, 56, 75, 76]. The gradual decline in memory CD8+ T cell numbers in the absence of IL-15 results from decreased proliferation by memory cells [33]. Interestingly, IL-7 can compensate for the missing survival signals in the absence of IL-15. When IL-7 is overexpressed in IL-15-/- mice, memory CD8+ T cells are generated [75], but removal of IL-7 and IL-15 completely inhibits the homeostatic proliferation of CD8+ memory T cells [76]. These findings emphasize the joint contribution of these two cytokines to promoting CD8+ memory T cell proliferation. Surprisingly, IL-2, a factor best known for its ability to stimulate T cell proliferation, appears to play a negative role in memory T cell survival [34].

4.3 CD8+ T Cell Memory

In comparison with effector CD8+ T cells, memory CD8+ T cells express high levels of bcl-2 mRNA and protein, explaining their relative resistance to apoptosis [44, 77]. One effect of IL-15 is to increase bcl-2 levels in memory T cells, providing a second IL-15-mediated mechanism for memory CD8+ T cell maintenance [78]. Cap structures that protect telomeres from degradation and terminal fusion play an essential role in stabilizing chromosome ends [79]. Telomeres tend to progressively shorten when cells proliferate, eventually resulting in death of the proliferating cell. Telomere length, however, can be maintained in cells with activated telomerase, which adds DNA to telomeres with each cell division [80]. Naïve as well as memory T cells undergo massive proliferation following antigen encounter. To compensate for telomere shortening, telomerase is more active in memory than naïve or effector T cells [81], potentially contributing to their long-term survival. 4.3.5 Models of CD8+ T cell Memory Generation

Although some aspects of memory T cell maintenance have been characterized, the mechanisms that generate memory CD8+ T cells are less clear. Several models for memory generation have been proposed and are outlined in this section. The recent introduction of methods that precisely quantify antigen-specific T cells during immune responses has provided immunologists with a framework upon which to build these models. The linear differentiation model of memory T cell formation proposes progressive differenttiation of T cells from naïve to effector to memory cells (Figure 4.1). Following initial stimulation, an activation program drives naïve T cell differentiation into effector cells [82], followed by further differentiation of a subset of effector T cells into memory T cells [83]. Early support for this model came from TCR repertoire analyses of effector and memory T cells. The TCR repertoire of primary CD8+ T cell responses is similar to that of memory CD8+ T cells, suggesting that memory cells are stochastically chosen from the population of effector CD8+ T cells activated during the primary infection [84, 85]. Although linear differentiation of memory T cells was supported by adoptive transfer studies with T cell receptor (TCR) transgenic (tg) CD8+ T cells specific for the male H-Y antigen [86], the most direct evidence in support of this model came from studies using a clever system for genetically marking T cells that had acquired effector function [87]. In this study, memory T cells were derived from effector T cells. When memory cells form during the course of an immune response (Figure 4.1) remains controversial. One recent study demonstrated that T cells require several weeks from the time of antigen encounter to differentiate into memory T cells [40]. Other studies showed that rechallenge of mice with a high inoculum of antigen 5 days after primary immunization resulted in a memory-like CD8+ T cell response, suggesting that memory T cells may already be present during the primary immune response [88]. A variation of the linear differentiation model proposes that different memory T cell subsets develop at different times following T cell priming. According to this model, primed effector T cells can, in the absence of further stimuli, develop into

79

80

4 Memory Model A: Gradual differentiation of memory cells

Model B: Early generation of memory cells

Model C: Pre-programmed memory cell potential

antigen & inflammation

1 week

2 weeks

naïve cell

memory cell

effector cell

memory precursor

3 weeks

Fig. 4.1 Models of programmed memory T cell generation. T lymphocytes may commit to becoming long-term memory T cells at different times during the course of activation. We propose three distinct models for programmed memory T cell development. Model A suggests that differentiation of memory T cells is a gradual process, with naïve T cells first differentiating into effector T cells and then, stochastically, further differentiating into memory T cells. Model B suggests that brief exposure to antigen results in two distinct effector T cell populations, one committed to long-term memory development, and the other to apoptotic death. Model C, on the other hand, proposes that naïve T cells differ in their potential to differentiate into memory T cells (see colour plates page XXXIII).

CCR7+ CD62L+ central memory cells, which home to lymph nodes and lack effector functions. In contrast, effector memory cells, which are CCR7- CD62L-, derive from effector cells that have undergone more prolonged stimulation with antigen. This subset of memory cells produces high levels of effector cytokines, maintains cytolytic activity [30], and traffics to peripheral tissues [31]. Some evidence suggests that effector memory cells can convert to central memory cells upon antigen clearance [89]. Evidence in support of this model comes from the analysis of T cell priming by live versus killed bacterial vaccines. Live bacteria, which induce substantial inflammation, result in large effector memory T cell populations, but killed bacteria, which induce an attenuated inflammatory response, give rise to T cells with a central memory phenotype [59].

4.3 CD8+ T Cell Memory

Another model for memory T cell development is the decreasing-potential model, which is based on the progressive loss of proliferative capacity [90, 91]. The underlying idea of this model is that successful memory T cell generation requires a short duration of antigenic exposure during T cell priming. According to this model, larger numbers of functional memory T cells should be produced when effector T cells are briefly exposed to antigen, thereby avoiding antigen-driven apoptosis (AICD). Support for this model comes from situations of overwhelming antigen dose or during chronic infections, such as with HIV or hepatitis-C, where antigen-specific T cells either disappear or become dysfunctional [92–94]. A variant of the decreasing potential model suggests that the timing of Tcell priming during an immune response determines which cells enter the memory lineage [95]. The circulation of lymphocytes between the blood and lymphatic system is a rather slow process, with turnover times of 12 to 24 hours. Thus, the time that it takes for individual lymphocytes to encounter antigen presented in secondary lymphoid organs can vary significantly. Since antigen presentation is transient [96], cells recruited later encounter antigen for a shorter time period than cells that are initially recruited. Brief exposure to antigen would be sufficient to induce their proliferation and differentiation into effector cells; however, the signal would be inadequate to trigger death pathways. Further studies are required to provide experimental support for this model. The third model for memory T cell generation is the instructive model, which posits that effector and memory T cell differentiation diverges during T cell priming. According to this model, memory T cells directly differentiate from naïve T cells without passing through the effector stage. Although experimental support for this model is sparse, the notion that naïve T cells might take their cues from the inflammatory and costimulatory context and undergo differentiation into either effector or memory T cells remains plausible. T cell programming is a relatively new concept that should be incorporated into models of memory T cell generation (Figure 4.2). Early studies demonstrated that

A.

0

1 2

B.

3 4 5 6 7 8 9 10 11 12 Days Following Infection

Bacterial infection

0

1 2

Innate Immune Response

3 4 5 6 7 8 9 10 11 12 Days Following Infection

Adaptive T cell Response

Fig. 4.2 Antigen-independent proliferation and memory generation. A. Upon infection, innate immune mechanisms initiate pathogen clearance and provide stimuli that enhance T cell priming. Following the contraction phase, a memory lymphocyte population remains. B. CD8+ T cell expansion, contraction, and memory formation do not require progressive infection or prolonged inflammation. After successful priming,T lymphocytes undergo a programmed, antigen-independent expansion.

81

82

4 Memory

CD8+ T cells specific for different epitopes undergo coordinate expansion and contraction in response to infection, despite substantial differences in antigen expression levels and stability of peptide–MHC complexes [97]. One explanation for this finding is the relatively short duration of effective in vivo antigen presentation, which results from down-regulation by the nascent T cell response [96]. Although feedback inhibition limits T cell priming to the very early phase of the infection, the brief period of priming is sufficient to initiate a program of antigen-independent T cell expansion [82, 83]. Remarkably, the process of T cell expansion, contraction [98, 99], and memory formation occur in the absence of both antigen and inflammation.

4.4 CD4+ T Cell Memory

Although CD8+ T cell memory has been extensively investigated, less is known about the generation and maintenance of memory CD4+ T cells. One explanation for this disparity is the difficulty of directly identifying antigen-specific CD4+ T cells during the course of an immune response. One recent study, however, has compared CD4+ and CD8+ memory T cell responses to LCMV and found that virus-specific memory CD4+ T cells decline in frequency over time while memory CD8+ T cells are maintained at high frequencies [100]. In this section we concentrate on recent studies focusing on memory CD4+ T cells. 4.4.1 Differentiation of Effector and Memory CD4+ T Cells

Naïve CD4+ T cells, upon in vivo priming, differentiate into either Th1 or Th2 effector cells. Although the mechanisms leading to Th1 or Th2 differentiation remain incompletely understood, the innate inflammatory response elicited by the invading pathogen plays a major role in this process. Many viruses and bacteria induce IL-12 and interferon-g (IFN-g) secretion, driving the differentiation of naïve CD4+ T cells into Th1 cells. In contrast, Th2 immunity, which is induced by intestinal helminth infection, is associated with innate inflammatory responses that produce IL-4, driving naïve CD4+ T cell differentiation into Th2 cells. Although the Th1/Th2 lineage decision has important consequences for the primary immune response, long-term memory T cells maintain the phenotype induced at the time of priming. Thus, although memory CD4 T cells do not produce cytokines in the absence of stimulation, upon reencountering antigen they rapidly reexpress the cytokines elicited during their primary activation. Several studies have demonstrated that epigenetic chromatin remodeling during the primary T cell response accounts for specific cytokine expression profiles of reactivated memory T cells [101].

4.4 CD4+ T Cell Memory

4.4.2 Phenotype of Memory CD4+ T Cells

Memory CD4+ T cells have a lower threshold for activation than naïve T cells. Indeed, memory CD4+ T cells respond more rapidly to antigen, with enhanced cytokine secretion and greater proliferation in response to low antigen doses [102]. In addition to greater responsiveness to antigen, memory CD4+ T cells are also present at higher frequencies in immune animals [103]. Although cytokine production by naïve CD4+ T cells is restricted to IL-2 and IL-3, memory CD4+ T cells secrete a greater variety of cytokines [104]. Adoptive transfer of in-vitro generated antigen-specific Th1 and Th2 cells leads to long-lived memory cells, which produce a pattern of cytokines closely related to that of the originally transferred cells [104]. As mentioned in the previous section, epigenetic imprinting accounts for the fidelity of memory T cell cytokine production. 4.4.3 Memory Generation and Maintenance

Mechanisms for CD4+ memory T cell generation have not been defined. Although models similar to those outlined for CD8+ T cell memory formation may be applicable to CD4+ T cell memory generation, existing data most strongly support linear differentiation from naïve to effector to memory CD4+ T cells. In-vitro studies, for example, demonstrated that effector CD4+ T cells can differentiate into memory cells without the requirement for cell division [105]. However, the factors involved in the transition from effector to memory T cells remain unclear. Remarkably, CD4+ T cell memory is efficiently generated in the absence of IL-2, IL-4, or IFN-g [32]. As with CD8+ T cells, initial antigen stimulation is sufficient to initiate programmed expansion in CD4+ T cells [106], and extended antigenic stimulation is not required for differentiation into memory cells or for long-term persistence. Indeed, memory CD4+ T cells persist in the absence of both antigen and MHC class II molecules [72]. The cytokine requirements for long-term memory CD4+ T cell survival are distinct from those described for memory CD8+ T cells. For example, while memory CD8+ T cells decrease in frequency in the absence of IL-15, memory CD4+ T cells are maintained independently of IL-15. Consistent with this finding, CD122 is expressed at low levels on memory CD4+ T cells [107]. In addition, memory CD4+ T cells undergo homeostatic proliferation in the absence of both IL-7 and IL-15 [76], and CD4+ T cells from mice deficient in the common cytokine receptor g–chain, which is shared by receptors for IL-2, -4, -7, -9, and -15, can generate long-lived CD4+ memory T cells [108]. Differences in CD8+ and CD4+ T cell memory maintenance have been detected following viral infection: virus-specific CD4+ memory T cells gradually decline, while CD8+ memory T cells remain stable. Although many factors have been excluded as essential to CD4+ T cell memory formation, the underlying mechanisms that drive differentiation of effector into memory T cells remain mysterious.

83

84

4 Memory

4.4.4 Trafficking of Memory CD4+ T Cells

CD8+ as well as CD4+ T cells differentiate in memory subsets with distinct effector functions and migration capacities [30]. The differences in homing and trafficking of CD4+ T cells can be attributed to their expression of the selectin CD62L and the chemokine receptor CCR7. Central memory (CCR7+, CD62L+) CD4+ T cells preferentially home to lymphoid tissues, whereas effector memory (CCR7-, CD62L-) recirculate in peripheral tissues long after immunization. The localization of central and effector memory CD4+ T cells in different organs has been directly visualized by immunohistology on whole body sections [109].

4.5 B cell Memory 4.5.1 Generation of B Cell Memory

Similar to memory T cells, memory B cells respond rapidly to secondary exposure to antigen, proliferating and producing high affinity antibodies. B cells require accessory signals provided by helper T cells for full differentiation and are also activated by certain microbial stimuli. There are two distinct developmental pathways for antigen-specific B cells [110]. B-1 and marginal zone B cells proliferate and differentiate into antibody-secreting plasma cells, thereby providing the most rapid humoral response to antigen. Although many plasma cells have a life span limited to a few days or weeks, some develop into long-lived cells that mediate long-term humoral immunity. Some antigen-activated B cells migrate into follicles where they proliferate and form germinal centers (GCs), an important site of antibody secretion and affinity maturation. B cells expressing high affinity immunoglobulins receive positive signals from T helper cells, leading to B cell proliferation, survival, and maturation. Lymphotoxin (LT) is important for development of peripheral lymphoid organs, since mice lacking lymphotoxin-a (LT-a) receptor have no lymph nodes or Peyer’s patches and fail to form germinal centers. These structural deficits are linked to defective isotype-switching following primary or secondary immunization with T celldependent antigens [111]. The important role of germinal centers in memory B cell formation was demonstrated in adoptive transfer experiments [112]. B cells from LT-a-/- donors were capable of giving rise to a memory population, whereas a memory IgG B cell response could not be elicited in LT-a-/- hosts. These studies clearly support previous observations, which point out the important role of germinal center structures for memory B cell development [113–115]. Some of the factors determining the lineage decision between plasma cells and memory B cells have been identified [116–118] and include cell surface receptors, cytokines, and transcriptional regulators. Stimulation through CD40-CD154, IL-4, expression of PAX5 and BCL-6 inhibit plasma cell differentiation. On the other hand,

4.5 B cell Memory

absence of CD40, IL-3, IL-6, and IL-10 and the commensurate degradation of BCL-6 and induction of Blimp-1 (B-lymphocyte-induced maturation protein 1) promote plasma cell differentiation. CD4+ T cells are crucial for the generation of long-term humoral immunity. Direct antigen-specific T–B cell interactions have been visualized with adoptive transfer systems [119], and the molecular requirements for CD4+ T cell help were identified recently. One important participant in this process is the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP), which was originally identified as altered in X-linked lymphoproliferative syndrome (XLP). SAP controls signaling via the family of SLAM surface receptors, including CD84, CD150 (SLAM), CD229, and CD244 and hence plays a fundamental role in T cell function [120]. Mice deficient in the SAP gene (SAP-/-) mount strong antibody responses during an acute viral infection, but they fail to generate long-lived virus-specific plasma and memory B cells [121]. Adoptive transfer experiments demonstrated that SAP expression by CD4+ T cells, but not B cells, is essential for generation of long-term humoral immunity. 4.5.2 Maintenance of B Cell Memory

It has been proposed that long-term humoral immunity is maintained by memory B cells, which continuously differentiate into short-lived plasma cells [122, 123]. Recently, however, long-lived plasma cells were shown to survive for prolonged periods of time and maintain humoral immunity in the absence of memory B cells [124]. Maintenance of humoral immunity appears to be antigen independent, because memory B cells persist in the absence of antigen [125]. Some experiments support the hypothesis that survival of long-lived plasma cells is determined by microenvironment rather than intrinsic factors. In-vitro experiments, for example, show that plasma cells isolated from tonsils undergo apoptosis unless rescued by stromal cells [126]. Further support for this concept comes from the observation that plasma cell maintenance is restricted by the capacity of the splenic red pulp to provide `space' [127], suggesting that plasma cell homeostasis is regulated by competition for specific survival niches [128]. Nerve growth factor (NGF) regulates neuronal cell development and survival [129]. The finding that patients with autoimmune disorders often have elevated NGF plasma levels [130, 131] and that NGF receptor shares structural similarities with some cytokine receptors suggested a role for this cytokine in the immune system. B cells can produce NGF under basal conditions and constitutively express NGF receptors. It turns out that NGF acts as an autocrine survival factor for memory B cells and that its neutralization completely inhibits humoral memory responses [132].

85

86

4 Memory

4.6 Conclusions

The journey to deciphering memory T and B cell development continues to be a great scientific adventure, and many unanswered questions remain that will require additional clever models and experiments. The motivation for moving forward, however, is substantial. Delineating basic mechanisms is important, and applying the knowledge gained from an enhanced understanding of immunologic memory to the development of vaccines against both infectious diseases and malignancies will be especially satisfying.

Acknowledgements

We thank Drs. Phillip Wong, Heather van Epps, Amariliz Rivera, Adrian Davies, and Maria Lara-Tejero for useful discussions and critically reading the manuscript. We also thank Holger Dormann and Sarah Amsellem for technical assistance.

References 1. Thucydides,The Peleponnesian War. ed. W. Connor, Everyman Library Series, Charles E. Tuttle Co., Inc., Boston, 1993. 2. R. E. Halsband, The Complete Letters of Lady Mary Wortley Montagu. Clarendon Press, Oxford 1966. 3. E. Jenner, An Inquiry into the Causes and Effects of the Variolœ Vaccinœ, a Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox, 1st edition. Low, Sampson, London 1798. 4. Encyclopaedia Britannica Inc, Chicago, 15th Edition, 2001. 5. L. Pasteur, De l’attenuation du virus du cholera des poules, Comptes rendus de l’Academie des sciences 1880, 91, 673–680. 6. R. Koch, Untersuchungen über die Aetiologie der Wundinfectionskrankheiten. F. C. W. Vogel, Leipzig 1878. 7. S. Kitasato, Collected Papers of Shibasaburo Kitasato. Kitasato Institute, Tokyo 1977. 8. A. M. Silverstein, A History of Immunology. Academic Press, San Diego 1989. 9. J. B. Murphy, A. W. M. Ellis, Journal of Experimental Medicine 1914, 20, 397–403.

10. A. M. Silverstein, Nat. Immunol. 2001, 2, 569–571. 11. T. Gibson, P. M. Medawar, Journal of Anatomy 1943, 77, 299. 12. P. M. Medawar, Journal of Anatomy 1944, 78, 176. 13. P. M. Medawar, Journal of Anatomy 1945, 79, 157. 14. K. Landsteiner, M. W. Chase, Proc. Soc. Exp. Biol. Med. 1942, 49, 688–689. 15. M. W. Chase, Proc. Soc. Exp. Biol. Med. 1945, 59, 134–135. 16. G. B. Mackaness, R. V. Blanden, Prog Allergy 1967, 11, 89–140. 17. J. L. Gowans, E. J. Knight, Proc. R. Soc. London Ser. B 1964, 159, 257–282. 18. V. T. Marchesi, J. L. Gowans, Proc. R. Soc. London Ser. B 1964, 159, 283–290. 19. F. C. Lane, E. R. Unanue, J. Exp. Med. 1972, 135, 1104–1112. 20. R. J. North, Cell Immunol. 1973, 7, 166–176. 21. S. H. Kaufmann et al., J. Exp. Med. 1979, 150, 1033–1038. 22. I. Muller et al., Infect. Immun. 1987, 55, 2037–2041. 23. T. Pedrazzini et al., J. Immunol. 1987, 139, 2032–2037.

References 24. B. K. Cho et al., Proc. Natl. Acad. Sci. USA 1999, 96, 2976–2981. 25. C. Zimmermann et al., Eur. J. Immunol. 1999, 29, 284–290. 26. R. M. Kedl, M. F. Mescher, J. Immunol. 1998, 161, 674–683. 27. M. Pihlgren et al., J. Exp. Med. 1996, 184, 2141–2151. 28. A. Mullbacher, K. Flynn, Immunol. Rev. 1996, 150, 113–127. 29. R. C. Budd et al., J. Immunol. 1987, 138, 3120–3129. 30. F. Sallusto et al., Nature 1999, 401, 708–712. 31. D. Masopust et al., Science 2001, 291, 2413–2417. 32. R. W. Dutton et al., Annu. Rev. Immunol. 1998, 16, 201–223. 33. A. W. Goldrath et al., J. Exp. Med. 2002, 195, 1515–1522. 34. C. C. Ku et al., Science 2000, 288, 675– 678. 35. A. Cerwenka et al., J. Immunol. 1998, 161, 97–105. 36. A. W. Goldrath et al., J. Exp. Med. 2000, 192, 557–564. 37. K. Murali-Krishna, R. Ahmed, J. Immunol. 2000, 165, 1733–1737. 38. V. Appay et al., Nat. Med. 2002, 8, 379– 385. 39. M. F. Bachmann et al., J. Exp. Med. 1999, 189, 1521–1530. 40. S. M. Kaech et al., Cell 2002, 111, 837– 851. 41. J. D. Bui et al., Cell 2000, 100, 457–467. 42. S. Agarwal, A. Rao, Immunity 1998, 9, 765–775. 43. B. J. Swanson et al., Immunity 2002, 17, 605–615. 44. J. M. Grayson et al., J. Immunol. 2001, 166, 795–799. 45. M. F. Bachmann et al., Eur. J. Immunol. 1999, 29, 291–299. 46. H. Veiga-Fernandes et al., Nat. Immunol. 2000, 1, 47–53. 47. T. K. Teague et al., Proc. Natl. Acad. Sci. USA 1999, 96, 12691–12696. 48. Y. Yang et al., J. Exp. Med. 1998, 188, 247–254. 49. J. Hendriks et al., Nat. Immunol. 2000, 1, 433–440. 50. M. Suresh et al., J. Immunol. 2001, 167, 5565–5573.

51. H. W. Mittrucker et al., J. Immunol. 2001, 167, 5620–5627. 52. W. Chen et al., J. Virol. 2002, 76, 10332–10337. 53. J. L. Cannons et al., J. Immunol. 2001, 167, 1313–1324. 54. E. M. Bertram et al., J. Immunol. 2002, 168, 3777–3785. 55. J. L. Cannons et al., J. Immunol. 2002, 169, 2828–2831. 56. T. C. Becker et al., J. Exp. Med. 2002, 195, 1541–1548. 57. K. S. Schluns et al., J. Immunol. 2002, 168, 4827–4831. 58. E. M. Janssen et al., Nature 2003, 421, 852–856. 59. G. Lauvau et al., Science 2001, 294, 1735–1739. 60. D. J. Shedlock et al., J. Immunol. 2003, 170, 2053–2063. 61. S. R. Bennett et al., Nature 1998, 393, 478–480. 62. S. P. Schoenberger et al., Nature 1998, 393, 480–483. 63. J. P. Ridge et al., Nature 1998, 393, 474–478. 64. C. Bourgeois et al., Science 2002, 297, 2060–2063. 65. R. A. Tuma et al., J. Clin. Invest. 2002, 110, 1493–1501. 66. E. M. Shevach, Nat. Rev. Immunol. 2002, 2, 389–400. 67. M. Kursar et al., J. Exp. Med. 2002, 196, 1585–1592. 68. K. M. Kerksiek et al., J. Immunol. 2003, 170, 1862–1869. 69. K. M. Kerksiek et al., J. Exp. Med. 1999, 190, 195–204. 70. K. B. Urdahl et al., Nat. Immunol. 2002, 3, 772–779. 71. K. Murali-Krishna et al., Science 1999, 286, 1377–1381. 72. S. L. Swain et al., Science 1999, 286, 1381–1383. 73. G. Kassiotis et al., Nat. Immunol. 2002, 3, 244–250. 74. J. Sprent, C. D. Surh, Annu. Rev. Immunol. 2002, 20, 551–579. 75. W. C. Kieper et al., J. Exp. Med. 2002, 195, 1533–1539. 76. J. T. Tan et al., J. Exp. Med. 2002, 195, 1523–1532. 77. J. M. Grayson et al., J. Immunol. 2000, 164, 3950–3954.

87

88

4 Memory 78. T. S. Wu et al., J. Immunol. 2002, 168, 705–712. 79. T. de Lange, Oncogene 2002, 21, 532– 540. 80. C. W. Greider, E. H. Blackburn, Cell 1985, 43, 405–413. 81. K. S. Hathcock et al., J. Immunol. 2003, 170, 147–152. 82. P. Wong, E. G. Pamer, J. Immunol. 2001, 166, 5864–5868. 83. S. M. Kaech, R. Ahmed, Nat. Immunol. 2001, 2, 415–422. 84. D. J. Sourdive et al., J. Exp. Med. 1998, 188, 71–82. 85. D. H. Busch et al., J. Exp. Med. 1998, 188, 61–70. 86. J. T. Opferman et al., Science 1999, 283, 1745–1748. 87. J. Jacob, D. Baltimore, Nature 1999, 399, 593–597. 88. D. H. Busch et al., J. Immunol. 2000, 164, 4063–4070. 89. E. J. Wherry et al., Nat. Immunol. 2003, 4, 225–234. 90. R. Ahmed, D. Gray, Science 1996, 272, 54–60. 91. S. M. Kaech et al., Nat. Rev. Immunol. 2002, 2, 251–262. 92. V. Appay et al., J. Exp. Med. 2000, 192, 63–75. 93. S. Kostense et al., Eur. J. Immunol. 2001, 31, 677–686. 94. F. Lechner et al., J. Exp. Med. 2000, 191, 1499–1512. 95. J. Sprent, D. F. Tough, Science 2001, 293, 245–248. 96. P. Wong, E. G. Pamer, Immunity 2003 in press. 97. D. H. Busch et al., Immunity 1998, 8, 353–362. 98. R. Mercado et al., J. Immunol. 2000, 165, 6833–6839. 99. V. P. Badovinac et al., Nat. Immunol. 2002, 3, 619–626. 100. D. Homann et al., Nat. Med. 2001, 7, 913–919. 101. J. J. Bird et al., Immunity 1998, 9, 229– 237. 102. P. R. Rogers et al., J. Immunol. 2000, 164, 2338–2346. 103. L. M. Bradley et al., J. Exp. Med. 1991, 174, 547–559. 104. S. L. Swain, Immunity 1994, 1, 543– 552.

105. H. Hu et al., Nat. Immunol. 2001, 2, 705–710. 106. W. T. Lee et al., J. Immunol. 2002, 168, 1682–1689. 107. X. Zhang et al., Immunity 1998 8, 591– 599. 108. O. Lantz et al., Nat. Immunol. 2000, 1, 54–58. 109. R. L. Reinhardt et al., Nature 2001, 410, 101–105. 110. I. C. MacLennan, D. Gray, Immunol. Rev. 1986, 91, 61–85. 111. M. Matsumoto et al., Science 1996, 271, 1289–1291. 112. Y. X. Fu et al., J. Immunol. 2000, 164, 2508–2514. 113. I. C. MacLennan, Annu. Rev. Immunol. 1994, 12, 117–139. 114. K. Rajewsky, Nature 1996, 381, 751–758. 115. G. Kelsoe, Immunity 1996, 4, 107–111. 116. Y. J. Liu, J. Banchereau, Semin. Immunol. 1997, 9, 235–240. 117. K. L. Calame, Nat. Immunol. 2001, 2, 1103–1108. 118. K. L. Calame et al., Annu. Rev. Immunol. 2003, 21, 205–230. 119. P. Garside et al., Science 1998, 281, 96– 99. 120. M. Morra et al., Annu. Rev. Immunol. 2001, 19, 657–682. 121. S. Crotty et al., Nature 2003, 421, 282– 287. 122. D. Gray et al., Immunol. Rev. 1996, 150, 45–61. 123. R. M. Zinkernagel et al., Annu. Rev. Immunol. 1996, 14, 333–367. 124. M. K. Slifka et al., Immunity 1998, 8, 363–372. 125. M. Maruyama et al., Nature 2000, 407, 636–642. 126. P. Merville et al., J. Exp. Med. 1996, 183, 227–236. 127. D. M. Sze et al., J. Exp. Med. 2000, 192, 813–821. 128. R. A. Manz et al., Curr. Opin. Immunol. 2002, 14, 517–521. 129. Y. A. Barde, Prog. Growth Factor Res. 1990, 2, 237–248. 130. E. Dicou et al., Neuroreport 1993, 5, 321–324. 131. L. Bracci-Laudiero et al., Neuroreport 1993, 4, 563–565. 132. M. Torcia et al., Cell 1996, 85, 345–356.

89

5 T Cell-based Vaccines Katharina M. Huster, Kristen M. Kerksiek, and Dirk H. Busch

Summary

Most vaccines currently in use focus on the priming of B cells. For many infections, however, protective immunity is mediated predominantly by T cells. To develop effective vaccines against diseases such as HIV, malaria, and tuberculosis, it is therefore necessary to obtain more information about the mechanisms required for in vivo induction of antigen-specific effector T cells and the generation of long-living memory T cell populations. In this chapter we summarize recent advances in the analysis of antigen-specific T cell responses and T cell memory and discuss the importance of distinct T cell parameters and characteristics for the development of vaccines intended to induce T cell-mediated immunity.

5.1 Introduction

The goal of vaccine development is the induction of effective protective immunity. Naturally occurring protective immunity, which can develop after primary exposure to infectious agents and protects against reinfection with the same pathogen, was recognized already in ancient Greek times; as early as 430 BC, during the Peloponnesian War, Thucydides recorded that people who had recovered from the plague could care for infected individuals without getting the disease a second time [1]. With vaccination, the immune system is exposed to antigen in a noninfectious or mildly infectious way, with the goal of protection against subsequent infection. Vaccination has been attempted since the 11th century, when the Chinese inoculated children by inhalation of scab from the smallpox pustules of mildly infected people or by rubbing the dried material into a scratch. However, general acceptance of this technique was understandably limited, due to the high risk of accidentally inducing lethal infection with human smallpox material. Jenner overcame this problem by using a cross-reactive bovine analog of smallpox, vaccinia or cowpox (vacca = cow). This vaccination strategy was so successful that the WHO declared the eradication of smallpox in 1980.

90

5 T Cell-based Vaccines

Although the phenomenon of protective immunity has been recognized for more than 2500 years, the mechanisms necessary to achieve and maintain pathogen-specific immunity are still not well understood. It is known that subpopulations of B cells, which make up the humoral part of the adaptive immune system, as well as T cells, composing the cellular part of the adaptive immune system, can become memory cells, which respond faster and more effectively to a second – or after vaccination, the ‘real’ – infection. Most vaccines are designed to initiate a humoral, or B cellmediated, response. B cells reexposed to their specific antigen undergo changes resulting in the secretion of higher affinity antibodies, and the persistence of these cells over years ensures enduring antigen-specific protection [2]. Antibody responses to vaccination have been studied extensively over the past decades, facilitated by the ease of determining specific antibody serum levels ex vivo. These studies have revealed that qualitative (e. g., neutralizing capacity, affinity, antibody isotype) and quantitative (e. g., serum concentration) parameters of antigen-specific antibodies can be directly correlated with the efficacy of protective immunity against distinct pathogens [3]. Some of these parameters have been successfully translated into clinical applications designed to assess the efficacy of vaccination, monitor the maintenance of protective antigen-specific antibodies, and determine the necessary timepoints for effective booster vaccination. B cell-based vaccination strategies do not, however, provide effective immunity against all pathogens; numerous intracellular infectious agents, such as viruses and many bacteria and parasites, can circumvent the effects of neutralizing antibodies. Control and elimination of infection by these pathogens is mediated by other effector arms of the immune system, particularly by T cells. The cellular compartment of the adaptive immune system can be divided into two main subsets: T helper cells and cytotoxic T cells are defined by their coreceptors CD4 and CD8, respectively, and use their specific T cell receptor (TCR) to recognize peptide antigen in association with MHC molecules. CD4+ T cells recognize endosome-derived antigens on MHC class II molecules, and CD8+ T cells detect peptides in the context of MHC I molecules, which usually present antigen derived from the cytosolic compartment. Furthermore, T cells help B cells in the induction of antibody responses, and recent work has demonstrated that CD4+ T cell help is crucial for the development of CD8+ T cell-mediated protective immunity. With the recent development of better tools for the analysis of antigen-specific T cell responses directly ex vivo, we can now characterize the functional changes and mechanisms required for effective generation of T cell-mediated protective immunity. These tools also allow us to directly monitor the effects of different vaccination strategies on the T cell compartment, an advance that provides enormous support for the development of new vaccines with strong induction of memory T cells. In this chapter we give an overview of T cell-based vaccination strategies, with emphasis on how their success can be monitored directly ex vivo. Our discussion focuses largely on the value of distinct T cell parameters (such as phenotypical and functional T cell subpopulations and T cell avidity) as markers for the success and quality of protective immunity induced by various vaccination strategies.

5.2 Ex-vivo Detection of Antigen-specific T Cells

5.2 Ex-vivo Detection of Antigen-specific T Cells

It is indisputable that improvement of vaccination strategies often requires stronger in vivo induction of antigen-specific effector and memory T cells or, for therapeutic vaccination, modulation of already existing antigen-specific T cell populations. Indeed, many vaccination protocols and reagents have been developed over the past decades with the specific goal of improving T cell immunogenicity. However, improvement of T cell-based vaccination is dependent on accurate monitoring of the success of T cell vaccination and correlation of vaccine-induced T cell status with the quality of protection. The presence and frequencies of antigen-specific T cells in vivo can be detected by ‘function-dependent’ and ‘function-independent’ methods. Until recently, the limiting dilution assay (LDA) was the only technique available for determination of antigen-specific T cell frequencies [4]. LDA is based on sequential dilution and in vitro expansion of cell samples in 96-well plates, followed by functional assays (such as proliferation or cytotoxicity assays) to ascertain the number of wells containing antigenspecific cell lines or clones. Recent studies using more advanced methods for ex vivo T cell analysis demonstrated that the numbers obtained by LDA assays often substantially underestimated the true in vivo T cell frequencies [5–7]. The development of assays that require only very brief in vitro restimulation, such as the enzymelinked immunospot assay (ELISPOT) [8] and intracellular cytokine staining [5], considerably improved determination of T cell frequencies (Figures 5.1 and 5.2). In these assay systems, T cells responding specifically to antigen are detected through their ability to rapidly produce effector cytokines such as IFNg, TNFa, IL-2, or IL-4. Cytokine capture is achieved by using an affinity matrix, which can be established extracellularly (e. g., by using nitrocellulose, ELISPOT) or on the cell surface (a socalled cytokine capture assay, CCA [9]). Another method, intracellular cytokine staining (ICS), is based on accumulation of cytokines within the cell by blocking the secretion apparatus (e. g., in the presence of brefeldin A or monensin) and subsequent intracellular staining for the cytokine of interest (Figure 5.1). All these assays have proven to be very sensitive, allowing ex vivo detection of antigen-specific T cell populations with frequencies as low as 0.02 %. One advantage of the ELISPOT assay is that relatively little cell material is needed in comparison to flow cytometry-based detection systems (CCA, ICS). However, flow cytometry allows simultaneous staining of different cytokines and surface antigens, providing a more precise phenotypic analysis of the responding cell populations. Multiparameter ELISPOT assays have recently been developed to compensate for some of the limitations of this method [10]. The CCA keeps cells alive, and its combination with cell separation techniques such as FACS or sorting with paramagnetic beads allows purification of antigen-specific T cells for further analysis of the cell population. All these assays detect antigen-specific T cells based on an effector function – rapid production of cytokines in response to in vitro restimulation with antigen. Only T cells capable of responding with the readout effector function under the chosen in vitro restimulation conditions are detected. Because antigen-specific T cell populations under in vivo conditions seem to

91

92

5 T Cell-based Vaccines

MHC Multimers

ELISPOT enzyme

MHC

antigen-specific stimulation

cytokine

membrane

CCA

fluorochrome

streptavidin

TCR

MHC Streptamers

d-biotin streptactin

ICS

Brefeldin A

Figure 5.1 Methods for ex vivo detection of antigen-specific T cells. Left: Function-dependent T cell assays. Enzyme-linked immunospot assay (ELISPOT) capture the secreted cytokine on the surface of a membrane; cytokine-spots are visualized by enzyme/ substrate reactions. Cytokine-capture assays (CCA) are based on the same principle, but secreted cytokines are captured on the cell surface and detected with fluorescence-conjugated antibodies; the stained T cell remains alive. Intracellular cytokine staining (ICS) involves accumulation of cytokines within the stimulated cell and detection with fluorescence-conjugated antibodies following membrane fixation and permeabilization. Right: Function-independent T cell assays. MHC multimers bind with higher avidity to T cells than MHC monomers and can be used to directly stain epitope-specific T cell populations. To avoid strong T cell stimulation through surface-bound MHC multimers, modified reagents (Streptamers) can be removed from the cell surface after competitive disruption (staining and removal at 4 °C) (see colour plates page XXXIV).

⇒ disassembly of MHC multimers

5.2 Ex-vivo Detection of Antigen-specific T Cells

be quite heterogeneous, especially in respect to their functional phenotypes, it is unlikely that function-dependent T cell detection assays will be able to detect the entire population. For this reason, T cell detection methods that are independent of effector functions and do not require in vitro incubation, the so-called MHC multimer techniques, have been developed [7, 11, 12]. The basic principle of the MHC multimer is to use the natural T cell receptor ligand, the MHC–epitope complex, as a staining probe (Figures 5.1 and 5.2). Because of the low affinity of TCR–MHC interactions, it is not possible to achieve stable binding by using monomeric MHC–epitope complexes. Multimerization, however, increases the relative binding avidity of the reagent to surface TCRs to a degree that allows epitope-specific binding to T cells. MHC multimer reagents conjugated with fluorochromes can be used for identification of T cells by flow cytometry, with staining characterized by high specificity and sensitivity [13]. The most successful system for ex vivo T cell staining has been the multimerization of MHC–peptide complexes to tetrameric molecules by specifically biotinylating a sequence tag fused to the C-terminus of the MHC heavy chain, followed by oligomerization of the MHCs with streptavidin, which has four biotin binding sites [7, 12]. The increase in relative binding avidity to specific TCRs achieved by MHC multimerization is sufficient to enable detection of antigen-specific T cells within a wide range of physiological binding strengths for their ligand. Even ‘low–affinity’ T cells can be stained with MHC tetramers, and several studies have demonstrated that MHC tetramer staining allows identification of more that 99 % of a given epitope-specific cell population [7]. Dimerization of MHC molecules, usually generated as Ig-fusion proteins, also allows epitope-specific T cell staining, but ‘low–affinity’ T cells might not be detected as well as with MHC tetramers [14]. The MHC multimer has revolutionized T cell research over the past few years. MHC class I multimer reagents have been used for extensive phenotypic characterizations of antigen-specific T cell populations in both animal models and humans. MHC class II multimer reagents are more difficult to generate, and the epitope sequences have often not been precisely determined. However, several recent studies have demonstrated that the general approach of MHC multimer staining can be used effectively for detecting T helper cells [15, 16]. As long as MHC multimer staining is performed at 4 °C, T cells can be identified and purified without altering their original phenotype. However, since MHC multimer reagents represent the natural ligand bound to the TCR, placement of purified MHC multimer-stained T cell populations into in vitro cell culture results in functional alterations such as TCR internalization, activation, overstimulation, and cell death [17–20]. This intrinsic shortcoming of conventional MHC multimer staining substantially limits the applications of the technology for further analysis of ex vivo purified T cells as well as for clinical medicine. To address the problem, a modified MHC multimer technology has been developed [20]; so-called MHC streptamers (Figure 5.1) allow removal of surface-bound MHC multimer reagents after cell staining and purification, conserving the phenotypical and functional status of isolated cell populations. This very promising approach might further broaden the applications of MHC multimer technologies for ex vivo T cell analysis.

93

10

100

1000

10000

10000

IFNγ

1

1000

1

1000

10

100

0.36

10000

10

10

IFNγ

1

100

1

c)

1

100

1000

10000

1

10

10

1000

10000

100

3

0.001

100

1000

10000

a)

75.6

1

1

10

10

100

100

TNFα

1000

0.35

1000

4.58

10000

10000

100

1000

10000

1000

10000

unstained

1 100

100

1000

10000

1 10

0.002

10

1

d)

TNFα

1

10

100

1000

10000

1

10

10

1000

10000

10

76.6

0.006

100

1

b)

100

1000

10000

CD8α CD8α

CD8α

CD4

CD8

10

10

100

100

1000

9.79

1000

10000

10000

H2-Kb/SIINFEKL

1

1

0.55

94

5 T Cell-based Vaccines

5.3 In vivo Kinetics of Antigen-specific T Cell Responses 3 Fig. 5.2 Direct ex vivo analysis of antigen-specific CD8 + and CD4+ T cells. C57BL/6 mice were infected twice with Listeria monocytogenes expressing the model antigen Ovalbumin. Splenocytes were harvested 5 days after recall infection, followed by intracellular cytokine staining or MHC multimer staining. Dot plots show lymphocyte staining for lineage markers (y-axis) and cytokine or MHC multimer (x-axis); percentages of double-positive cells are indicated. (a) Splenocytes were incubated in the absence (left) or presence (right) of 10 –6 M SIINFEKL peptide for 5 hours; for the last 3 hours, Brefeldin A (BfA) was added. Intracellular staining for IFN g is shown. (b) Same procedure as in (a) but intracellular staining for TNF a. (c) Splenocytes were restimulated in vitro with the MHC class II-restricted Listeria epitope LLO 190–202 in the presenceof BfA as describedin (a) and subsequently stained for intracellular IFN g (left) or TNF a (right). (d) On the same splenocytes as in (a-c), H2-K b/SIINFEKL multimer staining was performed (right; left is unstained control). Note that different frequencies of antigen-specific T cells are detected when using different methods. Differences between frequencies staining for intracellular IFNg and TNF a are observed in the CD8 + T cell compartment (a, b) but not in the CD4+ T cell compartment (c).

5.3 In vivo Kinetics of Antigen-specific T Cell Responses

The development of MHC multimer technologies has enabled analysis of antigenspecific T cell responses in far more detail than previously possible. Originating from a very small precursor population of naive T cells [21, 22], clonally expanding antigen-specific T cells are first detectable 3–5 days after primary antigen exposure and usually reach their maximal size of expansion after 7–8 days [7, 23]. During this proliferation phase, activated T cells differentiate and mature into effector T cells and are detectable in both lymphoid and nonlymphoid tissues throughout the body, with some accumulation close to the site of antigen presence. After the effector phase, many of the expanded T cells are rapidly deleted by apoptosis (contraction phase), and only a small number of antigen-specific cells are maintained as memory T cells. Whereas effector T cells are capable of conferring protection against an infection early after priming, memory T cells have the exclusive task of maintaining T cellmediated protective immunity for longer periods of time. Interestingly, in comparisons of different antigen-challenge systems, T cell responses to immunodominant or subdominant epitopes, or CD8+ vs. CD4+ T cell responses, and the general kinetics of T cell expansion and contraction during primary immune responses are remarkably similar [7]. This observation has led to the recent finding that early instructive events during the initial priming period induce cellular programs of differentiation, expansion, and contraction that are remarkably independent of antigen prevalence and other environmental factors [24–26]. These experimental results are very important for our understanding of how to design and improve T cell-based vaccines, because they suggest that optimization of antigen delivery to antigen-presenting cells

95

96

5 T Cell-based Vaccines

(APC) and in vivo T cell priming conditions during the early vaccination period will be more effective than efforts to prolong the time of antigen presence or to provide T cell growth/survival factors later during the immune response. If the primary immune response supports effective generation of antigen-specific memory T cells, a secondary challenge with the same antigen results in a much more rapid immune response [27]. Kinetics of recall responses therefore differ from those of the primary antigen challenge; memory cells exhibit effector function within a few hours after activation and expand to a maximal population size (burst size), which is often significantly larger than that of the primary response, 2–3 days earlier than antigen-specific cells reacting to the first antigen exposure. However, when comparing different antigens, delivery systems, and cell subtypes, recall immune responses are far more heterogenous than primary responses. Determination of the mechanisms resulting in these differences is of major importance for the design of more effective T cell-based vaccines. Reimmunization procedures (booster vaccinations) are often needed to elevate frequencies of protective cell populations above a threshold required for measurable protection against the real pathogen [28]. Thus, although an ideal T cell vaccine should be capable of mimicking the effect of any naturally occurring infections, inducing long-lasting and effective protective immunity after a single application most currently available vaccination strategies are dependent on boost vaccinations. There are several possible explanations for the diverse outcomes of immunization. For example, the presence of antigen-specific memory T cells with immediate early effector function might inhibit development the local microenvironmental conditions required for further T cell activation and expansion, a scenario that would particularly affect vaccination strategies employing live attenuated vector systems. The efficacy of live vectors clearly depends on initial replication within tissues, which is necessary for expression of sufficient antigen and induction of inflammatory responses [29]. Clearance of the vector before it can reach lymphoid tissue, which is believed to be the unique site for T cell priming and expansion [30], can inhibit the development of a recall response. Another factor that might dramatically affect vaccine efficacy is the delivery of antigen to subpopulations of APC, specifically to dendritic cells (DC), which are believed to be absolutely essential for initiation of T cell responses [31]. Antigen-specific T cells compete for epitope recognition, especially when the number of APC is very low [32–34]. The kinetics of epitope generation and presentation can also favor the activation and expansion of T cells specific for a distinct epitope. These differences might not become apparent during a primary response, when the time window for T cell priming is relatively large, but they could substantially shape the quality of recall responses. In addition, the in vivo life span of antigen-presenting DC appears to be negatively regulated through the effector functions of antigen-specific T cells, particularly those with cytotoxic activity [35]. Thus, a successful immunization strategy needs not only to deliver antigen efficiently to distinct APC, it must also reach sufficient numbers of APC to overcome the counterproductive negative feedback mechanisms of memory T cells. As discussed later in this chapter, an attractive approach to the enhancement of T cell immunogenicity during primary and recall im-

5.4 Effector Function and Subtypes of Effector T Cells

mune responses might be selective delivery of survival factors to APC, prolonging their in vivo life span in the presence of high frequencies of cytotoxic memory T cell.

5.4 Effector Function and Subtypes of Effector T Cells

T cells exert their antimicrobial activity through a variety of effector functions. These can generally be divided into cell–cell contact-dependent (e. g., killing of infected cells via Fas-FasL) and cell contact-independent (e. g., activation of macrophages through secreted IFNg) functions. Subtypes of T cells are characterized by distinct effector functions, and the in vivo activation and differentiation requirements of these T cell subsets might differ substantially. Mediation of the best protective immunity against different types of infection is likely to require induction of T cell subtypes with specific effector function patterns. Thus, a thorough understanding of the nature of protective T cell populations is crucial for the design of vaccines optimized for specific diseases. (A detailed discussion of differences in disease- and pathogen-specific vaccine requirements is beyond the scope of this brief overview of T cell-based vaccines; you can find more detailed information about vaccine development for specific diseases in the other chapters of this book.) CD4+ T cells, also known as T helper (TH) cells, can be divided into at least three subsets (TH0, TH1, and TH2) based on their cytokine secretion patterns [36]. TH0 cells are naive CD4+ cells that have not yet differentiated into a functional TH subtype. The type and amount of antigen and the APC subset encountered during the first antigen exposure play critical roles in the further differentiation of TH0 cells into either a TH1 or TH2 phenotype [37, 38]. In the presence of IL-4, naive CD4+ precursors preferentially differentiate into TH2 cells that secrete cytokines such as IL-4, IL5, IL-10, and IL-13. In contrast, production of IL-12 and/or IL-18 by APC results in differentiation of CD4+ precursors into TH1 cells that secrete TNFa and IFNg. It is generally believed that several rounds of cell division are required for completion of this differentiation process [39]. Some recent reports indicate that proliferation is not always a prerequisite for naive TH cell differentiation, but this does not appear to be a general phenomenon [40]. The close connection between proliferation and differentiation is not apparent for memory TH cells, which are usually characterized by rapid and vigorous effector cytokine production long before cell division occurs. Once initial polarization towards a TH1 or TH2 phenotype has been established, the process is self-perpetuating: TH1 cells secrete cytokines that further enhance TH1 responses and down-regulate TH2 responses, and vice versa. Another population of TH cells, the regulatory T cell subset (Treg), is characterized by immunomodulation of other T lymphocytes. Treg are best known for their capacity to inhibit proliferation of ‘conventional’ T cells [41]. The main functional role of Treg during an immune response is probably prevention of overzealous clonal expansion of antigen-specific T cells and proliferation of potentially autoreactive T cells out of the pool of polyclonal pathogen-specific T cells. Different types of Treg have been described, most of which are characterized by overexpression of the transcription factor

97

98

5 T Cell-based Vaccines

Foxp3 [42, 43] and surface expression of CD25 (alpha chain of the IL-2 receptor) [44]. Although some Treg seem to recognize foreign epitopes, similar to conventional T cells, it is likely that the majority detect self-peptides presented by MHC class II molecules. Treg subtypes also differ in the mechanisms of their regulator function: some inhibit cell proliferation through a poorly understood cell–cell contact-dependent pathway, while others regulate via secretion of IL-10 and TGF-b. Knowledge of Treg cell activation and inactivation in vivo is highly relevant for T cell-based vaccines because these populations might be interesting targets for modulation of T cell responses. Preliminary studies indicate, for example, that the efficacy of Toll-like receptor ligands such as CpG-DNA and LPS as adjuvants is due in part to release of factors from activated APCs that temporarily suppress Treg functions [45]. Treg cells appear to influence in vivo reexpansion of memory T cells even more than T cell priming [46], indicating that they should be taken into consideration when addressing improvement of booster vaccinations. The majority of CD8+ T cells are cytotoxic T cells, which lyse infected target cells through expression of Fas ligand on their cell surface or by the release of effector molecules such as perforin and granzymes from large secretory granules. Directly bactericidal substances (e. g., granulysin), which are released from the same type of granules, have been identified in the human system [47]. Most CD8+ effector cells can be defined as Tc1 cells, which secrete TH1-like cytokines (TNFa, IFNg). As described for the TH cell system, CD8+ T cell populations with other differentiation patterns exist [48], but these cell subtypes are not as well characterized as those in the CD4+ T cell compartment. Nevertheless, some CD8+ T cells clearly show a TH2-like phenotype (Tc2 cells), and others have characteristics of regulatory T cells (CD8+ suppressor cells) [49, 50]. Different subpopulations of effector T cells interact with distinct target cell populations. For example, cytokines secreted by TH1 or Tc1 cells activate macrophages, enabling them to kill intracellular microorganisms more efficiently. TH2 cells, on the other hand, influence the production of antibodies with different Ig subclasses by B cells. As described above, the development of function-based methods for ex vivo T cell analysis has enabled precise monitoring of the differentiation of antigen-specific T cell populations. ICS and CCA are the most useful techniques for measurement of cytokine expression patterns (Figure 5.2), particularly when used in combination with improved multicolor flow cytometry technologies that allow simultaneous detection of several different cytokines on the single-cell level [51]. The effector function of cytotoxic T cell populations can also be analyzed in vitro [52] and in vivo [53] by CTL assays, which measure the ability to lyse epitope-presenting target cells. The cytotoxicity of CD8+ T cells is often so effective that CTL assays can detect very low frequencies of antigen-specific effector-memory T cells directly ex vivo (Figure 5.3). The sensitivity of such assays can be enhanced by cell enrichment (e. g., for CD8+ T cells [54]) or selective purification of the antigen-specific population with MHCstreptamer reagents [20].

5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition

5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition

The TCR repertoire of naive T cell populations specific for foreign, pathogen-derived epitopes is often highly diverse and consists of T cells with various binding affinities for their cognate MHC–epitope complexes [55–57]. The strength of the interaction between TCR and MHC molecules is an important factor in the regulation of immune responses. This is best characterized for the selection of T cells in the thymus, where positive selection occurs only within a distinct range of binding affinities to MHC–self-peptide complexes. However, TCR–MHC binding affinity in the periphery also plays an important role in the quality of antigen-specific T cell responses and the maintenance of T cell populations over time. It is generally believed that in–vivo activation and expansion of T cell subpopulations with relatively high binding affinities for MHC loaded with a pathogen-derived epitope is advantageous for rapid control of infection and the development of effective protective immunity [58]. As shown in both adoptive transfer experiments on animal models and preliminary clinical studies, high-affinity T cells can respond rapidly to low amounts of presented epitope, enabling early interruption of the progression of infection. Identification of the requirements for induction of high-affinity T cells is therefore important for vaccine design. Accordingly, many efforts have been made in recent years to develop assays to measure TCR affinities of polyclonal T cell populations. Techniques based on surface plasmon resonance, which have been the ‘gold standard’ of TCR MHC affinity measurements, require large-scale purification of each receptor–ligand pair and therefore cannot be used for analysis of complex polyclonal T cell populations. Various TCR affinity assays based on the binding and dissociation kinetics of MHC–epitope complexes [56, 59, 60] or changes in effector functions in response to decreasing concentrations of epitope (Figure 5.3 [56, 61]) have been developed; each can be used for direct ex vivo T cell analysis and applied to highly polyclonal T cell populations. Assays measuring dissociation kinetics of surface-bound MHC–peptide complexes are probably the best existing indicator of the relative binding strengths of MHC– peptide complexes on polyclonal T cell populations [60]. Values obtained from function-based avidity assays are influenced by a variety of additional factors, such as the quality of signal transduction required to trigger effector function, which may not be directly related to the structural binding complex [61]. The use of different readout systems can result in quite different experimental findings, even when analyzing the same T cell populations. It has therefore been proposed that the experimental source of T cell avidity data be indicated by the terms ‘structural’ and ‘functional’ avidity [61]. Despite the continuing debate, it is safe to say that studies based on these new methods have demonstrated that, although interaction of the TCR with epitope-presenting MHC complexes affects the overall binding strength, coreceptor binding (e. g., CD8 [62]), membrane composition (e. g., organization of TCR in membrane rafts [63]), and T cell activation status [64] are also important factors. Most people therefore prefer to use the term ‘avidity’ to describe the binding strength of a T cell. The in vivo dynamics of

99

5 T Cell-based Vaccines 75

mouse 1 % specific lysis

100

mouse 2 50

mouse 3

25

0

-8

-9

-10

-11

-12

-13

PBS

peptide concentration (10 X)

Fig. 5.3 Direct ex vivo detection of antigen-specif ic target cell lysis. Chromium release assay using cells isolated directly ex vivo from mice 35 days after primary infection with Listeria monocytogenes. Splenocytes were enriched for CD8 + T cells by depletion (magnetically activated cell sorting, MACS, Miltenyi, Germany). Functional analysis of LLO91–99-specific effector-memory T cells (approx. 0.5 % of all CD8 + T cells, as determined by MHC multimer staining) was performed at 5–6 different peptide concentrations (‘ functional avidity’); peptide sensitivity profiles for 3 individual mice are shown.

T cell avidity have been most impressively demonstrated by experiments using T cells derived from TCR-transgenic mouse lines, in which all cells have exactly the same T cell receptor; even under these truly monoclonal conditions, T cells with different avidities can be found [64]. These avidity differences seem to depend primarily on the in vivo activation status of the T cell. Primary T cell responses to pathogen-derived epitopes usually result in the expansion of populations characterized by diverse TCR repertoires and different structural and functional avidities. By using experimental mouse models, we and others recently demonstrated that repetitive antigen challenge further shapes the composition of antigen-specific T cell populations [56, 65]: during antigen challenge, cells with higher structural avidity for MHC–epitope complexes respond faster and, through selective expansion, increasingly become the predominant subpopulation. These changes can also be observed on the level of the TCR repertoire, which becomes more restricted and oligoclonal during avidity maturation [55]. Selective expansion and avidity maturation might be explanations for the requirement of booster vaccinations for effective protective immunity against many pathogens. Selective expansion of high-avidity T cell populations might also have certain disadvantages. For example, T cells with high avidity for one specific epitope can suppress in vivo development of T cell responses with specificity for other epitopes [65]. This so-called ‘superdomination’ of T cell responses, which may occur during vaccination with multiple pathogen-derived epitopes, may be due to T cell competition on the APC cell surface [32–34]. The consequences of epitope competition are believed to be more pronounced during antigen rechallenge, when responding T cells rapidly

5.6 Functional Heterogeneity of T Cell Memory

exert effector functions that can reduce the half-life of the APC. Because high-avidity T cells bind faster to MHC–epitope complexes, form contact zones (synapses) more rapidly, and respond to very low amounts of epitope, they interfere with the activation of lower-avidity T cells. Suboptimal activation of T cells can result in diminished survival [66], leading to the loss of specific T cell populations. Different epitopes may also be presented with distinct kinetics by the same APC; for example, viral and bacterial antigens are turned on or off at different stages during infection. Here, T cells specific for epitopes presented early during infection may have an advantage. Focusing of immune responses through superdomination might be especially problematic for vaccination against chronic viral infections, in which the pathogen often has time to employ mechanisms of escape from specific immune responses. For example, effective epitope-specific T cell populations responding to HIV infection have been circumvented by mutations within the viral genome that specifically eliminated the T cell epitope [67]; if the T cell response is focused on a single epitope, the consequences of such a mutation are dramatic. In other situations, the greater peptide sensitivity of high-avidity T cells may prove disadvantageous to the immune response, not by interfering with other T cell populations (through superdomination), but via negative effects on the high-avidity T cells themselves. High-avidity T cells are sensitive to high antigen concentrations, and data from experimental models suggest that, in the presence of too much antigen, deletion of high-avidity cells by overstimulation-induced cell death or exhaustion may result [68, 69]. Thus, it will be important to optimize antigen-rechallenge conditions that promote induction of high-avidity T cells. T cell avidity, epitope presentation kinetics, and epitope competition are central mechanisms controlling immunological phenomena, including immunodominance and T cell affinity maturation, and they must be taken into consideration during the design of T cell-based vaccines. In particular, although ex vivo measurement of T cell avidities is still new, the potential clinical value of avidity as a parameter for assessment of the quality and efficacy of vaccination strategies should encourage scientists to include avidity assays in their future studies.

5.6 Functional Heterogeneity of T Cell Memory

Most vaccines are designed to induce protective immunity in an individual who might require protection at an undefined time in the future (preventive vaccination). Design of preventive vaccines must focus on the generation of long-living memory cells. In contrast, for other clinical applications of vaccination, such as therapeutic vaccination of a patient with an ongoing infectious disease or post-exposure vaccination given immediately after a potential infection with the pathogen, it might be advantageous to support the generation of effector cells (Figure 5.4 [70]). Memory T cells are characterized by their ability to functionally respond more rapidly than naïve T cells to antigen reexposure, and they can – in contrast with effector cells – survive for a long period of time, sometimes an entire lifetime [71]. Most

101

5 T Cell-based Vaccines naive

effector

effector

1° memory

primary response

recall response (variable)

expansion expansion

2° memory

antigen

antigen

antigen challenge

antigen-specific T cells

102

contraction

contraction

time Fig. 5.4

In vivo kinetics of antigen-specific T cell responses.

recent studies support the view that persistence of antigen depots is not required for long-term survival of memory T cells, although this is still a matter of debate. Continuous interactions with self–MHC complexes [72] and increased responsiveness to cytokines such as IL-7 and IL-15 [73], which trigger anti-apoptotic pathways (e. g., bcl2– bclXL up-regulation [74]), are believed to be primary factors in the longevity of memory T cells, but the exact underlying mechanisms are not well understood. The mechanisms of memory T cell generation also remain unclear. Are they generated during the priming period as a distinct cell lineage, developing in parallel with expanding effector T cells, or do they represent a subpopulation of effector T cells that receive (stochastically?) a signal during the contraction phase to survive as post-effector cells in the memory T cell pool? Although the ‘post-effector cell’ model was favored in the recent past [75, 76], more recent data have shown that T cells with a typical memory phenotype can be found early during the priming period, an observation that fits the ‘lineage model’. Antigen-specific memory T cells cannot be regarded as a homogeneous cell population because the pool of memory T cells contains several subpopulations with distinct differentiation patterns and migration characteristics (Figure 5.5 [77]). A central memory T cell subpopulation (TCM) resides preferentially in lymphoid organs, lacks immediate effector functions, and is characterized by vigorous homeostatic and antigen-driven proliferation; maintenance of TCM appears to be dependent on T cell growth factors such as IL-2, IL-15, and IL-7, which signal through common g-chain receptors. The peripheral effector memory T cell subpopulation (TEM), in contrast, is characterized by immediate effector function upon antigen reencounter and migrates preferentially to nonlymphoid organs, where cell maintenance depends on survival factors provided by the local micromilieu. In humans, the different memory T cell subsets can be discriminated by CCR7 expression in combination with staining for CD45RA [77]. In the mouse, L-selectin (CD62L) expression, which mediates T cell migration into lymphoid organs, has been used as a marker to distinguish

5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination

TCM from TEM [7, 78]. However, better markers are needed to allow the subpopulations to be clearly distinguished and to facilitate detailed analysis of their functional roles in protection and long-term maintenance of T cell memory. Our current working hypothesis is that TEM are the main players in conferring protection against invading pathogens; they are preferentially located in nonlymphoid, mucosa-associated tissues (e. g., lung and gut [79, 80]), the entry site for most pathogens, and they rapidly activate their effector mechanisms. When this first line of antigen-specific defense cannot control the local infection and antigen reaches lymphoid tissue, TCM become the source for expansion of antigen-specific effector T cells. TCM are characterized by slow baseline proliferation in the absence of antigen; perhaps some of their daughter cells permanently differentiate into TEM, refreshing the TEM pool in nonlymphoid tissues. According to this hypothesis, TCM is the memory subset crucial for maintenance of T cell memory. The relatively new concept of T cell memory diversification, with different subpopulations contributing distinct functions, has direct consequences for the future development of T cell-based vaccines. The heterogeneity of memory T cells may help explain why several vaccination procedures, in particular the use of particulate vaccines made from inactivated organisms or purified antigens, induce protection inefficiently despite clearly demonstrable generation of antigen-specific memory T cells [81]. It is important to understand the exact mechanisms required for in vivo generation of the various memory T cell subtypes, since they may become attractive targets for modulation of the efficiency or quality of vaccine-induced protective immunity. Recent studies have demonstrated that the composition and quality of the CD8+ memory T cell pool is shaped by instructive, T helper cell-dependent events early during the initial priming period [82–84]. These data suggest that the crucial time window for interventions designed to modulate in vivo memory T cell generation exists early after vaccination.

5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination

As mentioned previously, nearly all vaccines made from inactivated organisms or purified antigens generate poor T cell responses, inducing detectable T cell-mediated protection only when combined with strong adjuvants. The function of adjuvants and their specific immunogenicity-improving qualities, the different adjuvant compositions currently in use, and the recent development of improved adjuvants, especially those based on current knowledge of the Toll-like receptor (TLR) system, are discussed extensively in other chapters of this book. In the context of T cell-based vaccination, it is particularly important to understand the ability of adjuvants to activate APC, especially DC, and create a micromilieu at the site of T cell priming that promotes development of T cell responses. Induction of IL-12 secretion, which is required for strong TH1 and Tc1 responses, and local inhibition of regulatory immune cells (such as Treg), which might otherwise suppress the development of T cell responses [45], are two examples of adjuvant-mediated ef-

103

104

5 T Cell-based Vaccines

a)

b) 10000

50.1

0.067 1000

1000

100

100

49.2

24.1 10

10

1

1

0.00 1

10

100

1000

10000

1

CD8

10

100

1000

10000

c) 10000

19.8

76.7

1000

100

CD127

HLA*A0201/MP 58-66

10000

10

0.072 1 1

10

100

CCR7 Fig. 5.5 Heterogeneity of antigen-specific memory T cell populations. (a) Human peripheral blood lymphocytes from a donor who suffered years ago from infection with influenza virus were analyzed by multiparameter flow cytometry. Dot plot shows double-staining for HLA-A*0201/MP 58–66 multimer reagents (y-axis) and CD8 surface expression (x-axis); frequencies of cell populations within the two regions are indicated. (b) CD8+, HLA-A*0201/MP58–66 tetramer-positive memory T cells can be further subdivided into CCR7+ central memory T cells and CCR7- effector memory T cells. CCR7 (xaxis) versus CD127 (y-axis) expression is shown; percentages of cells within the different quadrants are indicated. (c) Same staining as in (b), but cells are gated on CD8 +, HLA-A*0201/ MP58–66 tetramer-negative cells. Note the presence of an additional subpopulation of CD127/CCR7 double-negative cells, which probably represent a population of ‘ real ’ effector cells.

1000

10000

5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination

fects that can have a major impact on the efficacy of T cell-based vaccination. However, even in combination with potent adjuvants, the T cell immunogenicity of most particulate vaccines remains poor, especially in comparison with results obtained from vaccination with live vectors such as attenuated vaccinia virus strains (e. g., modified vaccinia virus Ankara or MVA [85]) or attenuated bacteria (Salmonella, Yersinia, Listeria [29]). These differences probably reflect the optimal combination of antigen delivery and local induction of inflammatory immune responses provided by live vectors, conditions that have yet to be effectively simulated by strategies employing adjuvants. Direct conjugation of purified antigens with defined TLR ligands is a promising approach for future vaccine development [86, 87]; because TLR expression is celltype-specific, with preferential expression on various APC subpopulations, TLR ligands might be able to shuttle antigen to distinct APC subtypes and simultaneously induce activation of the antigen-exposed APC. Preliminary studies in experimental models have demonstrated that antigen–TLR-ligand conjugates can substantially increase the T cell immunogenicity of purified antigens [86, 87]. Although live vectors induce potent T cell responses, the simultaneous elicitation of strong vector-specific immune responses is a clear disadvantage of this system; as discussed above, a dominating anti-vector response can suppress T cell responses to other antigens (e. g., the recombinant antigen of interest), especially during antigen challenge. For this reason, boost vaccinations should be performed with different vector systems or, as often necessitated by the limited availability of live vector systems, other vaccination strategies must be included in prime–boost protocols [28]. A boost-vaccination protocol combining DNA vaccination and recombinant MVA challenge induces strong antigen-specific CD8+ memory T cell responses [88]. DNA vaccination, the use of naked plasmid DNA encoding antigenic proteins, is most commonly applied by intramuscular injection [89]. In recent studies, plasmid DNA has also been successfully transduced into eukaryotic cells by using live bacterial vectors (such as Listeria or Salmonella [90, 91]) as vehicles to target the vaccines to professional APC. Coexpression of immunomodulatory molecules (e. g., IL-2, IL-12, GM-CSF) and increasing the content of nonmethylated, immunostimulatory DNA motifs (CpG motifs), which activate innate immune cells through TLR9, are two strategies that have been used to increase the immunogenicity of plasmid DNA. The development of culture protocols for efficient in vitro generation of large quantities of DC, the most potent APC, has made DC immunization possible. Protocols in which DC are loaded with antigens and subsequently transferred into recipients have, depending on the source of DC and their degree of maturation, proven to be effective T cell vaccines in some experimental animal models as well as in humans [92]. These examples of recent vaccine developments, which are discussed in more detail in the chapters of part IV ‘Classical and Novel Vaccination Stretegies: A Comparison’ summarizing the current status of specific vaccination strategies, demonstrate that our increasing knowledge of the basic mechanisms of in vivo antigen-specific T cell responses have already started to influence the design of new vaccines.

105

106

5 T Cell-based Vaccines

5.8 Concluding Remarks

The development of vaccines capable of inducing strong T cell-mediated immunity requires consideration of certain aspects of T cell responses, several of which are addressed in this chapter. Major advances in analysis of antigen-specific T cells ex vivo and a more detailed knowledge of the in vivo mechanisms that regulate and modulate specific T cell responses are building the basis for a more rational design of vaccines targeting this distinct arm of the immune system. MHC multimer techniques and function-based, ex vivo T cell assays allow us to monitor the success of vaccination in vivo. These techniques will have a major impact on the speed and quality of future vaccine development. Until recently, T cell research in vaccinology was focused mainly on the identification of pathogen-derived, immunodominant T cell antigens and epitopes and analysis of their potential contribution to protective immunity. The close interaction between the innate and adaptive immune systems is now being increasing addressed in vaccine research, and we are beginning to understand that the requirements for an effective vaccine will depend strongly on the pathogen, the kinetics of disease (acute or chronic), and the clinical goal of the vaccination (preventative, therapeutic, or post-exposure). Several types of specialized APC exist; in vivo induction of T cells with distinct effector functions requires targeting of antigen to the appropriate APC subpopulation. APC activation is a necessary prerequisite for up-regulation of coregulatory molecules and secretion of soluble immunomodulatory molecules, factors essential for the development of protective, antigen-specific T cell responses. With the identification of receptors such as the TLR, which can specifically stimulate subtypes of APC, we are now able to develop more defined adjuvants, some of which will be especially effective for induction of distinct types of T cell responses. Protocol design for therapeutic and post-exposure vaccinations will likely focus on the rapid development and expansion of effector T cell populations capable of immediately fighting infection. Induction of long-term memory, on the other hand, requires induction of sufficient frequencies of effector-memory T cells and/or maintenance of this population over time through the presence of central-memory T cells. Some epitope-specific T cell responses might negatively interfere with others, which could lead to the suppression of cell populations crucial for protection; potentially counterproductive mechanisms that may surface during immune responses to different pathogens or antigens need to be identified and subsequently considered during vaccine design. Modulation of the function of distinct regulatory T cell populations may even provide a promising target for increasing the immunogenicity of otherwise weak vaccines.

References

References 1 R. Ahmed and D. Gray, Immunological memory and protective immunity: understanding their relation. Science, 1996, 272, 54–60. 2 M. K. Slifka and R. Ahmed, Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol, 1998, 10, 252–258. 3 J. F. Griffin, A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery. Adv Drug Deliv Rev, 2002, 54, 851–861. 4 M. Pimsler and J. Forman, Estimates of the precursor frequency of cytotoxic T lymphocytes against antigens controlled by defined regions of the H-2 gene complex: comparison of the effect of H-2 differences due to intra-H-2 recombination vs. mutation. J Immunol, 1978, 121, 1302–1305. 5 M. Murali-Krishna, J. D. Altman, M. Suresh, D. J. D. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky and R. Ahmed, Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity, 1998, 8, 177–188. 6 E. A. Butz and M. J. Bevan, Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity, 1998, 8, 167–176. 7 D. H. Busch, I. M. Pilip, S. Vijh and E. G. Pamer, Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity, 1998, 8, 353–362. 8 Y. Miyahira, K. Murata, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. M. Rodriguez and F. Zavala, Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods, 1995, 181, 45–54. 9 R. Manz, M. Assenmacher, E. Pfluger, S. Miltenyi and A. Radbruch, Analysis and sorting of live cells to secreted molecules, relocated to a cell-surface affinity matrix. Proc Natl Acad Sci USA, 1995, 92, 1921–1925. 10 J. E. Snyder,W. J. Bowers, A. M. Livingstone, F. E. Lee, H. J. Federoff and T. R.

11

12

13

14

15

16

17

18

Mosmann, Measuring the frequency of mouse and human cytotoxic Tcells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med, 2003, 9, 231–235. J. P. Schneck, Monitoring antigen-specific T cells using MHC-Ig dimers. Immunol Invest, 2000, 29, 163–169. J. D. Altman, P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael and M. M. Davis, Phenotypic analysis of antigen specific T lymphocytes. Science, 1996, 274, 94–96. A. McMichael and C. O'Callaghan, A new look at T cells. J Exp Med, 1998, 187, 1367–1371. L. K. Selin, M. Y. Lin, K. A. Kraemer, D. M. Pardoll, J. P. Schneck, S. M. Varga, P. A. Santolucito, A. K. Pinto and R. M. Welsh, Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity, 1999, 11, 733–742. W. W. Kwok, N. A. Ptacek, A. W. Liu and J. H. Buckner, Use of class II tetramers for identification of CD4+ T cells. J Immunol Methods, 2002, 268, 71–81. A. McMichael and A. Kelleher, The arrival of HLA class II tetramers. J Clin Invest, 1999, 104, 1669–1670. X. N. Xu, M. A. Purbhoo, N. Chen, J. Mongkolsapaya, J. H. Cox, U. C. Meier, S. Tafuro, P. R. Dunbar, A. K. Sewell, C. S. Hourigan,V. Appay, V. Cerundolo, S. R. Burrows, A. J. McMichael and G. R. Screaton, A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity, 2001, 14, 591–602. J. A. Whelan, P. R. Dunbar, D. A. Price, M. A. Purbhoo, F. Lechner, G. S. Ogg, G. Griffiths, R. E. Phillips, V. Cerundolo and A. K. Sewell, Specificity of CTL interactions with peptide– MHC class I tetrameric complexes is temperature dependent. J Immunol, 1999, 163, 4342–4348.

107

108

5 T Cell-based Vaccines 19 M. A. Daniels and S. C. Jameson, Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med, 2000, 191, 335–346. 20 M. Knabel, T. J. Franz, M. Schiemann, A. Wulf, B. Villmow, B. Schmidt, H. Bernhard, H. Wagner and D. H. Busch, Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med, 2002, 8, 631–637. 21 J. N. Blattman, R. Antia, D. J. Sourdive, X. Wang, S. M. Kaech, K. MuraliKrishna, J. D. Altman and R. Ahmed, Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med, 2002, 195, 657–664. 22 P. Bousso,V. Wahn, I. Douagi, G. Horneff, C. Pannetier, F. Le Deist, F. Zepp, T. Niehues, P. Kourilsky, A. Fischer and G. de Saint Basile, Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci USA, 2000, 97, 274–278. 23 K. Murali-Krishna, J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky and R. Ahmed, Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity, 1998, 8, 177–187. 24 M. J. van Stipdonk, E. E. Lemmens and S. P. Schoenberger, Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol, 2001, 2, 423–429. 25 S. M. Kaech and R. Ahmed, Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol, 2001, 2, 415–422. 26 R. Mercado, S. Vijh, S. E. Allen, K. Kerksiek, I. M. Pilip and E. G. Pamer, Early programming of T cell populations responding to bacterial infection. J Immunol, 2000, 165, 6833–6839. 27 D. Busch and E. Pamer,T lymphocyte dynamics during Listeria monocytogenes infection. Immunol Lett, 1999, 65, 93–98. 28 H. McShane, Prime–boost immuniza-

29

30

31

32

33

34

35

36

37

tion strategies for infectious diseases. Curr Opin Mol Ther, 2002, 4, 23–27. E. Medina and C. A. Guzman, Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine, 2001, 19, 1573–1580. A. F. Ochsenbein, S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner and R. M. Zinkernagel, Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature, 2001, 411, 1058–1064. S. Jung, D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, E. G. Pamer, D. R. Littman and R. A. Lang, In vivo depletion of CD11 c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity, 2002, 17, 211–220. P. Grufman, E. Z. Wolpert, J. K. Sandberg and K. Karre, T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol, 1999, 29, 2197– 2204. R. M. Kedl,W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler and P. Marrack, T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med, 2000, 192, 1105–1113. M. J. Palmowski, E. M. Choi, I. F. Hermans, S. C. Gilbert, J. L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, P. Liljestrom, P. R. Dunbar and V. Cerundolo, Competition between CTL narrows the immune response induced by prime–boost vaccination protocols. J Immunol, 2002, 168, 4391–4398. P. Wong and E. G. Pamer, Feedback regulation of pathogen-specific T cell priming. Immunity, 2003, 18, 499–511. T. R. Mosmann and R. L. Coffman, TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol, 1989, 11, 191–221. P. A. Morel and T. B. Oriss, Crossre-

References

38

39

40

41

42

43

44

45

46

47

gulation between Th1 and Th2 cells. Crit Rev Immunol, 1998, 18, 275–303. S. Romagnani, Induction of TH1 and TH2 responses: a key role for the ‘natural’ immune response? Immunol Today, 1992, 13, 379–381. J. J. Bird, D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, J. R. Sider, T. F. Gajewski, C. R. Wang and S. L. Reiner, Helper T cell differentiation is controlled by the cell cycle. Immunity, 1998, 9, 229–237. Y. Laouar and I. N. Crispe, Functional flexibility in T cells: independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity, 2000, 13, 291–301. S. Sakaguchi, Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000, 101, 455–458. J. D. Fontenot, M. A. Gavin and A. Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003, 4, 330–336. S. Hori, T. Nomura and S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299, 1057–1061. S. Sakaguchi, N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, M. Itoh,Y. Kuniyasu, T. Nomura, M. Toda and T. Takahashi, Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev, 2001, 182, 18–32. C. Pasare and R. Medzhitov,Toll pathway-dependent blockade of CD4+CD25+ Tcell-mediated suppression by dendritic cells. Science, 2003, 299, 1033–1036. M. Kursar, K. Bonhagen, J. Fensterle, A. Kohler, R. Hurwitz, T. Kamradt, S. H. Kaufmann and H. W. Mittrucker, Regulatory CD4(+)CD25(+) T cells restrict memory CD8(+) T cell responses. J Exp Med, 2002, 196, 1585–1592. S. Stenger, D. A. Hanson, R. Teitelbaum, P. Dewan, K. R. Niazi, C. J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Melian, C. Bogdan, S. A. Porcelli, B. R. Bloom, A. M. Krensky

48

49

50

51

52

53

54

55

56

and R. L. Modlin, An antimicrobial activity of cytolytic T cells mediated by granulysin. Science, 1998, 282, 121–125. S. Sad, R. Marcotte and T. R. Mosmann, Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity, 1995, 2, 271– 279. Z. Liu, S. Tugulea, R. Cortesini and N. Suciu-Foca, Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28– T cells. Int Immunol, 1998, 10, 775–783. L. Cosmi, F. Liotta, E. Lazzeri, M. Francalanci, R. Angeli, B. Mazzinghi,V. Santarlasci, R. Manetti, V. Vanini, P. Romagnani, E. Maggi, S. Romagnani and F. Annunziato, Human CD8+CD25+ thymocytes sharing phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood, 2003; online publication Juli 31. N. Baumgarth and M. Roederer, A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods, 2000, 243, 77–97. K. T. Brunner, J. Mauel, J. C. Cerottini and B. Chapuis, Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology, 1968, 14, 181–196. P. Aichele, K. Brduscha-Riem, S. Oehen, B. Odermatt, R. M. Zinkernagel, H. Hengartner and H. Pircher, Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity, 1997, 6, 519–529. D. H. Busch and E. G. Pamer, T cell affinity maturation by selective expansion during infection. J Exp Med, 1998, 189, 701–709. D. H. Busch, I. Pilip and E. G. Pamer, Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection. J Exp Med, 1998, 188, 61–70. D. H. Busch and E. G. Pamer, T cell affinity maturation by selective expansion

109

110

5 T Cell-based Vaccines

57

58

59

60

61

62

63

64

65

66

during infection. J Exp Med, 1999, 189, 701–709. D. J. Sourdive, K. Murali-Krishna, J. D. Altman, A. J. Zajac, J. K. Whitmire, C. Pannetier, P. Kourilsky, B. Evavold, A. Sette and R. Ahmed, Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med, 1998, 188, 71–82. M. Derby, M. Alexander-Miller, R. Tse and J. Berzofsky, High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol, 2001, 166, 1690–1697. F. Crawford, H. Kozono, J. White, P. Marrack and J. Kappler, Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity, 1998, 8, 675–682. P. Savage, J. Boniface and M. Davis, A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity, 1999, 10, 485–492. T. N. Bullock, D. W. Mullins and V. H. Engelhard, Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol, 2003, 170, 1822– 1829. K. C. Garcia, C. A. Scott, A. Brunmark, F. R. Carbone, P. A. Peterson, I. A. Wilson and L. Teyton, CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature, 1996, 384, 577–581. T. M. Fahmy, J. G. Bieler, M. Edidin and J. P. Schneck, Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity, 2001, 14, 135–143. A. Amrani, J. Verdaguer, P. Serra, S. Tafuro, R. Tan and P. Santamaria, Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature, 2000, 406, 739–742. R. M. Kedl, J. W. Kappler and P. Marrack, Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol, 2003, 15, 120–127. A. V. Gett, F. Sallusto, A. Lanzavec-

67

68

69

70

71

72

73

74

75

76

77

chia and J. Geginat, T cell fitness determined by signal strength. Nat Immunol, 2003, 4, 355–360. A. J. McMichael and R. E. Phillips, Escape of human immunodeficiency virus from immune control. Annu Rev Immunol, 1997, 15, 271–296. M. A. Alexander-Miller, G. R. Leggatt, A. Sarin and J. A. Berzofsky, Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med, 1996, 184, 485–492. D. H. Busch and E. G. Pamer, MHC class I/peptide stability: implications for immunodominance, in vitro proliferation and diversity of responding CTL. J Immunol, 1998, 160, 4441–4448. S. M. Kaech, E. J. Wherry and R. Ahmed, Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol, 2002, 2, 251–262. J. Sprent and C. D. Surh, T cell memory. Annu Rev Immunol, 2002, 20, 551– 579. C. Tanchot, F. A. Lemonnier, B. Perarnau, A. A. Freitas and B. Rocha, Differential requirements for survival and proliferation of CD8 naive or memory Tcells. Science, 1997, 276, 2057–2062. M. Prlic, L. Lefrancois and S. C. Jameson, Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med, 2002, 195, F49–52. J. M. Grayson, A. J. Zajac, J. D. Altman and R. Ahmed, Cutting edge: increased expression of Bcl-2 in antigenspecific memory CD8+ T cells. J Immunol, 2000, 164, 3950–3954. J. Opferman, B. Ober and P. AshtonRickardt, Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science, 1999, 1745–1748. J. Jacob and D. Baltimore, Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature, 1999, 399, 593–597. F. Sallusto, D. Lenig, R. Forster, M. Lipp and A. Lanzavecchia, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 1999, 401, 708–712.

References 78 E. J. Wherry,V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian and R. Ahmed, Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol, 2003, 4, 225–234. 79 R. L. Reinhardt, A. Khoruts, R. Merica, T. Zell and M. K. Jenkins, Visualizing the generation of memory CD4 T cells in the whole body. Nature, 2001, 410, 101–105. 80 D. Masopust,V. Vezys, A. L. Marzo and L. Lefrancois, Preferential localization of effector memory cells in nonlymphoid tissue. Science, 2001, 291, 2413–2417. 81 G. Lauvau, S. Vijh, P. Kong, T. Horng, K. Kerksiek, N. Serbina, R. A. Tuma and E. G. Pamer, Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science, 2001, 294, 1735–1739. 82 E. M. Janssen, E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath and S. P. Schoenberger, CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 2003, 421, 852–856. 83 D. J. Shedlock and H. Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003, 300, 337–339. 84 J. C. Sun and M. J. Bevan, Defective CD8 T cell memory following acute infection without CD4 T cell help. Science, 2003, 300, 339–342. 85 B. Moss, M. W. Carroll, L. S. Wyatt, J. R. Bennink,V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg and G. Sutter, Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol, 1996, 397, 7–13. 86 A. Heit, T. Maurer, H. Hochrein, S. Bauer, K. M. Huster, D. H. Busch and H. Wagner, Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation

87

88

89

90

91

92

of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol, 2003, 170, 2802–2805. H. Tighe, K. Takabayashi, D. Schwartz, R. Marsden, L. Beck, J. Corbeil, D. D. Richman, J. J. Eiden, Jr., H. L. Spiegelberg and E. Raz, Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol, 2000, 30, 1939–1947. J. Schneider, J. A. Langermans, S. C. Gilbert, T. J. Blanchard, S. Twigg, S. Naitza, C. M. Hannan, M. Aidoo, A. Crisanti, K. J. Robson, G. L. Smith, A. V. Hill and A. W. Thomas, A prime–boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine, 2001, 19, 4595–4602. J. A. Wolff, R. W. Malone, P. Williams,W. Chong, G. Acsadi, A. Jani and P. L. Felgner, Direct gene transfer into mouse muscle in vivo. Science, 1990, 247, 1465–1468. G. Dietrich, A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H. E. Kaufmann, J. Hess, A. A. Szalay and W. Goebel, Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nature Biotechnology, 1998, 16, 181–185. A. Darji, C. A. Guzman, B. Gerstel, P. Wachholz, K. N. Timmis, J. Wehland, T. Chakraborty and S. Weiss, Oral somatic transgene vaccination using attenuated S. typhimurium. Cell, 1997, 91, 765–775. M. V. Dhodapkar, R. M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S. M. Donahoe, P. R. Dunbar, V. Cerundolo, D. F. Nixon and N. Bhardwaj, Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest, 1999, 104, 173–180.

111

Part III Adjuvants

115

6 Microbial Adjuvants Klaus Heeg, Stefan Zimmermann, and Alexander Dalpke

6.1 Introduction

The central goal of vaccination is the achievement of an efficient, protective, and long-lasting immune response of the adaptive immune system. Immunological memory and secondary responses are the major characteristic hallmarks of the adaptive response of T and B lymphocytes. This system evolved late in phylogeny and has reached its most sophisticated form in mammals. In contrast, innate immunity is phylogenetically old, does not include memory, and lacks enhanced secondary responses. Until recently, both systems were considered principally as two independent limbs of immunity. This view was changed when researchers recognized that innate immunity holds the key for initiation and primary activation of adaptive immune responses [1]. This new perception was fruitful in explaining the adjuvanticity of certain compounds and may lead to new strategies for developing effective vaccines. Innate immune cells control adaptive immune responses by two interrelated restriction points. First, they take up antigen, process it, and present it as peptide fragments to lymphocytes. Second, they recognize infectious danger, become activated, and are then able to provide a second signal to lymphocytes necessary for their effective activation (Figure 6.1). Secondary signals constitute costimulatory signals delivered by specialized ligand–receptor interactions (e. g., B7–CD28) and the secretion of regulatory cytokines like TNF, IL-1, IL-18, and IL-12. Dendritic cells (DC) are the most crucial innate immune cell type in this process. Antigen alone fails to initiate an adaptive immune response, but rather, induces immunological tolerance. During microbial infection the infectious agents provide both signals. It is well known that specific microbial proteins and even carbohydrates can be recognized as humoral antigens. However, it also became clear that in vaccination, antigen alone fails to induce an effective adaptive immune response. Instead, addition of ill-defined components to antigen was necessary to elicit the desired response. These compounds were termed adjuvants; however, their mode of action was elusive. During natural infection, microbial infectious agents obviously induce protective secondary responses and thus are capable of delivering a sufficient activation signal

116

6 Microbial Adjuvants microbe

PAMP

antigen

Danger TLR

INNATE SYSTEM

⊕ SIGNAL 2

Innate immune cell (DC)

costimulation

antigen processing and presentation

SIGNAL 1 TCR

ADAPTIVE SYSTEM

T cell

Figure 6.1 Innate and adaptive immunity are interconnected during infection.

to innate immune cells. However, the nature of this natural adjuvant signal was not known until recently. The compounds triggering these signals were recently defined and characterized as conserved microbial molecular patterns. These conserved microbial structures are composed of various microbial cell wall components, specific microbial structural proteins, lipoproteins and lipopeptides, and microbial nucleic acids. The complete set of these structures has been termed pathogen-associated molecular pattern (PAMP), which can be sensed by the innate immune system. An array of receptors are expressed in the host, called PAMPrecognition receptors (PRR); they include the family of Toll-like receptors (TLR), scavenger receptors, and carbohydrate receptors in cell-bound and soluble forms. TLR seem to play a pivotal role in recognizing microbial infection (Table 6.1). PAMPs can be typified as evolutionarily conserved danger signals leading to activation of innate immunity in the host, which is crucial for subsequent activation of adaptive immune responses. Indeed, some previously defined adjuvants now have been characterized as microbial or microbial-derived components that activate innate immune cells in TLR-dependent and TLR-independent manners. Moreover, new synthetic TLR agonists have been identified that possess adjuvant activity and which can be used as well-defined pharmaceutical agents in new vaccine formulations (Table 6.2). New antigendelivery system such as emulsions, liposomes, microparticles, and ISCOMs might possess intrinsic adjuvant activity too that might be enhanced by addition of defined adjuvants. This chapter focuses on microbial and microbial-derived natural and synthetic danger signals that can be used as adjuvants in vaccination.

6.2 Microbial Danger Signals Tab. 6.1 Toll-like receptors (TLR) and their natural ligands. TLR

Microbial ligand

TLR1

Cooperation with TLR2, triacylated lipoproteins.

TLR2

Lipoproteins and lipopeptides (E. coli, M. tuberculosis, B. burgdorferi, T. pallidum, M. fermentans, S. epidermidis, H. influenzae, S. flexneri). Peptidoglycan, yeast cell walls, lipoarabinomannan, glycolipids (Treponema), GPI anchors (T. cruzi), lipoteichois acid (LTA), lipopolysaccharide (Leptospira, Porphyromonas).

TLR3

Viral RNA, poly (I:C).

TLR4

LPS, F-protein from RS-virus, fungal components (Aspergillus, Cryptococcus).

TLR5

Flagellin (L. monocytogenes, S. typhimurium).

TLR6 + TLR2

Peptidoglycan, zymosan, MALP-2 (Mycoplasma), lipoproteins.

TLR7

? (synthetic: imidazoquinolines).

TLR8

? (human: synthetic: imidazoquinolines).

TLR9

Bacterial DNA (synthetic: CpG–ODN).

TLR10

?

Tab. 6.2 Microbial and microbial-derived adjuvants. Activators of the innate immune system Toxins cholera toxin, heat-labile toxin (E. coli) Toll-like receptor-dependent bacterial compounds derivatives of lipid A (MPL) muramyl dipeptides (MDP) lipopeptides, MALP other components (flagellin) bacterial CG DNA Toll-like receptor-dependent synthetic compounds synthetic CpG DNA AGPs Other low molecular synthetic agonists imidazoquinolines

6.2 Microbial Danger Signals 6.2.1 Toxins (CT and LT)

During infection, microbes not only activate innate immune cells by their PAMPS but also are able to influence cellular responses by specifically released toxins. Some of these toxins act as adjuvants. The most powerful toxin adjuvanticity found so far

117

118

6 Microbial Adjuvants

is that of cholera toxin (CT) and heat-labile toxin from E coli (LT). Both agents act as strong mucosal adjuvants in experimental models. CT and LT are the underlying pathophysiological principles of cholera and traveler’s diarrhea. Therefore, the use of wild-type CT and LT in humans is precluded. CT and LT are composed of two subunits (A and B). Subunit B binds to cellular receptors, and subunit A crosses the cellular membrane and influences the activity of adenylate cyclase, causing its permanent activation and accumulation of cAMP. Genetically defined mutants of CT and LT have been obtained that lack toxicity yet retain their immunological activity. These mutants are currently being tested for applicability in humans. However, recent studies have shown that intranasally applied CT and LT might be taken up and found in the brain [2], which would preclude their use as local mucosal adjuvants. Although the powerful mucosal adjuvanticity of CT and LT has been demonstrated convincingly, their mode of action is still unknown. CT-aided responses are characterized by a predominant activation of the Th2 type of CD4 T cells. This is due to increased induction of IL-4, IL-5, and IL-10 while IL-12 receptor expression is suppressed. In contrast, LT seems to activate Th1 and Th2 cells concomitantly. Recently CT and LT were shown to activate human monocyte-derived dendritic cells (DC) in a cAMP-dependent way [3]. Thus, direct DC activation might be one underlying mechanism of CT- and LT-mediated adjuvanticity that could be orchestrated by direct release of regulatory cytokines from various innate immune cells. 6.2.2 Toll-like Receptor-dependent Microbial Adjuvants 6.2.2.1 Lipopolysaccharide and Lipid A Derivatives Lipopolysaccharide (LPS) is a constituent of the outer membrane of gram-negative bacteria. Its proinflammatory activity and its role as a sepsis-inducing factor in severe infections were recognized long ago. In simplified terms, LPS consists of a core polyacylated disaccharide (lipid A) and various attached carbohydrate chains. Lipid A was defined as the active part of LPS. The number and positions of acyl side chains were found to be important for the proinflammatory activity of LPS [4]. Although known for a long time, only recently has the receptor system mediating recognition of LPS been elucidated. TLR4 molecules in combination with CD14 and a soluble protein (MD-2) sense LPS and lead to cellular activation [5]. LPS preparations are highly toxic; however, heroic trials in the early 20th century suggested that LPS might possess immunomodulatory and immunostimulatory activity. Chemically defined derivatives of LPS were identified that display reduced toxicity yet retain the immunomodulatory properties of wild-type LPS. One of these components is monophosphoryl lipid A, which was further refined and which is now used as adjuvant (MPL) [6]. MPL has been evaluated in numerous studies and was tested in more than 10 000 individuals in various vaccine formulas: it was an effective mucosal adjuvant and activated humoral as well as cellular immune responses. Vaccination against infectious diseases (herpes, HBV, influenza) induced lasting, effective immune responses. Although shown to be effective, its exact mode of action has still to be defined. How-

6.2 Microbial Danger Signals

ever, since TLR4 gene-defective mice do not respond to MPL, involvement of TLR4 in the adjuvanticity effect of MPL is strongly suggested. MPL activates human DC to maturate, express costimulatory molecules (CD80, CD86, CD40, CD83), enhance antigen presentation (HLA-DR), and induce secretion of regulatory cytokines (IL-12). However, its intrinsic activity in vitro is lower than that of wild-type LPS. Moreover, MPL also might directly act on T cells via TLRs [7]. 6.2.2.2 Peptidoglycan and Lipoteichoic Acid Peptidoglycans (PG) are essential constituents of all bacterial cell walls. PGs are recognized by innate immune cells in context with TLR2 and TLR6. Although PG clearly represent a PAMP, their role as an adjuvants is limited. So far, isolated PG was shown to possess only limited immunostimulatory activity relative to other TLR ligands. Similar conclusions can be drawn for lipoteichoic acid (LTA). LTA clearly represents a PAMP; however, again its intrinsic activity is rather low. Recently, pure alanylated fractions of natural LTA with improved activity were successfully prepared [8]. However, compared to other TLR ligands, the activity was rather low, and in addition, LTA was a very poor inducer of IL-12. Thus, natural LTA does not seem to be a promising candidate for a new adjuvant. 6.2.2.3 Other Microbial Components (Lipopeptides, Flagellin) Bacterial lipopeptides exert potent immunostimulatory activity [9]. Because bacteria of the species Mycoplasma contain neither LPS nor PG, they have been used to study the effects of bacterial lipoproteins in detail. A mycoplasmal-derived lipopeptide, termed macrophage-activating lipopeptide-2 (MALP-2) was shown to stimulate DC activation and maturation via TLR2 and TLR6 [10]. MALP therefore was used as a mucosal adjuvant and proved to be applicable [11]. Flagellin is a protein of many gram-negative bacteria, which also may be secreted. Flagellin is a member of the PAMP family and is recognized by innate immune cells. A rather intriguing property of flagellin is its recognition in combination with TLR5 [12]. However, flagellin is a rather weak stimulus for innate immune cells. Although it stimulates up-regulation of costimulatory molecules of DC, its intrinsic ability to stimulate cytokine secretion is low. Nevertheless, flagellin has been used in experimental animal models and was effective as adjuvant for CD4+ T cells [13]. Due to its complicated isolation process, its practical use as an adjuvant will be limited. 6.2.2.4 Bacterial DNA It is well known that the base compositions of bacterial and vertebrate DNA differ. Vertebrate DNA exhibits so-called CG suppression, that is, a reduced overall frequency of the dinucleotide CG compared to the statistically expected value of 1/16. Moreover, CG islands in vertebrate DNA are DNA regions that are involved in gene regulatory processes and possess methylated cytosine residues. In contrast, regulative mechanisms relying on DNA methylation are lacking in bacterial genomes. As a consequence, bacterial DNA contains much more unmethylated (free) CG dinucleotides than vertebrate DNA does. Accordingly, the frequent presence of CG dinucleotides in DNA molecules distinguishes bacterial from vertebrate DNA and thus ful-

119

120

6 Microbial Adjuvants

fills the requirements of a PAMP. These concepts were not known when bacterial DNA was recognized as a natural adjuvant in the early 1980s [14]. Preparations of Mycobacteria exert anti-tumor effects when injected at the tumor-bearing site. Delineation of the active principle revealed that mycobacterial DNA was responsible for the immunological effects. Moreover, it was shown that DNA containing CG dinucleotides was most effective. These discoveries have led to multiple approaches that are now used in clinical immunology, including the use of Mycobacteria (and thus bacterial) DNA to treat patients with urinary bladder carcinomas [14]. Similar to many PAMPs, TLRs are responsible for recognition of bacterial DNA. Gene knockout experiments have revealed a central role of TLR9 in recognition of bacterial DNA [15]. TLR9 belongs to a subset of TLRs (TLR7, 8, 9) that share some unique features. Canonical TLRs are expressed on the cell surface by multiple innate immune cell types, including DC, macrophages, and granulocytes, and even epithelial cell types and lymphocytes. In contrast, TLR7–9 show a rather restricted cellular expression profile, confined to intracellular endosomal compartments. Accordingly, bacterial DNA has to be taken up from extracellular sources into endosomes or has to be released from phagocytosed microbes prior to triggering TLR9 receptors. The expression profiles of TLR9 differ in mice and humans. Although mice express TLR9 on macrophages, DC, and B cells, in humans macrophages and conventional DC fail to express TLR9. Only a minor subset of peripheral DC, the plasmacytoid DCs, show TLR9 expression and are thus fully responsive to bacterial DNA (see below). In-vitro isolated and purified bacterial DNA triggers strong innate immune responses, including cellular activation and release of proinflammatory cytokines, which eventually lead to lethal shock syndrome, as does injection of LPS. However, the role of bacterial DNA during infection is still elusive [16]. So far, only limited information on the fate of infections in TLR9 gene-deficient mice is available. However, purified bacterial DNA is a strong inducer of IL-12 and thus preferentially triggers Th1 immune responses. Moreover, bacterial DNA prevented Th2-dominated allergic immune reactivities [17]. These observations support the hygiene hypothesis of the prevalence of allergies in developed countries. Lack of childhood infections with bacteria in developed counties, due to excessive cleanliness is believed to cause a reduced Th1 profile and thus favor allergy development [18]. Accordingly, bacterial DNA is now considered to be a major factor during bacterial infection, which leads to a Th1 bias in subsequent immune responses, thus preventing induction of allergic reactivities. Immunization with naked plasmid DNA encoding antigen induces strong humoral and cellular immune responses. Interestingly, ongoing immune responses were skewed towards a Th1 type of reactivity [19]. It turned out that plasmid DNA sequences not encoding the antigen were responsible for the efficacy as well as the induced Th1 bias [20]. CG motifs in these regions were found to be important in this respect. Hence, CG motifs seem to contribute to the overall effectiveness of DNAbased vaccines. DNA plasmid vaccines can therefore be classified as a two-component vaccine. DNA encodes the vaccine antigen, and at the same time, plasmid DNA acts as an intrinsic adjuvant [21]. However, the matter might be more complicated than initially thought. First, DNA motifs in viral, bacterial, and mammalian DNA

6.2 Microbial Danger Signals

have been described that inhibit CG-mediated effects. Thus, certain DNA sequences might specifically suppress activation of innate immune cells and therefore prevent activation and immunization against antigens [22]. Second, in contrast to mice, in humans the expression of TLR9 seems to be tightly restricted to subpopulations of DC. Therefore, the contribution of CG sequences in DNA vaccines could be less effective in humans. Indeed, recent experience with DNA vaccines in human trials seems to support this notion. 6.2.3 Toll-like Receptor-dependent Synthetic Compounds 6.2.3.1 Synthetic CpG DNA A major breakthrough in research on immunostimulatory CG DNA was the finding that short synthetic single-stranded oligonucleotides mimic the effects of bacterial DNA [23]. Moreover, it now was possible to synthesize defined oligonucleotides (ODN) to elucidate the DNA sequence requirements necessary for optimal activation. It turned out that a minimal hexameric DNA motif (5´-R-R-C-G-Y-Y-3´) within an oligonucleotide was sufficient to induce activation of innate immune cells. These active ODN were termed CpG oligonucleotides (CpG ODN) (where p stands for the phosphate bond). Moreover, CpG ODN proved to be of superior usefulness compared to bacterial DNA, because CpG ODN could be produced with high purity [24]. CpG ODN could additionally be manufactured with synthetic backbone modifications different from the natural phosphodiester backbone (PO), which conveyed nuclease resistance and in turn allowed greater in-vivo stability. Usually phosphorothioate backbone modifications (PTO) are used. CpG ODN have to be taken up to meet their receptor, presumably within the endosome. CpG ODN induce activation, maturation, and induction of effector function in innate immune cells (like DC and macrophages), but also induce proliferation and Ig secretion in B lymphocytes. A special peculiarity of CpG ODN is their profound capacity to induce IL-12 production, which may explain their capacity to preferentially induce Th1-biased immune responses (Figure 6.2). The underlying mechanisms for these effects are not yet known. In mice, IL-12 and IL-18 mediated activation of NK cells induces high amounts of IFN-gamma. DC respond with upregulation of their machinery for antigen processing and antigen presentation. Macrophages activate their innate effector functions, such as phagocytosis, iNOS induction, and production of reactive oxygen species (ROS). Therefore, CpG ODN are not only excellent candidates as vaccine adjuvants but also potent immune activators that can augment the effector phase of anti-microbial immune responses (Figure 6.2) [25]. Although direct injection of CpG ODN into joints induces autoimmune arthritis, no such autoimmune phenomena have been observed so far after local injection in the course of an experimental vaccination [26]. Hence, CpG ODN could be used as an agent to prevent Th2-mediated immune reactions or even as drug to treat Th2-dominated diseases. Intensive recent work on DNA sequences and ODN modifications has shown that CpG ODN effects are much more complicated than initially anticipated. Although

121

122

6 Microbial Adjuvants CpG DNA

Macrophage

DC

B cell

activation of innate effector functions: phagocytosis, iNOS, ROS

IL-12 IL-18

NK cell

induction of adaptive immune responses: antigen presentation costimulation cytokine milieu

antimicrobial immune response

Figure 6.2 CpG DNA and the initiation of innate and adaptive immune responses in mice.

backbone modifications are advantageous when stability and long-term activity are concerned, at the same time, in experimental murine models they show undesired effects, including long-term lymphadenopathy and DNA sequence-independent stimulation of B lymphocytes. In vivo, natural PO backbone CpG ODN were almost ineffective; however, addition of certain DNA sequences restored their activity [27, 28]. This indicates that the pharmacology of CpG ODN can still be improved. In addition, species-specific sequence differences became evident. CpG ODN sequences that were optimal for murine cells were almost ineffective on human cells, and vice versa. Species-specific sequence alterations in TLR9 were responsible for these effects [29]. As mentioned above, there exist further differences in TLR9 expresion between mouse and man. In human peripheral blood, in addition to B cells, only plasmacytoid DCs express TLR9 and are thus CpG reactive. However, some ODN effects can be triggered independently on TLR9, indicating that other receptor systems (e. g., scavenger receptors) are involved too. Extensive DNA sequence analyses have further revealed that different types of ODN exist for human cells (Figure 6.3). D-type ODN require an unmethylated CpG dinucleotide, a palindrome with CG in the center, and a phosphorothioate backbone in the palindrome-flanking regions. D-type ODN preferentially stimulate IFNgamma production by human NK cells. In contrast, K-type ODN consist of multiple

6.2 Microbial Danger Signals Mice: 5'-x-x-...-G-A-C-G-T-T-...-x-x-3' (PTO modification allowed)

murine TLR9

Human: "K"-type ODN 5'-x-x-..T-C-G-T-T(A)-..-T-C-G-T-T(A)-..x-x-3' (PTO modification allowed)

human TLR9

"D"-type ODN 5'-x-x-.. ..-x-x-3' A •• T T ••A C–G

? other receptors ?

(or other palindromic sequences with central CG) palindrome: no PTO modification allowed

Figure 6.3

CpG DNA sequence motifs.

CpG dinucleotides, with a thymidine immediately 5´, and a TpT or TpA at the 3´ of the CpG. K-type ODN effectively stimulate monocytes and B cells, inducing proliferation, cytokine secretion, and Ig secretion [30]. Preferentially, K-type ODN have been used for preclinical studies in primates and proved their applicability [31]. Moreover, CpG ODN seem to require fewer booster injections of classical antigen to achieve protective antibody responses, as compared to vaccinations using conventional adjuvants. Finally, direct coupling of antigens to CpG ODN combines cellular delivery of antigen to DCs with concomitant activation and increased capability of antigen presentation within the same immune cell. This allows the amount of CpG ODN used for vaccination to be reduced and might enhance the immunogenicity of CpG antigen preparations in vaccination trials [32]. Although one advantage of CpG ODN is their marked adjuvanticity for the induction of T-cell responses, as shown in murine models, in primates so far, no information on CTL induction is available. Nevertheless, the data so far qualify CpG ODN as a novel vaccine adjuvant that could be used in vaccines aimed to vaccinate B and T lymphocytes and, in addition, induce a Th1-prone status of the immune system [33]. 6.2.3.2 Other Synthetic TLR ligands Due to the increasing knowledge of TLR4 and its interaction with LPS or lipid A analogues, novel synthetic aminoalkylglucosaminide phosphates (AGP) have been developed. These acylated monosaccharides are structurally related to lipid A [6] and possess strong adjuvant activity. Since AGPs are chemically synthesized, changes in

123

124

6 Microbial Adjuvants

their chemical moieties can be tested for improvement of activity, stabilization, and degradation with less pyrogenicity. Preclinical studies suggest that AGPs might be as effective as adjuvant as MPL is [6]. The minimal essential structure of peptidoglycan is MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine). MDP has been synthesized and tested for adjuvant activity; it stimulated human DC and induced up-regulation of costimulatory molecules. However, HLA DR was not affected [34]. Therefore, in comparison to other TLR ligands, the results are not yet promising. However, new chemical modifications (adamantylacetyl derivative of peptidoglycan monomers) seem to be more encouraging [35]. Synthetic lipopeptides have been used as adjuvant and combined antigen/adjuvant compositions. They amalgamate adjuvanticity and peptide-based antigen delivery. Synthetic lipopeptides can deliver CTL epitopes into the class I presentation pathway and concomitantly activate APC. Thus, effective T cell activation is brought about. TLR2 is crucially involved in activation of DC and thus in the adjuvant activity of lipopeptides [10]. In addition, preclinical trials have been performed to study vaccinations against HIV, HBV, HCV, CMV, HSV, and malaria [36]. Moreover, synthetic lipopeptides also promise future use in mucosal vaccines. 6.2.3.3 Low Molecular Weight TLR Agonists

Imidazoquinolines (Imiquimod, R848) Low molecular weight compounds of the imidazoquinoline family are active in stimulating adaptive immunity. They induce prophylactic and therapeutic reactivities against HSV infection and enhance Th1-mediated immune responses. Accordingly, these agents are called immunomodifiers. When compared with CpG DNA, imidazoquinolines induced similar cytokine and reaction profiles, albeit slightly less effectively [37]. Importantly, imidazoquinolines also induce IFN-alpha and thus might play an important role in aiding anti-viral responses. It was a surprise when TLR7 was identified as the recognition structure of imidazoquinolines in mice and humans [38]. Accordingly, imidazoquinolines activate the innate immune system in a MyD88-dependent pathway and thus can be classified as a synthetic ligand of an undefined microbial PAMP acting on TLR7 and possibly also TLR8. It is so far unknown whether the low molecular weight imidazoquinolines act directly on TLR7 or have to be bound to so-far-undefined matrixes. Since cellular and subcellular expression profiles of TLR7 and TLR9 seem to broadly overlap, and since imidazoquinolines share some properties of CpG DNA (e. g., Th1-inducing capacity), these compounds might be a new alternative to a microbial-derived synthetic PAMP that can be used effectively as adjuvants [39]. Because these compounds have been used already as an immune-response modifier in viral infection, they might be included in vaccine formulas soon. Moreover, their marked Th1-inducing capacity might qualify imidazoquinolines as Th1-promoting agents useful in allergy vaccines. Moreover, chemical modifications of the imidazoquinolines, which can be achieved easily, could sharpen the reactivity profile and enhance the intrinsic activity. Nevertheless, the natural ligands for TLR7 and TLR8 are not yet defined. One could speculate that low molecular compounds of mi-

6.3 Conclusion

crobial metabolism are natural ligands. This in turn would further catalyze the development of new synthetic TLR ligands with high and selective adjuvanticity.

6.3 Conclusion

Delineation of microbial PAMP and their receptors on innate immune cells has led to tremendous progress in understanding the mechanisms of sensing infectious danger and initiating innate and adaptive immune responses. The TLR systems and the respective microbial ligands play fundamental roles in this process. This knowledge has allowed us to understand the means by which microbial PAMPs and their derivatives, which were defined empirically, act as vaccine adjuvants (Figure 6.4). Based on these findings, natural microbial PAMPs can be modified and further developed, or synthetic compounds can be improved to be utilized as new efficient adjuvants in vaccination.

Cholera Toxin (CT) Heat labile Toxin (LT) adenylate cyclase MDP MALP-2 lipopeptides

MPL

TLR 2/6

TLR 4

ACTIVATION

TLR 5

flagellin

TLR 9

CpG DNA imidazoquinolines

TLR 8

endosome

innate immune cell

Figure 6.4

Microbial adjuvants and TLR.

125

126

6 Microbial Adjuvants

References 1. Medzhitov, R. and Janeway, C.A., Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997, 9, 4–9. 2. Hagiwara,Y., Iwasaki, T., Asanuma, H., Sato,Y., Sata, T., Aizawa, C., Kurata, T., and Tamura, S., Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine 2001, 19, 1652–1660. 3. Bagley, K.C., Abdelwahab, S.F., Tuskan, R.G., Fouts, T.R., and Lewis, G.K., Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect Immun 2002, 70, 5533–5539. 4. Rietschel, E.T., Brade, H., Holst, O., Brade, L., Müller-Loennies, S., Mamat, U., Zähringer, U., Beckmann, F., Seydel, U., Brandenburg, K., Ulmer, A.J., Mattern, T., Heine, H., Schletter, J., Loppnow, H., Schönbeck, U., Flad, H.-D., Hauschildt, S., Schade, U.F., di Padova, F., Kusumoto, S., and Schumann, R.R., Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 1996. 216, 39–81. 5. Shimazu, R., Akashi, S., Ogata, H., Nagai,Y., Fukudome, K., Miyake, K., and Kimoto, M., MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189, 1777–1782. 6. Persing, D.H., Coler, R.N., Lacy, M.J., Johnson, D.A., Baldridge, J.R., Hershberg, R.M., and Reed, S.G., Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002, 10, S32–S37. 7. Ismaili, J., Rennesson, J., Aksoy, E.,Vekemans, J.,Vincart, B., Amraoui, Z., Van Laethem, F., Goldman, M., and Dubois, P.M., Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002, 168, 926–932.

8. Morath, S., Stadelmaier, A., Geyer, A., Schmidt, R.R., and Hartung, T., Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med 2002, 195, 1635–1640. 9. Bessler, W.G., Heinevetter, L., Wiesmuller, K.H., Jung, G., Baier,W., Huber, M., Lorenz, A.R., Esche, U.V., Mittenbuhler, K., and Hoffmann, P., Bacterial cell wall components as immunomodulators. I. Lipopeptides as adjuvants for parenteral and oral immunization. Int J Immunopharmacol 1997, 19, 547–550. 10. Hertz, C.J., Kiertscher, S.M., Godowski, P.J., Bouis, D.A., Norgard, M.V., Roth, M.D., and Modlin, R.L., Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001, 166, 2444–2450. 11. Rharbaoui, F., Drabner, B., Borsutzky, S.,Winckler, U., Morr, M., Ensoli, B., Muhlradt, P.F., and Guzman, C.A., The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 2002, 32, 2857–2865. 12. Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R.,Yi, E.C., Goodlett, D.R., Eng, J.K., Akira, S., Underhill, D.M., and Aderem, A., The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410, 1099–1103. 13. Krogsgaard, M., Wucherpfennig, K.W., Canella, B., Hansen, B.E., Svejgaard, A., Pyrdol, J., Ditzel, H., Raine, C., Engberg, J., and Fugger, L., Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)DR2-MBP 85–99 complex. J Exp Med 2000, 191, 1395–1412. 14. Yamamoto, S.,Yamamoto, T., and Tokunaga, T., The discovery of immunostimulatory DNA sequence. Springer Semin Immunopathol 2000, 22, 11–19. 15. Hemmi, H., Takeuchi, O., Kawai, T.,

References

16.

17.

18.

19.

20.

21.

22.

23.

24. 25.

Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S., A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745. Dalpke, A., Zimmermann, S., and Heeg, K., CpG–DNA in the prevention and treatment of infections. BioDrugs 2002, 16, 419–431. Van Uden, J. and Raz, E., Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999, 104, 902–910. Parronchi, P., Brugnolo, F., Sampognaro, S., and Maggi, E., Genetic and environmental factors contributing to the onset of allergic disorders. Int Arch Allergy Immunol 2000, 121, 2–9. Raz, E., Tighe, H., Sato,Y., Corr, M., Dudler, J.A., Roman, M., Swain, S.L., Spiegelberg, H.L., and Carson, D.A., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996, 93, 5141–5145. Sato,Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M.D., Silverman, G.J., Lotz, M., Carson, D.A., and Raz, E., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273, 352–354. McCluskie, M.J.,Weeratna, R.D., and Davis, H.L., The role of CpG in DNA vaccines. Springer Semin Immunopathol 2000, 22, 125–132. Krieg, A.M.,Wu, T., Weeratna, R., Efler, S.M., Love-Homan, L.,Yang, L., Yi, A.K., Short, D., and Davis, H.L., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998, 95, 12631–12636. Krieg, A.M.,Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A., and Klinman, D.M., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546–549. Krieg, A.M., Now I know my CpGs. Trends Microbiol 2001, 9, 249–252. Wagner, H., Toll meets bacterial CpG– DNA. Immunity 2001, 14, 499–502.

26. Deng, G.M., Nilsson, I.M., Verdrengh, M., Collins, L.V., and Tarkowski, A., Intra-articulary localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999, 5, 702– 705. 27. Agrawal, S. and Kandimalla, E.R., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med 2002, 8, 114–121. 28. Dalpke, A., Zimmermann, S., and Heeg, K., Immunopharmacology of CpG DNA. Biol Chem 2002, 383, 1491– 1500. 29. Bauer, S., Kirschning, C.J., Hacker, H., Redecke,V., Hausmann, S., Akira, S., Wagner, H., and Lipford, G.B., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad SciUSA 2001, 98, 9237– 9242. 30. Gursel, M.,Verthelyi, D., Gursel, I., Ishii, K.J., and Klinman, D.M., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002, 71, 813–820. 31. Verthelyi, D., Kenney, R.T., Seder, R.A., Gam, A.A., Friedag, B., and Klinman, D.M., CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002, 168, 1659–1663. 32. Tighe, H., Takabayashi, K., Schwartz, D., Marsden, R., Beck, L., Corbeil, J., Richman, D.D., Eiden, J.J., Jr., Spiegelberg, H.L., and Raz, E., Conjugation of protein to immunostimulatory DNA results in a rapid, longlasting and potent induction of cellmediated and humoral immunity. Eur J Immunol 2000, 30, 1939–1947. 33. Singh, M. and O'Hagan, D.T., Recent advances in vaccine adjuvants. Pharm Res 2002, 19, 715–728. 34. Todate, A., Suda, T., Kuwata, H., Chida, K., and Nakamura, H., Muramyl dipeptide-Lys stimulates the function of human dendritic cells. J Leukoc Biol 2001, 70, 723–729. 35. Ljevakovic, D., Tomasic, J., Sporec,V., Spoljar, B.H., and Hanzl-Dujmovic, I., Synthesis of novel adamantylacetyl derivative of peptidoglycan mono-

127

128

6 Microbial Adjuvants mer: biological evaluation of immunomodulatory peptidoglycan monomer and respective derivatives with lipophilic substituents on amino group. Bioorg Med Chem 2000, 8, 2441–2449. 36. BenMohamed, L., Wechsler, S.L., and Nesburn, A.B., Lipopeptide vaccines: yesterday, today, and tomorrow. Lancet Infect Dis 2002, 2, 425–431. 37. Vasilakos, J.P., Smith, R.M., Gibson, S.J., Lindh, J.M., Pederson, L.K., Reiter, M.J., Smith, M.H., and Tomai, M.A., Adjuvant activities of immune response modifier R-848: comparison

with CpG ODN. CellImmunol 2000, 204, 64–74. 38. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3, 1–5. 39. Hengge, U.R., Benninghoff, B., Ruzicka, T., and Goos, M., Topical immunomodulators: progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001, 1, 189–198.

129

7 Host-derived Adjuvants Norbert Hilf, Markus Radsak, and Hansjörg Schild

7.1 Introduction

The immunogenicity of most antigens, such as proteins or peptides, is very limited when applied as pure substances. Therefore, these antigens are mixed with substances known as adjuvants (adiuvare (Latin): to help), which facilitate and amplify the induction of an immune response. The earliest discovered adjuvants are aluminum salts, which have been in use since Glenny and coworkers discovered in 1926 that alum-precipitated diphtheria toxoid is a more potent vaccine than the toxoid alone [1]. As early as 1937, Freund developed the most effective adjuvant known, an oil-in-water emulsion containing killed mycobacteria [2]. This mixture became famous as ‘complete Freund's adjuvant’ (CFA). The components of these and other classical adjuvants are chemicals or are derived from pathogenic microorganisms. However, several substances of mammalian origin possess adjuvant-like features and are therefore also candidates for use in vaccinations. Today, adjuvants are believed to contribute to the immune response in at least two distinct ways. First, they convert the antigen into a form that is more accessible to the immune system. For example, alum-precipitated antigen is more particulate and therefore more readily ingested by phagocytes. Moreover, the antigen is released with delayed kinetics. Second, adjuvants provide immunostimulatory signals that tell the adaptive immune system to take the provided antigen seriously. During a challenge with pathogenic microorganisms or viruses, this second signal is provided by danger signals that are either pathogen-derived structures or substances released by the host itself. This chapter focuses on the latter: endogenous substances with immunostimulatory capacities. Several cytokines, low molecular weight substances, and proteins are able to provide immunostimulatory signals. However, heat shock proteins (HSPs) possess in addition amazing ‘immunological’ properties that serve the adaptive arm of immunity. Therefore, they are the focus of this chapter.

130

7 Host-derived Adjuvants

7.2 Heat Shock Proteins in Immunology 7.2.1 General Remarks

Elevated expression of HSPs is initiated in every cell in response to a variety of stress situations, such as high temperature, anoxia, heavy metals, or glucose starvation, which promote the denaturation of proteins. Because the structural integrity of proteins is crucial for all biological processes, the survival of cells is threatened under these conditions. HSPs bind to hydrophobic stretches of denatured proteins, thereby preventing their aggregation (chaperone function). Moreover, HSPs initiate the refolding of their bound substrate or proteolytic degradation if the unfolding was irreversible. These proteins thus confer elevated stress tolerance to the cells they are expressed in [3]. However, also under nonstressed conditions most HSPs are constitutively expressed in high copy numbers and fulfil their chaperone function – assistance in de novo protein folding, subunit assembly, and transport between cellular compartments [4]. HSPs are divided into six protein families that are named according to their molecular weight: small HSPs, HSP40, HSP60, HSP70, HSP90, and HSP100. The individual members of these families – although most are very similar in sequence – are located in different subcellular compartments and are differentially regulated. For example, the HSP70 family is represented in the ER by BIP, in the mitochondrion by Grp75, and in the cytosol by the constitutively expressed Hsc70 and the stress-inducible Hsp70. The most intensely studied HSP from the immunological point of view is the ER-resident Hsp90 homologue Gp96, but other proteins mainly from the HSP60, HSP70, and HSP90 families have also been described as possessing immunological functions (Table 7.1). Tab. 7.1 Chaperones with immunogenic functions. Chaperone family

Member with immune functions

Localization

Peptide APC binding 1) activation2)

HSP60 HSP70

Hsp60 Hsc70 (Hsp73) (constitutive form) Hsp70 (Hsp72) (stress-inducible form) Hsp110 (Hsp105) Grp170 (Orp150) Hsp90 a/b (Hsp86/Hsp84) Gp96 (Grp94, endoplasmin) calreticulin (calregulin, Erp60)

mitochondrial cytoplasmic

– ++

++ +

cytoplasmic

++

+

cytoplasmic ER lumen cytoplasmic ER lumen ER lumen

+ + ++ ++ +

– – + + –

HSP110 subfamily GRP170 subfamily HSP90 Calreticulin family

1) – not demonstrated or proposed; + indirect evidence by cross-presentation or immunization experiments; ++ additional direct proof by peptide elution or x-ray structure for HSP70 chaperones 2) – not demonstrated or proposed; + some evidence, but contradicting reports; ++ clear evidence, well accepted

7.2 Heat Shock Proteins in Immunology

7.2.2 Heat Shock Proteins Are Immunogenic

The immunogenic potential of HSPs was first demonstrated by Srivastava and coworkers (reviewed in [5]). Gp96 purified from tumor cells was able to confer protective immunity in mice against a subsequent challenge with the same tumor, but not with a distinct one. Moreover, treatment of mice with HSPs could be used for therapy against a pre-existing primary tumor and its metastases [6]. Again, only tumorderived, but not liver-derived, Gp96 was able to elicit a specific immune response against the tumor. But in these experiments the HSPs purified from the tumor were not mutated compared to HSPs in healthy tissue. Instead, immunity was induced by tumor-specific peptides bound to the HSPs. The requirement for peptide binding has been validated by findings that HSPs deprived of peptides do not induce immunity [7] and that loading of ‘empty’ HSPs with peptides results in reconstitution of HSP immunogenicity [8]. Although Gp96 is the best described HSP concerning its role in the induction of specific immune responses, other HSPs have since been shown to perform similar functions: the constitutive and inducible cytosolic members of the HSP70 family [7], Hsp90 [9], calreticulin [10, 11], Hsp110, and Grp170 [12]. All these proteins have the ability in common to bind intracellular peptides and form potent immunogenic HSP-peptide complexes that can be used as vaccines. HSP-mediated immunity is independent of the MHC haplotype of the cell from which the HSPs were isolated. Peptides complexed by HSPs purified from cells with one haplotype induce immunity in mice of a different MHC haplotype [13]. This phenomenon – the independence of priming from cellular MHC haplotype – has been called cross-priming [14] and was recently shown to be required if the antigen is not expressed by the professional APC itself [15]. In vivo, cross-priming would be essential for inducing immune responses against non-APCs that have been infected by viruses or other pathogens or have turned into tumor cells. Viral or tumor antigens would then be transferred to APCs, where they are cross-presented to elicit a potent T cell response. A model for the mechanism by which HSP-bound peptides are cross-presented by APCs to prime specific CD8+ T cells is depicted in Figure 7.1 and explained in the following sections. 7.2.3 Heat Shock Proteins Bind Peptides

The fact that several HSPs can act as peptide carriers is not really surprising, in terms of their primary chaperone function: they bind to partially unfolded proteins preventing their aggregation. This is achieved by interaction with hydrophobic stretches, which are normally buried and not exposed on the surface. The HSP70 family members bind with high affinity to small hydrophobic segments in extended conformation. Due to negatively charged surfaces at the ends of the hydrophobic binding tunnel, basic residues flanking a hydrophobic core of 4 to 5 residues are preferred. Since the affinity for the bound peptide segment seems not to be altered by distant parts of the substrate proteins [16], small peptides bind as strongly as pep-

131

132

7 Host-derived Adjuvants

Fig. 7.1 The current model for the physiological role of HSPs in cross-priming. During the courseof, for example, a viral infection, pathogen-derived proteins are produced by the infected host cell. Due to the usual protein turnover, viral peptide fragments are generated by the proteasome and may be presented on MHC class I molecules. HSPs are associated with such peptides in vivo. If the virus causes necrotic death of the infected cells, the HSP–peptide complexes are released and can be taken up by APCs in a receptor-mediated fashion via CD91 and LOX-1. The APC can represent the HSP-ligated viral peptides on its MHC class I molecules, thereby enabling its recognition by naive CD8+ T cells. Moreover, released HSP activates APCs via TLR4 and TLR2, resulting in the up-regulation of costimulatory molecules and in the secretion of various proinflammatory cytokines and chemokines. This second signal enables the priming of the naive CD8+ T cells, triggering their development into effector cytotoxic T cells (CTLs). These cells are now able to kill virus-infected cells without further costimulatory signals (see colour plates page XXXV).

tides, in the context of partially denatured proteins. Substrate binding to HSP70s is regulated by adenosine nucleotides. Binding of ATP to the conserved N-terminal domain of the chaperone induces a conformational change that allows rapid substrate exchange. However, spontaneous hydrolysis of the cofactor to ADP traps the bound substrate, which can then be released only after ADP–ATP exchange [17]. The 90kDa heat shock proteins also possess a nucleotide binding pocket, but its role is less clear. ATP binds with low affinity to Hsp90 and induces the formation of a ‘molecular clamp’ [18]. The function of this conformational transition is still unclear, but

7.2 Heat Shock Proteins in Immunology

ATP binding to Hsp90 is crucial for the function of this chaperone in vivo [19]. The anti-tumor drug geldanamycin binds exclusively to the unusual nucleotide binding pockets of Hsp90 and Gp96 [20]. Several functional studies with nucleotide derivatives have been performed, and an influence of nucleotide binding on oligomerization and substrate affinity was observed for both HSPs [21–23]. Therefore, it was proposed that at least for Gp96, ADP and ATP work as negative regulators of substrate binding [23]. The peptide binding motif of Gp96 is even less well defined than that of Hsp70, but a preference for uncharged residues at positions 2 and 9 of the peptide has been reported [24]. HSPs can be loaded with peptides in vitro [8], but how do they acquire peptides inside the cell? Most peptides inside the cell are generated by the proteasomes. They are produced as intermediates of protein turnover and are further degraded by cytosolic and ER-resident peptidases [25–29]. There are hints that the concentration of free peptide in the cytosol is very low and that their half-life is in the range of seconds [30]. Therefore, only a very small fraction of the generated peptides escape via the TAP transporter into the ER and can be presented on MHC class I molecules. Nevertheless, there are hints that HSPs can associate with peptides in vivo. The cytosolic Hsp70 and Hsc70 are physically linked to the proteasome via BAG-1 and might therefore be able to bind to peptides directly after their generation and before their destruction by peptidases [31]. Similarly, Hsp90 binds directly to the proteasome, thereby inhibiting its proteolytic activity [32, 33]. Gp96 and Grp170 are peptide acceptors in the ER in vivo, although their peptide binding capacities are clearly exceeded by that of protein disulfide isomerase (PDI) [24, 34]. It has been proposed that the peptides that end up in the MHC binding groove never occur as free molecules, but are chaperoned by HSPs from their place of origin to the MHC class I molecule, in the cytosol as well as inside the ER. But so far, little functional evidence supports this intriguing ‘relay line hypothesis’ [35], although the drug deoxyspergualin, which specifically binds to Hsp70 and Hsp90, inhibits the presentation of generated antigenic peptides on MHC class I molecules, for example after virus infection [36]. In the same study, HSP chaperoned peptide elicited a stronger immune response than free peptide when introduced into the cytosol. Because of their broad binding specificity, HSPs are associated with a pool of peptides that represent the protein content of the cell they originate from. This pool also includes several possible MHC ligands. Purification of HSPs from tumor cells or infected cells therefore represents an important alternative for the acquisition of immunogenic material without the need to identify individual antigens. 7.2.4 Receptor-mediated Uptake of HSPs

The simple fact that HSPs bind peptides does not explain the amazing immunogenic potential of HSP–peptide complexes. As little as 9 mg of tumor-derived Gp96 injected subcutaneously into a mouse is sufficient to initiate a protective immune response against a subsequent tumor challenge [9]. Moreover, only a very small portion of the injected HSP carries immunogenic peptides. It was proposed very early that

133

134

7 Host-derived Adjuvants

receptor-mediated uptake of the antigenic material by specialized APCs might contribute to this enormous sensitivity [35]. The first evidence to support this hypothesis was provided by EM binding studies using gold particle-labeled Hsc70 and Gp96 [37]. In this study, specific binding to monocytic and dendritic cell lines and subsequent endocytosis was shown. This observation was confirmed in confocal microscopy studies [38]. Evidence for binding to specific receptors was finally provided by flow cytometry studies, using fluorochrome-labeled Hsc70 [39] or Gp96 [40]. In these reports, saturation and competition by nonlabeled Gp96 was shown, demonstrating the specificity of the HSP–receptor interaction. It was also revealed that only APCs like macrophages, DCs, and B cells, but not T cells, bind Gp96 in a receptormediated fashion. Our current knowledge of HSP receptors is summarized in Table 7.2. CD91, also known as a2-macroglobulin receptor or low-density lipoprotein receptor-related protein, was identified as the first HSP receptor by cross-linking experiments with immobilized Gp96 [41], and it was suggested that CD91 is a common receptor for Gp96, Hsp90, Hsp70, and calreticulin [42]. The classical ligands for CD91 are proteases or proteases complexed by their cognate inhibitors (e. g., a2-macroglobulin) Tab. 7.2 Proposed HSP receptors and their functions. Receptor

Interacting HSPs (ligands)

Expressing cells

CD91

Gp96, Hsp90, Hsp70, calreticulin, (activated a2-macroglobulin)

DCs, macrophages, endocytosis, platelets signaling

CD36

Gp96, (thrombospondin, macrophages, Plasmodium falsiparum, platelets oxidized LDL)

scavenger receptor

unknown

LOX-1

Hsp70, (oxidized LDL)

DCs

scavenger receptor

important for cross-presentation of ligand associated peptides

CD40

mycobacterial Hsp70, (CD40L)

APCs

APC activation CC-chemokine release

TLR4, MD-2, Hsp70, Hsp60, Gp96, CD14 (LPS)

APCs, monocytes, neutrophils, regulatory T cells

cell activation

upregulation of costimulation, cytokine and chemokine secretion, NO synthesis

TLR2

APCs, monocytes, neutrophils

cell activation

upregulation of costimulation, cytokine and chemokine secretion, NO synthesis

Hsp70, Hsp60, Gp96, (lipoproteins, zymosan)

General function

Immunological function important for cross-presentation of ligand associated peptides

7.2 Heat Shock Proteins in Immunology

[43]. These ligands are then endocytosed and degraded, thereby regulating the extracellular proteolytic activity. Interestingly, a2-macroglobulin itself can associate with peptides, and the resulting complexes can prime CD8+ T cell responses in vivo [44]. However, open questions remain regarding the role of CD91 as an HSP receptor, because CD91+ Chinese hamster ovary (CHO) cells do not bind GP96 [45]. Also, scavenger receptors have been proposed to be at least partly responsible for HSP binding to APCs: macrophages from CD36-deficient mice show a 50 % reduced Gp96 binding compared to wild-type cells, and expression of this scavenger receptor in an otherwise nonexpressing cell line conferred on the cells the ability to bind Gp96 [46]. Concerning Hsp70 binding on dendritic cells, the scavenger receptor lectin-like oxidized lipoprotein receptor-1 (LOX-1) (and not CD36) was shown to be the main receptor that mediates cross-presentation of Hsp70-bound peptides [47]. Finally, CD40 has been identified as an HSP receptor, which is expressed on APCs and was originally described as transmitting activating signals from CD4+ T helper cells mediated by CD40 ligand. Direct interaction of mycobacterial and human Hsp70 with CD40 has been demonstrated, and this binding is enhanced in the presence of Hsp70 peptide substrates [48, 49]. However, the interplay of all these receptors and their relevance for the interaction with HSPs still have to be worked out in more detail. On the other hand, it is now well established that the receptor-mediated targeting of chaperone–peptide complexes to APCs is an important feature that strongly enhances their immunogenicity. 7.2.5 Cross-presentation Pathways for HSP–Peptide Complexes

The receptor-mediated uptake of HSP–peptide complexes is a prerequisite for efficient re-presentation of the associated peptide, but it is not the only requirement: antigens presented by MHC class I molecules usually derive from cytosolic proteins [50]. However, the so-called cross-presentation of exogenous antigens on MHC class I molecules has been shown for antigens supplied in several different forms; among these are HSP–peptide complexes [51]. The pathways taken by the chaperone-associated peptides inside the cell are still not fully understood and remain controversial. It is well accepted, however, that receptor-mediated endocytosis of HSPs is crucial for the re-presentation of associated peptides [39;40]. Some reports indicate that uptake via CD91 is required for the re-presentation of HSP-associated peptides [41, 42] and can be inhibited by the CD91 ligand a2-macroglobulin and antibodies against CD91. But CD91-independent re-presentation has also been reported [45]. In these experiments Gp96 did not colocalize with CD91 after endocytosis and re-presentation was not inhibited by excess of a2-macroglobulin. During the next step, endocytosed Gp96, in contrast to HSP taken up by pinocytosis, travels to vesicles enriched in MHC class I and II molecules but does not reach late endosomes [40, 52]. Two distinct pathways for the cross-presentation have been described (Figure 7.2): on the one hand, a cytosolic route depending on proteasomal activity and TAP [53]; on the other hand, an endosomal pathway in which the endocytosed antigen meets MHC molecules in endocytic vesicles. As a variation of the lat-

135

136

7 Host-derived Adjuvants

Fig. 7.2 The two pathways of cross-presentation. Two pathways for the presentation of HSP-ligated peptides inside the APC have been proposed after their receptor-mediated uptake. (A) The endosomal pathway includes the transfer of HSP–peptide complexes into special endosomal compartments, where they colocalize with MHC class I and II. There the peptides are possibly transferred onto recycled empty MHC molecules from the cell surface. (B) The cytosolic pathway requires the transfer of peptide or HSP–peptide complex into the cytosol. This process remains enigmatic. However, once the peptides have reached the cytosol, they are processed via the usual class I presentation pathway. The proteasome is required for peptide trimming, and the TAP transporter shuttles the generated peptides into the ER, where they are presented on MHC class I molecules.

ter pathway, the peptides generated by processing in endocytic vesicles might be ‘regurgitated’ and loaded onto empty MHC molecules at the cell surface [54]. Concerning Gp96–peptide complexes, hints for both pathways have been described. Re-presentation of the peptide from Gp96 complexed with the Kb-restricted CTL epitope SIINFEKL from ovalbumin probably occurs via the endosomal pathway, because it does not require de novo synthesis of MHC class I molecules [52]. The re-presentation of an elongated epitope derived from vesicular stomatitis virus requires proteasomal and TAP function, favoring the cytosolic pathway [42]. For Hsp70, a dependency of the preferred pathway on the nature of the associated peptides has been demonstrated [39]: C-terminally extended epitopes have to take the cytosolic route and require proteasomal processing; N-terminally extended peptides can be trimmed via

7.2 Heat Shock Proteins in Immunology

the endosomal pathway. However, the mechanism of antigen delivery to the cytosol is still enigmatic, and the rules that define whether an antigen is processed via either or both of these routes still have to be determined in more detail. 7.2.6 Danger Signals – The Importance of the Second Signal

The surprising path of HSP-associated peptides into the binding groove of MHC molecules of APCs is not sufficient for the induction of a specific immune response. In 1975 Lafferty and Cunningham performed experiments that suggested the requirement of a second signal for priming of naive T cells [55]. This signal, named ‘costimulation’, is received by T cells from stimulator cells (today known as antigenpresenting cells, APCs). Costimulation was later assigned to molecules on the APC site including CD80, CD86, and CD137, which specifically interact with receptors on the T cell site (e. g., CD28). This interaction leads to interleukin-2 (IL-2) responsiveness and IL-2 expression in T cells and therefore allows their proliferation and maturation in an autocrine and paracrine fashion. The absence of costimulation during TCR engagement leads to tolerance instead of priming. But the expression of costimulatory signals on APCs is activation-dependent, and APC activation is a critical key point in the induction of a specific immune response. In the original self–nonself (SNS) model proposed by Burnet and supported by experiments of Medawar, the induction of an immune response depends only on cells of adaptive immunity (B and T lymphocytes), which are taught the definitions of ‘self ’ early in their development. Janeway refined the SNS model to account for the importance of costimulation and proposed a distinct sense of self–nonself discrimination [56]. He proposed that APCs are poor T cell stimulators (due to lack of costimulation) until they are activated by pathogen-associated molecular patterns (PAMPs) recognized via a few germline-encoded pattern-recognition receptors. According to this, the decision made by APCs is between ‘infectious-nonself ’ and ‘noninfectious-self ’. In 1994, the model was further refined by Matzinger, who introduced the ‘danger model’ (reviewed in [57]): she proposed that the immune system does not care about self and nonself or infectious and harmless, but is activated upon receiving danger signals, either exogenous PAMPs or endogenous substances released from suffering cells, such as those exposed to pathogens, toxins, or mechanical damage. 7.2.7 Heat Shock Proteins as Danger Signals

Bacterial lipopolysaccharide (LPS) was perhaps the first stimulus with proven APCstimulating capacities, but discoveries of many other pathogen-derived substances followed [58]. Moreover, the content of cells undergoing necrosis (but not apoptosis) can activate macrophages and DCs [59]. This is in line with Matzinger’s model, because harmful (necrotic) cell death should lead to the release of danger signals. Surprisingly, the first component of this immunostimulatory cocktail to be identified was a heat shock protein. Chlamydial [60], as well as human Hsp60 [61], was demon-

137

138

7 Host-derived Adjuvants

strated to activate macrophages, vascular endothelium, and smooth muscle cells; and this activation is mediated in a CD14-dependent manner [62] via Toll-like receptor (TLR) 4 in combination with the secreted cofactor MD-2 or via TLR2 [63, 64]. It is unlikely that Hsp60 is involved in cross-presentation, as shown for the HSPs from the HSP90 and HSP70 families, because no peptide-binding capacities have been found so far. HSP90 and HSP70, both have peptide-binding capacities and are able to activate APCs: Gp96 [65, 66], Hsp90 [65], and Hsp70 [67] activate dendritic cells, and their signal is mediated via TLR4/MD-2 and TLR2 [68, 69]. Interestingly, Hsp60 and Gp96 have to be endocytosed for transduction of activating signals, possibly because they meet the TLRs in endocytic vesicles [64, 69]. The maturation signals provided by HSPs are mediated inside the cell via the usual downstream TLR signaling pathways [70]: the adaptor protein myeloid differentiation factor 88 (MyD88) links the activated receptor to the serine kinase IL-1 receptor-associated protein kinase (IRAK), which is subsequently phosphorylated. Phosphorylated IRAK dissociates from the receptor complex and associates with TNF receptor-activated factor 6 (TRAF6). Via further unknown mechanisms, this leads to activation of the transcription factors c-Jun N-terminal kinase (Jnk), p38 mitogen-activated protein kinase (MAPK), and NF-kB. Finally, stimulation of APCs with HSPs leads to secretion of proinflammatory cytokines, such as TNF- a and IL-6, which strongly promote TH1 responses, to the production of the inflammatory mediator nitric oxide by macrophages [63, 71], and to up-regulation of costimulatory molecules that are required for priming naive T cells. Therefore, these antigen-independent immunostimulatory capacities accomplish the function of HSPs as cross-priming carrier perfectly, making them a powerful tool for the induction of specific immune responses. The activating stimuli provided by HSPs are still controversial. It is a major concern that these observations might be due to minor endotoxin contaminations in the protein preparations. Two groups report that recombinant human Hsp70 with very low endotoxin content showed no APC-activating capacities [72, 73]. In one report, human Gp96 failed to induce activation of human monocytes and DCs under serum-free conditions [74]. But there is growing evidence that, for Gp96 at least, the protein itself is responsible for APC maturation. First, Gp96-induced, but not endotoxin-induced, DC maturation is heat-sensitive and polymyxin-insensitive (Braedel et al., unpublished observations). Second, cells transfected with membrane-bound Gp96 [75] (and Hilf et al., unpublished observations) and cells that secrete Gp96 [76] activate APCs in the absence of bacterial contamintions. Third, the threshold for DC activation is independent of the observed endotoxin content of the protein preparations and reaches saturation at about 50 mg mL –1 Gp96 (Hilf et al., unpublished observations). Interestingly, this amount equals the concentration that favors complete dimerization of the cytosolic equivalent Hsp90 [77]. Therefore, the activating capacities of Gp96 might depend on the protein dimer. Of course, the fact that endotoxins and HSPs use the same receptors to mediate their maturation signal tempts speculation about endotoxin contaminations, and it is still possible that Gp96 potentiates the effect of very low LPS concentrations by binding and delivering it via receptormediated uptake to cells. But on the other hand, several different exogenous PAMPs from very different pathogens have been shown to bind to, for example TLR2. There-

7.2 Heat Shock Proteins in Immunology

fore, and in line with Matzinger's danger hypothesis [57], it is not surprising that several and – for HSPs – also endogenous danger signals bind to a single TLR. The message given by LPS and released HSPs is the same: something is wrong, and adaptive and innate immunity have to be alert. The APC activation mediated by HSPs might even be sufficient to lead to the expansion of T cells of a certain specificity in the absence of antigenic peptide [78]. Recently, a publication from Nicchitta’s laboratory attributed the protective immunity conferred by Gp96 mainly to the general immunostimulatory features of the HSP [76]. In these experiments, immunization with transfected cells that secrete soluble Gp96 induced some tumor protection (slower tumor growth) irrespective of the cell type chosen as source of the protein. Moreover, Gp96 retarded tumor growth even in the absence of its C-terminal domain, which possesses a peptide binding site [79]. These results obviously contradict the early observations of Srivastava and of others that tumor protection is restricted to the tumor the Gp96 had been purified from. However, with the tumor system chosen by Nicchitta and coworkers, no specific immune response could be induced, even with tumor lysate – the tumor line was simply not immunogenic. In the experiments published by Srivastava, the tumor lysate did induce tumor protection and the success of Gp96 vaccination was limited to the tumor from which the protein was purified [80]. But even in this work a slight tumor-independent retardation of tumor growth was observed, which is likely to be mediated by the general immunostimulatory capacities of Gp96. Therefore, it is reasonable to ascribe the immunogenicity of HSPs to both their cross-presentation function, serving specifically the adaptive immune system, and their APC activating capacities, which generally support immune responses. 7.2.8 Heat Shock Proteins as Endogenous Adjuvants

It is a matter of speculation whether the in vivo concentrations of Gp96 and other endogenous heat shock proteins after necrotic cell death are high enough to elicit APC activation. However, measurable concentrations of Gp96 have been detected in the supernatant of cells infected with a lytic virus [81] and in the wound fluid of patients with severe tissue damage (S. Herter, unpublished observations). Gp96 is the most abundant protein in the ER. Release of the ER contents after necrosis might therefore lead to a very high local concentration of this HSP. Moreover, the intradermal injection of as little as 1 mg of Gp96 led to massive infiltration of CD11c+ DCs into the draining lymph nodes from the point of injection. These DCs were of the mature phenotype and were highly efficient in stimulating T cells [82]. Taking into account that all endogenous danger signals released after necrotic cell death may act synergistically it is very likely that sufficient concentrations for APC activation can occur in vivo. If cell death leads to the release of danger signals at APC-activating concentrations, this signal has to be controlled in situations in which sustained inflammation and potential autoimmune responses have to be prevented, such as in wound healing or systemic shock after release of inflammatory substances in the blood. The ef-

139

140

7 Host-derived Adjuvants

fects of Gp96 in the blood might be neutralized by excessive amounts of the CD91 ligand, a2 macroglobulin [41], and by the huge number of platelets that have been shown to bind this HSP [83]. The control of Gp96 action by platelets might be even more effective in the prevention of chronic inflammation after injury. In this scenario, activated platelets express 10-fold higher amounts of Gp96 receptors and are able to interfere with Gp96-induced DC activation. But APCs and platelets are not the only bone-marrow-derived HSP-targeted cells. Recently, it was shown that granulocytes and monocytes express Gp96 receptors [84]. In particular, neutrophils comprise the major fraction of blood leukocytes and are an important part of the innate immune response. The binding of Gp96 to these cell types triggers IL-8 release and enhances phagocytic activity of neutrophils. Interestingly, the cross-priming induced by Gp96–peptide complexes requires a positive feedback loop between NK cells and DCs to allow expansion of specific CD8+ T cells, which also requires perforin and IFN- g [85]. Although the mechanism of this interaction is not clear, these data demonstrate that HSP-induced immunity results from a complex interplay of several components of the immune system. The direction in which an immune response is guided by an adjuvant is another important point that has to be considered. For HSPs, this question has not yet been definitely answered. It is reported that Gp96 expressed on the surface of LPS-activated B cells functions as a TH2-promoting molecule [86]. In contrast to this, recent data from our laboratory indicate that Gp96-activated DCs, in contrast to LPS-activated DCs, favor the expansion of antigen-specific CD8+ T cells over CD4+ T cell expansion in vivo and in vitro [87]. 7.2.9 Clinical Use of Heat Shock Proteins

The combined properties of HSPs to prime specific immune responses by the transfer of antigenic peptides with concurrent activation of innate immune cells is the rationale behind utilization of HSPs in clinical settings. These approaches include the induction of therapeutic immune responses by vaccination in patients with malignant and also infectious diseases. HSP-based immunization therapy using a personalized tumor vaccine is currently under clinical evaluation. This vaccine is produced from individual tumor tissue and is called heat shock protein peptide complex 96 (HSPPC-96; Oncophage). HSPPC96 consists of purified Gp96 from patient cancer tissue complexed with peptides specific for a patient's tumor and has been tested in several clinical trials, including on patients with melanoma, colorectal cancer, gastric cancer, kidney cancer, and several other cancers. The clinical results of using HSPPC-96 in various cancer patients so far demonstrate that this kind of treatment is well tolerated and can induce favorable immune responses against tumor or virus [88]. On the other hand, the results also show that HSP-based vaccination might not be effective in all patients, but only in a subpopulation. Several studies, including a phase III trial with HSPPC-96, are still under way, but at this point no research group has reported of any severe adverse events,

7.3 Cytokines as Adjuvants

again indicating the feasibility and safety of this approach. Further studies are needed to determine the efficacy of such treatments and to define patient populations who will benefit most from HSP-based vaccination treatment. Over all, these studies are encouraging and indicate that it is possible as well as feasible to improve an antigen-specific immune response by using adjuvants that mediate distinct signals to innate immune cells, for example, via TLRs. In particular, HSPs enhance and influence the immune response in several ways that are more than a simple, unspecific immunostimulatory function.

7.3 Cytokines as Adjuvants

The HSPs discussed so far as endogenous adjuvants are unique in that these proteins can deliver antigens to antigen-presenting cells and concurrently provide the inflammatory signals needed in addition to mount an adaptive immune response. As already mentioned, these inflammatory signals include the up-regulation of costimulatory molecules, as well as the release of proinflammatory cytokines by local cells, for example, resident DCs. Therefore, another way to induce specific immune responses by vaccination is to provide the antigen and add proinflammatory substances, to mimic or induce an inflammatory environment and recruit immune cells to present the respective antigen. A variety of such inflammatory mediators of endogenous origin are known, available as recombinant proteins, and used as adjuvants in vaccination protocols. Several reports have shown that subcutaneous or intradermal administration of granulocyte macrophage colony-stimulating factor (GM-CSF) together with an antigen is able to induce CTL responses in cancer patients [89–91]. Also IL-1a and IL-1b or fragments of IL-1b have proven efficacy, for example, in mucosal immunizations [92, 93]. Further studies have evaluated the adjuvant application of T cell-stimulating cytokines such as IL-2 or IL-12 for cancer immunotherapy. IL-2 has already demonstrated beneficial effects as single agent without additional antigen administration against renal cancer and other tumor entities [94]. Although studies using IL-12 as a single agent were disappointing, since it lacked efficacy in the course of repeated administration at the maximal tolerated dosages [95], IL-12 at low doses, as well as IL-2, have demonstrated powerful properties as adjuvants in both animal models and humans [96, 97]. Although tremendous efforts have been put into research on utilizing cytokines as adjuvants, and the basic proof-of-concept has been made, it is still unclear what cytokines will give the best results in vaccination [96]. More recent studies suggest that the maximum dose may not be the one that will give the best response [98]. In addition, evidence is accumulating that a combination of cytokines might be more effective than a single cytokine. For example, GM-CSF in combination with IL-12 or CD40L is synergistic in CTL induction [99, 100]. Also, the triple combination of GMCSF, IL-12, and TNF-a was most effective in some mouse models [101].

141

142

7 Host-derived Adjuvants

7.4 Concluding Remarks

Recent discoveries clearly underline the importance of the influence of the innate immune system on the development of adaptive immune responses. Cytokines produced and surface molecules expressed during the activation of innate immune cells determine whether a TH1- or TH2-biased immune response is initiated. Learning more about this interaction will allow us to modulate immune responses in vaccination protocols. HSPs might be of special interest in this regard, since they have the unique feature of combining antigenicity and adjuvanticity, which determine immunogenicity, within the same molecule. Their use in clinical trials will determine if these features can be exploited in a therapeutic setting.

References 1 Glenny, A.T., Pope, C.G., Waddington, H., and Wallace,V., J Path Bact 1926, 29, 38–45. 2 Freund, J., Casals, J., and Hosmer, E.P., Proc Soc Exp Biol Med 1937, 37, 509–513. 3 Lindquist, S., Annu Rev Biochem 1986, 55, 1151–1191. 4 Bukau, B., Deuerling, E., Pfund, C., and Craig, E.A., Cell 2000, 101, 119– 122. 5 Srivastava, P., Annu Rev Immunol 2002, 20, 395–425. 6 Tamura,Y., Peng, P., Liu, K., Daou, M., and Srivastava, P.K., Science 1997, 278, 117–120. 7 Udono, H. and Srivastava, P.K., J Exp Med 1993, 178, 1391–1396. 8 Blachere, N.E., Li, Z., Chandawarkar, R.Y., Suto, R., Jaikaria, N.S., Basu, S., Udono, H., and Srivastava, P.K., J Exp Med 1997, 186, 1315–1322. 9 Udono, H. and Srivastava, P.K., J Immunol 1994, 152, 5398–5403. 10 Basu, S. and Srivastava, P.K., J Exp Med 1999, 189, 797–802. 11 Nair, S., Wearsch, P.A., Mitchell, D.A., Wassenberg, J.J., Gilboa, E., and Nicchitta, C.V., J Immunol 1999, 162, 6426–6432. 12 Wang, X.Y., Kazim, L., Repasky, E.A., and Subjeck, J.R., J Immunol 2001, 166, 490–497. 13 Arnold, D., Faath, S., Rammensee, H.,

14 15 16

17

18

19

20

21

22 23

and Schild, H., J Exp Med 1995, 182, 885–889. Bevan, M.J., J Immunol 1976, 117, 2233–2238. Sigal, L.J., Crotty, S., Andino, R., and Rock, K.L., Nature 1999, 398, 77–80. Zhu, X., Zhao, X., Burkholder,W.F., Gragerov, A., Ogata, C.M., Gottesman, M.E., and Hendrickson,W.A., Science 1996, 272, 1606–1614. Pierpaoli, E.V., Sandmeier, E., Baici, A., Schonfeld, H.J., Gisler, S., and Christen, P., J Mol Biol 1997, 269, 757–768. Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J.E., Roe, S.M., Piper, P.W., and Pearl, L.H., EMBO J 2000, 19, 4383–4392. Obermann, W.M., Sondermann, H., Russo, A.A., Pavletich, N.P., and Hartl, F.U., J Cell Biol 1998, 143, 901– 910. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., and Pavletich, N.P., Cell 1997, 89, 239– 250. Chadli, A., Ladjimi, M.M., Baulieu, E.E., and Catelli, M.G., J Biol Chem 1999, 274, 4133–4139. Rosser, M.F. and Nicchitta, C.V., J Biol Chem 2000, 275, 22798–22805. Wassenberg, J.J., Reed, R.C., and Nicchitta, C.V., J Biol Chem 2000, 275, 22806–22814.

References 24 Spee, P. and Neefjes, J., Eur J Immunol 1997, 27, 2441–2449. 25 Saric, T., Chang, S.C., Hattori, A., York, I.A., Markant, S., Rock, K.L., Tsujimoto, M., and Goldberg, A.L., Nat Immunol 2002, 3, 1169–1176. 26 Serwold, T., Gonzalez, F., Kim, J., Jacob, R., and Shastri, N., Nature 2002, 419, 480–483. 27 Stoltze, L., Schirle, M., Schwarz, G., Schroter, C., Thompson, M.W., Hersh, L.B., Kalbacher, H., Stevanovic, S., Rammensee, H.G., and Schild, H., Nat Immunol 2000, 1, 413–418. 28 Stoltze, L., Nussbaum, A.K., Sijts, A., Emmerich, N.P., Kloetzel, P.M., and Schild, H., Immunol Today 2000, 21, 317–319. 29 Seifert, U., Maranon, C., Shmueli, A., Desoutter, J.F.,Wesoloski, L., Janek, K., Henklein, P., Diescher, S., Andrieu, M., de la, S.H., Weinschenk, T., Schild, H., Laderach, D., Galy, A., Haas, G., Kloetzel, P.M., Reiss,Y., and Hosmalin, A., Nat Immunol 2003, 4, 375–379. 30 Reits, E., Griekspoor, A., Neijssen, J., Groothuis, T., Jalink, K., van Veelen, P., Janssen, H., Calafat, J., Drijfhout, J.W., and Neefjes, J., Immunity 2003, 18, 97–108. 31 Luders, J., Demand, J., and Hohfeld, J., J Biol Chem 2000, 275, 4613–4617. 32 Wagner, B.J. and Margolis, J.W., Arch Biochem Biophys 1995, 323, 455–462. 33 Tsubuki, S., Saito,Y., and Kawashima, S., FEBS Lett 1994, 344, 229–233. 34 Spee, P., Subjeck, J., and Neefjes, J., Biochemistry 1999, 38, 10559–10566. 35 Srivastava, P.K., Udono, H., Blachere, N.E., and Li, Z., Immunogenetics 1994, 39, 93–98. 36 Binder, R.J., Blachere, N.E., and Srivastava, P.K., J Biol Chem 2001, 276, 17163–17171. 37 Arnold-Schild, D., Hanau, D., Spehner, D., Schmid, C., Rammensee, H.G., de la Salle, H., and Schild, H., J Immunol 1999, 162, 3757–3760. 38 Wassenberg, J.J., Dezfulian, C., and Nicchitta, C.V., J Cell Sci 1999, 112(13), 2167–2175. 39 Castellino, F., Boucher, P.E., Eichelberg, K., Mayhew, M., Rothman, J.E.,

40

41

42

43 44

45

46

47

48

49

50

51 52

53 54

Houghton, A.N., and Germain, R.N., J Exp Med 2000, 191, 1957–1964. Singh-Jasuja, H., Toes, R.E., Spee, P., Munz, C., Hilf, N., Schoenberger, S.P., Ricciardi-Castagnoli, P., Neefjes, J., Rammensee, H.G., Arnold-Schild, D., and Schild, H., J Exp Med 2000, 191, 1965–1974. Binder, R.J., Han, D.K., and Srivastava, P.K., Nat Immunol 2000, 1, 151– 155. Basu, S., Binder, R.J., Ramalingam, T., and Srivastava, P.K., Immunity 2001, 14, 303–313. Herz, J. and Strickland, D.K., J Clin Invest 2001, 108, 779–784. Binder, R.J., Karimeddini, D., and Srivastava, P.K., J Immunol 2001, 166, 4968–4972. Berwin, B., Hart, J.P., Pizzo, S.V., and Nicchitta, C.V., J Immunol 2002, 168, 4282–4286. Panjwani, N., Popova, L., Febbraio, M., and Srivastava, P.K., Cell Stress Chaperones 2000, 5, 391. Delneste,Y., Magistrelli, G., Gauchat, J., Haeuw, J., Aubry, J., Nakamura, K., Kawakami-Honda, N., Goetsch, L., Sawamura, T., Bonnefoy, J., and Jeannin, P., Immunity 2002, 17, 353–362. Wang,Y., Kelly, C.G., Karttunen, J.T., Whittall, T., Lehner, P.J., Duncan, L., MacAry, P.,Younson, J.S., Singh, M., Oehlmann,W., Cheng, G., Bergmeier, L., and Lehner, T., Immunity 2001, 15, 971–983. Becker, T., Hartl, F.U., and Wieland, F., J Cell Biol 2002, 158, 1277– 1285. Morrison, L.A., Lukacher, A.E., Braciale,V.L., Fan, D.P., and Braciale, T.J., J Exp Med 1986, 163, 903–921. Heath, W.R. and Carbone, F.R., Annu Rev Immunol 2001, 19, 47–64. Berwin, B., Rosser, M.F., Brinker, K.G., and Nicchitta, C.V., Traffic 2002, 3, 358–366. Kovacsovics-Bankowski, M. and Rock, K.L., Science 1995, 267, 243–246. Pfeifer, J.D.,Wick, M.J., Roberts, R.L., Findlay, K., Normark, S.J., and Harding, C.V., Nature 1993, 361, 359– 362.

143

144

7 Host-derived Adjuvants 55 Lafferty, K.J. and Cunningham, A.J., Aust J Exp Biol Med Sci 1975, 53, 27–42. 56 Janeway, C.A., Jr., Cold Spring Harb Symp Quant Biol 1989, 54 Pt 1, 1–13. 57 Matzinger, P., Science 2002, 296, 301– 305. 58 Janeway, C.A., Jr. and Medzhitov, R., Annu Rev Immunol 2002, 20, 197–216. 59 Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N., J Exp Med 2000, 191, 423–434. 60 Peetermans, W.E., Raats, C.J., van Furth, R., and Langermans, J.A., Infect Immun 1995, 63, 3454–3458. 61 Kol, A., Bourcier, T., Lichtman, A.H., and Libby, P., J Clin Invest 1999, 103, 571–577. 62 Kol, A., Lichtman, A.H., Finberg, R.W., Libby, P., and Kurt-Jones, E.A., J Immunol 2000, 164, 13–17. 63 Ohashi, K., Burkart,V., Flohe, S., and Kolb, H., J Immunol 2000, 164, 558–561. 64 Vabulas, R.M., Ahmad-Nejad, P., Da Costa, C., Miethke, T., Kirschning, C.J., Hacker, H., and Wagner, H., J Biol Chem 2001, 276, 31332–31339. 65 Basu, S., Binder, R.J., Suto, R., Anderson, K.M., and Srivastava, P.K., Int Immunol 2000, 12, 1539–1546. 66 Singh-Jasuja, H., Scherer, H.U., Hilf, N., Arnold-Schild, D., Rammensee, H.G., Toes, R.E., and Schild, H., Eur J Immunol 2000, 30, 2211–2215. 67 Asea, A., Kraeft, S.K., Kurt-Jones, E.A., Stevenson, M.A., Chen, L.B., Finberg, R.W., Koo, G.C., and Calderwood, S.K., Nat Med 2000, 6, 435–442. 68 Asea, A., Rehli, M., Kabingu, E., Boch, J.A., Bare, O., Auron, P.E., Stevenson, M.A., and Calderwood, S.K., J Biol Chem 2002, 277, 15028–15034. 69 Vabulas, R.M., Braedel, S., Hilf, N., Singh-Jasuja, H., Herter, S., AhmadNejad, P., Kirschning, C.J., Da Costa, C., Rammensee, H.G.,Wagner, H., and Schild, H., J Biol Chem 2002, 277, 20847–20853. 70 Akira, S., Takeda, K., and Kaisho, T., Nat Immunol 2001, 2, 675–680. 71 Panjwani, N.N., Popova, L., and Srivastava, P.K., J Immunol 2002, 168, 2997–3003.

72 Gao, B. and Tsan, M.F., J Biol Chem 2003, 278, 174–179. 73 Bausinger, H., Lipsker, D., Ziylan, U., Manie, S., Briand, J.P., Cazenave, J.P., Muller, S., Haeuw, J.F., Ravanat, C., de la, S.H., and Hanau, D., Eur J Immunol 2002, 32, 3708–3713. 74 Bethke, K., Staib, F., Distler, M., Schmitt, U., Jonuleit, H., Enk, A.H., Galle, P.R., and Heike, M., J Immunol 2002, 169, 6141–6148. 75 Zheng, H., Dai, J., Stoilova, D., and Li, Z., J Immunol 2001, 167, 6731–6735. 76 Baker-LePain, J.C., Sarzotti, M., Fields, T.A., Li, C.Y., and Nicchitta, C.V., J Exp Med 2002, 196, 1447–1459. 77 Richter, K., Muschler, P., Hainzl, O., and Buchner, J., J Biol Chem 2001, 276, 33689–33696. 78 Breloer, M., Fleischer, B., and von Bonin, A., J Immunol 1999, 162, 3141– 3147. 79 Linderoth, N.A., Popowicz, A., and Sastry, S., J Biol Chem 2000, 275, 5472– 5477. 80 Srivastava, P.K., Menoret, A., Basu, S., Binder, R.J., and McQuade, K.L., Immunity 1998, 8, 657–665. 81 Berwin, B., Reed, R.C., and Nicchitta, C.V., J Biol Chem 2001, 276, 21083–21088. 82 Binder, R.J., Anderson, K.M., Basu, S., and Srivastava, P.K., J Immunol 2000, 165, 6029–6035. 83 Hilf, N., Singh-Jasuja, H., Schwarzmaier, P., Gouttefangeas, C., Rammensee, H.G., and Schild, H., Blood 2002, 99, 3676–3682. 84 Radsak, M.P., Hilf, N., SinghJasuja, H., Braedel, S., Brossart, P., Rammensee, H.G., and Schild, H., Blood 2003, 101, 2810–2815. 85 Strbo, N., Oizumi, S., Sotosek-Tokmadzic,V., and Podack, E.R., Immunity 2003, 18, 381–390. 86 Banerjee, P.P.,Vinay, D.S., Mathew, A., Raje, M., Parekh,V., Prasad, D.V., Kumar, A., Mitra, D., and Mishra, G.C., J Immunol 2002, 169, 3507–3518. 87 Haager, S., Singh-Jasuja, H., Hofmann, M., Braedel, S.,Wiemann, K., Rammensee, H.G., Steinle, A., and Schild, H. (unpublished data). 88 Belli, F., Testori, A., Rivoltini, L.,

References

89

90

91

92

Maio, M., Andreola, G., Sertoli, M.R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni, G., Lombardo, C., Arienti, F., Marchiano, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J.J., Srivastava, P., and Parmiani, G., J Clin Oncol 2002, 20, 4169–4180. Jager, E., Hohn, H., Necker, A., Forster, R., Karbach, J., Freitag, K., Neukirch, C., Castelli, C., Salter, R.D., Knuth, A., and Maeurer, M.J., Int J Cancer 2002, 98, 376–388. Hunger, R.E., Brand, C.U., Streit, M., Eriksen, J.A., Gjertsen, M.K., Saeterdal, I., Braathen, L.R., and Gaudernack, G., Exp Dermatol 2001, 10, 161–167. Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L., and Kwak, L.W., Nat Med 1999, 5, 1171–1177. Staats, H.F. and Ennis, F.A., Jr., J Immunol 1999, 162, 6141–6147.

93 Boraschi, D. and Tagliabue, A., Methods 1999, 19, 108–113. 94 Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory,Y.L., Skibber, J.M., Shiloni, E., and Vetto, J.T., N Engl J Med 1985, 313, 1485–1492. 95 Rodolfo, M. and Colombo, M.P., Methods 1999, 19, 114–120. 96 Rosenberg, S.A., Nature 2001, 411, 380–384. 97 Egilmez, N.K., Jong,Y.S., Sabel, M.S., Jacob, J.S., Mathiowitz, E., and Bankert, R.B., Cancer Res 2000, 60, 3832– 3837. 98 Portielje, J.E., Gratama, J.W., van Ojik, H.H., Stoter, G., and Kruit, W.H., Cancer Immunol Immunother 2003, 52, 133–144. 99 Hill, H.C., Conway, T.F., Jr., Sabel, M.S., Jong,Y.S., Mathiowitz, E., Bankert, R.B., and Egilmez, N.K., Cancer Res 2002, 62, 7254–7263. 100 Operschall, E., Schuh, T., Heinzerling, L., Pavlovic, J., and Moelling, K., J Clin Virol 1999, 13, 17–27. 101 Ahlers, J.D., Belyakov, I.M., and Berzofsky, J.A., Curr Mol Med 2003, 3, 285–301.

145

147

8 Microparticles as vaccine adjuvants and delivery systems Derek T. O’Hagan and Manmohan Singh

8.1 Introduction

Traditional vaccines have mainly consisted of live attenuated pathogens, whole inactivated organisms, or inactivated bacterial toxins. These approaches have mainly been successful due to the induction of antibody responses, which neutralize viruses or toxins, inhibit the binding of microorganisms to cells, or promote their uptake by phagocytes. However, to develop vaccines against more ‘difficult’ pathogens, which often establish chronic infections, for example HIV, HCV, TB, and malaria, the induction of more potent cellular immune responses may be required, including the induction of Th1 cytokines and cytotoxic T lymphocyte (CTL) responses. Unfortunately, nonliving vaccines have generally proven ineffective at inducing potent Th1 responses or CTL. Although live vaccines can induce CTL, live attenuated vaccines may cause disease in immunosuppressed individuals, and some pathogens are difficult or impossible to grow in culture (e. g., HCV) or present significant safety concerns (e. g., HIV). As a result of the limitations of traditional approaches, several new approaches to vaccine development have emerged in recent decades, including (1) recombinant protein subunits, (2) synthetic peptides, (3) protein–polysaccharide conjugates, and (4) plasmid DNA. Although these new approaches offer advantages, a general problem is that they are often poorly immunogenic. Traditional vaccines often contained contaminating components that can elicit additional T cell help or function as adjuvants, for example, bacterial cell components, including LPS. However, these components have been largely eliminated from new-generation vaccines, to make them safer and less reactogenic. Therefore, they are likely to need more potent adjuvants to allow them to be effective vaccines. A notable exception is protein– polysaccharide conjugate vaccines, which contain the same bacterial toxoids that were included in traditional vaccines. The toxoids function by providing T cell help for antibody induction against the conjugated polysaccharides. Therefore, conjugate vaccines have so far proven effective with only ‘traditional’ adjuvants, based on insoluble aluminum salts. Immunological adjuvants were originally described by Ramon [1] as ‘substances used in combination with a specific antigen that produced a more robust immune

148

8 Microparticles as vaccine adjuvants and delivery systems

response than the antigen alone’. This broad definition encompasses a very wide range of materials [2]. However, despite extensive evaluation of a large number of candidates over many years, the only adjuvants included in products approved by the US Food and Drug Administration are aluminum-based mineral salts, which are generically called alum. Although alum has an excellent safety record, comparative studies show that it is a weak adjuvant for antibody induction to recombinant protein vaccines and induces Th2, rather than Th1 cellular response [3]. In addition, alum is not effective for the induction of mucosal immunity and can induce IgE antibody responses, which have been associated with allergic reactions in some people [3, 4]. Although alum has been used as an adjuvant for many years, its mechanism of action remains poorly defined. It was originally thought to provide a ‘depot’ effect, resulting in persistence of antigen at the injection site. However, more recent studies suggest that alum does not establish a depot [5], but appears to up-regulate costimulatory signals on human monocytes and promotes the release of IL-4 [6], a Th2 cytokine. Importantly, alum may contribute to a reduction in toxicity for some vaccines, due to the adsorption of contaminating LPS [7]. A key issue in adjuvant development is toxicity, since safety concerns have restricted the development of adjuvants since alum was first introduced more than 70 years ago [8]. Many experimental adjuvants have advanced to clinical trials and some have demonstrated high potency, but most have proven too toxic for routine clinical use. For standard prophylactic immunization of healthy individuals, only adjuvants that induce minimal adverse effects will prove acceptable. Additional practical issues that are important for adjuvant development include biodegradability, stability, ease of manufacture, cost, and applicability to a wide range of vaccines.

8.2 The Role of Adjuvants in Vaccine Development

Adjuvants can be used to improve the immune response to vaccine antigens in several different ways, including (1) increasing the immunogenicity of weak antigens, (2) enhancing the speed and duration of the immune response, (3) modulating antibody avidity, specificity, isotype, or subclass distribution, (4) stimulating CTL, (5) promoting the induction of mucosal immunity, (6) enhancing immune responses in immunologically immature or senescent individuals, (7) decreasing the dose of antigen in the vaccine to reduce costs, and (8) helping to overcome antigen competition in combination vaccines. Unfortunately, the mechanisms of action of most adjuvants are complex and often remain poorly understood. Nevertheless, significant advances have been made in this area recently, following the identification of key receptors on cells of innate immunity which are activated by a variety of known adjuvants. However, if one accepts the geographical concept of immune reactivity, in which antigens that do not reach the local lymph nodes do not induce responses [9], it becomes easier to propose mechanistic interpretations for adjuvants which work predominantly through a ‘delivery’ mechanism, including microparticles. If antigens that do not reach lymph nodes

8.2 The Role of Adjuvants in Vaccine Development

do not induce responses, then any adjuvant or delivery system that enhances delivery of antigen into the cells that traffic to the lymph node may enhance the response. A subset of dendritic cells (DC) are thought to be the key cells for antigen presentation; these cells circulate in peripheral tissues and act as ‘sentinels’, being responsible for the uptake of antigens and their transfer to lymph nodes. Circulating immature DCs are efficient for antigen uptake, which then mature and present antigen to T cells in lymph nodes. Hence, antigen uptake into DC, the trafficking of DC to lymph nodes, and the triggering of DC maturation are thought to be key components in the generation of potent immune responses. Although DC are thought to be the most effective antigen-presenting cells (APC), macrophages are also effective APC. Although adjuvants are notoriously difficult to classify, and many examples resist easy definitions, they can be divided into two broad groups based on their principal modes of action, according to whether or not they have direct immunostimulatory effects on APC or function as ‘delivery systems’ to promote antigen uptake into APC. Adjuvants that have direct effects on APC are often derived from pathogens and are referred to as displaying pathogen-associated molecular patterns (PAMP) [10, 11]. PAMP adjuvants are perceived as ‘danger signals’ and induce the release of proinflammatory cytokines from innate immune cells, which triggers and controls the adaptive immune response [12, 13]. Traditional vaccines, including bacterial toxoids and inactivated viruses, often contain most of the components of pathogens and induce potent immune responses. In contrast, new-generation vaccines, including recombinant proteins, are highly purified, lack many of the features of the original pathogen, and do not evoke strong responses. Therefore, the role of adjuvants in recombinant vaccines is to ensure that the vaccine sufficiently resembles an infection to initiate a potent immune response [10, 12]. In addition, adjuvants can control the type of acquired immune response induced [14]. Although this chapter focuses primarily on microparticles as vaccine-delivery systems, microparticles have also been used as delivery systems for adjuvants. Therefore, we also briefly introduce some of the immunostimulatory adjuvants that have been used in conjunction with microparticles. In addition, we briefly discuss alternative particulate-delivery systems, including emulsions, liposomes, and ISCOMs, which have also been used as delivery systems for antigens and adjuvants. Formulating adjuvants into delivery systems, including microparticles, serves two principal purposes – the adjuvants can be targeted to APC to enhance their effects, and their potential for toxicity can be minimized by limiting their systemic distribution. In relation to the minimization of toxicity, controlled release of adjuvants has significant potential, since the peak concentration of adjuvant can be dramatically reduced.

149

150

8 Microparticles as vaccine adjuvants and delivery systems

8.3 Immunostimulatory Adjuvants 8.3.1 MPL

MPL (monophosphoryl lipid A) is derived from the LPS of the gram-negative bacteria Salmonella minnesota and therefore represents an archetypal PAMP. Like LPS, MPL is thought to interact with Toll-like receptor 4 (TLR4) on APC, resulting in the release of proinflammatory cytokines. In several preclinical studies, MPL was shown to induce the synthesis and release of IL-2 and IFN-g, which promote the generation of Th1 responses [15, 16]. Clinically, MPL has often been used as a component of complex formulations, including liposomes and emulsions, and has also been used in combination with alum and QS21 [17]. Overall, MPL has been extensively evaluated in the clinic (>12,000 subjects immunized) for cancer (melanoma and breast) and infectious disease vaccines (genital herpes, HBV, malaria and HPV), and for allergies, with an acceptable profile of adverse effects. MPL is marketed in Europe for use in combination with allergy vaccines [18]. 8.3.2 CpG

In the past few years, a whole new class of adjuvants have been identified, following the demonstration that bacterial DNA, but not vertebrate DNA, had direct immunostimulatory effects on immune cells in vitro, inducing B cells to proliferate and produce immunoglobulins [19, 20]. The immunostimulatory effect is due to the presence of unmethylated cytosines in the CpG [21], which are under-represented and methylated cytosines in vertebrate DNA. Unmethylated CpG, in conjunction with selective flanking sequences, is believed to be recognized by the innate immune system to allow discrimination of pathogen-derived DNA from self DNA [22]. Active CpG exert their effects on many cell types, including a subset of DC, called plasmacytoid DC, which mature and secrete cytokines in response to CpG activation. Cellular responses to CpG DNA depend on the presence of TLR9 [23]. In addition, CpG are taken up by nonspecific endocytosis, and endosomal maturation is necessary for cell activation and the release of proinflammatory cytokines [24]. The potent Th1 adjuvant effect of CpG appears to be maximized by their conjugation to protein antigens [25]. CpG appears to have potential for the modulation of preexisting immune responses, which may be useful in various clinical settings, including treatment of allergies [26]. 8.3.3 QS21

A third group of immunostimulatory adjuvants is the triterpenoid glycosides, or saponins, derived from Quil, which is extracted from the bark of a Chilean tree,

8.4 Particulate Vaccine Delivery Systems

Quillaja saponaria. Saponins have been widely used as adjuvants for many years and have been included in several veterinary vaccines. QS21, which is a highly purified fraction from Quil A, is a potent adjuvant for Th1 cytokines (IFN-g) and antibodies of the IgG2 a isotype, which indicates a Th1 response in mice [27]. Saponins intercalate into cell membranes, through interaction with structurally similar cholesterol, forming holes or pores [28]. However, it is currently unknown if the adjuvant effect of saponins is related to pore formation in cells. Several clinical trials have been performed, using QS21 as an adjuvant, initially in cancer vaccines (melanoma, breast and prostate), and subsequently in vaccines for infectious diseases, including HIV-1, influenza, herpes simplex, malaria, and hepatitis B [29]. More than 3500 people have been immunized with QS21. Doses of 200 mg or higher of QS21 have been associated with significant local reactions [29], but lower doses appear to be better tolerated. 8.3.4 Cytokines

Most cytokines have the ability to modify and redirect the immune response. The cytokines that have been evaluated most extensively as adjuvants include IL-1, IL-2, IFN-g, IL-12, and GM-CSF [30]. However, all of these molecules exhibit dose-related toxicity. In addition, since they are proteins, they have stability problems, have a short in vivo half-life, and are relatively expensive to produce. Therefore, it is unlikely that cytokines will prove broadly acceptable for use as adjuvants in vaccines designed to protect against infectious diseases. Nevertheless, considerable progress has been made in the use of cytokines for the immunotherapy of cancer [31]. Microparticles have been used as delivery systems for cytokines, including GM-CSF [32] and IL-12 [33], mostly for use in oncology.

8.4 Particulate Vaccine Delivery Systems

Particulates (e. g., emulsions, microparticles, ISCOMs, liposomes, virosomes, and virus-like particles) have comparable dimensions to the pathogens that the immune system evolved to combat and are efficiently taken up by APC. Therefore, these agents have been used as vaccine-delivery systems. Immunostimulatory adjuvants may also be included in the delivery systems to enhance the level of response or to focus the response toward a desired pathway. In addition, formulating potent immunostimulatory adjuvants into delivery systems may limit adverse events, through restricting the systemic circulation of the adjuvant.

151

152

8 Microparticles as vaccine adjuvants and delivery systems

8.4.1 Lipid-based Particles as Adjuvants

A potent oil-in-water (o/w) adjuvant, the Syntex adjuvant formulation (SAF) [34], was developed by using a biodegradable oil (squalane) in the 1980s, as a potential replacement for Freund’s adjuvants. Freund's adjuvants are potent, but toxic, water-inmineral oil adjuvants, which may also contain killed mycobacteria [35]. However, SAF contained a bacterial cell wall-based synthetic adjuvant, threonyl muramyl dipeptide (MDP), and a nonionic surfactant, poloxamer L121, and proved too toxic for widespread use in humans [8]. Therefore, a squalene o/w emulsion was devloped (MF59), without the presence of additional immunostimulatory adjuvants, which proved to be a potent adjuvant with an acceptable safety profile [36]. MF59 enhanced the immunogenicity of influenza vaccine [37–39] and is a more potent adjuvant than alum for hepatitis B vaccine (HBV) in baboons [40] and in humans [41]. Subsequently, the safety and immunogenicity of MF59-adjuvanted influenza vaccine (FLUAD) was confirmed in elderly subjects in clinical trials [42, 43], and these data allowed this product to be approved for licensure in Europe in 1997. In addition, MF59 was shown to be safe and well tolerated in newborn infants in a HIV vaccine trial [44]. MF59 has also been used as an effective booster vaccine, following a priming immunization with live virus [45] or DNA [46] vaccines. In summary, MF59 is a safe and well tolerated vaccine adjuvant in humans and is effective for the induction of potent antibody responses. In many subsequent studies, similar emulsions have been used as delivery systems for immunostimulatory adjuvants, including MPL and QS21. Liposomes are phospholipid vesicles and have been evaluated both as adjuvants and as delivery systems for antigens and adjuvants [47, 48]. Liposomes have been commonly used in complex formulations, often including MPL, which makes it difficult to determine the contribution of the liposome to the overall adjuvant effect. Nevertheless, several liposomal vaccines based on viral membrane proteins (virosomes) without additional immunostimulators have been extensively evaluated in the clinic and are approved as products in Europe for hepatitis A and influenza [49]. The immunostimulatory fractions from Quillaja saponaria (Quil A) have been incorporated into lipid particles comprising cholesterol, phospholipids, and cell membrane antigens, which are called immune-stimulating complexes or ISCOMs [50]. In a study in macaques, an influenza ISCOM vaccine was more immunogenic than a classical subunit vaccine and induced enhanced protective efficacy [51]. A similar formulation has been evaluated in human clinical trials and was claimed to induce CTL responses [52]. The principal advantage of the preparation of ISCOMs is that it allows a reduction in the dose of the hemolytic Quil A adjuvant and targets the formulation directly to APCs. In addition, within the ISCOM, the Quil A is bound to cholesterol and is not free to interact with cell membranes. Therefore, the hemolytic activity of the saponins is significantly reduced [50, 53]. However, a potential problem with ISCOMs is that inclusion of antigens in the adjuvant is often difficult and may require extensive antigen modification [54].

8.4 Particulate Vaccine Delivery Systems

8.4.2 The Adjuvant Effect of Synthetic Particles

The adjuvant effect achieved as a consequence of linking antigens to synthetic particles has been known for many years and was previously reviewed by O’Hagan [55]. However, the particles used in the early studies were nondegradable and were therefore not appropriate for development as vaccine adjuvants for human use. In addition, antigens were often chemically conjugated to the nondegradable particles, adding an extra level of complexity and making commercial development less likely [56]. Particulate delivery systems present multiple copies of antigens to the immune system and are thought to promote trapping and retention of antigens in local lymph nodes. In addition, antigen uptake by APC is enhanced by association of antigen with particles. Biodegradable and biocompatible polyesters, the polylactide-coglycolides (PLG), are the primary candidates for the development of microparticles as adjuvants, since they have been used in humans for many years as resorbable suture material and as controlled-release drug-delivery systems [57, 58]. The adjuvant effect achieved through the encapsulation of antigens into PLG microparticles was first demonstrated by several groups in the early 1990s [59–62]. 8.4.3 Uptake of Microparticles into APC

It is assumed that the uptake of microparticles into APC is important for the particles’ ability to function as vaccine adjuvants, but the uptake of microparticles (< 5 mm) by phagocytic cells has been demonstrated on many occasions. An early paper [63] described the uptake of microparticles (1–3 mm) by macrophages, but showed that 12-mm microparticles were not taken up. It was subsequently shown that maximal uptake of microparticles occurred with particles of < 2 mm [64, 65]. In addition, the surface charge and hydrophobicity of the microparticles modified their uptake [65]. It has also been reported that macrophages that carry microparticles to lymph nodes can mature into DC [66]. In addition, uptake of PLG microparticles directly into DC has been demonstrated both in vitro [67] and in vivo [68]. 8.4.4 Microparticles as Adjuvants for Antibody Induction

The adjuvant effect achieved through the encapsulation of antigens into PLG microparticles was first demonstrated by several groups in the early 1990s [59–62]. Both O’Hagan et al. (1991) and Eldridge et al. (1991) showed that microparticles with entrapped antigens, ovalbumin (OVA) and staphylococcal B enterotoxoid, respectively, had immunogenicity comparable to that of Freund’s adjuvant. Particle size is an important parameter affecting the immunogenicity of microparticles, since smaller particles (< 10 µm) were significantly more immunogenic than larger ones [59, 62]. The effect of particle size on immunogenicity is likely to be a consequence of enhanced uptake of smaller particles into APC. The adjuvant effect of microparticles can be

153

154

8 Microparticles as vaccine adjuvants and delivery systems Fig. 8.1 Serum IgG antibody responses following intramuscular immunization of mice with recombinant p55gag protein adsorbed to PLG microparticles (PLG/ p55) or p55 gag alone (25 mg), at 0 and 4 weeks. Geometric mean titer (GMT) ± s.e. is shown for each group (n = 10).

further enhanced by their coadministration with additional adjuvants [61, 69]. Early studies in mice suggested that microparticles induced antibodies of predominantly the IgG2 a isotype, indicating a Th1 response [70]. However, the potential of microparticles as adjuvants has been limited by many reports describing the denaturation of antigens during and following microencapsulation [71]. Therefore, we developed a novel approach, in which the antigen is adsorbed onto the surface of PLG microparticles that have been modified to promote adsorption [72]. This approach allowed the induction of significantly enhanced antibody titers in mice with an adsorbed recombinant p55 gag antigen from HIV-1 (Figure 8.1). Similar anionic microparticles have also been used to induce potent antibody responses against a recombinant antigen from Neisseria meningitides type B, and the potency of the microparticles did not depend on the choice of anionic surfactant used to make them (Table 8.1). A somewhat related approach was also described, in which a novel charged polymer was used to prepare nanoparticles, which were able to adsorb tetanus toxoid for mucosal delivery of antigens [73].

Tab. 8.1 Immunogenicity of a model meningitis B vaccine on PLG microparticles. Formulation PLG/DSS/MB1 + CpG PLG/SDS/MB1 + CpG PLG/PVA + MB1 + CpG Alum/MB1 + CpG

Two weeks after 3rd immunization Geometric mean titer MB1 Bactericidal titer 67 921 29 911 1065 12 236

4096 4096 < 16 1024

Serum antibody and bactericidal titers in groups of mice immunized with PLG microparticles prepared with two alternative anionic detergents, dioctyl sodium sulfosuccinate (DSS) and sodium dodecyl sulfate (SDS). The anionic PLG microparticles performed as a delivery system for an adsorbed recombinant antigen from Neisseria meningitides type (MB1) and were compared with alum formulations ± CpG adjuvant and also with the antigen in Freund's complete adjuvant (CFA). Geometric mean titers and BCA for each group (n = 10) are shown.

8.4 Particulate Vaccine Delivery Systems

8.4.5 The Induction of Cell-mediated Immunity with Microparticles

Several early studies showed that microparticles exerted an adjuvant effect for the induction of CTL responses in rodents [74–77]. Moreover, microparticles also induced a delayed-type hypersensitivity (DTH) response and potent T cell proliferative responses [75]. In a recent study, we evaluated the ability of microparticles with adsorbed p55 gag to induce CTL responses in rhesus macaques. Previously, we showed that this formulation induced CTL responses in rodents (Figure 8.2) [72] and was more potent than microparticles with entrapped antigen (unpublished data). Although the anionic PLG microparticles were not effective for CTL induction in nonhuman primates, they did induce potent antibody and T cell proliferative responses. Although we did not evaluate microparticles with entrapped antigens, we do not believe that they would have been any more potent than the formulations with adsorbed antigen. Hence, microparticles appear to be capable of inducing CTL responses in rodents with protein antigens, but are ineffective in nonhuman primates. In contrast to the adjuvanted protein approaches, naked DNA was a potent inducer of CTL responses in macaques. 8.4.6 Microparticles as Delivery Systems for DNA Vaccines

DNA vaccines have been repeated shown to offer significant potential for the induction of potent CTL responses [78]. Nevertheless, the potency of DNA vaccines in humans has so far been disappointing, particularly in relation to their ability to induce antibody responses [79, 80]. This has prompted investigators to work on adjuvants and delivery systems for DNA vaccines and also to use DNA in a prime–boost setting with alternative modalities [81–83].

Fig. 8.2 Cytotoxic T lymphocyte (CTL) responses from splenocytes (measured as specific lysis of peptide-pulsed target cells at different effector/target cell ratios) in groups of mice ( n = 5) immunized intramuscularly with soluble recombinant p55 gag protein at 10 mg, 25 mg, or 50 mg, or with 10 mg p55 adsorbed onto PLG microparticles (PLG/gag). As a positive control, a group of mice were infected intraperitoneally with recombinant vaccinia virus vector expressing the p55 gag and polymerase proteins.

155

156

8 Microparticles as vaccine adjuvants and delivery systems

An early study suggested that microparticles with entrapped DNA may have potential as an improved DNA vaccine, although there was no direct comparison with naked DNA [84, 85]. Nevertheless, it soon became clear that the approach of encapsulating DNA into microparticles had several limitations, similar to those previously described for protein antigens, involving damage during microencapsulation and low encapsulation efficiency [86–88]. To avoid these problems, we developed a novel cationic PLG microparticle formulation, which adsorbed DNA onto the surface [85]. Importantly, the cationic microparticles induced enhanced immune responses in comparison to naked DNA (Figure 8.3), and this enhancement was apparent in all species evaluated, including nonhuman primates (Figure 8.4). In addition, the cationic microparticles efficiently adsorbed DNA and could deliver several plasmids simultaneously at high loading levels [89, 90]. The microparticles appear to be effective predominantly as a consequence of efficient delivery of the adsorbed DNA into DC [91]. A similar approach was recently described, in which DNA was adsorbed onto the surface of novel cationic emulsions [92].

Fig. 8.3 Serum IgG antibody responses following intramuscular immunization in mice at 0 and 4 weeks with PLG/DNA (encoding p55 gag) administered in doses of 1 and 10 mg, in comparison to naked DNA at the same dose levels. Geometric mean titer (GMT) + s.e. is shown for each group (n = 10).

Fig. 8.4 Serum IgG antibody responses in two groups of rhesus macaques after intramuscular immunization at 0 and 4 weeks with PLG/DNA (encoding p55 gag) in 500 mg dosesin comparison to naked DNA at the same dose level. Geometric mean titer (GMT) + s.e. is shown for each group (n = 5).

8.4 Particulate Vaccine Delivery Systems

8.4.7 Microparticles as Delivery Systems for Adjuvants

The potency of microparticles with adsorbed antigens has been significantly improved by their coadministration with adsorbed adjuvants [93]. Simultaneous delivery of antigens and adjuvants on microparticles ensures that both agents are delivered into the same APC population. We used cationic PLG microparticles to adsorb the polyanionic adjuvant CpG, to induce enhanced serum antibody responses against HIV-1 gp120 protein that was also adsorbed to microparticles [93]. Tabata and Ikada were the first to entrap an adjuvant, muramyl dipeptide (MDP), in microspheres [94], and Puri and Sinko [95] showed that MDP entrapped in microspheres induced enhanced immune responses. However, Tabata and Ikada [64] previously showed that the pyrogenicity of MDP was reduced by microencapsulation, establishing that microparticles can improve potency and also reduce reactogenicity for adjuvants. PLG microparticles have also been used for delivery of QS21 adjuvant in combination with gp120 antigen [96]. However, although studies with an implantable osmotic pump showed that higher titers were obtained with a discontinuous rather than a continuous release profile for the adjuvant [96], the studies also showed that, although the adjuvant was critical for induction of high initial titers, it was not required for the secondary response. Therefore, the easiest approach was to suspend the microparticles containing the antigen in a solution containing the adjuvant, so that it was immediately available to enhance titers. It remains to be determined whether it is more attractive to encapsulate adjuvants, to adsorb them onto microparticles, or to simply to coadminister them, which may vary for different adjuvants. Encapsulation or adsorption offers the opportunity to minimize the peak local concentrations of adjuvant, which might reduce adverse effects, and to ensure that the adjuvant is taken up efficiently into APCs. Although both approaches offer the potential for controlled release of the adjuvant, the duration of release is expected to be longer for an entrapped agent. Nevertheless, it may be more desirable to have the adjuvant available early in the response, for optimal enhancement. Hence, simple coadministration might work for some adjuvants, but this might depend on their mechanism of action. If they need to be internalized in APC to interact with receptors, then association with the microparticle might be preferred. Adsorption might be preferred to ensure maximal availability of adjuvant after uptake into APC. Microparticles can also be used in conjunction with traditional adjuvants, including alum [97, 98]. In addition, microparticles can also be combined with emulsionbased adjuvants to improve their potency [99, 100]. In a recent study, we highlighted the potential of microparticles as a cancer vaccine [101]. 8.4.8 Microparticles as Single-dose Vaccines

In the early to mid 1990s, several studies were undertaken to evaluate the potential of controlled-release microparticles for the development of single-dose vaccines,

157

158

8 Microparticles as vaccine adjuvants and delivery systems

which would result in improved vaccine compliance, particularly in the developing world. The majority of this work focused on tetanus toxoid (TT), although additional work was also performed with diphtheria toxoid (DT), gp120, hepatitis B surface antigen, and human chorionic gonadotrophin [102]. Commercially, PLG microparticles have been developed as controlled-release formulations for a variety of drugs, including a recombinant protein (human growth hormone). Although microparticle formulations with entrapped antigens could induce potent, long-lasting immune responses in rodents, it was clear that microencapsulated toxoids had significant instability problems [103, 104]. Various approaches have been undertaken to attempt to stabilize toxoids in microparticles, but with limited success [105, 106]. Although the successful development of a product with an entrapped recombinant protein shows that that instability problems can be overcome for PLG microparticles, the solution applied to hGH involved both a novel process and also protein-specific modifications [71]. Unfortunately, experience suggests that each protein for microencapsulation will present its own difficulties, requiring specific solutions, and there is unlikely to be a universal formulation approach that can be applied to all vaccine antigens. Recently, a multivalent approach was described, with four childhood vaccines entrapped in PLG microparticles [107]. Nevertheless, although vaccines entrapped in PLG microparticles have induced long-term responses in small-animal models, early studies showed that alum formulations could also induce similar responses [74, 108]. Hence, the slow decay kinetics of antibody responses in rodents makes them less than ideal for evaluating the potential of controlled-release formulations in which ‘pulses’ of antigen release are designed to provide booster responses. Overall, there is little evidence for formulations providing in vivo boosting in rodents, but it is difficult to see how a response that is maintained at a high level can be boosted. An additional problem relates to the optimal release profile that might be preferred to induce long-term responses in larger animals, including humans. The maintenance of high titers for extended periods in small animals makes them less than ideal for evaluating the effects of different release formulations. Although there have been many claims that a ‘pulse’ of antigen release is preferable to continuous release, the earliest studies showing the benefits of controlled-release technology for vaccines showed that a continuous release profile induced high titers [109]. Moreover, many subsequent studies have shown that both continuous- and discontinuous-release formulations can induce potent immune responses in small-animal models. When we developed a PLG microparticle formulation that was designed specifically for continuous release, we were surprised to find that it induced immune responses comparable to those of PLG microparticles previously designed for discontinuous release [110]. Overall, which release profile is desirable to induce the most potent immune responses in larger animals, including humans, remains unclear. Moreover, it seems unlikely that such questions can be adequately addressed in small-animal models. It is disappointing to note that, after more than 10 years of work, we cannot find any studies in which PLG microparticles with entrapped vaccines have been evaluated in nonhuman primates or humans, although there have been suggestions for some time that clinical trials are imminent [111].

8.5 Alternative Routes of Immunization

8.4.9 Alternative Particulate Delivery Systems

Alternative polymers, including polyanhydrides, poly(ortho)esters, hyaluronic acid, chitosan, and starch, have been evaluated as microparticles for antigen delivery [102], as have polymers that self-assemble into particulates (poloxamers) [112] and soluble polymers (polyphosphazenes) [113]. However, the potency, safety, and tolerability of these approaches remain to be further evaluated. Although advantages are often claimed for these approaches, they are often not clear and are rarely demonstrated in comparative studies. The commercial use of PLG in several marketed products continues to make it an attractive approach, despite some well-documented limitations [102]. Recombinant proteins that naturally self-assemble into particulates are also an attractive approach for enhancing delivery of antigens to APC. The first recombinant protein vaccine, based on hepatitis B surface antigen (HBsAg), was expressed in yeast as a particulate protein [114]. Recombinant HBsAg is potently immunogenic and can be used to prime CTL responses [115]. HBsAg and other virus-like particles (VLPs) can also be used as adjuvants for coexpressed proteins [116]. For example, recombinant VLPs expressed from the yeast Saccharomyces cerevisiae prime CTL responses in mice after a single immunization [117]. In addition,VLPs induce CTL activity in macaques against coexpressed SIV p27 [118]. In addition, clinical trials of VLPs showed them to be safe and immunogenic in humans [119].

8.5 Alternative Routes of Immunization

Although most vaccines have traditionally been administered by intramuscular or subcutaneous injection, mucosal administration of vaccines offers several important advantages, including easier administration, reduced adverse effects, and the potential for frequent boosting. In addition, local immunization induces mucosal immunity at the sites where most pathogens initially establish infection. In general, systemic immunization fails to induce mucosal IgA antibody responses. Oral immunization would be particularly advantageous in isolated communities, where access to health care professionals is difficult. Moreover, mucosal immunization would avoid the potential problem of infection due to the reuse of needles. Several orally administered vaccines are commercially available, which are based on live-attenuated organisms, including vaccines against polio virus,Vibrio cholerae, and Salmonella typhi. In addition, a wide range of approaches is currently being evaluated for mucosal delivery of vaccines [120], including many approaches involving nonliving adjuvants and delivery systems, including microparticles [121, 122]. The most attractive route for mucosal immunization is oral, due to the ease and acceptability of administration through this route. However, due to the acidity of the stomach, the broad range of digestive enzymes in the intestine, and a protective coating of mucus that limits access to the mucosal epithelium, oral immunization with

159

160

8 Microparticles as vaccine adjuvants and delivery systems

nonliving antigens has proven extremely difficult. However, novel delivery systems and adjuvants may be used to significantly enhance immune responses following oral immunization. 8.5.1 Mucosal Immunization with Microparticles

In mice, oral immunization with PLG microparticles induces potent mucosal and systemic immunity to entrapped antigens [55, 123–125]. In addition, mucosal immunization in rodents with microparticles induces protective immunity against challenge with Bordetella pertussis [126–129], Chlamydia trachomatis [130], Salmonella typhimurium [131], Streptococcus pneumoniae [132], and ricin toxin [133]. In primates, mucosal immunization with microparticles has induced protective immunity against challenge with SIV [134] and staphylococcal enterotoxin B [135]. Comparative studies in small-animal models have shown that microparticles are one of the most potent adjuvants available for mucosal delivery of vaccines [136]. In addition, microparticles have shown promise for the mucosal delivery of DNA [137, 138]. The ability of microparticles to perform as effective adjuvants following mucosal administration is largely a consequence of their uptake into specialized mucosal-associated lymphoid tissue (MALT) [139], including MALT in the nasal cavity of rodents [140]. The potential of microparticles and other polymeric delivery systems for mucosal delivery of vaccines was recently reviewed [121, 122], as was the use of alternative delivery systems [141]. Mucosal delivery of vaccines has been undertaken with microparticles prepared from a range of polymers, including PLG, starch, chitosan, sodium alginate, and hydrogels. However, encouraging data is largely restricted to small-animal models, and studies in larger animals, including studies in humans, have largely been disappointing [142, 143]. Hence, although microparticle formulations have significant potential for the mucosal delivery of vaccines, accumulated experimental evidence suggests that simple encapsulation of vaccines into microparticles is unlikely to result in the successful development of oral vaccines and that improvements in the current technology are clearly needed [144]. Nevertheless, microparticles may contribute to the successful development of mucosal vaccines by functioning as delivery systems for both antigens and adjuvants. 8.5.2 Microparticles as Delivery Systems for Mucosal Adjuvants

The most potent mucosal adjuvants currently available are the bacterial toxins from Vibrio cholerae and Escherichia coli, cholera toxin (CT) and heat-labile enterotoxin (LT). However, since CT and LT are respectively the causes of cholera and travelers’ diarrhea, they are considered too toxic for mucosal administration in humans. Therefore, they have been genetically manipulated to reduce toxicity [145–147]. Single amino acid substitutions in the enzymatic A subunit of LT allowed the development of mutant toxins that retained potent adjuvant activity but showed negligible or dramatically reduced toxicity [148–150]. LT mutants have been administered by the oral

8.5 Alternative Routes of Immunization

route to induce protective immunity in mice against H. pylori challenge [151]. In addition, LT mutants have been shown to be potent oral adjuvants for influenza vaccine [152] and model antigens [153]. Nevertheless, due to the significant challenges associated with the development of oral vaccines, which should not be under-appreciated, LT mutants have been evaluated for alternative routes of immunization, including nasal, intravaginal, and intrarectal. Of these, intranasal immunization offers great promise, because of the potent responses induced by this route, the easy access, and the simple administration devices that already exist. On many occasions, the ability of LT mutants to induce potent immune responses after intranasal immunization has been demonstrated [154]. Moreover, in recent studies, LT mutants have induced protective immunity against challenge with B. pertussis [155], S. pneumoniae [156], and herpes simplex virus [157]. In addition, intranasal immunization with LT mutants induces potent CTL responses [158, 159]. We recently showed that the potency of LT mutants can be enhanced by their formulation into a novel bioadhesive microsphere delivery system (Figure 8.4) [93]. A similar observation was made in a second study, confirming the ability of bioadhesive microspheres to enhance the potency of LT mutants [160]. Importantly, we showed recently that the potency of LT mutants for intranasal immunization with a second vaccine was not affected by the presence of preexisting immunity to the adjuvant [161].

Tab. 8.2 Evaluation of an influenza vaccine on bioadhesive HYAFF microparticles. Formulation

Route

HA alone (25 mg)

Intramuscular

HA (25 mg) + LTK63 (100 mg)

Intranasal

HA (25 mg) + LTK63 (100 mg) + HYAFF (25 mg)

Intranasal

Hemagglutination inhibition (HI) titers 640 160 160 80 1280 640 320 40 2560 1280 640 320

Serum hemagglutination inhibition titers at week 6, after immunization at weeks 0 and 4, in 3 groups of 4 micropigs with either 25 mg hemagglutinin (HA) alone by the intramuscular (IM) route, intranasally (IN) with the mucosal adjuvant LTK63 (HA+LTK63), or IN with the mucosal adjuvant LTK63 delivered with bioadhesive microspheres (HYAFF) prepared from esterified hyaluronic acid (HA+LTK63+HYAFF). The table shows responses of individual animals.

161

162

8 Microparticles as vaccine adjuvants and delivery systems

8.6 Adjuvant for Therapeutic Vaccines

It seems increasingly likely that novel adjuvants may prove sufficiently potent to allow the development of therapeutic vaccines and that microparticles may have a role to play here by improving the potency of the adjuvants. Rather than preventing infection, therapeutic vaccines would be designed to eliminate or ameliorate existing diseases, including (1) chronic infectious diseases, for example those caused by HSV, HIV, HCV, HBV, HPV, or H. pylori; (2) tumors, for example melanoma, breast, or colon cancer; and (3) allergic or autoimmune disorders, for example multiple sclerosis, Type I diabetes, and rheumatoid arthritis. Generally speaking, the level of toxicity acceptable for an adjuvant to be used in a therapeutic situation is likely to be higher than for a prophylactic vaccine designed to be used in healthy individuals, particularly if the vaccine is designed to treat cancer or the life-threatening consequences of an infectious disease. Recently PLG microparticles with encapsulated DNA have been evaluated in humans as a cancer vaccine and have shown some evidence of clinical benefit [162]. In addition, cationic microparticles with adsorbed DNA have also shown potency as a cancer vaccine in a preclinical study [101].

8.7 Future Developments in Vaccine Adjuvants

Several recent problems highlight the urgent need for the development of new and improved vaccines. These problems include (1) the lack of success of traditional vaccine approaches against ‘difficult’ organisms, for example HIV and HCV; (2) the emergence of new diseases, for example Ebola, West Nile, and Hanta viruses; (3) the reemergence of ‘old’ infections, for example TB; (4) the continuing spread of antibiotic-resistant bacteria; and (5) the potential use of microorganisms for bioterrorism. The induction of CTL responses may be necessary for some vaccines, including HIV, but accumulated information shows that induction of potent CTL is difficult with protein-based vaccines. Therefore, DNA is an attractive approach, but needs to be delivered more effectively to improve its potency in humans. Microparticles may have a significant role to play in improving the potency of DNA vaccines (Figures 8.3 and 8.4). Targeted delivery of antigens and adjuvants to specific APC populations via microparticles may reduce the adverse effects of adjuvants or help to achieve a specific desired response. Targeting may be achieved at several different levels, including tissue-specific delivery to local lymph nodes, cell-specific targeting to APC, or targeting to subcellular compartments within APC, for example the proteasome to promote CTL or the nucleus for DNA vaccines. However, targeting may also be achieved through the use of ligands designed to specifically interact with receptors on APC, including TLR, which evolved to recognize various components of bacteria and viruses. An alternative target is the mannose receptor, which has been used to target

References

liposomes to APCs [163]. For mucosal delivery, lectins have been used to target antigens [164], liposomes [165], and microparticles [166] to the MALT. In addition, lectin targeting has also been used to enhance the extent of uptake of microparticles following oral delivery [167]. Recently, novel approaches have been applied in an attempt to identify receptors on M cells that can be exploited for vaccine delivery [168]. However, the use of targeting ligands for microparticles requires the construction of a very complex formulation, which will need to show dramatic improvements over nontargeted systems to justify scale-up and commercialization. An interesting approach to targeting APCs has been described, which involves coexpression of two linked proteins, with a bacterially-derived targeting component and an adjuvant signal [169–171]. Similarly, an alternative bacterial toxin fusion protein has been constructed to deliver antigens specifically for CTL induction [172]. Future developments in adjuvants and delivery systems are likely to include the development of more site-specific delivery systems for both mucosal and systemic administration. In addition, the identification of specific receptors on APCs is likely to allow targeting of adjuvants for the optimal induction of potent and specific immune responses. However, further developments in novel adjuvants and their delivery will likely be driven by a better understanding of the mechanism of action of currently available adjuvants – and this area of research requires additional work.

Acknowledgments

We thank our colleagues at Chiron Corporation for their contributions to the ideas contained in this review, particularly Rino Rappuoli. We also thank all the members of the Vaccine Adjuvants and Delivery Group at Chiron. Thanks are also due to Nelle Cronen for her help in preparing the manuscript.

References 1. Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann Inst Pasteur 1924, 38, 1. 2. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, eds. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995, 141–228. 3. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Delivery Rev 1998, 32, 155–172. 4. Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998, 16, 1016–1023.

5. Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 1996, 14, 1412–1416. 6. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA, Moingeon P. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001, 69, 1151–1159. 7. Shi Y, Hogen-Esch H, Regnier FE, Hem SL. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001, 19, 1747–1752.

163

164

8 Microparticles as vaccine adjuvants and delivery systems 8. Edelman R. Adjuvants for the future. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. Vol. 2. New York: Marcel Dekker, 1997, 173–192. 9. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156, 199–209. 10. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp Quant Biol 1989, 54(1C), 1–13. 11. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91, 295–298. 12. Fearon DT. Seeking wisdom in innate immunity. Nature 1997, 388, 323–324. 13. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996, 272, 50–53. 14. Yip HC, Karulin AY, Tary-Lehmann M, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999, 162, 3942– 3949. 15. Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 1992, 143, 483–488. 16. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. Pharm Biotechnol 1995, 6, 495–524. 17. Ulrich JT. MPLr immunostimulant: adjuvant formulations. In: O'Hagan DT, ed. Vaccine Adjuvants: Preparation Methods and Research Protocols. Totowa, NJ: Humana Press, 2000, 273–282. 18. Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001, 126, 135–139. 19. Messina JP, Gilkeson GS, Pisetsky

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991, 147, 1759–1764. Tokunaga T,Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. 1984, 72, 955–962. Krieg AM,Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 6546–6549. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet 1987, 3, 342–347. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745. Sparwasser T, Koch ES,Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998, 28, 2045–2054. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999, 17, 19–25. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998, 161, 7054–7062. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996, 13, 1–55. Glaueri AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature 1962, 196, 953. Kensil CR, Kammer R. QS-21: a watersoluble triterpene glycoside adjuvant. Exp Opin Invest Drugs 1998, 7, 1475– 1482. Heath AW. Cytokines as immunological adjuvants. Pharm Biotechnol 1995, 6, 645–658. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998, 68, 122–138. Pettit DK, Lawter JR, Huang WJ, et al. Characterization of poly(glycolideco-D,L-lactide)/poly(D,L-lactide) micro-

References

33.

34.

35.

36.

37.

38.

39.

40.

41.

spheres for controlled release of GMCSF. Pharm Res 1997, 14, 1422–1430. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000, 60, 3832–3837. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 1986, 95, 157–168. Lindblad EB. Freund’s adjuvants. In: O'Hagan D, ed. Vaccine Adjuvants: Preparation Methods and Research Protocols. Vol. 42. Totowa, NJ: Humana Press, 2000, 49–64. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, eds. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995, 277–296. Cataldo DM,Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997, 15, 1710–1715. Higgins DA, Carlson JR,Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996, 14, 478–484. O'Hagan DT, Ott GS,Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997, 3, 69–75. Traquina P, Morandi M, Contorni M,Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996, 174, 1168–1175. Heineman TC, Clements-Mann ML, Poland GA, et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999, 17, 2769–2778.

42. Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999, 15, 573–576. 43. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17, 3094–3101. 44. Cunningham CK,Wara DW, Kang M, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 2001, 32, 801–807. 45. Team TAVEGP. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001, 183, 563–570. 46. Cherpelis S, Srivastava I, Gettie A, et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-celldepleted rhesus macaques. J Virol 2001, 75, 1547–1550. 47. Alving CR. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta 1992, 1113, 307–322. 48. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990, 11, 89–97. 49. Ambrosch F,Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15, 1209–1213. 50. Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv Drug Delivery Rev 1998, 32, 247–271. 51. Rimmelzwaan GF, Baars M, van Beek R, et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and ISCOM vaccines. J Gen Virol 1997, 78(4), 757–765.

165

166

8 Microparticles as vaccine adjuvants and delivery systems 52. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMs). Virology 1999, 259, 256–261. 53. Soltysik S, Wu JY, Recchia J, et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995, 13, 1403– 1410. 54. Lovgren-Bengtsson K, Morein B. The ISCOMTM Technology. In: O'Hagan D, ed. Vaccine Adjuvants: Preparation Methods and Research Protocols. Vol. 42. Totowa, NJ: Humana Press, 2000, 239–258. 55. O'Hagan DT. Microparticles as oral vaccines. In: O'Hagan DT, ed. Novel Delivery Systems for Oral Vaccines. Boca Raton: CRC Press, 1994, 175–205. 56. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993, 90, 4942– 4946. 57. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995, 12, 1–99. 58. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations [published erratum appears in Nat Biotechnol 1998, 16, 478]. Nat Biotechnol 1998, 16, 153–157. 59. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-coglycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991, 59, 2978–2986. 60. O’Hagan DT, Rahman D, McGee JP, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73, 239–242. 61. O’Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 1991, 9, 768–771.

62. O’Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11, 965–969. 63. Kanke M, Sniecinski I, DeLuca PP. Interaction of microspheres with blood constituents. I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenter Sci Technol 1983, 37, 210–217. 64. Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 1988, 22, 837–858. 65. Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci 1990, 94, 107–141. 66. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999, 11, 753–761. 67. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002, 19, 1480–1487. 68. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002, 60, 480–486. 69. O’Hagan DT, Ugozzoli M, Barackman J, et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV1. Vaccine 2000, 18, 1793–1801. 70. Vordermeier HM, Coombes AG, Jenkins P, et al. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 1995, 13, 1576–1582. 71. Johnson OL, Cleland JL, Lee HJ, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996, 2, 795–799.

References 72. Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Controlled Release 2000, 67, 347–356. 73. Jung T, Kamm W, Breitenbach A, Klebe G, Kissel T. Loading of tetanus toxoid to biodegradable nanoparticles from branched poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: a mechanistic study. Pharm Res 2002, 19, 1105–1113. 74. O’Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11, 965–969. 75. Maloy KJ, Donachie AM, O’Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994, 81, 661–667. 76. Moore A, McGuirk P, Adams S, et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIVspecific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995, 13, 1741–1749. 77. Nixon DF, Hioe C, Chen PD, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996, 14, 1523–1530. 78. Seder RA, Gurunathan S. DNA vaccines: designer vaccines for the 21st century. N Engl J Med 1999, 341, 277– 278. 79. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282, 476– 480. 80. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351, 1320– 1325. 81. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998, 4, 397–402. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408, 605–609. Amara RR,Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292, 69–74. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 1998, 4, 365–368. Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000, 97, 811– 816. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. Pharm Res 1999, 61, 361–374. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 1999, 88, 126–130. Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Controlled Release 2000, 66, 229–241. Briones M, Singh M, Ugozzoli M, et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 2001, 18, 709–711. O’Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J Virol 2001, 75, 9037–9043. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles

167

168

8 Microparticles as vaccine adjuvants and delivery systems

92.

93.

94.

95.

96.

97.

98.

99. 100.

101.

mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000, 7, 2105–2112. Ott G, Singh M, Kazzaz J, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Controlled Release 2002, 79, 1–5. Singh M, Ott G, Kazzaz J, et al. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res 2001, 18, 1476– 1479. Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J Pharm Pharmacol 1987, 39, 698–704. Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J Controlled Release 2000, 69, 69–80. Cleland JL, Barron L, Daugherty A, et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J Pharm Sci 1997, 85, 1350–1357. Singh M, Li XM,Wang H, et al. Immunogenicity and protection in smallanimal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997, 65, 1716–1721. Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998, 16, 1822–1827. O’Hagan DT. HIV and mucosal immunity. Lancet 1991, 337, 1289. O’Hagan DT, Singh M, Kazzaz J, et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 2002, 20, 3389–3398. Luo Y, O’Hagan D, Zhou H, et al. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003, 3674, 1–10. O’Hagan DT, Singh M, Gupta RK. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Delivery Rev 1998, 32, 225–246. Schwendeman SP, Costantino HR, Gupta RK, Siber GR, Klibanov AM, Langer R. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc Natl Acad Sci USA 1995, 92, 11234–11238. Xing X, Liu V, Xia W, et al. Safety studies of the intraperitoneal injection of E1A–liposome complex in mice. Gene Ther 1997, 4, 238–243. Johansen P, Gander B, Merkle HP, Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol 2000, 18, 203–211. Sasiak AB, Bolgiano B, Crane DT, Hockley DJ, Corbel MJ, Sesardic D. Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Vaccine 2001, 19, 694–705. Boehm G, Peyre M, Sesardic D, et al. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm Res 2002, 19, 1330–1336. Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995, 13, 683–689. Preis I, Langer RS. A single-step immunization by sustained antigen release. J Immunol Methods 1979, 28, 193–197. McGee JP, Davis SS, O’Hagan D. The immunogenicity of a model protein entrapped in poly (lactide-co-glycolide) microparticles prepared by a novel phase separation technique. J Controlled Release 1994, 31, 55–60. Johansen P, Estevez F, Zurbriggen R, et al. Towards clinical testing of a single-administration tetanus vaccine

References

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

based on PLA/PLGA microspheres. Vaccine 2000, 19, 1047–1054. Newman MJ, Balusubramanian M, Todd CW. Development of adjuvant-active nonionic block copolymers. Adv Drug Delivery Rev 1998, 32, 199–223. Payne LG, Jenkins SA,Woods AL, et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16, 92–98. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298, 347–350. Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J. Nucleic-acid vaccination primes hepatitis-b virus surface antigen-specific cytotoxic T-lymphocytes in nonresponder mice. J Virol 1995, 69, 5929–5934. Gilbert SC. Virus-like particles as vaccine adjuvants. In: O’Hagan D, ed. Vaccine Adjuvants: Preparation Methods and Research Protocols. Vol. 42. Totowa, NJ: Humana Press, 2000, 197–210. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997, 15, 1280–1284. Klavinskis LS, Bergmeier LA, Gao L, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996, 157, 2521–2527. Martin SJ,Vyakarnam A, Cheingsong-Popov R, et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. Aids 1993, 7, 1315–1323. Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998, 351, 1375–1376. O’Hagan D. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Delivery Rev 1998, 34, 305–320. Vajdy M, O’Hagan DT. Microparticles

123.

124.

125.

126.

127.

128.

129.

130.

for intranasal immunization. Adv Drug Delivery Rev 2001, 51, 127–141. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O’Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 1992, 76, 164–168. Challacombe SJ, Rahman D, O’Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 1997, 15, 169–175. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Controlled Release 1990, 11, 205–214. Cahill ES, O’Hagan DT, Illum L, Barnard A, Mills KH, Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995, 13, 455–462. Jones DH, McBride BW, Thornton C, O’Hagan DT, Robinson A, Farrar GH. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun 1996, 64, 489–494. Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun 1995, 63, 1195– 1200. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001, 19, 1940–1950. Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDo-

169

170

8 Microparticles as vaccine adjuvants and delivery systems

131.

132.

133.

134.

135.

136.

137.

138.

nald AB. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med 1996, 2, 1116–1121. Allaoui-Attarki K, Pecquet S, Fattal E, et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DLlactide-co-glycolide) microspheres. Infect Immun 1997, 65, 853–857. Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 2002, 70, 1143– 1149. Kende M,Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 2002, 20, 1681–1691. Marx PA, Compans RW, Gettie A, et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993, 260, 1323–1327. Tseng J, Komisar JL, Trout RN, et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect Immun 1995, 63, 2880– 2885. Ugozzoli M, O’Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 1998, 93, 563– 571. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. Poly(DL-lactideco-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15, 814–817. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997, 386, 410–414.

139. O’Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 1996, 189(3), 477–482. 140. Eyles JE, Spiers ID, Williamson ED, Alpar HO. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J Pharm Pharmacol 2001, 53, 601–607. 141. Michalek SM, O'Hagan DT, GouldFogerite S, Rimmelzwaan GF, Osterhaus ADME. Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and ISCOMs. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstrock J, McGhee JR, eds. Mucosal Immunology. San Diego: Academic Press, 1999, 759–778. 142. Tacket CO, Reid RH, Boedeker EC, et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 1994, 12, 1270–1274. 143. Lambert JS, Keefer M, Mulligan MJ, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV1 seronegative human subjects. Vaccine 2001, 19, 3033–3042. 144. Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 2001, 14, 183–189. 145. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995, 63, 1617–1623. 146. Douce G, Turcotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995, 92, 1644–1648. 147. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997, 65, 2821– 2828. 148. Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a

References

149.

150.

151.

152.

153.

154.

155.

156.

nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996, 64, 974–979. Giannelli V, Fontana MR, Giuliani MM, Guangcai D, Rappuoli R, Pizza M. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect Immun 1997, 65, 331–334. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADPribosyltransferase activity. J Exp Med 1998, 187, 1123–1132. Marchetti M, Rossi M, Giannelli V, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998, 16, 33–37. Barackman JD, Ott G, Pine S, et al. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin Diagn Lab Immunol 2001, 8, 652–657. Douce G, Giannelli V, Pizza M, et al. Genetically detoxified mutants of heatlabile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun 1999, 67, 4400–4406. Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999, 20, 493–500. Ryan EJ, McNeela E, Murphy GA, et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 1999, 67, 6270–6280. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with non-

157.

158.

159.

160.

161.

162.

163.

164.

toxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999, 67, 5892– 5897. O’Hagan D, Goldbeck C, Ugozzoli M, et al. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 1999, 17, 2229–2236. Simmons CP, Mastroeni P, Fowler R, et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 1999, 163, 6502–6510. Neidleman JA, Ott G, O’Hagan D. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In: Walker JM, ed. Methods in Molecular Medicine. Vol. 42. Totowa, NJ: Humana Press, 2000, 327–336. Baudner BC, Balland O, Giuliani MM, et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun 2002, 70, 4785–4790. Ugozzoli M, Santos G, Donnelly J, O'Hagan DT. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. coli (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant. J Infect Dis 2001, 183, 351–354. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 2002, 8, 1028–1037. Toda S, Ishii N, Okada E, et al. HIV-1specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferongamma antibody. Immunology 1997, 92, 111–117. Giannasca PJ, Boden JA, Monath TP. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-direc-

171

172

8 Microparticles as vaccine adjuvants and delivery systems

165.

166.

167.

168.

169.

ted lectins. Infect Immun 1997, 65, 4288–4298. Chen H, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 1996, 13, 1378–1383. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998, 16, 536–541. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectinconjugated nanoparticles in the rat. Pharm Res 1997, 14, 613–618. Lo D, Hilbush B, Mah S, et al. Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling. Adv Drug Delivery Rev 2002, 54, 1213–1223. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation

by cholera toxin A1 subunit. J Immunol 1997, 158, 3936–3946. 170. Agren LC, Ekman L, Lowenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999, 162, 2432–2440. 171. Agren L, Sverremark E, Ekman L, et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J Immunol 2000, 164, 6276– 6286. 172. Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc Natl Acad Sci USA 1997, 94, 12059–12064.

173

9 Liposomes and ISCOMs Gideon Kersten, Debbie Drane, Martin Pearse, Wim Jiskoot, and Alan Coulter

9.1 Introduction

A dilemma currently facing vaccinologists is that the often rule is: the more defined and purified an antigen, the lower its immunogenicity. Starting with a pathogen, the removal of nucleic acids, endotoxin, cell wall components, host cell components, and other ‘irrelevant’ components in general yields a well-defined, pharmaceutically acceptable and safe vaccine. Unfortunately, such a vaccine rarely elicits strong, longlasting immune responses. After the process of stripping, purification, and polishing, the antigen needs to be reformulated and presented in a multimeric, particulate form together with an adjuvant with a high safety profile. The development of antigen carriers that mimic the outside of pathogens is a logical, and in principle, straightforward approach. Therefore, it is not surprising that within 10 y after the first description of liposomes in 1965 [1] and of ‘virus like particles’ after saponin treatment of membrane viruses in 1973 [2] their potential as antigen carriers was investigated [3, 4]. Since then, more than a 1000 papers about lipidic vesicles related to vaccinology and immunology have appeared in the literature (reviewed in [5–8]). Although immune stimulating complexes, (ISCOMs) have a profoundly different structure than liposomes (an important structural component is the Quillaja saponin adjuvant) (Figure 9.1D), they are included in this chapter because they belong to the large family of amphiphile-based vesicular antigen carriers (Table 9.1). The most important developments in the preparation and characterization of these carriers, their mechanism of action, their in vivo effects, and their status with respect to use in registered vaccines is discussed in this chapter. The archetypal, classical liposome is a vesicle composed of phospholipids (Figure 9.1A). Liposomes are highly versatile with regard to composition, size, physicochemical, and immunological characteristics. This allows a flexible design with the aim of maximizing functionality. Instead of liposomes as a single entity, one can define a whole group of liposome-like structures, many of which are being tested as antigen carriers. Most of these structures are discussed in this chapter, although

174

9 Liposomes and ISCOMs Fig. 9.1 Diagrams and electron micrographs of liposomes (A), virosomes (B), cochleates (C), and ISCOMs (D). Liposome s shown are small unilamellar vesicles (about 100 nm) prepared by detergent removal. The virosome size is about 150 nm. The virosome diagram shows hemagglutinin (trimers) and neuraminidase. Cochleates are fused bilayers kept rolled up by intercalated calcium ions. ISCOMs are profoundl y different from lipid vesicles. Their main constituents are cholesterol and saponin from Quillaja saponaria. Size is 40 nm. Micrographs A and C are freeze-fracture images. B and D are negative staining. Sources: (A, diagram) W. Jiskoot, Universit y of Utrecht, (A, micrograph) A. Verkleij, University of Utrecht, (B, diagram) T. Wyler, University of Berne. Reprinted from Vaccine 21, Zurbriggen, 921, 2003 Elsevier Science,with permission, (B, micrograph) Waeltie and Gluck, Int. J. Cancer 77, 728, 1998 Wiley-Liss. Used by permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc, (C, micrograph) L. Zarif et al., Drug Delivery 2, 2002, with permission, (D, diagram) Reprinted from [5] 1995 Elsevier Science with permission, (D, micrograph) courtesy of K. Teppema, M. Burger, RIVM, Bilthoven.

some may disagree on the classification ‘liposome-like’ for some vehicles, e. g., niosomes, cochleates, or outer membrane vesicles. Sometimes a different name for a certain vesicle type is merely semantic or guided by commercial motives, and sometimes the structures are really different from classical liposomes. Unlike ISCOMs, most liposomal structures contain an internal space separated from the environment (except for cochleates, Figure 9.1C). This allows the incorporation of hydrophilic antigens (or adjuvants), apart from bilayer association of more amphiphilic antigens, although it is difficult to achieve high loading yields. ISCOMs, on the other hand, are spherical structures, typically 40 nm in diameter. Unlike liposomes, ISCOMs cannot be loaded with water-soluble antigens because the vesicle contains pores [9].

9.1 Introduction Tab. 9.1 Colloidal antigen delivery systems discussed in this chapter. Name

Composition

Structure and characteristics

Liposome

phospholipids, cholesterol

bilayer vesicles, 50 nm to 10 mm characteristics highly versatile

Transfersome

phospholipids, cholate

ultradeformable bilayer vesicles optimised for transdermal delivery

Niosome

nonionic surfactants, cholesterol

nonphospholipid liposomes high chemical stability, modest physical stability

Virosome

viral phospholipids, viral membrane proteins (HA)

bilayer vesicles, ~ 150 nm intrinsic targeting properties

Proteosome/OMV

membrane proteins, phospholipids, LPS

bilayer(?) bacterial vesicles, 60–100 nm high protein : lipid ratio

Archaeosome

Archaeobacterial lipids

bilayer vesicles high chemical stability

Cochleate

phospholipids, cholesterol, calcium

nonvesicular; rolled up bilayer sheets rigid and stable, no internal aqueous space

ISCOM

Quillaja saponin, cholesterol, phospholipid

spherical aggregates of ringlike micelles, ~ 40 nm, no isolated internal volume; no bilayer(?) very high intrinsic adjuvant activity

OMV: outer membrane vesicle; HA: hemagglutinin; LPS: lipopolysaccharide; See text for details.

Another difference between liposomes and ISCOMs is that ISCOMs have potent intrinsic adjuvant properties, whereas liposomes generally have modest intrinsic adjuvant activity. Phospholipids, or other bilayer-forming molecules, are the key components of liposomes. The main building blocks of ISCOMs are saponins from Quillaia saponaria, cholesterol, and phospholipid. Phospholipid is necessary, probably as a fluidizer of the rigid cholesterol–saponin complexes, but bilayer structures are thought to be absent. Initially, ISCOMs were designed to carry membrane proteins, however today, ISCOM vaccines can be prepared with almost all types of antigens (see section 9.3.1.3). Furthermore, in some circumstances, physical association of the antigen with the ISCOM is not necessary to induce potent immune responses. Because of the noted differences in the structure and properties of liposomes and ISCOMs, they are discussed separately below.

175

176

9 Liposomes and ISCOMs

9.2 Liposomes and Related Structures 9.2.1 Composition, Characteristics, and Preparation Methods of Liposomes 9.2.1.1 Composition and Characteristics of Liposomes As mentioned in the Introduction, classical liposomes, i. e., vesicles composed of phospholipids and often cholesterol, are just one type of a relatively large group of colloidal particles composed of lipidic or lipid-like constituents suitable for antigen delivery. In this section the different vesicle types are described and their potential as vaccine component is discussed. Liposomes The physical properties of liposomes can vary widely as a function of composition and method of preparation. Phospholipids are the primary bilayer components. Cholesterol is often added to increase bilayer rigidity, resulting in increased membrane stability. Application of phospholipids with high phase-transition temperatures has the same effect. Surface charge and pH sensitivity (see section 9.2.2) are also modifiable. The size of liposomes ranges from 50 nm to several micrometers. They are uni- or multilamellar, depending on the method of preparation. Efficient incorporation of antigens may require extensive optimization. Liposomes can be freeze-dried, that is to say, in the drying phase liposomes partly disintegrate but reform after reconstitution. For membrane-associated antigens this is not necessarily a problem, but when hydrophilic antigens are present in the aqueous interior, freeze-drying is not possible without losing part of the load. In general, classical liposomes are good, but not very good, enhancers of the immune response. Incorporation of amphiphilic adjuvants circumvents this potential problem. Adjuvants of this type are monophosphoryl lipid A (MPL) and other LPS derivatives and dioctadecyl ammonium bromide (DDA). Interesting results in humans have been obtained with lipid A-adjuvanted liposomes (see also section 9.2.3). Liposomes can be included in oil-in-water emulsions, making it possible to employ the advantages of both delivery systems: induction of strong humoral responses by the emulsion and induction of CTL responses against liposome-encapsulated soluble antigen [9]. Liposomes can be optimized for certain tasks. For oral application, polymerization of the lipids protects the interior against low pH, proteolytic enzymes, and bile salts [10]. By using lipids conjugated to polyethylene glycol (PEG), liposomes acquire ‘stealth’ properties and are sterically stabilized. For vaccination purposes this generally is less desirable but, combined with specific targeting to antigen-presenting cells (APC), PEGylation may be beneficial [11] (see also section 9.2.2.2). Transfersomes A disadvantage of parenteral immunization is the use of needles. Reuse of needles in developing countries causes many hepatitis B and HIV infections. Second, fear of

9.2 Liposomes and Related Structures

needles and perceived pain in part of the population have encouraged vaccine developers to look for alternatives. One of these is dermal delivery of antigen by active or passive skin penetration. The rationale is that the number of dendritic cells in the viable epidermis, just under the top layer (the stratum corneum), is very high. On the other hand, the barrier function of the stratum corneum (consisting of keratin and multiple bilayers of ceramides) is formidable, and it is difficult to get macromolecules through the skin. Transfersomes are ultradeformable liposomes with enhanced skin-penetration properties. They are composed of phosphatidylcholine (PC) and cholate (9 : 2 molar ratio). It is claimed that the presence of cholate makes the vesicle ultradeformable. This enables them to squeeze through pores in the stratum corneum with a diameter down to 10 % of the transfersome size. As a result, 200- to 300-nm vesicles can pass the stratum corneum. It is thought that a hydration gradient from the dry surface to the wet viable tissue drives the transfersomes through the stratum corneum. Studies with water-soluble as well as membrane-associated model antigens have shown that dermal application of transfersomes induces responses equal to parenteral immunization [12]. There is some debate about the validity of claims that transfersomes are very effective (trans)dermal delivery systems. Experiments with other vesicular structures with potential skin-penetrating properties, such as fluid liposomes (i. e., consisting of lowmelting-point phospholipids), niosomes (see below), or ‘ethosomes’ (liposomes with high levels of ethanol), do not come close to the claimed delivery potential of transfersomes (see [13] for review). Niosomes Vesicles can be prepared without any phospholipids. As a substitute, nonionic surfactants are used. Niosomes (reviewed in [14]) are also called nonionic surfactant vesicles (NISV) [15] or Novasomes [16]. They have some advantages over classical liposomes. Synthetic nonionic surfactants are chemically more stable than phospholipids. Phospholipids are especially prone to oxidation (of unsaturated fatty acids). Surfactants are much cheaper than phospholipids. Finally, some surfactants have an intrinsic adjuvant activity, improving the immunogenicity of niosome-encapsulated antigens. Bovine serum albumin (BSA) in niosomes was shown to be as immunogenic as BSA with complete Freund’s adjuvant [11, 13]. Niosomes can be tailored to meet specific needs. Coincorporation of bile salts like deoxycholate into niosomes results in vesicles (bilosomes) that enhance immune responses after oral immunization [17]. The vesicles show some promise as transdermal delivery vehicles and may be suitable antigen carriers for this immunization route. Virosomes Liposomes prepared from viral envelopes supplemented with endogenous phospholipids are called virosomes (Figure 9.1B). They resemble small unilamellar vesicles. The presence of viral membrane proteins make virosomes more efficient in binding to APC and/or cytosolic delivery (see section 9.2.2). Virosomes prepared from influenza virus envelopes, also called IRIVs (immunopotentiating reconstituted influenza virosomes) are in advanced stages of development (see also section 9.2.3 and

177

178

9 Liposomes and ISCOMs Tab. 9.2 Examples of clinical trials with liposome-like structures and products on the market. Vehicle

Antigen

Stage

Read out

Ref.

Lipid A-containing liposomes, Al(OH)3

malaria antigen (recombinant protein)

phase 1/2

seroconversion

95, 47

Meningococcal proteosomes

Shigella flexneri LPS

phase 1/2 (intranasal)

seroconversion

96

MDP-containing virosomes

influenza HA/NA

phase 1

functional seroconversion (HA inhibition)

97

Influenza virosomes

HepA

registered (Epaxal)

seroconversion

98–101

Influenza virosomes

influenza HA/NA

registered (Infexal V)

functional seroconversion (HA inhibition), protection

102–104

HLT containing influenza virosomes

influenza HA/NA

phase 1/2

functional seroconversion (HA inhibition)

105,106

Outer membrane vesicles

Neisseria meningitidis pore protein A

phase 1/2, phase 3

functional seroconversion (bactericidal activity), protection

49–52, 107–109

Al(OH)3 : alminum hydroxide; LPS: lipopolysaccharide; MPD: muramyl dipeptide; HA/NA: hemagglutinin/neuraminidase; HepA: hepatitis A; HLT: heat-labile toxin (E. coli).

Table 9.2). Coincorporation of membrane proteins generally induces enhanced (cellular) immune responses against these antigens. Virosomes not only show promise as parenteral delivery vehicles but also are able to boost the immune response after intranasal application (Table 9.2). Proteosomes and Outer Membrane Vesicles Proteosomes and outer membrane vesicles are of bacterial origin and, as a result, contain large amounts of bacterial components, including membrane proteins. They are prepared by solubilization of bacterial outer membranes, followed by purification steps such as ammonium sulfate precipitation and dialysis against detergent-containing buffer [18]. Electron micrographs reveal liposomal vesicles with a size of about 100 nm, but the protein:lipid ratio is higher than can be achieved with purified protein incorporated into liposomes. Proteins and peptides are noncovalently complexed to the proteosomes, making them highly immunogenic (see [19] for review). Several groups are or have been developing vesicle-based vaccines against Meningococci. These are outer membranes from Neisseria meningitidis type B containing pore proteins as antigens. Immunization with these vesicles leads to the induction of functional antibodies (see section 9.2.3 and Table 9.2).

9.2 Liposomes and Related Structures

Archaeosomes Archaeobacteria are extremophiles, often living in hostile habitats. They are resistant to low pH, high temperature, or high salt concentrations. Membranes of Archaeobacteria contain lipids that are chemically distinct from those of eukaryotic and prokaryotic species. The saturated, branched C-20, -25, and -40 phytanyl chains can form liposomes with unique properties with respect to physical and chemical stability and uptake by APCs [20]. They are less sensitive to oxidative stress, high temperature, alkaline pH, phospholipases, and bile salts. Immune responses comparable to immunization with complete Freund’s adjuvant and superior to immunization with conventional liposomes have been reported after immunization with archaeosomes [21, 22]. Cochleates Cochleates are elongated supramolecular assemblies and differ from other members of the liposome group in that they are not spherical (see [23] for review). They are bilayer sheets consisting of phosphatidyl ethanolamine (PE), negatively charged phosphatidyl serine (PS), and cholesterol. Calcium ions are added and intercalate with the bilayers. This results in a rolled-up bilayer sheet without internal volume. Despite the latter fact, cochleates can contain many types of molecules. Hydrophobic and amphiphilic molecules are taken up by the bilayer, whereas negatively and positively charged compounds interact with the calcium ions or with the phosphatidyl serine. respectively, by electrostatic interactions. The size and aggregation behavior of cochleates is influenced by the method of preparation (see section 9.2.1.2). The benefits of cochleate-based vaccines (compared to true liposomal formulations) are not yet clear and may be antigen dependent (see [24] for review). Influenza antigens in cochleates are as immunogenic (humoral response) as influenza antigens in liposomes. Cochleates may be efficient vehicles for DNA vaccines, however. Experiments with HIV-1 gp 160-encoding plasmid DNA resulted in superior induction of antigen-specific cytotoxicity in mice. For the oral route, cochleate vaccines may be beneficial because the delivery vehicle is very stable, due to the tight bilayer– bilayer interaction. It remains unclear whether the preparation of cochleates is really necessary to provide antigen protection via the oral route, since calcium levels in saliva and the stomach are high enough to fuse phosphatidyl serine liposomes into cochleates [24]. 9.2.1.2 Preparation Methods of Liposomes The preparation of plain liposomes on a small scale is not very difficult. This does not mean that high incorporation efficiency of the antigen, incorporation of the antigen with minimal activity loss, or scaling up of production is without problems. For the preparation of liposomes on a laboratory scale, many procedures have been published. The mechanisms behind three regularly used basic procedures are: (1) hydration of lipids by energy input, (2) mixing of a nonpolar phase containing the lipids with the aqueous phase, followed by removal of the organic solvent (also called reverse-phase evaporation when organic solvents are used that are not miscible with water), and (3) solubilization of the lipids by a detergent and subsequent removal of the detergent:

179

180

9 Liposomes and ISCOMs

(1) Lipid can be simply dispersed in water by vigorous shaking in the presence of glass beads, by bubbling a stream of nitrogen gas through the mixture, or by highshear homogenization and/or ultrasonic treatment. Liposomes prepared this way are generally large multilamellar vesicles (MLV), although rigorous ultrasonic treatment or extrusion may generate smaller, unilamellar vesicles (SUV). MLVs are suitable for the incorporation of water-soluble molecules in the liposome interior. However, high concentrations of lipids have to be used to achieve high incorporation efficiencies for this class of compounds. (2) The reverse-phase evaporation method provides large unilamellar liposomes with a higher encapsulation efficiency per mole of lipid for water-soluble, hydrophilic molecules. The lipids are solubilized in an organic solvent (chloroform), water is added, and the solvent is evaporated under vigorous stirring. (3) A method to obtain unilamellar vesicles without applying a high energy input or using an organic solvent, both of which may be destructive of (protein) antigens, requires the use of detergents [25]. The lipids are solubilized with a detergent. The detergent should have a high critical micelle concentration (CMC), so that it is easily removed by dialysis. Octylglucoside, with a CMC of 25 mM in water, is often used. During dialysis the liposomes are formed. A model for the conversion from mixed micelles to spherical structures via bilayer disks was described by Lasic [26]. Dilution is a fast way of lowering the detergent concentration. With this method SUVs can be produced with a narrow size distribution [27]. The average size of these vesicles can range from 80 to 200 nm, depending on lipid composition, protein content, and dilution rate. After the liposome-forming dilution step, the detergent is removed by dialysis. The detergent-removal method has proven to be useful for the incorporation of membrane proteins in the bilayer. The preparation of cochleates differs somewhat from that of liposomes. They can be prepared by the slow addition of a solution of calcium chloride to PE–PS liposomes. This results in liposome aggregation and subsequent formation of stacked sheets with macroscopic dimensions. Direct dialysis of mixed detergent–phospholipid micelles against calcium chloride solution generates intermediate-sized cochleates, probably without the formation of a liposome intermediate. Small cochleates are formed when calcium chloride intercalates slowly with small liposomes, which can be achieved by dialysis of preformed liposomes against a solution of calcium chloride. Relatively few immunogenicity studies have been performed with cochleates, and the importance of particle size on in vivo performance is not clear. Large-scale manufacturing processes for liposomes are available, although often these are optimized for the incorporation of relatively small drugs that can withstand the presence of organic solvents or high mechanical stress [28]. 9.2.2 Mechanisms of Action of Liposomes

Classical liposomes consisting of neutral phospholipids are relatively ineffective at enhancing the immunogenicity of antigens. The phospholipids do not act as adjuvants, and it is probably merely the multimeric presentation form that causes higher re-

9.2 Liposomes and Related Structures

sponses as compared to antigen alone. Among the exceptions are the archaeosomes. In vivo, these liposomes enhance immune responses by recruitment and activation of APC [29]. The adjuvant effect of liposomes without additional adjuvant can be optimized by manipulating the composition. The beneficial effect of lipid-based carriers may occur during one or more of the three phases between administration and antigen presentation by APC: transport from the site of administration to the APC, binding to the APC, or uptake by the APC and processing via the appropriate intracellular route. Based on this, the known mechanisms of action of liposomal systems are (1) protection and stabilization of the antigen, including the mimicry (of pathogen surface) function, (2) enhanced binding to and uptake by APC by passive or active targeting, and (3) enhanced or controlled antigen processing after uptake. 9.2.2.1 Protection, Stabilization, and Mimicry It is tempting to speculate that, for membrane antigens, the bilayer provides an environment that promotes native conformation and stabilization. Some experimental evidence suggests that this is true. Purified, detergent-solubilized Meningococcal pore protein A does induce high antibody levels but these are not functional, i. e., in the presence of complement the antibodies do not exhibit bactericidal activity. Worse, when they are mixed with bactericidal antibodies, they inhibit the bactericidal action [30]. Integration of the pore protein into liposomes does not lead to an increase in the antigen-specific antibody titers but the functional, i. e., bactericidal, titers are as high as after immunization with ‘natural’ outer membrane vesicles. Similar findings were reported for recombinant PorA [31]. Because protein conformation is important for the induction of bactericidal responses, this suggests that the liposomal formulation restores, to a certain extent at least, the conformation of the antigen. The relevance of this ability of course depends on the importance of the conformation for the induction of a functional immune response. There are indications that, in general, liposomes are no better in their capacity to refold proteins than mixed micelles consisting of lipids and detergents [32]. Mixed micelles are, however, less suitable as antigen carriers, because their structure is much more dynamic and concentrationdependent, and therefore pharmaceutically less acceptable. Dilution of mixed micelles leads to the formation of liposomes or aggregates. Some liposome-like formulations, e. g., cochleates, are likely to exert their immune-stimulating effect by efficient protection of the antigen against pH shifts, proteolytic enzymes, and, perhaps most important, dilution. The protective, containment-providing properties of liposomes are of utmost importance when demanding immunization routes, such as the oral route, are used. Inclusion of soluble antigen in the aqueous interior or membrane association by electrostatic interaction provides protection, but the classical liposomes themselves are sensitive to bile salts and therefore less suitable for immunization via the oral route. The stability of liposomes after parenteral immunization is not known, but rapid disintegration at the injection site may not be beneficial for the immune response. At least this is suggested by the observation that many physically stable formulations, such as cochleates, polymerized liposomes, and archeaosomes, are effective antigen carriers, some even via the oral route [10, 20, 24].

181

182

9 Liposomes and ISCOMs

9.2.2.2 Targeting Liposomal structure can be designed in such a way that binding to APC is facilitated. The most straightforward method is to include cationic lipids. Most eukaryotic cells are negatively charged. As a consequence, positively charged liposomes bind to APC (and other cells). There is evidence that this also leads to better uptake and in vivo CTL and humoral responses. Anionic and neutral liposomes are less potent in this respect (reviewed in [33]). Arigita et al. [34] showed that, in vitro, cationic liposomes containing meningococcal PorA interact much more efficiently with APC than neutral liposomes. In vivo, this resulted in more responders but not in higher bactericidal antibody titers. This type of targeting is of course not very specific, since most cells are negatively charged. The results that have been obtained with cationic liposomes show that an improved response is achievable, but it is not always clear whether this is due to enhanced binding to APC or a better loading of the liposomes or to other (unknown) mechanisms. Cationic liposomes, for example, are an excellent vehicle for genetic vaccination [35]. DNA entrapment is a simple procedure, resulting in more immunogenic (humoral as well as cellular responses) vaccines compared to naked DNA, regardless the immunization route. It is speculated that the response is more efficient because of higher direct uptake of liposomes by APC instead of transfection of myocytes, the main mechanism after intramuscular immunization with naked plasmid DNA. Specific targeting to APC can be achieved by incorporation of ligands or antibodies for receptors that are more or less specific for APC. These include the mannose receptor [34, 36, 37], the Fc receptor [38], surface IgG, or MHC molecules like HLA-DR [33]. Sterically stabilized liposomes with anti-HLA-DR Fab fragments attached to PEG chains resulted in enhanced accumulation in the lymphoid organs [11]. Although the latter approach was developed for anti-viral drug delivery, it may have applications for antigen delivery as well. Targeting with mannosylated entities can lead to improved binding in vitro [34, 37], as well as improved humoral (number of responders) [34] and CTL responses in vivo [39, 40]. The length of the spacer is critical for cellular uptake, at least for macrophages [41]. A last type of targeting that should be mentioned here is the use of influenza virosomes, containing HA as a ligand. HA binds to sialic acid residues on the cell surface, allowing receptor-mediated endocytosis by APC. For oral delivery, targeting strategies to the M-cells of intestinal Peyer’s patches have been developed [42]. The ligand used was lectin incorporated in polymerized liposomes. Double to triple increases in liposome uptake were observed, depending on the type of lectin. 9.2.2.3 Enhanced or Controlled Processing Cytoplasmic delivery of antigen is necessary for the induction of class 1 restricted antigen presentation. Fusogenic liposomes are efficient inducers of CTL responses. Three approaches are being investigated to make liposomes fusogenic. (1) The above mentioned influenza virosomes are taken up by receptor-mediated endocytosis. Endosomal acidity causes conformational changes in the HA, which render the virosome fusogenic, delivering its contents to the cytoplasm. (2) Sendai virus virosomes

9.2 Liposomes and Related Structures

containing at least F-protein seem to deliver their contents to the cytoplasm via an endocytosis-independent pathway, i. e., plasma membrane fusion [43, 44]. (3) The use of liposomes containing pH-sensitive lipids. Bilayers containing unsaturated phospholipids and dioleoylphosphatidyl ethanolamine (DOPE) are not very stable. This is because DOPE has a cone shape, reducing the ‘fit’ in bilayers and promoting nonbilayer structures such as reversed micelles. Actual pH-induced destabilization is achieved by incorporation of acidic amphiphiles such as palmitoylhomocysteine or cholesterol hemisuccinate. Protonation, for instance in the endosomal compartment, results in fusion with the endosomal membrane. These liposomes can generate CTL responses in vitro and in vivo [45]. Despite the ability of pH-sensitive liposomes to deliver their contents efficiently to the cytoplasm in vitro, in vivo the superiority of these liposomes largely disappears. It may be that in vivo APC are present at different stages of maturation, meaning that pH-sensitivity contributes only marginally to the eventual immune response [46]. Liposomes that are not fusogenic are also able to deliver antigen to the MHC class 1 route. An example are the ‘Walter Reed liposomes’ containing monophosphoryl lipid A (see [45] for review). 9.2.3 Liposome Performance and Products It is difficult to rank antigen-delivery systems according to their potential. Comparative studies are seldom performed, and with good reason. Comparative studies are large and expensive and do not provide general answers. Probably, there are no general answers. The antigen–adjuvant–carrier combination is what determines immunogenicity. A carrier that works well with antigen A may give moderate results with antigen B. Then there is the problem of reproducible preparation of these vaccines. Also, apparently insignificant differences in the methods of preparation, the quality of the raw materials, the purity of the antigens, the immunization scheme, the dose, and the animal species and strain can make the difference between failure or success. Finally, a success-determining factor is the willingness of research institutes and industry to move to human trials as soon as preclinical data permit. Numerous studies have been published demonstrating the ability of liposomal formulations to protect experimental animals (see [47] for review), but further product development and human trials are extraordinarily expensive. Nevertheless, a few general conclusions about safety and potency of liposomal structures can be drawn. To start with, liposomes without additional adjuvant are able to improve the humoral and cellular immune response against incorporated antigens. Addition of adjuvants, targeting molecules, or certain lipids may lead to more potent products without compromising safety. Second, liposomes are very safe. We are not aware of human trials reporting serious side effects. Several liposomal vaccine formulations have been tested in the field (Table 9.2). What has to be taken into consideration, however, is that the results of trials with a negative outcome are often not published. Berna in Switzerland has two virosome-based products: Infexal V, a flu-virosome and Epaxal, a hepatitis A virosome vaccine (www.bernabiotech.com, March 2003). The so-called Walter Reed liposomes have been tested in several human studies. Reports of these studies show high immunogenicity and minimal adverse effects. It is thought that the Walter

183

184

9 Liposomes and ISCOMs

Reed formulations display these beneficial effects because of the presence of lipid A or MPL as well as Al(OH)3 as additional adjuvants. Al(OH)3 has the additional advantage that it neutralizes the potential residual endotoxin activity of the LPS derivatives [48]. A group of vesicular vaccines that is approaching market are meningococcal vesicle vaccines containing pore protein A. Several human trials have been performed by Norwegian, Cuban, and Dutch groups, demonstrating that these vaccines are safe and induce bactericidal antibody responses in humans [49–51]. A complicating issue is that the protective immune response is serosubtype-specific. For an acceptable coverage of such a vaccine, several serosubtypes have to be included in the vaccine. Hexavalent vaccines have been tested in human trials with good results. The vaccine was well tolerated by children and seroconversion rates were high [52].

9.3 ISCOMs 9.3.1 Composition, Characteristics, and Preparation Methods of ISCOMs 9.3.1.1 Composition Two basic types of ISCOM structures have been described. The first, termed the classical ISCOM vaccine [53], is formed by the combination of saponin, cholesterol, phospholipid, and amphipathic protein. The second, termed the ISCOMATRIX adjuvant, is essentially the same structure but without the protein [54]. Although these are the basic structures, there are several different types of formulations:

. . .

Classical ISCOM vaccines in which an amphipathic antigen is incorporated into the structure during formation. ISCOM vaccines in which the antigen is mixed with and associates with preformed ISCOMATRIX adjuvant. ISCOMATRIX vaccines in which the antigen is mixed with but does not associate with the ISCOMATRIX adjuvant.

The typical cage-like structures of ISCOM formulations (Figure 9.1D) are composed of saponin/cholesterol/phospholipid micelles that are held together by hydrophobic forces [55]. The components of the ISCOMATRIX adjuvant are saponin, cholesterol, and phospholipid. Saponins interact strongly with cholesterol and biological membranes containing cholesterol [8, 56]. The saponin used in ISCOM formulations is isolated from the bark of the Quillaja saponaria tree, is usually referred to as Quillaia saponin, and contains adjuvant activity [57]. Although the basic structure of the Quillaia saponin is known (Figure 9.2), many structural variations exist, making them a highly complex group of molecules [58, 59]. Early ISCOM vaccines used Quil A saponin. This is a commercially available, partly refined preparation that is still a very heterogeneous mixture of Quillaia saponins and is suitable for veterinary use only.

9.3 ISCOMs

Fig. 9.2 Important structural features of the Quillaia saponin. The core is the hydrophobic quillaic acid residue. Carbohydrates are attached to C3 and C28.

Further studies of the crude Quillaia saponin identified three groups of components, QH-A, QH-B, and QH-C, of particular interest for ISCOM formulation [60]. Criteria were low toxicity, strong adjuvant activity, and ability to form ISCOM structure. More recent characterization of these components has led to the development of ISCOPREP saponin by CSL Ltd. ISCOPREP saponin is a purified saponin fraction prepared by a proprietary process that is robust and highly reproducible. ISCOPREP saponin is well defined and has been extensively characterized. Product-development programs now focus on ISCOPREP saponin, which has been used in several human studies and is an acceptable component of human vaccines. Cholesterol is a second key component of the ISCOM formulation and is available commercially from many suppliers. The source of the cholesterol is not critical, and both natural and synthetic types are available. The importance of lipid in ISCOM formulations has been shown [61], and several lipids have been used. Synthetic dipalmitoylphosphatidyl choline (DPPC) has been used in the formulations tested to date in humans. 9.3.1.2 Characteristics of ISCOMs ISCOM formulations have been defined as an antigen-delivery system with built-in adjuvant providing an optimal immune response [53]. The induction of particular immune responses by ISCOM formulations is a key characteristic of the adjuvant system

185

186

9 Liposomes and ISCOMs

and is discussed in more detail in section 9.3.2. The ISCOMATRIX adjuvant has been extensively characterized and forms the basis of this discussion on characteristics. The ISCOMATRIX adjuvant morphology has been studied by a variety of approaches. Transmission electron microscopy (TEM) showed the ISCOMATRIX adjuvant to be composed of subunit rings in typically cage-like spherical structures of approximately 40 nm [54, 62]. Recent work using cryopreservation electron microscopy, atomic force microscopy, as well as a number of particle-sizing techniques confirms the TEM observations (unpublished). The hemolytic activity of saponin due to its action on biological membranes is well recognized. The hemolytic activity of the purified Quillaia saponin, QS21, has been linked with significant local reactions observed in humans with this adjuvant [63]. One of the characteristics of the ISCOMATRIX adjuvant is the substantial reduction (>100 fold) in the hemolytic activity of the saponin once it is incorporated into the structure [60]. Little to no hemolytic activity is detected with the ISCOMATRIX adjuvant. Other important characteristics of the ISCOM adjuvant system include the simplicity and scalability of the manufacturing process for ISCOMATRIX adjuvant and the stability of both the ISCOMATRIX adjuvant and ISCOM vaccines. Stability studies are continuing, but to date, both the physicochemical and biological properties of the ISCOMATRIX adjuvant have remained stable for over 4 years when stored at 2–8 °C at pH 7.2. ISCOMATRIX adjuvant also remained stable at 37 °C for up to 1 y and can be frozen, freeze-dried, and even spray-dried with no deleterious effects [64]. 9.3.1.3 Preparation of ISCOMs ISCOM preparation methods are based on detergent-removal techniques. Saponin, cholesterol, and phospholipid (with or without amphipathic antigen) are mixed in the presence of detergent. The ISCOM structure forms spontaneously as the detergent is removed [53]. Classical ISCOM vaccines were originally prepared by the centrifugation method [53] that was developed with viral membrane proteins as antigens. A dialysis procedure was also developed, which enabled the use of a broader range of proteins and is now most commonly used [65, 66]. More recently, ultrafiltration techniques have been used, enabling the process to be performed on an industrial scale. Traditionally, amphipathic antigens have been incorporated into ISCOM vaccines via hydrophobic regions found naturally in the antigen. This restriction limited ISCOM vaccines to use with predominantly membrane-associated antigens, and so a number of techniques have been developed to increase the range of antigens suitable for use in ISCOM vaccines. Exposure of hydrophobic regions, by methods such as low pH treatment, and chemical conjugation of lipids to proteins enabled some nonmembrane antigens to be incorporated into classical ISCOM vaccines during formation [67]. More recently, methods to produce recombinant fusion proteins with a hydrophobic tag have been developed; these potentially enable an even broader range of antigens to be incorporated into the ISCOM structure [68]. Several strategies have been developed to form ISCOM vaccines by association of antigens with the preformed ISCOMATRIX adjuvant. These include chemically cou-

9.3 ISCOMs

Fig. 9.3 Flow chart showing the ISCOMATRIX adjuvant manufacturing process. Mega10 is a nonionic detergent: N-(D-gluco-2,3,4,5,6-pentahydroxy hexyl)-N-methyldecanamide.

pling antigens to activated lipids in the ISCOMATRIX structure and, more recently, techniques in which simple admixing of the antigen and the ISCOMATRIX adjuvant results in association. Electrostatic interactions, which take advantage of the negative charge of the ISCOMATRIX adjuvant, allow association of antigens containing positively charged regions. Electrostatically driven association can be improved by increasing the negative charge of the ISCOMATRIX adjuvant or, alternatively, the positive charge of the antigen [69]. Other novel methods of achieving association include the chelating ISCOMATRIX adjuvant, in which a metal-chelating group is incorporated into the structure, which can then bind antigens containing a hexahistidine tag (Malliaros, J. et al., unpublished). The strategies described above should enable the development of procedures for formulating virtually any antigen as an ISCOM vaccine. Due to the ease of manufacture, vaccine development programs now focus on the use of preformed ISCOMATRIX adjuvant to formulate either ISCOM or ISCOMATRIX vaccines. Procedures for manufacture of the ISCOMATRIX adjuvant have been developed at industrial scale (Figure 9.3). This process is GMP-compliant and has been optimized to produce a robust procedure that is well controlled and highly reproducible. Batch sizes of hundreds of liters (approximately 10 million vaccine doses) can be manufactured by this process. 9.3.2 Immunology and Mode of Action of ISCOM Vaccines 9.3.2.1 Immune Responses to ISCOM Vaccines Parenteral Immunization of Mice It is now nearly 20 years since ISCOM vaccines were first described [53], and over that period ISCOM vaccines have demonstrated protective immune responses in

187

188

9 Liposomes and ISCOMs

many species [70]. In the mouse, ISCOM vaccines induce strong antibody and cellular immune responses. Please see the review of Sjölander et al [70] for a detailed summary of mouse immune responses to ISCOM vaccines. ISCOM vaccines are effective at low antigen and adjuvant doses. They also induce long-lived antibody and cellular responses [59, 67, 71]. ISCOM vaccines can induce CTL against many antigens, both naturally occurring immunogens and also recombinant proteins [72–75]. Parenteral Immunization of Nonhuman Primates Sjölander et al. [70] also summarized the nonhuman primate responses to ISCOM vaccines; a variety of antigens including influenza, HIV, and SIV were used. In the monkey models, ISCOM vaccines induced T-helper and CTL responses as well as antibody responses. Experiments in Rhesus macaques with ISCOM vaccines containing the hepatitis C core protein were recently shown to prime strongly for CD4+ and CD8+ T-cell responses [75]. The immune response to E1E2 was also improved when the core ISCOM vaccine was mixed with E1E2 protein. More recently, experiments in guinea pigs, sheep, and baboons have shown the benefits of ISCOM vaccines in terms of their dose-sparing capability. We have shown in guinea pigs that the HIV antigen MNrgp120, combined with ISCOMATRIX adjuvant, gave strong immune responses with 10–100 fold less antigen than was required with aluminum hydroxide adjuvant (Boyle, J. et al., unpublished). In sheep [76] and nonhuman primates (baboons) given influenza vaccine antigens, serum HAI titers were equal or better with an ISCOMATRIX vaccine that contained 1/10 the antigen dose compared to unadjuvanted vaccine (Figure 9.4).

Fig. 9.4 Baboons were vaccinated twice with inactivated vaccine containing three virus strains. The serum responses to the B strain are shown. Similar responses were obtained for the HINI and H3N2 strains. The time between doses was 3 weeks; animals were bled 3 and 4 weeks after the first dose.

9.3 ISCOMs

Mucosal Immunization The use of ISCOM vaccines for nasal vaccination was recently reviewed by Hu et al. [77]. Most of this work has been performed in mouse models where, almost always, good protective immune responses have been obtained after intranasal vaccination. In mice, influenza ISCOM vaccines induce CTL as well as strong mucosal and systemic immune responses when delivered intranasally [78]. These responses were equivalent to or better than those obtained with the strong mucosal adjuvant LT (E. coli heat-labile enterotoxin). Responses at distant mucosal sites after intranasal delivery with ISCOM vaccines have also been observed [76, 78]. Responses in other species have been obtained after intranasal delivery, although they were not as good as in the mouse. This may be due to inefficient nasal delivery of vaccine to immune effector sites in the species concerned. Effective Immunization with ISCOM Vaccines in the Presence of Preexisting Antibody Vaccination strategies that stimulate protective responses even in the presence of preexisting immune responses to a particular immunogen would be valuable against a range of human and veterinary diseases. Many diseases are capable of eliciting antibody responses that are unable to eliminate the disease, e. g., various cancers, hepatitis, HIV, and many others. A vaccine adjuvant capable of stimulating immune responses in the presence of these antibodies is critical if therapeutic intervention is to be considered (see also section 9.3.3.2). ISCOM vaccines have shown potential at overcoming the vaccine-neutralizing effects of passively acquired antibody in neonatal mice, horses, and macaques [79–81]. In nonhuman primates and horses, active immunity was induced in the presence of maternal antibody against measles virus and equine herpes 2 virus, respectively, with ISCOM vaccines, but not with conventional killed vaccines. Furthermore, ISCOM vaccines can induce Th1 immune responses in neonates [79]. Conventional vaccines, on the other hand, elicit mainly Th2 responses in this age group. 9.3.2.2 Mode of Action of ISCOM Vaccines As described above, ISCOM vaccines are potent inducers of antibody as well as CD4+ and CD8+ T cell responses. By necessity, such a broad immune response as this is dependent on the induction of multiple innate and adaptive immune mediators and cellular processes and on the interplay between these elements. The details of this complex process are yet to be fully elucidated. However, with the available information regarding the immune responses induced by ISCOM vaccines, together with a greater understanding of immunological processes such as antigen processing, a clearer understanding is emerging. When mice are immunized with ISCOM vaccines, many of the known cytokines are up-regulated as a result. Up-regulation of proinflammatory IL-1 was the first cytokine response observed to be related to the adjuvant activity of ISCOM vaccines [82]. Since then, many cytokines have been shown to be stimulated by the adjuvant action of ISCOM vaccines; these include IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IFNg [70, 71]. This broad range of cytokines is consistent with the mixed Th1/Th2 responses observed with ISCOM vaccines.

189

190

9 Liposomes and ISCOMs

The depot effect, by which antigen is trapped at the site of administration in order to attract antigen-presenting cells (APCs), is considered to be an important function of adjuvants [83]. However, unlike aluminum- and oil-based adjuvants, ISCOM vaccines are likely to be cleared rapidly from the site of injection to the draining lymph nodes, although there is some evidence of dose site effects such as cellular infiltration. Recent studies using a sheep afferent lymph node cannulation model have shown that ISCOMATRIX adjuvant alone, in the absence of antigen, results in effects at the level of the draining lymph node such as an increase in lymphocyte recruitment and the expression of proinflammatory cytokines (IL-1, IL-6, IL-8, and IFN-g) [84]. Furthermore, ovalbumin ISCOM vaccine injected intraperitoneally in mice recruited a range of inflammatory cells (macrophages, dendritic cells, and lymphocytes), resulting in the production of a variety of immune mediators including IL-1, IL-6, IL-12, and IFNg [85]. The production of inflammatory mediators by immune effector cells is now recognized as being critical for the induction of primary immune responses. Cellular recruitment and activation are greatly reduced in IL-12 knockout mice given ISCOM vaccines, suggesting that IL-12 is important for ISCOM adjuvant activity. Together, these observations suggest that ISCOM vaccines activate innate immune responses, with IL-12 playing a key role. IL-12 is a macrophage-produced cytokine, which regulates the expression of IFN-g and is required for the differentiation of CTL. Clearly, the saponin component is critical for the immunomodulatory properties of ISCOM vaccines. Saponin per se has adjuvant potential; however, optimal CTL induction is achieved when it is formulated as an ISCOM vaccine (Lenarczyk, A., et al., unpublished). The most likely explanation for this is that ISCOM vaccines, because of their particulate nature, are targeted to and more efficiently taken up by cells of the immune system such as APCs (see also section 9.2.2). Consistent with this, ISCOM vaccines are efficiently taken up in vitro by dendritic cells. Furthermore, the vaccine antigens are processed and presented to CD8+ T cells (Maraskovsky et al., unpublished). Soltysik et al. [86] have shown that the full adjuvant activity of Quillaia saponin-based adjuvants depends on the aldehyde group and the aliphatic sidechain of the saponin, suggesting that cellular uptake may be mediated by the interaction of these moieties with the cell membrane. To date, there is little evidence to suggest that ISCOM formulations bind to specific receptors, although this should not be discounted and, unlike other activators of innate immune responses such as CpGs, LPS, and DNA, they do not appear to activate Toll-like receptors (TLRs) (unpublished). It therefore remains an open question as to how ISCOM vaccines cause cellular activation and up-regulate cytokine expression. After cellular uptake, ISCOM structures were found to be approximately equally distributed between the cytosol and intracellular compartments [72], which in part explains their capacity to access both the endosomal and proteosomal compartments for MHC class I and II antigen-processing, respectively. Access to the class I pathway is clearly critical to the ability of ISCOM vaccines to induce strong CTL responses. Although not completely understood, it is thought that the membrane-disrupting properties of the saponin component of the ISCOM structure might aid endosomal escape, thereby releasing antigen to the cytosol. ISCOM vaccines also induce up-regulation of MHC class II expression [72].

9.3 ISCOMs

9.3.3 Performance and Products 9.3.3.1 Protection Afforded by ISCOM Vaccines in Animal Models As described in the preceding section, ISCOM vaccines are potent inducers of both humoral and cellular immunity. Consistent with this, ISCOM vaccines elicit protective immunity in a variety of animal species against a range of pathogens (summarized in Table 9.3 and reviewed by Sjolander et al. [70]). Of particular relevance to human vaccine development, ISCOM vaccines formulated with HIV-1 gp120, HIV-1 multicomponent antigens (gp120, p24,V2 and V3 peptides), SIV antigens [87, 88], and EBV gp340 [89] have been shown to protect monkeys against viral challenge with these pathogens. Another key feature of ISCOM vaccines is the longevity of response. Polakos et al. [75] have shown that Rhesus macaque monkeys receiving an HCV core ISCOM vaccine produced strong HCV core-specific CTL responses, which were detected up to 12 months post-vaccination (the last time point tested). In contrast, CTL responses had waned to baseline levels in animals vaccinated with an HCV core retroviralbased vaccine. Similarly, protection against clinical disease, and in some cases infection, 15 months after vaccination was observed in horses receiving an equine influenza ISCOM vaccine [90]. Two ISCOM vaccines are currently registered for veterinary applications. The first is an equine influenza ISCOM vaccine – to date, more than 1 million doses have been administered with no adverse effects reported. The second registered ISCOM vaccine, also for horses and referred to as EquityTM, consists of a peptide analogue of gonadotropin-releasing factor mixed with ISCOMATRIX adjuvant. Equity induces a state of immune anestrus, thus controlling estrusrelated behavior in mares and fillies. 9.3.3.2 Human Clinical Trials with ISCOMs To date, a range of ISCOMATRIX and ISCOM vaccines have been tested in humans. These include vaccines containing influenza viral proteins, the purified recombinant Tab. 9.3 ISCOM vaccines: protective immune responses in animals. Species

Infectious agent

Rhesus macaques Cottontop tamarins Horse Guinea pig Cat Rabbit

SIV EBV (gp340) equine influenza virus RSV FIV HIV, influenza, Eimeira falciformis, Plasmodium falciparum BVDV, Toxoplasma gondii pseudorabies virus Adenovirus, Boophilus microplus avian influenza virus, Salmonella

Sheep Pig Cow Turkey

191

192

9 Liposomes and ISCOMs Tab. 9.4 Human data with ISCOM vaccines. Antigen

Immune response (% responders) 1) 2) CD4 CTL Antibody

Influenza NY-ESO-1 HPV E6E7

> 80 100 100

1) 2) 3) NT

NT 55 92

1

25–80 30 3 42 3

Comment

Rapid antibody responses [92, 93] To be published Evidence of viral load reduction in cervical cells

Determined using DTH or IFN-g expression Determined using 51Cr –release assay Determined using ELISPOT or tetramer assays Not tested

antigen HPV E6E7 fusion protein, and the purified recombinant antigen NY-ESO-1 (human cancer testis antigen, which is expressed in a variety of tumors [91]) (Table 9.4). In a randomized double-blind controlled clinical study, both ISCOM- and ISCOMATRIX-based influenza vaccines induced higher antibody responses within the first week of vaccination compared to conventional influenza vaccines. This accelerated development of antibody responses could be advantageous in influenza epidemics or any other setting where a rapid response may be of particular advantage in reducing morbidity or mortality. Furthermore, both the ISCOM- and ISCOMATRIX-based influenza vaccines induced virus-specific CTL responses in 25 %– 80 % of recipients after a single vaccination, compared to 5 % of those receiving a standard influenza vaccine [92, 93]. In mice, influenza-specific CTLs can contribute to protective immunity, even against antigenic-drift variants of influenza A viruses [94]. Whether this also occurs in humans remains to be determined. Double-blind placebo-controlled phase I studies of safety and immunogenicity were also recently completed for two cancer/neoplasia vaccines. In the first, women with cervical dysplasia (CIN 1–3) due to human papilloma virus (HPV) were vaccinated with varying doses of E. coli-expressed recombinant HPV16 E6E7 fusion protein (20, 60 and 200 mg) combined with 120 mg of ISCOMATRIX adjuvant. The vaccine was well tolerated, and vaccinated subjects mounted strong HPV16 E6E7-specific humoral and cellular immune responses (Frazer, I. et al., unpublished). E6- and E7-specific antibody (100 %), CD4 (92 %), and CTL responses (42 %) were detected in vaccine-treated subjects. Furthermore, there was evidence of reduced viral load in vaccinated subjects. A similar phase I study was also recently completed with an NY-ESO-1 ISCOM vaccine in patients with NY-ESO-1 positive cancers and minimal residual disease (Cebon et al., unpublished). The NY-ESO-1 ISCOM vaccine was well tolerated and induced strong humoral and cellular vaccine-specific immunity. Antibody responses were observed in 100 % of the vaccine recipients, and CD4+ and CD8+ T cell responses in 69 % and 38 %, respectively. Importantly, CD8+ T cell responses were observed in individuals with and without preexisting antibodies to NY-ESO-1, suggesting that the ISCOM vaccine was effective even in the presence of preexisting antibo-

9.4 Perspectives

dies to the vaccine components. This observation is consistent with the results of studies performed with mice (Lenarczyk, A. et al., unpublished). Currently, a popular approach to CTL induction is to prime with a DNA vaccine and boost with a live viral vector. ISCOM vaccines obviate the need for separate prime and boost vaccines, because no neutralizing antibody response is induced to the ISCOMATRIX adjuvant per se. As a result, ISCOM vaccines can be used for repeat dosing. In addition to the obvious manufacturing, registration, and cost advantages of using the same vaccine for all doses, ISCOM vaccines have additional safety benefits over DNA and live vector approaches, such as lack of integration potential. Together, the results of these trials indicate that ISCOM vaccines are potent inducers of both humoral and cellular immunity in humans and therefore suitable for a wide range of applications that require the induction of an integrated immune response, e. g., cancer and chronic infectious diseases. The issue of reactogenicity with saponin-based adjuvants has been raised as a potential impediment to their widespread use in human and veterinary vaccines. This suggestion was largely based on mouse studies involving the administration of large adjuvant doses. However, in all other species tested, including chickens, cats, monkeys, dogs, sheep, cattle, and horses, little reactogenicity has been observed with parenterally administered ISCOM vaccines [70]. GLP toxicity studies have been performed on ISCOPREP saponin, ISCOMATRIX adjuvant, and both ISCOM and ISCOMATRIX vaccines. In all instances, the formulations were well tolerated, with little evidence of reactogenicity after repeated dosing. To date, ISCOM vaccines have been administered to approximately 1000 people with no serious vaccine-related adverse events. The most common adverse event is pain or ache at the injection site, which is mild-to-moderate and transient (2–3 days), resolving without the need for medical intervention.

9.4 Perspectives

Liposomal vaccines have been around for about 30 years. Classical liposomes as antigen carriers have been studied in depth. Simultaneously, a number of liposome variants have been developed, some with evident immune-stimulating properties and an attractive safety profile. Some are now available as registered products or in advanced stages of clinical testing. Combined with the use of safe adjuvants, increased knowledge of immunology, and improved, scalable manufacturing methods, more products should reach the market within 10 years. From the many studies with ISCOM vaccines in animal models and in human clinical trials, we can conclude that ISCOM vaccines are safe and immunogenic. The key features of ISCOM vaccines for humoral responses are the magnitude, speed, and longevity of responses and the capacity for dose sparing of antigen. ISCOM vaccines are ideal for applications that require a rapid immune response, such as pandemic influenza, or in situations where antigen is limited due to the high cost of manufacture. The key features of ISCOM vaccines for cellular immune responses

193

194

9 Liposomes and ISCOMs

are their ability to induce long-lived T helper and CTL responses without the need for different formulations for prime and boost. These features of ISCOM vaccines support their use in immunotherapeutic vaccines directed at chronic infectious agents and diseases such as hepatitis B, hepatitis C, HIV, malaria, HSV-1 and 2, and H. pylori and also for use in cancer immunotherapy.

References 1. A.D. Bangham, M.M. Standish, J.D. Watkins, J. Mol. Biol. 1965, 13, 238– 251. 2. M.C. Horzinek, Progr. Med. Virol. 1973, 16, 109–156. 3. A.G. Allison, G. Gregoriadis, Nature 1974, 252, 252. 4. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, A. Osterhaus, Nature 1984, 308, 457–460. 5. G.F.A. Kersten, D.J.A. Crommelin, Biochim. Biophys. Acta Rev. Biomembranes 1995, 1241, 117–138. 6. I.G. Barr, G.F. Mitchell, Immunol. Cell Biol. 1996, 74, 8–25. 7. I.G. Barr, A. Sjolander, J.C. Cox, Adv. Drug Del. Rev. 1998, 32, 247–271. 8. G.F.A. Kersten, D.J.A. Crommelin, Vaccine 2003, 21, 915–920. 9. J.M. Muderhwa, G.R. Matyas, L.E. Spitler, C.R. Alving, J. Pharm. Sci. 1999, 88, 1332–1339. 10. H.M. Chen,V. Torchilin, R. Langer, J. Contr. Rel. 1996, 42, 263–272. 11. J. Bestman-Smith, P. Gourde, A. Desormeaux, M.J. Tremblay, M.G. Bergeron, Biochim. Biophys. Acta 2000, 1468, 61–74. 12. A. Paul, G. Cevc, B.K. Bachhawat, Eur. J. Immunol. 1995, 25, 3521–3524. 13. B.W. Barry. Eur. J. Pharm. Sci 2001, 14, 101–114. 14. M. Conacher, J. Alexander, J.M. Brewer in: Synthetic Surfactant Vesicles Uchegbu IF, ed., 2000, 185–205, International Publishers Distributors#Q1#. 15. J.M. Brewer, J. Alexander,Vaccine 1994, 12, 613–619. 16. R.K. Gupta, C.L. Varanelli, P. Griffin, D.F. Wallach, G.R. Siber,Vaccine 1996, 14, 219–225. 17. M. Conacher, J. Alexander, J.M. Brewer,Vaccine 2001, 19, 2965–2974.

18. G.H. Lowell, L.F. Smith, R.C. Seid, W.D. Zollinger, J. Exp. Med. 1988, 167, 658–663. 19. G.H. Lowell in: New Generation Vaccines. Second edition, M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon, eds., 1997, 193–206, Marcel Dekker, New York. 20. G.B. Patel, G.D. Sprott, Crit. Rev. Biotechnol. 1999, 19, 317–357. 21. J.W. Conlan, L. Krishnan, G.E. Willick, G.B. Patel, G.D. Sprott,Vaccine 2001, 19, 3509–3517. 22. L. Krishnan, C.J. Dicaire, G.B. Patel, G.D. Sprott, Infect. Immun. 2000, 68, 54–63. 23. L. Zarif, J. Control. Rel. 2002, 81, 7–23. 24. S. Gould-Fogerite, M.T. Kheiri, F. Zhang, et al., Adv. Drug Del. Rev. 1998, 32, 273–287. 25. J. Brunner, P. Skrabal, H. Hauser, Biochim. Biophys. Acta 1976, 455, 322– 331. 26. D.D. Lasic, Biochim. Biophys. Acta 1982, 692, 501–502. 27. W. Jiskoot,T. Teerlink, E.C. Beuvery, D.J. Crommelin, Pharm. Weekbl. Sci. 1986, 8, 259–265. 28. D.D. Lasic,Trends Biotechnol. 1998, 16, 307–321. 29. L. Krishnan, S. Sad, G.B. Patel, G.D. Sprott. J. Immunol. 2001, 166, 1885– 1893. 30. C. Arigita, G.F.A. Kersten,T. Hazendonk,W.E. Hennink, D.J.A. Crommelin,W. Jiskoot,Vaccine 2003, 21, 950– 960. 31. I. Idanpaan-Heikkila, S. Muttilainen, E. Wahlstrom, et al.,Vaccine 1995, 13, 1501–1508. 32. G. Zardeneta, P.M. Horowitz, Anal. Biochem. 1994, 223, 1–6.

References 33. G. Chikh, M.P. Schutze-Redelmeier, Biosci. Rep. 2002, 22, 339–353. 34. C. Arigita, Towards an improved Neisseria meningitidis type B vaccine: vesicular PorA formulations, 2003,Thesis, University of Utrecht. 35. G. Gregoriadis, A. Bacon,W. Caparros-Wanderley, B. Mccormack,Vaccine 2002, 20 Suppl. 5, B1-B9. 36. N. Garcon, G. Gregoriadis, M.Taylor, J. Summerfield. Immunology 1988, 64, 743–745. 37. M.J. Copland, M.A. Baird,T. Rades, J.L. McKenzie, B. Becker, F. Reck, P.C. Tyler, N.M. Davies,Vaccine 2003, 21, 883–890. 38. P. Machy, K. Serre, L. Leserman, Eur. J. Immunol. 2000, 30, 848–857. 39. M. Fukasawa,Y. Shimizu, K. Shikata, M. Nakata, R. Sakakibara, N.Yamamoto, M. Hatanaka,T. Mizuochi, FEBS Lett. 1998, 441, 353–356. 40. S. Toda, N. Ishii, E. Okada, K.I. Kusakabe, H. Arai, K. Hamajima, I. Gorai, K. Nishioka, K. Okuda, Immunology 1997, 92, 111–117. 41. A. Engel, S.K. Chatterjee, A. al Arifi, D. Riemann, J. Langner, P. Nuhn, Pharm. Res. 2003, 20, 51–57. 42. H. Chen,V. Torchilin, R. Langer, Pharm. Res. 1996, 13, 1378–1383. 43. J. Kunisawa, S. Nakagawa,T. Mayumi, Adv. Drug Deliv. Rev. 2001, 52, 177–186. 44. L. Bungener, K. Serre, L. Bijl, L. Leserman, J. Wilschut,T. Daemen, P. Machy,Vaccine 2002, 20, 2287–2295. 45. M. Rao, C.R. Alving, Adv. Drug Deliv. Rev. 2000, 41, 171–188. 46. L. Bungener, A. Huckriede, J. Wilschut,T. Daemen, Biosci. Rep. 2002, 22, 323–338. 47. C.R. Alving in: New Generation Vaccines. Second edition, M.L. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon, eds., 1997, 207–13. Marcel Dekker, New York. 48. C.R. Alving,V. Koulchin, G.M. Glenn, M. Rao, Immunol. Rev. 1995, 145, 5–31. 49. G. Bjune, E.A. Hoiby, J.K. Gronnesby et al., Lancet 1991, 338, 1093–1096. 50. L.G. Milagres, M.C.A. Gorla, C.T. Sacchi, M.M. Rodrigues, Infect. Immun. 1998, 66, 4755–4761. 51. E.D. de Kleijn, R. de Groot, A.B. Lafe-

52. 53.

54.

55.

56. 57. 58. 59. 60. 61. 62.

63. 64.

65. 66.

67.

68.

69. 70.

ber et al., J. Infec. Dis. 2001, 184, 98– 102. E.D. de Kleijn, R. de Groot, J. Labadie et al.,Vaccine 2000, 18, 1456–1466. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, A. Osterhaus, Nature 1984, 308, 457–460. G.F. Rimmelzwaan, A.D.M.E. Osterhaus, in: Vaccine Design,The Subunit and Adjuvant Approach, M.F. Powell, M.J. Newman, eds., 1995, 543–558, Plenum, New York, London. M. Ozel, S. Hoglund, H.R. Gelderblom, B. Morein, J. Ultrastr. Molec. Str. Res. 1989, 102, 240–248. A.M. Glauert, J.T. Dingle, J.A. Lucy, Nature 1962, 196, 953–955. K. Dalsgaard, Dan. Tidsskr. Farm. 1970, 44, 327–331. R. Higuchi,Y. Tokimitsu,T. Komori, Phytochemistry 1988, 27, 1165–1168. I.G. Barr, A. Sjolander, J.C. Cox, Adv. Drug Del. Rev. 1998, 32, 247–271. B. Rönnberg, M. Fekadu, B. Morein, Vaccine 1995, 13, 1375–1382. K. Lövgren, B. Morein,Biotechnol. Appl. Biochem. 1988, 10, 161–172. G.F.A. Kersten, A. Spiekstra, E.C. Beuvery, D.J.A. Crommelin, Biochim. Biophys. Acta 1991, 1062, 165–171. D.C. Waite, E.W. Jacobson, F.A. Ennis, et al.,Vaccine 2001, 19, 3957–3967. L. Macdonald, M. Kleinig, J. Cox, Proc. Intl. Symp. Control. Rel. Bioact. Mater. 1997, 24, 231–232. I. Claassen, A. Osterhaus, Res. Immunol. 1992, 143, 531–541. S. Hoglund, K. Dalsgaard, K. Lövgren, B. Sundquist, A. Osterhaus, B. Morein, Subcell. Biochem. 1989, 15, 39– 68. B. Morein, K. Lövgren, B. Rönnberg, A. Sjölander, M. Villacrés-Eriksson, Clin. Immunother. 1995, 3, 461–475. C. Andersson, L. Sandberg, H. Wernerus, M. Johansson, K. LovgrenBengtsson, J. Immunol. Meth. 2000, 238, 181–193. T.T.T. Le, D. Drane, J. Malliaros, et al.,Vaccine 2001, 19, 4669–4675. A. Sjölander, D. Drane, E. Maraskovsky et al.,Vaccine 2001, 19, 2661– 2665.

195

196

9 Liposomes and ISCOMs 71. A. Sjölander, J.C. Cox, I.G. Barr, J. Leukocyte Biol. 1998, 64, 713–723. 72. M.C. Villacres, S. Behboudi,T. Nikkila, K. Lovgren-Bengtsson, B. Morein, Cell. Immunol. 1998, 185, 30–38. 73. A.D. Wilson, K. Lö vgren-Bengtsson, M. Villacres-Ericsson, B. Morein, A.J. Morgan,Vaccine 1999, 17, 1282– 1290. 74. J.T.M. Voeten, G.F. Rimmelzwaan, N.J. Nieuwkoop, K. Lovgren-Bengtsson, A.D.M.E. Osterhaus,Vaccine 2001, 19, 514–522. 75. N.K. Polakos, D. Drane, J. Cox et al., J. Immunol. 2001, 166, 3589–3598. 76. A. Coulter, R. Harris, R. Davis et al., Vaccine 2003, 21, 946–949. 77. K.-F. Hu, K. Lovgren-Bengtsson, B. Morein. Adv. Drug Del. Rev. 2001, 51, 149–159. 78. S. Sjolander, D. Drane, R. Davis, L. Beezum, M. Pearse, J. Cox,Vaccine 2001, 19, 4072–4080. 79. B. Morein, K.L. Bengtsson, Immunol. Cell Biol. 1998, 76, 295–299. 80. A. Osterhaus, G. van Amerongen, R. van Binnendijk,Vaccine 1998, 16, 1479–1481. 81. B. Morein, K. Lövgren-Bengtsson, J. Cox in: Concepts in Vaccine Development, S.H.E. Kaufmann, ed., 1996, 243– 263,Walter de Gruyter, Berlin, New York. 82. S. Behboudi, B. Morein, M.Villacres-Eriksson, Scand. J. Immunol. 1999, 50, 371–377. 83. J.C. Cox, A.R. Coulter,Vaccine 1997, 15, 248–256. 84. R.G. Windon, P.J. Chaplin, L. Beezum et al.,Vaccine 2001, 19, 572–578. 85. R.E. Smith, A.M. Donachie, D. Grdic, N. Lycke, A.M. Mowat, J. Immunol. 1999, 162, 5536–5546. 86. S. Soltysik, J.-Y. Wu, J. Recchia et al., Vaccine 1995, 13, 1403–1410. 87. A. Osterhaus, P. de Vries, B. Morein, L. Akerblom, J. Heeney, AIDS Res. Hum. Retroviruses 1992, 8, 1507–1510. 88. P. de Vries, J.L. Heeney, J. Boes et al., Vaccine 1994, 12, 1443–1452. 89. A.J. Morgan, S. Finerty, K. Lovgren, F.T. Scullion, B. Morein, J. Gen. Virol. 1988, 69, 2093–2096. 90. J.A. Mumford, D. Jessett, U. Dunleavy et al.,Vaccine 1994, 12, 857–863.

91. T.-T. Chen, M.J. Scanlan, U. Sahin et al., Proc. Natl. Acad. Sci. USA 1997, 94, 1914–1918. 92. F.A. Ennis, J. Cruz, J. Jameson, M. Klein, D. Burt, J. Thipphawong, Virology 1999, 259, 256–261. 93. G.F. Rimmelzwaan, N. Nieuwkoop, A. Brandenburg et al.,Vaccine 2001, 19, 1180–1187. 94. S. Sambhara, A. Kurichh, R. Miranda et al., Cell. Immunol. 2001, 211, 143–153. 95. L.F. Fries, D.M. Gordon, R.L. Richards et al., Proc. Natl. Acad. Sci. USA 1992, 89, 358–362. 96. L.F. Fries, A.D. Montemarano, C.P. Mallett, D.N. Taylor,T.L. Hale, G.H. Lowell, Infect. Immun. 2001, 69, 4545– 4553. 97. M. Kaji,Y. Kaji, M. Kaji, K. Ohkuma,T. Honda,T. Oka, M. Sakoh, S. Nakamura, K. Kurachi, M. Sentoku, Vaccine 1992, 10, 663–667. 98. M. Just, R. Berger, H. Drechsler, S. Brantschen, R. Gluck,Vaccine 1992, 10, 737–739. 99. Y. Poovorawan, A. Theamboonlers, S. Chumdermpadetsuk, R. Gluck, S.J. Cryz,Vaccine 1995, 13, 891–893. 100. L. Loutan, P. Bovier, B. Althaus, R. Gluck, Lancet 1994, 343, 322–324. 101. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, S.J. Cryz, J. Clin. Invest. 1992, 90, 2491– 2495. 102. R. Gluck, R. Mischler, B. Finkel, J.U. Que, B. Scarpa, S.J. Cryz, Lancet 1994, 344, 160–163. 103. C. Herzog, I.C. Metcalfe, U.B. Schaad,Vaccine 2002, 20 Suppl 5, B24-B28. 104. P. Marchisio, R. Cavagna, B. Maspes et al., Clin. Infect. Dis. 2002, 35, 168–174. 105. R. Gluck, R Mischler, P. Durrer et al., J. Infect. Dis. 2000, 181, 1129–1132. 106. U. Gluck, J.O. Gebbers, R. Gluck, J. Virol. 1999, 73, 7780–7786. 107. E. de Kleijn, L. van Eijndhoven, C. Vermont et al.,Vaccine 2001, 20, 352–258. 108. E.D. de Kleijn, R. de Groot, A.B. Lafeber et al.,Vaccine 2000, 19, 1141–1148. 109. E.D. de Kleijn, R. de Groot, A.B. Lafeber et al., J. Infect. Dis. 2001, 184, 98– 102.

197

10 Virosomal Technology and Mucosal Adjuvants Jean-François Viret, Christian Moser, Faiza Rharbaoui, Ian C. Metcalfe, and Carlos A. Guzmán

10.1 Overview

Immune responses are remarkably versatile adaptive processes, in which an organism activates specifically reactive molecules and cells in response to contacts with dangerous entities, including pathogenic microorganisms. The global immune system is composed of two major lines of defense, innate immunity and adaptive or acquired immunity, both of which rely on complex inter-regulated networks of humoral and cellular components. Innate immunity may be considered an emergency fight mechanism and plays a pivotal role at the time of first contact with a pathogenic agent, not only by providing a rapid response but also in the fine-tuning of the ensuing and more specific adaptive response (Figure 10.1). In this context, the actual challenge of vaccinology is to develop new strategies able to prime the immune system in such a way that an optimal balance of all key components of the immune responses is achieved, resulting in effective long-term protection. The ability of a vaccine to induce protective immune responses requires optimal presentation of pathogen-specific epitopes, as well as qualitatively and quantitatively appropriate immunopotentiating properties. Advances in vaccinology and immunology have provided an increasing array of candidate antigens suitable for vaccination against a variety of diseases. However, these novel antigens (e. g., synthetic peptides, purified subunits) generally require additional adjuvants to optimize their immunostimulating potential. This is especially true for the stimulation of efficient cellular immune responses. Although often antibodies alone may be sufficient for protection, costimulation of a cellular immune response is essential to induce sustained immunity (i. e., memory) and is generally considered indispensable for therapeutic approaches. Adjuvants can be subdivided into two major groups, vehicles and immunomodulators, depending on their primary mechanism of action [1]. Further subdivision allows the categorization of three types of adjuvant according to the underlying effect on the immune response [2]. Namely, (1) the protection of vulnerable antigens from rapid extracellular degradation or elimination by formation of a depot of antigen at

198

10 Virosomal Technology and Mucosal Adjuvants

1

1

4

APC Epithelium

10

5

2 8

B-Cell

6

11

PMN, Mo, NK 3

CD8+

CD4+

7

9

Fig. 10.1 Interactions between microorganisms and the immune system. (A) The innate immune system. For many microorganisms, the first contact with a potential host is via epithelia, mainly at mucosal surfaces. This tight barrier forms the first line of defense against pathogens and often is sufficient to block productive infections by means of fast, unspecific antibacterial and antiviral activities, i. e., the innate immune system. Many cell types, in particular, epithelial and immune cells, feature a sophisticated sensing system (1) capable of recognizing specific pathogen-associated molecular patterns (PAMPs)via Toll-like receptors (TLRs) and similar molecules expressed on the cell surface (e.g., for bacterial cell wall components) or located inside the cell (e.g., for double-stranded RNA). These in turn feed into the intracellular signaling network, leading to a PAMP-specif ic response. An increasing number of closely related sensor molecules have been identified in recent years in a wide variety of organisms, such as plants, insects, and mammals, indicating that this defense mechanism has been conserved throughout evolution. The PAMP-induced changes in the concentrations and phosphorylation patterns of intracellular signaling molecules and transcription factors lead to activation of proinflammatory and antimicrobial genes, as well as metabolic pathways, depending on the specific type of PAMP and the activated sensing molecules (2). The activated state of epithelial cells in reaction to contact with PAMPs induces release of locally active chemokines, cytokines, and molecules directly active against pathogens, such as defensins. The release of these warning signals acts as a chemoattracta nt for effector cells of the innate immune system, such as polymorphonuclear cells

(PMNs), macrophages, and natural killer cells (NK cells) (3). Furthermore, the surrounding epithelial cells are also primed for reaction to the microbial threat. The sum of the local and semispecific defense mechanisms, the so-called innate immunity, is often sufficient to eliminate the pathogen, even before an adaptive immune response is fully induced. This information is reviewed in references [131–136]. (B) The adaptive immune system.Professional antigen-presenting cells (APC) and precursors are resident in most tissues and are attracted in larger numbers by chemokines secreted by activated or infected cells. APC take up pathogens and their degradation products via phagocytosis (4) and process these antigens for presentation (5). Two distinct pathways for presenting antigens are referred to as the endogenous and the exogenous pathway, which result in the presentation of antigen-derived peptides in the context of MHC I (6) and MHC II (8) molecules, respectively. The default pathway for extracellular antigen taken up by APC is degradation in endosomes followed by loading onto MHC II and transport to the cell membrane (8). MHC II is expressed only by professional APC such as dendritic cells (DC) and macrophages. Presentation of peptides on MHC II molecules is required, together with costimulatory signals, for activation of antigen-specific CD4+ T-lymphocytes, most of them being the T-helper type. Activated helper T cells secrete interleukins and other cytokines,which further stimulate proliferation and maturation of B and T cells already activated by antigen recognition (9). MHC-I is expressed on all nucleated cell types. Peptides presented in the context of MHC I usually originate from the intracellular synthesis of foreign antigens, e.g., of viral or bacterial origin, and are

10.1 Overview

the site of application, which enables prolonged exposure to the antigen, thereby leading to immunopotentiation; (2) the increased uptake of antigen into antigen-presenting cells (APC), particularly dendritic cells (DC), macrophages, and B lymphocytes; and (3) the induction of synthesis and secretion of immune response enhancing factors, such as cytokines. Certain adjuvants also enable specific antigen targeting to APC and its channeling to specific subcellular locations, allowing efficient presentation in the context of both MHC I and II molecules. Adjuvant-associated nonspecific immunostimulatory effects unrelated to the respective antigen may also be evoked, e. g., binding to receptors or interfering with signaling pathways involved in innate and adaptive immunity. Adjuvants may also be instrumental in inducing long-term immunological memory [3–6]. During the past two decades, a variety of technologies have been investigated to improve on the widely used but suboptimal aluminum-based adjuvants. Aluminum adjuvants tend to strengthen the antigen-specific antibody response but lack the ability to stimulate CTL responses and may present undesirable side effects [7]. One of the most promising new approaches relies on liposome-based adjuvant systems. The approach adapted for so-called virosome adjuvanted vaccines is of particular interest, because they combine several properties known to contribute to immunostimulation and at the same time, due to the biocompatible nature of their constituents, are unlikely to produce unwanted side effects, such as cytotoxicity or unspecific inflammation at the site of injection. The mechanisms underlying the adjuvant properties of virosomes and the validation of the concept with two licensed vaccines are described in the second part of this chapter. In addition, novel routes of administration (i. e., mucosal vaccination) have been investigated for the induction of more effective immune responses at the site of first contact between the pathogen and its host. Due to the nature of the mucosa – mucociliary clearance in the respiratory tract, low pH and digestive enzymes in the gastrointestinal tract, and a general protective coating of mucus – this potentially advantageous route of immunization presents inherent obstacles. As described in the first part of this chapter, adjuvanted vaccines can be used to significantly enhance immune responses after mucosal administration. Fig. 10.1 (continued) recognized as an attack signal for antigen-specific cytotoxic CD8+ T cells (7). The starting point for intracellular antigen processing is the cytoplasm, where proteosomal degradation yields peptide fragments, which are subsequently transported into the endoplasmic reticulum (ER), loaded there onto MHC-I molecules, and finally presented on the cell surface. The humoral arm of the adaptive immune response depends primarily on activation of circulating immature B cells as a result of antigen binding to and cross-linking of the immunoglobulin chains

expressed on their surfaces (10). For further activation and full differentiation into antibody-secreting plasma cells, costimulatory signals are required from CD4+ T-cells and APC (11), both locally at the site of infection and in the lymphatic tissues, which in turn depend on MHC II presentation of processed antigen. The cytokine profile secreted by the accessory cells involved (APC and T cells) determines the type and kinetics of antibody maturation and the generation of memory B cells.

199

200

10 Virosomal Technology and Mucosal Adjuvants

10.2 Mucosal Adjuvants 10.2.1 Introduction

Most infectious agents are restricted to the mucosa or need to cross mucosa to cause disease. The administration of vaccine antigens by the parenteral route induces antigen-specific immune responses that are essentially restricted to the systemic compartment. In contrast, immunization by the mucosal route triggers immune responses at both systemic and mucosal levels. Thus, mucosal vaccination is considered the most appropriate immunization regime to stimulate local responses at the level of the pathogens’ port of entry. This can promote protection not only against disease, but also against infection (i. e., colonization) and leads to reduced pathogen shedding, thereby reducing the likelihood of horizontal transmission from infected to susceptible individuals. However, the mucosal epithelium constitutes a natural barrier to invading organisms; a barrier from which vaccine antigens are rapidly cleared (e. g., rapid degradation, peristaltic motility, poor penetration). Mucosal sites may also exhibit relatively strong tolerance to a large variety of antigens [8, 9]. Consequently, the use of special delivery strategies and vaccine formulations, such as mucosal adjuvants, is essential to breach this immunological barrier. The term ‘mucosal adjuvant’ has been quite broadly defined. Some of these so-called mucosal-adjuvant molecules correspond to chemically defined entities that exhibit intrinsic adjuvant activity and have been obtained by purification from biological sources or chemical synthesis. Recent advances in the field of mucosal vaccinology have resulted from enhanced comprehension of the interplay among the components of the immune system, greater understanding of the interactions between pathogens and the mucosal immune system, and improved knowledge of the biological effects triggered by adjuvant molecules. Considering that the use of a particular adjuvant can strongly influence the quality of the immune responses elicited against a given vaccine antigen, it is crucial to understand the mechanisms of adjuvanticity of candidate molecules. A large part of the research on vaccine adjuvants has been focused on the development of strategies that preferentially induce either a Th1 or a Th2 type T-cell helper response. However, since the quality of the induced immune responses is characteristic of a given adjuvant–antigen combination, it is extremely difficult to predict the results that will be obtained with a new antigen. This is particularly true for those antigens exhibiting immunomodulatory properties by themselves. The characteristics of the different types of mucosal adjuvants are discussed further below, using specific examples to highlight the advantages and limitations of the candidate molecules. 10.2.2 Families of Mucosal Adjuvants

Mucosal adjuvants cover a broad range of structures, as summarized in Table 10.1. Leader candidate molecules and their main derivatives are discussed below.

10.2 Mucosal Adjuvants Tab. 10.1 Types of mucosal adjuvants. Bacterial toxins

Cholera toxin (CT) CT derivatives: CT atoxic mutants, CTB subunit heat-labile enterotoxin (LT) LT-derivatives: LT atoxic mutants (LTK63, LTR72, LTR192G) chimeras: LT/CT, CTA1-DD

Bacterial lipoproteins, mucopeptides, lipopolysaccharides (LPS)

MALP-2 muramyl dipeptide (MDP) MPL-A (LPS derivative) lipopeptides derived from Gram-negative bacteria

Oligodeoxynucleotides (ODN)

CpG-ODN non-CpG-ODN

Anti-viral drugs and derivatives

imidazoquinolines adamantanes (amantadine and rimantadine), adamantyl dipeptide (AdDP)

Mineral salts and chemical adjuvants

aluminum hydroxide, aluminum phosphate, calcium phosphate saponin (QS21)

Host-derived adjuvants

cytokines (GM-CSF, IL-10, IL-12, etc.)

Previously, based on results obtained in animal models and partially shown in humans, researchers have assumed that stimulation of the common mucosal-immune system (CMIS) would induce an immune response at any remote mucosal-effector site [10, 11]. This has been superseded by the concept of compartmentalization of the CMIS. Stimulation of the various mucosal-inductive sites results in an uneven distribution of immune responses at the various effector sites [12]. Accordingly, the most effective means of inducing an immune response at a specific effector site is localized stimulation, or at least stimulation at a mucosal-inductive site related to the effector site in terms of lymph drainage [13]. Bacterial enterotoxins and their derivatives are among the first molecules to have been used as mucosal adjuvants. They are characterized by the presence of an A moiety with enzymatic activity and a B moiety that mediates toxin binding to the target cells. Cholera toxin (CT) and the closely related Escherichia coli heat-labile toxin (LT) are powerful adjuvants when coadministrated with soluble antigens by the mucosal route. They have been extensively used in preclinical research; however, their use has been limited to specific strategies in humans due to uncertainties concerning their toxicity [14, 15]. Various approaches (e. g., mutation, deletion, generation of chimeras) have been pursued to detoxify these molecules [13, 16–20]. These results led to the identification of nontoxic mutant derivatives, which retain adjuvanticity, at least in animal models. However, recent studies in the mouse indicate that even these derivatives or the B subunit alone may lead to potential non-target effects, such as retrograde transport of adjuvant and antigen to the olfactory nerves and olfactory bulb when such vaccines are administered by the nasal route [21].

201

202

10 Virosomal Technology and Mucosal Adjuvants

Several components from Gram-positive and -negative bacteria have also been explored for their activity as mucosal adjuvants. The monophosphoryl lipid A (MPL), a derivative of lipopolysaccharide (LPS), retains much of the immunostimulatory properties of LPS without the inherent toxicity [22]. The muramyl dipeptide (MDP) is derived from bacterial cell-wall peptidoglycan and exhibits a variety of biological activities. To improve bioavailability and decrease its toxicity, various derivatives have been generated. MDP-Lys18 shows antiviral activity and exhibits a potent effect as a mucosal adjuvant [23]. On the other hand, the N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) moiety of peptidoglycan has good bioavailability when administered by the oral route [24]. In addition, the fibronectin binding protein I of Streptococcus pyogenes is an efficient mucosal adjuvant able to improve cellular, humoral, and mucosal responses when coupled to or coadministered with antigens administered by the nasal route [25, 26]. Many reports have demonstrated the capacity of microbial lipoproteins to induce cytokine secretion [27, 28]; these studies also demonstrated that the lipid moiety of those molecules is responsible for this activity. A lipoprotein of Mycoplasma fermentans can activate monocyte macrophages at picomolar concentrations. A 2-kDa synthetic derivative, MALP-2 (macrophage-activating lipopeptide), retains the stimulatory capacity of the native lipopeptide [29]. In addition, cellular and humoral immune responses, both at systemic and mucosal levels, against soluble antigens were significantly improved when coadministered with MALP-2 by the intranasal route (Figure 10.2) [30]. The high potency, well-defined chemical structure, and lack of immunogenicity of this compound render it particularly attractive for vaccine development. Studies in the field of peptide-based vaccines have also shown the advantages associated with administration of lipidated antigenic peptides by the mucosal route [31]. Bacterial DNA, but not eukaryotic DNA, exhibits direct immunostimulatory effects on immune cells [32]. These effects are mainly due to the presence of unmethylated CpG motifs, which are generally absent in mammalian DNA. Various base combinations have immune stimulatory effects, some of which were defined as optimal (GACGTT, GTCGTT [33]). Interestingly, some non-CpG-ODN also present adjuvant effects when codelivered with antigens at mucosal sites [34]. Mechanisms of cytokine synergy are essential for vaccine protection against viral challenge [35]. In immunoprophylactic or therapeutic interventions, cytokines can be directly used as natural adjuvants, as an alternative to cytokine-inducing adjuvants. Parenteral cytokine treatment could lead to unwanted toxicity; however, their mucosal delivery results in low, but still biologically active, cytokine levels in serum [36]. Therefore, various cytokines have been used to accomplish a general immune activation or to promote a distinct pattern of immune response in preclinical settings [36, 37]. Various molecules with antiviral activity can also potentiate immune responses. Derivatives of these molecules are now considered to be a novel class of mucosal adjuvants. For example, the imidazoquinolines facilitate the clearance of genital warts by inducing the expression of proinflammatory cytokines [38, 39]. These properties can be used to improve conventional (protein-based) as well as DNA vaccines. On the other hand, adamantanes (amantadine and rimantadine) have been used for many

10.2 Mucosal Adjuvants

Lung IgA control

control

Vagina IgA Serum IgG Cell proliferation

ß-gal + MALP

ß-gal + MALP

ß-gal + CTB

ß-gal + CTB

ß-gal

ß-gal

10000

1

10

100

100000

1000

1000000

1000000

Ratio versus control group Fig. 10.2 b-gal-specific immune responses after intranasal immunization of mice with 50 mg b-gal mixed with 0.5 mg MALP-2 or 10 mg CTB as adjuvant. The results are expressed as the ratio of the mean signal of the b-gal-immunized mice group ( n = 5) to the mean signal of control mice that received PBS. Standard deviations are indicated by horizontal lines.

years as antiviral drugs. They inhibit viral uncoating by blocking the proton channel activity of the influenza A viral M2 protein. However, their use was limited by their lack of activity against influenza B, inherent toxicity, and rapid development of resistance [40]. Adamantylamide dipeptide (AdDP) is a nontoxic compound obtained by linking the L-alanine-D-isoglutamine residue of MDP to amantadine [41]. Recent studies have demonstrated that AdDP is an effective immunoadjuvant with an adequate safety profile when administered by the oral route in rabbits and mice [42]. A last group of immunostimulatory adjuvants is composed of mineral salts and saponins. QS21 is a nontoxic derivative of saponin, the highly purified complex triterpene glycoside isolated from the bark of the Quillaja saponaria Molina tree [43, 44]. This adjuvant has been included in several clinical trials, when the antigens were delivered by the parenteral route. However, QS21 is also under extensive investigation for mucosal use, particularly in combination with other adjuvants. Aluminum salts still remain the standard adjuvants licensed for human use. Interestingly, these cationic compounds also work as an absorption enhancer for nasal drug delivery [45] and have been included in various mucosal vaccine prototypes.

203

204

10 Virosomal Technology and Mucosal Adjuvants

10.2.3 Administration Strategies

Attenuated or inactivated microorganisms, proteins, or polypeptides, as well as DNA, can be used for mucosal vaccination. Vaccine efficacy depends on the antigen itself (inherent immunogenicity), the specific route of administration, the mucosal adjuvant added to the preparation, and the final formulation. Mucosal administration of purified proteins or peptides is usually accompanied by an important loss of immunogenicity. The presence of degrading enzymes and the poor penetration of antigens through the mucosal barrier constitute the major obstacles for the development of efficacious peptide- or protein-based mucosal vaccine formulations. Thus, major features of any mucosal adjuvant are its capacity to prevent antigen clearance, as well as the ability to promote rapid and efficient antigen uptake by APC. 10.2.3.1 Direct Admixing of Antigen and Adjuvants Simple admixing of the mucosal adjuvant with the antigen constitutes the most desired strategy, due to highly efficient, consistent manufacturing. As stressed above, although the existence of a common mucosal immune system [46] is generally accepted, it seems that antigen-specific B cells preferentially home into mucosal effector sites that are anatomically related to the immunization site. Despite this compartmentalization, effective mucosal responses in distant mucosal areas have been also obtained, depending on the inductive site stimulated through vaccination (e. g., better mucosal responses in the genitourinary tract after nasal than oral vaccination). Thus, in addition to selection of the appropriate mucosal adjuvant, the efficacy of immunization depends to a great extent on the administration route. In fact, it was recently demonstrated that the lipopeptide MALP-2 [30] can be used to stimulate efficient mucosal responses against the HIV-1 Tat protein in the genitourinary tract when both are coadministered by the intranasal route [47]. Only a few successful peptide-based vaccine formulations have been developed. Simmons et al. [48] exploited LT and LTK63 in an attempt to elicit CD8+ CTL responses against peptides from the M2 protein of the respiratory syncytial virus after intranasal vaccination. Induction of specific CTL responses depended on using the mucosal adjuvant. A new vaccination approach, DNA vaccination, has been developed in the past decade. It consists of the use of eukaryotic expression vectors encoding vaccine-relevant antigens rather than the purified antigen itself. However, only a few studies have demonstrated the efficacy of DNA vaccines when they are administered by the mucosal route. Etchart et al. [49] showed that induction of hemagglutinin-specific CTL responses was enhanced by coadministration of the mucosal adjuvant CT or cationic lipids. To further increase the efficacy of vaccine formulations administered by the mucosal route, combinations of adjuvants belonging to different families of molecules have been coadministered with the antigen, leading to synergistic effects [50–52]. However, variable effects have been observed in terms of the dominant Th pattern of the immune response elicited [51, 53]. This approach might facilitate the rational de-

10.2 Mucosal Adjuvants

sign of vaccines against specific diseases by coadministration of selected adjuvants, which promote the quality of immune response required to achieve protection. However, the use of complex adjuvant mixtures would represent a real challenge to the registration of a vaccine. 10.2.3.2 Covalent Linkage of the Adjuvant and Antigen or Adjuvant Incorporation into other Mucosal Delivery Systems The covalent linkage of antigen and mucosal adjuvant has been described as a powerful strategy to improve the efficacy of mucosally delivered antigens [54, 55]. Here, in addition to its biological activity, the adjuvant can also assume the role of a carrier and a stabilizing moiety. The linkage can be achieved by chemical coupling or genetic fusion. Covalent coupling has been largely used with CT, LT, and their derivatives [54]. This strategy seems particularly attractive for small antigenic molecules, such as peptides [56, 57]. In the specific example of DNA vaccines, CpG adjuvant motifs can directly be integrated into the plasmid or the DNA sequence of interest. Several studies have demonstrated the benefit resulting from combination of mucosal adjuvants with other antigen-delivery systems, such as liposomes, virosomes (see second part of the chapter), microparticules, or ISCOMs [58, 59]. One particular approach for an intranasal influenza vaccine included the use of virosome-adjuvant technology. This subunit vaccine contained LT as mucosal adjuvant and evoked promising results in preclinical [60] and clinical trials [61, 62]. Additional studies have demonstrated that ISCOMs containing a fusion protein encompassing the peptide OVA (323–339) linked to the chimeric derivative of CT, CTA1-DD, were highly immunogenic when given by the oral or nasal route [59]. On the other hand, preliminary studies on biocompatible microspheres gave more controversial results. Oral coadministration of antigen-containing particles with CT triggered similar responses to those observed when unprotected antigens were mixed with the adjuvant [63]. Live attenuated carriers (bacteria or viruses) can also be used as delivery systems for recombinant antigens. This strategy combines the invasive capacity of the carrier, the specific targeting of APC at the inductive site, and the immunostimulatory potential of bacterial components, such as LPS and CpG DNA motifs, with the delivery of the foreign antigen [64]. More recently, nonviable biological particles, so-called bacterial ‘ghosts‘, have also been exploited for a similar purpose [65, 66]. A further option consists in combining live or inactivated biological vectors with mucosal adjuvants. For instance, recombinant strains expressing cytokines or costimulatory molecules were more efficient than non-expressing strains [67, 68]. Coexpression of an antigen with CTA2 and B protein subunits in Salmonella also resulted in an improved immune response in preclinical studies [68]. Thus, these approaches expand the capacity to modulate the immune responses elicited by mucosal antigen-delivery systems. 10.2.3.3 Adjuvant in Prime–Boost Vaccination Strategies Recent studies have investigated the possibility of eliciting desired immune responses at systemic and mucosal levels by combining different strategies and tech-

205

206

10 Virosomal Technology and Mucosal Adjuvants

nology platforms for antigen delivery in prime–boost vaccination protocols [51, 70]. In such immunization protocols, administration routes can be combined by giving a parenteral or mucosal prime followed by a mucosal or parenteral boost, respectively. In some studies, adjuvants that are also amenable to mucosal use have been employed for parenteral administration, such as CpG [51]. Prime–boost strategies seem particularly efficient for inducing mucosal immune responses at proximal and distal locations [71]. In this context, using the nasal route offers several advantages. Indeed, the local microenvironment is less aggressive to the antigen preparation than that at other mucosal sites, and nasal immunization results in the broadest dissemination of effector cells to distant mucosal sites of the CMIS. Studies performed using the hepatitis B surface antigen administered with CpG, CT, or aluminum salts as adjuvants have shown that efficient immune responses can be induced by using prime–boost protocols in which parenteral and mucosal (intranasal) vaccinations were alternated [51]. We recently obtained excellent humoral and cellular immune responses against viral antigens by combining parenteral vaccination using protein or DNA with intranasal vaccination using protein and MALP-2 as an adjuvant (unpublished data). 10.2.4 Interaction of Mucosal Adjuvants with the Innate Immune System

A better understanding of the underlying mechanisms of adjuvanticity is a prerequisite to fully exploit the potential of novel immune stimulants to fine-tune elicited responses, as well as to comply with regulatory requirements for vaccine licensing. Elucidation of the chemical nature of the adjuvant molecules and identification of their ligands constitute critical parameters to be defined. This knowledge would also allow rational screening for novel molecules with similar or improved biological activity. A good understanding of the interactions between the innate and adaptive immune systems plays a pivotal role in this process (Figure 10.1). The human immune system has evolved to recognize entities that represent a danger to the host. The innate immune system recognizes danger signals, thereby leading to the activation of specific cells bridging the innate and adaptive immune systems. In this context, the innate immune response not only provides the first line of defense against infection or altered-self agents, but also determines the nature of the acquired immune response. Innate immune recognition relies on receptors that bind conserved motifs (pattern-recognition receptors), such as the various Toll-like receptors (TLR) and the complement system [72]. This basic knowledge provides us with essential clues to identify the putative receptors for microbial-derived mucosal adjuvants. For example, imidazoquinolines are both TLR7 agonists [73, 74] and ligands of TLR8 [75]. On the other hand, unmethylated CpG binds to TLR9 [76], and the heterodimer TLR2/TLR6 corresponds to the receptor of the lipopeptide MALP-2 [77, 78]. Studies dealing with the functions of TLR suggest that they can discriminate between different structures, thereby leading to the stimulation of distinct responses [79]. The TCR-mediated signaling pathways have not yet been completely elucidated [79, 80]. However, the activation and translocation of NF-kB constitute central relay

10.2 Mucosal Adjuvants

points within the signaling cascade, which can be achieved by MyD88-dependent or independent pathways. The activation of this nuclear factor is critical for innate immunity, being required for the production of proinflammatory cytokines (e. g., IFNa, TNFa, IL-6, IL-12). The distribution of TLR in mucosal tissues is only partially known [81, 82]. However, it is clear that TLR are expressed on key APC, such as DC and macrophages. The early stages of an immune response stimulated by mucosal adjuvants play a key role in the subsequent polarization of the adaptive immune response. Thus, the choice of the most appropriate mucosal adjuvant for a given vaccine antigen depends to a large extent on the quality of the immune response required for protective immunity (e. g., neutralizing antibodies, CTL, Th1 versus Th2 response). The differential activation of APC during the initial phase of the immune response has a pivotal role in the subsequent development of naive T cells [83]. In vitro studies have demonstrated that mucosal adjuvants can affect the maturation and activation of DC and macrophages [29, 32, 73, 83–86]. Additional studies have also shown that they can exert a mitogenic effect on B-cells [32, 38, 87–89]. The observed up-regulation in the expression of MHC class II, costimulatory (CD80, CD86), and adhesion molecules correlates with improved antigen-presentation functions. Activated APC also release cytokines, promoting a local microenvironment favoring T-cell priming. Thus, mucosal adjuvants allow the lowering of the antigen concentration threshold required for activation of immune cells, thereby allowing an efficient T-cell priming even when APC express little of the MHC class II molecules. The observed expression of chemokines and chemokine receptors also suggests that the use of mucosal adjuvants leads to increased cellular trafficking [90–92]. In this context, nasal application of MALP-2 leads to up-regulation of activation markers on APC isolated from the nasal-associated lymphoid tissues and to macrophage recruitment [30]. Recent studies suggest that different APC do not respond identically during infection, particularly with respect to their effects on naive T-cell polarization [93]. A comparison of the cytokine profiles of infected cells revealed that DC, but not macrophages, express the Th1-promoting cytokine IL-12. Accordingly, functional in vitro studies of mucosal adjuvants will have to address specific cellular populations from the target mucosal tissues. 10.2.5 Conclusion

The efficient prevention of mucosal transmission of infectious microorganisms is the primary goal of mucosal vaccines. Several strategies and tools have been developed to achieve this aim, such as the use of mucosal adjuvants. Available data suggest that, by combining different molecules and/or approaches, it would be possible to generate efficient and predictable immune responses. However, only a few compounds have been identified so far which exhibit this property. In addition, many molecules do not exhibit a safety profile allowing their use in humans, so that most studies have been restricted to experimental animal models. Thus, there is a crucial need to identify novel adjuvants, as well as to assess the efficacy of the most promis-

207

208

10 Virosomal Technology and Mucosal Adjuvants

ing candidates in human trials. A better understanding of the rules governing innate and adaptive immune responses, as well as unravelling the structure and function of the mucosal immune system will play key roles in achieving these aims.

10.3 Virosomal Technology 10.3.1 Introduction

The detailed production of virosomes was recently discussed [94]; here, it is sufficient to describe the structure of virosomes as reconstituted empty influenza virus envelopes, devoid of a nucleocapsid and of the genetic material of the source virus. Ultrastructurally, virosomes are spherical, unilamellar vesicles with a mean diameter of ~150 nm and short surface projections of 10–15 nm. In contrast to liposomes, virosomes contain functional viral envelope glycoproteins, e. g., influenza virus hemagglutinin (HA) and neuraminidase (NA) intercalated in their phospholipid bilayer membrane. The properties of virosomes enable stimulation of both the MHC I and the MHC II antigen-presentation pathways, depending upon antigen formulation (see also Figure 10.1). Antigens can be incorporated into virosomes [95], adsorbed to the virosome surface [96], or integrated into the lipid membrane [96], via a hydrophobic domain or via lipid moieties cross-linked to the antigen [97] (Figure 10.3). Antigens linked to the surface of virosomes are partially proteolysed within the endosome of APC upon endosomal fusion. This results in presentation of antigen-derived peptides in the context of MHC class II molecules. APC stimulation of specific CD8+ T cells by class I MHC-associated peptides is only achieved if an exogenous antigen escapes the default pathway, as a result of fusion activity of the carrier virosome. In this situation, the antigen is delivered to the cytosol of the APC, where it is processed and transported to the endoplasmic reticulum for association with nascent MHC class I molecules [95]. The stimulation of both helper and cytotoxic T lymphocyte (CTL) responses is discussed in more detail below.

4

2

1

3

Fig. 10.3 Options for association of antigen to virosomes : incorporation (1), membrane integration via inherent hydrophobic domains (2) or via crosslinking to a lipid molecule (3), and adsorption to the virosomal surface via electrostatic interaction (4).

10.3 Virosomal Technology

10.3.2 Adjuvant Properties of Virosomes

Virosomes have been successfully used as a carrier system for a variety of non-influenza antigens [99–101]. Physical association between the virosome carrier and the antigen of interest is a prerequisite for the full adjuvant effect of virosomes [96, 100]. In the context of the definition of an adjuvant mentioned in the Overview of this chapter, virosomes fulfil all major characteristics associated with vaccine adjuvants [1, 2]: (1) their virus-like structure provides regular, repetitive antigen presentation to B lymphocytes [102]; (2) they allow for partial antigen protection from extracellular degradation and depot effect [96]; (3) the presence of fully functional, fusion-active, influenza HA envelope proteins anchored in the virosomal membrane enables receptor-mediated uptake and intracellular processing of the antigen by, e. g., DC, leading to MHC I and II presentation and ultimately to costimulation of CD8+ and CD4+ T cells [101, 103]. 10.3.2.1 Virosome Structure and Immunopotentiation The majority of infectious agents, including viruses, bacteria, and parasites, expose highly ordered repetitive antigenic epitopes on their surfaces. Activation of B cells is enhanced by repetitive antigen presentation [102]. The repetitively arranged epitopes present on viral envelopes efficiently cross-link immunoglobulins expressed on the surface of immature B cells, resulting in a T cell independent activation. This indicates that B cells determine foreignness and are therefore activated by antigen organization [104]. Virosomes and natural viruses share structural similarities with regard to antigen presentation (Figures 10.1 and 10.4). The significance of this structural resemblance is manifested in the way in which virosomes mimic the viral induction of an immune response, providing the integral benefits of virosome technology in stimulating immune responses.

1 3 2

4

5 6

APC

B-Cell

6

CD4+

CD8+

Fig. 10.4 Virosomal adjuvant functions: (1) Antigen is protected from extracellular degradation, resulting in a depot effect; (2) the virus-like repetitive structure of antigens activates specific B cells to differentiate into antibody-producing plasma cells; (3) antigen is taken up by APC via receptor-mediated endocytosis and processed for presentation in the context of MHC I (4) and MHC II (5), which in turn is required for activation of antigen-specific CD8+ and CD4+ T lymphocytes, respectively. MHC I presentation depends on the pH-induced fusion activity of HA incorporated in the virosomeand leads to activation of specific CD8+ T cells. (6) Activated CD4+ T cells secrete soluble factors (cytokines), which modulate and define the humoral and cellular immune responses.

209

210

10 Virosomal Technology and Mucosal Adjuvants

10.3.2.2 Depot Effect Protection of the antigen from extracellular degradation allows efficient delivery of immunogenic molecules such as proteins to the cytosol of target cells and may also lead to prolonged exposure of the antigen for immunopotentiation. Prolonged exposure of antigens forming a depot effect has been claimed to be important for costimulation-dependent immune responses [3]. Post-vaccination antibody production depends on antigen retention on follicular DC within the draining lymph node [105]. Therefore, after a primary immune response, the persistence of antigen in the lymph node or injection site is likely to contribute to the duration of the immune response [106]. A depot effect has been shown with biotinylated virosomes in the mouse, by using 125 I-labeled streptavidin as a model antigen [96]. The results of this study showed that 28 days after vaccination, significant amounts of the streptavidin coupled to virosomes could still be detected at the site of injection. Slow release of peptide from a local depot represents an additional factor for optimal T cell priming in regional lymph nodes. Long-term clinical evaluation of a virosome-formulated hepatitis A vaccine showed consistent antibody profiles in vaccinees several years after vaccination [107]. A single vaccination induced high antibody after two weeks, and levels were retained 12 months later, at which time a booster dose was administered. 10.3.2.3 The Pivotal Role of Fusion-active Virosomal Hemagglutinin The unique properties of virosomes are predominantly related to the fusion-active influenza HA anchored in their membranes, so that great care is taken during the manufacturing process to keep this molecule biologically active [94]. This viral glycoprotein confers structural stability and homogeneity to virosomal formulations. In addition, HA provides the fusion properties characteristic of virosomes, a mechanistic feature clearly distinguishing virosomes from other liposomal or proteoliposomal adjuvants and carrier systems. The structure of influenza HA is related to that of other viral membrane fusion proteins [108, 109] and was the first such structure to be solved [110]. The molecular mechanism by which the envelope glycoprotein HA of influenza virus induces membrane fusion has been intensively studied [reviewed in 112, 117]. Influenza HA is a homotrimeric integral membrane protein. Each monomer is composed of two polypeptide domains [113] that are processed through post-translational cleavage of HA into two subunits, HA1 and HA2, which remain attached by a disulfide bond [114]. The HA1 globular head contains a receptor site that enables binding to the numerous sialic acid residues present on human cells, including APC [115, 116]. The fibrous subunit HA2 possesses a fusion peptide (amino-terminal peptide) and is anchored in the virosome membrane. Under neutral pH conditions, HA1 confines the HA2 subunit in an inactive, metastable state in which the fusion peptides are constrained by a network of hydrogen bonds [117]. A shift in pH from neutral to acidic results in a conformational change of the HA that exposes the hydrophobic domains of HA2 and triggers fusion with a target membrane. During natural influenza virus infection, such membrane fusion occurs between the viral

10.3 Virosomal Technology

membrane and the phagolysosomal membrane and results in release of the viral genetic material into the cytoplasm of the infected cell. Under artificial conditions, in the absence of a target membrane, exposure of influenza HA to pH 5 at 37 °C inactivates its fusogenic capacity [118]. The specific uptake and intracellular processing of virosome-associated antigen in APC, particularly DC, is conditioned by the action of the influenza HA. As stressed above, HA not only mediates attachment to sialic acid residues on the cell surface, followed by receptor-mediated endocytosis; but after acidification of the endosome through fusion with lysosomes, HA is also responsible for the pH-induced fusion of virosomal and phagolysosomal membranes. At this point, the antigen associated with virosomes may be degraded in the late lysosome and presented in the context of MHC II, according to the default pathway for an exogenous antigen. Alternatively, due to the HA-mediated membrane fusion with the acidified endosome, the antigen can also be released into the cytoplasm, from where it is channeled into the classical MHC I presentation pathway for endogenously synthesized antigens [reviewed in 119]. In fact, virosome-encapsulated antigens were shown to be efficiently delivered to the cytoplasm of DC in vitro [96] and to induce a strong CTL response in mice [120], two characteristics that strictly depended on the presence of a fusion-active influenza HA in the virosomal membrane. It is conceivable that the method of formulation, e. g., encapsulation as opposed to adsorption to the surface, may influence the preferred presentation pathway, MHC I or MHC II, to some extent. Further studies are required to fully explore the extent to which the type of virosomal antigen formulation can be used to direct the pattern of the immune response induced. Additional immunopotentiating effects have been proposed for influenza HA. Indeed, studies have provided evidence for the stimulation of peritoneal B-lymphocytes by HA via a so-called B-cell ‘superstimulatory’ antigen effect [121]. The implications are that the superstimulatory properties of the influenza virus glycoprotein activate, not only conventional B2 cells, but in addition a B-cell subset, so-called B1 cells, that represents a formidable first line of defense against invading pathogens. The potency of B1 cells in establishing an immediate immune response against antigens is reflected by their increased susceptibility to cross react with ‘third party’ antigens [121]. In addition, B-cell superstimulatory influenza viruses of the H2-subtype may induce B-cell proliferation by a Ca2+-independent protein kinase C (PKC)-activating mechanism [122]. 10.3.2.4 Effect of Pre-existing Immunity to Influenza Virus When virosomes are used as an antigen carrier system in a vaccine, the resulting immune response is also directed against the influenza glycoproteins, as observed for a virosomal hepatitis A vaccine [100]. Large proportions of vaccinees have preexisting immunity against influenza at the time of immunization with a virosomal vaccine, as a result of prior contacts with influenza viruses. Thus, the question of interference of preexisting immunity with the immune response to a virosomal vaccine is justified. Preclinical studies aimed at studying the possibility of such interference have shown that preexisting antibodies against the influenza glycoproteins HA and NA at the time of immunization do not interfere with the adjuvant function of virosomes,

211

212

10 Virosomal Technology and Mucosal Adjuvants

but rather enhances the immune response against virosome-bound antigen [100]. This presumably occurs via facilitated opsonization, which allows for more efficient uptake of antigen-loaded virosomes by APC. 10.3.3 Validation of the Virosomal Vaccine Concept

The virosome adjuvant technology platform is well tolerated and highly effective at immunopotentiation for a number of antigens. The initial virosome-adjuvanted vaccine for hepatitis A was launched in 1994, and a subsequent trivalent virosome-adjuvanted vaccine against influenza was licensed in 1997. During development of a novel hepatitis A vaccine, the initial clinical work demonstrated that the selected hepatitis A virus (HAV) antigen, RG-SB, was immunogenic in humans when administered as an aluminum-hydroxide-adsorbed formulation. The formalin-inactivated RG-SB strain was then incorporated into a virosomeadjuvanted vaccine for comparison trials. Comparison of virosome-formulated vaccine, soluble (no adjuvant) HAV antigen, and aluminum-adsorbed HAV antigen with respect to immunogenicity and tolerability after intramuscular administration showed that (Table 10.2): . All recipients (100 %) of the virosomal vaccine were seroprotected (620 mIU mL –1) after 14 days compared with 32% of those receiving soluble antigen and 71% of those receiving aluminum-adsorbed vaccine. . Antibody titers were higher after administration of the virosomal formulation than after the other two formulations [123]. Furthermore, the virosomal vaccine was significantly better tolerated than the aluminum-adsorbed vaccine in terms of local pain and swelling/induration. Subsequent work showed that a single dose of 500 RIA units of HAV antigen is sufficient to elicit a protective immune response lasting for at least 12 months. A large field efficacy study in Nicaragua, an area of high endemicity of HAV, demonstrated the safety and protective capacity of the virosome-adjuvanted HAV vaccine [124]. The re-

Tab. 10.2 Seroprotection after vaccination with three formulations of hepatitis A antigen [123]. Seroprotection day 14 day 28 day 180

GMT (mIU mL – 1) day 14 day 28 day 180

100 %

100 %

100 %

92

283

1550

Aluminum-based (n = 10)

71%

100 %

100 %

43

267

604

Soluble (n = 28)

32 %

100 %

100 %

22

160

622

Type of vaccine Virosomal (n = 40)

All subjects received 1000 RIA units of HAV antigen as a single dose.

10.3 Virosomal Technology

sults showed 100 % (p = 0.00007) protection from week 6 to month 15 in vaccinees who were seronegative at baseline. Mathematical modeling of the follow-up data from the Nicaragua trials, in which subjects were followed for several years after a booster vaccination performed one year after primary vaccination, indicated an extensive period of protection provided by the virosome technology [125]. The results of this study suggested a median duration of protection of 55.5 years. After 25.3 years, 95 % of the vaccinees should have a projected titer above the minimum protective level (defined as 10 mIU mL–1). If the higher titer of 20 mIU mL –1 is used, the median duration of protection is 46.8 years, and 95 % of subjects should be protected after 21.5 years. Based on these results, the virosome-adjuvanted HAV vaccine is registered to be protective for at least 20 years. Clinical trials comparing the virosome-adjuvanted hepatitis A vaccine against a traditional aluminum-adjuvanted vaccine have also been undertaken [126]. This study showed clear benefits in terms of local tolerability to the virosome vaccine. Studies have also compared the tolerability of virosome-formulated vaccines with other technology platforms and adjuvants. The excellent local tolerability to the trivalent virosome-adjuvanted influenza vaccine, consisting of a mixture of three types of monovalent virosomes, each harboring the HA and NA glycoproteins from one of the three strains recommended yearly by the World Health Organisation (WHO), has also been shown by comparison with an alternatively adjuvanted subunit vaccine and a vaccine based on whole influenza viruses [127, 128]. The immunogenicity of the virosome-adjuvanted influenza vaccine versus conventional influenza vaccines has been shown to be superior, with a statistically significant improvement in comparison to other vaccines: a 64-fold increase in anti-HA antibodies in elderly people [129]. Importantly, as with the virosomal hepatitis A vaccine [96], no evidence of an anti-phospholipid response was obtained in vaccinees [130]. 10.3.4 Conclusion

The increasing demand for safer and more effective adjuvants for modern vaccines has led researchers to investigate a broad array of adjuvant candidates, very few of which have resulted in viable concepts. Virosome-adjuvanted vaccines, which may include inactivated virus, recombinant proteins, synthetic peptides, or DNA-encoded antigens, have shown great potential for the development of prophylactic and therapeutic vaccines. The optimal antigen presentation provided by virosomes results in elicitation of highly efficient humoral and cellular immune responses. In addition, the well-defined components constituting virosomes, combined with a lack of preservatives or detergents, result in excellent tolerability. These conclusions are supported by the fact that virosome-adjuvanted vaccines against both hepatitis A and influenza are already on the market. These vaccines are registered in most EU countries and are distinguished by an excellent safety and tolerability record.

213

214

10 Virosomal Technology and Mucosal Adjuvants

References 1. G.B. Ebbert, E.D. Mascolo, H.R. Six. In: Vaccines (third ed), Saunders, Philadelphia, PA, USA, 1999, 40–46. 2. G. Ada. In: Vaccines (third ed), Saunders, Philadelphia, PA, USA, 1999, 28– 39. 3. V.E. Schijns. Curr Opin Immunol. 2000, 12, 456–463. 4. D.T. O’Hagan, M.L. MacKichan, M. Singh. Biomol Eng. 2001, 18, 69–85. 5. M. Singh, D.T. O’Hagan. Pharm Res. 2002, 19, 715–728. 6. R.L. Hunter. Vaccine. 2002, 20, S7–12. 7. R.K. Gupta. Adv Drug Deliv Rev.1998, 32, 155–172. 8. H.R. Jiang, N. Taylor, L. Duncan, et al. Br J Ophthalmol. 2001, 85, 739–744. 9. L.V. Collins, K. Eriksson, R.G. Ulrich, A. Tarkowski. Infect Immun. 2002, 70, 2282–2287. 10. M.R. McDermott, J. Bienenstock. J. Immunol. 1979, 122, 1892–1898. 11. C. Czerkinsky, S.J. Prince, S.M. Michalek, et al. Proc Natl Acad Sci USA. 1987, 84, 2449–2453. 12. H.Y. Wu, M.W. Russell. Immuno Res. 1997, 16, 187–210. 13. Z. Moldoveanu, M.W. Russell, H.Y. Wu, et al. Adv Exp Med Biol. 1995, 371, 97–101. 14. C.O. Elson, Cholera toxin as a mucosal adjuvant in Mucosal Vaccines, 1996. 59– 72. 15. L.C. Freytag and J.D. Clements. Curr Top Microbiol Immunol 1999, 236, 215– 236. 16. M. Martin, D.J. Metzger, S.M. Michalek, T.D. Connell, M.W. Russell. Infect Immun 2000, 68, 281–287. 17. J. Sanchez, G. Wallerstrom, M. Fredriksson, J. Angstrom, J. Holmgren. J Biol Chem 2002, 277, 33369–33377. 18. M. Pizza et al. Vaccine 2001, 19, 2534– 2541. 19. P.N. Boyaka et al. J Immunol 2003, 170, 454–462. 20. M.N. Kweon et al. J Infect Dis 2002, 186, 1261–1269. 21. K. Fujihashi, T. Koga, F.W. van Ginkel,Y. Hagiwara, J.R. McGhee. Vaccine 2002, 20, 2431–2438.

22. A. Moore, L. McCarthy, K.H. Mills. Vaccine 1999, 17, 2517–2527. 23. A. Fukushima et al. Vaccine 1996, 14, 485–491. 24. K.C. Lyons, W.N. Charman, R. Miller, C.J. Porter. Int J Pharm 2000, 199, 17– 28. 25. K. Schulze, C.A. Guzman. FEMS Immunol Med Microbiol. 2003, 37, 173– 177. 26. E. Medina, S.R. Talay, G.S. Chhatwal, C.A. Guzman. Eur J Immunol 1998, 28, 1069–1077. 27. D.A. Kostyal, G.H. Butler, D.H. Beezhold. Infect Immun 1994, 62, 3793– 3800. 28. Y. Ma and J.J. Weis. Infect Immun 1993, 61, 3843–3853. 29. P.F. Muhlradt, M. Kiess, H. Meyer, R. Sussmuth, G. Jung. J Exp Med 1997, 185, 1951–1958. 30. R. Rharbaoui, B. Drabner, S. Borsutzky, et al. Eur J Immunol 2002, 32, 2857–2865. 31. L. BenMohamed,Y. Belkaid, E. Loing, et al. Eur J Immunol 2002, 32, 2274– 2281. 32. A.M. Krieg. Annu Rev Immunol 2002, 20, 709–760. 33. G. Hartmann, A.M. Krieg. J Immunol 2000, 164, 944–953. 34. M.J. McCluskie, H.L. Davis. Vaccine 2000, 19, 413–422. 35. J.D. Ahlers, I.M. Belyakov, S. Matsui, J.A. Berzofsky. Int Immunol 2001, 13, 897–908. 36. P.N. Boyaka, J.R. McGhee. Adv Drug Deliv Rev 2001, 51, 71–79. 37. P.N. Boyaka, J.W. Lillard Jr., J. McGhee. Immunol Res 1999, 20, 207–217. 38. U.R. Hengge, B. Benninghoff, T. Ruzicka, M. Goos. Lancet Infect Dis 2001, 1, 189–198. 39. M.A. Stanley. Clin Exp Dermatol 2002, 27, 571–577. 40. R. Kandel, K.L. Hartshorn. BioDrugs 2001, 15, 303–323. 41. K. Masek, J. Seifert, M. Flegel, M. Krojidlo, J. Kolinsky. Methods Find Exp Clin Pharmacol 1984, 6, 667–669.

References 42. P.D. Becker, R.S. Corral, C.A. Guzman, S. Grinstein. Vaccine 2001, 19, 4603–4609. 43. C.R. Kensil, U. Patel, M. Lennick, D. Marciani. J Immunol 1991, 146, 431–437. 44. G. Liu, C. Anderson, H. Scaltreto, J. Barbon, C.R. Kensil. Vaccine 2002, 20, 2808–2815. 45. H. Natsume et al. Int J Pharm 1999, 185, 1–12. 46. H. Tlaskalova-Hogenova, L. Tuckova, R. Lodinova-Zadnikova, et al. Int Arch Allergy Immunol. 2002, 128, 77–89. 47. S. Borsutzky, V. Fiorelli, T. Ebensen, et al. Eur. J. Immunol. 2003, 33, 1548– 1556. 48. C.P. Simmons, T. Hussell, T. Sparer, G. Walzl, P. Openshaw, G. Dougan. J Immunol 2001, 166, 1106–1113. 49. N. Etchart, R. Buckland, M.A. Liu, T.F. Wild, D. Kaiserlian. J Gen Virol 1997, 78, 1577–1580. 50. M.J. McCluskie, R.D. Weeratna, H.L. Davis. Mol Med 2000, 6, 867–877. 51. M.J. McCluskie, R.D. Weeratna, P.J. Payette, H.L. Davis. FEMS Immunol Med Microbiol 2002, 32, 179–185. 52. Olive, T. Clair, P. Yarwood, M.F. Good. Vaccine 2002, 20, 2816– 2825. 53. M. Huber, W. Baier, W.G. Bessler, L. Heinevetter. Immunobiology 2002, 205, 61–73. 54. J. Holmgren, N. Lycke, C. Czerkinsky. Vaccine 1993, 11, 1179–1184. 55. Rask, M. Fredriksson, M. Lindblad, C. Czerkinsky, J. Holmgren. Apmis 2000, 108, 178–186. 56. I. Takahashi, N. Okahashi, K. Matsushita, M. Tokuda, T. Kanamoto, E. Munekata, M.W. Russell, T. Koga. J Immunol 1991, 146, 332–336. 57. H.J. Hernandez, L.I. Rutitzky, M. Lebens, J. Holmgren, M.J. Stadecker. Parasite Immunol 2002, 24, 423–427. 58. Harokopakis, N.K. Childers, S.M. Michalek, S.S. Zhang, M. Tomasi. J Immunol Methods 1995, 185, 31–42. 59. A.M. Mowat, A.M. Donachie, S. Jagewall, et al. J Immunol 2001, 167, 3398– 3405. 60. R. Zurbriggen, I.C. Metcalfe,

61. 62.

63. 64.

65. 66.

67.

68. 69.

70.

71.

72. 73. 74. 75.

76. 77.

78.

79.

R. Glück, J.-F. Viret; C. Moser. Exp Rev Vaccines 2003, 2, 89–98. R. Gluck. J Aerosol Med 2002, 15, 221– 228. R. Gluck, R. Mischler, P. Durrer, E. Furer, A.B. Lang, C. Herzog, S.J. Cryz Jr. J Infect Dis 2000, 181, 1129–1132. D.J. Brayden. Eur J Pharm Sci 2001, 14, 183–189. L.P. Londono, S. Chatfield, R.W. Tindle, K. Herd, X.M. Gao, I. Frazer, G. Dougan. Vaccine 1996, 14, 545–552. F.O. Eko et al. Vaccine 1999, 17, 1643– 1649. K. Panthel,W. Jechlinger, A. Matis, M. Rohde, M. Szostak,W. Lubitz, R. Haas. Infect Immun 2003, 71, 109– 116. E. Kass, D.L. Panicali, G. Mazzara, J. Schlom, J.W. Greiner. Cancer Res 2001, 61, 206–214. C.D. Rosenkranz et al. Vaccine 2003, 21, 798–801. E. Harokopakis, G. Hajishengallis, T.E. Greenway, M.W. Russell, S.M. Michalek. Infect Immun 1997, 65, 1445–1454. T.S. Kanellos, D.K. Byarugaba, P.H. Russell, C.R. Howard, C.D. Partidos. Immunol Lett 2000, 74, 215–220. S.K. Eo, M. Gierynska, A.A. Kamar, B.T. Rouse. J Immunol 2001, 166, 5473– 5479. C.A. Janeway Jr., R. Medzhitov. Annu Rev Immunol 2002, 20, 197–216. S.J. Gibson et al. Cell Immunol 2002, 218, 74–86. Hemmi et al. Nat Immunol 2002, 3, 196–200. M. Jurk, F. Heil, J. Vollmer, C. Schetter, A.M. Krieg, H. Wagner, G. Lipford, S. Bauer. Nat Immunol 2002, 3, 499. Hemmi et al. Nature 2000, 408, 740– 745. O. Takeuchi, T. Kawai, P.F. Muhlradt, M. Morr, J.D. Radolf, A. Zychlinsky, K. Takeda, S. Akira. Int Immunol 2001, 13, 933–940. M. Morr, O. Takeuchi, S. Akira, M.M. Simon, P.F. Muhlradt. Eur J Immunol 2002, 32, 3337–3347. T. Horng, G.M. Barton, R.A. Flavell,

215

216

10 Virosomal Technology and Mucosal Adjuvants

80. 81.

82.

83.

84.

85.

86.

87.

88.

89. 90. 91.

92.

93. 94. 95. 96.

97.

R. Medzhitov. Nature 2002, 420, 329– 333. L.A. O’Neill. Mol Cell 2002, 10, 969– 971. O. Takeuchi, T. Kawai, H. Sanjo, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, K. Takeda, S. Akira. Gene 1999, 231, 59–65. V. Hornung, S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, G. Hartmann. J Immunol 2002, 168, 4531–4537. A. Boonstra, C. Asselin-Paturel, M. Gilliet, C. Crain, G. Trinchieri, Y.J. Liu, A. O’Garra. J Exp Med 2003, 197, 101–109. A. George-Chandy, K. Eriksson, M. Lebens, I. Nordstrom, E. Schon, J. Holmgren. Infect Immun 2001, 69, 5716–5725. J. Garcia, B. Lemercier, S. Roman-Roman, G. Rawadi. J Biol Chem 1998, 273, 34391–34398. M.C. Gagliardi, F. Sallusto, M. Marinaro, A. Langenkamp, A. Lanzavecchia, M.T. De Magistris. Eur J Immunol 2000, 30, 2394–2403. C. Galanos, M. Gumenscheimer, P. Muhlradt, E. Jirillo, M. Freudenberg. J Endotoxin Res 2000, 6, 471–476. G.A. Bishop,Y. Hsing, B.S. Hostager, S.V. Jalukar, L.M. Ramirez, M.A. Tomai. J Immunol 2000, 165, 5552–5557. H. Bone, S. Eckholdt, N.A. Williams. Int Immunol 2002, 14, 647–658. U. Deiters, P.F. Muhlradt. Infect Immun 1999, 67, 3390–3398. H.P. Jones, L.M. Hodge, K. Fujihashi, H. Kiyono, J.R. McGhee, J.W. Simecka. J Immunol 2001, 167, 4518– 4526. F. Sallusto, C.R. Mackay, A. Lanzavecchia. Annu Rev Immunol 2000, 18, 593–620. S.P. Hickman, J. Chan, P. Salgame. J Immunol 2002, 168, 4636–4642. R. Mischler, I.C. Metcalfe. Vaccine. 2002, 20, B17–23. L. Bungener, K. Serre, L. Bijl, et al. Vaccine. 2002, 20, 2287–2295. R. Zurbriggen, I. Novak-Hofer, A. Seelig, R. Gluck. Prog Lipid Res. 2000, 39, 3–18. F. Poltl-Frank, R. Zurbriggen,

99.

100. 101.

102. 103. 104.

105. 106. 107. 108. 109.

110. 112. 113. 114.

115. 116.

117.

118.

119.

120.

A. Helg, et al. Clin Exp Immunol. 1999, 117, 496–503. B. Mengiardi, R. Berger, M. Just, R. Gluck. Vaccine. 1995, 13, 1306– 1315. R. Zurbriggen, R. Gluck. Vaccine. 1999, 17, 1301–1305. M.G. Cusi, R. Zurbriggen, P. Correale, et al. Vaccine. 2002, 20, 3436– 3442. T. Fehr, M.F. Bachmann, E. Bucher, et al. J Exp Med. 1997, 185, 1785–1792. L. Bungener, J. Idema, W. ter Veer, et al. J Liposome Res. 2002, 12, 155–163. M.F. Bachmann, H. Hengartner, R.M. Zinkernagel. Eur J Immunol. 1995, 25, 3445–3451. J.G. Tew, R.P. Phipps, T.E. Mandel. Immunol Rev. 1980, 53, 175–201. C. Caux,Y.J. Liu, J. Banchereau. Immunol Today. 1995, 16, 2–4. R. Gluck, R. Mischler, S. Brantschen, et al. J Clin Invest. 1992, 90, 2491–2495. I.A. Wilson, J.J. Skehel, D.C. Wiley. Nature. 1981, 289, 366–373. P.A. Bullough, F.M. Hughson, J.J. Skehel, D.C. Wiley. Nature. 1994, 371, 37–43. J.J. Skehel, D.C. Wiley. Cell. 1998, 2395, 871–874. J.J. Skehel, D.C. Wiley. Annu Rev Biochem. 2000, 69, 531–569. P. Durrer, C. Galli, S. Hoenke, et al. J. Biol. Chem. 1996, 271, 13417–13421. X. Han, J.H. Bushweller, D.S. Cafiso, L.K. Tamm. Nat Struc Biol. 2001, 8, 715– 720. P. Schoen, L. Leserman, J. Wilschut. FEBS Lett. 1996, 390, 315–318. S. Gunther-Ausborn, P. Schoen, I. Bartoldus, J. Wilschut, T. Stegmann. J Virol. 2000, 74, 2714–2720. L.D. Hernandez, L.R. Hoffman, T.G. Wolfsberg, J.M. White. Annu Rev Cell Dev Biol. 1996, 12, 627–661. T. Weber, G. Paesold, C. Galli, R. Mischler, G. Semenza, J. Brunner. J. Biol. Chem. 1994, 269, 18353–18358. L. Bungener, A. Huckriede, J. Wilschut, T. Daemen. Biosci Rep. 2002, 22, 323–338. A. Arkema, A. Huckriede, P. Schoen, J. Wilschut, T. Daemen. Vaccine. 2000, 18, 1327–1333.

References 121. O. Rott, J. Charreire, K. MignonGodefroy, E. Cash. J Immunol. 1995, 155, 134–142. 122. O. Rott, J. Charreire, M. Semichon, G. Bismuth, E. Cash. J Immunol. 1995, 154, 2092–2103. 123. M. Just, R. Berger, H. Dreschler, S. Brantschen, R. Glueck. Vaccine 1992, 10, 737–739. 124. O. Mayorga Perez, C. Herzog, M. Zellmeyer, A. Loasiga, G. Froesner, M. Egger. J Infect Dis 2003 (in press) 125. P.A. Bovier, J. Bock, L. Loutan, T. Farinelli, R. Glück, C. Herzog. J Med Virol. 2002, 68, 489–493. 126. B.R. Holzer, C. Hatz, D. Schmidt-Sissolak, et al. Vaccine. 1996, 14, 982–986. 127. F. Pregliasco, C. Mensi,W. Serpilli,

128. 129. 130. 131. 132. 133. 134. 135. 136.

L. Speccher, P. Masella, A. Belloni. Aging (Milano). 2001, 13, 38–43. R. Glück, R. Mischler, B. Finkel, et al. Lancet. 1994, 344, 160–163. P. Conne, L. Gauthey, P. Vernet, et al. Vaccine 1997, 15, 1675–1679. S.J. Cryz, J.U. Que, R. Gluck. Vaccine. 1996, 14, 1381–1383. A. Dunne, L.A. O’Neill 2003. Sci STKE 171:re3 G. Trinchieri Nat Rev Immunol. 2003, 3, 133–146. D. Werling, T.W. Jungi Vet Immunol Immunopathol. 2003, 91, 1–12. G.M. Barton, R. Medzhitov Curr Top Microbiol Immunol. 2002, 270, 81–92. S. Gordon Cell. 2002, 111, 927–930. M. Schnare, G.M. Barton, A.C. Holt, K. Takeda, S. Akira, R. Medzhitov Nat Immunol. 2001, 2, 947–950.

217

Part IV Classical and Novel Vaccination Strategies: A Comparison

221

11 Classical Bacterial Vaccines Thomas Ebensen, Claudia Link, and Carlos A. Guzmán

11.1 Bacterial Vaccines: Introductory Remarks

The successful control of bacterial infections depends on two opposing forces: on the one in-hand, host-specific and unspecific defense mechanisms, which are designed to restrict bacterial survival and multiplication; on the other hand, the coordinated expression of bacterial virulence factors, which are responsible for their subversion and/or circumvention. The host immune system provides two different lines of defense against infectious agents. The first nonspecific defense line is given by the innate immune system, and the pathogen-specific adaptive immune response constitutes the second. Cellular components of the innate immune system also represent the critical bridge between these two responses (e. g., dendritic cells). Vaccination constitutes the most cost-efficient strategy for preventing bacterial diseases through the stimulation of pathogen-specific adaptive responses, which are able to protect against subsequent challenge. Most bacterial pathogens are either restricted to the mucosae or need to transit across them to cause disease. Thus, elicitation of a local mucosal immune response after vaccination represents a clear advantage. In fact, the stimulation of a potent local response at the site in which the first line of defense is laid allows promoting protection against both disease and infection (i. e., colonization), thereby reducing the risk of pathogen transmission to other susceptible hosts. Human vaccination against bacterial diseases has been practiced with success for many years. Despite this success, however, human society continues to suffer millions of deaths and multi-billion dollar economic losses annually due to bacterial diseases. This is in part due to the lack of vaccines against many diseases, as well as to the fact that not all available vaccines are completely satisfactory in terms of immunogenicity, efficacy, and safety. In addition, not all efficacious vaccines are used properly. Anti-vaccine movements in developed countries and economic constraints in the developing world prevent optimal vaccine use. To reduce these losses, there is a critical need to develop new, better, safer, and cheaper vaccines, which are able to promote long-lasting immune responses. Various strategies have been exploited to develop antibacterial vaccines (Figure 11.1). Whole-cell vaccines are produced by inactivating the virulent organisms

222

11 Classical Bacterial Vaccines

Fig. 11.1

Main vaccination strategies.

(e. g., by chemicals, heat). Alternatively, bacteria can be attenuated in such a way that the organisms are not able to cause disease in their natural hosts, but are still able to induce protective immunity. Thus, attenuated organisms are not able to produce clinical disease, but they retain the ability for transient colonization and/or self-limiting replication. These attenuated bacteria can also be used as live carriers (i. e., bacterial vectors) for the delivery of heterologous antigens from other pathogenic organisms (see Chapter 15). It is also possible to use organisms from a related but nonpathogenic species, as an alternative to attenuated organisms. However, it is essential that they share enough similarity to promote a cross-protective immune response. In other cases, mixed approaches have been established, such as the use of a microorganism from a different species that has been attenuated (e. g., attenuated Mycobacterium bovis BCG to protect against tuberculosis). Purified subcellular components from pathogenic bacteria, which are critical targets for the elicitation of protective responses, can also be used to develop subunit vaccines. Subunit vaccine components can be inactivated toxins, capsular polysaccharides, structural proteins, or nonstructural components. The used antigens can be native or obtained by recombinant DNA technology. Subunit vaccines usually exhibit a better safety profile than whole-cell vaccines. However, they are often less immunogenic, have higher production costs, and demand expensive storage procedures. A new approach has emerged in the vaccinology field in the last decade, the socalled DNA vaccines. This approach consists in the use of eukaryotic expression vectors encoding the antigen of interest, which are delivered to the vaccinees. Then, the biosynthetic machinery of the eukaryotic cells is responsible for synthesis of the vaccine-specific antigens. More recently, attenuated bacteria have been successfully exploited as a delivery system for DNA vaccines against both infectious agents and tumors [1]. The availability of different mutants and highly sophisticated expression tools, as well as the possibility to coadminister immune modulators (e. g., cytokines) allow predictable immune responses to be triggered, according to the specific needs.

11.2 Inactivated Vaccines

11.2 Inactivated Vaccines

Many vaccines against human or animal infectious diseases are composed of whole organisms, which have been inactivated to prevent in vivo multiplication, but retain their immunogenicity. Many of them have been empirically designed, without having a clear understanding of either the protective antigens or the immune protective mechanisms. Furthermore, these vaccines are generally associated with a high incidence of side effects. 11.2.1 Methods of Inactivation

Whole-cell vaccines are usually inactivated by heating and/or treating with chemicals, and the final vaccine preparation does not usually undergo further purification. Formaldehyde was the reagent first used for chemical inactivation, but glutaraldehyde and phenol have also been used. However, this procedure may affect the immunogenic epitopes present in the antigens. The use of colicin E2, a potent DNA endonuclease that enters target bacterial cells without disrupting cellular integrity, has also been proposed for bacterial inactivation [2]. A special inactivation approach is based on the use of phage lysis systems. The controlled expression of PhiX174 gene E in Gram-negative bacteria results in the formation of a transmembrane tunnel through the cell envelope complex [3]. The resulting so-called bacterial ghosts have intact envelope structures, but are devoid of cytoplasmic contents. This process was successfully exploited in a variety of Gram-negative bacteria, including Escherichia coli, Salmonella spp.,Vibrio cholerae, and Actinobacillus pleuropneumoniae. The well-preserved surface structures of bacterial ghosts stimulate efficient immune responses when administered by various routes. This seems to be due, at least in part, to the specific targeting of antigen-presenting cells, in which they promote maturation through the potent danger signal delivered by their structural components (e. g., lipopolysaccharides). Ghosts can be not only used as vaccines against diseases caused by the inactivated microorganisms, but also as a technology platform for antigen delivery. In this approach, they can be directly loaded with antigens or, alternatively, recombinant antigens can be expressed before lysis. 11.2.2 Advantages and Limitations of Inactivated Vaccines

Efficient bacterial inactivation leads to vaccine candidates with an extremely good safety profile, which can be administered even to immune-deficient individuals. However, nonreplicating organisms are generally less immunogenic than live bacteria, and multiple doses are required (Table 11.1). On the other hand, all virulence factors can be expressed by the strain used in the preparation of the vaccine, whereas key virulence factors may be missing in the attenuated vaccine strain. However, in vitro cultivation of bacteria does not necessarily lead to the expression of all virulence

223

224

11 Classical Bacterial Vaccines Tab. 11.1 Comparison of live and killed whole-cell vaccines. Live/attenuated vaccines

Killed/inactivated vaccines

Attenuated microorganisms are used Replicate in the host Single or few doses are required Smaller number of microorganisms Less stable No adjuvants are required Can be delivered by natural infection route Stimulate antibody and cellular responses Promote cellular and humoral memory Sometimes spread from vaccinated to unvaccinated individuals Variable safety in immunocompromized patients Shorter shelf-life Easy transport and storage Higher development costs

Virulent bacteria can be used Do not replicate Multiple doses are required Larger number of microorganisms More stable Adjuvants often required Generally given by parenteral route Induce good humoral but poor cellular responses Stimulate weaker cellular memory No spread to unvaccinated individuals Excellent safety in immunodeficient patients Usually longer shelf-life Easy transport and storage Lower development costs

factors, whereas live vaccines are capable of eliciting immune responses also against in vivo expressed antigens. The reactogenicity of inactivated and live vaccines is usually greater than that of other types of vaccines (e. g., subunit vaccines). Vaccines may loose efficacy as a result of accumulated mutations in circulating strains of pathogens. This risk is lower for inactivated than for subunit vaccines, due to the presence of all potential antigens from the pathogen. However, the presence of multiple antigens may result in reduced vaccine efficacy, due to the suppression of immune responses against sub-dominant antigens by the immune dominants. In contrast to live vaccines, in which the immune response closely resembles that against natural infection, the immune responses against parenterally administered inactivated vaccine are limited to the systemic compartment. In addition, humoral rather than cellular responses are stimulated. Finally, inactivated vaccines are not shed, thus they are unable to infect unvaccinated individuals. On the one hand, they do not lead to herd immunity. On the other hand, they do not represent a risk for immunosuppressed contacts. Finally, the development costs of inactivated vaccines are usually lower than those of live or subunit vaccines. However, quality control (e. g., potency tests, killing tests) of inactivated vaccines may be very difficult.

11.3 Live Vaccines

Live vaccines lead to a self-limited asymptomatic infection, thereby stimulating similar immune responses to those observed after natural infections. Therefore, this

11.3 Live Vaccines

kind of vaccine closely matches some of the criteria for an ideal vaccine, since it stimulates long-lasting protection with minimal reactogenicity after a single or a few doses. 11.3.1 Attenuation

Attenuation of the microorganism eliminates its disease-causing capacity and can be obtained by biological or technical manipulations (e. g., multiple passages through unusual hosts, growth at suboptimal conditions, chemical mutagenesis). In the past, attenuation was performed by empirical techniques. However, the explosive development of our knowledge in the fields of microbial pathogenesis and recombinant DNA technology allows the identification of molecular targets for attenuation and thereby enables rational and precise construction of vaccine strains containing welldefined deletions in these genes. In strains generated by recombinant DNA technology, the attenuation should be sufficient to limit pathogenicity without risk of reverting to the wild-type phenotype. Thus, it is desirable to introduce at least two independent attenuating mutations. The attenuation should not rely on a fully functional host immune system. Furthermore, it must not be reversible by diet or by host modification of diet constituents, including the host's resident microbial flora. Finally, it is also necessary that the attenuation does not induce a persistent carrier state in vaccinees. 11.3.2 Advantages and Limitations of Live Bacterial Vaccines

Live vaccines have several advantages and disadvantages in comparison to subunit vaccines (Table 11.2). Although live attenuated vaccines replicate in the host, subunit or inactivated vaccines are unable to replicate. Therefore, attenuated vaccines usually

Tab. 11.2 Comparison of live and subunit vaccines. Live vaccines

Subunit vaccines

Live/attenuated microorganisms Replicate in the host Variable safety Can spread to unvaccinated individuals Potential risk of reversion Potential risk to immunosuppressed patients Usually more reactogenic Stimulate humoral and cellular responses May require fewer doses Generally long-lasting protection Lower production costs Easy administration logistics

Subcellular components of microorganisms Do not replicate in the host Excellent safety Not transmissible to contacts No risk of reversion No risk to immunosuppressed patients Usually less reactogenic Trigger mainly humoral responses Multiple doses are required Periodic boosters required Higher production costs More complicated/expensive administration logistics

225

226

11 Classical Bacterial Vaccines

promote long-lasting immune responses, which mimic those obtained after natural infections. However, the presence of preexisting or cross-reactive immune responses against the vaccine strain may affect its overall efficacy. Live vaccines are less stable and may be easily damaged or destroyed by heat or light. However, cold storage is required for all vaccines registered up to now. Depending on the degree of attenuation and the specific vaccine, multiple doses may be required. The risk of reversion to the wild type phenotype, which was certainly an issue with the undefined first-generation attenuated vaccines, is now made negligible by the introduction of multiple well-defined independent deletions in second-generation vaccines (see Chapter 15). However, live vaccines can generally be considered more reactogenic. This also depends on the route of administration, since oral attenuated vaccines against typhoid fever are less reactogenic than parenteral ones. A specific issue to be taken into consideration is the potential risk associated with administration or transmission (i. e., shedding) to immunodeficient individuals. In addition, a careful and exhaustive evaluation of the potential impact of environmental release, including duration and rate of shedding, as well as the risk of horizontal gene transfer, needs to be carried out. A clear advantage of attenuated vaccines is the fact that they have lower production costs than subunit vaccines. In addition, technology transfer to developing countries is facilitated by the simplicity of the upstream and downstream processes. They are also associated with much simpler and less expensive administration logistics when they are given via the mucosal route. The mucosal route also provides better safety, since parenteral vaccination is an important cause of spreading of HIV and hepatitis in the developing world.

11.4 Vaccines for Human Bacterial Diseases

Bacterial infections play a major role in human disease. Although the development and use of anti-infective agents has resulted in reduced morbidity and mortality, increases in antibiotic resistance complicate the clinical management of infected patients. Furthermore, the implementation of therapeutic approaches does not reduce the human suffering and costs associated with disease. Vaccines have played a major role in the fight against bacterial diseases that have cost mankind heavily in terms of human lives, such as diphtheria, tetanus, whooping cough, meningitis, and tuberculosis. Thus, it is necessary to foster the use of available vaccines and to develop new ones against those diseases for which no vaccine is yet available. 11.4.1 Anthrax (Bacillus anthracis)

Anthrax is primarily a disease of herbivorous animals acquired via the ingestion of Bacillus anthracis spores. Humans occasionally acquire the disease through contact with infected animals or contaminated animal products via the skin (95 %) or by ingestion or inhalation. Without treatment, the cutaneous forms of anthrax have 20 %

11.4 Vaccines for Human Bacterial Diseases

mortality, whereas gastrointestinal and pulmonary anthrax reach mortality rates of 25 %–75 % and more than 80 %, respectively. The emerging threat of bioterrorism has awakened the general interest in both the pathogenesis of B. anthracis and vaccine development. Factors contributing to the pathogenesis process are the plasmid (pXO1 and pXO2) -encoded capsule components, the protective antigen, the lethal factor (LF), and the edema factor (EF) [4]. The capsule helps the bacterium to evade immune clearance, and the toxins are responsible for inducing edema and shock. Anthrax was the first bacterial disease for which vaccination was successfully demonstrated. In 1881 Pasteur observed protection in sheep after injection of a heat-attenuated B. anthracis strain. In 1937 the Sterne vaccine strain was developed, which is nonencapsulated (cured from pXO2) but retains the toxins [5]. The worldwide implementation of this vaccine has contributed to the successful control of the disease in livestock and wild animals. However, it cannot be used in sensitive animals, due to its residual virulence. More recently, several live vaccine candidates lacking EF and LF were developed [6]. However, they were considered not suitable for human use, since they still retain a certain degree of virulence [7]. In 1970 an anthrax vaccine was licensed for human use, which consists of a sterile filtrate of microaerophilic cultures of a nonencapsulated avirulent strain [8]. 11.4.2 Cholera (Vibrio cholerae)

Cholera is a serious water- and foodborne epidemic disease caused by V. cholerae, which has killed millions of people and continues to be a major health problem worldwide. Bacteria colonize the small intestine and produce an exotoxin, cholera toxin (CT), consisting of an enzymatically active subunit A and five identical B subunits. CT disrupts the function of ion pumps, leading to changes in the net flows of sodium, chloride, and water, and resulting in massive diarrhea, electrolyte imbalance, and circulatory collapse. According to the lipopolysaccharide (LPS), two serogroups are circulating (O1 and O139). O1 organisms are classified as classical or El Tor biotypes, according to the phenotype. V. cholerae O1 El Tor biotype is the predominant cause of cholera worldwide; however, a minority of cholera cases are caused by V. cholerae O139 [9]. Convalescents develop a protective immune response, as demonstrated by both volunteer studies and patients follow-up [10, 11]. Serological responses against LPS and CT are observed after a cholera episode, and can block colonization and neutralize CT. The first recorded attempt to develop a vaccine against cholera was in the late 1880s. This killed whole-cell vaccine was injected into the bloodstream, but failed to elicit protective immunity and was associated with high rates of side effects. However, a phenol-killed V. cholerae Ogawa and Inaba vaccine administered by parenteral route is licensed, which stimulates high titers of vibriocidal antibodies in 50 %–90 % of vaccinees and shows an efficacy of about 50 % for about 6 months [12]. To obtain a good local immune response in the gut, an oral vaccine based on heatkilled classic Inaba and Ogawa and formalin-killed El Tor Inaba and classic Ogawa,

227

228

11 Classical Bacterial Vaccines

coadministered with 1 mg of the CT B subunit (CTB), has been developed and showed 60 %–85 % efficacy in humans [13]. Another oral vaccine is based on a genetically attenuated V. cholerae O1 classical Inaba strain (CVD 103-HgR), contains a deletion in the CT enzymatically active subunit, and has been marked with a gene coding for mercury resistance that permits differentiation between recombinant and wild-type circulating isolates. This vaccine was licensed in Switzerland in 1994 and is now also available in several other countries. Placebo-controlled trials in several countries have shown the safety and immunogenicity of a single dose of CVD 103HgR, even in HIV-infected individuals. Side effects, such as mild nausea, abdominal cramping, and diarrhea, were rarely observed. A single dose conferred 95 % and 65 % protection against V. cholerae classical and El Tor, respectively, in volunteers in challenge studies [14, 15]. Another candidate vaccine is the V. cholerae O1 El Tor Inaba Peru-15 strain, which was obtained by incorporating a series of genetic deletions and modifications [16]. A seroconversion rate of 97 % for vibriocidal antibodies was observed, and none of the volunteers showed moderate or severe diarrhea after challenge with V. cholerae O1 El Tor Inaba strain. None of theses vaccines is expected to confer protection against V. cholerae O139. However, candidates based on these approaches against O139-expressing V. cholerae are being developed. 11.4.3 Enterotoxigenic Escherichia coli

Enterotoxigenic E. coli (ETEC) is the most common cause of traveler’s diarrhea, which is acquired by ingestion of contaminated food or water. Whole-cell vaccines, which mimic natural infections, seem to promote longer immunoprotection and are being evaluated in clinical trials. A nonreplicating whole-cell anti-ETEC vaccine was prepared by treating the enterotoxigenic E. coli strain H-10407 (O78:H11, CFA/I), which produces heat stable and heat labile (LT) toxins, with colicin E2 [2]. After two oral doses, 77.3 % and 86.4 % of the volunteers showed anti-CFA/I and anti-LT sIgA responses, respectively, and 90 % showed antibodies to either CFA/I, LT, or both [17]. On the other hand, a formalin-killed oral ETEC vaccine expressing the most common colonization-factor antigens (i. e., CFA/I, CFA/II, and CFA/IV) and recombinant CTB was given to volunteers in Sweden. An increment in IgA-secreting cells and in the levels of intestinal sIgA against CTB and various CFA components were detected in the majority of volunteers after two doses [18]. Oral vaccination with a killed ETEC plus CTB vaccine in Egyptian children evoked a fourfold rise in antitoxic IgA and IgG titers in 93 % and 81% of the vaccinees. The vaccine was also safe and immunogenic in 2–12-year-old children [19]. Besides the use of whole-cell E. coli vaccines, other approaches have been pursued to stimulate efficient anti-ETEC immune responses, such as the use of purified fimbriae, toxoids, or carrier organisms expressing ETEC antigens.

11.4 Vaccines for Human Bacterial Diseases

11.4.4 Plague (Yersinia pestis)

Yersinia pestis is the etiological agent of plague, a disease that has caused over 200 million human deaths [20]. Plague is primarily a disease of rodents, but it can also affect humans. Thee main forms of plague occur in humans: bubonic, septicemic, and pneumonic. The common form is bubonic plague, which arises following a bite from a flea that previously fed on an infected animal. The most-feared form is pneumonic plague, which is transmitted from person to person via droplets and has mortality rates of up to 100 %. To prevent the disease, both killed whole-cell and live attenuated vaccines have been used [21]. Killed Y. pestis bacteria have been used as veterinary vaccines since 1897, and the first killed vaccine for human use was developed in 1946. Various methods have been exploited for inactivation, including formaldehyde and heat treatment [22]. The Commonwealth Serum Laboratories are currently producing a heat-killed Y. pestis vaccine (strain 195/P), which is given subcutaneously in three doses over a period of 2 months. This vaccine is mainly used in individuals who may be exposed to the pathogen, e. g., veterinarians, researchers, and persons who are deployed to work in areas where the disease is endemic. However, 10 % of immunized individuals show side effects such as malaise, headache, fever, and lymphadenopathy. In addition, no clinical trials have demonstrated the efficacy of killed whole-cell vaccines, and some studies suggest that killed vaccines do not provide protection against pneumonic plague. A live attenuated strain of Y. pestis (EV76) was derived from a fully virulent strain by in vitro passages. The vaccine has been in use since 1908, especially in the former Soviet Union and the French colonies [21]. Studies in mice indicate that this vaccine provides protection against bubonic and pneumonic plague. However, the safety of this vaccine in humans is questionable. In recent years we have seen a renewed interest in the development of efficient and safer vaccines against this old pathogen, due to the potential risk of illegitimate use of Y. pestis as a biological weapon. 11.4.5 Shigellosis (Shigella species)

Shigellosis is a diarrheal disease, which is transmitted via contaminated food and water or through person-to-person contact. As few as 10 organisms can cause infection, leading to diarrhea or dysentery with frequent mucous bloody stools and severe abdominal cramps. Shigellosis is caused by four main species, S. flexneri, the most common in endemic areas; S. dysenteriae type 1, most frequent in overcrowded areas and associated with large epidemic outbreaks; S. sonnei, more active in developed countries; and S. boydii. Infections caused by S. dysenteriae type 1 can also lead to severe complications, such as hemolytic-uremic syndrome. Between 1966 and 1997, the annual number of Shigella episodes worldwide was estimated to be 164.7 million, 69 % of them being children under the age of 5 [23]. Approximately 500 000 deaths occur each year due to this disease.

229

230

11 Classical Bacterial Vaccines

Soon after isolation of S. dysenteriae in 1898, heat-killed cultures were tested to assess their potential as vaccines. However, there is still no vaccine available to prevent Shigella infections. In 1950 the first efforts to develop an attenuated vaccine strain were undertaken. The strains T32-ISTRATI, which was isolated after 32 passages on nutrient agar, and S. flexneri 2 a SmD, which was dependent on streptomycin, yielded promising results, but they were associated with side effects [24, 25]. Subsequent efforts were focused on the use of a hybrid E. coli K-12 containing the invasion plasmid that codes for somatic antigens of S. flexneri 2 a (E. coli EcSf2a-2 hybrid). More recently, work has addressed the development of recombinant strains containing mutations in the genes responsible for the biosynthesis of essential aromatic compounds (e. g., aroA, aroD) and/or virulence factors (icsA, iuc, virG, sen, set, stxAB). These mutants undergo only minimal intracellular replication or are deficient in intracellular and cell-to-cell spread. Promising results were obtained in clinical trials with volunteers after vaccination with some of these candidates. Finally, subunit vaccines, such as O antigen coupled to a carrier protein (conjugate vaccines), vesicles of Neisseria outer membrane proteins and O-polysaccharide (proteosome vaccines), and noncovalent complexes of O-polysaccharide and ribosomal particles (ribosomal vaccines) also gave encouraging results in preclinical and clinical studies [26–28]. 11.4.6 Tuberculosis (Mycobacterium tuberculosis)

Mycobacterium tuberculosis remains a major health problem worldwide, with about 2 million people dying of tuberculosis each year [29]. M. bovis Bacillus Calmette– Guérin (BCG), is the only available vaccine against tuberculosis and constitutes the most widely used live bacterial vaccine in the world. The original strain was attenuated by performing >200 successive in vitro passages over 13 years [30]. This strain was then distributed to several laboratories worldwide, where it was produced and maintained. Of the vaccines currently in use, more than 90 % belong to 4 main strains: the French Pasteur strain 1173 P2, the Danish strain 1331, the Glaxo strain 1077, and the Tokyo strain 172. Despite the WHO’s attempts to standardize production and vaccine characteristics, the concentration ranges from 50 000 to 3 million bacteria per dose. Some vaccines (Pasteur 1173 P2 and Danish 1331) induce strong immunogenicity in animal models, whereas the strains Glaxo 1077 and Tokyo 172 stimulate weak responses. Side effects differ from strain to strain and are predominantly related to infection or to errors in achieving intradermal inoculation (e. g., local reactions, lymphadenitis, osteitis). Recently, the BCG strains have been carefully characterized [31] and shown to lack expression of certain antigens present in M. tuberculosis, which might be important for protective immunity. Therefore, BCG is the most controversial vaccine in current use [32]. It is generally accepted that BCG protects children from meningeal and miliary tuberculosis. However, protection of adults from the most common form of the disease, pulmonary tuberculosis, varies in different studies from 80 % in the UK to 0 % in South India [33]. This variable efficacy can be due to many reasons, such as vaccine strain, vaccine quality, host genet-

11.4 Vaccines for Human Bacterial Diseases

ics, nutrition, exposure of the vaccine to UV, infection incidence, and clinical study protocols. Fundamental questions need to be addressed concerning the rational design of novel tuberculosis vaccines, preclinical and clinical tests, and future implementation in the field (see Chapter 21). 11.4.7 Typhoid Fever (Salmonella enterica serovar Typhi)

Typhoid fever affects about 17 million people worldwide each year, with approximately 600 000 deaths. The disease is caused by Salmonella enterica serovar Typhi, after ingestion of contaminated food or water. Typhoid fever and infections caused by other serovars in humans and animals are a serious medical and veterinary problem (see section 11.5.5). Thus, the development of vaccines against this pathogen has constituted an important focus of research. Whole-cell inactivated or attenuated vaccines, as well as subunit vaccines, have been used with variable results [34]. However, most licensed typhoid vaccines confer only about 70 % protection, show poor efficacy in young children, and are not used for routine vaccination. The first parenteral whole-cell typhoid fever vaccine was introduced 1896 in England. Using heat, alcohol, acetone, or formalin, different whole-cell vaccines were constructed and tested in field trials [35]. These vaccines conferred 51%–88 % protection to children and young adults, lasting for up to 12 years. However, inactivated vaccines often lead to local and systemic side effects, such as fever (6 %–30 %), headache (10 %), and severe local pain (up to 35 %). This type of vaccines also requires regular boosts; thus, they are rarely included in public health programs. The first human trials using attenuated strains against salmonellosis were made in the early 1970s with a streptomycin-dependent mutant of serovar Typhi [36]. However, no significant protection was conferred by this vaccine. Then, a live-attenuated vaccine strain (Ty21a) was developed by chemical mutagenesis. This strain is administered by the oral route and carries, among others, the galE mutation, which renders bacteria extremely susceptible to lysis in the presence of galactose. Ty21a constitutes one of the few licensed attenuated bacterial vaccines for human use and the only live vaccine against serovar Typhi. Two different formulations of Ty21a live oral typhoid vaccine have been commercialized. The liquid formulation provides better protection than enteric-coated capsules. Three doses of Ty21a in liquid formulation stimulated 77 % protection over three years and 78 % over five years of follow-up [37]. Ty21a caused minimal side effects, with nausea being the only adverse event appearing more frequently in vaccinees than in the control group. A post-marketing surveillance study showed only 743 spontaneous reports of adverse effects in more than 38 million vaccinees. On the other hand, a parenteral subunit vaccine based on purified capsular polysaccharide (Vi antigen) was shown to provide 64 %–72 % protection over 21 months [38]. A conjugate of Vi with nontoxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) showed enhanced immunogenicity in adults and also in children 5–14 years of age and stimulated a booster response in 2–4-year-old children. Interestingly, an efficacy of over 90 % in 2–5-year-old children was reported after intradermal immunization with the Vi-rEPA conjugate vaccine [39]. The im-

231

232

11 Classical Bacterial Vaccines

proved knowledge of bacterial physiology, pathogenesis mechanisms, and host immune response has allowed developing a new generation of live attenuated vaccine strains. They have been generated by introducing defined nonreverting mutations into genes coding for metabolic or virulence functions. These vaccines have given promising results in preclinical and clinical studies (see Chapter 15). 11.4.8 Tularemia (Francisella tularensis)

Tularemia, caused by Francisella tularensis, is a primary disease of a wide variety of wild mammals and birds, but it can also be transmitted to humans. Type A strains of F. tularensis found in North America are more virulent than type B strains found in Asia, Europe, and North America. Human infections can be caused by as few as 10 bacteria, which enter the host via the skin, mucous membranes, gastrointestinal tract, or the lungs [40]. The high disease incidence in the United States and Russia during the first half of the 20th century led to an intensive research aimed at the development of efficient vaccines, because it was observed that previously infected individuals were protected against reinfection. However, vaccine candidate strains inactivated by heat, acetone, or phenol treatment did not show a satisfactory efficacy in animal studies or human volunteers [41, 42]. During the same period, the Soviet Union developed attenuated strains, which were used to immunize millions of individuals living in tularemiaendemic areas by intradermal route until 1960. Attenuation was obtained by repeated subculturing in media supplemented with antiserum. One of those attenuated strains was brought to the United States in 1956, F. tularensis LSV, and was routinely used to protect technical personal against laboratory-acquired infections [43]. F. tularensis has been considered a potential biological weapon since 1932. Due to the current danger of bioterrorism, the LSV vaccine is currently under review by the US Food and Drug Administration to assess its future potential as a vaccine [40]. 11.4.9 Whooping cough (Bordetella pertussis)

Whooping cough is a highly contagious respiratory infection caused by the Gram-negative bacillus Bordetella pertussis. This pathogen still remains an important killer of children, although there has been a global decline in incidence, consistent with the overall increase in immunization. In 2001 over 12 million cases of pertussis were estimated to occur worldwide, which led to more than 285 000 deaths [44]. After the isolation and propagation of the causative agent in 1906, major efforts were focused in the development of a vaccine. In 1914, a whole-cell ‘whooping cough vaccine’ was listed in the USA [45]. Over the following decades, several whole-cell vaccines were generated, which consist of chemically- or heat-killed B. pertussis cells. In 1942, the inactivated whole-cell B. pertussis vaccine was combined with diphtheria and tetanus toxoids, leading to a triple vaccine (DTP) that is still in use and confers more than 80 % protection. The incidence of whooping cough has been greatly reduced by mass immunization with DTP.

11.5 Veterinary Bacterial Vaccines

Whole-cell vaccines were frequently associated with local side effects (pain, redness, swelling). Some children also showed transient fever, protracted inconsolable crying, hypotonic–hyporesponsive episodes, and seizures [46]. Additional studies showed that the vaccine does not cause sudden infant death syndrome, spasms, or epilepsy and that the risk of developing an acute encephalopathy was less than 1 : 100 000 [47–50]. Thus, the benefits associated with whole-cell vaccines clearly outweigh the risks of side effects, and vaccine-mediated neurological damage or death has never been conclusively proven. However, increasing concern about adverse effects has led to a reduction in public vaccine acceptance and a consequent increase in the incidence of the disease. Thus, efforts were made to develop acellular subunit vaccines against whooping cough based on key virulence factors (pertussis toxoid, pertactin, filamentous hemagglutinin), which are now in the market (see Chapter 12). These vaccines show much lower rates of adverse effects and have replaced whole-cell vaccines in developed countries. However, due to their lower costs, wholecell vaccines are still used in developing countries [51]. One of the major advantages of subunit vaccines is that they can be also used in older children and adults. Thus, they are particularly useful for boosting. This is particularly important, because both natural infection and vaccination with whole-cell or acellular vaccines induce protection against reinfection only for a limited time (about 5–15 years). Adolescents and adults become gradually susceptible, as demonstrated by the increased incidence of atypical whooping cough cases in these age groups [52].

11.5 Veterinary Bacterial Vaccines

Bacterial pathogens cause a wide range of diseases in animals and have a tremendous economic impact. In addition, individuals with occupational or chronic exposure can acquire zoonotic diseases (e. g., veterinarians, farm workers, butchers, pet owners). Thus, animal diseases should be combated both to improve the quality of animal products and to prevent human disease. The use of antibiotics does not constitute a valid alternative, due to both actual regulations for human food and the increased risk of emergence of antibiotic resistance. Therefore, vaccination is the best alternative for tackling this problem. The use of vaccines allows reduction of (1) the clinical symptoms and the consequent economic impact of veterinary diseases, (2) the risk of carrier development, and (3) bacterial shedding and horizontal transfer to susceptible hosts. Since the early 1900s, massive research efforts have been invested in preventing bacterial diseases in animals. Incomplete knowledge of the causative agents and limited information about clearance mechanisms rendered this task difficult. However, by the end of the 20th century the use of bacterial vaccines has led to a significant reduction in the incidence of infectious diseases in the veterinary field [53]. Thus, there are many examples of veterinary diseases for which vaccines were successfully implemented. Interestingly, the number of inactivated or attenuated classical bacterial vaccines is consistently larger in the veterinary than in the human

233

234

11 Classical Bacterial Vaccines

field. This is due, at least in part, to broader margins in terms of acceptable side effects and to the critical need of keeping costs low. Furthermore, combined formulations containing different bacterial and/or viral components are the rule rather than the exception. Although the presentation of a fully comprehensive report of all veterinary vaccines goes beyond the scope of this chapter, several examples are given below. The focus is on those diseases that have the biggest impact, with a particular emphasis on those for which classical bacterial vaccines have been introduced into the market. 11.5.1 Infections Caused by Bordetella and Pasteurella Species

Symptomatic and asymptomatic infections caused by Bordetella bronchiseptica are extremely widespread in the veterinary field, with infection rates that may reach 80 %– 100 % in intensively reared animals. This microorganism produces a variety of pathological syndromes and predisposes infected animals to viral or bacterial superinfections (e. g., Pasteurella multocida Type D and Mycoplasma hyopneumoniae in pigs). Pigs infected with B. bronchiseptica and toxigenic strains of P. multocida can develop atrophic rhinitis [54]. The dermonecrotic toxin released by P. multocida affects osteocytes and osteoblasts, promoting bone resorption and leading to systemic manifestations, and is responsible for progressive atrophic rhinitis. The signs of the disease appear by 8–12 weeks of age and progress throughout the growing period. Infected animals show severe atrophy of the nasal turbinate bones, accompanied by lateral deviation or shortening of the nose. A British survey on abattoir pigs showed that 92 % of herds were infected, with 36 % of animals exhibiting atrophic changes. This may result in a 5 %–15 % reduction on live weight gain (25–40 g/day), which in turn may lead to an annual loss of output or resource wastage of 1–4 million £. Thus, parenteral vaccines against atrophic rhinitis, which are based on inactivated B. bronchiseptica in combination with P. multocida Type D dermonecrotic toxoid alone or together with chemically inactivated Pasteurella, are widely used in pigs. Vaccinated animals and their progeny develop high titers of antibodies against B. bronchiseptica and P. multocida dermonecrotic toxoid. Both sows and gilts and their piglets are vaccinated, leading to reduced bacterial colonization, toxin neutralization, better growth, increased average daily weight gain (ADG), better snout scores, and reduced mortality [55]. In some cases, these vaccines are combined with inactivated Erysipelothrix rhusiopathiae to prevent erysipelas in sow herds. In addition to inactivated B. bronchiseptica vaccines for pigs, field studies have been performed with live attenuated prototypes, which stimulate immune responses that can reduce morbidity rates relative to unvaccinated controls [56]. Vaccines against Bordetella spp. and Pasteurella spp. have also been developed for other animal species. Among them, attenuated B. bronchiseptica vaccines, for intranasal administration to dogs to prevent infectious tracheobronchitis (kennel cough), are generally combined with other antigens (e. g., attenuated canine parainfluenza virus). Live attenuated vaccines against the poultry pathogen Bordetella avium were introduced into the market to protect turkeys against rhinotracheitis.

11.5 Veterinary Bacterial Vaccines

Pasteurella pneumoniae is estimated to be the top killer of cattle in the United States, and Pasteurella haemolytica is the main contributor to shipping fever, costing millions of dollars annually in deaths and treatment costs. Thus, attenuated P. multocida strains are combined with P. haemolytica in formulations for cattle. Viral components, such as rhinotracheitis virus, bovine respiratory syncytial virus, parainfluenza, and bovine diarrhea virus are added to the basic formulations to cover a broad range of pathogens. Infections of domestic and wild birds with P. multocida lead to fowl cholera, a contagious, widely distributed disease with high morbidity and mortality. The disease is typically characterized by sudden septicemia and fibrinous pneumonia; however, chronic and asymptomatic infections also occur. P. multocida subspecies multocida is the most common cause of fowl cholera, although subspecies septica and gallicida may also cause a fowl cholera-like disease [57]. P. multocida is classified into 16 serotypes based on its lipopolysaccharide antigens, and the strains most frequently causing fowl cholera are A:1, A:3, and A:4 [58]. Live attenuated and inactivated (e. g., Cholervac-PM-1) P. multocida vaccines have been introduced into the market. Whole-cell inactivated vaccines (bacterins) can provide protection, but only against the homologous serotype. On the other hand, live attenuated vaccines can protect under in vivo conditions against heterologous serotypes. However, attenuated vaccines retain a low level of virulence, and these strains can be implicated in infection outbreaks. For the prevention of fowl cholera, the most commonly used live vaccines are the P. multocida M-9 and PM-1 strains. Current experimental studies revolve around identification of the specific cross-protective antigens that might be incorporated into vaccine formulations, such as the outer membrane protein Oma87, a type4 fimbrial subunit (PtfA), and a transferrin binding protein (Tbpl) [58]. Although conclusive evidence concerning a potential role of the capsule in virulence is still missing, the genes involved in capsule biosynthesis have been characterized as potential attenuation targets [58]. More recently, attenuated auxotrophic P. multocida aroA derivatives have been generated by recombinant DNA technologies and are able to protect against homologous and heterologous challenges in chickens [59]. 11.5.2 Brucellosis (Brucella spp.)

Brucellosis is a worldwide distributed zoonotic disease caused by Brucella spp. Infective cells can persist in the environment for weeks, and dried preparations can retain virulence for years. B. melitensis commonly infects goats and sheep and is particularly virulent in humans, whereas B. abortus, B. ovis, and B. suis preferentially infect cattle, sheep, and swine, respectively. The disease can be transmitted to humans by consumption of raw animal products or by direct contact with infected animals or their carcasses, through skin lesions or by inhalation. Because of the serious economic and medical consequences of brucellosis, consistent efforts have been invested to develop vaccines. However, no human vaccine is currently available against brucellosis, and the disease is mainly controlled by animal vaccination. Antibodies and cell-mediated immunity can influence the course of the

235

236

11 Classical Bacterial Vaccines

infection. However, cell-mediated responses (e. g., CTL) are required for clearance of intracellular bacteria [60, 61]. These responses are best stimulated by using live vaccines or by multiple injections of protective antigens with adjuvants. Only a few effective candidates have been identified so far, that reduce abortion but not necessarily infection [62]. Live vaccines retain some virulence and, depending on the administered dose, abortions may occur during pregnancy. The strain B. abortus 19 has been the most widely used to prevent brucellosis in bovines. However, the efficacy differs according to the age, dose, route of administration, and disease prevalence in vaccinated herds. The strain was originally isolated from cow milk in 1923, and, after being kept at room temperature, it was found to be attenuated. The live attenuated B. melitensis strain Rev.1 can stimulate protection against B. melitensis in sheep and goats. This strain also protects rams against infection with B. ovis. Strains 19 and Rev.1 can be horizontally transferred from vaccinated to unvaccinated animals and change to a rough form, since they persist in some animals. Another disadvantage is that the vaccine strains are fully virulent to humans, and many accidental infections have been reported. Other attenuated strains have not been widely adopted, such as a mucoid derivative of B. suis (M vaccine), the B. abortus 104-M vaccine, B. suis strain 2, and B. melitensis strain 5, which were used as oral vaccines in China [63]. The smooth vaccine strains 19 and Rev.1 stimulate anti-O-chain antibodies, thereby preventing differentiation between vaccinated and infected animals. Therefore, efforts were addressed towards the development of a marker vaccine that would not interfere with eradication programs. The smooth B. abortus strain 45/20 was isolated in 1922 and became rough after 20 passages in guinea pigs. This strain was protective but tended to revert to the virulent form. Thus, it was used as an inactivated preparation with adjuvants based on water and oil emulsions. However, this vaccine was discontinued because its efficacy varied greatly from batch to batch and was associated with severe local reactions. B. abortus strain RB51, which lacks the Ochain, was very stable after multiple in vitro and in vivo passages [64]. Its efficacy after subcutaneous vaccination was similar to that of strain 19, but so far it has not led to deleterious side effects [65, 66]. Thus, strain RB51, which also induces protection in swine against B. suis and in goats against B. melitensis, is replacing strain 19 in several countries. Oral vaccination with RB51 stimulates protective immunity in mice and cattle [67, 68]; hence, a practical approach to wildlife immunization seems possible. Prevention of human brucellosis is best achieved by control or eradication of the disease in animals, combined with adequate heat treatment of potentially contaminated food products. However, in some countries this is not feasible. Therefore, attempts have been made to protect humans by vaccination. This has been reinforced by the renewed interest in Brucella resulting from its potential as a biological weapon; however, the results obtained have been generally disappointing. A derivative of strain 19 (19-BA), which was administered by scarification in the former USSR, stimulates short-time protection but leads to severe reactions [69]. Strain RB51 shows minimal pathogenicity in humans, but is resistant to rifampicin, which makes it unsuitable for human use.

11.5 Veterinary Bacterial Vaccines

11.5.3 Porcine Pleuropneumonia ( Actinobacillus pleuropneumoniae)

Actinobacillus pleuropneumoniae is the etiologic agent of a highly contagious porcine pleuropneumonia, characterized by fibrinous, hemorrhagic, and necrotic lung lesions [70]. The disease shows a morbidity of 15 %–30 % and is associated with high mortality rates in acute outbreaks (100 % of affected pigs) and a decrease in the ADG of up to 35 %. So far, 15 serotypes have been identified. Different vaccines have been introduced into the market; some are based on inactivated bacteria (bacterins), and other formulations are based on purified and detoxified Apx toxins I, II, and III (subunit vaccines). Many of these vaccines are combined with other agents, such as chemically inactivated E. rhusiopathiae or Haemophilus parasuis. Natural or experimental infection with live bacterial cells seems to offer the greatest level of protection against reinfection, suggesting that a live strain would be the ideal vaccine candidate. Several attenuated A. pleuropneumoniae strains have been constructed and conferred various degrees of protection against disease; these included temperature-sensitive, metabolic, nonencapsulated, and nontoxigenic mutants [71–74]. More recently, an attenuated mutant deficient in the biosynthesis of aromatic compounds (HS25 aroQ) has been safely delivered to pigs [75]. 11.5.4 Diseases Caused by Mycoplasma spp.

Mycoplasma spp. cause upper and lower respiratory tract infections in various animals species. These microorganisms contain the smallest bacterial genomes, lack cell walls, and are strictly dependent on the host for survival. Mycoplasma hyopneumoniae is a main player in the porcine respiratory disease complex, leading to significant economic losses. The prevalence of enzootic pneumonia ranges from 30 % to 80 % in different countries. M. hyopneumoniae also creates a port of entry for other pathogens. This phenomenon, known as Mycoplasma-induced respiratory disease (MIRD), aggravates the seriousness of the clinical signs and increases economic losses. MIRD can considerably affect the feed efficiency index (up to 14 %) and the ADG (up to 17.4 %). This situation results in an increase in the fattening period, which in turn leads to decreased rotation rates, increased labor and feeding costs, and reduced annual production. Infections spread from the infected sow to its litter and from older to younger susceptible pigs. Commercial vaccines have been available since 1991. They are based on inactivated and adjuvanted bacteria and are administered to baby or feeder pigs, as well as to breeding stocks. Some of the vaccine preparations have been combined with antigens from other pathogens, such as inactivated E. rhusiopathiae or H. parasuis, the etiologic agent of Glasser disease (i. e., polyserositis). Mycoplasma gallisepticum is also an important pathogen that causes chronic respiratory disease in chicken. Vaccination with killed or living vaccines is an option for controlling infections in poultry flocks when hygienic measures fail. Live attenuated M. gallisepticum vaccines include the strains F, ts-11, and 6/85. The F-strain (ad-

237

238

11 Classical Bacterial Vaccines

ministered in drinking water or by aerosol) reduces the decline in egg production but has residual virulence. On the other hand, strain ts-11 is less virulent and immunogenic, but still provides effective long-term protection [76]. Temperature-sensitive mutants of M. gallisepticum (TS100) were used to immunize newly hatched chickens and protected them from developing air-sac lesions [77]. Mycoplasma agalactiae is the causal agent of contagious agalactia in small ruminants. The disease, which is more frequent in the Mediterranean region, north Africa, and the Middle East, is characterized by mastitis, arthritis, and pneumonia. Killed organisms are usually administered in combination with adjuvants. Inactivation with phenol seems to confer better protection than formalin- or heat-inactivation [78]. The lack of protection observed in the field may be due to infections with other Mycoplasma spp. Improved protection in comparison to killed vaccines was observed with live attenuated strains of M. agalactiae [79]. 11.5.5 Salmonellosis in Animals

Salmonella causes diseases characterized by acute or chronic enteritis and septicemia in many animal species, which are the principal reservoirs for human infections. Transmission to humans occurs by contaminated drinking water or food products (e. g., milk, meat, eggs), and their incidence has increased worldwide due to the intensification of livestock production. S. enterica serovar Typhimurium became the second-most-important cause of salmonellosis in humans. Since vaccination is compulsory for poultry meat producers, and EU regulations also require monitoring of broiler-breeder flocks and slaughter of infected flocks, efforts have been made to develop efficacious multivalent vaccines for poultry [80]. One of these vaccines consists of iron-restricted inactivated S. typhimurium and S. enteritidis. After intramuscular vaccination, chickens are protected against an oral challenge, but colonization still occurs [81]. Other mutants, e. g., dam, show better results with respect to protection and colonization [82]. The first live oral vaccine against S. typhimurium and S. enteritidis was launched by Lohmann Animal Health in 2003 (TAD Salmonella). Three doses administered into the birds’ drinking water give protection throughout the laying period. The efficacy of live vaccine candidates against Salmonella choleraesuis (e. g., Argus SC), which causes infections in pigs, has also been evaluated. Vaccinated pigs were able to maintain normal weight after challenge [83], and field studies demonstrated that this type of vaccine can lower the prevalence of Salmonella in swine herds. Salmonella gallinarum and S. pullorum cause fowl typhoid and pullorum disease in birds. The clinical manifestations include anorexia, diarrhea, hepatitis, splenitis, myocarditis, pneumonia, ophthalmitis, and high mortality due to septicemia. This leads to decreased egg production and fertility. Thus, inactivated and live attenuated vaccine strains have been developed for poultry [80]. Since 1950 attenuated derivatives of S. gallinarum strain 9 have been extensively assessed. One of them was attenuated by passage in a medium of low nutritional quality, leading to the so-called 9R fowl typhoid strain, which confers strong protection to adult chickens after intramus-

11.5 Veterinary Bacterial Vaccines

cular injection. However, this strain retains some virulence, may persist for many months, and can be transmitted through the egg. To obtain a more avirulent strain, an aro A mutant was developed, but it was less effective [84]. A single oral immunization with a S. gallinarum nuoG derivative reduced the mortality in 2-week-old chickens following challenge with virulent S. gallinarum from 75 % to less than 8 % [85]. Another approach was the intramuscular application of attenuated ‘phage type’ PT4 S. enteritidis. 11.5.6 Leptospirosis (Leptospira spp.)

Leptospirosis is one of the most widespread diseases in livestock and is caused by over 250 immunologically distinct serovars. Bacteria are spread by contact of skin or mucous membranes with contaminated products. Infected animals contribute to further spreading of the disease by actively shedding bacteria. Infections may be asymptomatic or symptomatic (e. g., fever, icterus, hemoglobinuria, renal failure, infertility, abortion, and death). Of the distinct pathogenic serovars, only a small number have been isolated from domestic animals. It is remarkable that only moderate cross-immunity between serovars is observed. Cattle, swine, and horses are the most economically relevant affected species. Because leptospirosis in domestic animals is leading to significant economic losses and infected animals are a potential source of human infection, vaccination with polyvalent vaccines have been widely implemented. Certain occupational groups, such as farmers, sewer workers, and meat workers, have special risks of acquiring the disease. Outdoor leisure activities can also lead to exposure to infection. Inactivated polyvalent vaccines containing different Leptospiras (e. g., grippotyphosa, hardjo, icterohaemorrhagiae, canicola, pomona) are commercially available for preventing abortions and stillborns in livestock and pets. Most of them have been combined with components against other pathogens, such as E. rhusiopathiae, parvovirus, Campylobacter, bovine rhinotracheitis virus, bovine diarrhea virus, and bovine respiratory syncytial virus. 11.5.7 Other Commercially Relevant Animal Diseases

Vaccines that are able to prevent other diseases in livestock and pets have also been developed and implemented in the field. Among them are inactivated oil-adsorbed vaccines against Haemophilus paragallinarum, which is responsible for infectious coryza in chickens. This disease is characterized by swelling of the infraorbital sinuses, facial edema, oculonasal discharge, and sneezing and may cause significant losses in the poultry industry. Inactivated adjuvanted vaccines based on various strains of Fusobacterium necrophorum and/or Bacteroides nodosus are also available to prevent and treat chronic foot rot in sheep and acute foot rot in cattle. It is also possible to immunize against equine monocytic ehrlichiosis by using a whole-cell inactivated Ehrlichia risticii preparation. For pigs, killed vaccines against Streptococcus suis have also been developed. In addition, inactivated vaccines that are based on inactivated

239

240

11 Classical Bacterial Vaccines

enterotoxigenic and enteropathogenic E. coli combined with toxoids are available for preventing post-weaning diarrhea. Chlamydia psittaci is responsible for respiratory infections in cats, leading to serous conjunctivitis, sneezing, and nasal discharge. Vaccinated cats have mild clinical disease and are protected from severe clinical disease after challenge exposure. Due to the frequent emergence of adverse effects (e. g., lethargy, anorexia, lameness, and fever), the use of vaccines is frequently restricted to cats at risk of exposure. Live attenuated vaccines may cause atypical reactions in about 3 % of vaccinated cats. Finally, vaccines have been also developed to prevent bacterial infections in fish. A live attenuated vaccine is used to prevent the enteric septicemia caused by Edwardsiella ictaluri, which costs millions of dollars to the catfish industry.

11.6 Conclusions

During the past 200 years, various vaccines have been developed and exploited to control major diseases. In many instances, however, the exact mechanisms of action of successful vaccines were not fully understood. A new generation has emerged, of well-defined recombinant and/or subunit vaccines that exhibit a considerably improved safety profile. However, classical bacterial vaccines have not only played a critical role in the efficient control of infectious diseases in the past, they are still instrumental for the prevention of infections in both humans and, particularly, animal populations.

Acknowledgements

We thank Joan Plana Duran (Fort Dodge Veterinaria S. A.), Guido Dietrich (Berna Biotech Ltd.), and Lothar Staendner (GBF) for helpful discussions and critical reading of the manuscript. This work was supported in part by grants from DFG (GU 482/2–1 and GU482/2–2), EU (QLK2-CT-1999–00310), and BMBF (PathoGenoMik 601III4–1/1VIIZV-21) to CAG.

References 1. Dietrich, G., Spreng, S., Favre, D. et al. Curr Opin Mol Ther 2003, 5, 10–19. 2. Evans, D., Evans, D., Opekun, A. et al. FEMS Microbiol Immunol 1988, 1, 9–18. 3. Lubitz,W. Expert Opin Biol Ther 2001, 1, 765–771. 4. Mock, M. and Fouet, A. Annu Rev Microbiol 2001, 55, 647–671. 5. Turnbull, P. Vaccine 1991, 9, 533–539.

6. Brossier, F.,Weber-Levy, M., Mock, M. et al. Infect Immun 2000, 68, 1781–1786. 7. Welkos, S. L. Microb Pathog 1991, 10, 183–198. 8. Friedlander, A.,Welkos, S. and Ivins, B. Curr Top Microbiol Immunol 2002, 271, 33–60. 9. Ryan, E. T. and Calderwood, S. B. Clin Infect Dis 2000, 31, 561–565.

References 10. Levine, M. M., Kaper, J. B., Black, R. E. et al. Microbiol Rev 1983, 47, 510–550. 11. Clemens, J. D., van Loon, F., Sack, D. A. et al. Lancet 1991, 337, 883–884. 12. Sack, D., Cadoz M Cholera Vaccines, in: Vaccines, eds Plotkin S., Orenstein, WA, 1999, 639–649. 13. Clemens, J. D., Sack, D. A., Harris, J. R. et al. Lancet 1990, 335, 270–273. 14. Levine, M. M. and Kaper, J. B. Vaccine 1993, 11, 207–212. 15. Tacket, C. O., Cohen, M. B., Wasserman, S. S. et al. Infect. Immun. 1999, 67, 6341–6345. 16. Kenner, J. R., Coster,T. S.,Taylor, D. N. et al. J Infect Dis 1995, 172, 1126– 1129. 17. Evans, D., Evans, D., Opekun, A. et al. FEMS Microbiol Immunol 1988, 1, 117– 125. 18. Ahren, C., Jertborn, M. and Svennerholm, A.-M. Infect. Immun. 1998, 66, 3311–3316. 19. Savarino, S., Hall, E., Bassily, S. et al. J Infect Dis 1999, 179, 107–114. 20. Perry, R. and Fetherston, J. Clin. Microbiol. Rev. 1997, 10, 35–66. 21. Titball, R. W. and Williamson, E. D. Vaccine 2001, 19, 4175–4184. 22. Titball, R., Eley, S.,Williamson, E. et al. Plague, in: Vaccines, eds Plotkin S., Orenstein,WA, 1999, 734–742. 23. Kotloff, K. L.,Winickoff, J. P., Ivanoff, B. et al. Bull World Health Organ 1999, 77, 651–666. 24. Meitert,T., Pencu, E., Ciudin, L. et al. Arch Roum Path Ecp Microbiol 1984, 43, 251–278. 25. Mel, D. M., Papo, R. G.,Terzin, A. L. et al. Bull World Health Organ 1965, 32, 637–645. 26. Cohen, D., Ashkenazi, S., Green, M. S. et al. Lancet 1997, 349, 155–159. 27. Fries, L. F., Montemarano, A. D., Mallett, C. P. et al. Infect Immun 2001, 69, 4545–4553. 28. Levenson,V. J., Mallett, C. P. and Hale,T. L. Infect Immun 1995, 63, 2762– 2765. 29. Dye, C., Scheele, S., Dolin, P. et al. JAMA 1999, 282, 677–686. 30. Weill-Halle, B. Oral vaccination, in: BCG vaccination against tuberculosis, ed Rosenthal S. R., 1957, 175–182.

31. Behr, M. A.,Wilson, M. A., Gill,W. P. et al. Science 1999, 284, 1520–1523. 32. Collins, H. L. and Kaufmann, S. H. Lancet Infect Dis 2001, 1, 21–28. 33. Colditz, G. A., Brewer,T. F., Berkey, C. S. et al. JAMA 1994, 271, 698–702. 34. Garmory, H. S., Brown, K. A. and Titball, R. W. FEMS Microbiol Rev 2002, 26, 339–353. 35. Engels, E. A., Falagas, M. E., Lau, J. et al. BMJ 1998, 316, 110–116. 36. Levine, M. M., Dupont, H. L., Hornick, R. B. et al. J Infect Dis 1976, 133, 424–429. 37. Levine, M. M., Ferreccio, C., Abrego, P. et al. Vaccine 1999, 17, S22–S27. 38. Klugman, K. P., Gilbertson, I. T., Koornhof, H. J. et al. Lancet 1987, 2, 1165–1169. 39. Lin, F. Y. C., Ho,V. A., Khiem, H. B. et al. N Engl J Med 2001, 344, 1263– 1269. 40. Dennis, D. T., Inglesby,T. V., Henderson, D. A. et al. JAMA 2001, 285, 2763– 2773. 41. Coriell, L., King, E. and Smith, M. J Immunol 1948, 58, 183–202. 42. Kadull, P., Reames, H., Coriell, L. et al. J Immunol 1950, 65, 425–435. 43. Burke, D. S. J Infect Dis 1977, 135, 55– 60. 44. WHO World Health Report, 2002. 45. Gordon, J. and Hood, H. Am J Med Sci 1951, 222, 333–361. 46. Stewart, G. T. Lancet 1977, 1, 234–237. 47. Hoffman, H. J., Hunter, J. C., Damus, K. et al. Pediatrics 1987, 79, 598–611. 48. Melchior, J. C. Arch Dis Child 1977, 52, 134–137. 49. Baraff, L. J., Shields,W. D., Beckwith, L. et al. Pediatrics 1988, 81, 789–794. 50. Miller, D.,Wadsworth, J., Diamond, J. et al. Dev BiolStand 1985, 61, 389– 394. 51. Wilson, C. B. and Marcuse, E. K. Nat Rev Immunol 2001, 1, 160–165. 52. Campins-Marti, M., Cheng, H. K., Forsyth, K. et al. Vaccine 2001, 20, 641– 646. 53. Makela, P. H. FEMS Microbiology Reviews 2000, 24, 9–20. 54. Elias, B., Albert, M.,Tuboly, S. et al. J Vet Med Sci 1992, 54, 1105–1110. 55. Riising, H., van Empel, P. and

241

242

11 Classical Bacterial Vaccines

56.

57. 58. 59. 60. 61.

62.

63. 64. 65.

66. 67. 68. 69.

Witvliet, M. Vet Rec 2002, 150, 569– 571. Ehser, U., Mehlhorn, G. and Mietke, H. Dtsch Tierårztl Wochenschr 1993, 100, 355–359. Confer, A. Vet Microbiol 1993, 37, 353– 368. Adler, B., Bulach, D., Chung, J. et al. J Biotechnol 1999, 73, 83–90. Scott, P., Markham, J. and Whithear, K. Avian Dis 1999, 43, 83–88. Zhan,Y.,Yang, J. and Cheers, C. Infect Immun 1993, 61, 2841–2847. Murphy, E., Sathiyaseelan, J., Parent, M. et al. Immunology 2001, 103, 511– 518. Schurig, G. G., Sriranganathan, N. and Corbel, M. J. Veterinary Microbiology 2002, 90, 479–496. Xin, X. Vaccine 1986, 4, 212–216. Schurig, G., Roop, R., Bagchi,T. et al. Vet Microbiol 1991, 28, 171–188. Lord,V., Schurig, G., Cherwonogrodzky, J. et al. Am J Vet Res 1998, 59, 1016–1020. Palmer, M., Olsen, S. and Cheville, N. Am J Vet Res 1997, 58, 472–477. Stevens, M., Olsen, S., Palmer, M. et al. Infect. Immun. 1996, 64, 4534–4541. Elzer, P., Enright, F., Colby, L. et al. Am J Vet Res1998, 59, 1575–1578. Kolar, J. Brucellosis in eastern European countries. In: Brucellosis : Clinical and Laboratory Aspects, eds Young E., Corbel M.,1989, 163–172.

70. Sebunya,T. and Saunders, J. J Am Vet Med Assoc1983, 182, 1331–1337. 71. Byrd,W. and Hooke, A. Curr Microbiol 1997, 34, 149–154. 72. Fuller,T.,Thacker, B. and Mulks, M. Infect. Immun. 1996, 64, 4659–4664. 73. Inzana,T.,Todd, J. and Veit, H. Infect Immun 1993, 61, 1682–1686. 74. Prideaux, C., Pierce, L., Krywult, J. et al. Curr Microbiol 1998, 37, 324–332. 75. Ingham, A., Zhang,Y. and Prideaux, C. Veterinary Microbiology 2002, 84, 263– 273. 76. Whithear, K. Rev Sci Tech 1996, 15, 1527–1553. 77. Lam, K., Lin,W.,Yamamoto, R. et al. Avian Dis 1983, 27, 803–812. 78. Tola, S., Manunta, D., Rocca, S. et al. Vaccine 1999, 17, 2764–2768. 79. Foggie, A., Etheridge, J. R., Erdag, O. et al. Res Vet Sci 1970, 11, 477–479. 80. Zhang-Barber, L.,Turner, A. K. and Barrow, P. A. Vaccine1999, 17, 2538– 2545. 81. Clifton-Hadley, F. A., Breslin, M., Venables, L. M. et al. Vet Microbiol 2002, 89, 167–179. 82. Dueger, E. L., House, J. K., Heithoff, D. M. et al. Int J Food Microbiol 2003, 80, 153–159. 83. Kramer,T., Roof, M. B. and Matheson, R. R. Am J Vet Res1992, 53, 444–448. 84. Griffin, H. G. and Barrow, P. A. Vaccine 1993, 11, 457–462. 85. Zhang-Barber, L.,Turner, A., Dougan, G. et al. Vaccine 1998, 16, 899–903.

243

12 Subunit Vaccines and Toxoids Maria Lattanzi, Giuseppe Del Giudice, and Rino Rappuoli

12.1 Introduction

An ideal subunit vaccine is a vaccine that contains those antigen(s) essential for the microbial pathogenesis and virulence against which it is important to induce a protective immune response. Historically, detoxified bacterial toxins were the first subunit vaccines ever developed. This was made possible by the discovery in the 1920s that formaldehyde treatment was able to detoxify tetanus and diphtheria toxin and by the demonstration that animals immunized with the toxoids were protected against challenge with the wild toxin [26, 69]. Since then, the development of new subunit vaccines has been focused towards more and more purified antigens, like native and recombinant proteins, either alone or conjugated with bacterial poly- or oligosaccharides. These highly purified proteins are much more characterized at the molecular level than the first old vaccines, which contained impurities from the pathogen or from the purification process.

12.2 Toxoids

Toxins are virulence factors that are produced by a pathogen and secreted into extracellular space. Sometimes, the release of a potent toxin can induce clinical manifestations of a disease, even in the absence of an invasive infection, as with diphtheria and tetanus. Therefore, both diseases can be prevented solely by the presence of toxin-neutralizing antibodies, which can be induced by active immunization with nontoxic forms of the toxin or be provided by passive immunization. The discovery of an effective method to detoxify tetanus and diphtheria toxins by formaldehyde treatment, made in 1924 by Ramon in France [69, 70] and Glenny and Hopkins in England [26], allowed the introduction of mass immunization that led to the almost complete elimination of both diseases from developed countries. For these two vaccines, the titers of serum antibodies to antitoxin correlate well with protection. Diphtheria and tetanus vaccines are presently still prepared by the method described

244

12 Subunit Vaccines and Toxoids

by Ramon and are mostly used in combination with other antigens (whole-cell or acellular pertussis, inactivated polioviruses, Haemophilus influenzae type b capsular polysaccharide, hepatitis B surface antigen) for infant immunization. Tetanus vaccines combined with a low dose of diphtheria toxoid are used to boost immunity in adults [71].

12.3 Subunit Vaccines: Conventional Vaccinology Approach 12.3.1 Polysaccharide Vaccines

Host defense against encapsulated bacteria depends on the phagocytic uptake and killing of bacteria by polymorphonuclear neutrophils. The presence of anticapsular polysaccharide IgG antibodies triggers the direct complement-mediated killing and/ or uptake of bacteria by phagocytes through opsonization. Moreover, the observation that mutants without the capsule are nonpathogenic, due to their high susceptibility to serum complement, led to the use of the capsular polysaccharide as the antigen of choice for the development of subunit vaccines [27, 28]. Purified capsular polysaccharides have been used to develop vaccines against Neisseria meningitidis group C (MenC), group A (MenA), group Y (MenY), and group W135 (MenW135) [39, 52], against 23 serotypes of Streptococcus pneumoniae [101], against Haemophilus influenzae type b [95], and against Salmonella typhi using the Vi polysaccharide [63]. All these vaccines have several disadvantages. Capsular polysaccharides are T-independent antigens: they can induce only transient antibody responses (mainly of IgM and IgG2 isotypes) mainly in adults. Their immunogenicity and efficacy are very poor or absent in children, especially those below two years of age. Moreover, polysaccharides do not induce any immunological memory, and repeated immunizations not only are unable to increase specific antibody titers, they can sometimes even provoke tolerance in adults [29]. In meningococcal meningitis, polysaccharide vaccines have proved useful for control of epidemic MenA disease in adults in Africa, but they are a poor public health tool for prevention of epidemics by routine childhood vaccination [35]. Many studies have suggested that the vaccines do not substantially affect carriage of serogroup A meningococci 1 year after vaccination and that they do not provide herd immunity [35, 96]. With S. pneumoniae, the efficacy of the 23-valent polysaccharide vaccine against pneumonia and invasive diseases is still questionable [101]. There is agreement, however, that this vaccine fails to decrease the carriage rates in children and adults [13]. The solution to the issues related to polysaccharide vaccines was found by conjugating the polysaccharides with the toxoids. This procedure converts T-independent antigens into T-dependent antigens by providing a source of appropriate T-cell epitopes (present in the carrier protein) able to prime carrier-specific T cells, which provide help to B cells for the production of sugar-specific antibodies. This technology

12.3 Subunit Vaccines: Conventional Vaccinology Approach

has been successfully applied to the development of conjugate vaccines, which now represent a powerful tool replacing the plain polysaccharide vaccines. 12.3.2 Recombinant DNA Technology for Subunit Vaccines

To develop a subunit vaccine (which consists only of one or a few pathogen components) a superior knowledge and a more advanced technology is needed than to develop a killed whole-cell vaccine. For these reasons, with the important exception of diphtheria and tetanus toxoids, which even today are manufactured with an 80-year-old technology, subunit vaccines are the newest vaccines to be developed and introduced into routine immunization programs. This was possible thanks to the development of modern molecular biology and recombinant DNA technology in the late 1970s, which represented a real revolution in vaccinology. Despite the introduction of these new technologies, one of the major issues for the development of subunit vaccines is the identification of protective antigens from a given microorganism. With a conventional biotechnological approach, the pathogen is first studied to identify the key factors in pathogenesis and immunity, and the identified factors are then produced in large scale by recombinant DNA. Several steps are needed in this approach, to develop a new vaccine. First, the pathogen is grown under laboratory conditions, to identify its individual components. Each component is produced in pure form and then tested for its ability to induce immunity. This approach takes time, allows only one antigen to be taken into consideration each time, and, significantly, achieves identification only of those components that are expressed or can be purified in large quantities. Unfortunately, the most abundant proteins are not necessarily the most suitable vaccine candidates, and the genetic tools required to identify the less available components may be inadequate or not available. Moreover, it can also happen that antigens that play an important role during infection in vivo are not equally well expressed in vitro. Therefore, this conventional biotechnological approach can require decades to develop a vaccine, and sometimes it can fail completely. Once a suitable antigen is identified, it needs to be produced in genetically engineered prokaryotic or eukaryotic vectors and then purified as a recombinant protein. Although successful in several cases, the conventional vaccinology approach took a long time to provide vaccines against those pathogens for which the solution was simple. In marked contrast, this approach cannot produce a product for those complex pathogens, bacteria and parasites, that do not have evident immunodominant protective antigens. The conventional approach also means that vaccine development is not possible when the pathogen cannot be grown in the laboratory. However, despite these limitations, this approach has generated three very efficacious recombinant vaccines: the hepatitis B vaccine, the acellular vaccine against Bordetella pertussis, and the recombinant vaccine against Lyme disease.

245

246

12 Subunit Vaccines and Toxoids

12.3.2.1 HBV Vaccine In the 1970s it was shown that the antibody response to the hepatitis B surface antigen (HBsAg), which circulated in the bloodstream in large quantities, correlated with protection against disease. These discoveries led to the development of plasmaderived HBsAg subunit vaccines [47]. The application of recombinant DNA technology allowed the production of safer yeast- and mammalian cell-derived vaccines, which replaced the older vaccine. This represents the first recombinant subunit vaccine developed [93]. The recommended series of three intramuscular doses induce a protective antibody response in >90 % of healthy adults younger that 40 years of age. After age 40, the cumulative age-specific decline in immunogenicity drops below 90 %; however, by the age 60, 75 % of vaccinees develop protective levels of anti-HBs [77, 99]. In 1992, the Global Advisory Group of the World Health Organization recommended that all countries integrate hepatitis B vaccine into national immunization programs by 1997 [47]. By June 2001, 129 countries had included hepatitis B vaccine as part of their routine immunization programs, and by the end of 2002, 41 out of the 51 countries of the WHO European Region had implemented universal hepatitis B immunization [94]. The ultimate goal of hepatitis B vaccination programs is to decrease the incidence of HBV-related chronic liver disease and hepatocellular carcinoma. Recent studies in Taiwan have clearly demonstrated a reduction in the incidence of primary liver cancer in children born after the implementation of routine infant hepatitis B vaccination programs [41]: these results provide assurance that the strategy of routine infant immunization is a well-conceived public health practice that will benefit generations to come. In addition, these results show that vaccination against cancers due to infectious diseases is feasible. This may pave the way to development of vaccines against other cancers, e. g., cervical cancer by papilloma viruses [44], gastric cancer by Helicobacter pylori [16]. Efforts are under way to develop better HBV vaccines, the goal being to improve vaccine immunogenicity and simplify the delivery. Several strategies are being pursued: using novel adjuvants such as MF59 [37], the AS04 (MPL plus aluminum hydroxide) adjuvant system [19], or CpG oligonucleotides [14, 15]; adding other HBV protein sequences such as the preS sequence [5, 74]; or encapsulating the vaccine in control-released microparticles to achieve single-dose vaccination [86]. 12.3.2.2 Acellular Pertussis Vaccine A vaccine composed of whole, inactivated B. pertussis cells has been available for mass vaccination since the late 1940s [43]. This vaccine was very efficacious in preventing the disease, but the presence of severe adverse reactions, although never proved to be caused by the vaccine, caused a drop in vaccine compliance in the 1970s and stressed the need for a new, safer vaccine. Because pertussis toxin represents one of the major virulence factors of B. pertussis, several researchers developed acellular pertussis vaccines containing chemically inactivated purified PT. However, it is recognized that chemical treatment of PT with formaldehyde and glutaraldehyde is associated with significant reversion rates [53]. To overcome these problems, Pizza and coworkers applied genetic engineering to develop a mutant PT that had all the antigenic properties, without the toxic effects: this genetically

12.3 Subunit Vaccines: Conventional Vaccinology Approach

detoxified pertussis toxin is the first bacterial recombinant subunit vaccine ever developed [61]. The safety and immunogenicity of genetically inactivated PT has been tested in clinical trials, both in adult volunteers and in infants and children, as a monovalent mutant PT alone [64, 66], in association with FHA and pertactin [65, 67], and also with FHA and pertactin in association with diphtheria and tetanus toxoids (DTaP) [32, 56]. These trials showed that the various acellular vaccine formulations containing the nontoxic PT mutant were extremely safe and much safer than whole-cell pertussis vaccines. Furthermore, all formulations induced high titers of anti-PT neutralizing antibodies and very strong antigen-specific T-cell proliferative responses. Interestingly enough, about 5 to 6 years after the primary immunization schedule, this vaccine still exhibited an efficacy of about 80 %, and both antigen-specific antibody and CD4+ T-cell responses were still detectable at significant levels [20, 80]. 12.3.2.3 Lyme Disease Vaccine Early research demonstrated protection in hamsters given whole-cell preparations of Borrelia burgdorferi [40]. However, concerns about cross-protection and the potential reactogenicity and toxicity of a whole-cell preparation provided the impetus for pursuit of a recombinant vaccine [100]. Among several candidate proteins, outer surface protein A (OspA) was immunogenic and protective in a mouse model of infection [23, 100]. In December 1998, the US FDA licensed the first vaccine to prevent Lyme disease, which consisted of lipidated recombinant B. burgdorferi OspA, adjuvanted with aluminum hydroxide. Subsequently, in 1999, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommended the vaccination for persons 15 to 70 years old who live in or visit high-risk areas and have frequent or prolonged exposure to ticks [1]. In a large phase III multicenter double-blind trial, the vaccine was administered on a 0-, 1-, and 12-month schedule. Efficacy for preventing symptomatic Lyme disease was 76 % after three doses and 49 % after two doses of vaccine. Efficacy for preventing asymptomatic disease was 100 % after the third dose and 83 % after the first two doses [85, 88]. The vaccine stimulates production of antibodies that are believed to destroy or inactivate the spirochetes in the midgut of the infected tick, preventing their transmission to the tick’s host [17, 18]. Because some patients with HLA-DR4 class II major histocompatibility complex (MHC) subtypes (0401 and 0404) and with elevated levels of antibodies to rOspA develop treatment-resistant arthritis after naturally acquired Lyme disease, some concerns were raised that Lyme arthritis could be induced by OspA-based vaccines. However, a recent comprehensive post-licensing study on serious adverse events of over 1.4 million doses of the Lime disease vaccine administered from December 1998 to July 2000 did not detect any unexpected or unusual patterns [45].

247

248

12 Subunit Vaccines and Toxoids

12.4 The Future of Subunit Vaccine Development : The Genomic Approach

The dawn of the new millennium coincides with the beginning of the golden era of genomics. In the 1970s, sequencing a gene was impossible. Sequencing became possible in the 1980s, but approximately a year was necessary for a research team to sequence a gene of 2000 base pairs. Today, the situation is completely changed: the possibility of determining the complete genome sequence of a bacterium in a few months at low cost has allowed the sequencing of the genome of most bacterial pathogens in a short period of time (Table 12.1). Moreover, even higher organisms like parasites can be studied with this approach, collecting huge amounts of useful information. Powerful technologies such as genome sequencing, in silico analysis, proteomics (two-dimensional (2D) gel electrophoresis and mass spectrometry), DNA microarrays, in vivo expression technology (IVET), and signature tagged mutagenesis (STM) have revolutionized the way of studying microbial pathogenesis and vaccine design. The possibility to have access to the whole genome sequences of microorganisms has completely reversed the conventional approach to vaccine development. The genomic approach, also called ‘reverse vaccinology’ [72], does not start from microbiology, but from the comprehensive genomic sequence of the pathogen and, by strict computer analysis, it can predict those antigens that are most likely to be vaccine candidates. Knowledge of the genome of a microorganism makes unnecessary the cultivation of the pathogen itself, in marked contrast with the conventional approach. Analysis of the genome allows all the protein antigens to be equally visible at once, no matter which of them is more or less abundantly expressed in vitro and in vivo or in which phase of growth. This avoids handling dangerous pathogens and also offers the possibility of developing vaccines even for pathogens that cannot be cultured. Moreover, the process allows the identification, not only of all the antigens selected by the conventional biochemical, serological, and microbiological methods, but also the discovery of novel, unknown antigens [73]. In this sense, the genomic approach is much more ‘democratic’ than the conventional one, because all protein antigens can be selected, regardless of their condition, function, etc. The availability of suitable animal models of infection and knowledge of immunological correlates of protection, however, are still essential for identifying good vaccine candidates. Unfortunately, since good correlates of protection are infrequent, this may limit the speed and effectiveness of the approach. Another limit of the genomic approach is its inability to identify nonprotein antigens, such as polysaccharides, which are components of successful vaccines (see above), or to identify CD1-restricted antigens such as glycolipids, which represent new promising vaccine candidates, as in tuberculosis [82]. 12.4.1 When Theory Becomes Reality: The MenB Example

The most obvious approach to the development of a vaccine against N. meningitidis serogroup B (MenB) would be a conjugate vaccine using the capsular polysaccharide,

12.4 The Future of Subunit Vaccine Development: The Genomic Approach Tab. 12.1 Microbial genomes sequenced as of March 18, 2003 (www.tigr.org). Filum

Species

Strain

Archaea

Aeropyrum pernix Archaeoglobus fulgidus Halobacterium sp. Methanobacterium thermoautotrophicum Methanococcus jannaschii Methanopyrus kandleri Methanosarcina acetivorans Methanosarcina mazei Pyrobaculum aerophilum Pyrococcus abyssi Pyrococcus furiosus Pyrococcus horikoshii shinkaj Sulfolobus solfataricus Sulfolobus tokodaii Thermoplasma acidophilum Thermoplasma volcanium

K1 DSM4304 NRC-1 delta H DSM2661 AV19 C2A Goe1 IM2 GE5 DSM 3638 OT3 P2 strain 7 DSM 1728 GSS1

Bacteria

Agrobacterium tumefaciens Agrobacterium tumefaciens Aquifex aeolicus Bacillus halodurans Bacillus subtilis Borrelia burgdorferi Brucella melitensis Brucella suis Buchnera aphidicola Buchnera sp. Campylobacter jejuni Caulobacter crescentus Chlamydia muridarum Chlamydia pneumoniae Chlamydia pneumoniae Chlamydia pneumoniae Chlamydia trachomatis Chlorobium tepidum Clostridium acetobutylicum Clostridium perfringens Corynebacterium glutamicum Deinococcus radiodurans Enterococcus faecalis Escherichia coli Escherichia coli O157:H7 Escherichia coli O157:H7 Fusobacterium nucleatum Haemophilus influenzae Helicobacter pylori Helicobacter pylori Lactococcus lactis subsp lactis

C58 Cereon C58 Uwash VF5 C-125 168 B31 16M 1330 Sg APS NCTC 11168 CB15 strain Nigg AR39 CWL029 J138 serovar D TLS ATCC824 13 ATCC 13032 R1 V583 K12-MG1655 EDL933 VT2-Sakai ATCC 25586 KW20 26695 J99 IL1403

Human pathogen

Genome used for vaccine development

✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓

✓ ✓

✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓

✓

249

250

12 Subunit Vaccines and Toxoids Tab. 12.1 (continued) Filum

Species

Strain

Listeria innocua Listeria monocytogenes Magnetococcus sp. Mesorhizobium loti Mycobacterium leprae Mycobacterium tuberculosis Mycobacterium tuberculosis Mycoplasma genitalium Mycoplasma pneumoniae Mycoplasma pulmonis Neisseria meningitidis Neisseria meningitidis Nostoc sp. Oceanobacillus iheyensis Pasteurella multocida Porphyromonas gingivalis Pseudomonas aeruginosa Pseudomonas putida Ralstonia solanacearum Rickettsia conorii Rickettsia prowazekii Salmonella enterica serovar Typhi Salmonella typhimurium Shewanella oneidensis Sinorhizobium meliloti Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pyogenes Streptococcus pyogenes Streptococcus pyogenes Streptomyces coelicolor Synechocystis sp. Thermoanaerobacter tengcongensis Thermosynechococcus elongatus Thermotoga maritima Treponema pallidum Ureaplasma urealyticum parvum Vibrio cholerae El Tor Xanthomonas axonopodis pv. Xanthomonas campestris pv. campestris Xylella fastidiosa Yersinia pestis Yersinia pestis

CLIP 11262 EGD-e MC-1 MAFF303099 TN CDC1551 H37Rv lab strain G-37 M129 UAB CTIP MC58 group A Z2491 PCC 7120 HTE831 PM70 W83 PAO1 KT2440 GMI1000 Malish 7 Madrid E CT18 LT2 SGSC1412 MR-1 1021 COL Mu50 MW2 N315 2603V/R R6 TIGR4 MGAS315 MGAS8232 SF370 type M1 A3(2) PCC6803 MB4(T) BP-1 MSB8 Nichols biovar serovar 3 N16961 citri 306 ATCC33913 9a5c CO92 KIM

Human pathogen

Genome used for vaccine development

✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓

✓

✓

✓

✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓

✓ ✓ ✓

✓ ✓

✓

✓ ✓

12.4 The Future of Subunit Vaccine Development: The Genomic Approach

as has been done for the other major meningococcal serogroups. Unfortunately, a polysaccharide-based approach cannot be used for this strain, because the MenB capsular polysaccharide is identical to a widely distributed human carbohydrate ( a(2–8)N-acetyl neuraminic acid, or polysialic acid). This renders the polysaccharide poorly immunogenic in humans. Furthermore, the use of this polysaccharide in a vaccine may elicit autoantibodies [24, 36]. An alternative approach to vaccine development is based on surface-exposed proteins contained in outer membrane vesicles (OMVs). These vaccines have been shown both to elicit serum bactericidal antibody responses and to protect against developing meningococcal disease in clinical trials [89]. These trials have provided strong evidence that efficacious vaccines against MenB are feasible. However, the utility of these vaccines is limited by the sequence variability of major protein antigens, which therefore can elicit an immune response only against homologous strains, especially in children less than 5 years old [89]. The attempts to develop noncapsular, non-OMV vaccines using potentially conserved proteins have also failed so far. The proteins that have been investigated the most either are variable at the level of amino acid sequence, such as the transferrinbinding protein B (TbpB) [76] or are expressed by only about 50 % of the MenB strains circulating, such as the neisserial surface protein A (NspA) [50]. Therefore, although in some instances existing vaccines can be used, especially in people more than 5 years old, these conventional approaches seem far from providing a universal vaccine against this bacterium. Given all these problems, the genomic approach was applied to identify novel potential vaccine candidates able to induce protective immunity against all different MenB strains. This was made possible by the knowledge that, for meningococci, protection correlates with titer of antibodies able to kill bacteria in vitro in the presence of complement (bactericidal antibodies). This implied that screening of potential candidates was possible. The entire genome of the virulent strain MenB MC58 was sequenced and analyzed [91]. The computer analysis predicted 600 novel antigens, 350 of which were expressed in Escherichia coli, purified, and used to immunize mice. Sera were tested for bactericidal antibodies, and 85 novel surface-exposed antigens were found, 25 of which induced bactericidal antibodies. Some of the antigens induced bactericidal titers similar to those induced by efficacious OMV vaccines. Surprisingly, the antigens identified by the genomic approach were different from those identified by a conventional biotechnology approach. In fact, in addition to classical outer-membrane proteins with variable loops, many of the new selected antigens were lipoproteins or surface-exposed proteins with a globular structure and without transmembrane domains. Furthermore, some of these antigens are not abundant on the bacterial surface. The detailed analysis of nucleotide and amino acid sequences of the new antigens in a large number of strains led to the observation that most of these newly described proteins were very well conserved in strains representative of the circulating meningococcal population, thus suggesting the potential of their use in a universal vaccine against MenB [62]. Some of these conserved antigens, which can induce bactericidal antibodies in mice against a large panel of MenB strains, are now being developed for testing in phase I trials in humans.

251

252

12 Subunit Vaccines and Toxoids

Because the genomic approach can identify new proteins regardless of their function, it is important to further characterize the new antigens and understand their role in the bacterial physiology. Some of the newly identified antigens, such as GNA33, NadA, GNA992, App, and GNA1870, have been further characterized biochemically and functionally. GNA33 is a lipoprotein highly conserved among all N. meningitidis serogroups and is surface-exposed on both noncapsulated and encapsulated bacteria. GNA33 shows 33 % identity to a membrane-bound lytic transglycosylase (MltA) from E. coli. Biochemical analysis confirmed that the molecule is a murein hydrolase of the lytic transglycosylase class, as it is capable of degrading both insoluble murein sacculi and unsubstituted glycan strands [38]. Recombinant GNA33 elicits a serum bactericidal response that is comparable to that obtained from the immunization with an outer membrane vesicle vaccine and confers passive protection against bacteraemia in infant rats by mimicking a surface-exposed epitope on loop 4 of porin A in strains with serosubtype P1.2 [30]. Epitope mapping of a bactericidal anti-GNA33 monoclonal antibody identified a short motif (QTP) present in GNA33, which is essential for recognition. The QTP motif is also present in the loop 4 of PorA and was also found to be essential but not sufficient for binding of the Mab to PorA [30]. NadA (neisseria adhesin A, NMB1994) induces strong bactericidal antibodies against both homologous and heterologous strains, suggesting that this protein can be a good candidate for a vaccine [11]. Sequence analysis revealed that NadA is homologous to YadA, a non-pilus associated adhesin of enteropathogenic Yersinia, and to UspA2, an ubiquitous protein involved in serum resistance of Moraxella catarrhalis. In spite of a low level of amino acid sequence homology, the three proteins show a well conserved secondary structure. These proteins have, in fact, a carboxyl terminal membrane anchor domain and an internal region with high coiled-coil probability. Interestingly, NadA forms high molecular weight oligomers that are extremely difficult to dissociate even after extensive boiling and treatment with detergents, and such oligomers are anchored to the outer membrane of meningococcus. Interestingly, the nadA gene is not ubiquitous in Neisseria strains, but it is present only in a subgroup of hypervirulent clonal complexes. When present, this antigen has a very well conserved primary structure, and only three defined alleles can be identified, perhaps suggesting recent acquisition of the gene. Furthermore, NadA can bind to human cells in vitro, suggesting a possible role of this novel MenB antigen in the pathogenesis of the disease [11]. GNA992 appears to be strictly related to two adhesins encoded by H. influenzae, Hsf and its allelic variant Hia, both involved in the formation of type b fibrils [87]. The elevated amino acid sequence similarity of GNA992 with Hsf and Hia (57 % and 51% identity, respectively) and the similar topology of the three proteins suggest that they could share a common role in the mechanism of adherence. The three adhesins have a modular structure and are composed of different numbers of repeats. The core of these repetitive units has been identified, and the conserved motif is present in other adhesive molecules of H. influenzae (HMW1), as well as in human proteins belonging to the family of cell adhesin molecules (CAMs), such as NB-2 [55], which also share a conserved folding. On the basis of these common features, GNA992 has been postu-

12.4 The Future of Subunit Vaccine Development: The Genomic Approach

lated to promote adherence of meningococcus to host cells by mimicking the cell–cell recognition phenomena that occur at the neural level [81]. By fluorescence-activated cell sorter (FACS) analysis and Western blots on outer membrane vesicles, GNA992 has been shown to be surface-exposed. Antibodies elicited by GNA992 are bactericidal against a subgroup of MenB strains, and this antigen is therefore being regarded as a possible component of a multi-component protein-based vaccine. App (adhesion and penetration protein) was described by Hadi and coworkers as a member of the autotransporter family and a homologue to the Hap (Haemophilus adhesion and penetration) protein of Haemophilus influenzae, a molecule that plays a role in the interaction with human epithelial cells [34]. Serruto and coworkers expressed App in E. coli to analyze the functional properties of the protein. They showed that the protein is exported to the E. coli surface, processed by an endogenous serine protease activity, and released in the culture supernatant. E. coli expressing app adhere to Chang epithelial cells, showing that App can mediate bacterial adhesion to host cells. The serine protease activity is localized at the amino-terminal domain, whereas the binding domain is in the carboxy-terminal region. The role of App in adhesion was confirmed also in N. meningitidis [84]. GNA1870 is a new surface-exposed lipoprotein of N. meningitidis that induces high levels of bactericidal antibodies. Sequencing of the gene in 71 strains representative of the genetic and geographic diversity of the N. meningitidis population showed that the protein can be classed into three variants. Conservation within each variant ranges between 91.6 % and 100 %, but between the variants the conservation can be as low as 62.8 %. Antibodies against a recombinant form of the protein elicit complement-mediated killing of the strains that carry the same variant and induce passive protection in the infant rat model. Therefore, this novel antigen is a top candidate for the development of a new vaccine against meningococcus [49]. 12.4.2 Further Applications of the Genomic Approach to Vaccine Development 12.4.2.1 Streptococcus pneumoniae Existing vaccines against S. pneumoniae are based on the capsular polysaccharide, either alone or conjugated with a carrier protein [101]. Although the conjugate vaccine is well tolerated and very efficacious against invasive disease caused by the seven serotypes covered by the vaccine [6], this type of vaccine has several potential limitations, including serotype replacement by strains that are not represented [46]. To circumvent these problems, the whole genome sequence was exploited: 130 open reading frames encoding proteins with secretion motifs or similarity to predicted virulence factors were identified; 108 of these proteins were successfully expressed in E. coli and used to immunize mice, and 6 of them conferred protection against disseminated S. pneumoniae infection. Flow cytometry confirmed the surface localization of several of these targets. Each of the six protective antigens showed broad strain distribution and immunogenicity during human infection, providing a good base for the development of improved vaccines against S. pneumoniae [98].

253

254

12 Subunit Vaccines and Toxoids

12.4.2.2 Staphylococcus aureus Despite the availability of potent antimicrobial agents, improved public health conditions, and hospital infection-control measures, S. aureus remains a major human pathogen. Indeed, the development of new antibiotic resistance and other epidemiological conditions have highlighted the need for an effective vaccine. The availability of the genomic sequence has allowed the development of a comprehensive approach for identification of the immunogenic proteins in this pathogen [22]. An approach based on genomic peptide libraries in combination with well characterized human sera was used. Small diversely sized peptide libraries, encoded by randomly fragmented genomic DNA, were generated, to ensure that all potential antigens encoded by the genome of the pathogen could be identified. S. aureus peptides were displayed on the surface of E. coli via fusion to one of two outer membrane proteins (LamB and FhuA) and were probed with sera selected for high antibody titer and opsonic activity. Magnetic cell sorting (MACS) was applied to screen these libraries: this step was able to determine the profile of antigens that are expressed in vivo and elicit an immune response in humans. More than 60 antigenic proteins were identified, most of which are predicted to be secreted or to be located on the cell surface of the bacterium. These antigens represent promising vaccine candidates for further evaluation [22]. 12.4.2.3 Porphyromonas gingivalis A process similar to the one used to develop a vaccine against MenB was used also for P. gingivalis, a key periodontal pathogen that has been implicated in the etiology of chronic adult periodontitis [92]. From a genomic sequence, 120 genes were selected by using a series of bioinformatics methods. The selected genes were cloned for expression in E. coli and then screened using a variety of P. gingivalis antisera before purification. This subset of recombinant proteins was then purified and used to immunize mice, which were subsequently challenged with live bacteria in a subcutaneous abscess model. Two of these recombinant proteins (showing homology to Pseudomonas sp. OprP protein) demonstrated significant protection in the animal model and therefore could represent potential vaccine candidates [78]. 12.4.2.4 Streptococcus agalactiae Streptococcus agalactiae, or group B streptococcus, is the leading cause of bacterial sepsis, pneumonia, and meningitis in neonates in the US and Europe [83]. The best protective known antigen in an animal model is the bacterium’s capsular polysaccharide [2]. Unfortunately, there are at least 9 different capsular serotypes and little or no cross protection among serotypes [3, 4, 42, 58, 59]. Therefore, reverse vaccinology was applied to develop a protein-based vaccine that could confer protection against all the different serotypes. The complete genome of a serotype V strain of S. agalactiae was determined and analyzed [90]. The genome is predicted to include 2175 ORFs, 650 of which were predicted to encode products exposed on the surface of the bacteria. Approximately 350 of these ORFs were successfully expressed in E. coli and their products used to immunize mice. By using the sera in ELISA and flow cytometric analysis against intact bacteria, it was demonstrated that 55 of these proteins are in fact measurably expressed on the surface of the bacterium. These

12.4 The Future of Subunit Vaccine Development: The Genomic Approach

new antigens are now being evaluated in in vitro and in vivo models for their capacity to protect against invasive infection by group B streptococcus. 12.4.2.5 Chlamydia pneumoniae C. pneumoniae is an obligate intracellular parasite with a complex biphasic lifecycle: an extracellular infectious phase characterized by a spore-like form, the elementary bodies (EB), and an intracellular replicative stage characterized by the reticular bodies (RB). The pathogen is a common cause of community-acquired acute respiratory infection and more recently has also been associated with atherosclerotic cardiovascular disease [31]. Because of the technical difficulties in working with C. pneumoniae and the lack of methods for its genetic manipulation, not much is known about the cell surface composition of the EB. To define the surface protein organization of C. pneumoniae, a reverse vaccinology strategy and proteome technology were combined [51]. The approach is based on six main experimental steps: (1) in silico analysis of the C. pneumoniae genome sequence to identify genes potentially encoding surface proteins (including outer and inner membrane and periplasmic proteins); (2) cloning, expression, and purification of selected candidates; (3) use of purified antigens to generate mouse immune sera; (4) analysis of sera specificity by Western blotting of total EB extracts; (5) assessment of antigen localization by FACS analysis on whole EBs; and (6) identification of FACS-positive antigens on 2DE maps of C. pneumoniae EB proteins. The results of this systematic genome–proteome approach represent the first successful attempt to define surface protein organization of C. pneumoniae and raise the possibility of finding suitable candidates for a purified vaccine. 12.4.3 The Genomic Approach to Parasite Vaccines

Despite many years of studies and several candidates that have reached Phase I or II clinical trials [75], we still are a long way from an efficacious vaccine able to combat malaria, the burden of which is increasing due to drug resistance and to worsening environmental and social conditions, mainly in Africa [33]. Development of a vaccine against malaria is a very hard task, for many reasons: immunity against malaria parasites is not only species-specific for the four species of human Plasmodia, but also specific for each stage of their development. Moreover, many parasite proteins exhibit polymorphism, which potentially limits the effectiveness of any vaccine not incorporating distinct variants of antigens. So far, antigen choice has been dominated by the arbitrary order in which antigens have been identified with the conventional vaccinology approach. The sequence of the Plasmidium falciparum genome recently published [24] is a great achievement for vaccine development, because it should allow selection of the very best vaccine candidates. Expression of genes predicted to be immunogenic as recombinant proteins or as DNA vaccines will eventually provide an effective vaccine against malaria. The task is not easy, since there is no small-animal model of malaria infection, which limits the possibilities of high-throughput screening of candidate

255

256

12 Subunit Vaccines and Toxoids Tab. 12.2 Parasite genomes sequence d or being sequence d at TIGR as of March 18, 2003 (www.tigr.org). Parasite

Chromosome

Status or reference

Bugia malayi Entamoeba histolytica Plasmodium falciparum Plasmodium yoelii yoelii Plasmodium vivax Schistosoma mansonii Toxoplasma gondii Trypanosoma brucei

Whole genome Whole genome Whole genome Whole genome Whole genome Whole genome Whole genome I a/b II a/b III a/b IV a/b V a/b VI a/b VII a/b VII a/b IX a/b X a/b XI a/b Whole genome

In progress In progress 25 9 In progress In progress In progress Completed

Tripanosoma cruzi

In progress

In progress

antigens. However, in recent years there has been growing interest of government and nonprofit organizations in developing a safe and effective malaria vaccine, with an increased amount of funds allocated for this task [54]. The genomic approach is not limited to malaria: the genome of other relevant human parasites are being sequenced or have already been sequenced, including P. vivax, Trypanosoma spp., Schistosoma mansoni, and Brugia malayi (Table 12.2). 12.4.4 The Genomic Approach to Viral Vaccines

The approach to vaccines against viral diseases has usually been conventional: only structural antigens (envelope and core) have been usually considered. This despite the fact that viral genomes have a small size and have been available for several years. Hepatitis C Virus (HCV) can be considered the forerunner of the genomic approach applied to virus discovery and vaccine development. The virus cannot be cultured and it has never been observed by electron microscopy. Cloning and sequencing of the HCV genome were the only instruments for identifying the virus [11] and for studying the envelope proteins that were then shown to be protective in a chimpanzee model of infection [10]. Conventional vaccinology has been applied also to HIV vaccine development with poor results: the envelope glycoproteins (gp120, gp140, and gp160) and other structural proteins encoded by the gag gene have been intensively studied by traditional

12.4 The Future of Subunit Vaccine Development: The Genomic Approach

approaches. It is now clear that other proteins, which are either not part of the final viral particle or are present in such low quantities that they cannot be purified from the virus, for example, Tat, Nef, Rev, and Pol, can be protective in experimental animal models and may be tested also in humans [7, 8, 21, 57, 60]. Even in the complicated field of HIV vaccine development, the reverse vaccinology approach has not only provided new promising antigens, that would have been completely ignored by a traditional approach, but has also taught us an important lesson: even nonstructural, non-superficial proteins, and even naturally poor immunogenic antigens can be suitable vaccine candidates when they are correctly expressed and correctly delivered to the host. In March 2003 the WHO issued a global alert for a new illness designated ‘severe acute respiratory syndrome’ (SARS) [97]. Several hundred cases of severe atypical pneumonia of unknown etiology were reported in Guangdong Province of the People’s Republic of China beginning late 2002. Similar symptoms were detected in patients in Hong Kong, Vietnam, and Canada during February and March 2003. In mid-March 2003, SARS was recognized in healthcare workers and household members who had cared for patients with severe respiratory illness. Many of these instances could be traced through multiple chains of transmission to a healthcare worker from Guangdong province who visited Hong Kong, where he was hospitalized with pneumonia and died. In response to this outbreak, WHO coordinated an international collaboration that included clinical, epidemiological, and laboratory investigations and initiated efforts to control the spread of SARS. Attempts to identify the etiology of the SARS outbreak were successful during the third week of March 2003, when laboratories in the United States, Canada, Germany, and Hong Kong isolated a novel corona virus (SARS-CoV) from SARS patients. Unlike other human corona viruses, it was possible to isolate SARS-CoV in Vero cells. Evidence of SARS-CoV infection has now been documented in SARS patients throughout the world. SARS-CoV RNA has frequently been detected in respiratory specimens, and convalescent-phase serum specimens from SARS patients contain antibodies that react with SARS-CoV. This virus was purified, its RNA extracted, and the approximately 30 000-bp genome sequenced and characterized [48, 79]. Availability of the SARS virus genome sequence is important from a public health perspective. It will allow the rapid development of PCR-based assays for this virus, which will allow the diagnosis of SARS virus infection in humans and play an important part in a public health strategy to control the spread of this syndrome. In the future, this information will assist in the development of antiviral treatments, including neutralizing antibodies, and development of a vaccine to treat this emerging and deadly new disease [48]. These results represent the best example of the power of the new technologies applied to microbiology: within a few weeks from the appearance of the new disease, the etiological agent has been detected, and its full genome has been sequenced. The last time that mankind faced a new disease was in the early 1980s, with the appearance of HIV: at that time, only 20 years ago, it took two years to identify the etiologic agent of the infection.

257

258

12 Subunit Vaccines and Toxoids

References 1. ACIP. 1999. Recommendations for the use of Lyme disease vaccine. MMWR 48, 1–17, 21–25. 2. Baker C.J., Kasper D.L. 1985. Group B streptococcal vaccines. Rev Infect Dis 7, 458–467. 3. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Carey V.J., Hickman M.E., Kasper D.L. 2000. Use of capsular polysaccharide–tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 182, 1129–1138. 4. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hickman M.E., Kasper D.L. 1999. Safety and immunogenicity of capsular polysaccharide–tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 179, 142– 150. 5. Bertino J.S., Tirell P., Greenberg R.N., et al. 1997. A comparative trial of standard of high dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, Pre-S1 and Pre-S2 particles for revaccination of healthy adult non-responders. J Inf Dis 175, 678–681. 6. Black S., Shinefield H., Fireman, B., et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19, 187–195. 7. Cafaro A., Caputo A., Fracasso C., et al. 1999. Control of SHIV-89.6P infection of cynomolgus monkeys by HIV-1 Tat vaccine. Nature Med 5, 643–650. 8. Cafaro A., Titti F., Fracasso C., et al. 2001. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgous monkeys upon infection with simian/ human immunodeficiency virus (SHIV89.6P). Vaccine 19, 2862–2877. 9. Carlton J.M., Angiuoli, S.V., Suh B.B., et al. 2002. Genome sequence and comparative analysis of the model rodent parasite. Plasmodium yoelii yoelii. Nature 419 (6906), 512–519. 10. Choo Q.L., Kuo G., Ralston R., et al.

11.

12.

13.

14.

15.

16.

17.

18.

19.

1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci. USA 91, 1294–1298. Choo Q.L., Kuo G., Weiner A.J., et al. 1989. Isolation of a cDNA clone derived from a blood-borne non-A and non-B viral hepatitis genome. Science 244, 359–362. Comanducci M., Bambini S., Brunelli B., et al. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195, 1445–1454. Dagan R., Melamed R., Muallem M., et al. 1996. Nasopharyngeal colonization in southern Israel with antibioticresistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 174, 1352–1355. Davis H.L., Suparto I., Weeratna R., et al. 2000. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18, 1920–1924. Davis H.L.,Weeratna R., Waldschmidt T.J., et al. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870–876 Del Giudice G., Covacci A., Telford J.L., Montecucco C., Rappuoli R. 2001. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19, 523–563. de Silva A.M., Telford S.R., Brunet L.R., Barthold S.W., Fikrig E. 1996. Borrelia burgdorferi rOspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 183, 271–275. de Silva A.M., Zeidner N.S., Zhang Y., Dolan M.C., Piesman J., Fikrig E., et al. 1999. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect Immun 67, 30–35. Desombere I.,Van der Wielen M.,Van Damme P., et al. 2002. Immune response of HLA DQ2 positive subjects,

References

20.

21. 22.

23.

24.

25.

26.

27.

28.

29.

30.

vaccinated with HbsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 20, 2597–2602. Di Tommaso A., Bartalini M., Peppoloni S., Podda A., Rappuoli R., de Magistris M.T. 1997. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 15, 1218–1224. Ensoli B., Cafaro A. 2002. HIV-1 Tat vaccines. Virus Res 82, 91–101. Etz H., Minh D.B., Henics T., et al. 2002. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99, 6573–6578. Fikrig E., Barthold S.W., Kantor F.S., Flavell R.A. 1992. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 60, 773–777. Finne J., Bitter-Suermann D., Goridis C., Finne U. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138, 4402–4407. Gardner M. et al. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498–511. Glenny A.T., Hopkins B.E. 1923. Diphtheria toxoid as an immunizing agent. Brit J Exp Pathol 4, 283–288. Goldschneider, I., Gotschlich, E.C., Artenstein, M.S. 1969a. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129, 1307–1326. Goldschneider, I., Gotschlich, E.C., Artenstein, M.S. 1969b. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129, 1327–1348. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. 1998. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178, 870–874. Granoff D.M., Moe G.R., Giuliani M.M., et al. 2001. A novel mimetic antigen eliciting protective antibody to Neis-

31.

32.

33. 34.

35.

36.

37.

38.

39.

40.

seria meningitidis. J Immunol 167, 6487– 6496. Grayston J.T. 2000. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181 (Suppl 3), S402–410. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofi degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D.L.,Wassilak S.G. (Progetto Pertosse Working Group) 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334(6), 341–348. Greenwood B., Mutabingwa T. 2002. Malaria in 2002. Nature 415, 670–672. Hadi H.A., Wooldridge K.G., Robinson K., and Ala’Aldeen D.A. 2001. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol Microbiol 41, 611–623. Hassan-King M.K.A., Wall R.A., Greenwood B.M. 1988. Meningococcal carriage, meningococcal disease and vaccination. J Infect 16, 55–59. Hayrinen J., Jennings H., Raff H.V., Rougon G., Hanai N., GerardySchahn R., Finne J. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 171, 1481–1490. Heineman T.C., Clements-Mann M.L., Poland G.A., et al. 1999. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17, 2769–2778. Jennings G.T., Savino S., Marchetti E., et al. 2002. GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lytic transglycosylase (MltA). Eur J Biochem 269, 3722–3731. Jodar L., Feavers I.M., Salisbury D., Granoff D.M. 2002. Development of vaccines against meningococcal disease. Lancet 359, 1499–1508. Johnson R.C., Kodner C., Russell M. 1986. Active immunization of hamster against experimental infection with Borrelia burgdorferi. Infect Immun 54, 897– 898.

259

260

12 Subunit Vaccines and Toxoids 41. Kao J.H., Chen D.S. 2002. Global control of hepatitis B virus infection. Lancet Infect Dis 2, 395–403 42. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., Baker C.J. 1996. Immune response to type III group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine. J Clin Invest 98, 2308–2314. 43. Kendrick P.L., Eldering G., Dixon M.K. 1947. Mouse protection tests in the study of pertussis vaccine: a comparative study using intracerebral route for challenge. Am J Publ Health 37, 803. 44. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., Jansen K.U., for the Proof-of-Principle Study Investigators. 2002. A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347(21), 1645–1651. 45. Lathrop S.L., Ball R., Haber P., et al. 2002. Adverse event reports following vaccination for Lyme disease, December 1998–July 2000. Vaccine 20, 1603– 1608. 46. Lipsitch M. 1999. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5, 336–345. 47. Mahoney F.J. 1999. Update on diagnosis, management, and prevention of hepatitis b virus infection. Clin Microbiol Rev 12, 351–366. 48. Marra M.A., et al. 2003. The genome sequence of the SARS-associated coronavirus. Science, published online 1 May 2003 (http://www.sciencemag.org/ cgi/rapidpdf/1085953v1.pdf). 49. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Aricò B., Brunelli B., Pieri A., Santini L., Savino S., Serruto D., Litt D., Kroll S., Welsch J.A., Granoff D.M., Rappuoli R., Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197, 789–799. 50. Moe G.R., Tan S., Granoff D.M. 1999. Differences in surface expression of NspA among Neisseria meningitidis

51.

52.

53.

54.

55.

56.

57.

58.

59.

60.

group B strains. Infect Immun 67, 5664– 5675. Montigiani S., Falugi F., Scarselli M. et al. 2002. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70, 368– 379. Morley S.L., Pollard A.J. 2002. Vaccine prevention of meningococcal disease, coming soon? Vaccine 20, 666– 687. National Bacteriological Laboratory, Sweden. 1988. A Clinical Trial of Acellular Pertussis Vaccine in Sweden. Technical Report 1988, National Bacteriological Laboratory, Stockholm. Nossal G.J. 2000. The global alliance for vaccine and immunization: a millennium challenge. Nature Immunol 1, 5–8. Ogawa J., Keneko H., Masuda T., Nagata S., Hosoya H., Watanabe K. 1996. Novel adhesion molecules in the contactin/F3 subgroup of the immunoglobulin superfamily: isolation and characterization of cDNAs from rat brain. Neurosci Lett 218(3), 173–176. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. (Ad Hoc Group for the Study of Pertussis Vaccines) 1997. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with wholecell pertussis vaccine. Lancet 350, 1569– 1577. Osterhaus A.D., van Baalen C.A., Gruters R.A., et al. 1999. Vaccination with Rev and Tat against AIDS. Vaccine 17, 2713–2714. Paoletti L.C., Kasper D.L. 2002. Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis 186, 123–126. Paoletti L.C., Pinel J., Johnson K.D., Reinap B., Ross R.A., Kasper D.L. 1999. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. J Infect Dis 180, 892–895. Pauza C.D., Trivedi P.,Wallace M., et al. 2000. Vaccination with Tat toxoid attenuates disease in simian/HIV-chal-

References

61.

62.

63.

64.

65.

66.

lenged macaques. Proc Natl Acad Sci USA 97, 3515–3519. Pizza M., Covacci A., Bartoloni A., et al. 1989. Mutants of pertussis toxin suitable for vaccine development. Science 246, 497–500. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., Jennings G.T., Baldi L., Bartolini E., Capecchi B., Galeotti C.L., Luzzi E., Manetti R., Marchetti E., Mora M., Nuti S., Ratti G., Santini L., Savino S., Scarselli M., Storni E., Zuo P., Broeker M., Hundt E., Knapp B., Blair E., Mason T., Tettelin H., Hood D.W., Jeffries A.C., Saunders N.J., Granoff D.M.,Venter J.C., Moxon E.R., Grandi G., Rappuoli R. 2000. Identification of vaccine candidates against serogroup B Meningococcus by wholegenome sequencing. Science 287, 1816– 1820. Plotkin S.A., Bouveret-Le Cam N. 1995. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 155, 2293–2299. Podda A., Carparella de Luca E., Titone L., Casadei A.M. Cascio A., Peppoloni S.,Volpini G., Marsili I., Nencioni L., Rappuoli R. 1992. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children. J Pediatr 120, 680–685. Podda A., Carparella de Luca E., Titone L., Casadei A.M., Cascio A., Bartalini M.,Volpini G., Peppoloni S., Marsili I., Nencioni L., Rappuoli R. 1993. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. J Pediatr 123, 81–84. Podda A., Nencioni L., de Magistris M.T., Di Tommaso A., Bossù P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P., Marsili I., D'Errico A., Tagliabue A., Rappuoli R. 1990. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertus-

67.

68.

69.

70. 71.

72. 73.

74.

75.

76.

77.

sis toxin mutant PT-9K/129G. J Exp Med 172, 861–868. Podda A., Nencioni L., Marsili I., Peppoloni S.,Volpini G., Donati D., Di Tommaso A., de Magistris M.T., Rappuoli R. 1991. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9, 741–745. Poolman J.T. 1995. Development of a meningococcal vaccine. Infect Agents Dis 1, 13–28. Ramon G. 1923. Sur le pouvoir floculant et sur les propriétés immunisantes d'une toxine diphthérique rendue anatoxique (anatoxine). C R Acad Sci 177, 1338–1340. Ramon G. 1925. Sur la production des antitoxins. C R Acad Sci 181, 157–159. Rappuoli R. 1997. New and improved vaccines against diphtheria and tetanus, in: New Generation Vaccines, 2nd edition, eds Levine M.M.,Woodrow G.C., Kaper J.B., Cobon G.S., Dekker, New York, 417–436. Rappuoli R. 2000. Reverse vaccinology. Curr Opin Microbiol 3, 445–450. Rappuoli R. 2001. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19, 2688–2691. Raz R., Dagan R., Galli A., et al. 1996. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 14, 207–211. Richie T.L., Saul A. 2002. Progress and challenges for malaria vaccines. Nature 415, 694–701. Rokbi B., Renauld-Mongenie G., Mignon M., et al. 2000. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect Immun 68, 4938–4947. Roome A.J., Walsh S.J., Cartter M.L., Hadler J.L. 1993. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 270, 2931– 2934.

261

262

12 Subunit Vaccines and Toxoids 78. Ross B.C., Czajkowski L., Hocking D. et al. 2001. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19, 4135–4142. 79. Rota P.A., et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science Published online 1 May 2003 (http://www.sciencemag.org/cgi/ rapidpdf/1085952v1.pdf) 80. Salmaso S., Mastrantonio P., Tozzi A.E., Stefanelli P., Anemona A., Ciofi degli Atti M.L., Giammanco A. (Stage III Working Group) 2001. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108, E81. 81. Scarselli M., Rappuoli R., Scarlato V. 2001. A common conserved amino acid motif module shared by bacterial and intercellular adhesions: bacterial adherence mimicking cell–cell recognition? Microbiology 147, 250–252. 82. Schaible U.E., Kaufmann S.H.E. 2000. CD1 molecules and CD1-dependent T cells in bacterial infections: a link from innate to acquired immunity? Semin Immunol 12, 527–535. 83. Schuchat A. 1999. Group B Streptococcus. Lancet 353, 51–56. 84. Serruto D., Adu-Bobie J., Scarselli M.,Veggi D., Pizza M.G., Rappuoli R., and Aricò B. 2003. Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Mol Microbiol 48, 323–334. 85. Sigal L.H., Zahradnik J.M., Lavin P., et al. 1998. A vaccine consisting of recombinant Borrelia burgdorferi outersurface protein A to prevent Lyme disease. N Engl J Med 339, 216–222. 86. Singh M., Li X.M., et al. 1997. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 15, 475–481. 87. St. Geme J.W., Cutter D., Barenkamp S.J. 1996. Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. J Bacteriol 178, 6281–6287.

88. Steere A.C., Sikand V.K., Meurice F., et al. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 339, 209–215. 89. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., Gheesling LL., Carlone G.M., Hoiby E.A., Holst J., Nokleby H., Rosenqvist E., Sierra G., Campa C., Sotolongo F.,Vega J., Garcia J., Herrera P., Poolman J.T., Perkins B.A. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile. JAMA 281, 1520– 1527. 90. Tettelin H., Masignani V., Cieslewicz M.J., Eisen J.A., Peterson S., Wessels M.R., Paulsen I.T., Nelson K.E., Margarit I., Read T.D., Madoff L.C., Wolf A.M., Beanan M.J., Brinkac L.M., Daugherty S.C., DeBoy R.T., Durkin A.S., Kolonay J.F., Madupu R., Lewis M.R., Radune D., Fedorova N.B., Scanlan D., Khouri H., Mulligan S., Carty H.A., Cline R.T., Van Aken S.E., Gill J., Scarselli M., Mora M., Iacobini E.T., Brettoni C., Galli G., Mariani M.,Vegni F., Maione D., Rinaudo D., Rappuoli R., Telford J.L., Kasper D.L., Grandi G. Fraser C.M. 2002. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 99, 12391– 12396. 91. Tettelin H., Saunders N.J., Heidelberg J., et al. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287, 1809–1815. 92. The American Academy of Periodontology. 1999. The pathogenesis of periodontal diseases. J Periodontol 70, 457– 470. 93. Valenzuela P., Medina A., Rutter W.J., et al. 1982. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298, 347–350. 94. Van Damme P.,Vorsters A. 2002. Hepatitis B control in Europe by universal

References

95.

96.

97.

98.

vaccination programmes: the situation in 2001. J Med Virol 67, 433–439. Ward J.I., Zangwill K.M. 1999. Haemophilus influenzae vaccines, in Vaccines, 3rd edition, eds Plotkin S.A., Orenstein W.A., Saunders, Philadelphia, 183–221. Wenger J., Tikhomirov E., Barakamfitiye D. et al. 1997. Meningococcal vaccine in sub-Saharan Africa. Lancet 350, 1709–1710. WHO. 2003. Severe Acute Respiratory Syndrome (SARS), http://www.who.int/ csr/sars/en/ Wizemann T.M., Heinrichs J.H., Adamou J.E., et al. 2001. Use of a whole genome approach to identify vaccine

molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69, 1593–1598. 99. Wood R.C., MacDonald K.L.,White K.E., Hedberg C.W., Hanson M., Osterholm M.T. 1993. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270, 2935– 2972. 100. Wormser G.P. 1995. Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis 21, 1267–1274. 101. Wuorimaa T., Kayhty H. 2002. Current state of pneumococcal vaccines. Scand J Immunol 56, 111–129.

263

265

13 Engineering Virus Vectors for Subunit Vaccines Joseph Patrick Nkolola and Tomas Hanke

13.1 Introduction

The field of vaccinology has made significant strides in fighting a variety of infectious diseases by using the traditional approaches of attenuated or inactivated microorganisms, protein subunits, toxoids, or capsular polysaccharides [1, 2]. With the exception of general health care measures such as water sanitation, vaccines are the most efficient and cost-effective means of controlling infections, as illustrated by the eradication of smallpox and the control of diseases such as polio, yellow fever, and measles. Vaccines save about 3 million lives each year and an additional 3 million could be saved through improved vaccine coverage. Overall, vaccines are currently available against more than 25 infectious agents; however, many more pathogens remain on the vaccine wish list. Some of these agents are new and some are re-emerging, and for others, such as the human immunodeficiency virus (HIV) and Plasmodium, conventional vaccine technologies are still inadequate. The huge impact that infectious diseases still have on global public health, and indeed countries’ economies, underlines the urgent need for new, more efficient, and safer vaccines. Of the new approaches, recombinant subunit vaccines vectored by rationally manipulated virus vectors have shown promise and are likely to play an important role in vaccine development in 21st-century medicine. The past 20 years have seen a wide range of viruses explored for their ability to induce specific immunological responses against passenger proteins derived from foreign pathogens. Many vaccine vectors engineered from diverse viruses with distinct tropisms and gene expression strategies are currently in preclinical and clinical studies and have generated much hope in the fight against infectious and malignant diseases. Although each viral vector has different biological characteristics, they generally offer advantages over more traditional vaccine technologies, such as high expression of foreign immunogens, potential adjuvanting or immunomodulating effects, and the possibility of targeted delivery of proteins directly to the specialized cells of the immune system. These vectors closely mimic natural infection and thus present immunogens in their natural form (i. e., with correct conformation, glycosylation, and oligomerization), prolong the immunogen delivery, and induce potent

266

13 Engineering Virus Vectors for Subunit Vaccines

CD8+ cytotoxic lymphocyte (CTL) responses through the introduction of immunogens into the major histocompatibility complex class I processing pathway. Each vector system is unique, and the ever growing list of them provides a flexibility to tailor vaccines for a particular disease. However, it is important to stress that the use of viral vectors is not without safety issues, all of which must be addressed before the vector can be used in humans and before their ultimate commercial application, especially if the target population is potentially immunocompromised. For vaccination to be successful, a certain copy number of the immunogen gene must be delivered to the target tissue so that sufficient amount of protein is synthesized and an appropriate immune response is induced, which then provides protection from infection and/or disease. In addition, an ideal vaccine should have an excellent safety profile with minimal risk of adverse reactions even in unscreened real world populations, should require only a single-dose administration, should induce protection for life, and should be cheap, stable, and easy to administer (e. g., orally). This chapter reviews the main types of recombinant viruses that are prominent in the field of vaccinology, the methodologies used in their generation, and their advantages and disadvantages.

13.2 Adenoviruses

Adenovirus-based vectors are among the most widely used viral vectors in preclinical studies of vaccines. Adenoviruses are nonenveloped double-stranded DNA viruses usually associated with upper respiratory tract infections. They efficiently infect and express their genes in a wide variety of cell types, including dividing and nondividing cells. The adenovirus genome is about 36 kbp long and is easy to manipulate with classical recombinant DNA techniques [4]. Although over 50 human adenoviral serotypes exist, recombinant adenoviral vectors (rAds) are primarily derived from serotypes 2 and 5 [5]. However, these vectors need to be administered in high doses because most people have preexisting vector immunity, resulting in a rapid neutralization of the adenovirus-vectored vaccines. Of note in current literature is a new recombinant adenoviral system based on serotype 35, which efficiently binds to and transduces cells that elicit a strong immune response, is not inactivated by the antiadenovirus antibodies that are present in the majority of individuals, and does not infect liver cells, which is an unwanted side effect of currently used vectors. As a consequence, it is expected that vaccines based on this system will result in strong immune responses, while using a 100-fold lower dose compared to current adenovirus vectors and improving overall safety and efficacy of the vaccines. 13.2.1 Replication Incompetent Adenoviruses

The first generation of recombinant Ad, and currently the most widely used, are replication-incompetent [6]. These rAds cannot replicate because of the deletion of the

13.2 Adenoviruses

essential viral E1 gene region containing two genes, E1 a and E1 b, which express several distinct proteins through alternative splicing (Figure 13.1). The removal of the E1 gene region creates room for the vaccine expression cassette and prohibits transactivation of viral genes required for viral replication. In addition to the E1 deletion, the viral E3 gene is dispensable for production of recombinant virus as well as the E4 gene, which reduces proinflammatory responses in vivo [6]. Adenoviral vectors without the E1 gene region have to be propagated in a cell line stably expressing a copy of the E1 region. Several cell lines, including human embryonic kidney (HEK) 293 [8] and human retinal cell 911 [9], have been generated that can propagate replication of E1-deficient rAds. The resulting rAd produced from these cell lines can be grown to titers as high as 1012 plaque-forming units per milliliter [4, 10]. After intravenous administration, most of the adenovirus vector is found in the liver, but direct injections can transduce most tissues [11]. Clinical application of rAd vectors has recently gained attention in the area of cancer immunotherapy in both ex vivo transduction of autologous tumor or dendritic cells and direct administration settings. This may be due in part to their efficiency in gene transfer but also because of their cellular toxicity and immunogenicity, which may actually enhance the antitumor response. Recent studies using replication-incompetent adenoviral vectors for disease prevention were encouraging. To this end, two recent reports in the nonhuman primate models of the Ebola virus and HIV [12, 13] have shown that priming with plasmid DNA followed by boosting with rAd augments responses compared with either vector alone [12]. When immunized animals in both studies were subsequently challenged with lethal doses of the virus they all showed resistance. In spite of the many positive attributes of replication-incompetent recombinant adenoviruses, some safety concerns about their acceptability as human vaccines remain to be resolved. During several in vivo studies with high virus inputs, inflammation and acute injury of infected tissues, and particularly the liver, occurred, causing hepatic necrosis and apoptosis [50]. To make these vectors more acceptable for clinical trials, there is a need to explore in depth the many factors involved in their use, including the molecular nature of the immune responses they invoke in the context of various genetic backgrounds, target organs, and routes of administration. This will, of course, require much longer development protocols, but any positive insights may make these vectors a more viable option for use as human vaccines. 13.2.2 Replication-selective Adenoviruses

Replication-selective or oncolytic adenoviruses have recently gained the attention of cancer vaccinologists [18]. These rAds are generated by selective growth and propagation in cells of solid tumors, which results in reduction of tumor mass without systemic toxicity (Figure 13.1). The most attractive feature of these viruses is that they can be propagated in selected unmodified cell lines, thereby facilitating the manufacturing process. To amplify the systemic and local potency of these vectors, techniques have been developed to equip these viruses with transgenes whose expression

267

268

13 Engineering Virus Vectors for Subunit Vaccines A. Ad genome L1

E1A

L2

L5

L4

L3

E1B

E3 E2B

E2A

E4

B. Ad vectors dl E1A/E1B

dl E3

(dl E4)

Replication incompetent Ag cassette

Helper dependent

ITR/psi +

ITR

‘Stuffer’-Ag cassette- ‘stuffer’ dl E1A or E1B

dl E3b

Replication selective Tissue-specific promoter

Fig. 13.1 Adenovirus (Ad)-based vaccines. A Schematic of genomic organization. Transcription of adenoviral genes occurs from both DNA strands, and expression is segregated temporarily, occurring either before (early genes E1–E4) or after DNA replication (late genes encoding structural proteins). B Configuration of replication-incompetent, helper-dependent, and replication-selective Ad-based vectors. Replication-incompetent vectors contain an antigen expression cassette substituted for the deleted E1A– E1B region. Typically, the E3 region is also deleted to accommodate larger insertions. Regions of E2 and/or E4 can be deleted to diminish expression of late viral genes. Helper-dependant vectors are deleted of all viral genetic information except the termini and the packaging sequence, which are required for vector propagation by helper systems. The antigen expression cassette is inserted into the deleted region together with a ‘filler’ sequence, so that the overall vector length is approximately the 36 kbp size similar to native Ad, to achieve efficient propagation. Replicationselective adenoviruses contain deletions in E1A or E1B, which render their propagation selective in cancer cells deficient in p53 or pRB function. Alternative ly, tissue-specific promoters can be substituted for the E1A promoter, so that productive virus infection occurs selectively in tumors having appropriate factors for activity of these promoters.ITR: inverted terminal repeats; psi: packaging signal. Adapted from [38].

cytokine

13.4 Poxviruses

is conditional on DNA replication, which preferentially occurs in cancer cells [19]. It is hoped that a combination of virus-induced oncolysis and cancer immunotherapy can enhance the extent and durability of the antitumor response.

13.3 Adeno-associated Viruses

Parvoviruses were initially discovered as a contaminant of an adenovirus preparation. At least 7 primate serotypes exist, of which the adeno-associated virus serotype 2 (AAV-2) has been studied the most. It has a 4680-bp DNA genome that is flanked by inverted terminal repeats (ITR). Because vaccine vectors need only ITRs and a packaging signal, recombinant AAV can accommodate 36 kbp of heterologous genetic material. In tissue culture, some AAV serotypes can integrate into the host cell chromosome. Integration in vivo is highly inefficient and has never been demonstrated in humans. Since no disease is associated with wild-type AAV infection, AAV make ideal candidates for vaccine vectors. However, human parvoviruses normally require helper viruses such as adenoviruses or herpes viruses for productive replication [14] and it has proved quite challenging to remove these helper viruses from purified AAV preparations. To circumvent this problem, an approach using the cre recombinase or loxP system to remove the packaging sequence from the helper virus has been developed, which greatly improves the production process [15]. Since the rAAV vector does not contain any parental virus coding sequences, the vector itself has not been associated with toxicity or any inflammatory response. It is generally produced by adding separate plasmids containing (1) the ITRs flanking the immunogen gene, (2) rep/cap genes encoding proteins required for viral genome replication and structural proteins, respectively, and (3) a helper adenovirus (Figure 13.2). Large-scale production of rAAV is labor-intensive but may become more commercially viable with the recent strides made in development of packaging cell lines and column chromatographic methods of vector purification [16, 17]. rAAV vectors are considered attractive vaccine vectors, essentially because of their abilities to accommodate large insertions, reduce vector-induced proinflammatory responses, and therefore prolong expression of the passenger immunogen. Thus, by use of rAAV vectors, the number of vaccinations required to deliver immunogenic antigens could be reduced.

13.4 Poxviruses

Poxviruses are large enveloped DNA viruses containing a linear double-stranded genome of 130–300 kbp. Genome and replication complexities have enabled these viruses to infect a wide array of hosts ranging from primates to birds. They are unique among DNA viruses in that their entire life cycle is restricted to the cytoplasm of the infected cell. As a direct consequence, the poxvirus genome can encode DNA and RNA poly-

269

270

13 Engineering Virus Vectors for Subunit Vaccines

Fig. 13.2 Generation of rAAV vaccines. A Life cycle of wild-type AAV. Latency is established after AAV infection of the target cells, which may involve genome integration. AAV virions are rescued after subsequent infection with helper virus, which provides the sequences needed for viral replication in trans. B Production of rAAV vaccines. Permissive cells are cotransfected with a plasmid containing the transcription unit (blue) flanked by the AAV ITRs (green) and plasmid containing the AAV genome without the ITRs. Subsequent infection of these cells with a helper adenovirus enables rescue of rAAV virions, following the packaging of the ITR-containing plasmid, along with helper virus. Helper and rAAV virions can then be separated after heating at 56 °C by centrifugation on a cesium chloride gradient. Adapted from [3] (see colour plates page XXXVI).

13.4 Poxviruses

merases, transcription factors, and DNA biosynthesis elements, in addition to the structural proteins required for virion assembly. As is true for most DNA viruses, transcription is modular, in that early promoters are active before DNA replication, and intermediate and late promoters drive transcription after replication. During the poxvirus replication cycle, four particle forms are generated: intracellular mature virus (IMV), intracellular enveloped virus (IEV), cell-associated enveloped virus (CEV), and extracellular enveloped virus (EEV). These particles differ in their content of envelope proteins. Early events in the vaccinia virus life cycle result in IMV particles being formed from noninfectious precursors (called crescents) within the cytoplasm of an infected cell. A small proportion of IMV can leave the cytoplasm on microtubules and subsequently become wrapped in a double layer of intracellular membranes derived from early endosomes or trans-Golgi network, to form IEV. Again using microtubules, IEV migrate to the cell surface where their outer membranes fuse with the plasma membrane, exposing an enveloped virion on the cell surface. A proportion of these particles are retained on the cell surface and are referred to as CEV, others are released and called EEV. The EEV form of vaccinia virus mediates long-range dissemination of virus, and CEV is important in cell-to-cell spread. It is the IMV that is routinely prepared for experimental recombinant vaccines. Poxvirus vaccine vectors have essentially developed from the Orthopoxvirus and Avipoxvirus genera. These vectors are probably the most-advanced, widely tested vaccine vectors, on the basis of data obtained from nonhuman primate and human clinical studies. Recombinant poxviruses can carry multiple large foreign genes, which are stably expressed at high levels, from the recombinant genome. Also, given the fact that poxviruses are relatively thermostable, vaccine vectors derived from them are attractive for application in developing countries where refrigeration facilities may not always be available. Two general strategies can be used to produce recombinant poxvirus vaccine vectors. The first and more commonly used method involves homologous DNA recombination within infected cells, using a shuttle plasmid that contains the passenger gene-expression cassette flanked by additional poxvirus sequences that direct recombination within the specified genome region [20, 21]. Recombinants can be identified by a variety of methods, including incorporation of reporter genes or drug-selection markers, recombination into the thymidine kinase (TK) locus, and selection in TK-negative cells. The second method of generating poxvirus vectors involves direct ligation of vaccine genes into selected restriction sites within the viral genome followed by transfection of the DNA into cells infected with a helper virus that contains a negative-selectable phenotype. 13.4.1 Mammalian Poxviruses

The first work elucidating the use of poxviruses as expression vectors made use of vaccinia virus [20, 21]. For clinical applications it is of paramount importance to ensure the highest levels of biosafety for any recombinant virus vaccine. Because vaccinia can cause severe disseminated disease in individuals with eczema or compromised immune systems, this prompted vaccinologists to try to develop vectors with

271

272

13 Engineering Virus Vectors for Subunit Vaccines

better safety profiles than those already in use. Of the candidate attenuated vaccinia viruses, one well-characterized strain, modified vaccinia virus Ankara (MVA), has been established as a very safe vaccine vector. It was generated from the Ankara strain by ~570 serial passages in chicken embryo fibroblasts (CEF), which resulted in extensive genome deletions and a replication limited to CEF cells and a few mammalian cell lines [22]. Strikingly, the defect for virus growth in mammalian cells does not impair transcription from the viral promoters for expression of heterologous genes within the vector format. This is a desirable and attractive property if MVA vectors are to be used as effective vaccine vectors. The safety and immunogenicity of MVA in preclinical studies have been extensively documented. In addition, immunization of well over 100 000 individuals during the smallpox eradication campaign has demonstrated the safety of MVA in humans. Based on these facts, a new attenuated poxvirus, NYVAC, was developed as a virus vector for vaccine delivery. NYVAC was generated by a rational deletion of 18 genes from the Copenhagen vaccine strain’s genome, several implicated in virulence and host-range phenotypes [23]. Like MVA, NYVAC efficiently expresses heterologous genes as a vaccine vector. 13.4.2 Avipoxvirus Vectors

Avipoxvirus vectors offer an attractive alternative to poxvirus vectors, due to their limited host range, favorable safety profile of attenuation, and nonneutralization by preexisting vaccinia immunity in the vaccinee. The Avipoxvirus genus can replicate only in avian cells, and thus, when used to infect nonavian cells, avipoxvirus vectors initiate an abortive infection, resulting in expression of genes without subsequent viral DNA replication and production of progeny virus [24]. Initial strategies in the development of avipoxvirus vector involved the use of an attenuated poultry vaccine known as fowl pox virus (FPV), but this was subsequently replaced by canary pox because of the higher immunogenicity of canary pox [25]. An example of a commonly used canary pox vector is derived from the ALVAC virus, a plaque derivative of the KANAPOX vaccine strain [23].

13.5 Herpes Simplex Viruses

The herpes simplex virus type 1 (HSV-1) is an enveloped, double-stranded DNA virus with a genome of 152 kbp encoding more than 80 genes. It has a wide host range and can infect cells lytically or establish latency. Because of its intrinsic ability to cause latent infection (where disease is absent) in human hosts with normal immune status and to persist and be reactivated after primary infection, HSV holds promise as a potent vaccine vehicle. HSV-1 is in fact currently the most extensively engineered herpes virus for purposes of vaccination. Approximately half of the genes present in HSV-1 are nonessential for virus replication in tissue culture, providing

13.5 Herpes Simplex Viruses

multiple sites for gene insertion within the viral genome and making HSV-1 a highcapacity vector capable of harboring at least 30 kbp of heterologous genes [26]. There are three types of HSV-based vectors: recombinant HSV vectors, amplicons, and disabled infectious single-cycle (DISC) HSV. A brief description of each is given below. 13.5.1 Recombinant HSV Vectors

Recombinant HSV vectors are generated by the insertion of transcriptional units directly into the HSV genome via homologous recombination events. To achieve this, HSV genomic DNA is cotransfected into a permissive cell line together with a shuttle plasmid harboring a transcriptional unit containing the passenger vaccine gene. During mitotic division, homologous recombination occurs between HSV sequences within the shuttle plasmid and the viral DNA. Recombined viral genomes that have replicated are subsequently processed and packaged into new virus particles. Just as in other systems, recombinant virus is then separated from parental virus by several rounds of plaque purification. 13.5.2 Amplicon Vectors

Amplicon vectors are the second type of HSV vectors currently under investigation for vaccine application. They are based on plasmids/amplicons of approximately 15 kbp, which bear, in addition to the transcriptional unit of the passenger gene, only an origin of replication and a packaging signal. Recombinant amplicons are usually cotransfected into a cell line together with a packaging-defective helper HSV genome, which enables the amplicon DNA to be packaged into infectious virions. Replication of HSV DNA occurs via a rolling-circle mechanism enabling amplicon vectors to contain several copies of the plasmid [27] (Figure 13.3). In spite of their many advantages, such as large capacity for insertion of foreign genes, ability to cause latent infection, and a wide host range, two major problems have limited the use of HSV as vaccine vectors. First, vector toxicity has been linked to the host protein shut-off functions of some viral gene products and the direct toxicity of others [28]. Second, the production of helper-dependant recombinant HSV has proved quite challenging, due to difficulties in producing materials that are not contaminated with wild-type HSV helper (a similar scenario as described for AAV preparations). In the particular case of HSV vectors, this problem has been recently addressed by using helper virus genome plasmids devoid of packaging signals, propagated in bacteria as bacterial artificial chromosomes [29]. The primary advantage of this new system is that it guarantees an almost helper-free preparation of recombinant amplicons. It is important to stress that, until systems can be developed in which the helper DNA is completely devoid of sequences similar to that of the amplicon vector, recombination between the amplicon and helper DNA will occur, raising the possibility of contamination of vector stocks with unwanted recombinants, some

273

274

13 Engineering Virus Vectors for Subunit Vaccines

Fig. 13.3 Generation of recombinant herpes simplex viruses(HSV) and HSV-derived amplicons. A Recombinant HSV vectors. HSV genomic DNA is cotransfected into permissive cells along with a plasmid containing the transcription unit (red) inserted in fragment of HSV genome (gray). During mitosis, homologous recombination occurs between the HSV genome sequences within the plasmid and HSV DNA. Both wild-type and recombined viral genomes are packaged into a mixed virus particle population, from which the recombinant viruses are isolated by plaque purification. B Amplicon-derivedHSV vectors. The amplicon plasmid containing the transcription unit

(red) and the viral cleavage and packaging site is cotransfected into permissive cells together with a helper virus genome, which contains all the regulatory and structural genes needed for viral growth, including the HSV hostshutoff protein, but is defective in packaging. Immediately after transfection, the amplicon plasmid undergoes DNA replication driven by helper proteins, which results in the generation of head-to-tail plasmid concatemers. These concatemers are then cleaved into genome unit-length moleculesand packaged into virus particles,which after concentration are ready for use. Adapted from [35] (see colour plates page XXXVII).

13.6 Retroviruses

of which might be replication-competent. In addition and as is true with other viruses, production systems dependant on transfection may be difficult to scale up and may not yield high virus titers. 13.5.3 Disabled Infectious Single-cycle HSV

Progress in the area of HSV vector development has highlighted a new vector known as disabled infectious single-cycle (DISC) HSV. This vector is designed to combine the safety advantages of inactivated vaccines with the immunogenic activity of live viral vaccines. The DISC HSV is based on either HSV-1 or HSV-2 and comprises live herpes simplex virus with the essential gene for glycoprotein H (gH) removed to disable the virus. DISC HSV can infect cells much the same as native HSV, and viral progeny are produced but are defective and cannot further replicate. These viral particles from the single cycle of DISC virus replication are nonpathogenic and are capable of inducing broad cytotoxic T-cell and humoral immune responses against multiple antigens. Several studies have shown the effectiveness of these vectors in preclinical [31] and clinical studies of cancer vaccines [52]. It is envisaged that in the coming years, DISC HSV vectors may hold promise as potent recombinant vaccine vectors.

13.6 Retroviruses

Retroviruses are lipid-enveloped single-stranded RNA viruses comprising a diploid genome of about 7–10 kb with four major ORF termed gag, pro, pol, and env. These gene regions encode for structural capsid proteins, viral protease/integrase, reverse transcriptase, and envelope glycoproteins, respectively. In addition, the retroviral genome contains a packaging signal and cis-acting sequences, termed long terminal repeats (LTRs), at each end, which play a role in transcriptional control and integration. Upon entry into target cells, the RNA genome is reverse-transcribed into linear double-stranded DNA and integrated into the host cell chromatin. Within the family of retroviruses, several candidates are being exploited for their potential use as vaccine delivery systems, namely, mammalian lentiviruses and avian C-type spumaviruses. Recombinant retroviral vectors are bioengineered such that they are devoid of all retroviral genes and contain only the LTRs and packaging signal sequences; as a result, propagation of recombinant retroviruses requires expression of the gag, pol, and env genes in trans. The use of recombinant retroviruses in vaccine development is fairly limited, due to several disadvantages. These include their ability to be integrated into the host genome, which could lead to oncogene activation or tumor-suppressor gene inactivation; limited insert capacity of about 8 kb; low titers; inactivation by human complement; inability to transduce nondividing cells; and the potential shutoff of transgene expression over time.

275

276

13 Engineering Virus Vectors for Subunit Vaccines

Of the family members of retroviruses, lentiviruses are probably the most studied and understood. They are complex retroviruses that can infect and express their genes in both mitotic and post-mitotic cells. Replication-defective lentivirus vectors were originally derived from human immunodeficiency virus 1 (HIV-1), the most commonly known lentivirus [30]. This vector system used HIV and the envelope glycoproteins of other viruses to target a broad range of cell types. The technique used to generate recombinant lentivirus vector requires a triple-plasmid cotransfection in 293 cells. The first of the three plasmids has no packaging signal but provides structural viral genes in trans, with the exception of env and genes for several accessory proteins. The second plasmid harbors the gene for the pseudotyped envelope protein. The third plasmid carries the transcription unit of the passenger immunogen alongside the cis-acting sequences of HIV required for packaging, reverse transcription, and integration. Reversion to replication of this HIV-derived vector is highly unlikely, because two independent homologous recombination events would have to take place. An added safety feature of this system is the fact that viral sequences present on the three separate plasmids have been generated to have low sequence homology, thus making a recombination event highly unlikely. As an alternative to the parental HIV, hybrid vectors derived from nonhuman simian, equine, and bovine lentivruses have been also developed as an additional safety precaution.

13.7 Alphaviruses

Alphaviruses belong to the Togaviridae family and have a small single-stranded positive-sense RNA genome of approximately 12 kb, which is both encapsidated and polyadenylated. Alphavirus virions are small (60 nm diameter), spherical, and posses a lipid envelope through which 80 glycoprotein spikes project. Mature particle assembly occurs at the plasma membrane of infected cells, where the cytoplasmic nucleocapsids become enveloped by budding at the membrane previously modified by the insertion of two viral glycoproteins. The development of alphavirus vaccine vectors began with studies on defective interfering (DI) particles, which require helper virus for their replication and propagation. DI particles were used to identify the cis-acting sequences essential for replication and packaging of alphavirus RNAs: the 5´ terminal, packaging signal, and 3´ terminal regions. This was followed by development of a self-replicating RNA (replicon) expression vector using an infectious clone of modified Sindbis virus (SIN) [31, 32]. The development of alphaviruses as vaccine vectors is not as advanced as that of other vectors like adenoviruses or vaccinia viruses, but recent publications have elucidated their use as viable and potent vaccination agents. Although some alphaviruses, such as the eastern equine encephalitis virus, are serious human pathogens, others, including SIN and Semliki Forest virus (SFV), are not. Indeed, SIN and SFV have served as models for molecular studies of alphaviruses and, together with the Venezuelan equine encephalitis virus (VEE), form the core of alphaviruses

13.7 Alphaviruses

developed into safe and efficient vaccine vectors. Several features of alphaviruses make them attractive. They infect a broad host range (including humans) with mild or no symptoms. Seropositivity to alphaviruses is, at least in the mild climate, infrequent, reducing the chances of immune interference. Alphaviruses may be engineered or may posses lymph-node tropism that results in effective antigen presentation and induction of strong, balanced immune responses. They induce apoptosis of infected cells and, in any case, replication of their genome occurs exclusively within the host cell cytoplasm as RNA and therefore their genome cannot integrate or persist. Finally, alphaviruses provide transient but high levels of gene expression through amplification of mRNA. Three major groups of alphavirus vectors have been developed: full-length infectious particles engineered to contain a duplicated subgenomic promoter for antigen expression, replicons engineered for insertion of genes of interest downstream of the subgenomic promoter, and versions of the replicon vector launched from DNA plasmids. A brief description of each of these vector types is given below. 13.7.1 Full-length Infectious Clones

Development of viral expression vectors derived from SIN, SFV, and VEE was preceded by earlier work that was able to generate full-length infectious clones of each of these alphaviruses [32–34]. SIN and VEE full-length clones contain a second subgenomic promoter upstream or downstream of the complete structural protein-coding region, resulting in heterologous genes under its control being expressed at high levels. With this system, it is possible to generate high-titer virus preparations without multiple tissue culture passages. 13.7.2 RNA Replicons

Of the various types of alphavirus expression vectors, replicons are probably the most developed. These RNAs are self-replicating and can express heterologous genes cloned downstream of a subgenomic promoter at very high levels. Replicon vectors lack structural polyprotein genes, which are replaced with the heterologous gene; however, the 5´- and 3´-end cis replication signals, the nonstructural replicase genes, and a natural subgenomic promoter are maintained. The absence of genes for structural protein abolishes the replicon’s spread from cell to cell, because the progeny virus cannot be formed, but it does not affect the RNA amplification and high-level expression of the heterologous gene within the target cell. 13.7.3 DNA Plasmid Replicons

In an effort to increase the potency of DNA vaccines, some alphavirus vectors have been engineered to be launched completely from DNA plasmids. In these vectors, a

277

278

13 Engineering Virus Vectors for Subunit Vaccines

nsP1 nsP2 nsP3 nsP4

Ag

Plasmid replicon

Figure 4. “Engineering Virus Vectors for Subunit Vaccines” Nkolola and Hanke

NUCLEUS

CYTOPLASM (+) strand m7G RNA

(-) strand RNA

Ag

5’

nsP1 nsP2 nsP3 nsP4

JR

Ag

AAAn 3’

AAAn 5’

3’

m7G

Ag

m7G

Ag

AAAn

m7G

Ag

AAAn

AAAn

Fig. 13.4 Plasmid DNA-based alphavirus replicon. The positioning of replicon cDNA immediately adjacent to the polymerase II transcription site provides for in-vivo synthesis of a positivestranded RNA replicon with an authentic 5´ end. After cytoplasmic RNA transport, translation of the four nonstructural genes (nsP1–4) as a polyprotein that is post-translationally processed results in an active replicase complex,which programs high-level cytoplasmic RNA amplification through a negative-stranded RNA intermediate. The replicase also mediates transcription of additional positive-strandedRNA and an abundant subgenomic mRNA encoding the antigen. Alphaviruses can be delivered as RNA, DNA, or particle replicons. Adapted from [38].

eukaryotic promoter drives transcription of the replicon RNA, which exits the nucleus and begins to amplify itself and express heterologous genes (Figure 13.4). Studies have shown that for several antigens this system significantly increases DNA vaccine potency in comparison with conventional cytomegalovirus (CMV) promoterdriven expression [37]. Furthermore, because plasmid-based alphavirus replicons are simply a plasmid DNA, they have all the other advantages of DNA vaccines.

13.8 Polioviruses

13.7.4 Particle-based Replicons

Although the first recombinant alphavirus vaccines tested in animals used doublesubgenomic vectors, more recent studies have tended to concentrate on particlebased replicons. These vectors are single-cycle viruses and work by delivering antigen via ‘infection’ using natural receptors. Packaged SFV, SIN, and VEE particlebased vaccines induce robust humoral, mucosal, and cellular immune responses in animals. Packaging of replicon RNA into particles is essentially achieved by way of cotransfection of permissive cells with in vitro transcribed replicon RNA and ‘helper’ RNA encoding the structural proteins under the control of their native subgenomic promoter. Helper RNA lacks any replicase genes or packaging signal but is required to maintain the 5´- and 3´-end cis signals needed for coamplification with the replicon. This original technique using a single helper system had an unforeseen complication, in that it also generated notable levels of replication-competent virus due to RNA recombination. To try to eliminate this problem, a two-helper system was developed in which three mRNAs are cotransfected into the packaging: one mRNA with the packaging signal coding for the SFV polymerase and an immunogen, and two other mRNAs supplying the capsid and envelope proteins in trans structure [53]. Even more recently, technological advances in this area have generated stable alphavirus replicon particle packaging cell lines that have immense potential in large-scale commercial applications. These packaging cell lines harbor two integrated DNA cassettes, encoding the capsid and envelope glycoprotein genes in a split helper configuration. Studies using alphavirus replicon particles bioengineered for delivery to dendritic cells (DCs) have shown in both mouse models [54] and humans [55] that these replicons induce activation and maturation of transfected DC. This unique DC-inducing capability of particle replicons is a desirable property in any vaccine, because it may improve induction of the immune responses.

13.8 Polioviruses

The poliovirus belongs to the Picornaviridae family and is a small positive-stranded RNA virus with a 7.5 kb genome, which is encapsidated within a nonenveloped protein shell. Two classes of poliovirus vaccine were developed over four decades ago: the formalin-inactivated poliovirus vaccine (IPV) developed by Jonas Salk and the live attenuated oral poliovirus vaccine (OPV) developed by Albert Sabin. Both vaccines were able to elicit effective humoral immune responses that protected from poliomyelitis, but only OPV induced strong mucosal immunity and was able to prime cellular immune responses [39]. As a result, all poliovirus vectors have been derived from the highly characterized and attenuated Sabin vaccine strains. The poliovirus is an attractive live viral vector for several reasons. It produces long-lasting and herd

279

280

13 Engineering Virus Vectors for Subunit Vaccines

immunity [39], it is very safe and very easy to experimentally manipulate [40], it has a proven safety and efficacy record in over one billion vaccinees [39], and it produces potent mucosal immune responses [41]. Given the favorable aspects and characteristics of the Sabin poliovirus vaccine, it is easy to see why it was envisaged that recombinant poliovirus expressing foreign antigens would be able to provide a convenient and safe vaccine vector system to induce protective immunity against other pathogens. Expression of poliovirus gene products occurs via a single long polyprotein that is post-translationally cleaved into the final products (Figure 13.5). Recombinant polioviruses have already been constructed that include a number of antigenic components from various infectious agents [42]. Early poliovirus vectors were essentially constructed as replicons, in which the virion coat protein genes VP2 and VP3 were replaced with a heterologous gene, by creating in-frame fusions with remaining portions of the capsid precursor protein P1. To release the expressed antigen from the large poliovirus polyprotein, the insert was flanked with engineered viral protease cleavage sites [43]. The actual technique by which replicon RNA is packaged into virus-like particles involves transfection of in vitro transcribed RNA into cells infected with helper poliovirus or with vaccinia virus recombinants expressing the intact poliovirus P1 region [44]. In an alternative approach, some poliovirus vaccine strains have been modified to express additional sequences as replication-competent vectors using the fusion protein approach coupled with the previously described

Proteolytic cleavage sites

Ag

Insertion

Substitution Cleavage site 5’ VPG

VP0

VP3 P1

VP1

2A

2B

2C

P2

Fig. 13.5 Construction of poliovirus-vectored vaccines. Replication-defective poliovirus replicons are constructed by replacing in-frame the virion coat protein gene sequences VP2 (portion of VP0) and VP3 with the antigen-encoding heterologous sequence flanked by protease cleavage sites. Replication-competent attenuated poliovirus vectors are constructed by insertion of the heterologous genes flanked by one or more protease cleavage sites at either the polyprotein amino terminus or the P1–P2 junction. Adapted from [38].

3A

3C P3

3D

An3’

13.9 Rhabdovirus Vectors

flanking protease cleavage sites. The major advantage of this alternative is that no helper strategy is required for production, because the generated vectors are replication-competent. Insertion of the heterologous gene(s) of interest at either the polyprotein amino terminus or the P1–P2 junction results in viable recombinant virus. Various studies have been undertaken using both replication-competent and replicon-based poliovirus vectors in mouse and primate models, with both vector platforms demonstrating immunogenicity. The capacity of poliovirus vectors to generate a strong mucosal immune response may be of particular importance in the fight against HIV-1, given that more than 90 % of the HIV type 1 (HIV-1) infections worldwide have occurred via sexual transmission [45]. Any strategy developed with the hope of controlling the current AIDS pandemic will have to include a vaccine that prevents the sexual transmission of HIV-1. Although poliovirus has many notable attributes that allow for its use as a vaccine vector, we must stress that its widespread use will probably not fully bloom until pertinent issues such as limitations in size and stability of heterologous gene inserts and preexisting vector immunity in the general population are addressed.

13.9 Rhabdovirus Vectors

Rhabdoviruses are negative-stranded RNA viruses with a genome of about 12 kb. Their genome encodes five monocistronic RNAs: the nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), the single transmembrane protein (G), and the viral polymerase (L). Transcription of these gene products occurs in a sequential manner as the polymerase moves across the genome in a linear manner, encountering distinct intergenic transcription stop and start signals. Several members of the rhabdoviridae family have been singled out as potential vaccine delivery vectors: the rabies virus (RV) and vesicular stomatitis virus (VSV). In both wild-type versions of these viruses, pathogenicity has been primarily linked with the G protein. With RV, studies showed that when the arginine residue at position 333 (R333) in the G protein is mutated to glutamic acid (E333) or aspartic acid (D333), complete abolishment of pathogenesis is observed [48]. For VSV, a recombinant VSV expressing influenza A virus hemagglutinin (HA) that contained a truncation of the VSV G-protein cytoplasmic domain was completely attenuated in a small-animal model [49]. The implications of these and other findings are that generation of suitable rhabdovirus expression vectors for use in clinical studies will need the G protein to be inactivated. Development of rhabdovirus expression vectors has essentially utilized duplication of the transcription start–stop signals flanking either side of the heterologous gene and positioning this cassette into the intergenic region following the G gene [46, 47] (Figure 13.6). The initial infectious viral stock is subsequently used for high titer amplification of the recombinant virus preparation. Recombinant rhabdoviruses offer genetic stability of the heterologous gene insert during virus passage and induce potent immune responses while expressing different antigens in murine models [49].

281

282

13 Engineering Virus Vectors for Subunit Vaccines stop-start

3’

N

P

M

G

Ag

stop-start

L

5’

Fig. 13.6 Generation of rhabdovirus-vectored vaccines. Construction of vectors is accomplished by insertion of the immunogen gene flanked by transcriptional start–stop signals on both ends into the intergenic region between the envelope glycoprotein (G) and polymerase (L) genes. (N, P, M, G, and L are rhabdovirus proteins). Adapted from [38].

13.10 Heterologous Prime–Boost Vaccination Strategies

First, induction of immunological memory involves an intricate network of interactions among a number of host cell types. Data are emerging that suggest that viruses with different biological properties stimulate different memory T cells or drive T cells into various stages of differentiation. Therefore, subunit vaccines vectored by different viruses will also differ in the T cell memory they stimulate. Second, as rule of thumb, the more attenuated the vaccine vector is, the less damage it causes and the less immunogenic it is likely to be. Therefore many vaccines, especially if they are replication-incompetent, require boosts for efficient induction of immune responses. However, multiple applications of the same vaccine render the boosts less efficient, due to the immune responses generated to the vector proteins themselves. Both the qualitative differences in induced T cell responses and the need to overcome antivector immunity may contribute to the increased immunogenicity of heterologous prime–boost regimens, which deliver the same passenger immunogen gene using different vectors. This combined approach is highly immunogenic for both humoral and cell-mediated immune responses.

13.11 Cell Lines Acceptable for Growing Human Recombinant Subunit Vaccines

All methodologies used to generate and grow recombinant viruses require the use of living cells. In view of the possibility of harmful elements that may be present in these cells and contaminate the vaccine preparations, it is of paramount importance to test and evaluate each cell line that is to be used to produce clinical-grade vaccines. Stringent rules have been laid down by regulatory authorities such as the Food and Drug Administration (FDA) in the United States [56], which can be applied to most if not all situations. The current approach to working with cell lines for vaccine production focuses on:

13.11 Cell Lines Acceptable for Growing Human Recombinant Subunit Vaccines

. Production, identification, and characterization of the cell substrate. . Validation of the manufacturing process for removal and/or inactivation of adventitious agents. . Testing the bulk and final product to assure safety. It is mandatory that the testing be performed in compliance with Good Laboratory Practice (GLP). The selection of tests depends on many variables, such as the nature of the cell line, manufacturing procedure, and the final product and its use. When a cell line has been identified as potentially suitable for vaccine production, its characterization requires a history and general characteristics of the cell line, use of the cell bank system, and quality control testing. A brief summary of each of these points is given below. In addition, there is often a need for validation studies regarding the inactivation and removal of adventitious agents by the manufacturing process. 13.11.1 History and General Characteristics of the Cell Line

The history of any cell line used for the production of recombinant virus vaccines should include: age, sex, and species of the donor for cell lines; the donor’s medical history; the culture history of the cell line, including methods used for isolation of the tissues from which the line was derived, passage history, media used, and history of passage in animals; and the results of previous identity tests and tests for all available adventitious agents. In looking at the general characteristics of the cell line, the growth pattern and morphological appearance of the cells should be determined and should be stable from the master cell bank to the end-of-production cells. If any specific markers may be useful in characterizing the cell line, these too are required to be characterized for stability. 13.11.2 The Cell Bank System

A cell bank system is primarily generated to assure that an adequate supply of equivalent cells exists for use over the entire life span of the product. In addition to providing a constant supply of starting material, the advantages of a cell bank system include a detailed characterization of the cell line and a decrease in the likelihood and increase in the detection of both cross- and adventitious-agent contamination of the cell line. 13.11.3 Quality Control Testing

Quality control of cell substrates used for production is an important part of the product quality control and covers areas such as cell culture media, management of cell cultures, and specific testing. Accurate records should be always kept of the composition and source of the cell culture medium, unprocessed and processed cell culture

283

284

13 Engineering Virus Vectors for Subunit Vaccines

fluids, and tests for the presence of bacteria, fungi, and mycoplasma. In addition, there may also be a need to conduct other tests to screen for viruses as well as for tumorigenicity of cell lines. Finally, in the generation of cell lines acceptable for growing human recombinant viral vaccines, it may be necessary to validate the elimination of adventitious viruses. Therefore, when choosing a vector for a candidate subunit vaccine, the readiness and ease with which these recombinant viruses can be produced on a large scale and to GLP standards should be taken into consideration.

13.12 Conclusion

The list of recombinant viral vectors described in this chapter is by no means exhaustive, but has included most of the approaches that are currently in clinical trials or under advanced preclinical studies or that have the potential to be breakthroughs in the coming years as candidate vaccine vectors. It is important to stress, however, that many new viral (and nonviral) vectors that may not even have been discovered yet are likely to appear. No single vector system is optimal for all potential vaccine applications. It is more likely that alternative vector systems may be required for different diseases or that a combination of different vectors could stimulate the best suited antigen-specific immune responses for a given application. Since the viruses described in this chapter are amenable to many types of manipulations, there is no doubt that future advances in immunology and virology will increase the utility of these viral vectors as vaccine delivery systems.

References 1. MÄkelÄ P.H. (2000) Vaccines, coming of age after 200 years. FEMS Microbiol. Rev. 24, 9–20. 2. Hilleman M.R. (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18, 1436–1447. 3. Schnell M.J. (2001) Viral vectors as potential HIV-1 vaccines FEMS Microbiol. Letters 200, 123–129. 4. Graham F.L., Prevec L. (1991) Manipulation of adenovirus vectors, in Methods in Molecular Biology. Gene Transfer and Expression Techniques, 7, 109–128 Clifton:Humana Press. 5. Horwitz M.S. (1996) Adenoviruses, in Fields Virology 3rd edition eds Fields B.N., Knipe D.M., Howley P.M., Cha-

6.

7.

8.

9.

nock R.M., Monath T.P., Melnick J.L., Roizman B., Straus S.E. LippincottRaven, Philadelphia, Pennsylvania pp. 2149–2171. Hitt M.M., Graham F.L. (2000) Adenovirus vectors for human gene therapy. Adv. Virus Res. 55, 479–505. Kay M.A., Glorioso J.C., Naldini L. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33– 40. Graham F.L., Smiley J., Russell W.C., Nairn R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 59–72. Fallaux F.J., Kranenburg O., Cramer

References

10.

11.

12.

13.

14.

15.

S.J., Houweling A.,Van Ormondt H., Hoeben R.C.,Van Der Eb A.J. (1996) Characterisation of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Human Gen. Therapy 7 215–222. Lowenstein P.R. (1996) The use of adenovirus vectors to transfer genes to identified target brain cells in vitro, in Protocols for Gene Transfer in Neuroscience:Towards Gene Therapy of Neurological disorders, eds Lowenstein P.R., Enquist L.W. chpt. 8 pp 93–114 London; John Wiley & Sons. Vrancken Peeters M.J., Perkins A.L., Kay M.A. (1996) Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20 278–285. Sullivan N.J., Sanchez A., Rollin P.E.,Yang Z.Y., Nabel G.J. (2000) Development of a preventative vaccine for Ebola virus infection in primates. Nature 408, 605–609. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J.,Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S.,Tang A., Chen M.,Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H.,Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E.,Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J.,Youil R., Kaslow D.C., Emini E.A. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335. Muzyczka N. (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158, 97–129. Toietta G., Pastore L., Cerullo V., Finegold M., Beaudet A.L., Lee B. (2002) Generation of helper-dependant

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

adenoviral vectors by homologous recombination. Mol. Ther. 5, 204–210. Hauswirth W.W., Lewin A.S., Zolotukhin S., Muzyczka N. (2000) Production and purification of recombinant adeno-associated virus. Methods Enzymol. 316, 743–761. Clark K.R., Liu X., McGrath J.P., Johnson P.R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031–1039. Yoon T.K., Shichinohe T., Laquerre S., Kasahara N. (2001) Selectively replicating adenoviruses for oncolytic therapy. Curr. Cancer Drug Targets 1, 85–107. Hawkins L.K., Hermiston T. (2001) Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 8, 1142– 1148. Mackett M., Smith G.L., Moss B. (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Sci. USA 79, 7415–7419. Panicali D., Paoletti, E. (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA 79, 4927–4931. Sutter G. & Moss B. (1992) Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847–10851. Tartaglia J., Perkus M.E.,Taylor J., Norton E.K., Audonnet J.C., Cox W.I., Davis S.W., van der Hoeven J., Meignier B., Riviere M. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217–232. Paoletti E. (1996) Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93, 11349– 11353. Taylor J.,Trimarchi C.,Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E. (1991) Efficacy studies on canarypox-rabies recombinant virus. Vaccine 9, 190–193. Krisky D.M., Marconi P.C., Oligino T.J., Rouse R.J., Fink D.J., Cohen J.B., Watkins S.C., Glorioso J.C. (1998) De-

285

286

13 Engineering Virus Vectors for Subunit Vaccines

27.

28.

29.

30.

31.

32.

33.

34.

velopment of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 5 1517–1530. Leib D.A., Olivo P.D. (1993) Gene delivery to neurons: is herpes simplex virus the right toool for the job? Bioessays 15, 547–554. Laquerre S. (1999) Gene-transfer tool: herpes simplex virus vectors. In The Development of Human Gene Therapy, 173–208. Ed T Friedman. New York: Cold Spring Harbor Laboratory Press. Saeki Y., Ichikawa T., Saeki A., Chiocca E.A.,Tobler K., Ackermann M., Breakefield X.O., Fraefel C. (1998) Herpes simplex virus type I DNA amplified as bacterial artificial chromosome in E. coli: rescue of the replicationcompetent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 9, 2787–2794. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H.,Verma I.M.,Trono D. (1996) In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 272, 263–267. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., Huang H.V. (1989) Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1188–1191. Rice C.M., Levis R., Strauss J.H., Huang H.V. (1987) Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. J. Virol. 61, 3809–3819. Liljestrom P., Lusa S., Huylebroeck D., Garoff H. (1991) In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6000-molecular-weight membrane protein modulates virus release. J. Virol. 65, 4107– 4113. Davis N.L.,Willis L.V., Smith J.F., Johnston R.E. (1989) In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171, 189–204.

35. Stone D., David A., Bolognani F., Lowenstein P.R., Castro M.G. (2000) Viral vectors for gene delivery and gene therapy within the endocrine system. J. Endocrinol. 164, 103–118. 36. Rayner O.J., Dryga S.A., Kamrud K. (2002) Alphavirus vectors and vaccination. Rev. Med. Virol. 12, 279–296. 37. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., Restifo N.P. (2000) Enhancement of tumor-specific immune responses with plasmid DNA replicon vectors. Cancer Res. 60, 51–55. 38. Polo J.M., Dubensky T.W. (2002) Virusbased vectors for human vaccine applications. Drug Discovery Today 7, 719– 727. 39. Sutter R.W., Cochi S.L., Orenstein W.A. (1999) Live attenuated poliovirus vaccines in S.Ploktin and W.Orenstein (ed.) Vaccines, 3rd ed. W.B. Saunders, Philadelphia, Pa., 364–408. 40. Melnick J.L. (1996) Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and new enteroviruses in Fields Virology, 3rd ed., eds Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Monath T.P., Melnick J.L., Roizman B., Straus S.E. vol. I Lippincott-Raven Publishers, Philadelphia, Pa. 655–712. 41. Morrow C.D., Novak M.J., Ansardi D.C., Porter D.C., Moldoveanu Z. (2000) Recombinant viruses as vectors for mucosal immunity. Curr. Top. Microbiol. Immunol. 236, 255–273. 42. Andino R., Silvera D., Suggett S.D., Achacoso P.L., Miller C.J., Baltimore D., Feinberg M.B. (1994) Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265, 1448–1451. 43. Choi W.S., Pal-Ghosh R., Morrow C.D. (1991) Expression of human immunodeficiency virus type 1 gag and pol proteins from chimeric HIV-1-poliovirus minireplicons. J. Virol. 65, 2875– 2883. 44. Porter D.C., Ansardi D.C., Choi W.S., Morrow C.D. (1993) Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 gag and pol proteins upon infection. J. Virol. 67, 3712–3719.

References 45. UNAids and World Health Organization. (1998) Report on the global HIV/ AIDS epidemic. World Health Organization, Geneva, Switzerland.. 46. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. (1996) Highly stable expression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. USA 93, 7310–7314. 47. Schnell M.J., Buonocore L.,Whitt M.A., Rose J.K. (1996) The minimal conserved transcription stop-strat signal promotes stable expression for a foreign gene in vesicular stomatitis virus. J. Virol. 70, 2318–2323. 48. Coulon P.,Ternaux J.P., Flamand A., Tuffereau C. (1998) An avirulent mutant of rabies virus is unable to infect motor neurons in vivo and in vitro. J. Virol. 72, 273–278. 49. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., Kawaoka Y., Rose J.K. (1998) Vaccination with vesicular stomatitis virus expressing an influenza virus hemagglutnin provides complete protection from influenza challenege. J. Virol. 72, 4704– 4711. 50. Lieber A., He C.Y., Meuse L., Schowalter D., Kirillova I.,Winther B. and Kay M.A. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after the infusion of recombinant adenovirus vectors. J. Virol. 71, 8798–8807. 51. Franchini M., Abril C., Schwerdel C., Ruedl C., Ackermann M., Suter M. (2000) Protective T-cell-based immu-

52.

53.

54.

55.

56.

nity induced in neonatal mice by a single replicative cycle of Herpes simplex virus. J. Virol. 75 (1), 83–89. Rees RC, McArdle S, Mian S, Li G, Ahmad M, Parkinson R, Ali SA. (2002) Disabled infectious single cycleherpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Curr. Opin. Mol. Ther. 4(1), 49–53. Polo J.M., Belli B.A., Driver D.A., Frolov I., Sherrill S., Hariharan M.J.,Townsend K., Perri S., Mento S.J., Jolly D.J., Chang S.M., Schlesinger S., Dubensky T.W. (1999) Stable alphavirus packaging cell lines for Sinbis virus- and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. USA 96, 4598–4603. MacDonald G.H.,Johnston R.E. (2000) Role of dendritic cells targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74, 914–922. Gardner J.P., Frolov I., Perri S., Ji Y., MacKichan M.L., zur Megede J., Chen M., Belli B.A., Driver D.A., Sherrill S., Greer C. E., Otten G.R., Barnett S.W., Liu M.A., Dubensky T.W., Polo J.M. (2000) Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 74, 11849–11857. Center For Biologics Evaluation and Research, Food and Drug Administration (1993) Points to consider in the characterization of cell lines used to produce biologicals. http://www.fda.gov/cber/ gdlns/ptccell.pdf.

287

289

14 Update on antiviral DNA vaccine research (2000–2003) Daniel Franke, Jovan Pavlovic, Tillmann S. Utesch, Max von Kleist, Jan Schultz, Guenter Dollenmaier, and Karin Moelling

Summary

DNA vaccines can induce protective cellular and humoral immune responses and have therefore been used during the past decade to develop vaccines against a variety of pathogens. Because current antiviral vaccines predominantly generate humoral immunity, DNA immunization may be especially useful to provide long-term protection against viral diseases that also require cellular immunity. A significant portion of published articles in the field of DNA vaccines deal with viral diseases, reflecting the need for better and alternative vaccination strategies against viruses. The success of DNA immunization depends on a variety of parameters, e. g., type of antigen, method of application, usage of adjuvants. Therefore, different strategies have been explored for modulating the induced immune response with respect to the requirements necessary to protect against a specific pathogen (e. g., induction of mucosal or cell-mediated immunity). This chapter provides an update on various aspects of antiviral DNA vaccine research for the period from the beginning of 2000 until the beginning of 2003. Previous reviews cover the literature before 2000 [1–4].

14.1 Effect of Antiviral DNA Vaccines in Mice

Genetic vaccines are under investigation against a number of human viral diseases. During the past two years research has focused on improving their efficacy, using viral infections in animal model systems. Table 14.1 summarizes the literature on DNA vaccines against viral infections for the period 2000 through the beginning of 2003 and is an update of previous overviews [2, 4]. During this period DNA vaccines have been described against many viral infections, such as bunyaviruses, including hantavirus and La Crosse virus; hepatitis D virus; flaviviruses, including Dengue virus type 1, Japanese encephalitis virus, Murray Valley encephalitis virus, central European encephalitis virus, and Russian spring/summer encephalitis virus; herpes viruses, including human cytomegalovirus and varicella zoster virus; and the toga-

290

14 Update on antiviral DNA vaccine research (2000–2003)

virus rubella virus. The efficacy of DNA vaccines was monitored by humoral or cellular immune responses or resistance to virus challenge. Table 14.1 summarizes the viruses, the specific gene(s) used for immunization, the model systems used, the responses, modes of application, and references.

Tab. 14.1 DNA vaccination to viruses (01/2000–03/2003). Virus

Antigen

Application

Host

Effect

Ref.

LCMV

NP

i.m.

mice

45

LCMV

NP

i.m.

mice

LCMV

NP

i.m.

mice

LCMV

NP

i.p.

mice

LCMV

NP

i.m.

mice

LCMV

NP

intragastrically mice

LCMV

GP33

i.m., i.d., peripheral lymph nodes

mice

DNA vaccination at birth resulted in rapid induction of antigen-specific CD8(+) T cells. Vaccination with plasmids expressing NP as an intracellular or secretory protein caused liver injury. Multiepitope DNA vaccines should be cocktail of plasmids, each with its own epitope, to allow maximal epitope dispersal among APCs. VV-based vaccines optimized prime–boost regimens. Described system for targeting proteins and minigenes to lysosomes. Mice vaccinated with vector expressing LCMV NP were protected against virus challenge. Immunization with DNA by direct injection, into a peripheral lymphnode enhances immunogenicity.

LCMV

NP

i.m.

mice

Protection from lethal and sublethal LCMV infections conferred well before the peak of CD8(+) T cell response.

54

Hantavirus envelope gene gun glycoproteins G1 and G2, N gene

55

Hantavirus NP

rhesus First immogenicity data for Hantavimonkeys, rus DNA vaccines in nonhuman prihamsters mates; Hantavirus M gene-based DNA vaccines could protect humans against the most severe forms of HFRS. i.m. mice Vaccination with DNA plasmids encoding NP combined with secretion signal. into leaf discs/ tobacco, Transgenic plants expressing Hantatuber discs potato viral proteins could be used for alterplants native vaccination strategies.

56

i.m.

58

Arena viridae

49

19

50 51 52

53

Bunya viridae

Hantavirus NP

Hantavirus NP

mice

DNA vaccination could be used for identification of highly immunogenic epitopes.

57

14.1 Effect of Antiviral DNA Vaccines in Mice Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

Hepatitis delta virus

HDAg

gene gun

woodchucks

Modification of the course of DNA immunization.

59

Hepatitis delta virus

HDAg

gene gun

woodchucks

DNA immunization with vectors expressing p24 could not induce protective immune response.

60

Hepatitis delta virus

large hepatitis D antigen

i.m.

mice

Large hepatitis D antigen DNA induced significant titers of anti-HDV antibodies.

61

HCV

E1, E2, NS3, i.m. NS4, NS5A and -B

mice

Revealed clustered organization of HCV immunogenic HLA.A2.1 epitopes and strategies to modulate their dominance.

62

HCV

E2

i.m.

chimpan- Titration in chimpanzees of diffezees rent HCV variants to provide wellcharacterized challenge pools.

63

HCV

E2 (cell-surface and intracellular)

i.m.

chimpan- DNA vaccine encoding cell surfacezees expressed E2 did not elicit sterilizing immunity in chimpanzees.

26

HCV

capsid, E1, i.m. E2, NS2, NS3

mice

Combination of naked DNA with nonreplicating canary pox booster encoding HCV.

35

HCV

envelope ge- i.m. nes E1, E2

buffalo rats

Addition of GM-CSF gene to envelope genes E1/E2 in a bicistronic plasmid augmented antibody and lymphoproliferative responses.

64

HCV

envelope E2 gene gun, protein, trun- i.m. cated form of E2 targeted to cell surface

rhesus macaques, mice

Targeting of E2 protein to cell surface increased its ability to induce humoral immune responses by DNA vaccination.

25

HCV

E2

i.m.

mice

DNA prime–protein boost induced stronger immune response than DNA or protein alone, evidenced by enhanced IgG2 a and CTL responses.

34

Dengue nonstructural i.m. virus type 1 proteins

mice

gp160 expressed from dengue virus replicons was considerably more toxic than GFP or gp120.

65

Dengue prememi.d., i.m. virus type 1 brane, envelope

rhesus Immunization protected 4 of 8 monkeys monkeys completely and 4 partially from developing viraemia.

66

Dengue prememi.d., i.m. virus type 1 brane/membrane, envelope

Aotus Immunization conferred complete nancymae or partial protection from viral chalmonkeys lenge.

67

Deltavirus

Flaviviridae

291

292

14 Update on antiviral DNA vaccine research (2000–2003) Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

Dengue prememsubcut., i.c. virus type 2 brane, envelope

mice

Induction of CD8 T-cell response specific for DEN-2 virus prM and E proteins protected against lethal dengue encephalitis.

28

Dengue prememvirus type 2 brane, envelope

i.m.

mice

Induction of neutralizing antibodies and memory B cells.

68

Japanese envelope encephalitis virus

oral

humans

JE vaccines including naked DNA, oral vaccination, and recombinant subunit vaccines.

69

Japanese envelope encephalitis virus

i.m., gene gun

mice

Adoptive transfer/antibody production by pE DNA vaccine.

70

preM, E, Japanese encephalitis NS1, NS2a virus

subcut.

humans

Double-blind clinical trial with attenuated recombinant poxviruses with JEV.

71

Japanese prememencephalitis brane, envelope virus

i.m.

mice

Single injection induced neutralizing antibody titers and prevented Japanese encephalitis.

72

Tick-borne envelope encephalitis (prime– virus boost)

i.m.

mice

Recombinant alpha virus RNA molecule elicited protection against 3 model virus diseases.

73

mice

Induction of antibody production and protective immunity.

74

Chimeric virus against WNV.

75

Tick-borne E-NS1, Eencephalitis NS3 virus West Nile virus

prM, E

Hepadna viridae HBV

HBsAg

i.m.

mice

DNA vaccines induced antigen-specific immune responses.

76

HBV

gB

i.m., i.d.

rhesus macaques, mice

5 juvenile macaques were immunized, developing antibodies to B virus, gB neutralizing activity.

77

HBV

surface and i.m. core antigens

mice

Modulation of antigen expression by Kazak's translation-initiation sequence.

78

HBV

HBsAg

i.v.

rhesus SHIV- and HBV-specific cytotoxicity macaques led to expansion of memory cells.

79

HBV

HBsAg

i.m.

chimpan- Immunization of chimpanzee HBV zees carrier using DNA followed by recombinant canary pox booster.

36

HBV

HBsAg

subcut.

mice

Dominant epitopes in human human D transgenic mouse model.

24

HBV

HBsAg

electro-poration

mice

Electroporation resulted in more rapid onset and more antibody formation.

80

14.1 Effect of Antiviral DNA Vaccines in Mice Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

HBV

HBsAg

i.d., i.m.

mice

Human desmin promoter/enhancer and CMV promoter induced comparable antibody and CTL responses.

81

Herpes viridae Human VP2 cytomegalovirus

chickens 2 herpes virus, complete protective immunity to chickens.

82

Human gB, pp65 cytomegalovirus

i.m.

mice

Mice inoculated at 3 sites.

83

Human pCMV/V-18 cytomegalovirus

i.v.

rats

Allograft tolerance in adult rat by pregraft donor-specific blood transfusion.

84

HSV-1

gB, gD

i.m., i.p.

mice

gD or gB plasmid alone or mixed with copolymers; immunized mice were protected.

85

HSV-1

gB

i.m., i.n., i.g.

mice

CCR7 ligands DNA administration; mucosal cotransfer provided significant increases of distal mucosal IgA responses; CCR7 ligands were useful adjuvants for genetic vaccination.

86

HSV-1

gB

i.m.

mice

Limited HSV-1 infection of sensitive ganglia.

87

HSV-1

gD

i.m.

mice

Immunity to HSV by gD-DNA immunization not strictly correlated with antibody levels.

88

HSV-1

gB

i.m.

rabbits

Local protein and systemic DNA administration elicited neutralizing antibody response.

89

HSV-1

gB

i.n.

mice

Value of CXC and CC chemokines in mucosal DNA vaccination.

HSV-1

gM

subcut.

mice

HSV-1 amplicon vectors appeared to be effective for cytokine-enhanced vaccination therapy of glioma.

90

HSV-1

gD

oral

lambs

Single oral exposure in utero to plasmid DNA encoding truncated form of glycoprotein D of bovine herpesvirus-1 induced detectable immune responses in 80 %.

91

HSV-1

gD

i.v.

mice

Targeting of herpes simplex virus type-1 glycoprotein D to liver by complexing it with an asialoorosomucoid DNA carrier system induced antigen expression in liver cells 6 days after immunization and influx of T cells.

92

9

293

294

14 Update on antiviral DNA vaccine research (2000–2003) Tab. 14.1 (continued) Virus

Antigen

HSV-2

Application

Host

Effect

Ref.

glycoprotein i.m., oral D

mice

Salmonella harboring pIL10; oral administration led to oral immunization.

7

HSV-2

gD (prime– boost)

gene gun

mice

Use of MVA and plasmid DNA vector dramatically enhanced immune response.

93

HSV-2

gD

oral

mice

Expression of plasmid was due to transcription of protein by eukaryotic nuclear process.

94

HSV-2

gD

i.m.

mice, guinea pigs

Guinea pigs were not protected by immunization with DNA encoding cytosolic gD2, mice were.

95

HSV-2

gD

i.m., i.d.

mice

Coinjection (GM-CSV) increased both humoral and cell-mediated responses.

HSV-2

gD

i.m.

mice

Despite weak expression in vitro restricted to myofibers, a myogenic DNA vaccine under control of a promoter derived from murine muscle creatine kinase gene induced virus-specific immunity that protectted HSV-2-infected mice from death.

96

HSV-2

gD

Coimmunization with lymphocyte function-associated antigen-3 (LFA-3) enhanced IgG-production, TH-proliferative responses, and survival rate.

8

6

Orthomyxo viridae Influenza virus

matrix protein

i.n., i.m.

mice

CD8 T cell populations induced by DNA/MVA prime–boost vaccination did not show enhanced capability to mediate protection in IFN-gammaindependent influenza challenge model.

42

Influenza virus

hemaggluti- i.m., i.n. nin (HA), HN

mice

Liposomal ISS-ODN coadministered with soluble antigen or liposomal antigen were up to 30 times more effective than formulations containing unencapsulated ISS-ODN in protecting against virus challenge.

97

Influenza virus

NP, matrix proteins

mice

Vaccination reduced replication of nonlethal H5N1 strain, protection against lethal challenge; DNA vaccination alone protected poorly against this highly virulent strain.

98

14.1 Effect of Antiviral DNA Vaccines in Mice Tab. 14.1 (continued) Virus

Antigen

Application

Host

Influenza virus

NP

i.m.

pigs

Influenza virus

HA

Influenza virus

HA

Influenza virus

M1, M2

Influenza virus

HA

Influenza virus

HA

Influenza virus

HA, NP

Influenza virus

HA

Influenza virus

HA

Influenza virus

HA

Effect

Fusion proteins M2eHBc and M2eNP induced antibody response against M2 e; M2eNP vaccine induced influenza virus-specific lymphoproliferation response. gene gun mice Attenuated murine caspase 2 and a chimera of murine caspase 2 prodomain and human caspase 3 strongly enhanced humoral and cell-mediated immune response to HA when coadministered with an immunogen DNA. gene gun pigs Coadministration of pIL-6 DNA did not significantly enhance immune responses to HA DNA vaccination or protect from challenge exposure. i.m., i.n. mice 70 %–80 % protection was observed in mice immunized with pME18SM plasmid followed by lethal infection with influenza viruses of the A/ WSN/33 and A/PR/8/34 strains. i.p. mice Inhibition period of anti-HA antibody in offspring born to dams immunized with DNA was shorter than that of offspring born to dams immunized with virus. gene gun pigs Administration of conventional inactivated influenza virus vaccine 4 weeks after a priming dose of HA DNA led to higher levels of virus-specific serum antibodies and protection from challenge virus infection. intratracheal baboons Neonatal DNA vaccination triggered (i.t.) virus-specific and neutralizing antibodies of titers and persistence, depending on vaccine dose. multiple injec- chickens Beneficial response was observed in tion sites birds boostered at 3 wk. of age, in birds given larger amounts of DNA, and with multiple injection sites. multiple injec- mice Neonatal mice coimmunized with tion sites HA-DNA and either IL-12 or IFNgamma-expressing DNA developed IgG2a-biased immune responses, regardless of inoculation method. i.m. mice Significant enhancement of cellular and antibody responses after electrotransfer for 1- and 10-mg DNA doses, respectively, but no effect at lower dose.

Ref. 20

99

10

100

101

102

104

105

11

106

295

296

14 Update on antiviral DNA vaccine research (2000–2003) Tab. 14.1 (continued) Virus

Antigen

Application

Influenza virus

HA, NA and i.m., NB, NP gene gun

Influenza virus

HA

Influenza virus

HA, NP

Influenza virus

HA

Influenza virus

HA

Influenza virus

HA

Influenza virus

neuraminidase from different subtype A viruses

Host

Effect

mice

HA and NA DNAs conferred complete protection against lethal challenge; both were used as vaccine components to provide effective protection against influenza B virus infection. i.n, i.t. chickens Birds challenged with dose of lethal parent virus were protected to different extents, depending on their age. i.v. pregnant Uptake of plasmid DNA by fetuses, mice protection against challenge by homologous influenza virus. i.m. Targeting HA-based DNA vaccine to APCs by fusion to CTLA-4 increased antibody response and reduced viral titers 100 fold after nonlethal viral challenge. electromice Electroporation with 10 mg HAporation, i.m., DNA, administered twice, induced mucosal strong antibody production, weak CTL response, and protection against lethal virus challenge; intranasal DNA immunization by electroporation provided reduced nasal virus titers. gene gun, mice APCs were detectable first in draini.m. ing lymph nodes and then in spleen of gene gun but not i.m. DNA immunized mice. gene gun, mice H3N2 virus NA-DNA conferred electro-poracross-protection against lethal chaltion muscle lenge with antigenic variants within same subtype did not protect against infection by different subtype virus (H1N1).

Ref. 107

108

48

27

109

110

111

Paramyxo viridae Measles virus

nucleocapsid oral (N) protein

Measles virus

H, F protein i.d., gene gun

Measles virus

H, nucleocapsid

i.d., i.m.

mice

Replication-deficient adenovirus construct expressing virus N protein elicited antibody and cytotoxic T cell responses. rhesus Protection correlated with levels of macaques neutralizing antibody and not with cytotoxic T lymphocyte activity. cotton DNA vaccination with both hemaggrats lutinin and fusion protein but not nucleocapsid induced T cell responses and antibody production and protected against experimental virus infection.

112

44

113

14.1 Effect of Antiviral DNA Vaccines in Mice Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

i.m.

mice

Challenge infection showed that RNA immunization elicited significant levels of protection against influenza A, RSV, tick-borne encephalitis virus.

73

Respiratory F- ,G-protein gene gun syncytial virus

mice

Complete protection against RSV infection was induced with DNA encoding fusion protein of RSV.

21

Respiratory G-protein syncytial virus

i.m.

mice, cot- DNA vaccination elicited balanced ton rats systemic and pulmonary Th1/Th2 cytokine responses, induced neutralizing antibodies, conferred protection against RSV infection, and did not provoke atypical inflammatory reaction.

114

Respiratory F-protein syncytial virus

Retroviridae HIV-1

env

oral (PLG)

mice

Intragastric administration of DNA encapsulated in PLG microparticles resulted in antigen expression in intestinal epithelium, type 1- and CTL responses in spleen and mucosal tissue, increased levels of IgA, and higher resistance to mucosal virus.

115

HIV-1

gp160

i.m., i.n.

mice

CMV promoter activation by 8-Br-cAMP increased immune response, as evidenced by elevations in IgG antibody titers, CTL activity, and DTH response.

116

HIV-1

env, gag

i.m.

rhesus Augmentation of antibody responmonkeys ses and tetramer-positive CD8+ T cells upon IL-2/Ig plasmid coadministration.

117

HIV-1

env, gag

i.m.

macaques CMV promoter is superior to LTR promoter in inducing humoral and cellular immune response.

118

HIV-1

env, rev

i.m.

humans

In a phase I study 300 mg of HIV env/rev DNA at 0, 4, 8, and 24 weeks induced antigen-specific lymphoproliferative responses and antigen-specific production of interferon-g and b-chemokine.

119

HIV-1

gag, env

electroporation

mice, guinea pigs, rabbits

Electroporation resulted in higher gag antibody titers and increased CD8+ T cell response.

80

HIV

multiepitope i.m.

mice

Semliki Forest virus was used as vector carrying HIV clade A for prime–boost regime.

120

297

298

14 Update on antiviral DNA vaccine research (2000–2003) Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

HIV-1

env

i.m.

mice, guinea pigs, rhesus monkeys

Immunogenicities of synthetic HIV1 env DNA prime and recombinant adenovirus boost vaccinations were evaluated.

41

HIV

gag

i.n.

mice

Similar effect to i.m. injection, strong boosting effect was observed in mice primed with DNA.

121

HIV

gag-pol, env-rev

i.v.

rhesus Plasmid vaccines supplemented by macaques IL-2 Ig cytokine gene adjuvants or boosted by recombinant MVA vectors expressing relevant SIV and HIV antigens prevented CD4(+) T-cell loss and lowered viral loads after pathogenic challenge.

13

HIV

structural, regulatory proteins

gene gun, i.m.

rhesus Chronically infected rhesus macamacaques ques were benefited by boosting in combination with antiretroviral therapy.

122

HIV-1

gp160

i.m, i.d, gene gun

mice

HIV-specific immune responses and protection were strongest in animals immunized with combination of subtypes A-, B-, and C-specific gp160 genes relative to subtype B only.

123

HIV-1

tat, rev, SFV-tat, SFV-rev

rectal

rhesus 3 different prime–boost regimes macaques were compared, no clear differences were shown.

124

HIV-1

SIVmac251

intravaginal

rhesus Intravaginal challenge of macaques; macaques monitored SIV- specific T cell responses in peripheral blood.

125

HIV

gag-pol, nef

intrarectal

rhesus Animals covaccinated multiple macaques times with Nef vaccine and pVpr/ Vpx plasmid suffered rapid and profound loss of CD4(+) T cells.

126

HIV

SIVmac239

intrarectal, i.d. rhesus Repertoire of immune responses macaques detected in peripheral blood after immunization and after infection substantially differed.

127

HIV-1

tat, gag, rev

intrarectal

rhesus Partial protection from virulent mumacaques cosal SHIV challenge detected only in prime–boosted macaques.

31

HIV

gag

i.m.

rhesus Vaccinated monkeys responded to macaques 25 epitopes and on average recognized a minimum of 2.7 epitopes.

15

HIV-1

gp-160

gene gun, i.d.

rhesus After prime–boost vaccination macaques SHIV-infected macaques were rechallenged with pathogenic SHIV89.6P; 4 of 6 animals showed normal CD4+ T-cell counts.

46

14.1 Effect of Antiviral DNA Vaccines in Mice Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

HIV

SIVmac239

rectal

rhesus DNA prime–modified vaccinia virus macaques Ankara boost regimen immunized rhesus macaques against nearly all SIV proteins.

128

HIV

env

i.v.

rhesus Plasmid DNA or recombinant modimacaques fied vaccina virus Ankara vaccinated rhesus macaques, after pathogenic simian–human IV challenge, generated secondary CTL responses to subdominant epitopes.

18

HIV

gag, env, pol i.d.

rhesus Gag-Pol DNA priming and Gag-Pol macaques rMVA boosting to evaluate contribution of anti-Env immune responses to viral control.

39

HIV-1

tat

i.m.

mice

Novel class of cationic block (PEG/ poly(dimethylamino) ethylmethacrylate) copolymer for DNA delivery was safe and possessed required biological characteristics.

129

HIV

tat

i.d.

rhesus Role of Tat-specific CTL in controlmacaques ling pathogenic SIV mac239 replication after Ankara boost.

130

HIV

gag-pol-env

rectal

rhesus SIV-specific mucosal antibodies macaques were detected; 4 of 7 vaccinees were protected.

16

HIV-1

gag, env

i.p.

mice

Investigation of primary cellular immune responses elicited by recombinant vesicular stomatitis viruses.

131

HIV-1

gp-160

i.m.

humans

HIV-1 gp-160 plasmid DNA vaccine was safe and did not induce antiDNA autoimmune antibodies.

132

HIV-1

tat

i.d.

cynoTat vaccination induced specific Th1 molgus responses, including CTLs. monkeys

22

HIV-1

env, gag

i.m.

rhesus Mutation within immunodominant macaques Gag epitope after vaccination and viral challenge resulted in viral escape.

14

HIV-1

gag

rhesus Several vaccine vector delivery macaques systems were examined.

40

HIV-1

gag

nasal, i.m., rectal, vaginal

mice

133

HIV

gag

intranasal

macaques All macaques vaccinated with prime–boost regimen were protected from depletion and showed greatly reduced peak viral loads compared with controls.

Mice were protected against VV-Gag replication in ovaries after rectal or vaginal immunization.

Ref.

37

299

300

14 Update on antiviral DNA vaccine research (2000–2003) Tab. 14.1 (continued) Virus

Antigen

Application

Host

HIV-1

env

i.v.

macaques Vaccinated macaques had lower levels of peak viremia, rapidly cleared virus from periphery, and developed delayed seroconversion to SIV core antigen prime–boost.

38

HIV-1

env, gp120

i.n., intraperitoneally, i.m.

mice

Single dose of gp120 DNA vaccine vector afforded significant protection against vaccinia-env challenge.

134

HIV-1

nef, rev, tat

i.m.

humans

Efficacy of DNA plasmid combination in inducing cellular immune responses was analyzed; no clinical advantages or adverse effects were noted.

135

HIV-1

env, gag, gp120

i.m.

humans

T cell memory to HIV-1 antigens and anti HIV-1 CTL activity were assessed after administration of vaccina virus.

136

HIV-1

gag

i.p.

mice

Immunized mice developed cytotoxic T lymphocyte response against HIV-1 gag.

137

HIV-1

env

subcut.

mice

Combination of DNA vaccination, vector infection, and passive transfer of infected DCs induced strong immunity.

138

HIV

env

gene gun

mice

Fusion of Env and complement component (C3 d) in DNA vaccine enhanced titers of antibody to Env.

29

HIV-2

env, gag, pol i.v., rectal

cynoALVAC HIV-2 vaccine followed by molgus exposure to live HIV-2 induced cross monkeys protection against mucosal infection with SIVsm and seemed more efficient than immunization with live HIV-2 vaccine only.

139

HIV-1

gag, pol

i.m.

mice

23

HIV

tat

i.m.

cynoInoculation of pCV-tat prevented the molgus CD4(+) T cell decline; undetectable monkeys virus replication and negative virus isolation correlated with presence of anti-tat CTLs.

HIV

env/rev, gag/pol

i.m.

Effect

Gag-Pol fusion proteins stimulated cytotoxic T lymphocyte and antibody responses, Gag-Pol pseudoparticle did not elicit substantial Pol responses.

rhesus Coadministration of IL-2 and IFNmacaques gamma cDNA resulted in enhancement of antigen-specific T cell mediated immune responses.

Ref.

140

12

14.2 Effect of Antiviral DNA Vaccines in Larger Species Tab. 14.1 (continued) Virus

Antigen

Application

Host

Effect

Ref.

HIV-1

gag, env

i.m.

17

HIV-1

gp120

i.m.

HTLV-1

tax

intraperitoneally

rhesus Plasmid DNA vaccination led to macaques high-frequency CTL responses specific for both epitopes. mice B7–1 or B7–2 administered concurrently with plasmid DNA vaccine fully costimulated vaccine-elicited CTL responses. rats DNA vaccine with Tax effectively induced Tax-specific CTL activity; transfer of these immune T cells effectively inhibited in-vivo growth of HTLV-1-transformed tumor. mice

143

141

142

Rhabdoviridae Rabies virus glycoprotein i.n. G Rabies virus glycoprotein G Rabies virus CRV, DRV

Rabies virus glycoprotein G

Rabies virus glycoprotein G

Rabies virus glycoprotein G

Immunized mice developed antibodies and remained resistant to challenge with otherwise lethal dose. gene gun, i.m. monkeys Antibody titers of gene gun-vaccinated animals were higher than titers of i.m.-vaccinated animals. i.m. mice Mice immunized with CRV (novel combination RV) developed higher levels of RVNA than those immunized with DRV and were completely protected against peripheral and intracerebral RV challenge. gene gun, rhesus Post-exposure vaccination with i.d. macaques DNA or HDCV in combination with one-time treatment with HRIG protected 50 %–75% of monkeys. i.m., i.d., mice Post-exposure therapy, substituting gene gun a DNA vaccine for HDCV, did not compromise protection against rabies virus. gene gun, i.d., mice The adjuvant monophosphoryl lipid i.m. A increased primary, but decreased booster antibody response.

144

145

146

147

148

14.2 Effect of Antiviral DNA Vaccines in Larger Species

Several DNA vaccines have shown efficacy in small-animal models, especially mouse. In larger species, DNA vaccines were less effective. However, monkeys were completely protected from dengue virus type 1 and measles virus infection. Furthermore, immune responses were induced by HCV, central European encephalitis virus, Russian spring/ summer encephalitis virus, and HIV antigens. In particular, the efficacy of HIV DNA vaccines was studied and enhanced by coadministration of cytokines, costimulators,

301

302

14 Update on antiviral DNA vaccine research (2000–2003)

and so-called DNA-prime-peptide boost strategies, which improved antibody and CD8+ T cell responses. Long-lasting antibody responses were generated in swine vaccinated with DNA coding for the premembrane and envelope proteins of Japanese encephalitis virus, and in dogs vaccinated with DNA coding for the rabies virus glycoprotein. Improvement of vector design and optimization of the quantitative and qualitative aspects of the immune response were approached by (1) modulating the mode of DNA application with respect to time, route of administration, and auxiliary means employed, (2) addition of genetic adjuvants, (3) modification of the plasmid design comprising the use of different promoters, CTL-epitope DNA vaccination, and attempts to target the expressed antigen to intracellular and extracellular compartments or the cell surface, (4) altering the DNA antigen carrier system, and (5) combining DNA with protein or other viral immunization strategies.

14.3 Genetic Adjuvants

Genetic adjuvants are vectors coding for a cytokine, a costimulatory molecule, or a ligand. Ertl and coworkers were the first to report the induction of profound imunomodulation by cytokine DNA codelivery [5]. In a rabies virus model, granulocytemacrophage colony-stimulating factor (GM-CSF) DNA strongly enhanced the antigen-specific B and T helper cell response. Meanwhile, cytokine DNA coadministration has proven efficacy in several other viral model systems. An important advantage over protein therapy may represent the low and long-lasting expression, which is a characteristic feature of genetic adjuvants and may be responsible for their effectiveness, feasibility, and low toxicity. Stimulation of antigen-presenting cells (APC) directs the immune response to the T-cell helper (TH)-1/TH-2 type by the production of an array of cytokines, comprising interleukin-12 (IL-12). IL-12 induces the differentiation of TH-0 to IL-2-, IFN-g-, and lymphotoxin-producing TH-1 type cells. Moreover, IL-12 activates natural killer cells (NK cells), which in turn also generate interferon-gamma (IFN-g. The main effector function of TH-1 type immune reactions represents the promotion of phagocytosis-mediated defense against infections. Then main effector cytokine is IFN-g, which enhances the microbicidal activity of phagocytes, the production of complement-fixing and opsonizing antibodies, and, in concert with IL-2, the proliferation and differentiation of CD8+ cells to CTLs. Delayed type hypersensitivity (DTH) responses are typical TH-1 type immune responses. In contrast, TH-2 type immune responses are characterized by IL-3, IL-4, IL-5, IL10, and IL-13 production. Thereby, TH-2 cells mediate allergic reactions and defense against helminthic and arthropod infections. Moreover, immune reactions of the TH-1 type are antagonized. Typical features of TH-2 immune reactions are IgE- and IgG-neutralizing antibody generation and activation of eosinophils. GM-CSF DNA showed substantial effectiveness against HSV-2 infections. Codelivery of DNA encoding GM-CSF with DNA encoding the HSV-2 full length glycoprotein D (gD) increased both the humoral and cellular immune response. A strong ac-

14.4 CTL-Epitope Immunization

tivation of IL-4-secreting cells was observed in the spleen and draining lymph nodes, together an increased number of IFN-g-secreting cells. A reduction of vaginal virus titer after intravaginal challenge was observed in mice coinjected with a GM-CSF encoding plasmid relative to those immunized with gD encoding plasmid only [6]. Oral coadministration of Salmonella harboring a plasmid encoding IL-10 together with Salmonella carrying a plasmid encoding HSV-2 gp D or B to mice led to severe lesions and death after virus challenge, compared to mice receiving the plasmid encoding gD only. [7]. Costimulation by coinjection of vectors coding for CD80 (B7.1) and HSV gp D induced a strong DTH reaction and an adjuvant effect upon viral challenge with HSV [6]. Coimmunization of a gp D plasmid vaccine with the cDNA of lymphocyte function-associated antigen-3 (LFA-3), an adhesion molecule present on antigen-presenting cells, which binds to CD2 on T cells, enhanced IgG-production, TH-proliferative responses, and survival rate upon challenge with HSV-2 [8]. Costimulation of plasmid DNA encoding gB with DNA coding for the conserved cystine residues (CC) chemokines, macrophage inflammatory protein 1beta (MIP1beta) and monocyte chemotactic protein 1 (MCP-1), biased the immunity to the Th2-type. Costimulation with DNA encoding CXC chemokine MIP-2 and the CC chemokine MIP-1alpha biased the immune responses to the Th1-type [9]. Coadministration of IL-6 DNA with a swine influenza virus hemagglutinin DNA vaccination did not lead to a significantly enhanced virus-specific antibody response [10]. Neonatal mice coimmunized with hemagglutinin DNA and either IL-12 or IFNgamma expressing DNA developed IgG2a-biased immune response. In contrast, there was no effect in adults. In neonatal and adult mice the Th1 genetic adjuvants also shifted the pattern of lymphokine production by recall splenocytes from a mixed response to exclusively IFN-g [11]. Coimmunization of rhesus macaques with plasmids encoding IL-2 or IFNgamma, combined with plasmids coding for HIV env/rev and SIV gag/pol, enhanced the antigen-specific T cell-mediated immune response. Coimmunization with plasmids encoding IL-2 did not lead to an enhanced immune response [12]. Plasmid vaccines encoding HIV gag-pol, env-rev proteins, supplemented by IL-2 Ig cytokine gene adjuvants or boosted by recombinant MVA vectors expressing relevant SIV and HIV antigens, prevented CD4(+) T-cell loss and lowered viral loads after pathogenic challenge [13]. One rhesus monkey immunized with env/gag plasmid DNA augmented by an IL-2-immunoglobulin plasmid and subsequently infected with SHIV showed undetectable plasma viral RNA. A single nucleotide mutation within an immunodominant Gag CTL epitope resulted in viral escape and finally in the monkey's death from AIDS-related complications [14].

14.4 CTL-Epitope Immunization

The importance of cellular immunity for vaccination against HIV and the ease with which DNA can be manipulated favor CTL-epitope immunization. Combination of epitopes may generate a broader immune response, providing a strategy for simulta-

303

304

14 Update on antiviral DNA vaccine research (2000–2003)

neous vaccination against multiple pathogens. Multiepitope DNA vaccination encoding 25 epitopes from the gag protein of HIV [15] induced an immune response biased toward more antigen-specific CD8(+) T cells. Multiple immunization of rhesus macaques with DNA encoding the SIV fusion epitope gag-pol-env led to a significant CTL response, but low-to-undetectable serum antibodies. SIV-specific mucosal antibodies and CTL were detected in rectal washes and gut-associated lymphoid tissues, respectively. Four of seven vaccinees were protected against infection [16]. Two additional studies tried to evaluate the benefit of immunization with both dominant and subdominant SIV epitopes by DNA vaccination of rhesus macaques. In the first study, immunization with the two epitopes SIV Gag p11C and HIV-1 Env p41A led to a high-frequency CTL response specific to both epitopes only in infected macaques vaccinated with the plasmid DNA [17]. The second study showed that immunization with a repertoire of viral epitopes greater than those typically generated in the course of viral infection rapidly induced a potent secondary CTL response to subdominant epitopes after a SHIV challenge [18]. Multi-epitope DNA vaccination against LCMV showed the strongest CTL response when every epitope was encoded by a separate plasmid DNA [19]. Epitope-specific CTL responses were also induced by DNA constructs encoding single epitopes or fusion proteins of influenza [20], respiratory syncytial virus [21], HIV-1 gag epitope [22], HIV-1 gag-pol fusion protein [12, 23], as well as the HBsAg of HBV [24].

14.5 Targeting DNA Vaccines to Cellular Compartments or the Cell Surface

In the past two years only a few studies on this vaccination strategy were ongoing. Targeting of the expressed antigen (1) to the cell surface, (2) to the extracellular compartment in general by the induction of secretion, and (3) to specific extracellular compartments had a profound impact on the immune response. Engineering a truncated form of the HCV envelope E2 protein directed the antigen to the plasma membrane and increased its ability to induce humoral immune responses [25]. Two chimpanzees vaccinated with this plasmid resolved a virus challenge early, whereas the control animal became chronically infected [26]. Targeting of APCs was accomplished by fusion of a HA-based influenza DNA vaccine to CTLA-4. CTLA-4 binds to B7–1 (CD80) and B7–2 (CD86) expressed on antigen-presenting cells. This construct increased the antibody response and reduced viral titers over a 100-fold after a nonlethal viral challenge [27].

14.6 DNA for Chimeric Antigens

The immunogenicity of epitopes may be improved by the use of chimeric DNA vaccine plasmids. These are composed of epitope-encoding DNA fragments inserted into genes, which function as DNA antigen carrier systems. The latter may modify

14.7

the immune response to the respective antigen. In one study, a chimeric yellow fever/dengue virus was constructed expressing the premembrane and envelope genes from dengue type 2 virus in a yellow fever virus genetic background. Immunized mice showed CD8 T-cell response and were protected against lethal dengue virus challenge [28]. In another study, mice were immunized with three different DNA plasmids encoding a fusion of a secreted form of HIV Env protein and the complement component C3d. Immunization with each plasmid accelerated the onset and the avidity maturation of antibody to Env [29]. A similar approach was performed by Barouch and coworkers to improve DNA vaccination against HIV. They constructed a plasmid expressing an IL-2/Ig fusion protein, which combined IL-2 functional activity with divalent avidity and a long in vivo half-life. Interestingly, coadministration of both the fusion protein and the IL-2/Ig expressing plasmid with the HIV immunogen augmented immune responses in mice and nonhuman primates [30]. Chimeric virus-like-particles consisting of multimerized HPV L1 proteins and fragments of SIV Gag p27, HIV-1 Tat and, Rev proteins were administered to macaques systemically and mucosally and led to antibody induction against HPV L1. Only macaques that received a priming vaccination with DNA encoding the same SIV and HIV-1 antigens prior to chimeric boosting showed significant but partial protection from a virulent mucosal SHIV challenge [31]. Antibody–cytokine fusion proteins, called immunocytokines, are also used to target cytokines into tumor microenvironment. Therapeutic efficacy has been shown in melanoma and neuroectodermal tumor models [32]. Finally, antipeptide antibody generation is often augmented by peptide fusion or chemical linkage to larger proteins, such as keyhole limpet hemocyanin (KLH), glutathione S-transferase (GST), or sparingly soluble nonantigenic protein (SSNAP) [33].

14.7 DNA-prime–Protein/Viral-boost Immunization

Prime–boost vaccination involves priming with DNA vaccines and boosting with either recombinant protein or attenuated recombinant viral vectors, including fowl poxvirus (FPV) and modified vaccinia virus Ankara strain (MVA). Prime–boost strategies aim at augmenting immune responses to pathogens that are not completely inhibited by DNA vaccination alone (e. g., HIV). DNA/protein boost strategies were employed for HCV and HIV vaccination and resulted in significantly enhanced specific antibody responses. Priming with DNA encoding the E2 protein of HCV and subsequent boosting with the respective recombinant protein induced a stronger humoral and cellular immune response than immunization with E2 DNA or protein alone, as evidenced by enhancement of E2-specific IgG2 a levels and CD8+ CTL responses. The immunological effects were further augmented by using two instead of one DNA priming [34]. Mice immunized with a combination of DNA encoding the HCV capsid and E1, E2, NS2, and NS3 genes with a nonreplicant canary pox booster containing the same genes showed enhanced CD8+ T cell response [35]. In another study, chronically HBV-infected chimpanzees

305

306

14 Update on antiviral DNA vaccine research (2000–2003)

were immunized first with DNA followed by a recombinant canary pox booster. One week after the booster, HBV DNA declined more than 400-fold and remained undetectable by quantitative PCR for 186 weeks. Interestingly, the plasma levels of hepatitis surface antigen declined for only a short time [36]. Attenuated recombinant viral vectors, such as FPV and MVA, have significant advantages over alternative immunization strategies. They are replication-deficient, nonintegrating, stable, and relatively easy to prepare. Boosting with recombinant FPV favors the induction of cellular immunity, which is of primary importance for HIV defense. DNA priming is thought to focus the immune responses to the antigen expressed by the DNA vaccine, whereas the recombinant pox virus booster immunization is thought to boost the response, both by expression of higher levels of the antigen and by the immunostimulatory activity of a pox virus infection. In this regard, macaques primed with an env and nef deletion-containing SHIV proviral DNA followed by a single booster with a Gag-expressing Sendai virus showed protection from CD4+ T cell deletion and significantly reduced viral load after virus challenge. Vaccination with either the DNA alone or the Gag-expressing Sendai virus alone did not lead to a consistent protection [37]. In another study, macaques were immunized with a V2-deleted HIV-1 envelope using a DNA-prime–protein-boost regime to evaluate the protective potential of the induced neutralization antibodies during acute infection. Therefore, the macaques were depleted of their CD8+ T cells were and were challenged with pathogenic SHIV. The vaccinated animals had lower levels of peak viremia and rapid clearance of the virus from periphery and developed delayed seroconversion to SIV core antigens [38]. In a study by Amara and coworkers, priming macaques with Gag-Pol-Env-expressing DNA and boosting with GagPol-Env-expressing rMVA was compared with Gag-Pol DNA priming and Gag-Pol rMVA boosting to evaluate the contribution of an anti-Env immune response to viral control. After mucosal challenge with a pathologic SHIV, the Gag-Pol-vaccinated group developed severe, sustained loss of CD4+ T cells. Interestingly, most of the lost CD4+ T cells in that group were uninfected cells. They suggested that the rapid appearance of anti-Env antibodies in gag-pol-env-vaccinated macaques helped to protect uninfected CD4+ T cells from Env-induced apoptosis [39]. Shiver and coworkers compared several vaccine vector-delivery systems containing plasmid DNA vector and MVA encoding SIV gag. After viral challenge, the most effective responses were elicited by a replicon-incompetent Adenovirus type 5 vector [40]. In additional studies, the immune responses of DNA-prime–virus-boost immunized animals were evaluated [41, 42].

14.8 Age-dependent Effectiveness of DNA Vaccines

DNA vaccines are intended to be used in infants, who have an immature immune system. In neonates, low doses of antigen are frequently associated with suboptimal responses, but higher doses may induce tolerance. Comparable to self-antigens, DNA vaccine-encoded antigens are endogenously synthesized and presented via the

References

MHC-class I pathway. Consistent with this concern, a DNA vaccine encoding the circumsporozoite protein of malaria induced tolerance in neonates [43]. Live attenuated measles vaccine is safe and immunogenic when administered to children over the age of nine months. However, it is less efficacious in younger infants, due to the immaturity of their immune systems and to transplacentally acquired maternal antibodies. Younger infants are especially predisposed to measlesassociated fatalities. Alternative strategies for immunization of infants against measles are therefore desirable. However, further development has been complicated by the occurrence of a severe atypical form of the disease when individuals previously immunized with a formalin-inactivated vaccine contracted measles. In contrast, DNA vaccination raises hope for nontoxic immunization of infants against measles. In a rhesus macaque model, DNA vaccines encoding measles virus glycoproteins were protective and did not induce atypical measles [44]. Another study examined the immune response of mice that were DNA-vaccinated at birth against LCMV and showed that, at least for CD8+ T cells, neonates are not as immunodeficient as previously supposed [45]. Rasmussen and coworkers vaccinated newborn macaques by HIV-1 gp160-encoding DNA priming and protein-boosting, followed by SHIV challenge. Containment of infection was observed in 4 of 15 animals given DNA-priming–protein-boost vaccination and in 3 of 4 animals given gp160 boosts only. Rechallenge with homologous virus of 6 animals that contained the first challenge virus resulted in rapid viral clearance or low viral loads [46]. Recently, DNA vaccination also proved to be efficacious for fetal immunization. Antibodies, as well as cell-mediated immune responses, were generated when DNA was delivered into the amniotic fluid in the oral cavity of fetal lambs. Fetal vaccination may be of particular importance for the prevention of neonatal diseases such as HSV, HIV, HBV, CMV, group B streptococcus, hemophilus, and chlamydia infections [47]. Finally, in another study, liposome-encapsulated DNA encoding antigens from HIV-1 and influenza virus were administered i.v. to pregnant mice. Examination of plasmid DNA uptake by the fetus was observed at 9.5 days postconception. DNA vaccination of the offspring of immunized dams mounted stronger specific immune responses than controls and were protected against challenge by homologous influenza virus [48].

References 1 Donnelly JJ, Ulmer JB, Shiver JW, Liu MA, DNA vaccines. Annu Rev Immunol 1997, 15, 617–648. 2 Kowalczyk A, Boens N, Ameloot M, Determination of ground-state dissociation constant by fluorescence spectroscopy. Methods Enzymol 1997, 278, 94– 113. 3 Gurunathan S, Klinman DM, Seder RA, DNA vaccines: immunology, appli-

cation, and optimization. Annu Rev Immunol 2000, 18, 927–974. 4 Schultz J, Dollenmaier G, Molling K, Update on antiviral DNA vaccine research (1998–2000). Intervirology 2000, 43, 197–217. 5 Ertl HC, Xiang ZQ, Genetic immunization. Viral Immunol 1996, 9, 1–9. 6 Flo J, Beatriz Perez A, Tisminetzky S, Baralle F, Superiority of intramus-

307

308

14 Update on antiviral DNA vaccine research (2000–2003)

7

8

9

10

11

12

13

14

cular route and full length glycoprotein D for DNA vaccination against herpes simplex 2: enhancement of protection by the co-delivery of the GM-CSF gene. Vaccine 2000, 18, 3242–3253. Elias F, Flo J, Modulation of the immune response mediated by oral transgene administration of IL-10. Cell Immunol 2002, 216, 73–81. Sin JI, Kim J, Dang K, Lee D, Pachuk C, Satishchandran C, Weiner DB, LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection. Cell Immunol 2000, 203, 19–28. Eo SK, Lee S, Chun S, Rouse BT, Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J Virol 2001, 75, 569– 578. Larsen DL, Olsen CW, Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs. Am J Vet Res 2002, 63, 653–659. Pertmer TM, Oran AE, Madorin CA, Robinson HL, Th1 genetic adjuvants modulate immune responses in neonates. Vaccine 2001, 19, 1764–1771. Kim JJ,Yang JS, Manson KH,Weiner DB, Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 2001, 19, 2496–2505. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, Israel Z, Montefiori DC, Ugen K, Miller N, Kim J, Boyer J, Weiner DB, A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in Rhesus macaques. Vaccine 2003, 21, 629–637. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL, Eventual AIDS vaccine failure in a rhesus

15

16

17

18

19

20

monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415, 335– 339. Caulfield MJ,Wang S, Smith JG, Tobery TW, Liu X, Davies ME, Casimiro DR, Fu TM, Simon A, Evans RK, Emini EA, Shiver J, Sustained peptidespecific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 2002, 76, 10038–10043. Fuller DH, Rajakumar PA,Wilson LA, Trichel AM, Fuller JT, Shipley T, Wu MS, Weis K, Rinaldo CR, Haynes JR, Murphey-Corb M, Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 2002, 76, 3309–3317. Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, Fu TM, Nam JH, Wyatt LS, Lifton MA, Krivulka GR, Nickerson CE, Lord CI, Moss B, Lewis MG, Hirsch VM, Shiver JW, Letvin NL, Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian–human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 2001, 75, 2462–2467. Santra S, Barouch DH, Kuroda MJ, Schmitz JE, Krivulka GR, Beaudry K, Lord CI, Lifton MA,Wyatt LS, Moss B, Hirsch VM, Letvin NL, Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian–human immunodeficiency virus infection. J Virol 2002, 76, 6376–6381. Rodriguez F, Harkins S, Slifka MK, Whitton JL, Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 2002, 76, 4251–4259. Heinen PP, Rijsewijk FA, de BoerLuijtze EA, Bianchi AT, Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after

References

21

22

23

24

25

26

27

28

challenge with influenza A virus. J Gen Virol 2002, 83, 1851–1859. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G, Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 2000, 19, 1038–1046. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B, Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002, 168, 197–206. Huang Y, Kong WP, Nabel GJ, Human immunodeficiency virus type 1specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 2001, 75, 4947–4951. Loirat D, Lemonnier FA, Michel ML, Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 2000, 165, 4748– 4755. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J, DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999, 17, 1992–2002. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, Davis HL, Emerson SU, Purcell RH, Bukh J,Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000, 32, 618–625. Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM, A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci USA 2000, 97, 6676–6680. van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH, Chimeric

29

30

31

32

33

34

35

yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 2000, 74, 8094–8101. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL, Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120–C3 d fusion proteins. AIDS Res Hum Retroviruses 2001, 17, 829–835. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM,Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL, Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290, 486–492. Dale CJ, Liu XS, De Rose R, Purcell DF, Anderson J, Xu Y, Leggatt GR, Frazer IH, Kent SJ, Chimeric human papilloma virus–simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 2002, 301, 176–187. Lode HN, Reisfeld RA, Targeted cytokines for cancer immunotherapy. Immunol Res 2000, 21, 279–288. Knuth MW, Okragly AJ, Lesley SA, Haak-Frendscho M, Facile generation and use of immunogenic polypeptide fusions to a sparingly soluble non-antigenic protein carrier. J Immunol Methods 2000, 236, 53–69. Song MK, Lee SW, Suh YS, Lee KJ, Sung YC, Enhancement of immunoglobulin G2 a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 2000, 74, 2920–2925. Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus ME, Prince AM, DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to

309

310

14 Update on antiviral DNA vaccine research (2000–2003)

36

37

38

39

40

HCV structural and nonstructural proteins. J Infect Dis 2000, 182, 18–27. Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM, DNA prime/ canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001, 33, 448–454. Matano T, Kano M, Nakamura H, Takeda A, Nagai Y, Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001, 75, 11891– 11896. Cherpelis S, Shrivastava I, Gettie A, Jin X, Ho DD, Barnett SW, Stamatatos L, DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-celldepleted rhesus macaques. J Virol 2001, 75, 1547–1550. Amara RR, Smith JM, Staprans SI, Montefiori DC,Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, Robinson HL, Critical role for Env as well as Gag-Pol in control of a simian–human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002, 76, 6138– 6146. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE,Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA,

41

42

43

44

45

46

47

Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ,Youil R, Kaslow DC, Emini EA, Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 2002, 415, 331– 335. Vinner L, Wee EG, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC, Hanke T, Fomsgaard A, Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 2003, 84, 203–213. Woodberry T, Gardner J, Elliott SL, Leyrer S, Purdie DM, Chaplin P, Suhrbier A, Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias. J Immunol 2003, 170, 2599–2604. Mor G,Yamshchikov G, Sedegah M, Takeno M, Wang R, Houghten RA, Hoffman S, Klinman DM, Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest 1996, 98, 2700–2705. Polack FP, Lee SH, Permar S, Manyara E, Nousari HG, Jeng Y, Mustafa F,Valsamakis A, Adams RJ, Robinson HL, Griffin DE, Successful DNA immunization against measles, neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 2000, 6, 776– 781. Zhang J, Silvestri N,Whitton JL, Hassett DE, Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines. J Virol 2002, 76, 11911–11919. Rasmussen RA, Hofmann-Lehman R, Montefiori DC, Li PL, Liska V,Vlasak J, Baba TW, Schmitz JE, Kuroda MJ, Robinson HL, McClure HM, Lu S, Hu SL, Rizvi TA, Ruprecht RM, DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 2002, 31, 40–60. Gerdts V, Babiuk LA, van Drunen

References

48

49

50

51

52

53

54

55

Littel-van den H, Griebel PJ, Fetal immunization by a DNA vaccine delivered into the oral cavity. Nat Med 2000, 6, 929–932. Okuda K, Xin KQ, Haruki A, Kawamoto S, Kojima Y, Hirahara F, Okada H, Klinman D, Hamajima K, Transplacental genetic immunization after intravenous delivery of plasmid DNA to pregnant mice. J Immunol 2001, 167, 5478–5484. Djilali-Saiah I, Lapierre P,Vittozi S, Alvarez F, DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol 2002, 169, 4889–4896. Harrington LE, Most RVR,Whitton JL, Ahmed R, Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002, 76, 3329–3337. Rodriguez F, Harkins S, Redwine JM, de Pereda JM,Whitton JL, CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol 2001, 75, 10421–10430. Djavani M,Yin C, Lukashevich IS, Rodas J, Rai SK, Salvato MS, Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol 2001, 4, 103–108. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, Oehen S, Kundig TM, Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001, 98, 3299–3303. Hassett DE, Slifka MK, Zhang J, Whitton JL, Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. J Virol 2000, 74, 8286–8291. Hooper JW, Custer DM, Thompson E, Schmaljohn CS, DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhe-

56

57

58

59

60

61

62

63

64

sus monkeys. J Virol 2001, 75, 8469– 8477. Bucht G, Sjolander KB, Eriksson S, Lindgren L, Lundkvist A, Elgh F, Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. Vaccine 2001, 19, 3820–3829. Kehm R, Jakob NJ, Welzel TM, Tobiasch E,Viczian O, Jock S, Geider K, Sule S, Darai G, Expression of immunogenic Puumala virus nucleocapsid protein in transgenic tobacco and potato plants. Virus Genes 2001, 22, 73–83. Koletzki D, Schirmbeck R, Lundkvist A, Meisel H, Kruger DH, Ulrich R, DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. J Biotechnol 2001, 84, 73–78. Fiedler M, Roggendorf M, Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax) model. Intervirology 2001, 44, 154–161. Fiedler M, Lu M, Siegel F, Whipple J, Roggendorf M, Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine 2001, 19, 4618–4626. Huang YH, Wu JC, Tao MH, Syu WJ, Hsu SC, Chi WK, Chang FY, Lee SD, DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology 2000, 32, 104–110. Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspe G, Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002, 76, 12735–12746. Bukh J, Forns X, Emerson SU, Purcell RH, Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 2001, 44, 132–142. Lee SW, Cho JH, Sung YC, Optimal induction of hepatitis C virus envelopespecific immunity by bicistronic plas-

311

312

14 Update on antiviral DNA vaccine research (2000–2003)

65

66

67

68

69

70

71

72

mid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998, 72, 8430–8436. Pang X, Zhang M, Dayton AI, Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV. BMC Microbiol 2001, 1, 28. Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG, Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000, 81, 1659–1667. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, Phillips IA, Ewing DF, Murphy GS, Porter KR, A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18, 3166–3173. Konishi E,Yamaoka M, Kurane I, Mason PW, A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 2000, 18, 1133–1139. Monath TP, Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 2002, 267, 105–138. Pan CH, Chen HW, Huang HW, Tao MH, Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol 2001, 75, 11457–11463. Kanesa-Thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB,Vaughn DW, Mason PW, Shope RE, Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus–poxvirus vaccines in vaccinianonimmune and vaccinia-immune humans. Vaccine 2000, 19, 483–491. Chang GJ, Hunt AR, Davis B, A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese ence-

73

74

75

76

77

78

79

80

81

phalitis in mice. J Virol 2000, 74, 4244– 4252. Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, Murphy M, Atkins GJ, Liljestrom P, Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001, 183, 1395–1398. Morozova OV, Popova RV, Maksimova TG, Mitrofanova EE, Bakhvalova VN, [A comparison of the immune response induced by DNA or by an inactivated vaccine against tick-borne encephalitis]. Zh Mikrobiol Epidemiol Immunobiol 2000, 54–57. Monath TP, Prospects for development of a vaccine against the West Nile virus. Ann NY Acad Sci 2001, 951, 1–12. Payette PJ,Weeratna RD, McCluskie MJ, Davis HL, Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms. Gene Ther 2001, 8, 1395–1400. Loomis-Huff JE, Eberle R, Lockridge KM, Rhodes G, Barry PA, Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine 2001, 19, 4865–4873. Musacchio A, Rodriguez EG, Herrera AM, Quintana D, Muzio V, Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens. Biochem Biophys Res Commun 2001, 282, 442–446. Borgne SL, Michel ML, Camugli S, Corre B, Le Grand R, Riviere Y, Expansion of HBV-specific memory CTL primed by dual HIV/HBV genetic immunization during SHIV primary infection in rhesus macaques. Vaccine 2001, 19, 2485–2495. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB, Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164, 4635–4640. Kwissa M, von Kampen K, Zurbriggen R, Gluck R, Reimann J, Schirmbeck R, Efficient vaccination by intra-

References

82

83

84

85

86

87

88

dermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control. Vaccine 2000, 18, 2337–2344. Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T, Mase M, Imada T,Yuasa N,Yamaguchi S, Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J Virol 2002, 76, 5637– 5645. Endresz V, Burian K, Berencsi K, Gyulai Z, Kari L, Horton H,Virok D, Meric C, Plotkin SA, Gonczol E, Optimization of DNA immunization against human cytomegalovirus. Vaccine 2001, 19, 3972–3980. Vignes C, Chiffoleau E, Douillard P, Josien R, Peche H, Heslan JM, Usal C, Soulillou JP, Cuturi MC, Anti-TCR-specific DNA vaccination demonstrates a role for a CD8+ T cell clone in the induction of allograft tolerance by donor-specific blood transfusion. J Immunol 2000, 165, 96–101. Baghian A, Chouljenko VN, Dauvergne O, Newmant MJ, Baghian S, Kousoulas KG, Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD. J Med Microbiol 2002, 51, 350–357. Eo SK, Lee S, Kumaraguru U, Rouse BT, Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 2001, 19, 4685– 4693. Caselli E, Grandi P, Argnani R, Balboni PG, Selvatici R, Manservigi R, Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection. Intervirology 2001, 44, 1–7. Nass PH, Elkins KL,Weir JP, Protective immunity against herpes simplex virus generated by DNA vaccination

89

90

91

92

93

94

95

96

compared to natural infection. Vaccine 2001, 19, 1538–1546. Caselli E, Balboni PG, Incorvaia C, Argnani R, Parmeggiani F, Cassai E, Manservigi R, Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection. Vaccine 2000, 19, 1225–1231. Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO, Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther 2000, 11, 1429–1438. Gerdts V, Snider M, Brownlie R, Babiuk LA, Griebel PJ, Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate. J Immunol 2002, 168, 1877–1885. Rogers JV, Hull BE, Fink PS, Chiou HC, Bigley NJ, Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver. Vaccine 2000, 18, 1522–1530. Meseda CA, Elkins KL, Merchlinsky MJ,Weir JP, Prime–boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 2002, 186, 1065–1073. Flo J, Tisminetzky S, Baralle F, Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 2001, 19, 1772–1782. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI, Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000, 182, 1304– 1310. Gebhard JR, Zhu J, Cao X, Minnick J, Araneo BA, DNA immunization utilizing a herpes simplex virus type 2 myogenic DNA vaccine protects mice from mortality and prevents genital herpes. Vaccine 2000, 18, 1837–1846.

313

314

14 Update on antiviral DNA vaccine research (2000–2003) 97 Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, Hayashi T, Takabayashi K, Barenholz Y, Kedar E, Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20, 3342–3354. 98 Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM, DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002, 8, 796–801. 99 Sasaki S, Xin KQ, Okudela K, Okuda K, Ishii N, Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun. Gene Ther 2002, 9, 828–831. 100 Okuda K, Ihata A, Watabe S, Okada E,Yamakawa T, Hamajima K,Yang J, Ishii N, Nakazawa M, Ohnari K, Nakajima K, Xin KQ, Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001, 19, 3681–3691. 101 Radu DL, Antohi S, Bot A, Miller A, Mirarchi A, Bona C, Effect of maternal antibodies on influenza virus-specific immune response elicited by inactivated virus and naked DNA. Scand J Immunol 2001, 53, 475–482. 102 Larsen DL, Karasin A, Olsen CW, Immunization of pigs against influenza virus infection by DNA vaccine priming followed by killed-virus vaccine boosting. Vaccine 2001, 19, 2842–2853. 103 Wong JP, Zabielski MA, Schmaltz FL, Brownlee GG, Bussey LA, Marshall K, Borralho T, Nagata LP, DNA vaccination against respiratory influenza virus infection. Vaccine 2001, 19, 2461–2467. 104 Bot A, Shearer M, Bot S, Avriette M, Garcia-Sastre A,White G, Woods C, Kennedy R, Bona C, Induction of immunological memory in baboons primed with DNA vaccine as neonates. Vaccine 2001, 19, 1960–1967. 105 Suarez DL, Schultz-Cherry S, The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in

106

107

108

109

110

111

112

113

chickens using an avian influenza model. Avian Dis 2000, 44, 861–868. Bachy M, Boudet F, Bureau M, Girerd-Chambaz Y, Wils P, Scherman D, Meric C, Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 2001, 19, 1688–1693. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S, Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 2001, 19, 1446– 1455. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML, Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278, 55–59. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S, Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000, 18, 2779– 2788. Boyle CM, Robinson HL, Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. DNA Cell Biol 2000, 19, 157–165. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S, Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000, 18, 3214–3222. Sharpe S, Fooks A, Lee J, Hayes K, Clegg C, Cranage M, Single oral immunization with replication deficient recombinant adenovirus elicits longlived transgene-specific cellular and humoral immune responses. Virology 2002, 293, 210–216. Schlereth B, Germann PG, ter Meulen V, Niewiesk S, DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol 2000, 81, 1321–1325.

References 114 Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M, Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000, 269, 54–65. 115 Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M,Wasik TJ, Kaneko Y, Kozbor D, Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000, 267, 8–16. 116 Arai H, Xin KQ, Hamajima K, Lu Y, Watabe S, Takahashi T, Toda S, Okuda K, Kudoh I, Suzuki M, 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV1 DNA vaccine. Gene Ther 2000, 7, 694– 702. 117 Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies ME, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, Strom TB, Shiver JW, Lewis MG, Letvin NL, Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000, 97, 4192–4197. 118 Galvin TA, Muller J, Khan AS, Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina. Vaccine 2000, 18, 2566–2583. 119 Boyer JD, Cohen AD,Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR,Weiner DB,Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000, 181, 476–483. 120 Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, Liljestrom P, Construction and immunogenicity in a prime–boost regimen of a

121

122

123

124

125

126

127

128

Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 2003, 84, 361–368. Xu F, Hong M, Ulmer JB, Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 2003, 21, 644–648. Lisziewicz J, Bakare N, Lori F, Therapeutic vaccination for future management of HIV/AIDS. Vaccine 2003, 21, 620–623. Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B, Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002, 302, 44–57. Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin AM, Sutter G, Erfle V, Girard M, Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIVBX08. DNA Cell Biol 2002, 21, 653–658. Shacklett BL, Ling B,Veazey RS, Luckay A, Moretto WJ,Wilkens DT, Hu J, Israel ZR, Nixon DF, Marx PA, Boosting of SIV-specific T cell responses in rhesus macaques that resist repeated intravaginal challenge with SIVmac251. AIDS Res Hum Retroviruses 2002, 18, 1081–1088. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Ayyavoo V, Zhang D, Manson K, Kim J, Boyer J,Weiner DB, Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 2002, 31, 179–185. Vogel TU, Horton H, Fuller DH, Carter DK,Vielhuber K, O'Connor DH, Shipley T, Fuller J, Sutter G, Erfle V, Wilson N, Picker LJ, Watkins DI, Differences between T cell epitopes recognized after immunization and after infection. J Immunol 2002, 169, 4511–4521. Horton H,Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers

315

316

14 Update on antiviral DNA vaccine research (2000–2003)

129

130

131

132

133

134

RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB,Watkins DI, Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002, 76, 7187–7202. Caputo A, Betti M, Altavilla G, Bonaccorsi A, Boarini C, Marchisio M, Butto S, Sparnacci K, Laus M, Tondelli L, Ensoli B, Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine 2002, 20, 2303–2317. Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, Piekarczyk M, Ruddersdorf R, O'Connor DH, Wang X, Wang C, Allison DB, Altman JD, Sette A, Desrosiers RC, Sutter G, Watkins DI, Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002, 76, 4108–4112. Haglund K, Leiner I, Kerksiek K, Buonocore L, Pamer E, Rose JK, High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 2002, 76, 2730–2738. Weber R, Bossart W, Cone R, Luethy R, Moelling K, Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur J Clin Microbiol Infect Dis 2001, 20, 800–803. Vajdy M, Gardner J, Neidleman J, Cuadra L, Greer C, Perri S, O’Hagan D, Polo JM, Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 2001, 184, 1613–1616. Shata MT, Hone DM,Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and anti-

135

136

137

138

139

140

141

viral protective immunity. J Virol 2001, 75, 9665–9670. Calarota SA, Kjerrstrom A, Islam KB, Wahren B, Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther 2001, 12, 1623–1637. Gorse GJ, Patel GB, Belshe RB, HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retroviruses 2001, 17, 1175–1189. McGettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ, Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 2001, 75, 8724–8732. Yoshida T, Okuda K, Xin KQ, Tadokoro K, Fukushima J, Toda S, Hagiwara E, Hamajima K, Koshino T, Saito T, Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin Exp Immunol 2001, 124, 445–452. Walther-Jallow L, Nilsson C, Soderlund J, ten Haaft P, Makitalo B, Biberfeld P, Bottiger P, Heeney J, Biberfeld G, Thorstensson R, Crossprotection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. J Gen Virol 2001, 82, 1601– 1612. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaft P, Butto S,Verani P, Ensoli B,Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/ human immunodeficiency virus (SHIV89.6P). Vaccine 2001, 19, 2862– 2877. Santra S, Barouch DH, Jackson SS,

References Kuroda MJ, Schmitz JE, Lifton MA, Sharpe AH, Letvin NL, Functional equivalency of B7–1 and B7–2 for costimulating plasmid DNA vaccine-elicited CTL responses. J Immunol 2000, 165, 6791–6795. 142 Ohashi T, Hanabuchi S, Kato H, Tateno H, Takemura F, Tsukahara T, Koya Y, Hasegawa A, Masuda T, Kannagi M, Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol 2000, 74, 9610– 9616. 143 Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC, Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002, 76, 2667–2675. 144 Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA, One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody re-

145

146

147

148

sponses and protection against rabies virus 1 year after vaccination. Vaccine 2001, 20, 838–844. Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN, Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 2001, 12, 1917–1922. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA, Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. Vaccine 2002, 20, 2221–2228. Lodmell DL, Ewalt LC, Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 2001, 19, 2468– 2473. Lodmell DL, Ewalt LC, Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 2000, 18, 2394–2398.

317

319

15 Live Recombinant Bacterial Vaccines Simon Clare and Gordon Dougan

Summary

The application of modern molecular techniques has generated renewed interest in live bacterial vaccines. Targeted mutagenesis can be used to construct genetically defined and attenuated derivatives of pathogens that can be exploited as live vaccines and as vectors for delivering heterologous antigens to the immune system. Such vaccines offer the potential for improved safety and quality control. Many candidate vaccines have been generated, and some of these have progressed to evaluation in the clinic. Problems have been encountered in translating data obtained from experimental models into successful candidate vaccines suitable for full development. This chapter focuses on candidate live vaccines based on enteric bacteria that are undergoing or close to clinical evaluation.

15.1 Introduction

Live vaccines have played a critical role from the very beginning of the practice of vaccination. Indeed, Jenner’s very first vaccination experiments utilized live viral vaccines based on poxviruses [1]. Live vaccines offer the potential advantage of mimicking aspects of natural infection and are readily recognized as ‘foreign and infectious’ by the immune system, a factor that can enhance their immunogenicity [2]. Live vaccines can be based on attenuated forms of a particular pathogen or on immunologically related microorganisms that are preferentially adapted to infect a host different from the one targeted for vaccination. Any microorganisms selected as a basis for live vaccine production must be able to establish a limited infection in the host targeted for vaccination but must also be unable to go on to cause full clinical disease. Hence, they must be attenuated with respect to the expression of full virulence. For many years the microorganisms selected for use as live vaccines were developed or identified by empirical approaches. They were attenuated by passage on laboratory medium or on an unnatural host animal or tissue culture cell line. For example, the tuberculosis vaccine strain Bacillus Calmette–Guerin (BCG) was isolated

320

15 Live Recombinant Bacterial Vaccines

after many years of passage on laboratory medium. An example of a vaccine based on a microorganism that caused a limited but protective infection in an unnatural host is the smallpox vaccine based on vaccinia, which is a poxvirus poorly adapted for growth in healthy humans. A consequence of the empirical approach is that the basis of attenuation usually remains undefined. Pathogenic microorganisms harbor specific genes that contribute to virulence, and attenuated derivatives harbor one or more mutations in these so-called virulence-associated genes. By using modern molecular approaches, such as whole genome DNA sequencing, it is possible to identify some of the potentially attenuating lesions in existing live vaccine strains. A simplified example of this approach is the sequencing of the different polio virus vaccine strain genomes, which has led to the identification of specific point mutations that contribute directly to attenuation [3]. Using this, together with related technologies, we can retrospectively analyze well-known live vaccine strains in an effort to decipher their mechanisms of attenuation. This information is useful for safety and quality control. By identifying the number and type of attenuating lesions present in a particular vaccine strain, it will be possible to more accurately calculate the potential for reversion to virulence and the stability of the strain. However, we should bear in mind that such approaches may not enable us to identify all mutations that contribute to attenuation. Interestingly, comparison of different stocks of BCG located around the world has highlighted significant differences in their genomes [4]. Some batches harbor more mutations or different combinations of mutations than others. This is believed to be a consequence of the fact that BCG isolates were distributed across the world before careful batch-management methodologies were introduced into the vaccine production industry. In consequence, significant genetic drift occurred involving the accumulation of mutations as BCG was passaged in different centers. Thus, BCG-based vaccines around the world may differ significantly in terms of their immunogenicity and protective potential. This may in part explain the different results obtained in tuberculosis efficacy studies performed around the world. Although retrospective characterization of existing vaccines provides useful scientific information and is potentially of enormous practical benefit, it is important to use more rational approaches to develop live vaccines for the future. One approach would be to introduce specific, well-defined attenuating mutations into fully virulent pathogens. Here, specific genes essential for survival and the expression of virulence in a particular host would be targeted. ‘Clean’ genetic techniques would be used to introduce well defined mutations into these genes in situ in the pathogen genomes, using manipulation techniques that do not favor the accumulation of secondary mutations. In this way a series of defined attenuating mutations can be introduced into an individual genome. This approach has been referred to as ‘rational attenuation’, in that specific genetic loci are targeted for manipulation and these loci provide a basis for attenuation and ultimately vaccine development [5–11]. The theoretical advantages of this approach are many. Knowledge of the genetic nature of the attenuating lesions can facilitate more informed and accurate quality assurance and control of vaccines

15.1 Introduction

based on these attenuated strains. Mutations can be identified that cannot readily revert or favor accidental selection of less attenuated forms of the vaccine strains. Indeed, several attenuating mutations can be built up in individual vaccine strains to limit the potential for reversion to virulence to theoretical levels. Also, it might be possible to engineer-in mutations that still attenuate even in severely immunocompromised individuals, limiting the potential for clinical complications in vulnerable groups [12]. The concept of rational attenuation is not a new one, and many attempts have been undertaken to exploit this approach since the development of recombinant DNA techniques. Attempts to rationally attenuate viruses, bacteria, and even eukaryotic parasites have reached different levels of sophistication, and vaccines based on these technologies have been evaluated in the clinic. Since this is relatively new technology, it will be important to thoroughly evaluate how such candidate vaccines perform in the clinic. In this chapter we concentrate on the generation of vaccines based on rationally attenuated enteric bacteria that have reached the level of clinical evaluation (Table 15.1). Enteric bacteria exhibit different patterns of infection and pathogenicity (Figure 15.1). Hence, significantly different approaches are required to attenuate different pathogens. Molecular approaches are now being applied to decipher the mechanisms involved in the infection process and to understand how the immune response deals with different pathogens. Tab. 15.1 Some key examples of live recombinant vaccines that have been tested in humans. Bacterial strain

Mutations

Comment

Ref.

541Ty, 543Ty

aroA purE

32

EX492 CVD908

galE via aroC aroD

CVD908-htrA Chi3927 ZH9 Ty800

aroC aroD htrA crp cya aroA aroC ssaV phoP phoQ

Regarded as over-attenuated; poorly immunogenic. Caused a typhoid like infection. Good immunogenicity but bacteria found in the blood. Good immunogenicity into phase 2 trials. Good immunogenicity but reactogenic. Good immunogenicity; in phase 2 trails. Good immunogenicity.

Typhoid Salmonella typhi

30 31 36, 37, 39 31 4, 7 44, 45

Bacterial dysentery Shigella flexneri SF124 CVD 1207

aroD virG sen set guaA

Good immunogenicity but reactogenic. Good immunogenicity with some reactogenicity.

69–71 75

ctxA hlyA

Good immunogenicity, protective in volunteers but poor results in the field.

53

Cholera Vibrio cholerae CVD103-Hg-R

321

322

15 Live Recombinant Bacterial Vaccines Immunological interaction

1. Commensal Colonisation

IgA, RNI Defensins Mucus

2. Attachment Attaching/Effacing (Vibrio cholerae, EPEC, ETEC)

M

3. Invasion (Salmonella, Shigella)

B

B T

T Lymph Nodes

4. Systemic spread (Salmonella Typhi)

Blood stream

Fig. 15.1 Patterns of intestinal colonization displayed by enteric pathogens.Distinct enteric pathogens exhibit different modesof pathogenicity after interaction with the gut. This diagram illustrates the typical types of enteric infection and the level of the gut tissueassociated with infection in a healthy human. EPEC enteropathogenic E. coli; ETEC enterotoxigenic E. coli (see colour plates page XXXVIII).

15.2 Early Efforts to Generate Recombinant Live Bacterial Vaccines

Enormous progress has been made in the past 20 years in our understanding of the molecular basis of infection caused by pathogenic bacteria. For example, a decade ago only a handful of genes involved in the pathogenesis of Salmonella infections had been identified. To date, over 100 genes that are involved in different aspects of Salmonella pathogenicity are known. Many of these virulence-associated genes are organized into discrete pathogenicity islands that harbor groups of genes with coordinated functions or expression patterns [13]. To date, there are ten different pathogenicity islands identified in Salmonella enterica and interestingly different S. enterica serovars can exhibit significant variation in the composition of some of these islands [14, 15]. Salmonella pathogenicity islands (SPI)-1 and SPI-2 are significant in that they encode Type III secretion systems involved in epithelial cell invasion and intracellular vacuole adaptation, respectively (Figure 15.2). The S. enterica type III secretion systems are molecular syringes designed to deliver packages of bacterial effector proteins that are injected into the cytoplasm of host cells to modify these cells to favor bacterial proliferation. Although many Salmonella genes are implicated in virulence, the vast majority have been identified by using the favored murine model of salmonellosis based on S. enterica serovars such as S. enterica serovar Typhimurium (S. Typhimurium). Because some S. enterica serovars, including S. enterica serovar Typhi (S. Typhi), the

15.2 Early Efforts to Generate Recombinant Live Bacterial Vaccines

Fig. 15.2 Interaction of Salmonella enterica with immune cells shown by confocal microsc opy. A. anti-Salmonella B. anti-LAMP-1 C. Merged image. Provided by Dr Liljana Petrovska, Imperial College London (see colour plates page XXXVIII).

cause of human typhoid, exhibit significant degrees of host restriction, it is important not to extrapolate data whole-sale from the mouse to other species. In other words, mutations that attenuate in the mouse may not attenuate in other host species or in other S. enterica serovars. Indeed, a number of genes, including htrA, have been identified for which this occurs for salmonellosis in cattle [16, 17]. A further caveat is that murine S. enterica infection does not mimic human gastroenteritis, normally associated with diarrhea, and it is not possible to model human gut disease in the mouse. The problem of host adaptation and the lack of suitable model systems is equally severe for many other bacterial diseases, including tuberculosis, shigellosis, and cholera. In any of these models it is also impossible to accurately measure the potential of strains to induce reactogenicity. So, taken together, all of these factors illustrate the enormous importance of clinical studies. The fact that so many different genes can be involved in pathogenicity illustrates the enormous complications of selecting candidate mutations. For some diseases, including cholera, where a single product such as the cholera enterotoxin plays a central role in the pathogenic process, the target genes speak for themselves. However, attenuation in itself is not sufficient, because any attenuated strain must retain immunogenicity and the capacity to be formulated into a practical vaccine. Hence, mutations that impair protective immunity or affect the integrity of the pathogen so as to make them unsuitable for storage of formulation (e. g., freeze drying) cannot be utilized. Few studies have been made to carefully compare the impact of different or combinations of attenuating mutations on the protective capacity of candidate vaccine strains. However, some useful examples exist that can be used to illustrate the con-

323

324

15 Live Recombinant Bacterial Vaccines

siderations involved. Hosieth and Stocker [18] used the murine model to show that aroA mutations of S. Typhimurium could be used as a basis on which to develop single-dose oral vaccines against salmonellosis. This work has subsequently been confirmed by many other workers [see 19]. aroA encodes an enzyme, 5-enolpyruvyl-shikimate-3-phosphate synthase, that is critical for biosynthesis of the aromatic ring by many bacteria. Since the availability of aromatic compounds in mammalian tissues is carefully regulated, S. enterica aroA mutants are starved of such compounds in vivo and fail to grow substantially in immunocompetent hosts. The construction of rationally attenuated Salmonella strains for practical use should ideally involve the generation of S. enterica derivatives harboring more than one attenuating mutation. Indeed, this is true for any live vaccine, in order to minimize the potential for reversion to virulence. Hence, although S. enterica aroA strains are useful experimental vaccines, it is important to identify compatible mutations to use in combination with aroA. Early efforts focused on mutations involving genes of the purine biosynthetic pathway, such as purA and purE [20, 21]. It was believed that targeting two metabolic pathways would be better than targeting a single (aro) pathway. Consequently, a candidate live oral typhoid vaccine was generated based on S. Typhi Ty2 harboring mutations in both aroA and purA. In volunteer studies (described later) this strain was not particularly immunogenic as a live oral vaccine. Subsequent studies in the mouse model showed that live oral vaccines based on S. Typhimurium aroA purA derivatives where significantly less immunogenic than similar vaccines based on isogenic S. Typhimurium aroA [22, 23]. Indeed, although S. Typhimurium aroA purA vaccines could induce the production of antibodies, they were unable to protect mice against virulent S. Typhimurium challenge, in contrast to vaccines based on S. Typhimurium aroA. Interestingly, vaccines based on S. Typhimurium purA were also unable to protect mice against virulent S. Typhimurium. Hence, purA appears to over-attenuate S. enterica in comparison to aroA. purE mutations, which act further down the purine biosynthetic pathway, only partially attenuate murine virulent S. Typhimurium, and are consequently totally unsuitable for live vaccine development [24]. However, combinations of different aro mutations, such as aroA and aroC or aroA and aroD, induce an indistinguishable level of attenuation compared to aroA alone, making feasible the generation of immunogenic S. enterica derivatives harboring multiple attenuating mutations [25]. Although these experiments provide a clear example of the impact of different combinations of mutations on virulence, attenuation, and immunogenicity, other factors, such as bacterial strain background and host genetics, may also have a significant impact on vaccine performance. Again, this points to the critical role of clinical studies for human vaccine development. The lessons taken from the example of the behavior of candidate S. enterica vaccines can be equally applied to the development of rationally attenuated live vaccines for other diseases.

15.3

15.3 Clinical Studies Involving the Development of Live Recombinant Vaccines 15.3.1 Live Recombinant Salmonella Vaccines

Theoretically it should be possible to develop a live recombinant vaccine against any of the numerous S. enterica serovars that differ in terms of their host range and pathogenicity. However, there is little evidence, except for a short period of nonspecific immunity detectable 2–4 weeks after live vaccination, that inter-serovar protection is particularly extensive [23]. Hence, S. Typhimurium vaccines are unlikely to protect against S. Typhi, for example. Few attempts have been made to develop human vaccines for any S. enterica serovars other than S. Typhi. Most S. enterica serovars cause localized gastroenteritis in humans, associated with diarrhea in the absence of significant systemic spread. The mouse is not a good model for this disease syndrome, but is believed to more closely mimic human typhoid. Because S. Typhi is already highly attenuated in the mouse, murine S. Typhi infections cannot be used to model levels of attenuation, and results are on the whole modeled from murine S. Typhimurium infections. However, as stated above, there are inherent limitations in this approach, which are perfectly illustrated in clinical studies on S. Typhi galE mutations. The first live oral typhoid vaccine to achieve general commercial success was the S. Typhi Ty2 galE derivative Ty21a. Ty21was developed by using chemical mutagenesis of S. Typhi Ty2, and consequently, the nature of the attenuating mutations in Ty21 a were not defined. Nevertheless, Ty21 a has proved to be a very safe vaccine in extensive use throughout the world [26, 27]. S. Typhi Ty21 a was designed to harbor mutations in the gene galE encoding UDP-glucose-4-epimerase, because early experiments had indicated that galE mutants of S. Typhimurium were significantly attenuated in the murine model [28]. The experience obtained with Ty21 a encouraged the development of a rationally attenuated S. Typhi Ty2 harboring a defined galE deletion mutation [29]. Once, such a S. Typhi gale-negative Vi-negative strain, EX462, was generated by using site-directed mutagenesis [30]. Interestingly, two of four volunteers who ingested 7 × 108 viable EX462 went on to develop typhoid-like disease within a few days, with viable EX462 organisms being isolated from their blood. Each of the individuals who ingested EX462 exhibited a rise in local and systemic antibodies to S. Typhi antigens. Clearly, the presence of galE and via mutations in combination in this strain was insufficient to completely attenuate S. Typhi. Interestingly, some of the early studies using galE mutations in S. Typhimurium had indicated that additional mutations to galE (linked to effects on bacterial cell susceptibility to lysis in the presence of galactose) might be required for full attenuation. However, these experiments illustrate the need for extreme caution when moving from mouse to man in such experiments. The experience with S. Typhi galE mutant strains instilled a note of caution into future S. Typhi live oral vaccine studies. Encouraged by the exciting data produced by studies on S. Typhimurium aroAbased vaccines, efforts were stepped up to develop an oral typhoid vaccine based on

325

326

15 Live Recombinant Bacterial Vaccines

aroA mutants. However, in these first experiments, instead of a single aroA mutation, the S. Typhi strains were constructed with double aroA purA mutations [31]. In volunteer studies, two S. Typhi Ty2 derivatives, 541 Ty aroA purA and 543 Ty aroA purA via were fed to volunteers in increasing doses (Table 15.1). Although no serious adverse reactions were observed in these volunteers, the humoral and local antibody responses to these vaccines were minimal, and they were deemed too poorly immunogenic to justify further volunteer studies. Retrospective assessment of this study and comparison with subsequent data obtained in the mouse suggests that purA mutations, particularly in combination with aro mutants, are potentially over-attenuating for S. Typhi [22]. Thus, follow-up experiments involved S. Typhi derivatives harboring double aro mutations (aroC aroD), since similar mutant combinations had performed well in the murine salmonellosis model. For the follow-up phase of volunteer studies, aroC and aroD deletion mutations were introduced into two different S. Typhi backgrounds. CVD 906 harbored aroC aroD in a Chilean S. Typhi isolate, whereas CVD 908 harbored the same mutations on a conventional Ty2 background [32]. CVD 906 was found to be quite immunogenic in terms of seroconversion to LPS and local antibody production, even when administered at a dose of 5 × 107 viable organisms. However, this vaccine was quite reactogenic in several volunteers (increased temperatures), and the vaccine strain was detected in the bloodstream of some of them. More encouraging results were obtained with CVD 908 in a series of volunteer studies. The strain proved consistently immunogenic, with high levels of seroconversion and appearance of IgA antiSalmonella antibody-secreting cells in the blood stream. Further, significant T cell responses were detected. However, although the strain was less reactogenic than CVD 906, significant numbers of volunteers harbored bacteria in their blood streams, socalled silent vaccinemia. These observations encouraged further modification of the CVD 906 and CVD 908 strains. HtrA is a gene encoding a serine protease involved in the Salmonella stress response and in clearance of misfolded proteins by a degradative pathway [33]. The HtrA protein is required for the efficient survival of Salmonella inside macrophages and facilitates the ability of these bacteria to resist killing by oxygen radicals. HtrA mutants of murine-virulent S. Typhimurium are attenuated, and S. Typhimurium aro htrA derivatives are excellent single-dose live oral vaccines in the mouse [34, 35]. CVD 906-htrA and CVD 908-htrA were developed and administered to volunteers as live oral vaccines [36]. Early studies using wet-harvested bacteria were encouraging, and volunteers tolerated well doses of between 107 and 109 bacteria. These strains retained some immunogenicity and, more significantly, bacteria were not detected in the bloodstream of volunteers, indicating that htrA had indeed further attenuated these strains. Work with CVD 908-htrA was recently extended to a phase II study incorporating the use of lyophilized preparations of vaccine [37]. Again, both safety and immunogenicity data were encouraging in terms of circulating IgA-producing cells and, to a lesser extent, seroconversion. Further human studies have indicated that CVD 908 and CVD 908-htrA can induce significant T cell proliferation to Salmonella antigens including flagellin, and circulating anti-Salmonella cytotoxic T cells have been detected [36–39]. Further aro htrA S. Typhi derivatives have been

15.3

generated and evaluated in volunteers. An S. Typhi aroA aroD htrA strain was constructed on a wild-type S. Typhi background CDC10–80 [32]. Interestingly, this derivative was apparently significantly more reactogenic in volunteers than CVD908, and some vaccinemias were detected. These data illustrate the influence of the S. Typhi strain background, as well as that of the combination of mutations, on the outcome of clinical studies. Another combination of mutations that received early attention for incorporation into live oral typhoid vaccines was cya crp – both involved in the gene regulation pathway involving cAMP generation in bacteria. S. Typhimurium cya crp mutants were effective live oral vaccines in the murine salmonellosis model, encouraging volunteer studies. Initial studies involved an S. Typhi Ty2 crp cya derivative 3927 [41]. This strain was highly immunogenic but quite reactogenic in volunteers, delaying subsequent volunteer studies. Subsequently, S. Typhi Ty2 cya crp cdt derivatives were further evaluated [42]. S. Typhimurium strains harboring mutations in the phoP phoQ two-component regulatory system are attenuated and good oral vaccines in the murine salmonellosis model [43]. An S. Typhi strain, Ty800 phoP phoQ, was constructed and evaluated in volunteers. This derivative performed well in a dose-escalation study in terms of immunogenicity, lack of adverse reactions, and lack of vaccinemias [44, 45]. In a recent study, the attenuation and immunogenicity of two novel Salmonella vaccine strains, ZH9 S. Typhi Ty2 aroC ssaV and WT05 S. Typhimurium TML aroC ssaV, were evaluated after oral administration to volunteers as single escalating doses of 107, 108, or 109 viable bacteria. The ssaV gene encodes a component of the SPI-2 type III secretion apparatus, and bacteria harboring mutations in ssaV are defective in their ability to replicate inside macrophages [46, 47]. This study is particularly interesting because it involved a direct side-by-side comparison of S. Typhi and S. Typhimurium derivatives harboring similar attenuating mutations. S. Typhimurium TML is a clinical isolate associated with gastroenteritis and diarrhea. S. Typhi ZH9 was well tolerated by the volunteers and was not detected in blood as a vaccinemia. In addition, this strain was only excreted in the stool for a short time after oral ingestion. Six out of nine volunteers elicited anti-S. Typhi LPS IgA antibody-secreting cell responses, and two out of three receiving 109 viable ZH9 bacteria elicited high-titer LPS-specific serum IgG. S. Typhimurium WT05 was also well tolerated by the volunteers, with no diarrhea, but interestingly, administration of 108 and 109 viable bacteria lead to shedding in stools for up to 23 days. Only volunteers immunized with 109 WT05 mounted detectable anti-S. Typhimurium LPS-specific antibody-secreting cell responses, and serum antibody responses were variable. Taken together, these data indicate that mutations in ssaV and type III secretion systems in general may provide a route to the development of live vaccines in humans. The study also highlights significant differences in the properties of S. Typhimurium- and S. Typhibased live vaccines.

327

328

15 Live Recombinant Bacterial Vaccines

15.3.2 Live Cholera Vaccines

Live oral vaccines against cholera have several attractions. Cholera, caused by the bacterial pathogen Vibrio cholerae, is a mucosal infection of the intestine and not an invasive disease. Consequently, local mucosal immunity could play an important role in protection. The best correlate of protection against cholera is the presence of vibriocidal antibodies in the serum of the host, and the critical target antigen appears to be somatically located on the bacteria rather than being antitoxic. Hence, although cholera enterotoxin plays a central role in cholera pathogenesis, antitoxic immunity does not appear to be essential for the induction of a protective immune response. The application of recombinant DNA technology to live oral cholera vaccine development has focused on inactivation of the cholera toxin gene encoding the A subunit, the ctxA gene. Several groups have created Vibrio cholerae O1 mutants harboring deletions within ctxA that completely obliterate the production of toxic enterotoxin [48–50]. Early studies utilized wild-type El Tor strains such as N16961 and classical strains such as 395 as hosts for ctxA deletion mutations. ctxA-negative derivatives of both these strains were significantly attenuated in volunteers, and one strain, JBK70 based on N16961, was able to induce protective immunity against virulent challenge with a dose as low as 106 viable bacteria. Unfortunately, JK70 and other early prototype candidate vaccines were also reactogenic, inducing some limited diarrhea and some nausea [51]. Further attenuated derivatives were generated by introducing mutations into either tcpA, encoding the subunit of the toxin coregulated pilus, or toxR, involved in expression of both the pilus and cholera enterotoxin. However, both these strains were markedly reduced in immunogenicity and were deemed unsuitable for oral vaccine development [52]. These early investigations were followed up by a series of volunteer studies designed to identify an immunogenic but nonreactogenic live oral cholera vaccine candidate. Extensive efforts led to the development of CVD 103-HgR [53]. This Vibrio cholerae 01 classical inaba strain 569B derivative harbors a deletion mutation in ctxA and has a mercury-resistance determinant inserted into the hemolysin hlyA gene, which acts as a genetic marker. CVD 103-HgR moved successfully through extensive volunteer studies with an excellent safety and immunogenicity profile. The strain was formulated as a live oral cholera vaccine for commercial development and was tested in several parts of the world for safety, immunogenicity, and efficacy. In volunteer studies using people from the USA or Europe, CVD 103-HgR consistently raised the detectable levels of vibriocidal antibodies in the serum of volunteers at least four fold after a dose of 5 × 105 viable organisms by mouth [54, 55]. When CVD 103-HgR was evaluated in volunteers from developing countries such as Thailand, it performed less well. In Thai volunteers, a dose of 5 × 109 viable organisms was required to get significant increases in vibriocidal antibodies. This lack of ‘take’ in individuals from developing countries was attributed to factors such as differences in the normal flora or to the presence of priming to cross-reactive antigens [56–58].

15.3

Eventually, a randomized, double-blind, placebo-controlled efficacy trial of the CVD 103-HgR live oral cholera vaccine was performed in Indonesia. Over 60 000 individuals were immunized in the study. The vaccine was extremely well tolerated overall, with vibriocidal blood responses detected in about 70 % of vaccinees. Significantly, the incidence of confirmed cholera cases was lower than expected throughout the duration of the trial, and little to no protective efficacy was observed [59]. Recent follow-up studies indicated that factors such as worm burden, immunosuppression, and small-bowel overgrowth in vaccinees can effect the immunogenicity of CVD 103-HgR, and this study highlighted the problems of moving live vaccines from Western volunteers out into the field in developing countries [60–62]. Other V. cholerae live vaccine candidates have been developed and are being evaluated [63, 64]. In efforts to complement the field studies, a randomized, double-blind, placebocontrolled, multicenter study of CVD 103-HgR vaccine efficacy was designed to test longer-term protection using 108 viable CVD 103-HgR against moderate and severe El Tor cholera challenge. American volunteers were challenged three months after immunization with wild-type V. cholerae O1 El Tor Inaba strain N16961. Over 90 % of the vaccinees had a greater than four-fold rise in serum vibriocidal antibodies after vaccination. The vaccine exhibited a protective efficacy of approximately 80 %, an indication that CVD 103-HgR could be used to prevent cholera in travelers [65]. Efforts continue to improve the formulation and potentially the efficacy of live oral cholera vaccines. One option is to expand the microbial target of vaccines to cover the novel V. cholerae O139 derivatives that have appeared in Bangladesh [66]. Much more needs to be learned about the impact of diet, normal flora, and other pathogens on the immunogenicity of live oral vaccines, and CVD 103-HgR is proving to be an excellent and safe model vaccine for this purpose. 15.3.3 Live Shigella Vaccines

Shigella species are the cause of dysentery in humans. Dysentery is a mucosal infection associated with invasion of the gut mucosal surface, inflammation, and cellular damage, leading to the generation of bloody diarrhea. Several antigenically distinct Shigella differ in the type of dysenteric syndrome they induce, with Shigella dysenteriae being associated with the most severe disease. A consequence of this antigenic variation is that Shigella vaccines are likely to protect only against the homologous serotype. Many attempts have been made to generate live oral vaccines against Shigella, but in the West we still do not have an acceptable live vaccine, although this type of work has progressed further in China. The key problem with developing live Shigella vaccines is that it has so far proved impossible to separate immunogenicity from reactogenicity. In other words, vaccines with acceptable levels of immunogenicity are usually over-reactogenic in volunteers. This again illustrates the problem of using surrogate models, even primates, for vaccine development. It is extremely difficult to predict reactogenicity in man from such models. Like S. Typhi, Shigella are host adapted and are often poorly pathogenic in many model systems, limiting their potential.

329

330

15 Live Recombinant Bacterial Vaccines

Early efforts with nonrecombinant, genetically manipulated Shigella derivatives indicated that oral vaccines could be protective in humans [67], with serum and local antibody production being correlated with different degrees to protection. Early efforts to apply recombinant technology to Shigella vaccine development focused on aro mutants [68]. Several aroD derivatives of Shigella flexneri were constructed and shown to have significantly reduced virulence in infection models, including monkeys. In a series of volunteer studies, different aro auxotrophic S. flexneri derivatives, including SFL124 aroD, were evaluated in various parts of the world. Overall, the vaccines proved to be immunogenic in terms of their ability to induce anti-LPS, but some reactogenicity was detected at higher doses of these vaccines [69–71]. Nevertheless, the results were encouraging enough to consider progressing Shigella aro derivatives in combination with other attenuating mutations. An example of this approach is the generation of the S. flexneri 2 a derivative CVD 1203, which harbors mutations in aroA and virG/icsA on strain background 2457T [72, 73]. virG, also called icsA, encodes an 120-kDa outer membrane protein involved in activating actin polymerization at the poles of Shigella cells. VirG enhances the ability of Shigella to spread within and between eukaryotic cells. Again, CVD1203 proved to be immunogenic in volunteers, but reactogenicity was detected at an increasing level with higher doses (up to 109 bacteria) [74]. An additional Shigella flexneri 2 a derivative known as CVD1207 was subsequently constructed. CVD 1207 harbors specific deletion mutations in virG, sen, set, and guaBA. Sen and set encode enterotoxins that contribute to Shigella-associated diarrhea, and guaBA are genes encoding enzymes involved in guanidine biosynthesis, with guaBA mutant derivatives being auxotrophic [75]. In a dose-escalation study, up to 1010 viable CVD 1207 were administered orally to American volunteers, and the vaccine was well tolerated except for some significant reactogenicity at the higher doses. An immunoglobulin A antibody-secreting cell response specific to S. flexneri 2 a O was detected in the blood of many volunteers; this was associated with a Th1like response when cells from the vaccinees were stimulated with Shigella antigens, with production of interferon g without detectable IL-4 or IL-5. Thus, CVD 1207 represents a lead candidate for further development of a live oral Shigella vaccine. Other efforts have been made to develop live oral Shigella vaccines. Perhaps the most advanced are S. flexneri 2 a SC602 harboring mutations in iuc (involved in iron acquisition via siderophore production) and virG and S. dysenteriae 1 derivative strain SC599 harboring mutations in entF virG stxA fes [76]. fes and entF inactivate the iron chelator enterochelin complex and stxA inactivates the shiga toxin.

15.4 Expression of Heterologous Antigens in Live Bacterial Vectors

Live vaccines are attractive, because they can be used to induce immune responses that mimic those detected following real infection. They can also be delivered by the natural infection route, inducing local as well as systemic immunity. Thus, live vaccines can potentially be administered parenterally, or, for vectors based on enteric

15.4 Expression of Heterologous Antigens in Live Bacterial Vectors

bacteria, via the oral route. This combination of potent immunogenicity and mucosal administration has highlighted the potential of live enteric vaccines as vectors for delivering heterologous antigens to the mammalian immune system. This approach involves the expression of foreign heterologous antigens in particular live vaccine derivatives. Heterologous antigens can theoretically be derived from any source, including bacteria, viruses, parasites, and even mammals. The foreign gene must be adapted to facilitate expression in the particular live vector of choice. This can involve the addition of appropriate transcription and translation signals or even the generation of codon-optimized synthetic genes. There are now many examples in the literature involving an array of different live vectors and heterologous genes. Live vectors have been used as a basis to develop experimental vaccines against infectious agents, cancer, and allergens [77]. Expression vectors have been designed that exploit expression of the foreign antigen within the bacterial vector or even within the host, using eukaryotic transcription/translation signals [78–81]. The latter approach involves designing vectors that direct the expression of the foreign antigen within target eukaryotic host cells after delivery of the DNA (usually an extrachromosomal plasmid element) by the live vector. There have been many descriptions of the successful application of live vector-based gene delivery for vaccination, in which protection was induced against a particular infectious agent or cancer, but so far, these studies have been mainly restricted to experimental models and not clinical disease. The choice of vector has a significant influence on the type of immune response induced against a particular heterologous antigen. Pathogens vary greatly in their mode of pathogenicity and in the type of immune response they induce. Even enteric pathogens exhibit a diverse range of pathogenic traits and infect different mucosal and systemic tissues to differing degrees (Figure 15.1). Pathogens such as V. cholerae colonize the mucosal surface of the intestine without any significant invasion, Shigella species invade and destroy the intestine epithelia, and Salmonella serovars such as S. Typhi can cause systemic infection after mucosal penetration. Thus, it is difficult to generalize about the immunogenicity and vaccine potential of different live vector systems. However, some systems have received far more attention than others. In enteric bacteria, most work has been done with S. enterica-based vectors. Experimental work has focused on S. Typhimurium and other mouse-adapted serovars, whereas human studies have concentrated on S. Typhi derivatives. S. Typhimurium has been exploited as a live vector system for several reasons. Some S. Typhimurium derivatives can be delivered in the mouse via various immunization routes, including mucosal routes (oral, intranasal, etc.). There are many different attenuated S. Typhimurium derivatives on which to base live vector systems, and the ability to genetically manipulate these derivatives is advanced and sophisticated. Further, many attenuated S. Typhimurium exhibit potent immunogenicity in the mouse, inducing significant local and systemic humoral and cellular responses [82, 83]. Extensive studies of the immune response to S. Typhimurium in mice has highlighted the types of immunity involved in controlling S. Typhimurium growth in vivo and the types of immunity induced by live Salmonella challenge [84] (Figure 15.3). A combination of humoral and cellular (primarily CD4-mediated) responses appear to be optimal for protection, although evidence exists for a role for lo-

331

15 Live Recombinant Bacterial Vaccines • TNF-α α (TNFR55) • IFN-γγ • IL-12 • IL-18 • Reactive nitrogen (iNOS) • Fe pool

• Nramp1 • Macrophages / PMNs • NADPH oxidase • C1q (KO)

• CD4+ α/β β TCR+ cells • H-2 genes • ICAM (immune only)

Death

Bacterial numbers

332

Suppression of bacterial growth in tissues

Carrier state

Bacterial clearance from RES

Control of early bacterial growth in RES 1

5-7

Days

15-20

variable

Fig. 15.3 Role of host genes in controlling Salmonella growth in the mouse. A summary of much of the information in the literature gleaned from studies using wild-type and gene knockout mice.

cal mucosal defense mechanisms. Certainly, Salmonella vectors appear to induce a Th1-biased response in the mouse and possibly in humans [85]. They can also be used to induce CTL responses to heterologous antigens, but these are often weak in comparison with other delivery systems [86]. Immunocompromised mice defective in different immune effector or regulatory genes can also be used to model the effect of immune deficiency on vaccine safety and immunogenicity [87]. The murine Salmonella model suffers the major disadvantage that it is a poor model of S. Typhimurium infections in humans and a very questionable model of human S. Typhi infections [88]. Genome sequencing analysis has revealed major differences in the genomes of S. Typhimurium and S. Typhi that may explain the different immunogenic and pathogenic potential of these two S. enterica serovars [88]. Indeed, early clinical experience with S. enterica live vector systems using volunteers were disappointing in comparison with the significant successes of experimental infections in mice [see 89–93 as examples]. There may be several reasons for this. The genetic differences between S. Typhimurium and S. Typhi may have compromised our selection of optimized live Salmonella vectors for use in humans, and we may be using substandard vectors. Also, the methods used to direct the expression of the heterologous antigens may not have been optimized for the most efficient delivery of antigen to the immune system. For example, many plasmid-based expression systems are either inherently unstable or exert significant stress on the host bacteria, favoring the accumulation of bacteria defective in antigen expression. Several systems are under development to facili-

15.5 The Future

Environmental or host cue O2, stress, osmolarity or the intracellular signal

In vivo activated promoter

Antigen

pnirB pdps pssaG

Antigen export

Plasmid stabilisation system

Chromosomal integration

Fig. 15.4 Methods for optimizing expression from live vectors. A summary of some of the options covered in the text open to the investigator.

tate the stabilization of antigen expression [94, 95] (Figure 15.4). One option may be to express the heterologous antigen from the bacterial chromosome [96]. Other approaches have favored the use of bacterial promoters that become activeted only after the vaccine derivative has entered the host or even host cells [97, 98]. The distribution of the vaccine antigen after expression could also influence immunogenicity, and efforts have been made to target antigen outside of the vector cell (using secretion signals) and even to target different locations within host cells [99, 100]. The rational is that secreted or targeted antigens may be processsed more efficiently by the host immune system. It is likely but not proven that a combination of these different technological options will result in improved performance of live vectors in the clinic. Other bacterial vectors that have been used experimentally to deliver heterologous antigens include Shigella [101], Listeria [102], Bordetella [103], and Mycobacteria [104]. Clinical experience with these different delivery systems is either limited or nonexistent. Often, the pace of clinical vector development based on these bacterial species has not kept up with Salmonella, and more basic clinical immunogenicity and safety studies are required before these vectors can be evaluated in the clinic. The exception here is BCG, where extensive clinical experience with the vector is available.

15.5 The Future

Although the interest in live bacterial vaccines and vectors remains high, the whole field is very much at a crossroads, particularly with the spread of blood-borne immu-

333

334

15 Live Recombinant Bacterial Vaccines

nocompromising diseases such as AIDS in many regions of the world. It will be important in the future to develop live vaccines that are safe in both healthy and compromised individuals. To some extent, this can be modeled by using various disabled in vivo model systems, but this cannot entirely replace careful clinical evaluation in the field. There is a need for much more extensive evaluation of a series of basic live attenuated vaccines in the clinic. These need to be evaluated for safety and immunogenicity by the most modern immunological and molecular techniques, and work must be extended out of S. Typhi and other favored models into other species, including recombinant Mycobacteria and Listeria. We need to understand much more about the physiological and immunological barriers that compromise the movement of experimental vaccines from clinical studies of healthy Western volunteers to similar studies of individuals in developing countries. Differences in commensal flora or local tissue development may be a compromising factor. We need to use optimized vectors and expression systems for the clinical evaluation of live vectors. So far, poor clinical performance has discouraged further exploitation of these approaches and we must in the future use vector systems that can be carried forward smoothly for vaccine development and licensing. Options include chromosomal integration, in vivo activated promoters, and tissue-targeting signals. Vaccines should be administered as properly formulated lots suitable for future production. Clearly, these sorts of studies are complicated and expensive.

Acknowledgements

This work was supported by grants from The Wellcome Trust and EU (MUCIMM, NEOVAC). References 1. H. Bazin, The Eradication of Smallpox. London Academic Press, 2000, 1st ed., 1–246. 2. M. M. Levine, G. C. Woodrow, J. B. Kaper, G. S. Cobon, New Generation Vaccines, Marcel Dekker, New York 1997. 3. P. D. Minor, A. J. Macadam, D. M. Stone, J. W. Almond, Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals, 1993, 21, 357–363. 4. M. A. Behr, M. A. Wilson,W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, P. M. Small, Comparative genomics of BCG vaccines by wholegenome DNA microarray. Science, 1999, 284, 1520–1523.

5. G. Dougan, The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development. Colworth Lecture. Microbiology, 1994, 140, 215–224. 6. M. M. Levine, J. Galen, E. Barry, F. Noriega, S. N. Chatfield, M. Sztein, G. Dougan, C. Tacket, Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol, 1996, 44, 193–196 7. J. C. Sirard, F. Niedergang, J. P. Kraehenbuhl, Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol Rev, 1999, 171, 5–26. 8. B. Raupach, S. H. Kaufmann, Bacter-

References

9.

10.

11.

12.

13.

14.

15.

ial virulence, proinflammatory cytokines and host immunity: how to choose the appropriate Salmonella vaccine strain? Microbes and Infection, 2001, 3, 1261–1269. M. T. Shata, L. Stevceva, S. Agwale, G. K. Lewis, D. M. Hone, Recent advances with recombinant bacterial vaccine vectors. Mol Med Today, 2001, 6, 66–71. J. H. Brumell, A. J. Perrinm, D. L. Goosney, B. B. Finlay, Microbial pathogenesis: new niches for Salmonella. Curr Biol, 2002, 12, 15–17. P. Mastroeni, F. Bowe, C. Simmons, R. Cahill, R., G. Dougan,Vaccines against gut pathogens. Gut, 1999, 45, 633–635. J. L. VanCott, S. N. Chatfield, M. Roberts, D. M. Hone, E. L. Hohmann, D. W. S. Pascual, M. Yamamoto, H. Kiyono, J. R. McGhee, Regulation of host immune responses by modification of Salmonella virulence genes. Nat Med, 1998, 4, 1247–1252. E. A. Groisman, H. Ochman, Pathogenicity islands: bacterial evolution in quantum leaps. Cell 1996 87, 791–794. J. Parkhill, G. Dougan, K. D. James, N. R. Thomson, D. Pickard, J. Wain, C. Churcher, K. L. Mungall, S. D. Bentley, M. T. G. Holden, M. Sebaihia, S. Baker, D. Basham, K. Brooks, T. Chillingworth, P. Connerton, A. Cronin, P. Davis, R. M. Davies, L. Dowd, N. White, J. Farrar, T. Feltwell, N. Hamlin, A. Haque, T. T. Hien, S. Holroyd, K. Jagels, A. Krogh, T. S. Larson, S. Leather, S. Moule, P. O'Goara, C. Parry, M. Quail, K. Rutherford, M. Simmonds, J. Skelton, K. Stevens, S. Whitehead, B. G. Barrell, The complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18 provides insight into the evolution of host restriction and antibiotic resistance. Nature 2001, 413, 848–853. M. McClelland, K. E. Sanderson, J. Spieth, S. W. Clifton, P. Latreille, L. Courtney, S. Porwollik, J. Ali, M. Dante, F. Du, S. Hou, D. Layman, S. Leonard, C. Nguyen, K. Scott,

16.

17.

18.

19.

20.

21.

22.

23.

24.

A. Homes, N. Grewal, E. Mulvaney, E. Ryan, H. Sun, L. Florea, W. Miller, T. Stoneking, M. Nhan, R. Waterton, R. K. Wilson, Complete genome sequence of Salmonella enterica serovar Typhimurium LT2 Nature, 2001, 413, 852–856. R. L. Santos, S Zang, R. M. Tsolis, R. A. Kingsley, L. G. Adams & A. J. Baumler, Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes Infect, 2001, 3, 1335–1344. B. Villarreal-Ramos, J. M. Manser, R. A. Collins,V. Chance, D. Eckersall, P. W. Jones, G. Dougan, Susceptibility of calves to challenge with Salmonella typhimurium 4/74 and derivatives harbouring mutations in htrA or purE. Microbiology, 2000, 146, 2775–2783. K. Hosieth, B. A. D. Stocker, Aromatic-dependant Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981, 291, 238– 239. D. K. Maskell, K. Sweeney, D. O'Callaghan, F. Y. Liew, C. E. Hormaeche, G. Dougan, Salmonella typhimurium aroA mutants as carriers of heterologous antigens to the immune system. Microbiol Pathogenesis, 1987, 2, 211–221 M. F. Edwards, B. A. D. Stocker, Construction of delta aroA his delta pur strains of Salmonella typhi. J Bacteriol, 1988, 170, 3991–3995. S. I. Miller, J. J. Mekalanos, Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun 1989, 57, 1858–1861. D. O’Callaghan, D. Maskell, F. Y. Liew, C. S. Easmon, G. Dougan, Characterization of aromatic- and purine-dependant Salmonella typhimurium: attenuation, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun 1988, 56, 419–423. D. O’Callaghan, D. Maskell, J. Tite, G. Dougan, Immune responses in BALB/c mice following immunization with aromatic compound or purine-dependent Salmonella typhimurium strains. Immunology 1990, 69, 184–189. P. Everest, A. Papaconstantinopoulou, P. Mastroeni, M. Roberts, G. Dougan, Salmonella typhimurium

335

336

15 Live Recombinant Bacterial Vaccines

25.

26.

27.

28.

29.

30.

31.

32.

infections in mice deficient in interleukin-4 production: role of IL-4 in infection-associated pathology. J Immunol, 1997, 15, 1820–1827. G. Dougan, S. N. Chatfield, D. Pickard, J. Bester, D. O'Callaghan, D. Maskell, Construction and characterization of vaccine strains of Salmonella harbouring mutations in two different aro genes. J Infect Dis, 1988, 158, 1329–1335. M. M. Levine, C. Ferreccio, R. E. Black, R. Germanier, Large-scale field trial of Ty21 a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1, 1049–1052. H. Kollaritsch, E. Fürer, C. Herzog, G. Wiedermann, J. U. Que, S. J. Cryz Jr., Randomized, double-blind placebocontrolled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21 a and Vibrio cholerae CVD103-HgR live oral vaccines. Infect Immun, 1996, 64, 1454–1457. R. Germanier, E. Fuer, Isolation and characterization of Gal E mutant Ty21 a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis, 1975, 131, 553–558. D. M. Hone, S. R. Attridge, B. Forrest, R. Morona, D. Daniels, J. T. La Brooy, R. C. Bartholomeusz, D. J. Shearman, J. Hackett, A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun, 1988, 56, 1326–1333. D. Hone, R. Morona, S. Attridge and J. Hackett , Construction of defined galE mutants of Salmonella for use as vaccines. J Infect Dis, 1987, 156, 167– 174. C. O. Tacket, D. M. Hone, R. Curtiss 3rd, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, M. M. Levine, Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun, 1992, 60, 536–541. M. M. Levine, D. Herrington, J. R. Murphy, J. G. Morris, G. Losonsky, B. Tall, A. A. Lindberg, S. Svenson, S. Baqar, M. F. Edwards, B. Stocker, Safety, infectivity, immunogenicity, and

33.

34.

35.

36.

37.

38.

39.

in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest, 1987, 79, 888–902. K. Johnson, I. Charles, G. Dougan, D. Pickard, P. O’Goara, G. Costa, T. Ali, I. Miller, C. Hormaeche, The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol, 1991, 5, 401–407. S. N. Chatfield, K. Strahan, D. Pickard, I. G. Charles, C. E. Hormaeche, G. Dougan, Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microbiol Pathogen, 1992, 12, 145–151. K. Johnson, I. Charles, G. Dougan, D. Pickard, P. O’Goara, G. Costa, T. Ali, I. Miller, C. Hormaeche, The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol, 1991, 5, 401–407. C. O. Tacket, M. B. Sztein, G. A. Losonsky, S. S. Wasserman, P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, M. M. Levine, Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun, 1997, 65, 452–456. D. M. Hone, C. O. Tacket, A. M. Harris, B. Kay, G. Losonsky, M. M. Levine, Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest, 1992, 90, 412– 420. M. B. Sztein, S. S. Wasserman, C. O. Tacket, R. Edelman, D. Hone, A. A. Lindberg, M. M. Levine, Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis, 1994, 170, 1508–1517. C. O. Tacket, M. B. Sztein, S. S. Wasserman, G. Losonsky, K. L. Kotloff, T. L. Wyant, J. P. Nataro, R. Edelman, J. Perry, P. Bedford, D. Brown, S. Chatfield, G. Dougan, M. M. Levine, Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in

References

40.

41.

42.

43.

44.

45.

46.

47.

U.S. volunteers. Infect Immun, 2000, 68, 1196–1201. D. A. Dilts, I. Reisenfeld-Orn, J. P. Fulginiti, E. Ekwall, C. Granert, J. Nonenmacher, R. N. Brey, S. J. Cryz, K. Karisson, K. Bergman, T. Thompson, B. Hu, A. H. Bruckner and A. A. Lindberg, Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000, 18, 1473–1484. R. Curtiss III, S. M. Kelly, Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun, 1987, 55, 3035– 3043. S. E. Frey, W. Bollen, D. Sizemore, M. Campbell, R. Curtiss, III, Bacteremia associated with live attenuated chi8110 Salmonella enterica serovar Typhi ISP1820 in healthy adult volunteers. Clin Immunol, 2001, 101, 32–37. J. E. Galan, R. Curtiss, III,Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microbiol Pathogen, 1989, 6, 433–443. E. L. Hohmann, C. A. Oletta, K. P. Killeen and S. I. Miller, phoP/phoQdeleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis, 1996, 173, 1408–1414. E. L. Hohmann, C. A. Oletta, S. I. Miller, Evaluation of a phoP/phoQ-deleted aroA deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine, 1995, 14, 19–24. S. A. Khan, R. Stratford, T. Wu, N. Mckelvie, T. Bellaby, Z. Hindle, K. A. Sinha, S. Eltze, P. Matroeni, D. Pickard, G. Dougan, S. N. Chatfield, F. R. Brennan, Salmonella typhi and Salmonella typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine, 2002, 21, 538–548. Z. Hindle, S. N. Chatfield, J. Phillimore, M. Bentley, J. Johnson, C. A. Cosgrove, M. Ghaem-Maghami, A. Sexton, M. Khan, F. R. Brennan, P. Everest, T. Wu, D. Pickard, D. W.

48.

49.

50.

51.

52.

53.

54.

55.

Holden, G. Dougan, G. E. Griffin, D. House, J. D. Santangelo, S. A. Khan, J. E. Shea, R. G. Feldman, D. J. Lewis, Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella Pathogenicity Island 2 Type III Secretion System (ssaV) mutations by immunization of healthy volunteers. Infect Immun, 2002, 70, 3457–3467. J. B. Kaper, H. Lockman, M. M. Baldini, M. M. Levine, A recombinant live oral cholera vaccine. Biotechnology, 1984, 2, 345–349. J. B. Kaper, H. Lockman, M. M. Baldini, M. M. Levine, Recombinant nontoxigenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature, 1984, 308, 655–658. J. J. Mekalanos, D. J. Swartz, G. D. Pearson, N. Harford, F. Groyne, M. de Wilde, Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature, 1983, 306, 551–557. M. M. Levine, J. B. Kaper, D. Herrington, G. Losonsky, J. G. Morris, M. L. Clements, R. E. Black, B. Tall, R. Hall,Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun, 1988, 56, 161–167. D. A. Herrington, R. H. Hall, G. Losonsky, J. J. Mekalanos, R. K. Taylor, M. M. Levine, Toxin-coregulated pili and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med, 1988, 1487–1492. M. M. Levine, J. B. Kaper, D. A. Herrington, Ketley, J., G. Losonsky, C. O. Tacket, B. Tall, S. Cryz, Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988, 2, 467–470. S. J. Cryz, M. M. Levine, J. B. Kaper, E. Furer, B. Althaus, Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine CVD 103-HgR in Swiss adults. Vaccine, 1990, 8, 577–580. C. O. Tacket, G. Losonsky, J. P. Nataro, S. J. Cryz, R. Edelman, J. B. Kaper, M. M. Levine, Onset and duration

337

338

15 Live Recombinant Bacterial Vaccines

56.

57.

58.

59.

60.

61.

of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992, 166, 837–841. S. Migasena¹ P. Pitisuttitham, P. Prayurahong, P. Suntharasamai, W. Supanaranond,V. Desakorn, U. Vongsthongsri, B. Tall, Ketley J., G. Losonsky, M. M. Levine, Preliminary assessment of safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in healthy Thai adults. Infect Immun, 1989, 57, 3261–3264. P. Su-Arehawaratana, P. Singharaj, D. N. Taylor, C. Hoge, A. Trofa, K. Kuvanont, S. Migasena, P. Pitisuttitham,Y. L. Lim, G. Losonsky, M. M. Levine, Safety and immunogenicity of different immunisation regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis, 1992, 165, 1042–1048. D. Suharyono, C. Simanjuntak, N. Witham, et al., Safety and immunogenicity single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year old Indonesian children. Lancet 1992, 340, 689–694. E. E. Richie, N. H. Punjabi,Y. Y. Sidharta, K. K. Peetosutan, M. M. Sukandar, S. S. Wasserman, M. M. Lesmana, F. F. Wangsasaputra, S. S. Pandam, M. M. Levine, P. P. O'Hanley, S. J. Cryz, C. H. Simanjuntak, Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine, 2000, 18, 2399–2410. P. J. Cooper, M. E. Chico, G. Losonsky, C. Sandoval, I. Espinel, R. Sridhara, M. Aguilar, A. Guevara, R. H. Guderian, M. M. Levine, G. E. Griffin, T. B. Nutman, Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis, 2000, 182, 1199–1206. R. Lagos, A. Fasano, S. S. Wasserman, V. Prado, O. San Martin, P. Abrego, G. A. Losonsky, S. Alegria, M. M. Levine, Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine

62.

63.

64.

65.

66.

67.

68.

69.

CVD 103-HgR. J Infect Dis, 1999, 180, 1709–1712. R. T. Perry, C. V. Plowe, B. Koumare, F. Bougoudogo, K. L. Kotloff, G. A. Losonsky, S. S. Wasserman, M. M. Levine, A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIVnoninfected adults in Mali. Bull World Health Org, 1998, 76, 63–71. C. O. Tacket, K. L. Kotloff, G. Losonsky, J. P. Nataro, J. Michalski, J. B. Kaper, R. Edelman, M. M. Levine, Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg, 1997, 56, 533– 537. C. O. Tacket, G. Losonsky, J. P. Nataro, et al., Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a DctxA, Dxot, Dace derivative of El Tor Ogawa Vibrio cholerae J Infect Dis, 1993, 168, 1536–1540. C. O. Tacket, M. B. Cohen, S. S. Wasserman, G. Losonsky, S. Livio, K. Kotloff, R. Edelman, J. B. Kaper, S. J. Cryz, R. A. Giannella, G. Schiff, M. M. Levine, Randomized, doubleblind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun, 1999, 67, 6341–6345. M. J. Alberts,Vibrio cholerae O139 Bengal, J Clin Microbiol, 1994, 32, 2345– 2349. D. M. Mel, B. L. Arsic, M. L. Radovanovic, S. Litvinjenko, Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung, 1974, 21, 109–114. A. A. Lindberg, A. Karnell, T. Pal, et al., Construction of an auxotrophic Shigella flexneri strain for use as a live vaccine. Microbiol Path, 1990, 8, 433– 440. A. Li, T. Pal, U. Forsum, A. A. Lindberg, Safety and immunogenicity of a live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine, 1992, 10, 395–404.

References 70. A. Li, A. Karnell, P. T. Huan, et al., Safety and immunogenicity of a live oral auxotrophic Shigella flexneri SL124 in adult Vietnamese volunteers. Vaccine, 1993, 11, 180–189. 71. A. Karnell, A. Li, R. Zhao, Safety and immunogenicity study of the auxotrophic Shigella flexneri 2 a vaccine SF1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine, 1995, 13, 88–99. 72. M. L. Bernardini, J. Mounier, H. D'Hauteville, et al., Identification of icsA, a plasmid locus of Shigella flexneri that governs intra- and inter-cellular spread through interaction with Factin. Proc Natl Acad Sci USA, 1989, 86 (10) 3867–3387. 73. F. R. Noriega, J. Y. Wang, G. Losonsky, et al., Construction and characterisation of a daroA dvirG S. flexneri 2 a strain CVD1203, a prototype oral vaccine, Infect Immun, 1994, 62, 5168–5172. 74. K. L. Kotfloff, F. Noriega, G. A. Losonsky, et al., Safety, immunogenicity and transmissibility in humans of CVD1203, a live oral Shigella flexneri 2 a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun, 1996 64, 4542–4528. 75. K. L. Kotloff, F. R. Noriega, T. Samandari, M. B. Sztein, G. A. Losonsky, J. P. Nataro,W. D. Picking, E. M. Barry, M. M. Levine, Shigella flexneri 2 a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun, 2000, 68, 1034–1039. 76. T. S. Coster, C. W. Hoge, L. L. Van De Verg, A. B. Hartman, E. V. Oaks, M. M. Venkatesan, D. Cohen, G. Robin, A. Fontaine-Thompson, P. J. Sansonetti, T. L. Hale,Vaccination against shigellosis with attenuated Shigella flexneri 2 a strain SC602. Infect Immun, 1999, 67, 3437–3443. 77. J. A. Chabalgoity, G. Dougan, P. Mastroeni, R. J. Aspinall, Live bacteria as the basis for immunotherapies against cancer. Expert Review of Vaccines, 2002, 1, 495–505. 78. D. R. Sizemore, A. A. Branstrom, J. C. Sadoff, Attenuated bacteria as an oral DNA delivery vehicle for DNA-mediated

79.

80.

81.

82.

83.

84.

85.

86.

immunization. Science, 1995, 270, 299– 302. C. A. Darji, B. Guzmán. P. Gerstel, S. Wachholz, K. N. Timmis, J. Wehland, T. Chakraborty, S. Weiss, Oral somatic transgene vaccination using attenuated S. typhimurium. Cell, 1997, 91, 765–775. G. Dietrich, A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H. Kaufmann, J. Hess, A. A. Szalay, W. Goebel, Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol, 1998, 1, 181–185. P. Paglia, E. Medina, I. Arioli, C. A. Guzman, M. P. Colombo, Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood, 1998, 92, 3172–3176. S. J. Dunstan, C. P. Simmons, R. A. Strugnell, Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect Immun, 1998, 66, 732– 740. P. Mastroeni, J. A. Chabalgoity, S. J. Dunstan, D. J. Maskell, G. Dougan, Salmonella: immune responses and vaccines. The Veterinary Journal, 2001, 161, 132–164. I. Gentschev, G. Dietrich, S. Spreng, A. Kolb-Måurer,V. Brinkmann, L. Grode, J. Hess, S. H. E. Kaufmann, W. Goebel, Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine, 2001, 19, 2621–2628. M. B. Sztein, M. K. Tanner,Y. Polotsky, J. M. Orenstein and M. M. Levine, Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J Immunol, 1995, 155, 3987–3993. C. E. M. Allsop, M. Plebanski, S. Gilbert, R. E. Sinden, S. Harris, G. Frankel, G. Dougan, G. Layton, A. V. S. Hill, Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunisation. Eur J Immunol, 1996, 26, 1951–1959.

339

340

15 Live Recombinant Bacterial Vaccines 87. J. Hess, U. Schaible, B. Raupach, S. H. Kaufmann, Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol, 2000, 75, 1–88. 88. D. Young, T. Hussell, G. Dougan, Chronic bacterial infections: living with unwanted guests. Nat Immunol, 2002 3, 1026–1032. 89. C. O. Tacket, S. M. Kelly, F. Schödel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, R. Curtiss III, Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmidencoded hepatitis B antigens stabilized by the asd-balanced lethal vector system. Infect Immun, 1997, 65, 3381– 3385. 90. C. Gonzalez, D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. Losonsky, J. P. Nataro, S. Hoffman, A. Malik, E. Nardin, et al., Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis, 1994, 169, 927–931. 91. M. D. DiPetrillo, T. Tibbetts, H. Kleanthous, K. P. Killeen, E. L. Hohmann, Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine, 2000, 18, 449–459. 92. C. O. Tacket, J. E. Galen, M. B. Sztein, G. Losonsky, T. L. Wyant, J. Nataro, S. S. Wasserman, R. Edelman, S. Chatfield, G. Dougan, M. M. Levine, Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol, 2000, 97, 146–153. 93. I. Angelakopoulos, E. L. Hohmann, Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun, 2000, 68, 2135–2141. 94. K. Nakayama, S. M. Kelly, R. Curtiss III, Construction of an Asd+ expression cloning vector: stable maintenance and high level expression of cloned genes in

95.

96.

97.

98.

99.

100.

101.

102.

a Salmonella vaccine strain. Biotechnology, 1988, 6, 693–697. J. E. Galen, J. Nair, J. Y. Wang, S. S. Wasserman, M. K. Tanner, M. B. Sztein, M. M. Levine, Optimization of plasmid maintenance in the attenuated live vaccine vector strain Salmonella typhi CVD 908-htrA. Infect Immun, 1999, 67, 6424–6433. R. A. Strugnell, D. Maskell, N. Fairweather, D. Pickard, A. Cockayne, C. Penn, G. Dougan, Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene, 1990, 88, 57–63. E. L. Hohmann, C. A. Oletta,W. P. Loomis, S. I. Miller, Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity. Proc Natl Acad Sci USA, 1995, 92, 2904–2908. D. Marshall, R. Fowler, G. Del Guidice, C. Dorman, G. Dougan, F. Bowe, Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in Salmonella vaccine strains. Vaccine, 2000, 18, 1298– 1306. J. Hess, I. Gentschev, D. Miko, M. Welzel, C. Ladel,W. Goebel, S. H. Kaufmann, Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA, 1996, 93, 1458–1463. H. Russmann, H. Shams, F. Poblete, Y. Fu, J. E. Galan, R. O. Donis, Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science, 1998, 281, 565–568. G. J. Fennelly, S. A. Khan, M. A. Abadi, T. F. Wild, B. R. Bloom, Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol, 1999, 162, 1603–1610. G. Dietrich, A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H. E. Kaufmann, J. Hess, A. A. Szalay, W. Goebel, Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Lis-

References teria monocytogenes. Nat Biotechnol, 1998, 16, 181–185. 103. N. Mielcarek, G. Riveau, F. Remoue, R. Antoine, A. Capron, C. Locht, Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat Biotechnol, 1998, 16, 454–457.

104. Y. D. Zhu, G. Fennelly, C. Miller, R. Tarara, I. Saxe, B. Bloom, M. McChesney, Recombinant bacille Calmette– Guerin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J Infect Dis, 1997, 176, 1445–1453.

341

343

16 Mucosal Vaccination Wieslawa Olszewska and Peter J. M. Openshaw

Summary

The immune system faces a dilemma. It must tolerate benign commensal organisms and antigens present in food and air, while rapidly mounting vigorous responses to the plethora of pathogens that enter via mucosal surfaces. The existing mucosal vaccines against poliomyelitis, influenza, and measles were developed on a largely empirical basis against transient self-limiting infections that themselves induce lifelong immunity. The challenge now is to exploit our new knowledge of immunoregulation to develop effective vaccines against more subtle agents that circumvent lifelong immunity, recur or persist. In this chapter, we review the successes and failures of mucosal immunization and the opportunities for exploiting developments in immunology to create new and effective mucosal vaccines.

16.1 Introduction

The mucous membranes lining the lung, gut, and urogential tract present unique problems to the host defense systems. They have specialized functions that necessitate close contact with the environment, yet most common infections enter by these routes. Immune defenses at mucosal surfaces therefore have to defend against pathogens while being tolerant of nonthreatening substances in food and inhaled air. Both innate and acquired mechanisms of immunity are involved in preventing microbial entrance and spread. Mechanisms of acquired immunity combine humoral (production of antigen-specific secretory IgA, S-IgA) and cell-mediated immune responses (Fig. 16.1). Mucosal immunization has the potential to induce protective immunity against infectious diseases or to elicit antigen-specific tolerance. The mucosal immune system has to be appropriately activated to achieve effective protection against colonization and invasion by infectious agents at mucosal surfaces. Although administration of vaccines directly to mucosal sites has many advantages, mucosal immunity can be

344

16 Mucosal Vaccination

also achieved by other routes of antigen delivery [1]. However, in this review we focus primarily on the mucosal route of vaccination. Because of the low absorption efficiency of mucosally delivered vaccines, almost all current vaccines are administered parenterally. In addition, suboptimal immune responses are frequently induced by mucosal immunization and the use of mucosal adjuvants is required. As a result, development of successful mucosal vaccines depends largely on improvements to mucosal delivery systems and on the discovery of new and effective mucosal adjuvants (Fig. 16.3).

16.2 Goals of Mucosal Vaccination

Most environmental pathogens enter the body through the mucosal membranes of the intestinal, respiratory, or genital tract. Some only replicate in the mucosa, but others use the mucosa to gain entry before dissemination to other sites. For purely mucosal infections (e. g., those caused by most common cold agents and infective diarrheal organisms), prevention of initial colonization is an essential but difficult aim of vaccination; when dissemination or toxin production is essential to disease pathogenesis, prevention of surface invasion may not be necessary. Mucosal vaccination is an attractive administration route for mass vaccination, as it does not require trained medical personnel and does not involve needles and syringes (Table 16.1). These factors affect the costs of vaccination and the risk of transmitting blood-borne infections (HIV or HepB) making mucosal vaccine particularly attractive for use in developing countries. New or improved vaccines are needed for a wide range of mucosal infections, including respiratory tract infections caused by Mycobacterium spp, Mycoplasma pneumoniae, influenza virus, rhinovirus, coronavirus, adenovirus, human metapneumovirus, and respiratory syncytial virus (RSV); urogenital tract infections caused by Chlamydia, HIV, Neisseria gonorrhoeae, Treponema pallidum, and herpes simplex virus (HSV); and gastrointestinal infections caused by Escherichia coli, Salmonella, Shigella spp, Helicobacter pylori,Vibrio cholerae, Campylobacter jejuni, Clostridium difficile, and rotaviruses. The challenge is to design vaccine preparations that induce neutralizing immunity to the pathogen or their Tab. 16.1 Comparison of mucosal and parenteral delivery of vaccines. Vaccination

Mucosal

Parenteral

Administration Risks Antigen Dose Formulation Immune Responses

Easy, self-administration Inaccurate dosing Usually high Need of mucosal adjuvant Stimulates mucosal immunity but may induce tolerance

Use in Humans

Only a few vaccines

Need for trained personnel Infection (HIV, hepatitis B) Low Mostly with alum Rarely induces mucosal responses but good systemic antibody and T cell responses Most vaccines

16.3 Benefits of Mucosal Vaccination

toxins, preventing their attachment to mucosal surfaces, tissue invasion, and spread. Induction of specific secretory IgA (S-IgA) is an essential aim of mucosal vaccination. Locally produced S-IgA is considered to be among the most important protective humoral immune factors and constitutes over 80 % of all antibodies produced in mucosa. In humans, S-IgA antibodies are usually dimeric whereas serum IgA is mainly monomeric. Antibodies secreted by mature plasma cells in various compartments of the common mucosal immune system are able to interact with invading pathogens, inhibit their attachment, and form immune complexes with potentially harmful molecules (‘immune exclusion’). S-IgA may neutralize viruses and directly participate in antibody-dependent, cell-mediated cytotoxicity (ADCC) in collaboration with macrophages and lymphocytes. However, natural killer cells and specific cytotoxic T cells are also key defenses in preventing infection with intracellular pathogens (Fig. 16.2). In testing vaccine efficacy, both antibody levels and cellular immunity should therefore be monitored.

16.3 Benefits of Mucosal Vaccination 16.3.1 Main Features of the Common Mucosal Immune System

A key issue in mucosal immunity is the necessity to distinguish between normal antigens, which are not harmful, and those that belong to dangerous pathogens. The discrimination between hazardous and nonhazardous antigens is determined by activation by pattern-recognition receptors (including Toll-like receptors), which may be displayed in intestinal crypts or in the cytoplasm of mucosal cells, and are therefore inaccessible to nonhazardous commensals. The anatomical placement of pattern-recognition receptors in inaccessible sites appears to be an important factor in allowing discrimination between hazardous and nonhazardous antigens. The mucosal immune system is highly adapted towards tolerance, the breakdown of which can result in disease (e. g., celiac disease). Mucosal exposure frequently induces regulatory T cells, of which there are several distinct types. First, ‘Th3’ cells produce transforming growth factor beta (TGF-beta); these are frequently induced by repeated feeding of low doses of antigen orally. Second, ‘Tr1’ cells are a subset of CD4 T cells, which produce IL-10, the production of which is promoted by IL-15 and Type 1 interferon. Third, CD4+ CD25+ cells are potent regulators of autoactivity in vivo and can also be induced by tolerogenic oral feeding. Fourth, CD8 T cells often have a regulatory role in the gut, but their exact functions have not been clearly defined. In addition, there is mounting evidence that gamma delta T cells may, under some conditions, also promote a tolerogenic state after oral feeding. All these subsets are readily induced by oral administration of antigen, but induction must be avoided if mucosal vaccination is to be successful.

345

346

16 Mucosal Vaccination

16.3.2 Distinctive Characteristics of Mucosal Immunity

In mammals, immune responses at mucosal surfaces are provided by a defense system known as mucosa-associated lymphoid tissue (MALT). It comprises an integrated network of cells and molecules anatomically grouped and functionally divided into sites of antigen uptake and effector function. Mucosal immune responses are triggered in specialized zones that sample foreign material from the epithelial surface. The main inductive site of the upper respiratory tract is in the nasal-associated lymphoid tissue (NALT), and in the gastrointestinal tract it is the Peyer's patch (PP), the appendix, and the solitary lymphoid nodules, collectively called the gut-associated lymphoid tissue (GALT). The respiratory epithelium contains four different cell types: alveolar macrophages, dendritic cells, M-cells, and intraepithelial lymphocytes. The latter are relatively scarce in the respiratory tract. M-cells are associated with lymphoid structures and differ in morphology from absorptive cells by their short microvilli, small cytoplasmic vesicles, and few lysosomes. The M cells selectively absorb antigen by endocytosis or pinocytosis and direct it to professional APC (macrophages, dendritic cells, B-lymphocytes) or directly process and present antigen to T cells (Fig. 16.1). In the gut, specialized M cells are thought to provide the main route by which complex antigens gain access to the immune system. Lymphocytes primed in the Peyer’s patches express a4 b7 integrin, which binds to the mucosal adressin cell-adhesion molecule 1 (MAD-CAM1), which is expressed at high levels by the vascular endothelium in mucosal surfaces. Gut-derived T cells also express the chemokine receptor CCR9, which allows them to respond to the chemokine CCL25, which is expressed selectively by small bowel epithelial cells. By contrast, T cells that are primed peripherally typically display the a4 b1 integrin and CCR4 and so do not migrate or respond in mucosal sites. This selective expression explains why mucosal vaccination is often required to protect against mucosal infections, and why peripheral administration of vaccine antigens is often ineffective against mucosal infections. The establishment and maintenance of the immune response requires close cooperation between many cell types. Activated T-cells help B-cells to develop into plasma cells, a process that depends on the nature of the antigen and on the cytokines produced by T helper cells. TGF-b , IL-10, and IL-4 promote the switch from IgM to IgA production from stimulated B-cells. Precursors of mucosal plasma cells derive from lymphoepithelial structures, mature in the regional lymph nodes, and enter the circulation via the thoracic duct. Then they can seed the lamina propria of distant mucosal sites (e. g., intestines, respiratory tract, genital tract, salivary gland, etc.), where they differentiate. In this way, antibodies can appear at different mucosal sites elsewhere within the common mucosal immune system. Natural killer cells may be also present in mucosal tissues and, together with CTLs, are important for eliminating virus-infected cells. There is strong evidence that various mucosal sites of the immune system can communicate. For instance, within 24 h of adoptive lymphocyte transfer, mesenteric lymph node (MLN) cells are found in recipient gut, cervix and vagina, uterus, and

16.3 Benefits of Mucosal Vaccination

mammary glands [2]. The ability of cells to migrate between mucosal zones has been extensively investigated. Thus, intranasal immunization may induce specific immunity in intestine, and boosted levels of IgA have been reported in the intestine after intranasal (rather than oral) administration [3]. In these experiments the relatively poor induction of gut immunity by oral administration could be due to degradation of antigen and dilution in the contents of the gastrointestinal tract. Several examples show that intranasal immunization can result in efficient immunity at distant mucosal sites. For instance, intranasal administration of a recombinant HIV envelope protein formulated in CTB-associated GM1 lipid vesicles enhances mucosal IgA antibody responses in nasal and gut tissues [4]. Administration of a DNA vaccine for herpes simplex induces antigen-specific cellular and secretory IgA responses in the gut, vagina, and oral cavity after intradermal, intraperitoneal, intravaginal, intranasal, or oral immunization [1]. Taking advantage of the functional integrity of the common mucosal system, vaccines easily administrated into the nose may in the future include those against herpes simplex virus or HIV. For instance, recombinant adenovirus used to deliver antigens derived from HSV and HIV has been demonstrated to induce protective immunity in mice vaginal mucosa, particularly when cholera toxin was included in the vaccine preparation [5, 6]. 16.3.3 Multivalent Mucosal Vaccines

Delivery systems that allow simultaneous delivery of several antigens derived from one or more pathogens may be used to design a multivalent vaccine. Such a vaccine potentially may reduce the number of administrations needed and increase protection in the populations studied. For example, RSV and human parainfluenza represent two of the most important viral agents of pediatric respiratory tract disease worldwide. Studies are under way that use recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3), with bovine F and HN genes replaced with their HPIV3 counterparts and expressing the major surface antigens of respiratory syncytial virus. Both recombinant viruses were shown to replicate efficiently in the respiratory tract of hamsters and induced serum antibody titers similar to those induced by RSV or HPIV3 infection. Immunization of hamsters with rB/HPIV3-G1, rB/HPIV3-F1, or a combination of both viruses resulted in high level of resistance to challenge with RSV or HPIV3 28 days later [7]. Schmidt et al. described a similar strategy for intranasal immunization against RSV subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine in monkeys [8]. 16.3.4 Edible Vaccines (see also chapter 18)

Transgenic plant technology allows the production of large quantities of transgenic antigen from pathogenic microorganisms at low cost and would have particular benefits in under-resourced areas. The first edible vaccine was obtained by inserting the

347

348

16 Mucosal Vaccination

gene encoding hepatitis B surface antigen into tobacco plants, resulting in an antigen very similar to that obtained from recombinant yeast [9]. Similar methods have been used to make vaccines containing genes of E. coli heat-labile enterotoxin B (LT-B) [10], rabies virus glycoprotein [11, 12], F protein of RSV [13], Norwalk virus capsid protein [14], and V. cholerae (CT-B) [15] in potatoes, tomatoes, and other plants. Materials from recombinant plants have been shown to be immunogenic in feeding experiments in animals, inducing systemic and mucosal responses [13, 16], and promising clinical trials show that specific anti-LT-B responses can be demonstrated in humans given transgenic potatoes expressing LT-B [17]. The possibility of using transgenic plants for the production of specific immunoglobulins for passive immunotherapy is also being explored [18], but the commercial viability of these technologies is unproven. Oral administration could theoretically induce tolerance to pathogens, resulting in serious adverse consequences. Fear of this effect has limited the clinical trials of oral vaccination against hepatitis B with edible potatoes expressing hepatitis surface antigens to preimmune individuals. 16.3.5 Overcoming Preexisting Immunity or Tolerance

Immunity to vaccinia potentially limits the utility of vaccinia vectors in people previously immunized against smallpox. However, the studies of Belyakov et al. [19] suggest that modified vaccinia Ankara (MVA) expressing HIV gp160 could successfully immunize via the mucosal route and induce potent specific systemic humoral and CTL responses in vaccinia-immune mice. It therefore seems possible that immune responses at mucosal sites may not be prevented by prior systemic immunization and that this mucosal naiveté may be exploited in generating immune responses in previously vaccinated individuals. Another challenge to immunization against RSV and measles is the inefficiency of vaccination in the presence of specific maternal antibody. It appears that mucosal immunization may overcome this difficulty. Mutwiri et al. [20] concluded from studying immune responses in neonatal lambs that enteric immunization with a human adenovirus vector may be an effective approach for inducing both mucosal and systemic immune responses in neonates. Similarly, in the cotton rat model of measles mucosal vaccination with vesicular stomatitis virus expressing the hemagglutinin of measles virus induces seroconversion in the presence of maternal antibodies and leads to protection against measles challenge [21]. Based on experience with highly effective live polio vaccine given at birth, it has been proposed that mucosal immunization may be safer and more effective than any other route of vaccination in young children [22].

16.4 Challenges for Mucosal Immunization

16.4 Challenges for Mucosal Immunization 16.4.1 Mucosal Delivery Systems 16.4.1.1 Live Bacterial Vectors Commensal Flora as Expression Vectors Genetic manipulation of normal surface bacteria is attractive, in that no pathogen is deployed in vaccine production and the bacteria themselves can exhibit probiotic properties. However, the risk is that such bacteria will be tolerated and thus no immune response will be generated. Considerable work has been done with Lactococcus lactis [23], some strains of Lactobaccillus [24, 25], Staphylococcus carnosus [26, 27], and Streptococcus gordonii [28, 29]. These bacteria are noninvasive or commensal organisms in healthy people. Internal adjuvanticity is provided by peptidoglycan, and lactobacilli tagged with green fluorescent protein are actively taken up by APC after intranasal administration, suggesting that antigens would be processed and presented [30]. Recombinant antigens that have been expressed in commensal bacteria include the V3 domain of HIV-1 gp120, fusion and hemagglutinin from measles virus, fragment B of diphtheria toxin, peptides from Plasmodium falciparum and epitopes from RSV [26–28, 31]. Pathogens as Expression Vectors Many bacterial pathogens naturally invade via mucosal surfaces and induce strong mucosal immunity. Attenuated Salmonella has been extensively studied as a vector both for oral and intranasal delivery. Interestingly, i.n. vaccination induces better systemic and local immune responses to inserted antigens (e.g., hepatitis B core antigen) than oral or rectal immunization [32]. Insertion of antigens from Helicobacter pylori into Salmonella, for instance, results in induction of specific CD4+ T cells producing IFN and IL-10 in a mouse model, as well as good protection after just two i.n. doses of vaccine [32]. Attenuated strains of Shigella are also promising live bacterial vectors. In animal models they were shown to induce specific serum antibody responses (IgG and IgA) to inserted antigens after i.n. immunization [33]. Bacille Calmette-Guérin (BCG) is the first attenuated vaccine introduced to humans and still is the most widely used vaccine in the world, since it is the only one available against tuberculosis. Since BCG induces cellular immunity and can accommodate foreign epitopes, it may work as a successful vector when specific cellular responses are needed. The safety of the vaccine given at birth suggests its relevance for immunizations required very early in life. Candidates would therefore include measles and RSV vaccine. Indeed, recombinant BCG producing measles nucleoprotein provided protection against virus challenge in intranasally immunized infant rhesus macaques [34]. Other examples of heterologous antigens expressed in BCG for mucosal vaccination include HIV [35], human papilloma virus [36], Schistosoma haematobium [37], Plasmodium yoelii [38], and Toxoplasma gondi [39].

349

350

16 Mucosal Vaccination

Recently, attenuated Bordetella pertussis emerged as a bacterial vector for i.n. vaccination. Deletion of genes coding for pertussis toxin diminished the virulence of the bacteria but preserved their ability to colonize mucosal sites [32]. Interestingly, the immunogenicity to the mayor antigen, filamentous hemagglutinin (FHA), was increased, as well as that to heterologous antigen fused to FHA. Additionally, significant protection was observed in a mouse model of S. mansoni infection following single i.n. immunization [40]. 16.4.1.2 Virosomes Cusi et al. [41] investigated the efficacy of a vaccine composed of the RSV fusion protein associated with influenza virosomes (IRIV), which was administered intranasally together with E. coli heat-labile toxin (LT). After an intramuscular `priming' with influenza virus vaccine, mice were i.n. immunized with RSV-F/IRIV+ LT or with RSV-F + LT or IRIV+ LT. The results showed that mice immunized with RSV-F+ LT developed Th2 type responses and that virosomal delivery greatly potentiated immune responses in animals. All mice immunized with RSV-F/IRIV+ LT developed a balanced Th1/Th2 cytokine profile with mucosal IgA and high levels of serum IgG. More importantly, histological analysis of lung tissue of RSV-challenged mice did not reveal vaccine-enhanced pulmonary eosinophilia [41]. 16.4.1.3 Mucosal DNA Vaccines The immunogenic potential of DNA vaccination has been extensively tested in animal models. DNA vaccination has many theoretical advantages, including ease of production, stability of vaccine preparations, and the ability to induce both antibody and cell-mediated immune responses (see chapter 14). The drawbacks are that success in animal models is poorly predictive of outcome in human studies and that long-term follow-up studies are necessary to assess the risk of vaccine involvement in autoimmune diseases or immune disregulation. DNA is not usually taken up in nondegraded form from mucosal surfaces. However, DNA immunization in mice and chickens has been shown to induce antibodies to influenza nucleoprotein and to trigger both mucosal and systemic cellular protective immune responses [42]. In a recent study, Sasaki et al. [43] described immune responses induced by intranasally and intramuscularly delivered DNA encoding HIV-1 proteins in mice. Both routes produced similar levels of cell-mediated immunity, but intranasal immunization induced higher levels of intestinal S-IgA than intramuscular immunization, and the adjuvant QS21 enhanced both intranasal and intramuscular immune responses. Encapsulation of DNA into microparticles prevents degradation of DNA and enhances immunogenicity; therefore is an attractive delivery system for a mucosal DNA vaccine. Such a vaccine, designed using rotavirus VP6 DNA encapsulated in PLG microparticles, was shown effective in inducing systemic and mucosal immunity after oral administration to mice.

16.4 Challenges for Mucosal Immunization

16.4.2 Mucosal Adjuvants

Many substances are known to have adjuvant properties; however, the majority are used for parenteral immunization and only a few are suitable for the mucosal route. Alum, the only universally licensed adjuvant for use in humans, is not a suitable adjuvant for mucosal immunization. The choice of an appropriate adjuvant for mucosal vaccination is very important to its success. Many mucosal adjuvants are based on bacterial toxins and their derivatives, CpG-containing DNA, and various cytokines and chemokines. Since most antigens are poorly immunogenic when introduced via the mucosal route if no adjuvant is added, induction of tolerance is likely. 16.4.2.1 Biodegradable Polymeric Particles Micro- and nano-particles may be used to encapsulate vaccine antigens. Many such polymers have the advantages of being biodegradable and at the same time of protecting the antigen from premature degradation. Slow degradation of polymers controls the release of entrapped antigen; therefore, such vaccines can induce immune responses over prolonged periods of time. Poly(D,L-lactide-co-glycolide) (PLG) polymer is probably the most extensively studied polymer because of its safety record in humans. The hydrolysis of PLG polymer to release encapsulated antigen is controlled by the polymer composition and its molecular weight. PLG particles may be suitable mucosal vaccine carriers, as shown by using fimbriae from B. pertusiss encapsulated in PLG particles for oral delivery to mice. The technique was able to induce serum and mucosal antibody responses in mice as well as to protect against live bacterial challenges. Baras et al. [44] demonstrated recently the feasibility of long-term in vivo release of antigens from PLG particles. They showed that a single nasal or oral immunization of glutathione S-transferase from S. mansoni in PLG microparticles could induce a long-lasting antigen-specific antibody response in mice, with a peak at 9–10 weeks after immunization. 16.4.2.2 Bacterial Toxins Bacterial toxins have been used for a long time as adjuvants in experimental models, and some chemically detoxified toxins have been employed to prevent bacterial infectious diseases (e. g., formalin inactivation of Corynebacterium diphtheriae or Clostridium tetani exotoxins). Although bacterial toxins posses excellent adjuvant properties, they have been prohibited from wide use as adjuvants in humans because of their high toxicity. Two bacterial toxins have found particular attention for application as mucosal adjuvants: cholera toxin (CT) produced by V. cholerae and heat-labile enterotoxin (LT) produced by E. coli have similar structures, since both contain subunits A and B and the toxicity originates from the A subunit, which catalyzes ADP-ribosylation of the stimulatory GTP-binding proteins on the surface of the epithelial cells and raises the intracellular levels of cAMP. This then leads to secretion of water and electrolytes into the mucosal lumen. Today it is possible to obtain detoxified derivatives by mutagenesis of the toxin genes. With this technology, the genes are modified in such a way as to encode different amino acid(s) that are no longer able to

351

352

16 Mucosal Vaccination

function in enzymatic activity. Such inactivated substances are safe and in the future could replace toxoids in existing vaccines as well as be used as mucosal adjuvants in new vaccination strategies. Several mutant toxins have already been described [45, 46], among them are mutations of the heat-labile toxin of E. coli: LTK63, LTR72, and LTG192. All of them have been studied in detail for their ability to induce systemic and local immune responses to coadministered antigen. LTR72 was the strongest adjuvant, as compared with the fully nontoxic LTK63 mutant, and showed only 0.6 % of the enzymatic activity of the wild-type LT. LTK63 was shown to be 100 000-fold less toxic but 20 times less effective than LT [47]. Moreover, CD4+ lymphocytes from animals immunized with ovalbumin together with LTR72 exhibited very strong proliferative responses, similar to those induced by wild-type LT [47]. LTK63 was also tested in the murine measles model, and mucosal coimmunization with the mutant and a synthetic peptide representing a CTL epitope from measles N protein was very effective in in vivo priming of peptide-specific and measles virus-specific CTL responses [48]. Similarly, the addition of LTK63 to peptide RSV vaccine induced strong CTL responses and protection after intranasal administration into a mouse [49]. Compared with administration of oral influenza vaccine alone, coadministration of vaccine with LTG192 provided enhanced protection from infection in the upper and lower respiratory tract, equivalent to and at similar doses as that obtained with wild-type LT. The mutant toxin augmented virus-specific IgG and IgA responses in serum, lung, and nasal washes and also the numbers of virus-specific antibody-forming cells in spleen, lung, and Peyer's patches in a manner comparable to that of wild-type LT [50]. Studies conducted in experimental animals have given promising results with respect to immune responses developed after intranasal vaccination by a number of delivery systems [51–53]. Cholera toxin B given intranasally with measles virus stimulated systemic neutralizing antibodies [54], and intranasal immunization with a chimeric synthetic peptide containing two T-helper epitopes (MVF: aa 288–302) and one B-cell epitope (MVF: aa 404–414) produced both systemic and mucosal antibody responses that conferred protection against encephalitis after infection with neuroadapted measles virus [55]. A novel nontoxic form of chimeric mucosal adjuvant that combines the A subunit of mutant cholera toxin E112K with the pentameric B subunit of heat-labile enterotoxin from enterotoxigenic E. coli was constructed [56]. Nasal immunization of mice with tetanus toxoid (TT) plus the new adjuvant elicited significant TT-specific immunoglobulin A responses in mucosal compartments and induced high serum immunoglobulin G and immunoglobulin A anti-TT antibody responses. The suitability of CT and LT and their mutants in human vaccinology remains to be determined. Several clinical trials did not report side effects; however, at least one influenza vaccine coadministered with LT had to be withdrawn from study due to several instances of facial paresis [57]. 16.4.2.3 CpG Oligodinucleotides Synthetic oligodeoxynucleotides (ODN) that contain unmethylated CpG motifs (CpG ODN) are also novel candidates as adjuvants for mucosal immunization. Initi-

16.4 Challenges for Mucosal Immunization

ally, it was reported that these motifs could induce in vitro production of IL-6 and IFN g by CD4+ T cells, IL-6 and IL-12 by B cells, and IFN g by NK cells [58]. Such properties led to the use of CpG ODNs as an adjuvant in several experimental models [59–63] and indeed, work published so far supports the view that Th1-type responses dominate after CpG coadministration with an immunogen. However, some authors indicate that these responses are very much dependent on the age of the primed animals [63, 64], the route of antigen delivery [64], or the nature of the antigen [62]. The potential of CpG motifs as adjuvants for delivery via mucosal surfaces is particularly promising, as can be judged from several recent publications [65–68]. 16.4.2.4 Cytokines and Chemokines Cytokines can be used as mucosal adjuvants, either added directly to a vaccine preparation or encoded in DNA. Recent advancements in cytokine applications are summarized in Table 16.2. As an example, combination of IL-1 and IL-12 or IL-18 and GM-CSF creates a potent stimulating environment for mixed Th1/Th2 immune responses with the effect of IFN g, IgA, and induction of CTL responses [69]. IL-2 and IL-6 coexpressed in recombinant bacteria significantly increase specific antibody in serum as well as mucosal IgA subsequent to i.n. inoculation in mice [70]. Likewise, some chemokines are being explored for use to potentiate mucosal immunity, as reported by Lillard et al. [71] and Eo et al. [72]. Particularly promising is RANTES, which is a chemoattractant for monocytes, T cells, and NK cells, and has strong ability to induce Th1 responses, particularly CTLs. Moreover, nasal coadministration of RANTES with a protein antigen was demonstrated to augment Th1 and Th2 local and systemic immune responses [71]. 16.4.2.5 Saponins Saponins purified from the bark of the tree Quillaja saponaria molina and their derivatives are being used experimentally for mucosal immunization. Quil A can be incorporated into more potent adjuvant systems, such as ISCOMs (see below). Onjisaponins were shown in studies of Nagai et al. [73] to be safe and potent adjuvants for intranasal inoculation together with influenza and DTP vaccines. Experiments in mice showed that the use of adjuvant significantly increased serum IgG and nasal IgA as well as inhibited proliferation of mouse-adapted influenza virus in BAL of infected mice [73]. 16.4.2.6 Immune Stimulating Complexes (ISCOMS) ISCOMs consist of cholesterol, phospholipids, viral proteins, and glycosides of the adjuvant Quil A [74]. For several viruses it has been shown that the incorporation of viral proteins into the ISCOM structure can dramatically enhance their immunogenicity. Strong B-cell and T-cell responses are usually observed together with induction of CTL responses, which are normally not evoked by nonreplicating vaccine preparations. ISCOM-based influenza vaccines are currently being evaluated in clinical trials, and initial studies have shown that individuals immunized with ISCOM preparations developed virus-specific CTL responses in addition to strong antibody responses [75, 76].

353

354

16 Mucosal Vaccination Tab. 16.2 Examples of cytokines and chemokines coadministered with mucosal vaccinesin mice. Cytokine/ chemokine

Delivery system

Route of delivery

IL-1

Protein

Intranasal

GM-CSF

Adenovector

Intranasal

Plasmid DNA

Effect

Reference

[102] [103]

Rectal/ vaginal

Increased IgG2 a and IgG1, elevated levels of IFN-g, TNF-a, and IL-10 Increased serum IgG, enhanced mucosal and fecal IgA

Plasmid DNAencapsulated in PLG microparticles Recombinant L. lacti Liposomes s

Oral

Enhanced CTL responses

[105]

Intranasal

Increased antibody titers

[70]

Intranasal

Increased P. aeruginosa polysaccharide-specific pulmonary plasma cells, reduced mortality from pneumonia

[106]

IL-4

Plasmid DNA

Rectal/ vaginal

Increased antibody levels; decreased CTL activity

[104]

IL-6

Recombinant L. lactis

Intranasal

Increased antibody titers

[70]

IL-12

Liposomes

Oral

[107]

Plasmid DNA

Rectal/ vaginal

Shift to IgG2 a and IgG3, decreased IgE Abs, enhanced serum IFN-g Decreased antibody levels, enhanced CTL activity

IL-1alpha, IL-12, and IL-18

Peptide

Intranasal

Specific anti-HIV IgA in saliva, fecal extracts, and vagina

[108]

RANTES

Peptide

Intranasal

Augmented Th1 and Th2 responses

[71]

IL-10

Plasmid DNA

Intranasal

Diminished Ag-induced delayedtype hypersensitivity, production of Th1 cytokines

[109]

CCR7 ligands

Plasmid DNA

Intranasal, intragastric

CD4+ T helper cell proliferation and CD8+ T cell-mediated CTL activity, serum IgG

[72]

IL-2

[104]

[104]

Intranasal delivery of inactivated influenza vaccine plus the ISCOMATRIX (IMX) adjuvant was able to induce serum hemagglutination inhibition (HAI) titers in mice better than those obtained with unadjuvanted vaccine delivered subcutaneously. Furthermore, the IMX-adjuvanted vaccine delivered intranasally induced mucosal IgA responses in the lung, nasal passages, and large intestine, together with high levels of serum IgA [77].

16.5 Vaccination via the Respiratory Tract

16.4.2.7 MF59 MF59 is an adjuvant approved for use in humans and elicits higher antibody titers than alum when used in combination with a variety of recombinant and natural subunit antigens [78]. MF59 is an oil-in-water emulsion that contains squalene (a metabolite of cholesterol), polysorbate 80 (a surfactant soluble in water), and sorbitan trioleate (a surfactant soluble in oil). Although the mechanisms responsible for the adjuvant action of MF59 are not fully understood, enhancement of humoral immune response to parenteral influenza vaccine has been shown in humans, and mucosal immune responses to intranasally-administered influenza vaccine were evoked in mice [79]. Thus, it appears that MF59 may be a promising formulation for future mucosal vaccines.

16.5 Vaccination via the Respiratory Tract

The first point of contact for inhaled pathogens is usually the nasal mucosa. Many infections are initiated at the mucosal surface and so it would appear desirable to induce neutralizing antibodies and specific cellular responses at the site of pathogen entry. The large, highly vascularized surface (150 cm2) [80] has the potential of very efficient absorption of delivered vaccine, and the presence of immune cells in this area enables the initiation of immune reactions. Nasal epithelium absorbs principally soluble antigens, so use of a suitable delivery system is likely to contribute to achieving protective responses after immunization via the nasal route. The technique of intranasal immunization is very important if large doses are administered. Some vaccine may be swallowed, leading to oral delivery, or, in anaesthetized animals, a proportion of the vaccine may reach the lung. The epithelial deposition of antigens in the respiratory mucosa depends on size of particles (aerodynamic diameter); therefore, in designing a vaccine for delivery via the respiratory route particle size is a critical issue. 16.5.1 Applications of Nasal Vaccination

Many preclinical studies have been conducted on vaccines administered via the respiratory tract. These are mostly delivered into nasal mucosa, but some trials involving deep lung deposition have also been described. As mentioned above, the functional integrity of mucosal system allows induction of immune responses in sites distant from the immunization site. It seems obvious, however, that intranasal immunization is particularly appropriate for prevention of those infectious diseases acquired by inhalation. Therefore we focus here on recent developments of nasal vaccines against some respiratory viral diseases. The protective efficacy of mucosal immunization with purified RSV fusion protein (F) or chimeric FG glycoprotein was shown in animal models when the vaccines were coadministered with CT adjuvant [81–83]. Complete protection was also de-

355

356

16 Mucosal Vaccination

monstrated in mice immunized with a synthetic peptide (residues 174–187) of the G protein mixed with CT, even though the peptide failed to induce a detectable level of secretory IgA [84]. Effective mucosal immunization against RSV was reported after using F protein and a genetically detoxified toxin CT-E29H [85] or CTL peptide from the M2 protein together with LTK63 as an adjuvant [49]. Recently, live, attenuated, cold-adapted viral vaccines have been developed as alternatives to inactivated vaccines. Thus, it is possible to produce an organism that replicates efficiently at 25–28 °C, i. e., the temperature of the nasal passage, but not at 37 °C (the temperature of the lungs). Intranasal administration of cold-adapted vaccines usually induces good immune responses – including local IgA responses and secretory IgA antibodies, which can provide protection against pathogens that infect mucosal sites – although the magnitude of the serum antibody response depends on the extent of virus replication [86–88]. Furthermore, live vaccines can induce CTL responses or can prime CTL responses induced during natural infection. Several vaccines against influenza are licensed for use in humans. Among them, few are administered via the intranasal route. The trivalent Nasalflu Berna vaccine consists of influenza virosomes formulated from inactivated influenza surface glycoproteins, combined with lecithin and heat-labile toxin of E. coli. This vaccine has been reported to induce high levels of influenza-specific hemagglutination inhibition IgG and IgA in nasal mucosa and in the saliva [89]. In clinical trials, 85 % efficacy was reported in adults and nearly 90 % efficacy in children. Although no significant adverse reactions were observed in initial studies, 43 instances of Bell’s palsy were encountered among the first season's vaccine recipients (totaling more than 100 000 people). This resulted in suspension of sales and the launch of a detailed investigation of potential side effects. Another human trial involving influenza vaccine compared intranasal and intramuscular trivalent whole virus vaccines in elderly people, and showed that the intranasal route was significantly more effective in inducing mucosal IgA response [90]. Additionally, combined vaccination involving intramuscular inactivated and intranasal cold-adapted influenza vaccines had significantly increased efficacy in an elderly population. A different human study involving MF59-adjuvanted or nonadjuvanted subunit influenza vaccines indicated that in these trials immune responses, including mucosal IgA production, were not influenced by the presence of adjuvant [91, 92]. Interesting results were obtained from a mouse study using a peptide mucosal influenza vaccine. A retro–inverso analogue, encompassing the protective B-cell epitope sequence from hemagglutinin (HA) (91–108) [93] conjugated to ovalbumin and coadministered with cholera toxin, produced strong systemic (serum IgG) and mucosal (lung IgA) antibody responses that protected against intranasal challenge with a lethal dose of influenza virus. The half-life of the retro–inverso analogue in the presence of lung homogenate proteases was at least 700 times greater than that of the parent L-peptide. These results demonstrated that peptido-mimetic analogues with high resistance to proteolytic degradation are very effective immunogens intranasal administration. Existing measles vaccines have been successful in young children when administered as an aerosol or via the intranasal route [94–96]. However, results from one

16.7 Conclusions

study did not support these findings and implied that further investigations of the immunization protocol were required [97].

16.6 Oral Vaccines

Oral administration of infectious nonpathogenic agents is an ideal method of vaccination, a principal aim being to induce specific mucosal IgA immune responses. An outstanding example of a successful oral vaccine is the Sabin polio vaccine, which induces both local and systemic immune responses and provides good protection against poliovirus infection. Other current oral vaccines include killed whole-cell B subunit and live–attenuated cholera vaccines, live–attenuated typhoid vaccine, and live adenovirus vaccine. Oral immunization with live–attenuated vaccine against adenovirus successfully eliminated frequent epidemics at trainee camps and was in routine use for 25 years in US army recruits. The decision to withdraw vaccination resulted in the reemergence of adenoviral infections and work is now in progress to bring back this effective and safe vaccine. Rotashield was a highly successful live oral vaccine giving good protection against infectious diarrhea, but was withdrawn because of possible links with intussusception [98–101]. Oral administration of nonliving antigens can induce oral tolerance to systemic and local autoantigens or allergens, thereby protecting against DTH. This approach could potentially be used to reduce inflammatory reactions in chronic infections, autoimmune disorders, or allergies. However, oral tolerance could hinder successful oral vaccine development, and in practice oral vaccines have proved difficult to develop; therefore relatively few have been licensed for human use.

16.7 Conclusions

An important key to the development of novel mucosal vaccines is to understand how mucosal adjuvants can lead to the induction of protective responses (particularly T cell immunity and local antibody production), while avoiding oral tolerance, induction of regulatory T cells, or immunopathogenic immunity. Genetically engineered live vaccines designed to exploit newly understood immune mechanisms of tolerance and immunoregulation offer fresh hope in the race to develop new mucosal vaccines.

Acknowledgements

This work was supported by the Wellcome Trust, UK (programme grant 054797/Z/ 98/Z) and European Union grant ‘Impressuvac’ (QLRT – PL1999–01044).

357

358

16 Mucosal Vaccination

Antigens

sIgA

M

M

M T

Plasma cell

B

MALT

APC

Lymphoblast

T

B

Lymph node B

APC

B

RBC

Spleen

?

Systemic antibodies

Fig. 16.1 Schematic representation of cells involved in immune reactions after mucosal challenge. APC, antigen-presenting cell; M, microfold epithelial cell; T, T cell; B, B cell; RBC, red blood cell (see colour plates page XXXIX).

TOXIN NEUTRALIZATION

ANTIBODY

Lumen

ATTACHMENT/ ENTRANCE

Mucosal surface

M

PREVENTION

APC ANTIBODY-DEPENDENT

APC

CELL MEDIATED CYTOTOXICITY

NK, CTL KILLING OF INFECTED CELLS

HEV

Fig. 16.2 Goals of mucosal immunization. Successful mucosal immunization may induce humoral and cellular immune responses. Possible roles of both are shown. M, microfold epithelial cell; HEV, high endothelial venule; APC, antigen-presenting cell; the 1 symbol indicates possible sites of immune intervention (see colour plates page XXXIX).

16.7 Conclusions

Vaccine Prevent proteolitic cleavage, preserve structure, target delivery site / colonization, (Virosomes, Virosomes, recombinant bacteria, DNA)

DELIVERY SYSTEMS

Mucosal surface

ADJUVANTS Direct immune response, prolong stimulation, (LT, CT, mutant toxins, CpG) CpG T

B

Stimulate T and B cells (Peptides, proteins, whole pathogens)

ANTIGENS

Fig. 16.3 Challenges for mucosal vaccination: schematic representation of key issues in mucosal vaccine development (see colour plates page XXXIX).

Reference List 1. Shroff, K. E.; Marcucci-Borges, L. A.; de Bruin, S. J.; Winter, L. A.; Tiberio, L.; Pachuk, C.; Snyder, L. A.; Satishchandran, C.; Ciccarelli, R. B.; Higgins,T. J. Vaccine 1999, 18 (3–4), 222–230. 2. McDermott, M. R.; Bienenstock, J. J. Immunol. 1979, 122 (5), 1892–1898. 3. Hvalbye, B. K.; Aaberge, I. S.; Lovik, M.; Haneberg, B. Infect. Immun. 1999, 67 (9), 4320–4325. 4. Lian, T.; Bui, T.; Ho, R. J. Vaccine 1999, 18 (7–8), 604–611. 5. Gallichan,W. S.; Rosenthal, K. L. Vaccine 1995, 13 (16), 1589–1595. 6. Hordnes, K.; Tynning, T.; Brown, T. A.; Haneberg, B.; Jonsson, R. Vaccine 1997, 15 (11), 1244–1251. 7. Schmidt, A. C.; McAuliffe, J. M.; Murphy, B. R.; Collins, P. L. J. Virol. 2001, 75 (10), 4594–4603. 8. Schmidt, A. C.; Wenzke, D. R.; McAuliffe, J. M.; St Claire, M.; Elkins, W. R.; Murphy, B. R.; Collins, P. L. J. Virol. 2002, 76 (3), 1089–1099.

9. Mason, H. S.; Lam, D. M.; Arntzen, C. J. Proc. Natl. Acad. Sci. USA 1992, 89 (24), 11745–11749. 10. Lauterslager, T. G.; Florack, D. E.; van der Wal, T. J.; Molthoff, J. W.; Langeveld, J. P.; Bosch, D.; Boersma, W. J.; Hilgers, L. A. Vaccine 2001, 19 (17–19), 2749–2755. 11. Yusibov,V.; Hooper, D. C.; Spitsin, S. V.; Fleysh, N.; Kean, R. B.; Mikheeva, T.; Deka, D.; Karasev, A.; Cox, S.; Randall, J.; Koprowski, H. Vaccine 2002, 20 (25–26), 3155–3164. 12. McGarvey, P. B.; Hammond, J.; Dienelt, M. M.; Hooper, D. C.; Fu, Z. F.; Dietzschold, B.; Koprowski, H.; Michaels, F. H. Biotechnology (NY) 1995, 13 (13), 1484–1487. 13. Sandhu, J. S.; Krasnyanski, S. F.; Domier, L. L.; Korban, S. S.; Osadjan, M. D.; Buetow, D. E. Transgenic Res. 2000, 9 (2), 127–135. 14. Mason, H. S.; Ball, J. M.; Shi, J. J.; Jiang, X.; Estes, M. K.; Arntzen, C. J.

359

360

16 Mucosal Vaccination

15.

16.

17.

18. 19.

20.

21. 22. 23.

24.

25.

26.

27.

28.

29.

30.

Proc. Natl. Acad. Sci. USA 1996, 93 (11), 5335–5340. Daniell, H.; Lee, S. B.; Panchal, T.; Wiebe, P. O. J. Mol. Biol. 2001, 311 (5), 1001–1009. Wigdorovitz, A.; Carrillo, C.; Dus Santos, M. J.; Trono, K.; Peralta, A.; Gomez, M. C.; Rios, R. D.; Franzone, P. M.; Sadir, A. M.; Escribano, J. M.; Borca, M. V. Virology 1999, 255 (2), 347–353. Tacket, C. O.; Mason, H. S.; Losonsky, G.; Clements, J. D.; Levine, M. M.; Arntzen, C. J. Nat. Med. 1998, 4 (5), 607–609. Ruedl, C.; Wolf, H. Int. Arch. Allergy Immunol. 1995, 108 334–339. Belyakov, I. M.; Moss, B.; Strober,W.; Berzofsky, J. A. Proc. Natl. Acad. Sci. USA 1999, 96 (8), 4512–4517. Mutwiri, G.; Bateman, C.; Baca–Estrada, M. E.; Snider, M.; Griebel, P. Vaccine 2000, 19 (9–10), 1284–1293. Niewiesk, S. Vaccine 2001, 19 (17–19), 2250–2253. Walker, R. I. Vaccine 1994, 12 (5), 387– 400. Robinson, K.; Chamberlain, L. M.; Schofield, K. M.; Wells, J. M.; Le Page, R. W. Nat. Biotechnol. 1997, 15 (7), 653–657. Mercenier, A.; Muller–Alouf, H.; Grangette, C. Curr. Issues Mol. Biol. 2000, 2 (1), 17–25. Pouwels, P. H.; Leer, R. J.; Boersma, W. J. J. Biotechnol. 1996, 44 (1–3), 183– 192. Fromen-Romano, C.; Drevet, P.; Robert, A.; Menez, A.; Leonetti, M. Infect. Immun. 1999, 67 (10), 5007–5011. Cano, F.; Plotnicky-Gilquin, H.; Nguyen, T. N.; Liljeqvist, S.; Samuelson, P.; Bonnefoy, J.; Stahl, S.; Robert, A. Vaccine 2000, 18 (24), 2743– 2752. Medaglini, D.; Pozzi, G.; King, T. P.; Fischetti,V. A. Proc. Natl. Acad. Sci. USA 1995, 92 (15), 6868–6872. Medaglini, D.; Oggioni, M. R.; Pozzi, G. Am. J. Reprod. Immunol. 1998, 39 (3), 199–208. Geoffroy, M. C.; Guyard, C.; Quatannens, B.; Pavan, S.; Lange, M.; Merce-

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

nier, A. Appl. Environ. Microbiol. 2000, 66 (1), 383–391. Pozzi, G.; Oggioni, M. R.; Manganelli, R.; Medaglini, D.; Fischetti, V. A.; Fenoglio, D.; Valle, M. T.; Kunkl, A.; Manca, F. Vaccine 1994, 12 (12), 1071–1077. Mielcarek, N.; Alonso, S.; Locht, C. Adv. Drug Deliv. Rev. 2001, 51 (1–3), 55– 69. Noriega, F. R.; Losonsky, G.; Lauderbaugh, C.; Liao, F. M.; Wang, J. Y.; Levine, M. M. Infect. Immun. 1996, 64 (8), 3055–3061. Zhu,Y. D.; Fennelly, G.; Miller, C.; Tarara, R.; Saxe, I.; Bloom, B.; McChesney, M. J. Infect. Dis. 1997, 176 (6), 1445–1453. Leung, N. J.; Aldovini, A.; Young, R.; Jarvis, M. A.; Smith, J. M.; Meyer, D.; Anderson, D. E.; Carlos, M. P.; Gardner, M. B.; Torres, J. V. Virology 2000, 268 (1), 94–103. Jabbar, I. A.; Fernando, G. J.; Saunders, N.; Aldovini, A.; Young, R.; Malcolm, K.; Frazer, I. H. Vaccine 2000, 18 (22), 2444–2453. Kremer, L.; Dupre, L.; Riveau, G.; Capron, A.; Locht, C. Infect. Immun. 1998, 66 (12), 5669–5676. Matsumoto, S.; Yukitake, H.; Kanbara, H.; Yamada, T. Vaccine 1999, 18 (9–10), 832–834. Supply, P.; Sutton, P.; Coughlan, S. N.; Bilo, K.; Saman, E.; Trees, A. J.; Cesbron Delauw, M. F.; Locht, C. Vaccine 1999, 17 (7–8), 705–714. Mielcarek, N.; Riveau, G.; Remoue, F.; Antoine, R.; Capron, A.; Locht, C. Nat. Biotechnol. 1998, 16 (5), 454–457. Cusi, M. G.; Zurbriggen, R.; Correale, P.; Valassina, M.; Terrosi, C.; Pergola, L.; Valensin, P. E.; Gluck, R. Vaccine 2002, 20 (29–30), 3436–3442. Ulmer, J. B.; Donnelly, J. J.; Parker, S. E.; Rhodes, G. H.; Felgner, P. L.; Dwarki,V. J.; Gromkowski, S. H.; Deck, R. R.; DeWitt, C. M.; Friedman, A.; Science 1993, 259, 1745–1749. Sasaki, S.; Sumino, K.; Hamajima, K.; Fukushima, J.; Ishii, N.; Kawamoto, S.; Mohri, H.; Kensil, C. R.; Okuda, K. J. Virol. 1998, 72 (6), 4931– 4939.

Reference List 44. Baras, B.; Benoit, M. A.; Dupre, L.; Poulain-Godefroy, O.; Schacht, A. M.; Capron, A.; Gillard, J.; Riveau, G. Infect. Immun. 1999, 67 (5), 2643–2648. 45. Del Giudice, G.; Pizza, M.; Rappuoli, R. Mol. Aspects Med. 1998, 19 (1), 1– 70. 46. Pizza, M.; Domenighini, M.; Hol, W.; Giannelli,V.; Fontana, M. R.; Giuliani, M. M.; Magagnoli, C.; Peppoloni, S.; Manetti, R.; Rappuoli, R. Molecular Microbiology 1994, 14 (1), 51– 60. 47. Giuliani, M. M.; Del Giudice, G.; Giannelli,V.; Dougan, G.; Douce, G.; Rappuoli, R.; Pizza, M. J. Exp. Med. 1998, 187 (7), 1123–1132. 48. Partidos, C. D.; Vohra, P.; Steward, M. W. Immunology 1996, 87 (2), 179– 185. 49. Simmons, C. P.; Hussell, T.; Sparer, T.; Walzl, G.; Openshaw, P.; Dougan, G. J. Immunol. 2001, 166 (2), 1106–1113. 50. Lu, X.; Clements, J. D.; Katz, J. M. Vaccine 2002, 20 (7–8), 1019–1029. 51. Welter, J.; Taylor, J.; Tartaglia, J.; Paoletti, E.; Stephensen, C. B. Vaccine 1999, 17 (4), 308–318. 52. Arnon, A.; Levi, R. Int. Arch. Allergy Immunol. 1995, 108 (4), 321–326. 53. Olszewska,W.; Erume, J.; Ripley, J.; Steward, M. W.; Partidos, C. D. Arch. Virol. 2001, 146 (2), 293–302. 54. Muller, C. P.; Beauverger, P.; Schneider, F.; Jung, G.; Brons, N. H. J. Gen. Virol. 1995, 76 (6), 1371–1380. 55. Hathaway, L. J.; Obeid, O. E.; Steward, M. W. Vaccine 1998, 16 (2–3), 135–141. 56. Kweon, M. N.; Yamamoto, M.; Watanabe, F.; Tamura, S.; Van Ginkel, F. W.; Miyauchi, A.; Takagi, H.; Takeda,Y.; Hamabata, T.; Fujihashi, K.; McGhee, J. R.; Kiyono, H. J. Infect. Dis. 2002, 186 (9), 1261–1269. 57. Eriksson, K.; Holmgren, J. Current Opinion in Immunology 2002, 14 (5), 666–672. 58. Klinman, D. M.; Yi, A. K.; Beaucage, S. L.; Conover, J.; Krieg, A. M. Proc. Natl. Acad. Sci. USA 1996, 93 (7), 2879– 2883. 59. Olszewska,W.; Partidos, C. D.;

60.

61.

62. 63.

64.

65.

66. 67. 68. 69.

70.

71.

72.

73.

74.

75.

Steward, M. W. Infect. Immun. 2000, 68 (9), 4923–4929. Lipford, G. B.; Bauer, M.; Blank, C.; Reiter, R.; Wagner, H.; Heeg, K. Eur. J. Immunol. 1997, 27 (9), 2340–2344. Davis, H. L.; Weeratna, R.; Waldschmidt, T. J.; Tygrett, L.; Schorr, J.; Krieg, A. M.; Weeranta, R. J. Immunol. 1998, 160 (2), 870–876. Lee, S. W.; Sung,Y. C. Immunology 1998, 94 (3), 285–289. Kovarik, J.; Bozzotti, P.; Love-Homan, L.; Pihlgren, M.; Davis, H. L.; Lambert, P. H.; Krieg, A. M.; Siegrist, C. A. J. Immunol. 1999, 162 (3), 1611–1617. Brazolot Millan, C. L.; Weeratna, R.; Krieg, A. M.; Siegrist, C. A.; Davis, H. L. Proc. Natl. Acad. Sci. USA 1998, 95 (26), 15553–15558. Moldoveanu, Z.; Love-Homan, L.; Huang, W. Q.; Krieg, A. M. Vaccine 1998, 16 (11–12), 1216–1224. McCluskie, M. J.; Davis, H. L. J. Immunol. 1998, 161 (9), 4463–4466. Broide, D.; Raz, E. Int. Arch. Allergy Immunol. 1999, 118 (2–4), 453–456. McCluskie, M. J.; Davis, H. L. Crit. Rev. Immunol. 1999, 19 (4), 303–329. Staats, H. F.; Bradney, C. P.; Gwinn, W. M.; Jackson, S. S.; Sempowski, G. D.; Liao, H. X.; Letvin, N. L.; Haynes, B. F. J. Immunol. 2001, 167 (9), 5386–5394. Steidler, L.; Robinson, K.; Chamberlain, L.; Schofield, K. M.; Remaut, E.; Le Page, R. W.; Wells, J. M. Infect. Immun. 1998, 66 (7), 3183–3189. Lillard, J. W., Jr.; Boyaka, P. N.; Taub, D. D.; McGhee, J. R. J. Immunol. 2001, 166 (1), 162–169. Eo, S. K.; Lee, S.; Kumaraguru, U.; Rouse, B. T. Vaccine 2001, 19 (32), 4685–4693. Nagai, T.; Suzuki,Y.; Kiyohara, H.; Susa, E.; Kato, T.; Nagamine, T.; Hagiwara,Y.; Tamura, S.; Yabe, T.; Aizawa, C.; Yamada, H. Vaccine 2001, 19 (32), 4824–4834. Morein, B.; Sundquist, B.; Hoglund, S.; Dalsgaard, K.; Osterhaus, A. Nature (London) 1984, 308 (5958), 457–460. Ennis, F. A.; Cruz, J.; Jameson, J.;

361

362

16 Mucosal Vaccination

76.

77.

78.

79.

80. 81. 82.

83. 84. 85.

86.

87.

88.

89.

Klein, M.; Burt, D.; Thipphawong, J. Virology 1999, 259 (2), 256–261. Rimmelzwaan, G. F.; Nieuwkoop, N.; Brandenburg, A.; Sutter, G.; Beyer, W. E.; Maher, D.; Bates, J.; Osterhaus, A. D. Vaccine 2000, 19 (9–10), 1180–1187. Coulter, A.; Harris, R.; Davis, R.; Drane, D.; Cox, J.; Ryan, D.; Sutton, P.; Rockman, S.; Pearse, M. Vaccine 2003, 21 (9–10), 946–949. Minutello, M.; Senatore, F.; Cecchinelli, G.; Bianchi, M.; Andreani, T.; Podda, A.; Crovari, P. Vaccine 1999, 17 (2), 99–104. Barchfeld, G. L.; Hessler, A. L.; Chen, M.; Pizza, M.; Rappuoli, R.; Van Nest, G. A. Vaccine 1999, 17 (7–8), 695–704. Almeida, A. J.; Alpar, H. O. J. Drug Target 1996, 3 (6), 455–467. Walsh, E. E. Vaccine 1993, 11 (11), 1135–1138. Oien, N. L.; Brideau, R. J.; Walsh, E. E.; Wathen, M. W. Vaccine 1994, 12 (8), 731–735. Walsh, E. E. J. Infect. Dis. 1994, 170 (2), 345–350. Bastien, N.; Trudel, M.; Simard, C. Vaccine 1999, 17 (7–8), 832–836. Tebbey, P. W.; Scheuer, C. A.; Peek, J. A.; Zhu, D.; LaPierre, N. A.; Green, B. A.; Phillips, E. D.; Ibraghimov, A. R.; Eldridge, J. H.; Hancock, G. E. Vaccine 2000, 18 (24), 2723–2734. Belshe, R. B.; Gruber, W. C. Pediatr. Infect. Dis. J. 2000, 19 (5 Suppl), S66– S71. Belshe, R. B.; Gruber, W. C.; Mendelman, P. M.; Mehta, H. B.; Mahmood, K.; Reisinger, K.; Treanor, J.; Zangwill, K.; Hayden, F. G.; Bernstein, D. I.; Kotloff, K.; King, J.; Piedra, P. A.; Block, S. L.; Yan, L.; Wolff, M. J. Infect. Dis. 2000, 181 (3), 1133–1137. Belshe, R. B.; Mendelman, P. M.; Treanor, J.; King, J.; Gruber, W. C.; Piedra, P.; Bernstein, D. I.; Hayden, F. G.; Kotloff, K.; Zangwill, K.; Iacuzio, D.; Wolff, M. N. Engl. J. Med. 1998, 338 (20), 1405–1412. Glueck, R. Vaccine 2001, 20 Suppl, S42–S44.

90. Muszkat, M.; Greenbaum, E.; Ben Yehuda, A.; Oster, M.; Yeu'l, E.; Heimann, S.; Levy, R.; Friedman, G.; Zakay-Rones, Z. Vaccine 2003, 21 (11–12), 1180–1186. 91. Boyce, T. G.; Hsu, H. H.; Sannella, E. C.; Coleman-Dockery, S. D.; Baylis, E.; Zhu,Y.; Barchfeld, G.; DiFrancesco, A.; Paranandi, M.; Culley, B.; Neuzil, K. M.; Wright, P. F. Vaccine 2000, 19 (2–3), 217–226. 92. Boyce, T. G.; Poland, G. A. Biomed. Pharmacother. 2000, 54 (4), 210–218. 93. Ben Yedidia, T.; Beignon, A. S.; Partidos, C. D.; Muller, S.; Arnon, R. Mol. Immunol. 2002, 39 (5–6), 323–331. 94. Sabin, A. B.; Flores, A. A.; Fernandez, D. C.; Albrecht, P.; Sever, J. L.; Shekarchi, I. JAMA 1984, 251 (18), 2363–2371. 95. Sabin, A. B.; Flores, A. A.; Fernandez, D. C.; Sever, J. L.; Madden, D. L.; Shekarchi, I.; Albrecht, P. JAMA 1983, 249 (19), 2651–2662. 96. Beck, M.; Smerdel, S.; Dedic, I.; Delimar, N.; Rajninger-Miholic, M.; Juzbasic, M.; Manhalter, T.; Vlatkovic, R.; Borcic, B.; Mihajic, Z. Dev. Biol. Stand. 1986, 65, 95–100. 97. Simasathien, S.; Migasena, S.; Bellini, W.; Samakoses, R.; Pitisuttitham, P.; Bupodom,W.; Heath, J.; Anderson, L.; Bennett, J. Vaccine 1997, 15 (3), 329–334. 98. Peter, G.; Myers, M. G. Pediatrics 2002, 110 (6), e67. 99. Chang, E. J.; Zangwill, K. M.; Lee, H.; Ward, J. I. Pediatr. Infect. Dis. J 2002, 21 (2), 97–102. 100. Simonsen, L.; Morens, D.; Elixhauser, A.; Gerber, M.; Van Raden, M.; Blackwelder, W. Lancet 2001, 358 (9289), 1224–1229. 101. Hochwald, C.; Kivela, L. Pediatr. Nurs. 1999, 25 (2), 203–204. 102. Staats, H. F.; Ennis, F. A., Jr. J. Immunol. 1999, 162 (10), 6141–6147. 103. Lu, H.; Xing, Z.; Brunham, R. C. J. Immunol. 2002, 169 (11), 6324–6331. 104. Kato, H.; Bukawa, H.; Hagiwara, E.; Xin, K. Q.; Hamajima, K.; Kawamoto, S.; Sugiyama, M.; Sugiyama, M.; Noda, E.; Nishizaki, M.; Okuda, K. Vaccine 2000, 18 (13), 1151–1160.

Reference List 105. Wierzbicki, A.; Kiszka, I.; Kaneko, H.; Kmieciak, D.; Wasik, T. J.; Gzyl, J.; Kaneko,Y.; Kozbor, D. Vaccine 2002, 20 (9–10), 1295–1307. 106. Abraham, E.; Shah, S. J. Immunol. 1992, 149 (11), 3719–3726. 107. Marinaro, M.; Boyaka, P. N.; Finkelman, F. D.; Kiyono, H.; Jackson, R. J.;

Jirillo, E.; McGhee, J. R. J. Exp. Med. 1997, 185 (3), 415–427. 108. Bradney, C. P.; Sempowski, G. D.; Liao, H. X.; Haynes, B. F.; Staats, H. F. J. Virol. 2002, 76 (2), 517–524. 109. Chun, S.; Daheshia, M.; Lee, S.; Eo, S. K.; Rouse, B. T. J. Immunol. 1999, 163 (5), 2393–2402.

363

365

17 Passive Vaccination and Antidotes: A Novel Strategy for Generation of Wide-spectrum Protective Antibodies Antonio Cassone and Luciano Polonelli

17.1 Introduction and Definitions

A broad and inclusive definition states that passive vaccination is the direct therapeutic or preventative use of those specific immunologic tools, expressing humoral or cellular reactivity, that are generated by natural infection, exposure to immunizing self- and non-self antigens, or active vaccination. In a more restrictive and specific sense, passive vaccination is nearly identical to immunotherapy, i. e., the use of antibodies or antibody fragments as therapeutic weapons, whereas the use of immune cells themselves should be called adoptive vaccination. Cytokine, cytokine receptors, and anti-cytokine therapy does not qualify as passive vaccination because of its nonspecificity. On the other hand, antibodies and their fragments, by virtue of their exclusive specificity, bioavailability, and mode of action, are suitable weapons to use as antidotes as a relief from acute intoxication with venoms or drugs. In the latter context, the term immunotoxicotherapy is now used. Historically, and importantly, therapy of infection and intoxication with immune sera, i. e., the most recognized vehicle for antibodies, preceded the use of both vaccines and antibiotics, since specific antisera for treatment and prevention of epidemic diseases were in use soon after, and sometimes before, the discovery of the causative infectious agents. In addition, Calmette reported as early as 1908 that animals can be detoxified from venoms with the serum of other animals that had been immunized with a venom [1]. Table 1 summarizes the main infections that were successfully treated with immune sera before the advent of antibiotics and, to some extent, of vaccines. We can immediately see that, although for some of them, e. g., meningitis and bacteremias due to Hemophilus influenzae and toxin-mediated diseases such as tetanus and diphtheria, vaccines have substantially eliminated the problem or kept it under control, for many others (for instance, septic infections by Streptococcus, anthrax, and tularemia) there is presently no preventive measure to protect the population. The use of immune sera was indeed highly effective in patients but the major, at that time unsolvable, obstacle was the need to obtain large quantities of serum from animals, and the associated development of various hypersensitivity reactions, some

366

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies Tab. 17.1 Passive vaccination and current relevance to immunity and disease control. Disease

Agent

Public health relevance

Meningitis

Neisseria meningitidis Hemophilus influenzae Streptococcus pneumoniae

Largely under control in developed countries, but gaps remain for serotype B meningococcus and less prevalent but numerous pneumococcal serotypes. Serious problems of antibiotic resistance in many countries.

Pertussis

Bordetella pertussis

Cellular and acellular pertussis vaccines safe and effective, serious problems of disease control in developing countries.

Pneumonia

Streptococcus pneumoniae Viral agents

Protection by pneumococcal vaccines largely undefined, probably low. No vaccines against viruses. Serious problems with resistance of S. pneumoniae to penicillin and macrolides.

Measles and mumps

Specific viral agents belonging to Paramyxovirus

The diseases can be controlled by vaccines but their implementation meets obstacles, mostly in developing countries.

Poliomyelitis

Poliovirus

Nearly eliminated.

Botulism, anthrax, tularaemia, plague

Bioterrorism class-A pathogens

No safe vaccines, perceived increasing risk of attack with one or more of these agents.

of them lethal, due to reactions of serum recipients to foreign proteins (collectively called ‘serum sickness’ – and disregarding the then unrecognized risk of transmitting other disease agents via human or animal serum!). As special, additional merits of passive vaccination, we should mention that the successful use of antibodies in immune sera has often suggested what the antigens may be useful for active vaccination, as with the anti-toxin vaccines. Moreover, the practice of preventing or curing diseases by administration of antibodies, although much restricted now, has remained viable and useful, as exemplified by the use in humans of anti-tetanus, antihepatitis, and anti-rabies immunoglobulins, several other immune sera in the veterinary field, as well as anti-venom antidotes (see also below). Besides infection, the use of antibodies in their various formats, has so widely expanded as to be currently under investigation for such diseases as asthma, cancers, and autoimmune disorders, with variable degrees of success [2]. The practice of immunotoxicotherapy has also expanded to include particularly valuable therapeutic tools against intoxication by potent cardiac (digoxin) or anti-gout (colchicine) drugs making use of Fab and Fab’ molecules, and there are valid prospects for antibody therapy against the deadly consequences of drug addiction [2, 3]. In numerous animal models, proof of principle that antibodies against addictive drugs may hinder access of the drug to the brain, thus inhibiting or relieving the devastating consequences of drug dependence, has been achieved. Such studies also gave impetus to the generation of therapeutic anti-nicotine and anti-cocaine vaccines

17.2 Emergence of New Agents of Disease

which are now in clinical trials, one of which has shown initial satisfactory results with respect to immunogenicity and safety [4–9]. Of particular interest are the anticocaine catalytic antibodies, which are designed not only to sequester or redistribute the drug so as to prevent its fixation to the cocaine receptors (as in most antidote antibodies) but also to degrade the drug to non-toxic products [10]. For the above reasons, the use of therapeutic and antidote antibodies is undergoing vigorous reappraisal, and many investigators now apply to competent authorities for grants in this area. Importantly, we are not dealing solely with sera or immunoglobulins, but rather with monoclonal antibodies, mono- or bispecific Fabs, and products derived from them by genetic engineering (recombinant single-chain variable-fragment antibody domains), and also with the administration of humanized and human antibodies. These antibodies are obtained by cloning human immunoglobulin genes by using a variety of highly efficient expression systems, such as filamentous phage display libraries and genetically-modified plants and animals. In this chapter, however, we restrict ourselves to briefly discussing anti-infectious applications of passive vaccination, particularly to presenting our novel approach with killer antibodies. At places, brief mention will be made of some outstanding progress in the area of immunotoxicotherapy. Readers who are more specifically interested in the latter field or in other areas of antibody therapy, particularly in oncology, may consult several excellent, recently published reviews [3, 10–12].

17.2 Emergence of New Agents of Disease

Infections by microbial pathogens remain a major threat to public health. In the past 30 years, about 40 new agents of disease have emerged, starting with Legionella and leading to, most recently, a new Coronavirus causing the current worldwide epidemics of severe acute respiratory infection (SARS). In between appeared the new deadly non-A, non-B hepatitis, hemorrhagic fevers, and AIDS viral agents. Moreover, well known infectious scourges caused by such agents as Mycobacterium tuberculosis and malaria plasmodia, remain out control in developing countries, and there are serious concerns that globalization of trading, immigration, and leisure trips could reintroduce high prevalence of these diseases into countries that had achieved substantial control of them. Finally, the threat is more vividly appreciated because of the increasingly disturbing phenomenon of antibiotic resistance, the paucity of novel antibiotics and chemotherapeutics, the widening spectrum of opportunistic infections in immuno-compromised persons (often affected by chemotherapy-resistant infectious agents), and the aging of populations in developed countries. In the face of this emergence, very few specific alternative countermeasures exist. In particular, only a dozen vaccines are currently in use and implemented worldwide to combat infectious diseases, despite the well known, highly successful stories of variola and polio eradication or quasi-elimination. Intense efforts are being made to fill this gap, but real difficulties inhibit the development of a satisfactory vaccine against highly variable and genetically flexible viruses and protozoa (for instance HIV, hepatitis C,

367

368

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

and malaria) or for those bacterial agents the defense against which predominantly relies on cellular rather than humoral immunity (for instance, tuberculosis). Generation of vaccines against these diseases is being intensely pursued, but the results are often frustrating, and there is no certainty of a happy outcome. Finally, vaccine generation has become a long and costly enterprise, and the concept of the cost-effectiveness of vaccination, so appealing to public health authorities, probably needs to be revised [13]. Overall, the need of adding alternative or integrative weapons to the arsenal of antibiotics and vaccines is widely recognized to be extremely urgent. In this perspective, the often neglected area of passive vaccination, i. e., the use of antibodies to cure or prevent an infectious disease, has attracted novel impetus and fascination.

17.3 Passive Vaccination and Antidotes : Advantages and Disadvantages

Whatever the natural or technological product employed for passive vaccination, as for all preventive or therapeutic interventions, advantages and disadvantages are associated with the use of antibodies or their fragments as anti-infectious or simply antidotal tools. This is exemplified in Table 2, pointing out an implicit comparison with anti-microbial drugs and vaccines, and Table 3 summarizes some basic prerequisites for successful use of antibodies as antidotes.

Tab. 17.2 Passive vaccination : pros and cons. Pros

Cons

Immediate, highly specific protection lasting for weeks.

No persistent immunity lasting years or lifelong as with active vaccination or natural infection. Short half lives of most antibodyengineered derivatives.

Universal protection regardless of the state of cellular/humoral effector of acquired immunity, thus its favored use in immunocompromized persons.

Mostly for current technological products, passive vaccination is expensive compared to use of drugs and vaccines.

Human or humanized antibodies and their active In contrast to most drugs and vaccines, pasfragments are natural, nontoxic products compared sive vaccination with hyperimmune sera ofto chemotherapeutics and, to some extent, vaccines. ten requires intravenous infusion. Can be used against toxins and antibioticresistant germs.

The most advanced biotechnologically-derived antibodies and antidotes target a single epitope: many pathogens can escape a singleepitope weapon. Costly cocktails are needed.

Biotechnology now allows the selection of practically any kind of antibody or fragment having a defined specificity.

As for vaccines, and in contrast to chemotherapy, exact knowledge of defense mechanisms is needed before attempting its use. Antibodies can enhance rather than control infections.

17.3 Passive Vaccination and Antidotes: Advantages and Disadvantages Tab. 17.3 Prerequisites for effective use of antibodies as antidotes. On the toxin side

On the antibody site

Immunogenic alone or when suitably conjugated with a carrier.

Selection of the appropriate antibody or antibody fragment not only in terms of antigen binding.

Kinetics of host distribution in parallel with know antibody time and sites of distribution.

The highest possible affinity and avidity for the antigen target (the apparent efficacy limit is >109).

Toxicity neutralizable, at least in part, by the achiev- Ease of generation of Fab or other suitable able amount of antibodies that can be perfused in fragment. the host. Reversibility of the toxic effect.

Stability of the immune complex.

Modified from [3].

Among the advantages of anti-infectious antibodies, the capacity of conferring immediate protection against a wide spectrum of infections, including those that usually affect or aggravate immunodepressed persons, is a major one. This usually requires knowledge of the fine specificity of the offending antigenic repertoire expressing microbial virulence, associated with determination of the fine specificity of the corresponding antibodies. It is not necessary, however, that only agents that are controlled by humoral immunity be the targets, because antibodies may well be active against agents that, in their natural history of infection, apparently do not elicit a protective humoral immunity. Microbial structures, such as some cell wall polysaccharide antigens critical for cell viability or virulence, are poor immunogens but can be highly reactive with preformed antibodies, and these antibodies may be protective, sometimes in collaboration with cellular mechanisms. Overall, passive vaccination, if suitably implemented with effective antibodies, can play a major role not only in individual therapy but also in epidemics; thus there is an urgent need to redefine the place of passive vaccination in the control of infectious diseases at large [14]. On the other hand, the advantages of immunotoxicotherapy are immediately evident, because antibodies – with their high affinity and highly selective specificity for the antigenic epitope, drug, or drug hapten – are certainly among the most powerful detoxification tools available. As usual with antibodies, however, they cannot repair damage to or within cellular structures already caused by the venom or the drug; thus they must be employed, in appropriate therapeutic dosage, at very early stages of intoxication. In addition, there are several limitations in the use of Fab complexed with high molecular weight microbial toxins, due the lack of glomerular filtration and instability of the antigen–antibody complex, possibly leading to late release of active toxin or toxic fragments. Clinical syndromes attributed to this phenomenon have been described [3]. Overall, advances in methods and approaches to immunotoxicotherapy are important research priorities, which include or touch the field of infectious diseases, but mainly have remarkable applications in other public health fields.

369

370

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

17.4 Passive Vaccination : Implementation and Obstacles

Despite the recognition that antibody therapy has not only a strong rationale and a strong historical background, but has also gained, from past and recent technological advances, a new state of expanded prospective applicability, very few infectious diseases are currently being treated with antibodies or antibody-based products. Very few options for preventative use of antibodies have been codified as well, in sharp contrast with the wealth of experimental novelties in antibody technology and the extreme variety of possible infectious targets. Indeed, antibodies are being studied experimentally, and a degree of efficacy has been demonstrated in novel applications for such various conditions as prion diseases [14] and parvovirus B19-associated chronic fatigue syndrome [15], to mention only a couple of applications. Bioterrorism class-A pathogens are also currently being addressed as targets of antibody therapy, also in view of the lack of effective vaccines for most of them and the threat that they could be made more aggressive and less curable by intentional insertions of antibiotic-resistance genes. An excellent perspective of the potential of passive vaccination against biological weapons has recently been published [17]. Experimentally, only a few infectious diseases did not respond to well-conducted antibody therapy, even when basic research did not support a role for antibodies in control of the disease. Sometimes, indeed, an intact cell-mediated immunity is needed for the efficacy of antibody treatment. Intramuscular injections of standard or hyperimmune human immunoglobulin preparations are currently used for both pre- and post-exposure prophylaxis of hepatitis A, hepatitis B, measles, varicella, tetanus, and rabies. They are prepared from pooled plasma of normal human donors or from immunized adults. Commercial preparations differ in isotype Ig prevalence and composition, with a possibility of adverse reactions due to allotype recognition. Other preparations for intravenous infusion require extensive purification, mostly to avoid aggregation yet retain full molecular integrity and target affinity. These preparations have shown a variable degree of efficacy for the prevention of septic bacteremias and cytomegalovirus infections in immunosuppressed patients, particularly those who are splenectomized or functionally asplenic and those undergoing organ transplant and immunosuppressive therapy. Clearly, the major disadvantages of the above preparations, and of immunoglobulin therapy as a whole, is their limited specificity and greatly limited supply, because of complete dependence on donor immunization and availability. Risks of transmitting unrecognized infectious agents are also always present, thus making it mandatory that treatment procedures and severe quality controls be in place, consequently also increasing the costs to unacceptable levels for routine medical practice. Monoclonal antibodies and genetically engineered antibody products and derivatives have the strong advantages of not only their fine, predetermined epitope specificity and possibility to be enriched to the high concentrations needed for specific therapy purposes, but also for their potentially unlimited supply and absolute safety. These strong points are, however, accompanied by several weaknesses, which include inferior stability and half-life in serum, and limited efficacy, since pathogenic

17.5 A Novel Strategy for Passive Vaccination: Concept and Relevance of Killer Antibodies

microorganisms and their toxic products rarely act through simple, unique epitopes. Pathogens are also prone to exhibit epitope variation in the presence of the selective therapeutic pressure. On the other hand, the use of antibody cocktails may be excessively expensive for routine practice. All these constrains explain why, despite intensive efforts, very few monoclonal or ScFv products are in use, although certainly many are in the pipeline, for anti-infectious therapy. To our knowledge, no more than a dozen monoclonal antibodies are currently licensed for human use, and no single-chain variable fragment or other antibody-engineered derivative is being employed as a specific anti-infectious tool or antidote.

17.5 A Novel Strategy for Passive Vaccination : Concept and Relevance of Killer Antibodies

As stated above, a major advantage of passive vaccination resides in the possibility of conferring a degree of prompt protection even to patients with defective immune responses, who are not the best candidates either for active vaccination or for chemotherapy. Antibodies that neutralize toxins or inhibit critically adhesive or tissueinvasive factors may work by themselves, as exemplified not only by all past applications (see above) but also by numerous recent reports encompassing a large number of widely diversified prospective applications (reviewed in 18). However, most other antibodies usually require some degree of immune competence in the host, either by the normal functioning of complement and phagocytic activity or by cell-mediated immunity. An important achievement in this area would be the generation of directly microbicidal antibodies, capable of inhibiting the functions of microbial molecules that are critical for survival. A further advantage would be conferred on this approach by a wide distribution of the antibody target among pathogens. This objective has usually been pursued, mostly in the field of oncology, by coupling toxins or radiotoxic compounds to antibodies working as targeting carriers [19]. Few attempts have been made to generate immune reagents that are by themselves endowed with killer potential, and we are not aware, in particular, of any attempt to use natural ecological phenomena involving many different microorganisms and critical, widespread microbial targets for this purpose. In the remainder of this chapter, we present our original strategy to produce antibodies and antibody-derived fragments and peptides for passive vaccination. By merging an ecologically widespread phenomenon such as killer toxins [20] with exploitation of the antibody idiotypic network [21], this approach matches microbial ecology to immunology. Since the main, though not at all exclusive, evidence for the validity of this approach in experimental models, and its potential for clinical application, has been provided with fungi and fungal infections, here we describe some aspects of these infections and their public health relevance. Fungal infections, although somewhat neglected in the past by microbiologists and immunologists as well, have recently gained remarkable relevance as models for both cell-mediated and antibodymediated immunity.

371

372

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

17.6 Fungi and Fungal Infections

Pathogenic fungi have gained increasing medical importance. Most are opportunistic, in that they cause disease in immunocompromized, or otherwise modified, hosts. In particular, interest in Pneumocystis carinii and Cryptococcus neoformans has grown tremendously since their recognition as leading causes of morbidity and mortality in AIDS. Furthermore, the incidence of disease caused by well known members of the genus Candida is not only frequent in their mucosal presentation (particularly vaginal and oral) but also has increased in other clinical settings to achieve, together with infections by Aspergillus spp, the record of being a primary cause of hospital-acquired systemic infections in immunocompromized patients [22]. Overall, the therapy of fungal infections is an area in need of substantial progress, due to the relative paucity and toxicity of current antifungal drugs, the increased resistance of fungi to some of the best-tolerated compounds such as the triazoles, and the absence of specific preventative measures such as vaccines [23]. Fungal opportunism is also of special interest to immunologists, particularly those interested in passive vaccination [24]. Many virulent pathogens express clear-cut aggressive factors, such as a potent toxin, a strongly antiphagocytic capsule, or even the ability to enter and multiply within phagocytic cells. The host attempts to mount an equally powerful immune response, specifically directed at neutralizing the function of the aggressive factor(s) and, possibly, eliminating the pathogen. However, the interaction of opportunistic fungal pathogens with the host is much more subtle, particularly if there is a clear commensalism (as for Candida) or repeated exposure, as for Cryptococcus and Aspergillus. Low-penetrance virulence factors produced by the microbe are kept under control by a network of natural and adaptive immune responses whose main function appears to be that of acting as ‘sentinels’ that keep the pathogen under surveillance and restrict its presence (in low numbers) at permissive body sites rather than attempting to eradicate it. This implies a persistent expression by the fungus of a variety of antigens and immunomodulating factors and, consequently, an expanded repertoire of fungus-directed host responses. The mere concept of a ‘protective response’ may be rather elusive, because the host is more likely to mobilize several possibly interchangeable or cooperating arms rather than a single, strong weapon. Despite this complexity, and somewhat surprisingly, therapy of fungal infection with passive vaccination has gained a primary place in the field, with seminal work having been done by several pioneers [17, 25]. Although strong clinical and experimental arguments point to cell-mediated immunity (CMI) as a core factor in antifungal protection [26], this does not rule out the therapeutic or even the preventive efficacy of passive vaccination, since strong links exist between CMI response and help for a functional Ab response, particularly for the induction and regulation of isotype switching, affecting the curative efficiency of administered antibodies. Moreover, various antibodies have been generated that are evidently protective in the same animal models in which CMI is elicited and advocated to be protective [28–33]. In addition, it is unlikely that for such kinds of opportunistic infections, active vaccination may clear the field, in view of the inability of

17.7 A Novel Approach to Passive Vaccination

profoundly immunodepressed persons, i. e., those in greatest need of antifungal medicines, to mount vaccine-driven responses. In conclusion, CMI and antibody responses are not necessarily mutually exclusive events, as the prevalent literature on fungal infections would appear to suggest. Rather, they may collaborate, and also interact with natural immunity, in defense against mycoses. In this context, the use of passive vaccination finds novel and promising routes.

17.7 A Novel Approach to Passive Vaccination through the Merging of Killer Phenomenon and Idiotypic Network 17.7.1 The Killer Phenomenon

Nature has selected sophisticated yet clear-cut biological mechanisms for the regulation of population dynamics in various microbial ecosystems. One of these mechanisms is the production, by several fungal species, of toxins that kill other taxonomically related or unrelated organisms. This is particularly widespread in yeasts, and the toxins they produce are called ‘yeast-killer toxins’ (YKT). The killer toxins generally exert their activity by binding to a killer toxin receptor (KTR) on the cell surface of a susceptible cell, thus inhibiting one or more essential steps in cell wall synthesis or plasma membrane function. A detailed review of the various aspects associated with action, resistance, and immunity to YKT has been published by Magliani and collaborators [34]. The killer system that has most attracted our interest is the one produced by Pichia anomala. One main reason for interest resides in the extremely wide spectrum of microorganisms that are susceptible to the toxins produced by this species, including many different fungi and bacteria. Examples include the dimorphic opportunistic yeast C. albicans among fungi and M. tuberculosis among prokaryotes [35]. A killer toxin identical or very similar to that produced by P. anomala has been purified from a strain of Williopsis saturnus var mrakii and partially characterized. It is a 85-kD glycoprotein and displays optimal activity under acidic conditions (pH 4.6) and at a temperature of 26–28 °C. It induces rapid cell wall permeation of susceptible microbial cells after binding to a beta-glucan cell wall receptor. In addition, Guyard et al. demonstrated that the killer toxin not only binds to but also hydrolyses the glucan receptor, acting as a canonical beta-glycosidase [36, 37]. This finding constitutes strong evidence that killer toxins may indeed target essential and viability-critical host molecules, which are very widespread in the microbial world. For instance, glucan molecules were recently characterized as important cell-surface molecules of M. tuberculosis [38]. From an evolutionary point of view, the possession of sophisticated, wide-spectrum microbecidal toxins clearly confers a strong competitive advantage. On the other hand, the unaltered maintenance during evolution of the toxin-susceptible phenotype in so many well-adapted and successful microorganisms seems rather

373

374

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies Tab. 17.4 Properties of yeast killer toxin (YKT)-like antibodies and anti-idiotypi c antibodies (IdAbs) relevant to their use as immunotherapeutic agents.

. .. . . .. .

Naturally induced by commensalism, colonization, and repeated exposure to (or infection by) the fungus or other infectious agent expressing YKTR. Found in blood and mucosal secretions, with high specificity and appropriate isotype. Fungicidal by mirroring, as functional internal images, the powerful killing activity of killer toxins. Protective in in-vivo and ex-vivo models of Candida, Pneumocystis, and Aspergillus infections, both under prophylactic and therapeutic regimens. Have an expanded spectrum of action due to cross reaction with surface determinants of different microbial pathogens bearing a common (cross-reactive) transphyletic receptor. The receptor may be critical for survival. Easily induced by idiotypic vaccination with an antibody against a YKT, reasonably expected to be induced by a vaccine based on the common transphyletic YKTR. Can be appropriately engineered by molecular immunology techniques to obtain biologically active derivatives (e. g., human recombinant Fab, single-chain FV active CDR peptides).

Adapted from [24].

surprising. Evidently, the receptorial machinery of the susceptible phenotype could not be altered without critical loss of microbial fitness and survival capacity. Microbial glucans meet this requirement because they are critical for cell wall construction, and thus survival, in fungi and highly relevant for adaptation to host environments in other pathogenic microorganisms. In the past, before knowing their biochemical characteristics, YKT were seriously considered for therapy of infection in various models, but they were obviously unsuccessful. In fact, fungi have evolved this system for competition in soils not in a host milieu. The toxins and their fragments are very unstable at physiological pH and temperature, and of course are rapidly neutralized by antibodies. Interestingly, a killer toxin secreted by Hansenula anomala (now known as Pichia anomala) was considered responsible for the severe intestinal injury occasionally caused by this yeast [39]. 17.7.2 Antibodies and the Idiotypic Network

It is well known that gene recombination and junctional diversity are responsible for the natural library of gene segments, the genomic rearrangement of which encodes the variable regions of light (VL) and heavy (VH) chains of any secreted antibody [40, 41]. During the recombination process, some imprecision may occur in the junctions between recombining variable gene segments, increasing the variability of the system. Additional immunoglobulin variance is due to the rate of mutation of V genes, which is the highest of any known gene. V gene somatic mutation in B cells, proliferating in the course of an antigen-driven response, leads to the emergence of high-affinity antibody variants perfectly tailored to the immunogen [43]. Overall, the antibodies encoded by these rearranged genes have such a degree of diversity as to recognize with sufficient affinity almost all potential antigens [42].

17.7 A Novel Approach to Passive Vaccination

The polypeptides produced by the VH and VL gene fragments in each B-cell clone, the heavy- and the light-chain variable regions, fold over each other so as to create a unique three-dimensional (3D) structure for the antigen-binding site. This site is essentially composed of six polypeptide loops, three belonging to the VL region and three to the VH region. The antibody moiety of the VL and VH regions involved in antigen binding has been called the complementarity-determining region (CDR) [44], and from what is said above, each antibody has 3 CDR for both chains. Further refined studies have shown that not all amino acids within every CDR are actually involved in binding. For instance, the CDR1 of the VL domain is composed of residues 24–34 but it is likely that only the inner part of this CDR segment, i. e., amino acids 26–32, actually form the loop protruding from the b-sheet framework and fitting the antigenic epitope [45]. The variations in the antibody molecules confer typical antigenic properties on them. In fact, each antibody molecule carries a set of multiple antigenic determinants called idiotopes, collectively defining its private idiotype (Id). In the course of an immune response, these determinants may induce the production of anti-variable region antibodies (anti-idiotypic antibodies or anti-idiotypes, IdAb). There are approximately 20 idiotopes in the V region of a single immunoglobulin molecule, which can be distinguished by the use of corresponding monoclonal anti-idiotopes. Thus, the variable region of any antibody can be characterized phenotypically by its serologic signature (idiotype) or genotypically by its antigen-binding property (CDR). The two distinctive properties are not mutually exclusive, since an Id may occur anywhere within the combining site or in the variable region of an antibody [46]. By recognizing the dual character of the antibody molecule (i. e., it is also an antigen for the producing host), the theory of the idiotypic network assumes that the interaction of idiotypes and anti-idiotypes is intimately involved in regulation of the immune system [21]. According to the enormous number of potentially different variable regions, any Id should be matched by a complementary 3D surface of another antibody variable region (IdAb). The idiotypic network theory has profound implications. An idiotype produced in the course of an immune response against a particular antigen can stimulate the production of a complementary anti-idiotype (autoanti-idiotype), a fact that has been repeatedly demonstrated [47–49]. An important implication of the Id network theory in the context of passive vaccination is that, among the 3D shapes of millions of different variable regions, the combining site of IdAb, being complementary to that of the antigen-complementary Id, may acquire the spatial conformation of structurally unrelated immunogenic determinants [50]. Among the variety of IdAb, some of them are likely to be the internal image of the external antigen and, in some circumstances, may mimic its biological activity [49]. 17.7.3 Yeast Killer Toxin Anti-idiotypes

A consequent implication of the network theory is that some IdAb, being the positive topochemical copies of the related antigens, may be expected to mimic not

375

376

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

only their steric structure but also, in a positive fashion, their biological function. It was therefore postulated that immunization with a high-affinity anti-YKT neutralizing monoclonal antibody would induce, among the variety of IdAb, some that could mimic YKT activity, as depicted in Figure 17.1. For the reasons mentioned above, a monoclonal antibody (mAb KT4) neutralizing the killer toxin from P. anomala (hereafter referred to as Pa-KT) was selected for this approach, and the exquisitely toxin-susceptible C. albicans used as the IdAb-target microorganism. MAb KT4 affinity chromatography-purified IdAb were investigated for their in vitro killing activity against C. albicans cells susceptible to yeast killer toxin. We conclusively showed that PaKT-like IdAb were indeed generated in different animal models and were able to efficiently kill C. albicans cells, working as true functional PaKT internal images. In fact, these IdAb competed with cold PaKT for binding to fungal cells, and their candidacidal activity in vitro, exactly like that by PaKT, was neutralized by mAb KT4. Importantly, the antibodies were highly protective in murine models of systemic and mucosal candidiasis [51–53]. In the latter model, rats were passively vaccinated by PaKT-like IdAb as well as by natural antibodies (KTAb) purified by affinity chromatography with mAbKT4 from the vaginal fluids of women with candidiasis [53] (see below). Interestingly, but in line with PaKT’s antimicrobial spectrum of activity, IdAb and natural PaKT-like natural antibodies exerted a strong growth-inhibitory effect against M. tuberculosis [35]. Immunofluorescence studies also suggested the presence of a KTR receptor on the C. albicans cell wall, expressed on growing yeast cells and particularly on elongating germ tubes and hyphae. Circumstantial evidence suggesting that this receptor is or contains a betaglucan structure (unpublished data) was subsequently strengthened by the identification of YKTR as a beta-glucan for the toxin secreted by W. saturnus var. mrakii, which is also neutralized by mAbKT4 [36].

YEAST KILLER TOXIN

ANTIBODY 1 anti-yeast killer toxin receptor-like antibody

epitope

anti-idiotype yeast killer toxin-like antiidiotypic antibody anti-receptor antibody anti-anti-yeast killer toxin antibody ANTIBODY 2

idiotype

receptor

idiotype-like yeast killer toxin cell wall receptor

YEAST CELL

Fig. 17.1 The theory of idiotypic network applied to the yeast killer toxin phenomenon for the generation of anti-idiotypic antibodies or anti-receptor antibodies mimicking the microbicidal activity of yeast killer toxin.

17.8 Microbicidal IdAb: Consequences and Extensions

17.8 Microbicidal IdAb: Consequences and Extensions

As discussed elsewhere [24], the demonstration that IdAb carry an internal image of PaKT and that their candidacidal action is mediated through interaction with a putative KTR on the Candida cell wall has some important implications. First, if KTR is the antigenic molecule expressed during normal colonization by or infection with the fungus (both of which are usual events in humans), the antibody repertoire should include anti-KTR molecules capable of mimicking PaKT by acting as special KTR ligands. These antireceptor antibodies should also functionally mimic IdAb. Thus, if KTAb and IdAb share common idiotopes, C. albicans (or, of course, any other microorganism expressing a YKTR) would not only boost Id vaccination with mAb KT4, but would also be capable, in the absence of any previous Id vaccination, of eliciting an antibody response that functionally mimics PaKT and IdAb activity. The hypothesis described above has been verified. Intravaginal or even intragastric inoculation with C. albicans dramatically boosted IdAb formation in rats immunized with mAb KT4, and the vaginal fluid of rats and women repeatedly exposed (artificially or naturally, respectively) to C. albicans contained candidacidal antibodies with immunochemical and functional properties of PaKT and IdAb. The affinity-purified candidacidal antibodies from human vagina reacted strongly with the putative KTR on C. albicans cells, exerted a remarkable candidacidal activity in vitro, and conferred significant passive protection in a mucosal candidiasis model [52] (Figure 17.2). It is relevant that the model of candidal vaginitis developed in oophorectomized rats strongly resembles human candidal vaginitis in its estrogen dependence and in the subset composition of intravaginal T lymphocytes [31, 33] (in fact, this is now a

◆

> 100

◆

◆

90 80

◆

Mean CFU (x10-3)

70 60 ◆ Untreated 50

Relevant Id Ab

◆ 40 30 20 10 0 0

1

2

5

7

Day

Fig. 17.2 Passive vaccination and anti-candidal protection by natural human candidacidal antibodies. For technical details and study protocol, see [52].

9

12

Irrelevant Id Ab

377

378

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

standard test for the preclinical activity of antimycotic and immunotherapeutic agents). Technically the model is based on oophorectomized female Wistar rats, maintained under pseudoestrus with estradiol, which are inoculated intravaginally with 107 C. albicans cells (strain SA-40): the end-point is the rate of fungus clearance from the vagina. In the context of the microbicidal protective KT-like IdAb, the existence of a large number of taxonomically unrelated but PaKT-susceptible pathogenic microorganisms is of great interest. For instance, P. carinii has proved to be exquisitely susceptible to PaKT because of the expression of a functional PaKTR. Subsequently, KTAb were found in the serum and in bronchial lavages of P. carinii-infected persons [54, 55]. Furthermore, the adhesion of cystic forms and trophozoites to lung epithelial cells in vitro, as well as P. carinii infectivity in nude rats, could be inhibited by both PaKT and the natural candidacidal KTAbs found in the vaginal fluid of women repeatedly exposed to Candida [56, 57]. An exciting corollary of these findings is the possible existence of cross-immunity against distant pathogens, mediated by antibodies directed against a common transphyletic YKTR. It was consequently suggested that highly specific molecularly engineered reagents could be generated and would be of potential benefit in several diseases. Thus, PaKT-mimicking mAb (obtained by conventional fusion of spleen lymphocytes of rats immunized with mAb KT4), as well as a single-chain variable-fragment (ScFv) recombinant PaKT-like Ab (obtained from a phage-display antibody library from splenocytes of mice immunized with mAb KT4), were found to be microbicidal in vitro against a variety of human pathogens and exerted passive protection in in vivo models of infection [58–61]. In the following sections of this chapter, we deal mostly with the applications of a particular single-chain variable antibody (termed H6) which proved remarkably interesting for passive vaccination studies as well as for the generation of suitable antibody fragments to use as anti-infectious tools.

17.9 Passive Vaccination with Single-chain Variable-fragment Antibodies Carried or Secreted by a Mucosal Live Bacterial Vector

A relevant application of the microbicidal potential of the H6 anti-idiotypic ScFv molecule as a local anti-infective therapy was addressed by Oggioni et al. [62, 63] through engineering a safe, human-commensal bacterium, Streptococcus gordonii, to express the H6 molecule both as surface-display and as secretion product. This approach is of particular interest for the potential capacity of the engineered mucosal commensal to act, by producing the recombinant microbicidal antibody, as a local anti-infective, thus reducing transmission at the pathogen entry site. This solution is more feasible and also of much lower cost in terms of treatment than continuous administration of a labile material such as a ScFv. Previous work established that S. gordonii as such can indeed colonize both oral and vaginal mucosa in the experimental animal [64, 65].

17.9 Passive Vaccination with Single-chain Variable-fragment Antibodies ...

The host–vector system employed is based on a two-step procedure in which, first, translational fusions to the streptococcal surface protein M6 are constructed in E. coli vectors, then these recombinant vectors are transformed in S. gordonii, where they integrate downstream from a strong chromosomal promoter (Figure 17.3). The gene fusions include the signal sequence and parts of the N-terminal region of the M6 protein responsible for efficient export. When the C-terminal anchor sequence of M6 is included in the construct, the recombinant protein becomes anchored to the cell surface, but when the anchoring sequence is omitted the protein is secreted. Two recombinant S. gordonii strains expressing the H6 ScFv were constructed: one, named GP1302, in which H6 is integrated in-frame into streptococcal M6 protein, leading to a surface-displayed fusion protein; and a second, named GP1303, in which a stop codon is introduced so that the ScFv lacks the C-terminal M6 domain necessary for surface anchoring, so that the fusion protein produced is secreted. Protein production and localization was confirmed on all strains by Western blotting and dot blotting of bacterial cell fractions and supernatants. The presence of M6–H6 fusion protein on the surface of recombinant S. gordonii GP1302 was also verified by flow cytometry of whole cells treated with anti-M6 polyclonal serum. Colonization experiments were carried out in estrogenized rats inoculated with 109 bacteria/rat on days 0, 1.4 and 2. Colonization in rats by recombinant streptococci gave counts (between 104 and 106 CFU/sample) comparable to those encountered in the murine model. Persistence of the bacteria was followed for 2 weeks after the last inoculum without noticing any significant decrease in bacterial load, irrespective to the streptococcal strain used in the experiment [63]. Experiments aimed at evaluating in vivo the therapeutic potential of H6-secreting recombinant bacteria were carried out in the previously mentioned rat model of vagiM6 -based fusion proteins

cell wall membrane chromosomal promoter

Em R

emm6 -based gene fusion

M6 protein in S. gordonii

M6 -based fusion proteins

Fig. 17.3 The host–vector system adopted for expression of heterologous proteins in S. gordonii. The M6 protein is naturally expressed as filaments protruding from the bacterial cell wall (electron micrograph of bacteria, left). The recombinant protein is expressed as a fusion product (right).

379

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies >

100 90

◆

80 70

Mean CFU (x10-3)

380

60

◆ Fluco

◆

50

Untreated Treated

◆

40

◆

30 20 10

◆ ◆

0 0

1

2

5

7

9

12

Day

Fig. 17.4 Anticandidal activity of H6-secreted ScFv in the rat vaginitis model. Fluco is fluconazole. For technical details and study protocol, see (63).

nal candidiasis in which the soluble H6 molecule was therapeutically active, as shown above. The in vivo data concerning the H6-secreting strain are shown in Figure 17.4, demonstrating that the recombinant S. gordonii strain substantially accelerated the clearance from the vagina of a high fungus burden. Importantly, the therapeutic effect of colonization by the ScFv H6-secreting streptococcal recombinant was comparable to that of a full therapeutic course of fluconazole (100 mg at 1, 24, and 48 h). The activity of the secreted molecule is probably favored in vivo due to a facilitated interaction with C. albicans cells owing to the bioavailability of the soluble product. Rats colonized with a strain expressing an unrelated ScFv did, as expected, respond similar to control animals that did not receive any treatment. This approach was thus demonstrated to be an effective and valid alternative to repeated inoculation with purified molecules, especially since it circumvents the problem of the short half-life of most polypeptides.

17.10 Antibody Peptide Fragments as Wide-spectrum Anti-infectives

The intrinsic limitations of all the above approaches in terms of potential for treating human infections are easily recognized. A practical problem related to therapeutic treatment with KT-ScFv is the requirement for continuous administration of a potentially expensive and labile product. Mucosal delivery of the candidacidal antibody fragment permanently expressed by a colonizing human commensal bacterium

17.10 Antibody Peptide Fragments as Wide-spectrum Anti-infectives

would appear to be safe and cost-effective, but the means for large scale production and standardization and the regulatory pathway for acceptance of new transgenic commensals need to be defined. In addition, this approach cannot be considered for treating systemic infections. In recognition of these constrains and because of our interest in dissecting the extraordinarily wide biological activity of the H6 molecule, we recently addressed the anti-microbial activity of peptides synthesized and optimized by alanine scanning of the H6 sequence, with special regard to the CDR domains, which contain the antigen-binding sites for specific interaction with susceptible cells. In preliminary studies for proof of concept, we selected C. albicans as the model organism. The overall approach for peptide design and generation from the singlechain molecule is schematically shown in Figure 17.5. Based on KT-ScFv sequence determination, a synthetic decapeptide including three CDR1 residues of the VL chain was selected for large-scale synthesis of soluble product because of its strong candidacidal activity in vitro in comparison with other decapeptides pertaining to CDRs and CDR-constituting peptides. This decapeptide P6 was analyzed by alanine scanning in an attempt to potentiate its activity, thus obtaining another more potent in vitro killer decapeptide (called KP). Importantly, the candidacidal activity of KP required the presence of the three CDR1 amino acids and was clearly inhibited, in a dose-dependent fashion, by laminarin, a b1–3-glucan preparation. The latter effect was highly specific, since it was not reproduced by pustulan, a b1–6-glucan preparation, thus suggesting that the peptide preferentially interacts

YEAST KILLER TOXIN LIKE ScFv ANTIIDIOTYPIC ANTIBODIES

SEQUENCING

1 2 3 . . . 94 95 96

A C E . . . X Z B

B D F . . . Y A C

C E G . . . Z B D

D F H . . . A C E

E G I . . . B D F

F H J . . . C E G

G I K . . . D F H

H J L . . . E G I

I K M . . . F H J

J L N . . . G I K

SYNTHESIS OF CDRs AND TWO RESIDUES DISPLACED PEPTIDES REPRODUCING scFv SEQUENCE SELECTION OF PEPTIDES BY CFU KILLING ASSAY

L M N O P Q R S T U SELECTED PEPTIDE ANALYSIS BY ALANINE SCANNING

A M N O P Q R S T U KILLER PEPTIDE

CFU KILLING ASSAY

KILLER PEPTIDE

SCRAMBLE DECAPEPTIDE

Fig. 17.5 Construction of synthetic peptides from the sequence of the H6 anti-idiotypic molecule. Alphabet sequenceletters replace the amino acid initials of the sequence.

P L U N M S Q T O R SCRAMBLE PEPTIDE

P A U N M S Q T O R SCRAMBLE PEPTIDE THERAPEUTIC TREATMENT

KILLER PEPTIDE

SCRAMBLE PEPTIDE

381

382

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies

with a receptor component containing b1–3-glucan. Whatever the precise b-glucan configuration recognized by KP, our data suggest that, similar to PaKT and PaKTIdAb, the decapeptide also interacts with b-glucan components of KTR. This suggestion is strengthened by the observation that KP, like PaKT, inhibited the binding of a KT-mAb to KTR of C. albicans cells, as shown by a direct immunofluorescence assay. The results of in vivo studies proved that KP can significantly accelerate clearance of a high fungus burden from the rat vagina, similar to a therapeutic course of fluconazole, a highly active, universally used, anticandidal drug. Similar to the H6 molecule itself (see above), KP greatly accelerated fungus elimination from rat vagina in the critical first 2–3 days of infection. Importantly, KP also eradicated infection caused by a fluconazole-resistant strain of C. albicans, a finding of special interest in view of the increased clinical concern about fluconazole resistance in this and allied fungi [66]. A potent therapeutic effect of KP in the mouse model of systemic candidiasis was also observed. In fact, the infection was cured in KP-treated mice, although control mice or mice treated with irrelevant (scramble) peptides died in 2–3 days. Noteworthy, this curative effect was exerted similarly in normal immunocompetent mice and in SCID mice, demonstrating that the therapeutic benefit did not require participation of the host's adaptive immunity, thus apparently meeting one of the prerequisites for killer antibodies mentioned above as one of the key issues for the benefits of passive vaccination to all those who may need it.

17.11 Conclusions and Perspectives

In this era of emergent and reemergent infections, with the associated threat of their diffusion into pandemic forms because of globalization, the generation of new therapeutic and preventative tools to combat infections must be seen as a fundamental need by scientists and public health authorities. Antibiotics have dominated the field of infection treatment for the past 50 years, and still they cannot be replaced. However, antibiotic resistance is now a serious problem. In addition to generating new vaccines (and expanding the use of old ones), there is a sound rationale for resorting to passive vaccination with antibodies and for expanding antibody usage as additions to or substitutes for infection therapy. As often happens in medicine, nothing is completely new: passive vaccination dates far back in the history of medicine as an immediate evidence of protection from infection, well before the development of vaccines and antibiotics. Simulating and exploiting the most successful natural mechanisms and coupling this approach with technology advancements has always been the key for success in our struggle to survive competition with other living creatures, for which we are only occasional, but not essential, hosts. If the outcome of any infectious struggle eventually depends on the capacity of the human host to mount a satisfactory immune response against the pathogen, what is better than using the arms of that response? The technology for generating antibody domains in the form of active anti-microbial peptides should not lead to forgetting

References

the essential role of the constant antibody regions in mobilizing the humoral and cellular branches of innate immunity, which keeps pathogens at bay. Moreover, the safety and ease of generating monoclonal antibodies and engineered derivatives must be balanced by the need of neutralizing the multiple epitopes with sufficient affinity for effective therapy. Nor should we forget that even the most satisfactorily designed and safest single-chain or antibody domain may also have nonprotective, infection-enhancing, properties. Overall, there is immense room for progress in the area of passive vaccination and the use of antibodies as antidotes, provided that progress is also made in basic biological studies of immune responses, in the mechanisms of cellular intoxication, as well as in knowledge of the mechanisms by which the offending pathogens exert their pathogenic and virulence properties.

Acknowledgements

We are grateful to numerous collaborators (see References) whose ideas, efforts, and technical skills have been fundamental for the progress of our scientific approach to passive vaccination. The invaluable technical and secretarial assistance of Mrs Anna Maria Marella is also gratefully acknowledged.

References 1. A. Calmette. Venoms,Venomous Animals, and Serotherapy. Masson, Paris, 1908. 2. J. M. Scherrmann, N. Terrien, M. Urtizberea, et al. J. Toxicol Clin. Toxicol. 1989, 27, 1–35. 3. C. Bismuth, S. W. Borron, F. J. Baud, P. Taboulet, J. M. Scherrmann. Hum. Exper. Toxicol. 1997, 16, 602–608. 4. C. Putterman, E. Ben-Chetrit,Y. Caraco, M. Levy. Seminars Arthritis Rheumatism 1991, 21, 143–155. 5. T. R. Kosten, M. Rosen, J. Bond, et al. Vaccine 2002, 20, 1196–1204. 6. C. J. Bunce, P. T. Loudon, C. Akers, J. Dobson, D. M. Wood. Curr. Opin. Mol. Ther. 2003, 5, 58–63. 7. M. R. Carrera, J. A. Ashley, B. Zhou, P. Wirsching, G. F. Koob, K. D. Janda. Proc. Natl. Acad. Sci. USA 2000, 97, 6202–6206. 8. S. X. Deng, P. de Prada, D. W. Landry. J. Immunol. Methods 2002, 269, 299– 310. 9. M. Berger,V. Shankar, A. Vafai. Am. J. Med. Sci. 2002, 324, 14–30.

10. K. M. Kantak. Drugs 2003, 63, 341–352. 11. B. N. Rehlaender, M. J. Cho. Pharm. Res. 1998, 15, 1652–1656. 12. J. S. Ross, K. Gray, G. S. Gray, P. J. Worland, M. Rolfe. Am. J. Clin. Pathol. 2003, 19, 472–485. 13. R. Rappuoli, H. I. Miller, S. Falkow. Science 2002, 297, 937–939. 14. R. M. Krause, N. J. Dimmock, D. M. Morens. J. Infect. Dis. 1997, 176, 549– 559. 15. A. R. White, et al., Nature 2002, 422, 80–83. 16. J. R. Kerr,V. S. Cunniffe, P. Kelleher, R. M. Bernstein, I. N. Bruce. Clin. Infect. Dis. 2003, 36, 100–106. 17. A. Casadevall. Emerg. Infect. Dis. 2002, 8, 516. 18. A. Casadevall, M. D. Scharff. Clin. Infect. Dis. 1995, 21, 150–161. 19. T. M. Behr, D. M. Goldenberg, W. S. Becker. Hybridoma 1997, 19, 2427– 2432. 20. D. J. Tipper, K. A. Bostian. Microbiol. Rev. 1984, 48, 125–156.

383

384

17 Passive Vaccination and Antidotes: A Novel Strategy for ... Antibodies 21. N. K. Jerne. Ann. Immunol. Inst. Pasteur 1974, 125C, 373–389. 22. M. B. Edmond, S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, R. P. Wenzel. Clin. Infect. Dis. 1999, 29, 239–244. 23. L. Polonelli, F. De Bernardis, S. Conti, M. Gerloni, A. Cassone. In: Idiotypes in Medicine: Autoimmune Infection and Cancer (Shoenfeld Y. et al. Eds.), Elsevier Science, N. 4. 1997, pp. 369–380. 24. A. Cassone, S. Conti, F. De Bernardis, L. Polonelli. Immunol. Today 1997, 18, 164–165. 25. J. P. Burnie, R. C. Matthews. J. Antimicrobial. Chemother. 1998, 41, 319–322. 26. L. Romani, A. Mencacci, U. Grohman, et al. J. Exp. Med. 1992, 176, 19– 25. 27. R. L. Coffmann, D. A. Lebman, P. Rothman. Adv. Immunol. 1993, 54, 229–270. 28. R. Matthews, J. Burnie. Trends Microbiol. 1996, 4, 354–358. 29. S. Mukherjee, S. C. Lee, A. Casadevall. Infect. Immun. 1995, 63, 573–579. 30. Y. Han, J. Cutler. Infect. Immun. 1995, 63, 2714–2719. 31. A. Cassone, M. Boccanera, D. Ariani, G. Santoni, F. De Bernardis. Infect. Immun. 1995, 63, 2619–2624. 32. C. Bromuro, A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, A. Cassone. Infect. Immun. 2002, 70, 5462–5470. 33. G. Santoni, M. Boccanera, D. Adriani, R. Lucciarini, C. Amantini, S. Morrone, A. Cassone, F. De Bernardis. Infect. Immun. 2002, 70, 4791– 4797. 34. W. Magliani, S. Conti, M. Gerloni, D. Bertolotti, L. Polonelli. Clin. Microbiol. Rev. 1997, 10, 369–400. 35. S. Conti, F. Fanti,et al., J. Infect. Dis. 1997, 177, 807–811. 36. C. Guyard, E. Dehecq, J. P. Tissier, L. Polonelli, E. Dei-Cas, J. C. Cailliez, F. D. Menozzi. Mol. Med. 2002, 8, 686–694. 37. C. Guyard, N. Seguy, J. C. Cailliez, H. Drobecq, L. Polonelli, E. Dei-Cas, A. Mercenier, F. D. Menozzi. J. Antimicrob. Chemother. 2002, 49, 961–971.

38. J. R. Schwebach, A. Glatman-Freedman, L. Gunther-Cummins, Z. Dai, J. B. Robbins, R. Schneerson, A. Casadevall. Infect. Immun. 2002, 70, 2566–2575. 39. M. Pettoello-Mantovani, A. Nocerino, L. Polonelli, G. Morace, S. Conti, L. Di Martino, G. De Ritis, M. Iafusco, S. Guandalini. Gastroenterol. 1995, 109, 1900–1906. 40. S. Tonegawa. Nature, 1983, 302, 575– 581. 41. H. Waldmann, L. K. Gilliland, S. P. Cobbold, G. Hale. Immunotheraphy, in Fundamental Immunology, 4th edition, ed W. E. Paul. Lippincott-Raven, Philadelphia 1999, chapter 45. 42. J. M. Tomlinson, J. P. L. Cox, E. Gheradi, A. M. Lesk, C. Chothia. EMBO J. 1995, 14, 4628–4638. 43. T. Manser, S. Y. Huang, M. L. Gefter. Science 1984, 226, 1283–1288. 44. E. A. Kabat, T. T. Wu. Ann. N.Y. Acad. Sci. 1971, 190, 382–393. 45. C. Chothia, A. M. Lesk. J. Mol. Biol. 1987, 196, 901–917. 46. H. G. Kunkel, M. Mannick, R. C. Williams. Science 1963, 140, 1218–1219. 47. N. J. Abdou, H. Wall, H. B. Lindsley, T. Suzuki. J. Clin. Invest. 1981, 67, 1297–1304. 48. D. S. Dwyer, R. J. Bradley, C. R. Urquhart, J. F. Kearney. Nature 1983, 301, 611–614. 49. B. A. Fields, F. A. Goldbaum, X. Ysern, R. J. Poljak, R. A. Mariuzza. Nature 1995, 374, 739–742. 50. N. R. Farid, T. C. Y. Lo. Endocr. Rev. 1985, 6, 1–23. 51. L. Polonelli, R. Lorenzini, F. De Bernardis, G. Morace. Mycopathol. 1986, 96, 103–107. 52. L. Polonelli, F. De Bernardis, S. Conti, M. Boccanera, W. Magliani, M. Gerloni, C. Cantelli, A. Cassone. J. Immunol. 1996, 156, 1880–1885. 53. L. Polonelli, F. De Bernardis, S. Conti, M. Boccanera, M. Gerloni, G. Morace, W. Magliani, C. Chezzi, A. Cassone. J. Immunol. 1994, 152, 3175–3182. 54. N. Seguy, E. L. Aliouat, E. Dei-Cas, L. Polonelli, D. Camus, J. C. Cailliez. J. Eukaryot. Microbiol. 1994, 41, 109.

References 55. N. Seguy, J. C. Cailliez, L. Polonelli, E. Dei-Cas, D. Camus. Parasitol. Res. 1996, 82, 114–116. 56. N. Seguy, L. Polonelli, S. Conti, E. Dei-Cas, D. Camus, J. C. Cailliez. J. Eukaryot. Microbiol. 1996, 43, 27 S. 57. S. Conti,W. Magliani, S. Arseni, R. Frazzi, A. Salati, L. Ravaneti, L. Polonelli. Mol. Med. 2002, 8, 313– 317. 58. S. Conti,W. Magliani, S. Arseni, et al. Mol. Med. 2000, 6, 613–619. 59. E. Cenci, A. Mencacci, A. Spreca, et al. Infect. Immun. 2002, 70, 2375– 2382. 60. W. Magliani, S. Conti, R. Frazzi, G. Pozzi, M. Oggioni, L. Polonelli. Biotech. Gen. Engineer. Rev. 2002, 19, 139–156. 61. S. Conti,W. Magliani, P. Fisicaro, E. Dieci, S. Arseni, A. Salati, L. Polonelli. Res. Immunol. 1998, 149, 334– 343.

62. M. R. Oggioni, C. Bennati, M. Boccanera, D. Medaglioni, M. R. Spinosa, T. Maggi, S. Conti,W. Magliani, F. De Bernardis, G. Teti, A. Cassone, G. Pozzi, L. Polonelli. Intern. Rev. Immunol. 2001, 20, 267–279. 63. C. Beninati, M. R. Oggioni, M. Boccanera, M. R. Spinosa, T. Maggi, S. Conti,W. Magliani, F. De Bernardis, G. Teti, A. Cassone, G. Pozzi, L. Polonelli. Nat. Biotechnol. 2000, 18, 1060– 1064. 64. G. Pozzi, M. Contorni, M. R. Oggioni, R. Manganelli, M. Tommasino, F. Cavalieri,V. A. Fischetti. Infect. Immun. 1992, 60, 1902–1907. 65. D. Medaglini, G. Pozzi, T. P. King, V. A. Fischetti. Proc. Natl. Acad. Sci. USA 1995, 92, 6868–6872. 66. L. Polonelli, W. Magliani, S. Conti, et al. Infect. Immun. 2003, 71, 6205– 6212.

385

387

18 Plant-based Oral Vaccines Kan Wang, Rachel Chikwamba, and Joan Cunnick

18.1 Introduction

Humanity have been using plants directly or indirectly as major sources of medicines for thousands of years. Many metabolic compounds, uniquely produced by plants for protection against their own pests and diseases, also have important therapeutic or preventive effects against human diseases. Such plant medicinal extracts used by our ancestors were mostly orally or topically administered. The turn of the 21st century witnesses an unprecedented rapid accumulation of knowledge, especially on the frontiers of human science. The advancement of genomic information and genetic modification technology enables scientists to understand the mechanisms of plant metabolite production more precisely; this enables the extraction and utilization of the metabolites as medicines more effectively. In addition, it is now possible to insert bacterial, human, or other nonplant genes into crop plants and use the plants as biological factories for pharmaceutical production. In this review, we briefly describe the mucosal immunization strategy and its application in prevention of infectious diseases. We present advantages of plant-based vaccine production systems with emphasis on potential use for mucosal immunization of humans and animals. We also review the current achievements on plant-produced antigens and their efficacies in animal test systems. The relative advantages and disadvantages of various plant tissues and organs that are used for vaccine delivery or production are also discussed. Finally, we summarize important factors essential for a successful plant-based antigen-production system, using maize as a case study.

18.2 Mucosal Immunization

The first vaccination is attributed to Edward Jenner in 1796, when he used the heterologous agent vaccinia virus (cowpox) to protect James Phipps from variola (smallpox). The second major development is attributed to Louis Pasteur's serendipitous discovery that infectious agents could be attenuated to lose pathogenicity, yet still be

388

18 Plant-based Oral Vaccines

used to protect against an infectious agent, beginning with fowl cholera. Pasteur's discovery during the ‘Golden Age of Microbiology’ (during which infectious agents for many known diseases were identified) gave birth to the search for protective vaccines [1]. Development of vaccines during most of the 20th century focused on parenteral (injectable) vaccines, with the notable exception of the oral polio vaccine. Attenuated live vaccines, like the oral polio vaccine, were successful because the attenuated organism could replicate to supply adequate immune stimulation, which was lifelong. However, the possibility of disease due to reversion of attenuated organisms or by attenuated organisms in immunocompromised individuals is a major concern and has limited their use. The reasons for the rapid development of parenteral vaccines are numerous and reviewed in [1] and [2]. Killed (inactivated) or subunit vaccines are safer, yet need to be administered at a much higher concentration and repeatedly to induce an adequate immune response without adjuvants. Overall, however, adjuvants for parenteral killed vaccines were developed more rapidly than those for oral vaccines. 18.2.1 Vaccination Strategies for Infectious Diseases

The degree of protection afforded by a vaccine depends on the nature of the infectious process, as well as the components and route of administration of the vaccine. For example, Clostridium tetani grows within tissues and induces spastic paralysis by production of tetanus toxin. The best vaccination strategy is to stimulate systemic Bcell antibody production of a type that can diffuse into tissues and neutralize the toxin (IgGs). Vibrio cholera also causes disease by production of a toxin. However, that toxin affects gut epithelial cells from the lumen side of the gut and requires antibodies that can neutralize toxins at the mucosal surface (IgA). To develop appropriate vaccines for viral diseases, it is also important to produce a vaccine that neutralizes the virus at the level of infection. For example, rabies virus is often transmitted by the bite of a rabid animal directly into tissues and must be neutralized as it passes from one infected neuron to the next on its way toward the brain; in this case IgG is required. The best vaccine for an organism like polio, which enters the body via the gastrointestinal tract, is one that induces mucosal antibodies to neutralize the virus before it can adhere to the mucosa (IgA). However, polio is an interesting example, because high concentrations of systemic antibodies (in sera) induced by inactivated polio vaccine (IPV) can prevent paralytic polio. IPV, however, does not prevent wild polio virus from replicating in the gut and being shed to infect nonimmunized individuals. Thus, induction of IgG alone is not sufficient to control this disease in areas where wild polio virus still exists [1]. There is a need for vaccines that can elicit adequate immune responses systemically, mucosally, or both. Numerous organisms cause infections by breaching mucosal surfaces such as the gut, lungs, nasal/sinus surface, or vaginal tract, which could be prevented by neutralization at the mucosal level. Examples of diseases caused by such organisms are found in animals and humans. Organisms that are particularly problematic at this time in history include rotavirus, respiratory syncytial virus

18.2 Mucosal Immunization

(RSV), Norwalk virus, porcine reproductive and respiratory syndrome (PRRS) virus, the newly identified sudden acute respiratory syndrome (SARS) virus, and diarrheacausing toxins from Vibrio cholera and Escherichia coli, which cause cholera and travelers' diarrhea, respectively. In all these instances a robust specific IgA antibody response at the appropriate mucosal surface may be important for neutralization of the infectious agent and prevention of disease pathology. Because most parenteral vaccines induce a primarily systemic IgG antibody response, vaccination strategies that induce an IgA response on the mucosal surfaces are currently an area of very active research [3]. 18.2.2 Mucosal Immunization vs. Parenteral Immunization

To obtain a robust, specific antibody response with high affinity, it is necessary to stimulate T-helper cells. T-helper cells respond to the protein portion of the antigen when it is presented by antigen-presenting cells [4]. Upon activation, the T-helper cells can differentiate into a T-helper 1 (TH1) phenotype or a T-helper 2 (TH2) phenotype. The TH1 and TH2 cells produce distinct partially overlapping arrays of cytokines, which result in activation of different immune cells and mechanisms. Both Thelper phenotypes can help B cells to produce antibody, but the antibody induced is of different isotypes with different functions. TH1 cells induce B cells to make IgG2 a, along with activating macrophages to clear intracellular organisms and activating T-cytotoxic cells to more efficiently kill virus-infected cells. TH1 activation induces an inflammatory response by activating macrophages, which are capable of producing proinflammatory cytokines (IL-1, IL-6, TNF-a) as well as IL-12, which can enhance TH1 activation. TH2 cells induce B cells to produce IgM, IgG1, IgA, and IgE, as well as activate eosinophil and mast cell production. In addition, TH2 cells produce IL-10 and IL-4, which are considered anti-inflammatory cytokines because they can suppress macrophage-induced inflammatory responses [4]. Activation of a TH1 or TH2 phenotype is partly determined by the presence of distinct cytokine microenvironments. The development of TH1 cells proceeds in an environment containing IL-12 and IFN-g, while the presence of IL-4 and IL-10 can induce TH2 cell differentiation. Often, activation and differentiation of both TH1 and TH2 phenotypes occurs, with one type predominating [4]. Interestingly, immunization at mucosal surfaces most frequently induces a TH2 type response, due to the presence of IL-4 and IL-10 in the mucosal microenvironment. Use of different adjuvants can also induce T-helper cell differentiation towards TH1 or TH2 phenotype [15]. Taken together, mucosal immunization can result in activation of TH2 cells and production of secretory IgA, which is needed for neutralization of viruses, toxins, and bacterial adhesins that attack at the mucosal surfaces. In addition, some immune responses that result in pathogenic inflammatory processes may benefit from mucosal immunization strategies. For example, oral immunization of non-obese diabetic mice with an insulin-CT conjugate produced anti-insulin antibodies (type IgG1), reduced insulitis (inflammation of pancreatic islets), and delayed the onset of diabetes [5].

389

390

18 Plant-based Oral Vaccines

At times, a TH1 response is necessary to resolve disease. Lepromatous leprosy, the severe form of leprosy, is a result of insufficient TH1 response or activation of macrophages. Tuberculoid leprosy, the milder form of the disease, is related to activation of TH1 cells and results in activation of infected macrophages to clear the infectious agent, Mycobacterium leprae. 18.2.3 Mucosal Immunization and Adjuvants

Orally delivered mucosal vaccines must overcome three identified hurdles [6]: (1) effective delivery of antigen to the mucosal immune system (they often must pass through the acidic, enzymatically active digestive system); (2) the need for very large amounts of antigen or an effective adjuvant, and (3) production of protective immunity at the desired site (mucosal, systemic, or both). An effective delivery system for oral administration of antigen must get past the digestive enzymes in saliva and the stomach. Oral immunizations of many mouse models use a combination of very high antigen concentrations and sodium bicarbonate to neutralize the acid proteases of the stomach [7]. The practical application of sodium bicarbonate 30 min prior to administering an oral antigen to humans is limited to research studies, because it complicates the ease of application sought in oral vaccines. Alternatively, production of the antigen in a live lactic acid bacteria or encapsulation of antigens in microspheres of synthetic polymer or water-soluble alginate or chitosan [8–10] can also protect the antigen. To reduce the need for large amounts of antigen, effective and safe adjuvants for mucosal systems are needed. Only in the last decade of the 20th century have immunologists identified possible mucosal adjuvants, in the form of cholera toxin (CT) from Vibrio cholera and heat-labile toxin (LT) from enterotoxogenic strains of E. coli. However, although the whole toxins are powerful adjuvants, they also are toxic if used in their entirety. Use of the binding subunit (B) of cholera toxin (CT-B) and E. coli heat-labile toxin (LT-B) reveal that LT-B is a better adjuvant [11, 12]. However, alteration of whole LT to reduce or abrogate the toxicity of the A subunit appears to enhance its adjuvanticity [12, 13]. More interesting than the amount of adjuvanticity associated with various LT derivatives is that different derivatives appear to drive the immune system to either a TH1- or TH2-dominant immune response [14–16], the implications of which are addressed above. In addition, excessive adjuvanticity may be undesirable [17]. Whole CT is a powerful adjuvant, but when it is administered with peanuts or ovalbumin, it can induce allergic Type 1 hypersensitivity [18, 19]. Targeting the immune response to the appropriate mucosal site when using oral vaccines appears to be straightforward, because immunization at any mucosal site yields cross protection of all mucosal sites, as well as robust systemic immunity. Antibodies to antigens administered orally with an adjuvant can be found in intestinal excretions, lung washes, and nasal washes, as well as systemically [14]. In addition, researchers have used intranasal delivery of antigens to induce antibody responses in intestinal and respiratory mucosa, as well as systemically [20]. It appears that intranasal administration of antigen requires less antigen per dose, but also re-

18.3 Plant-derived Edible Vaccines

quires coadministration of an adjuvant for a robust immune response. However, questions have arisen as to the safety of using adjuvants near the olfactory bulb and central nervous system during intranasal administration [17].

18.3 Plant-derived Edible Vaccines

The term ‘plant-derived edible vaccines’ refers to antigens produced in edible parts of a plant, such as fruits, leaves, roots, or tubers. Vaccines expressed in nonedible plant tissues may also be orally administered after processing. The term ‘edible vaccine’ may have created the misconception that individuals would be able to grow and administer their own vaccines without the supervision of pharmaceutical and health professionals. Ultimately, for practical applications, plant-expressed vaccines will require some form of processing to produce uniform doses for administration by oral and other routes. These products will be regulated, as all pharmaceuticals are, by government agencies such as the U.S. Food and Drug Administration (FDA), and their administration will require supervision by health care professionals. Also, not all plant-derived vaccine antigens are edible; they may be effective only when administered by the appropriate method (topically; intramuscularly, i.m.; intraperitoneally, i.p.; or subcutaneously, s.c.). 18.3.1 Advantages of the Plant-based System

Producing pharmaceuticals in plants has many potential advantages, which have been reviewed extensively [21–25]. Safety is a key attraction, since the production of recombinant proteins in plants minimizes potential human or animal pathogen and toxin contamination, such as occurs when a recombinant protein is produced in microbial or animal cultures. The potential for cost reduction is also enormous. This is especially significant for oral vaccines, because relatively large amounts are required. Plants are potentially more economical than industrial fermentation or bioreactor facilities [26], and the amounts of protein produced by plants are comparable to those produced by industrial approaches [27]. Scaling up production does not require huge investments up-front in setting up facilities, unlike the conventional systems. Often, technology already exists for harvesting and processing plant and plant products on a large scale. Purification and its associated costs may not be needed when the recombinant protein is produced in plant tissue that can be used as food or feeds (edible vaccine). The potential for oral administration and the convenient storage when the vaccines are produced in seeds and tubers could dramatically reduce the costs associated with syringes and needles and the requirement for cold storage. Elimination of needles in most vaccination programs will also cut back the risk associated with reuse of needles in some developing countries. Seed and tubers are convenient storage organs for relatively simple, cheap antigen storage. Plants offer enough flexibility that the recombinant proteins can be targeted to intracellular com-

391

392

18 Plant-based Oral Vaccines

partments where they are more stable. Alternatively, they can be expressed directly in those compartments or in organelles such as chloroplasts [23]. From a biological perspective, the plant’s protein-production system can perform post-transcriptional modifications, such as glycosylation, which are essential for the biological activity of some proteins. This is certainly an advantage over the use of microorganisms such as bacteria and fungal systems, in which problems of differences in codon usage, metabolic pathways, protein processing, and formation of inclusion bodies often arise. 18.3.2 Transient and Stable Systems for Production of Plant-derived Proteins

Proteins can be derived from plants by two major approaches: transient expression using modified viruses or stable transformation of the nuclear or plastid genome. In transient expression, DNA encoding the protein of interest is introduced into the plant cell, where it is recognized by the transcription machinery and expressed. Stable transformation, on the other hand, involves introduction into the plant cell of a foreign gene and its stable integration into the plant genome. Both methods have their advantages and disadvantages, which have been reviewed extensively [28]. Viral vectors are usually more appropriate for expressing products in leaf tissue of high biomass producing plants, such as tobacco, ultimately for extraction and purification. Two major viral expression systems have been engineered: the tobacco mosaic virus (TMV)-based system for tobacco and the cowpea mosaic (CPMV) system for cowpeas. The expression of foreign protein typically occurs 2–4 weeks after inoculation, and production of antigen is rapid as the engineered virus spreads and multiplies throughout the plant [29]. Transient expression usually achieves substantially higher levels of protein than does stable transformation, but it requires inoculation of large numbers of plants with the recombinant virus. With viral vectors, the inserted gene is often lost over time, which is important for containment of the transgene. Stable transformation offers multigenerational stable expression, compared to the use of viral vectors. The transgenes are incorporated into the plant genomes (in the nucleus or chloroplasts) and can be inherited by next generations. Expression of recombinant proteins by this method usually results in moderate to low expression, but higher levels of expression have been attained by using a number of regulatory sequence elements, such as strong promoters [30], optimized codon usage for plant expression [31], translation-enhancing leader sequences at the 5´ end, polyadenylation signals at the 3´ end [32], and microsomal retention sequences [33]. It is also possible to produce transplastomic plants with transgenes integrated in the chloroplast genome [23, 34] or into chloroplast-derived chromoplasts [35] to express high levels of foreign proteins. The ability in some species to sexually cross transgenic lines adds the flexibility of being able to express multiple proteins in the same plants (antigen stacking). However, stable transformation requires efficient transformation techniques and meticulous selection and breeding of the high-expressing transgenic lines.

18.3 Plant-derived Edible Vaccines

18.3.3 Choice of Plants and Plant Tissues

Several practical issues must be considered in the production of foreign proteins in plants, including selection of appropriate crop plants and plant tissues in which to produce and deliver the desired amount of antigenic protein. The choice of plant usually depends on its capacity for transformation or infectivity with genetically engineered viruses, and to date, scientists have often made this decision based on the system with which they are most competent. Some plants, such as tobacco, potato, and tomato, are more amenable to tissue culture and transformation, and others, such as corn, soybean, and wheat, are relatively more recalcitrant to in vitro manipulation. The desired method of administering the recombinant protein also plays an important role. Tobacco is most easily cultured and transformed, and thus has been used as a test system for many antigens. Tobacco produces large volumes of green tissue, and with several crops harvested per year by cutting the foliage, annual yields can be in excess of 100 metric tones (MT) per hectare [23]. However, tobacco is not palatable, and toxic alkaloids in the leaf tissue are not only incompatible with oral delivery but also necessitate costly protein purification prior to administration. Alfalfa is a palatable crop with a high leaf protein content and high annual yields of green leaf tissue. In this crop, pharmaceuticals could be administered in fresh or dried leaf or as leaf extract. Several proteins have been produced in alfalfa, including foot-and-mouth virus (FMDV) antigens [36]. Lettuce is a salad crop consumed raw, in which antigen production has been reported [37]. However, the inherently low protein content of its leaves presents a problem for practical protein production. When the idea of edible vaccines was first articulated, people envisioned that a crop like bananas, which are highly palatable raw, would be the ideal system for edible vaccine production. Bananas are also cultivated in many parts of the world, including the developing countries where low-cost vaccines are most needed. However, inefficient transformation, inadequate information on gene expression, fruit-specific promoters, and the difficulty and expense of cultivation in the greenhouse has hampered pharmaceutical production in this crop. Tomato fruits are edible raw, and the transformation system, industrial greenhouse culture, and processing are well established, making this crop an attractive choice. However, the inherently low protein content may result in poor yields of recombinant protein, and the acid nature of the fruit may be a drawback especially for children's vaccines (H. Mason, personal communication). Potato is another preferred crop because, not only is it convenient to transform, it also provides an edible tissue for use in immunological studies and for convenient storage of the protein. Some of the most comprehensive antigen production and immunological studies, including human clinical trials, were carried out with transgenic potato-derived antigens such as LT-B [31], CT-B [5], HBsAg [38], and Norwalk virus capsid proteins [39]. However, potato is not highly palatable and requires cooking, which may denature the antigens. Arakawa et al. [5] showed that cooking potatoes reduced the GM1-binding capacity of CT-B by about 50 %.

393

394

18 Plant-based Oral Vaccines

Cereals and seed legumes offer an attractive option for edible vaccines, because production of antigens in seeds makes for convenient administration of edible vaccines and simplified preparation of antibodies. These crops are particularly suitable for production of edible vaccines for humans and livestock, because many are natural components of food and livestock feeds. Yields of cereal grains such as wheat, rice, and maize are less abundant (3, 6, and 12 metric tonnes per hectare, respectively) than that of the green tissues of tobacco and alfalfa [23]. However, high-yield seed production in grains greatly simplifies the scale-up process. Unlike proteins synthesized in vegetative plant tissues, seed storage proteins are compartmentalized into protein bodies, specialized vacuoles in mature seeds. These provide a stable environment devoid of significant amounts of enzyme activity prior to germination. Promoters play an important role in tissue-specific expression. Seed-specific promoters are preferred for oral administration, simplified protein extraction, and where the presence of the antigen in growing tissues is detrimental to plant vigor [31] (R. Chikwamba, unpublished). Compared to proteins extracted from green tissues such as tobacco leaves, proteins extracted from seeds contain less contamination by plant secondary metabolites, which are undesirable for purification. Production of recombinant proteins in seeds has the added advantage of long-term storability of functional proteins in grain. Stoger et al. [40] reported no significant decrease in the levels of scFV antibody after storage of the transgenic rice seeds at room temperature for 6 months.

18.4 Plant-expression Systems for Antigen Production

Antigen production has been reported in many plant species. Table 18.1 is a summary of selected key antigens that have been produced in plants and tested in animal systems. The work presented in these reports demonstrated that plants, especially food crops, can be used to produce functional antigens in specific tissues. When such plant-derived antigens were administered directly by feeding or by injection of extracts in animals, specific antibodies against the antigen could be detected in immunized animals. In some instances, partial protection against a disease or toxin was achieved. The work of Tacket et al. [41] is notable in that it represents the first trial of a plant-produced vaccine in humans. The data on antibody responses was encouraging, comparing favorably with the responses obtained after administration of ETEC cells. Other human trials followed with the Norwalk virus capsid protein and the HBsAg (Table 18.1), and results published to date indicate a strong potential for plant-derived vaccines. These pioneering studies have demonstrated the feasibility of using plants as a future production and delivery system for oral vaccines. However, for most of the antigens produced to date, several problems have been encountered. The common ones include poor gene expression in desired tissues, unstable gene expression over generations, and poor immunogenicity upon oral administration. To qualify as an efficient production system, the quantity of plant tissue constituting a vaccine dose must be of a practical size for consumption, making it critical to achieve high expres-

18.4 Plant-expression Systems for Antigen Production Tab. 18.1

395

Selected antigens produced in plants and tested in animal and human systems.

Pathogen

Antigen

Human Pathogens Enteretoxigenic LT-B E. coli (ETEC)

Plant species Test system

Antigen administration

Observed responses

Ref.

potato

mice

oral

31

potato maize

humans mice

oral oral

maize

mice

oral

tomato

mice (dam & pup) mice

oral & passive oral

oral oral oral

Serum and mucosal Abs, partial protection Serum and mucosal Abs Serum and mucosal Abs, partial protection Serum and mucosal Abs, partial protection Serum IgG in both dam and pup Serum and mucosal Abs, partial protection; booster responses in previously immunized mice Serum Abs Serum and mucosal Abs Boosting Ab response Serum and mucosal Abs Increased IgA and IgG Ab-secreting cells Serum and mucosal Abs, increased IL-2, IFN-g, protection of passively immunized pups

78 39

41 98 46 114

Vibrio cholerae

CT-B

potato

Hepatitis B

HBsAg

lettuce potato potato

Norwalk virus

NVCP

potato potato

humans (naïve) mice humans (immunized) mice humans

Rotavirus

CT-B/NSP4 fusion, CT-A/ CF1 fusion

potato

mice

oral & passive

arabidopsis

mice

ip or oral

Elicit neutralizing Abs

117

potato tobacco corn

mice pigs pigs

ip or oral ip oral

alfalfa

pigs

ip or oral

Elicit neutralizing Abs Elicit neutralizing Abs Serum and mucosal Abs, partial protection Serum and mucosal Abs, partial protection

118 30 98, 106 36

potato leaf

mice

ip

119

mice

ip

Serum and mucosal Abs, partial protection Serum and mucosal Abs, complete protection

mice

ip or oral

Livestock Pathogens Transmissible full length and gastroenteritis N-terminus of virus (TGEV) S glycoprotein S glycoprotein

Foot-and-mouth VP1 capsid disease virus protein peptide (FMDV)

Canine parovirus (CPV)

VP1 epitope alfalfa fused with gus gene linear antigenic arabidopsis peptide from VP2 capsid protein

*) H. Mason et al., personal communication

oral oral

Serum IgG Ab

115

37 38 *)

116

120

121

396

18 Plant-based Oral Vaccines

sion. Transgenic lines should therefore have high expression levels of the gene of interest in appropriate tissues. In addition, the recombinant proteins produced in the plant should be structurally and functionally similar to their counterparts produced in bacterial, yeast, or mammalian systems. Moreover, the transgenic plants should be fertile and transmit and express the transgene predictably over generations. Several strategies have been adopted to address these issues. In general, improvement of protein production in plants can be achieved at three levels transcription, posttranscription, and post-translation. 18.4.1 Transcriptional Level 18.4.1.1 Choice of Promoters Promoters are available for tissue- or organ-specific, temporal, and/or induced expression. Promoter elements can be constitutive or tissue-specific, allowing developmental control of expression of the novel protein. Strong promoters are often used to achieve high gene expression. Promoters that work well in dicot plants do not necessarily work equally well in monocot plants and vice versa. Some of the promoters used for transgene expression in corn include the maize ubiquitin promoter [42], the cauliflower mosaic virus 35S RNA (CaMV 35S) promoter [43], and the maize seedspecific 27kDa g zein promoter [44]. Both maize ubiqutin promoter and CaMV 35S promoter (in its tandem duplicated form) are considered strong constitutive promoters for transgene expression in maize. Transgenes driven by these promoters are expressed in most maize tissues, such as leaves, roots, pollen, and silks, and can be detected at almost all stages of plant development. In corn seed, the gene expressions driven by these promoters are strongly localized in embryos and aleurone layers (Chikwamba, unpublished). Maize 27-kDa g zein promoter, on the other hand, is a seed-specific promoter. The transgene expression can be detected only in corn seed and predominantly in seed endosperm. Both constitutive and seed-specific promoters have been used successfully in production of nonplant proteins. Hood et al. [45] achieved high avidin expression by using the constitutive maize ubiquitin promoter. However, expression of a foreign protein with a strong constitutive promoter can have a detrimental effect on cell processes and plant growth. Mason and coworkers [31] noticed stunting of transgenic potato plants expressing a high level of the Escherichia coli heat-labile B subunit (LT-B) under the control of the enhanced CaMV 35S promoter. A similar effect was also observed by our group. When the same gene was introduced into maize plants, the developmental characteristics of the transgenic plants, such as height and fertility, especially in those plants showing high LT-B expression, were significantly compromised [46]. 18.4.1.2 Transcriptional Gene Silencing Transcriptional gene silencing (TGS) refers to transgene shutdown due to methylation of the promoter [47–50]. In plants, multiple copies of a transgene, especially of those with partial sequence homology to a gene already present in the plant cells, often cause methylation of its promoter and consequently, TGS. It is important, there-

18.4 Plant-expression Systems for Antigen Production

fore, to avoid multicopy integration of a transgene into a plant genome during transformation. Two major methods have been widely used for plant nuclear transformation: Agrobacterium tumefaciens (a soil bacterium with natural ability to deliver DNA segments into the plant cell) [51] and the biolistic gun [52]. Although Agrobacterium can transform most dicot plants, the biolistic gun method has been effective in transforming more-recalcitrant cereal and legumes crops [53]. However, the biolistic method often introduces a greater number of DNA segments into the plant cell than the Agrobacterium method. The higher copy number of transgene integration can result in lower gene expression, due to transgene silencing [54]. Unfortunately, there is currently no efficient way of predicting gene expression from a given transgenic plant line other than by screening a large number of putative candidates. The general rule is to use Agrobacterium-mediated transformation if the plant of interest is amenable to this method or to select low copy number transgenic events resulting from the biolistic method. Use of a low quantity of DNA in coating gold particles for bombardment in the biolistic transformation also helps to achieve low copy number transgenic events (L. Marcell, personal communication). Conducting effective molecular and bioassay analysis on a large number of transgenic lines early in the transformation process is critical to the overall success of obtaining best transgenic lines. 18.4.2 Post-transcriptional Level 18.4.2.1 Introns Many plant genes naturally contain intron sequences that positively affect gene expression by stabilizing the mRNA transcript and allowing its effective translation. In monocot plants such as corn, intron sequences placed between the promoter and a transgene may increase its level of expression [55–58]. The maize ubiquitin and Adh2 genes are examples. Callis et al. [55] showed that inclusion of introns in the 5´ untranslated region (UTR) may correlate with up to a 100-fold increase in protein accumulation. However, reverse genetics studies have also shown that introns naturally occurring within genes can be lost without loss of gene function [59]. The maize zein proteins are the most abundant proteins in maize seed [44]. However, the gene encoding for the 27-kDa g zein does not contain an intron. When an intron from the maize ADH gene was placed between the g zein promoter and the gus marker gene, no enhancement in GUS activity was detected compared to the construct in which no intron was included (Chikwamba, unpublished). 18.4.2.2 mRNA Stability and 3´ Terminator In eukaryotic cells, one of the most important forms of control of gene expression is regulation of mRNA stability [60]. Appropriate mRNA 3´-end regions can strongly influence the level of transgene expression in plant cells [61]. In addition, the presence of instability elements within the mRNA and inadequate 3´-end processing of the mRNA in the nucleus can decrease the mRNA half life and consequently decrease mRNA levels [61, 62]. Premature polyadenylation within transgenes also results in lower transgenic mRNA levels [63]. No consensus sequences functioning as stabiliz-

397

398

18 Plant-based Oral Vaccines

ing determinants have been recognized to be responsible for the long half-life of an extremely stable transcript in plant systems. On the other hand, the presence of adenylate/uridylate-rich elements (AUUUA) in transcripts indicates that they are selectively targeted for rapid decay [64]. Reporter transcripts containing 11 repeats of the AUUUA motif in their 3´ untranslated regions are degraded more rapidly in stably transformed tobacco cells and accumulate to a lower level in transgenic tobacco plants than those of the control construct [65]. Recently, it was recognized that gene silencing also occurs at the mRNA level: post-transcriptional gene silencing (PTGS), also called ‘cosuppression’. Introduction of transgenes or viral genes into plants can cause silencing of an endogenous gene having a sequence homologous to the introduced gene [66–69]. In PTGS, the transcript of the silenced gene is synthesized but does not accumulate because it is rapidly degraded. To avoid such a silencing effect on a transgene, it is important that no unnecessary homologous sequences are introduced into the plant. As well, lowcopy-number transgene integration will likely give rise to better gene expression (H. Shou, personal communication). 18.4.2.3 An Optimal Start Context and 5´-end Enhancer for Translation The process of translation is composed of three phases: initiation, elongation, and termination. Initiation is considered to be the rate-limiting step in the translation of most mRNAs [70]. It is also the phase most often subject to regulation. Most higher plant mRNAs are capped, have AU-rich leaders that reduce the potential for secondary structure formation, are less than 200 bp in length, and begin translation at the first AUG codon [71]. This means that, in the construction of transgenes, the presence of AUG codons upstream of the authentic initiation codon should be avoided. Extensive surveys of more than 5000 plant genes for their AUG context sequences indicated that 80 % of the sequences had purines present at the –3 and +4 positions, the two most influential positions for efficient translational initiation [72]. It is also interesting that the context of the AUG codon in dicot mRNAs is aaA(A/C)aAUGGCu, which is similar to the higher-plant consensus caA(A/C)aAUGGCg, and monocot mRNAs have c(a/c)(A/G)(A/C)cAUGGCG as a consensus that exhibits an overall similarity to the vertebrate consensus [72]. The 5´-end untranslated region can also serve as a site for regulatory sequences that actively control the rate of translational initiation. Most of those examined and used in plants have come from viral mRNAs, e. g., the O leader (68 bp) of tobacco mosaic virus [73], AMV leader (36 bp) of alfalfa mosaic virus RNA 4 [74], and TEV leader (144 bp) of tobacco etch virus [75]. The translation-enhancing effect of the O leader on transgenes seemed more profound in dicots than in monocots [76]. Mason et al. [77, 78] demonstrated enhanced expression of antigens such as hepatitis B surface antigen (HBsAg) and Norwalk virus capsid protein (rNV) in transgenic tobacco and potato when the TEV leader was included in the constructs. 18.4.2.4 Codon Usage Most amino acids are specified by more than one codon. For example, the codons GCU, GCC, GCA, and GCG all code for the amino acid alanine. However, genes of

18.4 Plant-expression Systems for Antigen Production

different organisms use these codons with different frequencies. Only a subset of the total number of codons is used by each species. The pattern of codon usage in plants is different from that of other organisms. As well, codon usage in dicots is different from that of monocots [79]. The most important difference in codon usage between dicots and monocots is the G+C content in the third position of a codon [80]. For example, the average %(G+C) in the first, second, and third positions of the codon in maize are 57%, 43%, and 61%, respectively, but in tobacco they are 51%, 40 %, and 39%, respectively (http://www.kazusa.or.jp/codon). Altering the composition of the heterologous cDNA to suit the plant's pattern can increase the rate of translation [21]. When the codon composition of a bacterial gene was modified to suit the preferred codon usage in tobacco, the expression level of the transgene was greatly enhanced [81]. This approach has been applied to other plant species, such as tomato, potato, rice, cotton, eggplant, and maize [82–89]. Mason et al. [31] synthesized the LT-B gene with a codon bias optimized for expression in potato and maize. They observed that the synthetic LT-B gene achieved higher LT-B expression in transgenic potatoes than did the unoptimized gene. The same gene was also expressed with success in maize [46]. 18.4.3 Post-translational Level and Beyond 18.4.3.1 Targeting and Retention Signals Subcellular localization is important for biological activity. Proper folding and stability of plant-synthesized proteins is critical and depends on the cellular environment where the protein is expressed and stored. Sometimes it is not desirable to target a protein to an intracellular compartment, because that may complicate extraction. On the other hand, expression of heterologous proteins in the cytoplasm could also be problematic, due to rapid degradation of foreign proteins by plant defense mechanisms, or because the accumulated protein may be toxic to plant cells. In plants, the default pathway for proteins transported through the ER is secretion, hence the proteins were localized in the extracellular space. The expectation was that higher levels of foreign protein would be obtained if the newly synthesized protein were targeted to the extracellular compartment. Alternatively, the protein could be sequestered into a compartment or organelle that may allow higher levels of protein accumulation. Signal peptides have been used to influence the levels of protein accumulation and its spatial distribution within transgenic plant tissue. The barley a-amylase signal peptide was used to target avidin [45] and aprotinin [90] to the extracellular matrix of maize cells. Yields of foreign proteins have reached up to 2 % (for avidin) and 0.069% (for aprotinin) of the aqueous soluble extracted protein from dry maize seed. Avidin targeted to the cytosol was completely toxic to engineered maize cells [45]. Targeting recombinant antibodies to the secretory pathway could significantly increase antibody yield compared to targeting to the cytosol [91]. It was observed that, although targeting proteins to the intercellular space beneath the cell wall increased expression levels, their retention in the lumen of the endoplasmic reticulum could result in 10- to 100-fold higher yields of recombinant antibody single chain Fv (scFv) in potato tubers, as well as tobacco leaves and seeds [91–93].

399

400

18 Plant-based Oral Vaccines

The SEKDEL (Ser-Glu-Lys-Asp-Glu-Leu) or KDEL (Lys-Asp-Glu-Leu) amino acid motifs have been used to retain the foreign proteins in the ER. The SEKDEL amino acid motif binds to the SEKDEL receptor in the ER [94]. Haq et al. [33] showed that the SEKDEL motif resulted in significantly higher LT-B accumulation compared with the LT-B gene without SEKDEL. These authors proposed that the cellular compartmentation of the SEKDEL protein could have facilitated oligomerization of LT-B monomers into pentamers detectable by ganglioside-dependent ELISA. In maize, the effect of SEKDEL on protein levels was seen in conjunction with certain promoters. Our early work [95] showed that, when a constitutive promoter (CaMV 35S) was used to drive the LT-B gene, the inclusion of the SEKDEL signal sequence did not enhance the LT-B level in maize plants (callus tissue or seed). However, when the sequence encoding SEKDEL was included in a construct in which the LT-B gene was driven by the 27-kDa g zein promoter (a seed-specific promoter), LT-B protein levels were significantly increased, up to 13 fold compared to the highest LTB expression from constructs carrying no SEKDEL. 18.4.3.2 Stability of Gene Expression and Transmission of the Transgene Differences in gene expression between transgenic events have been reported, perhaps due to different gene copy numbers and to the relative position of transgene insertion in the genome of the transgenic plants [66, 68, 96]. Variability in gene expression that was not attributable to any obvious genetic or environmental factors has also been observed. Molecular mechanisms causing unstable expression of foreign genes are not clearly understood, but the presence of multiple copies of the transgene and large variations in the amount of steady-state mRNA among individuals from the same transgenic event suggest that repeat-induced transgene silencing could be involved in regulation of foreign gene expression in transgenic plants [90]. Only those events expressing the desired levels of gene expression should be pursued. Variability in gene expression between generations has been observed [45, 90, 95]. The phenomenon of gene silencing in transgenic plants occurs in later generations of highly expressing transgenic lines. In our LT-B corn study, we monitored LTB levels under greenhouse and field conditions over three generations. Significant variability in gene expression was observed between transgenic events and between plants within the same event. A maximum of 0.3 % LT-B in TAEP (total aqueous extractable proteins) was measured in R3 seed of a transgenic line carrying a CaMV 35S promoter/LT-B construct. In R3 seed of a transgenic line carrying the g zein promoter/LT-B construct, up to 3.7 % LT-B in TAEP could be detected [95].

18.5 Maize as Production and Delivery System

Maize has been demonstrated to be an effective expression system for functional proteins of prokaryotic [46, 90, 97, 98], viral [98], and eukaryotic [45, 99] origin. The commercialization of b-glucosidase [97], aprotinin [90], and avidin [45] has demonstrated the viability of this expression system.

18.5 Maize as Production and Delivery System

There are several benefits to producing antigens for use as edible vaccines in maize. Maize is a major food and feed crop worldwide, which is well tolerated by both humans and animals. In addition, maize yields are high and its seed is a natural protein storage site, which can be harnessed as a novel-protein production factory for direct use as feed and food. According to Hood and coworkers [27], maize can be used to produce foreign proteins at rates of more than 2 kilograms per acre at a cost of a few cents per milligram. Breeding techniques can be used in this crop to enhance foreign protein expression [45, 95, 97, 98] and to stack several antigens in the same crop. Antigens produced in corn can be conveniently stored and transported in dry grain. Production of an efficacious maize-based oral vaccine will provide effective and less expensive control of some important gut pathogens, for which mucosal immunity is important for protection. Moreover, the infrastructure for large-scale grain production and seed processing is in place for the crop in the U.S. The production of oral vaccines in maize grain or silage presents an opportunity to add value to unprocessed maize and to increase income for farmers. Finally, the genetic transformation methods are well established, allowing introduction of transgenes with reasonable efficiency. We discuss here the production of the B subunit of the enterotoxigenic E. coli (ETEC) heat-labile enterotoxin (LT-B), and highlight some findings in the expression of a vaccine against transmissible gastroenteritis virus (TGEV) in transgenic maize seed. LT-B is part of the heat-labile toxin (LT) produced by enterotoxigenic strains of E. coli, a leading cause of diarrhea in developing countries [100]. About 66 % of enterotoxigenic strains of E. coli produce LT, and in half of these LT is the only toxin produced [101]. The bacterium is ingested in contaminated food or water and colonizes the gut, where it secretes toxins, including LT. LT is an 84-kDa polymeric protein composed of 2 major noncovalently associated, immunologically distinct regions or domains designated LT-A and LT-B. The A region (27 kDa) has the toxic enzymatic activity responsible for watery diarrhea [100]. LT-B is 55 kDa and consists of five noncovalently bound 11.6-kDa B subunits. These nontoxic B subunits are responsible for binding the protein to receptors on the surface of intestinal epithelial cells. Pentameric LT-B is responsible for binding the toxin to the host cell receptor, GM1 (galactosyl-N-acetylgalactosaminyl-sialyl galactosyl glucosyl ceramide), which is commonly found on the surface of eukaryotic cells. LT-B is a strong oral immunogen that could potentially be used as a component of a vaccine against ETEC diarrhea or as an adjuvant to enhance the effectiveness of coadministered vaccines [102]. Early work on LT-B expression in plants was reported in transgenic potato and tobacco plants [33]. In subsequent work a synthetic gene with codon usage optimized for expression in potato and maize was introduced into potato. Codon optimization resulted in increased expression of LT-B in potatoes [31]. Mice orally immunized with five 50-mg doses of LT-B over a 3-week period showed higher titers of anti-LT-B serum IgG and fecal IgA antibodies than in an earlier experiment [33]. These mice were partially protected from challenge with a 25-µg dose of LT. This work paved the way for subsequent work on LT-B expression in corn. To date, LT-B produced in potato and maize has been shown to be immunogenic in mice [31, 46, 98] and humans [41].

401

402

18 Plant-based Oral Vaccines

Antigens that are produced in maize seed can be directed to specific compartments within the seed. Expression can be directed to the endosperm by using endosperm-specific promoters or to embryo (germ) by using constitutive promoters as described in section 18.4.1.1. Endosperm and germ compose 83 % and 11% of a corn kernel, respectively [103]. The major chemical components of the endosperm fraction are starch (88 %) and protein (8 %); the germ contains fat (33 %), protein (18 %), and starch (8 %). The advantages of vaccine expression in germ are that it is rich in soluble proteins that are stable during storage, and it can be separated from other seed tissues to concentrate proteins and reduce dose size. Expression of vaccine in endosperm, on the other hand, may allow higher yields and ease of protein extraction, especially if the protein of interest can be separated together with the starch fraction. In practice, production of vaccine antigens in either tissue allows for processing of more palatable whole-corn snacks for humans or for production of unprocessed whole corn meal for livestock. 18.5.1 Antigen Production in Endosperm Tissue of Maize Seed

By using a codon-optimized synthetic LT-B gene [31], we have produced transgenic maize plants with LT-B expressed in either endosperm or germ of maize seed [46, 95]. We examined both seed-specific and constitutive expression using the maize 27kDa g zein and the CaMV 35S promoters, respectively, and also examined the effects of the SEKDEL endoplasmic reticulum retention motif. Ganglioside-dependent ELISA was used to determine the level of LT-B expression, because this technique detects only the correctly assembled pentameric form of LT-B which binds to gangliosides [100]. LT-B was analyzed in callus or ground whole kernel meal in a sodium phosphate buffer [46]. Constitutive expression resulted in levels of expression estimated at 0.01% LT-B in the total aqueous-extractable protein (TAEP) in R1 seed and 0.3 % in field-grown R3 kernels of the best-performing line. The maize 27-kDa g zein promoter, which directs endosperm-specific gene expression in maize kernels, showed higher expression and is discussed here in some detail. Use of the maize 27-kDa g zein promoter resulted in functional (ganglioside-binding) LT-B expression that was estimated as 0.07 % in R1 kernels of the selected highest-expressing transgenic event, which continued to increase in the R2 and R3 generations. Average individual ear expression was estimated to be about 3.7 % LT-B in total soluble protein. Inclusion of both SEKDEL and the g zein promoter resulted in a substantial increase in LT-B levels. Such an effect was not observed when this ER retention signal was combined with LT-B under the regulation of the constitutive CaMV35S promoter [95]. Significant variability of LT-B expression was noted between the different transgenic events, but perhaps most importantly, between plants within the same transgenic event. This variability could have important implications for the production of lines with high, stable, predictable levels of an antigenic vaccine in transgenic corn [95]. In our experiments, accurate quantification of LT-B in corn meal depended on the fineness to which the meal was ground, the length of time the meal was incubated

18.5 Maize as Production and Delivery System

in extraction buffer, the presence of detergents such as Triton-X100 in the extraction buffer, and suitable dilution of the seed extracts for the ELISA procedure. The presence of a high concentration of Triton in seed extracts inhibited the ELISA reaction and thus could lead to underestimation of the LT-B expression level (R. Chikwamba, unpublished). An intricate association was observed between LT-B and starch, which was shown by the persistence of LT-B in starch samples subjected to digestion by proteolytic enzymes. Digestion of whole kernel meal showed that the LT-B associated with maize tissues was 10 times more resistant to peptic degradation than recombinant LT-B mixed with an equal amount of nontransgenic corn meal [122]. Feeding experiments were conducted to determine the immunogenicity of the corn-derived LT-B. BALB/C mice were given four 1-g doses delivering 10 mg LT-B per dose in one gram of corn pellet on days 0, 3, 7, and 21. For positive controls, we used 10 mg of soluble recombinant LT-B from bacteria (John Clements) mixed with 1 g of nontransgenic corn; and for negative controls, we fed mice 1 g of nontransgenic corn. Analysis of sera and feces showed the induction of anti-LT-B and anti-CT-B serum and mucosal antibodies, which increased over the immunization period. The corn-derived LT-B was more immunogenic than an equivalent amount of soluble recombinant LT-B (positive control group). The orally immunized mice were then challenged with 25 µg of LT or CT toxins. The mice that received transgenic or recombinant LT-B showed less fluid accumulation in the gut than the nonimmunized controls fed with nontransgenic corn. Mice immunized with transgenic corn had the least fluid accumulation, showing that the transgenic corn was a more effective than recombinant LT-B from bacteria. We speculated from these observations that the natural bioencapsulation of LT-B in transgenic maize resulted in slow release of LT-B and perhaps prolonged exposure of the immune system to LT-B than with the recombinant (soluble) LT-B. Similar observations were made with yeast-derived recombinant and potato-encapsulated HBsAg [38]. We concluded from this work that LT-B generated in maize endosperm was a competent immunogen, and further studies will determine the potency of this antigen in humans. 18.5.2 Antigen Production in Embryo (Germ) Tissue of Maize Seed

Streatfield and coworkers [98, 104] also reported the production of synthetic LT-B in transgenic maize. They used an unspecified maize constitutive promoter to express a synthetic LT-B gene with a barley a-amylase signal peptide in maize. The bulk of the LT-B expression was primarily in the germ of transgenic kernels [98]. The level of LT-B expression reported was up to 9.2 % LT-B in TAEP for an individual R3 kernel. They used breeding techniques such as elite inbred lines to enhance the performance of LT-B-producing maize, using the transgenic lines as the pollen source. Their estimates of LT-B expression were based on total (as compared to functional) LT-B, which was quantified by using a polyclonal antibody as capture in a sandwich ELISA; however, in the study described in section 18.5.1, we used GM1 gangliosides to capture the multimeric form of LT-B, which is functional. Streatfield and cowor-

403

404

18 Plant-based Oral Vaccines

kers observed up to a 40 % difference in the amount of LT-B measured, depending on whether a polyclonal antibody or GM1 gangliosides were used as captures in sandwich ELISA assays. Polyclonal antibody resulted in higher estimates when used in conjunction with a biotinylated antibody to detect the captured LT-B. Oral delivery of this LT-B to BALB/c mice resulted in the induction of protective oral and systemic immune responses. One of the key findings of the work by Streatfield and coworkers [104] was that LT-B in transgenic maize kernel matrix was very heat resistant, withstanding temperatures up 170 °C, thus allowing heat extrusion to be used during processing. This is desirable for the industrial processing of maize expressing antigens into suitable formulations that can be practically administered. Streatfield and coworkers [98, 104] also reported the production of another edible vaccine against the swine transmissible gastroenteritis virus (TGEV), which causes a severe diarrheal disease with high mortality in young piglets. This disease is economically important in commercial swine operations. TGEV is a multisubunit positive-strand RNA virus, encoding the membrane (M), nucleocapsid (N), and the spike (S) protein [105]. The S protein is a large surface glycoprotein that is involved in virus neutralization. The S protein was expressed in transgenic maize kernels. Expression levels reported were substantial, allowing oral delivery of 2 mg of the S protein in 50 g of transgenic corn. Oral administration of the maize expressing the S protein to piglets resulted in induction of a protective immune response in young piglets and subsequent protection from clinical levels of the virus [106]. Dosage regimes are critical for the quality of immune responses elicited upon oral administration of plant-based vaccines. In many studies, a low yield of antigen expressed in transgenic plants resulted in poor immune responses after oral administration. In other studies, repeated dosages were necessary. Using the S protein corn or the commercial vaccine, Lamphear and coworkers (2002) [106] studied different dosage regimes (4, 8, or 16 consecutive days) in oral immunization. They reported that with challenge to TGEV the animals fed on the S protein-producing corn for a 4-day regimen showed no morbidity, but 50 % of animals fed nontransgenic corn displayed symptoms. The animals fed the transgenic corn for 8 and 16 consecutive days showed 20 % and 36 % morbidity, respectively, with challenge, indicating that the 4-day regimen was more effective in protecting the pigs. The frequency of dosage is therefore critical for obtaining effective protection against this pathogen. Piglets immunized with the commercial vaccine showed 9 % morbidity with challenge compared to no morbidity in the animals immunized with the corn-derived vaccine on the 4-day dosage regime. These data suggest that the corn-derived S protein was somewhat more effective than the currently available conventional vaccine. This study represents one of the most comprehensive studies done with a corn-based edible vaccine, demonstrating its clinical efficaciousness in a practical situation.

18.5 Maize as Production and Delivery System

18.5.3 Pharmaceutical Crop Production and Containment

Because maize is one of the most important crops globally, many issues arise regarding its use as a source of biopharmaceuticals. So far, no biopharmaceutical crops have been approved for commercial use, although nearly 40 plant-made pharmaceuticals and industrial products are nearing commercialization. Major concerns, especially relating to vaccine-producing maize plants, include whether the antigens will inadvertently enter the food chain and what preventive measures are in place. In the U.S., there are two types of growing systems for maize: commodity grain production and identity preservation. The first system is used for producing most maize grain in the United States, and the second system is used for specialty maizes, such as starch- or ethanol-producing maize. No specific regulations or restrictions cover either production system, except that in the identity-preservation system grains must be segregated from commodity maize during transportation and storage. For pharmaceutical-producing maize plants, a more stringent containment production system is required to prevent possible contamination from both directions. One major concern about contamination is the potential for pollen drifting to neighboring fields. However, maize pollen is heavy compared with that of other species, and the majority of shed pollen falls within several feet of the parent plant. In addition, the pollen has a relatively short half life. Its viability decreases drastically within minutes (less than 20 min) after it is shed [107]. Several measures can be taken to prevent pollen contamination by a vaccine-producing corn plant. First, any APHIS (Animal and Plant Health Inspection Service, USA)-approved pharmaceutical maize field release currently requires a distance segregation of 1 mile (1.6 km) from the nearest other maize plants. This physical isolation is eight times greater than the distance required for producing foundation corn seed or in the identity-preservation production system. Second, the confinement strategies for transgenic maize produced under permit include conditions that confine its pollen so that it cannot pollinate surrounding maize. APHIS currently rules that maize may be grown within a half mile (0.8 km) of the test site if the test site maize is control-pollinated (using detasseling or bagging procedures). Surrounding maize must also be temporally isolated by planting it no fewer than 28 days before or after the regulated maize being field tested. In addition to these physical and temporal isolations, it is also possible to produce vaccines in maize varieties that are male-sterile. Several cytoplasmic male-sterile varieties producing nearly 0 % variable pollen can be used for this purpose [108]. Transgenic male-sterile corn will grow only silk, the female flower, which will be pollinated by a nontransgenic maize pollen to set seed. Half the seed obtained from this breeding approach will contain the proteins of interest.

405

406

18 Plant-based Oral Vaccines

18.6 Concluding Remarks

Plant-derived edible vaccines have enormous potential in producing safe, efficacious, inexpensive vaccines benefiting mankind, especially in the developing world. Maize seed can potentially become one of the most productive biofactories for pharmaceuticals. The physiological yield potential of maize under nonlimiting conditions has been estimated to be 31.4 to 81.5 tons ha–1 [109]. In reality, average maize yields in the U.S. are around 8 tons ha –1, according to the U.S. National Corn Growers Association (http://www.ncga.com/03world/main/consumption.htm). Using the g zein promoter, we have obtained transgenic maize plants with LT-B levels up to 350 mg g –1 of dry kernel. This expression level is therefore more than what is required to induce a protective immune response in experimental mice. Mason et al. [31] suggested that up to 1.1 mg per dose would be required to induce a protective immune response in humans, and this dosage requirement could be met with 3 g of dry maize meal from these transgenic kernels. Thus, from a 1-ha maize field with an average yield of 8 tons ha –1, one can harvest about 2.8 kg of LT-B protein (350 mg × 8 × 106). Although edible plant vaccines have shown tremendous pharmaceutical promise, several hurdles remain to be overcome. In the maize work discussed above, experimental results have demonstrated that biologically functional antigens can be produced in plants, can be conveniently used to orally immunize animals, and protected some of the animals from challenge with toxins or disease pathogens. Although functionally similar, it is yet to determine whether these maize-derived antigens are glycosylated differently than those from other systems. The biosynthesis of the glycan moiety is different in plant and mammalian systems [110, 111]. This difference could present obstacles for plant-derived pharmaceuticals. For example, lack of proper glycosylation could lead to the plant-derived subunit vaccines being less immunogenic and less efficacious than those produced in mammalian systems. In addition, inappropriate glycosylation by the plant system could make the plant-derived proteins allergenic to mammals upon immunization. Research focusing in this area is just getting under way. Limited biochemical and immunological studies have indicated that plantderived antibodies have a greater diversity of glycan structures than the same products made in other expression systems [112, 113]. It is possible that plant-specific N-glycosylation could represent a limitation for the use of certain recombinant glycoproteins of human origin produced in transgenic plants. But the good news is that one may not have to be concerned about allergenicity of such products if they are produced in edible tissues of a well-tolerated crop plant, such as maize.

Acknowledgements

The authors wish to thank Dr. D. L. (Hank) Harris for his critical review of the manuscript and helpful discussion.

References

References 1. Atkinson W, Wolfe CS. Epidemiology and prevention of vaccine-preventable diseases. 7th ed. ed. Atlanta, GA, USA: Dept. of Health & Human Services, Public Health Service, Centers for Disease Control and Prevention, 2002. 2. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000; 18:1436–47. 3. Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 2002; 23:209–13. 4. Santana MA, Rosenstein Y. What it takes to become an effector T cell: The process, the cells involved, and the mechanisms. J Cell Physiol 2003; 195:392– 401. 5. Arakawa T,Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plantbased cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998; 16:934–38. 6. Cripps AW, Kyd JM, Foxwell AR. Vaccines and mucosal immunisation. Vaccine 2001; 19:2513–15. 7. Xu-Amano J, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD, Elson CO, Pillai S, McGhee JR. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993; 178:1309–20. 8. Morris W, Steinhoff MC, Russell PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12:5–11. 9. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15:1326–31. 10. Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 2002; 70:1143–49.

11. Millar DG, Hirst TR, Snider DP. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin. Infect Immun 2001; 69:3476–82. 12. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. Mucosal vaccines: non toxic derivatives of LTand CTas mucosal adjuvants. Vaccine 2001; 19:2534–41. 13. Bowman CC, Clements JD. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heatlabile enterotoxin hybrids. Infect Immun 2001; 69:1528–35. 14. Lu X, Clements JD, Katz JM. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 2002; 20:1019– 29. 15. McNeela EA, O'Connor D, JabbalGill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000; 19:1188– 98. 16. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KH. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 2000; 165:5750–59. 17. Del Giudice G, Podda A, Rappuoli R. What are the limits of adjuvanticity? Vaccine 2002; 20:S38-S41. 18. Snider DP, Marshall JS, Perdue MH, Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1994; 153:647–57.

407

408

18 Plant-based Oral Vaccines 19. Li XM, Serebrisky D, Lee SY, Huang CK, Bardina L, Schofield BH, Stanley JS, Burks AW, Bannon GA, Sampson HA. A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 2000; 106:150–58. 20. Constant SL, Lee KS, Bottomly K. Site of antigen delivery can influence Tcell priming: pulmonary environment promotes preferential Th2-type differentiation. Eur J Immunol 2000; 30:840–47. 21. Kusnadi AR, Nikolov ZL, Howard JA. Production of recombinant proteins in transgenic plants: Practical considerations. Biotechnology and Bioengineering 1997; 56:473–484. 22. Tacket CO, Mason HS. A review of oral vaccination with transgenic vegetables. Microbes Infect 1999; 1:777–83. 23. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci 2001; 6:219–26. 24. Koprowski H,Yusibov V. The green revolution: plants as heterologous expression vectors. Vaccine 2001; 19:2735–41. 25. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 2002; 8:324–29. 26. Pen J, Sijmons PC, van Ooijen AJJ, Hoekema A. Protein production in transgenic crops: Analysis of plant molecular farming. In: Hiatt A, ed. Transgenic plants: fundamentals and applications. New York: Elsevier, 1993 : 239–241. 27. Hood EE, Kusnadi A, Nikolov Z, Howard JA. Molecular farming of industrial proteins from transgenic maize. Adv Exp Med Biol 1999; 464:127–47. 28. Palmer KE, Arntzen CJ, Lomonossoff GP. Antigen Delivery Systems III. Transgenic Plants and Recombinant Plant Viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Mucosal Immunology. 2nd edition ed. San Deigo, CA, USA: Academic Press, 1999 : 793–807. 29. Cramer CL, Boothe JG, Oishi KK.

30.

31.

32.

33.

34.

35.

36.

37.

38.

Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Curr Top Microbiol Immunol 1999; 240:95–118. Tuboly T,Yu W, Bailey A, Degrandis S, Du S, Erickson L, Nagy E. Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants. Vaccine 2000; 18:2023–28. Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998; 16:1336–43. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000; 18:1167–71. Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995; 268:714–16. Tregoning JS, Nixon P, Kuroda H, Svab Z, Clare S, Bowe F, Fairweather N,Ytterberg J, van Wijk KJ, Dougan G, Maliga P. Expression of tetanus toxin Fragment C in tobacco chloroplasts. Nucleic Acids Res 2003; 31:1174–79. Ruf S, Hermann M, Berger IJ, Carrer H, Bock R. Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit. Nat Biotechnol 2001; 19:870–75. Wigdorovitz A, Carrillo C, Dus Santos MJ, Trono K, Peralta A, Gomez MC, Rios RD, Franzone PM, Sadir AM, Escribano JM, Borca MV. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999; 255:347–53. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O,Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. A plant-derived edible vaccine against hepatitis B virus. Faseb J 1999; 13:1796–99. Kong Q, Richter L,Yang YF, Arnt-

References

39.

40.

41.

42.

43.

44.

45.

46.

zen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci U S A 2001; 98:11539–44. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000; 182:302–05. Stoger E,Vaquero C, Torres E, Sack M, Nicholson L, Drossard J, Williams S, Keen D, Perrin Y, Christou P, Fischer R. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000; 42:583–90. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998; 4:607–09. Christensen AH, Quail PH. Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants. Transgenic Res 1996; 5:213–18. Odell JT, Nagy F, Chua NH. Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter. Nature 1985; 313:810–12. Marks MD, Lindell JS, Larkins BA. Quantitative analysis of the accumulation of Zein mRNA during maize endosperm development. J Biol Chem 1985; 260:16445–50. Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, Flynn P, Register J, Marshall L, Bond D, Kulisek E, Kusnadi A, Evangelista R, Nikolov Z, Wooge C, Mehigh RJ, Hernan R, Kappel WK, Ritland D, Li CP, Howard JA. Commerical production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Molecular Breeding 1997; 3:291–306. Chikwamba R, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K. A functional antigen in a practical crop:

47.

48.

49.

50.

51.

52.

53.

54.

55.

56.

LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res 2002; 11:479–93. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999; 286:481–86. Stam M,Viterbo A, Mol JN, Kooter JM. Position-dependent methylation and transcriptional silencing of transgenes in inverted T-DNA repeats: implications for posttranscriptional silencing of homologous host genes in plants. Mol Cell Biol 1998; 18:6165–77. Park YD, Papp I, Moscone EA, Iglesias VA,Vaucheret H, Matzke AJ, Matzke MA. Gene silencing mediated by promoter homology occurs at the level of transcription and results in meiotically heritable alterations in methylation and gene activity. Plant J 1996; 9:183–94. Matzke AJ, Matzke MA. Position effects and epigenetic silencing of plant transgenes. Curr Opin Plant Biol 1998; 1:142–48. Komari T, Kubo T. Methods of genetic transformation: Agrobacterium tumefaciens. In: Vasil IK, ed. Molecular Improvement of Cereal Crops. Great Britain: Kluwer Academic Publishers, 1999 : 43–82. Sanford JC. Turning point article The development of the biolistic process. In Vitro Cell Dev Biol 2000; 36:303–308. Birch RG. Application of gene transfer to crop improvement. In: O'Brien L, Henry RJ, eds. Transgenic cereals. St. Paul, Minnesota, USA: American Association of Cereal Chemists, 2000 : 267– 276. Dai S, Zheng P, Marmey P, Zhang S, Tian W, Chen S, Beachy RN, Fauquet C. Comparative analysis of transgenic rice plants obtained by Agrobacterium-mediated transformation and particle bombardment. Molecular Breeding 2001; 7:25–33. Callis J, Fromm M,Walbot V. Introns increase gene expression in cultured maize cells. Genes Dev 1987; 1:1183– 1200. Mascarenhas D, Mettler IJ, Pierce DA, Lowe HW. Intron-mediated en-

409

410

18 Plant-based Oral Vaccines

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

hancement of heterologous gene expression in maize. Plant Mol Biol 1990; 15:913–20. Luehrsen KR, Walbot V. Intron enhancement of gene expression and the splicing efficiency of introns in maize cells. Mol Gen Genet 1991; 225:81–93. Clancy M, Hannah LC. Splicing of the maize Sh1 first intron is essential for enhancement of gene expression, and a T-rich motif increases expression without affecting splicing. Plant Physiol 2002; 130:918–29. Rethmeier N, Seurinck J,Van Montagu M, Cornelissen M. Intronmediated enhancement of transgene expression in maize is a nuclear, genedependent process. Plant J 1997; 12:895–99. Gutierrez RA, MacIntosh GC, Green PJ. Current perspectives on mRNA stability in plants: multiple levels and mechanisms of control. Trends Plant Sci 1999; 4:429–438. Ingelbrecht IL, Herman LM, Dekeyser RA,Van Montagu MC, Depicker AG. Different 3´ end regions strongly influence the level of gene expression in plant cells. Plant Cell 1989; 1:671– 80. Mogen BD, MacDonald MH, Leggewie G, Hunt AG. Several distinct types of sequence elements are required for efficient mRNA 3´ end formation in a pea rbcS gene. Mol Cell Biol 1992; 12:5406–14. De Rocher EJ,Vargo-Gogola TC, Diehn SH, Green PJ. Direct evidence for rapid degradation of Bacillus thuringiensis toxin mRNA as a cause of poor expression in plants. Plant Physiol 1998; 117:1445–1461. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995; 20:465–70. Ohme-Takagi M, Taylor CB, Newman TC, Green PJ. The effect of sequences with high AU content on mRNA stability in tobacco. Proc Natl Acad Sci U S A 1993; 90:11811–15. Kooter JM, Matzke MA, Meyer P. Listening to the silent genes: transgene silencing, gene regulation and pathogen

67.

68.

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

control. Trends Plant Sci 1999; 4:340– 347. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999; 286:950–52. Fagard M,Vaucheret H. (Trans)gene siliencing in plants: How many mechanisms? Annu Rev Plant Physiol Plant Mol Biol 2000; 51:167–94. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2:110–19. Jagus R, Anderson WF, Safer B. The regulation of initiation of mammalian protein synthesis. Prog Nucleic Acid Res Mol Biol 1981; 25:127–85. Gallie DR. The role of post-transcriptional control in transgenic gene design. In: Owen MRL, Pen J, eds. Transgenic plants: a production system for indusctrial and pharmaceutical proteins. Chichester; New York: J. Wiley, 1996 : 50–74. Joshi CP, Zhou H, Huang X, Chiang VL. Context sequences of translation initiation codon in plants. Plant Mol Biol 1997; 35:993–1001. Gallie DR, Sleat DE, Watts JW, Turner PC, Wilson TM. The 5´ -leader sequence of tobacco mosaic virus RNA enhances the expression of foreign gene transcripts in vitro and in vivo. Nucleic Acids Res 1987; 15:3257–73. Jobling SA, Gehrke L. Enhanced translation of chimaeric messenger RNAs containing a plant viral untranslated leader sequence. Nature 1987; 325:622–25. Carrington JC, Freed DD. Cap-independent enhancement of translation by a plant potyvirus 5´ nontranslated region. J Virol 1990; 64:1590–97. Gallie DR, Lucas WJ, Walbot V. Visualizing mRNA expression in plant protoplasts: factors influencing efficient mRNA uptake and translation. Plant Cell 1989; 1:301–311. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89:11745–49. Mason HS, Ball JM, Shi JJ, Jiang X,

References

79.

80.

81.

82.

83.

84.

85.

86.

Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996; 93:5335–40. Gowri G, Campbell WH. Complementary DNA Clones for Corn Leaf Nadh Nitrate Reductase and Chloroplast NadPpositive Glyceraldehyde-3-Phosphate Dehydrogenase Characterization of the Clones and Analysis of the Expression of the Genes in Leaves as Influenced by Nitrate in the Light and Dark. Plant Physiology 1989; 90:792–98. Murray EE, Lotzer J, Eberle M. Codon usage in plant genes. Nucleic Acids Res 1989; 17:477–98. Perlak FJ, Fuchs RL, Dean DA, McPherson SL, Fischhoff DA. Modification of the coding sequence enhances plant expression of insect control protein genes. Proc Natl Acad Sci U S A 1991; 88:3324–28. Perlak FJ, Deaton RW, Armstrong TA, Fuchs RL, Sims SR, Greenplate JT, Fischhoff DA. Insect resistant cotton plants. Biotechnology (N Y) 1990; 8:939–43. Adang MJ, Brody MS, Cardineau G, Eagan N, Roush RT, Shewmaker CK, Jones A, Oakes JV, McBride KE. The reconstruction and expression of a Bacillus thuringiensis cryIIIA gene in protoplasts and potato plants. Plant Mol Biol 1993; 21:1131–45. Fujimoto H, Itoh K,Yamamoto M, Kyozuka J, Shimamoto K. Insect resistant rice generated by introduction of a modified delta- endotoxin gene of Bacillus thuringiensis. Biotechnology (N Y) 1993; 11:1151–55. Koziel GM, Beland GL, Bowman C, Carozzi NB, Crenshaw R, Crossland L, Dawson J, Desai N, Hill M, Kadwell S, Launis K, Lewis K, Maddox D, McPherson K, Meghji MR, Merlin E, Rhodes R,Warren GW, Wright MS, Evola SV. Field performance of elite transgenic maize plants expressing an insecticidal protein derived from Bacillus thuringiensis. Bio Technology 1993; 11:194–200. van der Salm T, Bosch D, Honee G, Feng L, Munsterman E, Bakker P,

87.

88.

89.

90.

91.

92.

Stiekema WJ,Visser B. Insect resistance of transgenic plants that express modified Bacillus thuringiensis cryIA(b) and cryIC genes: a resistance management strategy. Plant Mol Biol 1994; 26:51–59. Armstrong CL, Parker GB, Pershing JC, Brown SM, Sanders PR, Duncan DR, Stone T, Dean DA, Deboer DL, Hart J, Howe AR, Morrish FM, Pajeau ME, Petersen WL, Reich BJ, Rodriguez R, Santino CG, Sato SJ, Schuler W, Sims SR, Stehling S, Tarochione LJ, Fromm ME. Field evaluation of European corn borer control in progeny of 173 transgenic corn events expressing an insecticidal protein from Bacillus thuringiensis. Crop Science 1995; 35:550–557. Jansens S, Cornelissne M, De CR, Reynaerts A, Peferoen M. Phthorimaea operculella (Lepidoptera: Gelechiidae) resistance in potato by expression of the Bacillus thuringiensis CryIA(b) insecticidal crystal protein. Journal of Economic Entomology 1995; 88:1469–1476. Iannacone R, Grieco PD, Cellini F. Specific sequence modifications of a cry3B endotoxin gene result in high levels of expression and insect resistance. Plant Mol Biol 1997; 34:485–96. Zhong GY, Peterson D, Delaney DE, Bailey M,Witcher DR, Register JC, III, Bond D, Li CP, Marshall L, Kulisek E, Ritland D, Meyer T, Hood EE, Howard JA. Commercial production of aprotinin in transgenic maize seeds. Molecular Breeding 1999; 5:345–56. Conrad U, Fiedler U. Compartmentspecific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol Biol 1998; 38:101–09. Schouten A, Roosien J, van Engelen FA, de Jong GA, Borst-Vrenssen AW, Zilverentant JF, Bosch D, Stiekema WJ, Gommers FJ, Schots A, Bakker J. The C-terminal KDEL sequence increases the expression level of a singlechain antibody designed to be targeted to both the cytosol and the secretory

411

412

18 Plant-based Oral Vaccines

93.

94.

95.

96.

97.

98.

99.

100.

101.

102.

103.

pathway in transgenic tobacco. Plant Mol Biol 1996; 30:781–93. Fiedler U, Phillips J, Artsaenko O, Conrad U. Optimization of scFv antibody production in transgenic plants. Immunotechnology 1997; 3:205–16. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48:899–907. Chikwamba R, McMurray J, Shou H, Frame B, Pegg SE, Scott P, Mason H, Wang K. Expression of a synthetic E. coli heat-labile enterotoxin B subunit (LT-B) in maize. Mol. Breeding 2002; 10:253–265. Matzke MA, Matzke A. How and Why Do Plants Inactivate Homologous (Trans)genes? Plant Physiol 1995; 107:679–685. Witcher DR, Hood EE, Peterson D, Bailey M, Bond D, Kusnadi A, Evangelista R, Nikolov Z, Wooge C, Mehigh R, Kappel W, Register J, Howard JA. Commercial production of beta-glucuronidase (GUS): A method system for the production of proteins in plants. Molecular Breeding 1998; 4:301– 312. Streatfield SJ, Jilka JM, Hood EE, Turner DD, Bailey MR, Mayor JM, Woodard SL, Beifuss KK, Horn ME, Delaney DE, Tizard IR, Howard JA. Plant-based vaccines: unique advantages. Vaccine 2001; 19:2742–48. Yang SH, Moran DL, Jia HW, Bicar EH, Lee M, Scott MP. Expression of a synthetic porcine alpha-lactalbumin gene in the kernels of transgenic maize. Transgenic Res 2002; 11:11–20. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992; 56:622–47. Svennerholm AM, Holmgren J. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Adv Exp Med Biol 1995; 8:1623–28. Dickinson BL, Clements JD. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines: Academic Press, 1996 : 73–87. Johnson LA. Corn: The Major Cereal of the Amricas. In: Kulp K, Ponte Jr.

104.

105.

106.

107.

108.

109.

110.

111.

112.

JG, eds. Handbook of Cereal Science and Technology. 2nd edition ed. New York, NY, USA: Marcel Dekker Inc., 2000 : 31–80. Streatfield SJ, Mayor JM, Barker DK, Brooks C, Lamphear BJ, Woodard SL, Beifuss KK,Vicuna DV, Massey LA, Horn ME, Delaney DE, Nikolov ZL, Hood EE, Jilka JM, Howard JA. Development of an edible subunit vaccine in corn against enterotoxigenic strains of Escherichia coli. In Vitro Cell. Dev. Biol. – Plant 2002; 38:11–17. Jimenez G, Correa I, Melgosa MP, Bullido MJ, Enjuanes L. Critical epitopes in transmissible gastroenteritis virus neutralization. J Virol 1986; 60:131–39. Lamphear BJ, Streatfield SJ, Jilka JM, Brooks CA, Barker DK, Turner DD, Delaney DE, Garcia M, Wiggins B, Woodard SL, Hood EE, Tizard IR, Lawhorn B, Howard JA. Delivery of subunit vaccines in maize seed. J Control Release 2002; 85:169–80. Neuffer MG. Growing maize for genetic studies. In: Freeling M,Walbot V, eds. The Maize Handbook. New York, NY, USA: Springer, 1994 : 197–209. Gabay-Laughnan S, Laughnan JR. Male sterility and restorer genes in maize. In: Freeling M,Walbot V, eds. The Maize Handbook. New York, NY, USA: Springer, 1994 : 418–423. Tollenaar M. What is the current upper limit of corn productivity? Conference on Physiology, Biochemistry and Chemistry Associated with Maximum Yield Corn. St. Louis, Missouri, USA: Foundation for Agronomic Research and Patash and Phosphate Institute, 1985. Lerouge P, Cabanes-Macheteau M, Rayon C, Fischette-Laine AC, Gomord V, Faye L. N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol Biol 1998; 38:31–48. Jenkins N, Parekh RB, James DC. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol 1996; 14:975–81. Ma JK, Hikmat BY, Wycoff K,Vine ND, Chargelegue D,Yu L, Hein MB,

References

113.

114.

115.

116.

117.

118.

Lehner T. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 1998; 4:601–06. Samyn-Petit B, Gruber V, Flahaut C, Wajda-Dubos JP, Farrer S, Pons A, Desmaizieres G, Slomianny MC, Theisen M, Delannoy P. N-glycosylation potential of maize: the human lactoferrin used as a model. Glycoconj J 2001; 18:519–27. Walmsley AM, Kirk DD, Mason HS. Passive immunization of mice pups through oral immunization of dams with a plant-derived vaccine. Immunol Lett 2003; 86:71–76. Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotechnol 1998; 16:292–97. Yu J, Langridge WH. A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol 2001; 19:548–52. Gomez N, Carrillo C, Salinas J, Parra F, Borca MV, Escribano JM. Expression of immunogenic glycoprotein S polypeptides from transmissible gastroenteritis coronavirus in transgenic plants. Virology 1998; 249:352–58. Gomez N,Wigdorovitz A, Castanon S, Gil F, Ordas R, Borca MV, Escri-

119.

120.

121.

122.

bano JM. Oral immunogenicity of the plant derived spike protein from swinetransmissible gastroenteritis coronavirus. Arch Virol 2000; 145:1725–32. Carrillo C, Wigdorovitz A, Trono K, Dus Santos MJ, Castanon S, Sadir AM, Ordas R, Escribano JM, Borca MV. Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral Immunol 2001; 14:49–57. Dus Santos MJ,Wigdorovitz A, Trono K, Rios RD, Franzone PM, Gil F, Moreno J, Carrillo C, Escribano JM, Borca MV. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine 2002; 20:1141–47. Gil F, Brun A,Wigdorovitz A, Catala R, Martinez-Torrecuadrada JL, Casal I, Salinas J, Borca MV, Escribano JM. High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Lett 2001; 488:13–17. Chikwamba, R.K., Scott, M.P., Mejia, L.B., Mason, H.S.,Wang, K. Localization of a bacterial protein in starch granules of transgenic maize kernels. Proc. Natl. Acad. Sci. (USA) 2003, 100: 11127–11132.

413

415

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination Martin F. Bachmann and Gary T. Jennings

Summary

The immune system has been educated during evolution and development to distinguish between noninfectious self and infectious nonself. As a result, it can mount strong immune responses to microbial infections but usually fails to respond to self molecules. Understanding the mechanisms that the immune system employs to discriminate self from nonself is critical for our understanding of disease and our ability to rationally design vaccines. In recent years, it has become evident that several factors in addition to B and T cell tolerance contribute to self/nonself discrimination. Key parameters include the order and repetitiveness of antigenic epitopes as well as activation of the innate immune system. The use of virus-like particles (VLPs) for vaccine development may harness this knowledge: VLPs are highly organized, repetitive molecular structures allowing for the induction of strong B cell responses. Moreover, if administered together with stimuli of the innate immune system,VLPs can trigger powerful and protective T cell responses.

19.1 Immunology of Vaccines

Upon infection with a pathogen, the immune system usually mounts an early, innate immune response. This is followed by the adaptive immune reaction; the primary players of the adaptive immune system are B and T cells. The key function of B cells is the production of antibodies. The role of T cells is more diverse and ranges from lysis of infected cells, to secretion of cytokines, to stimulation of B cells and other regulatory functions. The importance of B cells versus T cells and of cytotoxic T cells (CTLs) versus helper (Th) T cells to resolution of infection varies from pathogen to pathogen and from primary to secondary responses (Table 19.1) (for review, see [1]). Although it is difficult to generalize, antibodies are usually more important during secondary infections. Indeed, most pathogens are controlled by antibodies during secondary infections. In contrast, T cells are more important during many primary infections and, in particular, for the containment of chronic infections.

416

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination Tab. 19.1 Effector mechanisms for the elimination of pathogens. Type of infection

Dominant effector mechanism

Example

Primary

antibody, T cell, innate

Secondary Chronic

antibody T cells

rotavirus (Ab), hepatitis B (T Cell), Streptococcus (innate) rotavirus, polio, hepatitis B HIV, HCV

Thus, for prophylactic vaccines, which aim at inducing effector mechanisms that protect from reinfection, the induction of neutralizing antibodies is usually the key parameter. In contrast, for therapeutic vaccination against chronic infection, the emphasis is usually on the stimulation of T cell responses. Hence, depending on the type of vaccine required, induction of antibodies, T cells, or both may be needed.

19.2 Immunology of VLPs 19.2.1 B Cell Responses

Virus-like particles are composed of one or several recombinantly expressed viral proteins that spontaneously assemble into supramolecular, highly repetitive, icosahedral or rod-like structures [2, 3]. Due to their highly repetitive surface, VLPs are able to induce strong B cell responses in the absence of adjuvants by efficiently cross-linking specific receptors on B cells. Moreover, the stimulation of B cells by VLPs is strong enough to elicit T cell-independent induction of IgM antibodies. Hence, VLPs are typical T-cell-independent (TI) B cell antigens. However, because they are composed of protein, they are also capable of inducing Th cells, resulting in an efficient switch from IgM to IgG. Experiments show that immunization of mice results in an early and rapid IgM response, followed by strong and long-lasting isotype-switched IgG responses and germinal center formation [4]. The magnitude of the B cell response is well illustrated by the observation that, three weeks after vaccination with 50 mg of VLPs derived from the bacteriophage Qb, 50 % of all isotypeswitched B cells are specific for the VLPs (unpublished data). The power of VLPbased vaccination is further underscored by the fact that classical adjuvants, such as IFA, alum, or bacterial DNA rich in CpG motifs do not usually further enhance antibody responses. Thus,VLPs seem to induce maximal B cell responses even in the absence of adjuvants. In addition to being used to induce antibody responses against the particle itself, the VLPs may also be used as a platform for inducing antibody responses against any antigen of choice. This can be achieved by incorporating antigenic epitopes into repetitive VLP structures by genetic fusion [2] or by conjugating antigens to VLPs [5, 6]. Genetic fusion is usually feasible for small peptide epitopes, but for larger anti-

19.2 Immunology of VLPs

gens and, in particular, full-length proteins, conjugation is the more promising approach. Antigens incorporated by either method become as immunogenic as the underlying VLP. The magnitude of the IgG responses is dictated by the degree of repetitiveness achieved for the antigenic determinants. The efficiency of such a B cell response is best illustrated by the fact that B cell tolerance may be broken by vaccination with VLPs or antigens coupled to VLPs, resulting in high titer, self-specific antibody responses [5–7]. Hence, VLPs may be used for vaccination in two different ways: VLPs may be used to vaccinate against the proteins making up the particles or, alternatively, against any antigen coupled to the VLPs. 19.2.2 T Cell Responses

Therapeutic vaccination against chronic viral infection and tumors remains a difficult task. Viruses mutate rapidly and are able to escape the immune response by changing epitopes recognized by the immune system. Tumors, on the other hand, often eliminate tumor-associated antigens, down-regulate the MHC class I presentation machinery, or produce factors that inhibit T cell responses. Thus, both viruses and tumors can escape the immune response, and immunity may therefore be only transiently achieved. Most experimental vaccines, however, fail at an earlier stage, since they are not able to induce and/or maintain potent effector T cell responses. Current vaccine strategies therefore mostly focus on induction of the strongest possible T cell responses. VLPs exhibit numerous features that enhance the induction of potent T cell responses and which therefore make them attractive candidates for vaccine development. First, VLPs are processed only by professional APCs and not by other cell types, such as T or B cells [8]. Since antigens presented by nonprofessional APCs turn T cell responses off rather than on, this property probably facilitates maintenance of effector T cell responses. Second,VLPs are efficiently processed via an endosomal, proteasome-independent pathway [8]. The proteasome of dendritic cells may produce peptides that are distinct from those produced in a tumor. Thus, vaccines that are presented via the classical MHC class I pathway in DCs may prime T cell responses that do not recognize the peptides presented by the tumor cells. These restrictions do not appear to occur for the endosomal pathway, facilitating the generation of tumor-specific CTL responses with VLPs. Third, the most successful methods for inducing potent T cell responses in primates and humans are based on prime– boost strategies. Specifically, individuals are primed with antigen presented by a first carrier before they are boosted with the same antigen presented by a second carrier. Priming with DNA followed by boosting with viral vectors is amongst the most successful combinations. VLPs come in many different families that do not induce cross-reactive immunity. Thus, it may be possible to prime with antigen attached to a first VLP before boosting with antigen attached to a second VLP. Surprisingly, VLPs induce poor T cell responses in the absence of additional stimuli. Despite efficient presentation of VLP-derived peptides on MHC class I molecules,VLPs usually induce weak T cell responses in vivo. This is especially so if highly

417

418

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

purified antigen preparations are used for immunization. The question is then raised as to why the CTL responses induced in vivo are relatively weak. An answer may be found in natural virus infection. Not only do live viruses replicating inside cells facilitate loading of MHC class I molecules, but they also stimulate the innate immune system by a variety of means, including induction of cell lysis, production of double-stranded RNA, triggering production of IFNs by APCs, etc. Essentially, VLPs fail to do this because, although VLP-derived peptides are efficiently presented to CTLs, they do not deliver additional stimuli to the innate immune system and, in particular, to APCs. In the absence of such stimuli, CTL responses remain inefficient and abortive. However, if dendritic cells and macrophages are stimulated while simultaneously vaccinating with VLPs, then very strong CTL responses may be induced [9]. In essence, coadministration of VLPs with stimuli of the innate immunity system closely mimics the course of events during a viral infection. Under such conditions, the highly repetitive surface of the VLP simulates potent B cell responses, and additionally, the particles are processed by activated DCs and presented to T cells in lymphoid organs, leading to potent T cell responses. Thus, combining the innate and specific immune systems leads to the most potent effector T cell responses (Figure 19.1). Figure 19.2 shows the immune response obtained after vaccination with a viral epitope covalently coupled to VLPs derived from the coat protein of the bacterioph-

Fig. 19.1 Collaboration between innate and adaptive immunity for protective T cell responses. For induction of protective T cell responses, antigens need to be presented by activated dendritic cells. This initial activation step is brought about by molecules or patterns associated with pathogens such as LPS, cell wall components, or bacterial DNA. Alternativ ely, the trigger may be delivered by neighboring antigen-presenting cells (APCs),releasing cytokines, etc. T cells that recognize antigens on such APCs may become activated and start to produce cytokines and factors from the TNF-family that enhance APC-activation, leading to a positive-feedback loop, resulting in proliferation and differentiation of effector T cells.

19.3 VLPs as Viral Vaccines

Qβ β xp33

Qβ β x33 / CpG

0.2

18

CD8

p33-H2-Db Fig. 19.2 Vaccination of mice with VLPs loaded with CpGs induces high CTL responses in vivo. Mice were vaccinated subcutaneously with 100 mg of VLPs displaying the immunodominant peptide of lymphocytic choriomeningitis virus (p33). The VLPs were either not loaded (left) or loaded with CpGs (right). p33specific CTL responses were measured 10 days later by tetramer staining.

age Qb. About 0.2 % of the CD8+ T cells were specific for the viral epitope 10 days after immunization. Thus, the response was barely above background. In contrast, if the VLPs were loaded with nonmethylated DNA rich in CpG motifs, up to 18 % of all CD8+ T cells were specific for the peptide. Several different stimuli for activation of APCs were tested, including ligands for Toll-like receptors 2, 3, 4, 5, 7, and 9. DNA containing CpG motifs, a ligand for Toll-like receptor 9, was by far the most potent adjuvant [10]. These results demonstrate the power of VLPs to induce T cell responses when combined with the proper stimuli. Because clinical trials with VLPs with the aim of inducing strong T cell responses have been performed with purified VLPs not containing triggers for the innate immune system, it may not be surprising that results to date have been disappointing. The poor immunogenicity of at least some VLPs for T cells can be harnessed for practical purposes. Specifically, VLPs alone may induce a strong antibody response in the absence of a sizeable T cell response. They are therefore ideal for vaccines that aim at inducing strong B cell responses in the absence of inflammatory T cells. In contrast, full-length antigen coupled to VLPs loaded with CpGs can induce strong B and T cell responses. Finally, CpG-loaded VLPs presenting T cell epitopes alone can trigger T cell responses in the absence of specific antibodies. Thus, VLPs may be a flexible platform for the generation of vaccines that induce antibodies alone, T cells alone, or both.

19.3 VLPs as Viral Vaccines

The most straightforward application of VLPs is to use them for vaccination against the virus from which they were derived. However, in many instances, the structural proteins capable of self-assembly into VLPs are derived from proteins with limited or no surface exposure, such as nucleoproteins. Examples of VLPs derived from inter-

419

420

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

nal viral proteins include gag proteins from retroviruses (HIV, RSV, etc.) and hepatitis B core antigen. Antibodies induced by such VLPs are not able to recognize the native virus from which they were derived and hence are not able to interfere with the course of virus infection. Such vaccines may theoretically be able induce T cell responses. However, prophylactic viral vaccines based on T cell responses have, to date, not been successful. Time will tell whether therapeutic VLP vaccines can be developed for treatment of chronic viral infections. Chances for success may be enhanced if such VLP vaccines are administered with the proper stimuli of the innate immune system (see above). Of most interest for the development of prophylactic antiviral vaccines are those VLPs composed of viral surface proteins, most particularly when those proteins are recognized by virus-neutralizing antibodies. Examples of VLPs that include such proteins are derived from hepatitis B virus (HBsAg), papilloma virus, hepatitis C virus, Norwalk virus, HIV (gp 120), rotavirus, and parvovirus. Many of these VLPs induce neutralizing antibodies and are protective in animal models [11–16]. In fact, VLPs derived from papilloma virus and Norwalk virus or hepatitis B virus have entered clinical development or are on the market, respectively (see below). In addition, VLP vaccines against infections from Blue Tongue virus, rota virus, and parvovirus are also being developed for veterinary applications.

19.4 VLPs as Carriers of B and/or T Cell Epitopes

The ability of VLPs to serve as carriers of B cell and CTL epitopes derived from either the parental virus or foreign sources has further enhanced and broadened their potential as prophylactic and therapeutic vaccines. As noted previously, not only may VLPs act as carriers of immunological epitopes derived from microbial pathogens, but they have also been successfully used to present self-antigens to the immune system and to overcome B cell tolerance. Target epitopes may either be genetically fused into subunit proteins of the VLP to form chimeras or be attached to the surface of the VLP by covalent or noncovalent means. 19.4.1 Fused Epitopes

VLP chimeras have been extensively explored as vaccine candidates since the mid1980s [2, 17]. The development of recombinant DNA engineering techniques, combined with structural knowledge emanating from X-ray crystallography and electron cryomicroscopy and immunology, has permitted the design of hundreds of chimeric VLPs. VLPs derived from both double- and single-stranded DNA and RNA viruses encompassing 14 different families of virus have been successfully used for the production of chimeras. Essentially, the DNA encoding linear or conformational immunological epitopes is cloned into the genes encoding the self-assembly-competent polypeptides of VLPs. Upon assembly of the hybrid subunit proteins into supramolecular

19.4 VLPs as Carriers of B and/or T Cell Epitopes

structures, the introduced epitopes are presented at a relatively high density (1 copy per VLP subunit) and, ideally, in an accessible and conformationally relevant manner. Numerous VLPs designed to present B and T cell epitopes in this manner have been tested in preclinical research, three of them have reached clinical testing (see below and Table 19.2). The final intended application of such vaccines spans human to veterinary use and prophylactic to therapeutic treatment. Epitopes have been derived from viral, bacterial, eukaryotic parasitic, and even self molecules, which may or may not be associated with disease (for comprehensive reviews see [2, 17, 18]).

Tab. 19.2 VLP technologies recently tested in clinical trials. Vaccine

Name

Type of vaccine and indication

Stage of clinical development

Institution or company

Norwalk virus capsid NV–VLP VLP

prophylactic B cell phase 1 vaccine for NV infect. completed gastroenteritis

Baylor College of Medicine

Norwalk virus capsid NV–VLP VLP in transgenic potatoes

prophylactic B cell phase 1 vaccine for NV infect. completed gastroenteritis

Center for Vaccine Development

HBcAg–CTL epitope MalariVaxR therapeutic CTL vaccine for malaria VLP chimera: HBcAg infection capsid–CTL epitope fusion

phase 1 ongoing

Apovia AG

Qb capsid VLP: Der–Qb DerP1 peptide covalently conjugated to VLP

B cell vaccine for allergy, proof of concept study

phase 1 completed

Cytos Biotechnology AG

Qb capsid VLP: nicotine derivative covalently linked to VLP

Nic–Qb

therapeutic B cell vaccine for smoking addiction

phase 1 completed phase 2 ongoing

Cytos Biotechnology AG

HPV 16 L1 capsid VLP

HPV 16 L1 prophylactic B cell vaccine for HPV infection

phase 1 completed phase 2 completed phase 3 planned

NCI and NIAID, US National Institutes of Health

phase 1/2 discontinued

Medigene AG; Schering AG

HPV L1 capsid VLPs: MEDI-501, prophylactic B cell HPV11/16/18 503, 504 vaccine for HPV combination vaccines infection

phase 2 ongoing

MedImmune Inc. GSK

HPV L1 capsid VLPs: HPV prophylactic B cell HPV6/11/16/18 6/11/16/18 vaccine for HPV single & quadriinfection valent vaccines

phase I completed phase 2 ongoing phase 3 ongoing

Merck Research Labs; CSL Australia

HPV 16 L1/E7 VLP: CVLP chimera: HPV capsid– CTL epitope fusion

therapeutic CTL vaccine for cervical dysplasias

421

422

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

The hepatitis B core antigen (HBcAg) is the most extensively investigated VLP carrier to date (for reviews see [2, 17, 19]). The particle can be expressed with high yields in numerous eukaryotic, prokaryotic, and plant expression systems and is relatively easily purified. Several sites within the HBcAg subunit permit the insertion of foreign epitope sequences; these include the N and C termini and the tip of the spike of the HBcAg particle, the major immunodominant region (MIR). The MIR is the most exposed region of assembled VLP and also the most favored location for the introduction of insertions. However, this site is also the most difficult in which to introduce foreign sequences and maintain their native structure. Nevertheless, some relatively large epitopes have been successfully inserted into the MIR of HBcAg, including 120 amino acids of the immunoprotective region of the hantavirus nucleocapsid [20] and 238 amino acids of GFP [21], but these tend to be the exception more than the rule. A recent noteworthy example of a successful application of chimeric VLP vaccine was described by Neirynck and coworkers [22], who fused the extracellular domain of the influenza virus M2 protein to the amino terminus of the HBcAg. Mice vaccinated with the chimera were protected from lethal infection with several influenza virus A strains, suggesting that the vaccine has potential as a broad-spectrum influenza A vaccine. The vaccine is currently being developed in conjunction with the biotechnology company Apovia AG. 19.4.2 Coupled Epitopes

From the point of view of commercial vaccine development, the use of chimeric VLPs has limited general applicability for the following reasons: self-assembly of chimeras is highly unpredictable, the length of the antigen that can be incorporated is restricted, folding of the antigen in association the VLP may not preserve conformational epitopes, it is impossible for the incorporated antigen to attain quaternary structure, and yields during expression and purification are often reduced. Several groups have examined the feasibility of modular systems as a potentially more flexible approach to displaying antigens on the surface of VLPs. In these systems, the native VLP and target antigen are synthesized separately and then assembled in vitro by covalently or noncovalently linking the antigen to the surface of the preassembled VLP. An added advantage of this approach is that the size and structure of the recombinant target antigen are not constrained by the folding of the VLP monomer and particle assembly. Indeed, independent synthesis of the recombinant antigen is most likely to improve the chance of incorporating a full-length, correctly folded target protein on the VLP and thus maximize vaccine quality. We have demonstrated the utility of a modular approach by successfully producing more than 50 polypeptide conjugate vaccines using a single VLP carrier, all of which induced high antibody titers against the respective antigens (unpublished data). Ten of the conjugates were either biologically active domains or full-length proteins with sizes ranging from 6.6 to 63 kDa. Moreover, four of these protein antigens were expressed and coupled as multimers.

19.4 VLPs as Carriers of B and/or T Cell Epitopes

A further advantage of the coupling approach is that the site of coupling to the VLP can be optimized so as to achieve maximal exposure of the coupled antigen. In fact, when the extracellular M2 domain of influenza virus was coupled to the surface of the hepatitis B core antigen, much higher antibody titers were reached than if the same domain was genetically fused to the N-terminus of the VLP [6, 22]. Certainly the most adaptable and flexible way of displaying antigens on the surface of VLPs is via covalent linkage, which can be achieved by the use of chemical cross linkers. Numerous conjugation strategies exist to achieve this end. One approach that is successfully employed involves the use of heterobifunctional conjugation reagents that contain two distinct reactive groups that couple to different functional targets, one on the VLP and the other on the antigen [6, 23]. With this approach, exposed amines on the surface of VLPs are first reacted with the amine-reactive NHS-ester of the cross-linker whilst preserving the activity of its sulfhydryl-reactive maleimide group (Figure 19.3). After the first reaction, the derivatized VLP is reacted with the target antigen under conditions permitting conjugation of the maleimide group to the sulfhydryl group of the antigen. To ensure that the antigen is coupled to the VLP in a directed and oriented fashion, peptide antigens can be engineered to contain either an amino- or carboxy-terminal amino acid linker sequence containing a free cysteine group. Among several examples of noncovalent attachment of proteins to the surface of VLPs, a method developed by Schiller and coworkers takes advantage of the strong interaction between streptavidin and biotin [5]. Recombinantly produced streptavidin–TNFa peptide fusions were successfully bound to biotinylated HPV VLPs and used to generate neutralizing anti-TNFa antibodies. Experimental VLP-based vector delivery systems have also utilized noncovalent interactions to attach targeting moleAntigen SO3Na

O

O

N O

+ VLP VLP

cys

N O

O O

Linker (Sulpho-MBS)

Fig. 19.3 Schematic representation of a method for covalently linking a target antigen to VLPs by chemical coupling. The VLP carrier is first reacted with a heterobifunctional cross-linking reagent such as sulfo-m-maleimidobenzoyl-N-hydroxysuccinimide ester. Exposed amines on the surface of VLPs are first reacted with the amine-reactive NHS ester of the cross-linker (arrow). After the first reaction, the derivatized VLP is reacted with the target antigen under conditions permitting conjugation of the maleimide group of the cross-linker (arrow) to the sulfhydryl group of the antigen. To ensure that the antigen is coupled to the VLP in a directed and oriented fashion, peptide antigens may be engineered to contain an amino- or carboxy-terminal amino acid linker sequence containing a free cysteine group.

Target antigen

423

424

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

cules. Tumor-specific antibodies have been coupled to polyoma VLP chimeras containing the antibody-binding domain of protein A fused into the HI loop [24]. Although not developed for vaccines per se, this design has the potential to be used for presenting B cell epitopes. In both these examples, the target antigen must be expressed as a fusion protein, which may again limit the overall utility. 19.4.3 Targeting Self Molecules by using VLPs

A novel application for VLP vaccines utilizes the principle of ordered, repetitive antigen presentation to overcome B cell tolerance and induce autoantibodies to self molecules that mediate disease. The use of VLPs to present self antigens to the immune system offers great promise for treatment of diseases such as cancer, allergies, arthritis, osteoporosis, and CNS disorders. Indeed, many of the molecules targeted by the numerous monoclonal antibodies in development may also be used in conjunction with VLPs for therapeutic vaccination. Potential advantages of such an active vaccination strategy over passive administration of antibodies include lower costs, avoidance of allotypic responses, less frequent administration, and better suitability for chronic treatment. Important safety issues, such as reversibility of the antibody response, must be carefully assessed. The feasibility of using VLPs conjugated with self molecules for active vaccination has been demonstrated on numerous occasions. High titers of IgG autoantibodies can be induced against self antigens attached in a highly ordered manner to the surface of viruses or VLPs [5, 7, 25, 26]. Furthermore, the autoantibodies have been shown to be either blocking or neutralizing and have therapeutic effect. Chimeric VLPs comprising the first external loop of the murine CCR5 chemokine receptor cloned into the immunodominant neutralizing epitope of BPV1 L1 were constructed and injected into mice without adjuvant [26]. CCR5 is the coreceptor for macrophage tropic HIV strains. High titers of CCR5-specific autoantibodies capable of blocking RANTES binding and recognizing CCR5 on the cell surface were generated. Interestingly, the anti-CCR5 sera were also capable of preventing infection by an M tropic HIV strain of cells expressing a hybrid mouse–human CCR5. We have produced and tested an experimental immunotherapeutic vaccine for the treatment of osteoporosis (unpublished data). The vaccine was designed to target RANK ligand (RANKL) and to disrupt interaction with its receptor, thereby inhibiting development and differentiation of bone-degrading osteoclasts. The vaccine was composed of the extracellular domain of murine RANKL covalently coupled, via a heterobifunctional cross linker, to VLPs derived from the bacteriophage Qb. Immunization of mice with RANKL-Qb in the absence of adjuvant produced high titers of anti-RANKL antibodies, demonstrating that tolerance was overcome. Immune sera were able to inhibit binding of RANKL to its cognate receptor and inhibit the formation of osteoclast precursor cells grown in vitro in the presence of RANKL. In vivo efficacy was assessed in a model of osteoporosis involving ovariectomy. Vaccination with RANKL-Qb significantly reduced both ovariectomy-induced decreased bone mineral density and cortical bone resorption.

19.5 Clinical Development

Such promising preclinical data validate the concept that vaccination with self-antigens, rendered highly ordered within the context of VLPs, can overcome tolerance and neutralize the activity of a target molecule in disease. Although clinical testing of non-VLP-based therapeutic vaccines targeting self molecules such as Ab1–42 and angiotensin are underway, no clinical trials using VLPs have yet been initiated. The advantages of using VLPs for induction of autoantibodies, such as the maintenance of efficacious antibody titers with human-compatible adjuvants and the likelihood of avoiding vaccine-induced side effects (such as those observed in a recent Ab vaccination trial), should hasten the appearance of VLP-based vaccines in the clinic.

19.5 Clinical Development

At present,VLP-based vaccines are in various stages of development, spanning preclinical evaluation to market. Vaccines in clinical development include those of the type in which the VLP itself represents the target epitope and those in which the VLP is used to present a non-VLP-derived epitope to the immune system. To date, vaccines tested in the clinic have been primarily designed to produce antiviral responses. However, for the first time, clinical trials using VLPs to target nonpathogen-related antigens have commenced. Clinical trials with VLP-based vaccines (Table 19.2) have shown they are well tolerated and can be administered by a number of routes, including intramuscular, subcutaneous, oral, or intranasal. VLP vaccines have also been demonstrated to be highly immunogenic and capable of stimulating protective immunity in a number of instances when administered with or without adjuvants. 19.5.1 Hepatitis B Virus VLP Vaccine

To date, there is only one VLP-based vaccine licensed for human vaccination, namely the well documented hepatitis B vaccine, which is actually a complex irregular lipoprotein structure rather than the ‘classic’ highly ordered protein complexes typically thought of as VLPs. This vaccine, marketed under the name of Engerix, is safe and very efficacious and is today the highest revenue-generating vaccine in the world. The discovery of the vaccine was prompted by observations that noninfectious particles consisting of membrane phospholipids and the major 24-kDa surface antigen HBsAg were found in the serum of infected individuals. These ‘Dane’ particles were highly immunogenic and elicited antibodies capable of neutralizing the authentic virus. The currently marketed form of the vaccine comprises the HBsAg recombinantly expressed in yeast from which immunogenic particles composed of HBsAg and yeast phospholipids are harvested by gradient centrifugation and which are subsequently properly disulfide-linked in vitro [27]. Current areas of research and development of the vaccine include combining the vaccine with CpGs to increase responder rates and titers, and expression in transgenic plants with the aim of producing edible vaccines.

425

426

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

19.5.2 Human Papilloma VLP Vaccines

Human papilloma virus (HPV) is estimated to infect 24–40 million men and women in the United States. Symptomatic infection by the virus is associated with a variety of clinical disorders ranging from relatively benign wart-like lesions of the anogenital urinary tract to lethal tumors. Almost invariably, cervical squamous cell carcinomas harbor DNA from high-risk HPV. Clinical and molecular epidemiological studies have shown that, although sexually transmitted HPV infections only rarely lead to malignancy, HPV infection is necessary and implicated in the development of about 50 % of all cervical carcinomas. Worldwide, this corresponds to nearly half a million new cases of cervical cancer caused by HPV every year. The situation is most grave in developing countries, where the greatest burden of disease exists and where cervical cancer may constitute 25 % of all female cancers. Compounding the problem is the lack of cytological screening programs, resulting in late diagnosis of disease. Vaccination strategies targeting HPV have the potential to be a highly effecttive means of reducing the incidence of HPV infection and associated neoplasias and carcinomas. The discovery that the L1 major capsid protein of papilloma viruses could self-assemble into VLPs that are structurally and antigenically similar to the original virion represented a watershed in HPV vaccine development [28]. Subsequently, at least 10 HPV types have been recombinantly expressed in mammalian, insect, yeast, and bacterial cell culture systems and purified for vaccination studies. Two vaccination strategies are being developed. The first and most basic involves the use of VLPs generated from the L1 major capsid protein. Neutralizing antibodies against conformational epitopes of the L1 protein have the potential to prevent anogenital infection. Early assessment of L1 VLP vaccines in rabbits, dogs, and cows demonstrated the feasibility of a prophylactic vaccination approach, when greater than 90 % protection against high-dose challenge with species-specific mammalian papilloma viruses was observed [11]. Several factors render the design of prophylactic VLP-based HPV vaccines difficult. There is no systemic infection by the virus, which is manifest as lesions and warts, and it evades immune surveillance by shedding to external surfaces. The etiology of HPV infection is complex, with more than 75 different types of HPV, of which 20 types have an association with cervical cancers. Within HPV types, there is considerable variation in L1 epitopes, and vaccines designed for one region of the world may not be suitable for others. Variations of epitopes within HPV types also exist. Nevertheless, only a few HPV types are implicated in the majority of cases of genital warts or cancer. The predominance of HPV 16 in cytologically normal women and in cervical cancers (approximately 50 % are positive) identified it as a primary candidate for vaccine development. Researchers from the US National Cancer Institute and the Johns Hopkins University initiated a series of clinical studies in humans to test the feasibility of a prophylactic vaccination strategy against HPV 16 infection. A HPV 16 VLP vaccine, produced from baculovirus-infected insect cells, was tested for safety and

19.5 Clinical Development

immunogenicity in a double-blind placebo-controlled dose-escalation study with 72 individuals [29]. Immune responses were measured by HPV16 L1 VLP-based ELISA and by a HPV16 pseudovirion neutralization assay. The vaccine was well tolerated, with 100 % seroconversion after the second dose. Titers were further boosted after the third and final dose. All subjects produced a predominately IgG1 response, which is the prominent IgG isotype in natural infection. Indeed, the majority of antibody titers were 40-fold higher than in naturally infected individuals. These promising results prompted the initiation of a phase II trial designed to test whether or not the vaccine can protect against HPV infection and cytological abnormalities. Although efficacy results have not been published, the vaccine administered without adjuvant demonstrated tolerability, 100 % responder rates, and high antibody titers (personal communication, J. Schiller). A phase III trial involving 10 000–15 000 women in Costa Rica is planned for the near future. Merck Research Laboratories have also been developing prophylactic HPV vaccines. A HPV16 VLP vaccine produced in Saccharomyces cerevisiae has recently completed testing in a multicenter, double-blind placebo-controlled phase II trial involving 2392 women aged between 16 and 23 years, of whom 1533 HPV16-negative women were included in the primary analysis [30]. None of the 768 volunteers who received the vaccine (3 doses) developed HPV16 infections after 18 months, compared to 41 cases of persistent HPV infection in the 765 subjects receiving placebo. A mulivalent HPV VLP vaccine that includes four HPV types (6, 11, 16, and 18) is also under development. This vaccine is designed to address the type specificity of vaccineinduced immunity and protection. An interim analysis of data from a phase IIb multicenter, dose-ranging study trial with the quadrivalent vaccine has shown that it is well tolerated and immunogenic. A Phase III trial with the quadrivalent vaccine is scheduled to begin in the near future. Glaxo Smith Kline and Medimmune are also developing single and multivalent vaccines for HPV11, HPV16, and HPV18. Data from phase 1 trials showed that HPV11, HPV16, and HPV18 VLP vaccines were well tolerated and induced high titers of binding and neutralizing antibodies [31]. Multiple phase II clinical trials with vaccines comprising single type and multivalent combinations adjuvanted in alum and 3-O-deacylated monophosphoryl lipid A are in progress. Preliminary evaluation of prevention of HPV16 and/or HPV18 infection revealed similar efficacy to that reported for the HPV16 vaccine [30]. Such demonstrations of tolerability, high efficacy, and responder rates, and the promise of effective multivalent vaccines, clearly show the potential of VLP-based vaccines for use in prophylactic vaccination to prevent HPV infection. A second type of HPV VLP vaccine is currently in clinical development, which offers an additional therapeutic potential for HPV VLP vaccines by inducing cellmediated immune responses. These vaccines employ chimeric HPV VLPs that have other HPV-derived peptides genetically incorporated into the L1 or L2 major capsid protein. The incorporated peptides include nonstructural viral oncoproteins such as E7 or E6, which are constitutively expressed within the tumor cells, and contain T cell epitopes making them potential targets for CTLs. Such vaccines may be used to treat HPV-induced premalignant cervical dysplasias or even to induce regression of

427

428

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

neoplastic lesions in cancer patients. Because the addition of CTL epitopes into HPV capsid proteins does not diminish antibody response to the VLP, these vaccines may also be used in a combined prophylactic and therapeutic way. The basis for this approach is that HPV VLPs have the unusual property of being able to induce CTL responses without the addition of strong nonspecific immune stimulators [11]. Numerous studies have demonstrated potent CTL responses in mouse models after lowdose vaccination, leading to suppression of HPV-induced tumors [11, 32]. However, the failure to boost CTL responses in mice, due to the presence of neutralizing antibodies, may represent a potential limitation to this vaccination strategy [33]. The diversity of HPV types and HLA in the human population and the need to use large sequences containing heterologous CTL epitopes further confound the approach. With the hope that efficacy can be achieved in humans by therapeutic vaccination, phase I/II clinical trials employing HPV16 L1/E7 (CVLP) chimera in healthy volunteers and in patients with precancerous lesions of the cervix were initiated by Medigene AG. Although the chimeric VLP vaccine was well tolerated the levels of efficacy, as judged by morphology of lesions, T cell responses were too low to meet efficacy criteria and to warrant continuation of the trial. Medigene will continue with the development of second-generation CVLP vaccines. 19.5.3 Norwalk Virus VLP Vaccines

Norwalk virus (NV) appears to account for more than 90 % of outbreaks of nonbacterial acute gastroenteritis throughout the world, with approximately 23 million cases occurring per year in the United States alone. Outbreaks are usually epidemic in nature and associated with crowding and poor sanitation. The potential for prophylactic vaccines based on NV–VLPs was realized when the 58-kDa NV capsid protein was shown to spontaneously assemble when expressed in insect cells infected with baculovirus [34]. NV–VLPs are very stable and have also been expressed in plants. Preclinical studies demonstrated that the VLPs are morphologically and antigenically similar to the native virus and induce systemic and mucosal immune responses in mice. Several phase I clinical trials have been performed, in which NV– VLPs were orally administered to volunteers either in water without adjuvant or via ingestion of transgenic potatoes. In both studies the vaccines were well tolerated. Vaccine delivered in water induced serum IgG responses in a dose-dependent manner, and 15 of the 18 subjects responded with serum IgG titers at least 4-fold higher than prevaccination levels. Titers could not be boosted with a second dose of vaccine [13]. NV–VLP vaccine administered on 2 to 3 occasions by ingestion of 150 g of transgenic potatoes was estimated to deliver 215 to 751 mg of recombinant vaccine per dose. The immune response was, however, weak, with fewer than half the volunteers developing specific IgG or IgA titers [35].

19.5 Clinical Development

19.5.4 VLPs Presenting Foreign Epitopes

A vaccine comprising chimeric Ty VLPs (p24-VLP), expressed in yeast and genetically engineered to contain part of the HIV-1IIIB Gag sequence p17/p24, has been tested in the clinic. In a phase 1 trial of healthy volunteers, the p24-VLP vaccine adjuvanted in aluminum hydroxide was well tolerated and induced antibody titers in 11 of 15 subjects after a fourth intramuscular immunization with 500 mg of vaccine. Proliferative T cell responses were induced in a majority of individuals, although no HLArestricted cytotoxic T cells were detected [36]. Subsequently, a double-blind, placebocontrolled, phase II trial involving 74 p24-antibody-positive asymptomatic HIV-infected persons was initiated [37]. Surprisingly, although most of the subjects generated antibodies against Ty, no anti-p24 specific antibody responses were induced. However, there was evidence that precursor frequencies of Gag-specific cytotoxic T cells and proliferative responses to p17 and p24 were increased at higher doses. Disappointingly, a long-term follow-up study of this trial showed no long-term effects on progression to clinical endpoints or development of disease [38]. As detailed above, numerous clinical trials that have demonstrated that VLPs are capable of generating effective antibody responses in humans. However, only recently has it been demonstrated that antigens covalently attached to the surface of VLPs are also highly immunogenic in humans. In a phase I study, 24 healthy volunteers were vaccinated with a VLP conjugate vaccine comprising a peptide antigen (Derp 1) covalently coupled to a VLP derived from the coat protein of the bacteriophage Qb. The study mainly investigated tolerability and the effects of dose and route of administration on immunogenicity. At an interim analysis, all subjects responded in a dose-dependent manner with specific antibody titers against both the target peptide and the VLP. Average anti-Qb titers for the 50-mg and 10-mg dose groups were 1 : 100 000 and 1 : 40 000, respectively. Anti-Derp 1 titers were detected in all subjects after one administration of the vaccine without adjuvants, and again there was a significant dose–response effect with average titers of 1 : 20 000 and 1 : 6000 for the high- and low-dose groups, respectively. The route of administration (intramuscular or subcutaneous) had no significant effect on titers. A phase 1 clinical trial for treating smoking addiction was performed using a nicotine derivative covalently coupled to the VLP Qb. The trial was designed to investigate tolerability and the effects of dose and formulation on immunogenicity. Preclinical assessment of the vaccine demonstrated that high titers of anti-nicotine antibodies were generated. Furthermore, the antibodies were capable of significantly reducing the uptake of nicotine into the brains of mice after an intravenous challenge with nicotine equivalent to two cigarettes in humans. The strategy of the therapeutic vaccination is to reduce the flux of nicotine to the brain of addicted individuals and thus to diminish peak nicotine levels. Interfering with the cycle of anticipation and reward provided by nicotine consumption is more likely to lead to cessation of smoking behavior. The phase I trial demonstrated both tolerability and immunogenicity of the vaccine. High nicotine specific antibody titres were obtained with 100 % of the volunteers responding to the vaccine. Based upon these results a phase II trial in smokers has been commenced.

429

430

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination

References 1. Bachmann MF, Kopf M 1999. The role of B cells in acute and chronic infections. Curr Opin Immunol 11, 332–339. 2. Pumpens P, Grens E 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44, 98–114. 3. Johnson JE, Chiu W 2000. Structures of virus and virus-like particles. Curr Opin Struct Biol 10, 229–235. 4. Bachmann, MF, Zinkernagel RM 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol 15, 235– 270. 5. Chackerian B, Lowy DR, Schiller JT 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108, 415–423. 6. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kundig T, Bachi T, Storni T, Jennings G, Pumpens P, Renner W, Bachmann MF 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104. 7. Bachmann MF, Rohrer UH, Kundig TM, Burki K,Hengartner H, Zinkernagel RM 1993. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451. 8. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF 2002. Crosspresentation of virus-like particles by skin-derived CD8(–) dendritic cells: a dispensable role for TAP. Eur J Immunol 32, 818–825. 9. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, Kundig TM, Ruedl C, Bachmann MF 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 168, 2880–2886. 10 Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard J, Röthlisberger P, Martin F. Bachmann MF 2003. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J. Immunol 33, 1465–1470.

11. Schiller J, Lowy D. 2001. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 28, 50–54. 12. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. 2003. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 100, 6753–6758. 13. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. 1999. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117, 40– 48. 14. Buonaguro L, Racioppi L, Tornesello ML, Arra C,Visciano ML, Biryahwaho B, Sempala SD, Giraldo G, Buonaguro FM. 2002. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res 54, 189– 201. 15. Madore HP, Estes MK, Zarley CD, Hu B, Parsons S, Digravio D, Greiner S, Smith R, Jiang B, Corsaro B, Barniak V, Crawford S, Conner ME 1999. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 17, 2461–2471. 16. Rueda P, Fominaya J, Langeveld JP, Bruschke C,Vela C, Casal JI 2000. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19, 726–734. 17. Pumpens P and Grens E. 2001 Artificial genes for chimeric virus-like particles, in: Artificial DNA, Methods and Applications (eds Khudyakov YE and Fields HA), pp. 249–327, CRC Press, Boca Raton, FL, USA. 18. Chimeric virus-like particles as vaccines (eds Gerlich WH, Kruger DH and Ulrich R) Intervirology 39 1–2 1996, Karger press Basel. 19. Ulrich R, Nassal M, Meisel H, Kru-

References

20.

21.

22.

23.

24.

25.

26.

27.

28.

ger DH 1998. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50, 141–182. Koletzki D, Lundkvist A, Sjolander KB, Gelderblom HR, Niedrig M, Meisel H, Kruger DH, Ulrich R 2000. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology 276, 364–375. Kratz PA, Bottcher B, Nassal M 1999. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 96, 1915–1920. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5, 1157–1163. Lechner F, Jegerlehner A, Tissot AC, Maurer P, Sebbel P, Renner WA, Jennings GT, Bachmann MF 2002. Virus-like particles as a modular system for novel vaccines. Intervirology 45, 212– 217. Gleiter S, Lilie H 2001. Coupling of antibodies via protein Z on modified polyoma virus-like particles. Protein Sci 10, 434–444. Fehr T, Bachmann MF, Bucher E, Kalinke U, Di Padova FE, Lang AB, Hengartner H, Zinkernagel RM 1997. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185, 1785–1792. Chackerian B, Lowy DR, Schiller JT 1999. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 96, 2373–2378. Wampler DE, Lehman ED, Boger J, McAleer WJ, Scolnick EM 1985. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci USA 82, 6830–6834. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89, 12180–1214.

29. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93, 284–292. 30. Koutsky LA, Ault KA,Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347, 1645–1651. 31. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M,White WI, Balsley J, Reichman RC 2001. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183, 1485–1493. 32. Gissmann L, Osen W, Muller M, Jochmus I 2001. Therapeutic vaccines for human papillomaviruses. Intervirology 44, 167–175. 33. Da Silva DM, Pastrana DV, Schiller JT, Kast WM 2001. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290, 350–360. 34. Jiang X, Wang M, Graham DY, Estes MK 1992. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66, 6527–6532. 35. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ 2000. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182, 302–305. 36. Weber J, Cheinsong-Popov R, Callow D, Adams S, Patou G, Hodgkin K, Martin S, Gotch F, Kingsman A 1995. Immunogenicity of the yeast recombinant p17/p24:Ty viruslike particles (p24-VLP) in healthy volunteers. Vaccine 13, 831–834. 37. Veenstra J,Williams IG, Colebunders R, Dorrell L, Tchamouroff SE, Patou G, Lange JM,Weller IV, Goe-

431

432

19 Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination man J, Uthayakumar S, Gow IR, Weber JN, Coutinho RA 1996. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 174, 862–866. 38. Lindenburg CE, Stolte I, Langen-

dam MW, Miedema F, Williams IG, Colebunders R, Weber JN, Fisher M, Coutinho RA 2002. Long-term followup: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 20, 2343–2347.

Part V Vaccines for Specific Targets

435

20 Helicobacter pylori Paolo Ruggiero, Rino Rappuoli, and Giuseppe Del Giudice

20.1 Introduction

Helicobacter pylori is a spiral-shaped, Gram-negative bacillus that has been cohabiting with humans for at least 100 000 years: indeed, at present it is possible to trace human migrations by studying H. pylori populations and subpopulations, thanks to peculiar gene sequences and distinct geographical distributions [1–3]. The first notices of bacteria in the mammalian stomach date back to the late 19th century, when spiral microorganisms were observed in the human stomach, and the idea of an association between bacteria and ulcer disease arose. In the same period, spiral bacteria were also found in dog stomachs, and their ability to infect mice was proven. During the first decades of 20th century these observations were sporadically confirmed and broadened, but the hypothesis of bacterial origin of peptic ulcer disease was not generally accepted (for an historical overview on Helicobacter see [4]). At the end of 1970s a ‘curved bacillus’ was described in human gastric biopsies, in 1982 it was isolated and cultured, and subsequently its relationship with gastritis in humans was proposed [5, 6]. The possibility of culturing this microorganism allowed studying and characterizing it. First named Campylobacter pyloridis, then corrected in C. pylori, in 1989 this bacterium was finally reclassified as Helicobacter pylori [7]. Since then, a number of Helicobacter species have been identified, which are specialized to live in the gastric mucosa or in other sites of humans or other mammalian species [8]. H. pylori represents the most important Helicobacter species for humans, since it chronically infects the gastric mucosa of more than 50 % of the human population worldwide, varying with geographic region and socioeconomic conditions. The majority of infections are asymptomatic; nevertheless, 15 %–20 % of infected individuals incur severe gastroduodenal diseases, such as gastritis, peptic ulcer, and gastric cancer. In 1994 H. pylori was classified as a category 1 carcinogen by the World Health Organization [9].

436

20 Helicobacter pylori

20.2 Epidemiology of H. pylori Infection

H. pylori infections are acquired early in life [10, 11], mostly within the family [12, 13]. Transient infections are common in childhood [14, 15], until a chronic infection becomes established. Most likely, transmission is oro-fecal and/or oro-oral [16–18]. In certain epidemiological contexts, one source of infection can be contaminated food or water sources [19, 20]. The suspicion that pets may be responsible for H. pylori zoonotic transmission has not been confirmed so far [21–23], and the potential role of houseflies as a vector of H. pylori is doubtful [24, 25]. H. pylori can assume a noncultivable coccoid form, which has been proposed to be either degenerative or dormant; if dormant, it could represent an important way of dissemination of the microorganism [26, 27]. Prevalence of H. pylori infection is much higher in developing countries, where it can exceed 90 % in adults, than in developed countries, where it ranges from 10 % to 50 % [28, 29]. Also, the H. pylori infection prevalence increases with age in most populations. In the developing world, H. pylori infection occurs earlier in life and with a higher frequency than in developed countries [29]. The decreasing risk of H. pylori infection during childhood in developed countries probably reflects improved sanitation and better hygiene practices and living conditions; however, population-based long-term follow-up studies in large groups of subjects must be performed to clarify the current development of H. pylori infection incidence in children [28].

20.3 H. pylori-related Diseases

H. pyloricauses chronic inflammation of the stomach, due to direct action of the microorganism as well as to the host’s response. In fact, bacterial products, such as some toxins that are described in detail below, act on the surrounding tissues, weakening the mucus layer protection, and damaging the gastric epithelial cells, also inducing apoptosis [30]. H. pylorican adhere to epithelial tight junctions, increasing the paracellular barrier permeability and changing the distribution of the tight-junction related molecules, conceivably to gain access to nutrients and ions [31]. On the other hand, the strong immune response elicited by H. pyloriinfection, even though unable to confer protection against the bacterium, may contribute to local inflammation [32, 33]. The H. pylori LPS mimics the human Lewis blood antigens [34]; thus, the immune response of the infected host can produce autoantibodies which exacerbate the inflammation by reacting with the same Lewis antigens expressed by the gastric epithelial cells [35]. There is strong evidence that H. pylori infection causes gastritis and peptic ulcer [6, 36]. The relationship between H. pylori infection and gastric mucosa-associated lymphoid tissue (MALT) lymphoma is very well established [37, 38]. The association between gastric cancer and H. pylori infection is indicated by the finding that the H. pylori-positive population has a significantly increased risk of gastric cancer compared with the noninfected population [39, 40], and the causative effect of H. pylori

20.4 H. pylori Antigens Relevant in Virulence and Pathogenesis

infection on gastric adenocarcinoma development has been experimentally demonstrated in animal models [41–43]. Possible association of H. pylori infection and T cell lymphoma has also been reported [44]. As described more in detail below, the most virulent, so-called type I H. pylori strains, which contain the cag pathogenicity island (cag PAI) in their genome and express CagA protein [45, 46], are often associated with the most severe complications of the infection (peptic ulcer, atrophic gastritis, gastric cancer). Conversely, type II strains, lacking cag PAI and CagA toxin, are mainly associated with mild forms of gastritis. This has been clearly shown both in experimentally infected animals [41] and in naturally infected people [47, 48]. The severity of H. pylori-associated pathologies can depend not only on the virulence of the H. pylori strain, but also on the host's genetic factors. For example, polymorphisms in the human IL-1b and IL-1 receptor antagonist genes can determine the outcome of infection [49–51], possibly related to the acid-suppressive effect of IL-1b. Upon H. pylori infection, people having high gastric acid secretion are likely to develop antral gastritis and duodenal ulceration, whereas people having lower acid output can develop corpus gastritis and gastric ulcer, with possible malignant outcome [49]. This is in agreement with the previous observation that individuals with duodenal ulcer disease are less likely to develop gastric adenocarcinoma than the average population, duodenal ulcer seeming to be in some way protective against gastric cancer [39, 52]. The association of H. pylori infection with some extragastric pathologies, and particularly with cardiovascular diseases, has been suggested, although formal demonstration of such association is still needed [53–57].

20.4 H. pylori Antigens Relevant in Virulence and Pathogenesis

H. pylori can penetrate the gastric mucus layer, thanks to its curved morphology and the motility conferred by the flagella located at one end of the bacillus, resulting in a screw-like movement. Motility is strictly required for gastric colonization, because nonmotile organisms lack such a colonizing ability [58]. After crossing the mucus layer, a redundant series of adhesins allow the microorganism to adhere to the gastric epithelial cells (for a detailed overview of H. pylori adhesins, see [59]). To survive in the hostile gastric environment and to escape immune response, H. pylori activates a series of mechanisms, including production of enzymes and toxins that can modify the microenvironment in favor of its own requirements and impair the host's phagocytic and antigen-presenting activities [31]. Here we describe in greater detail those H. pylori colonization and virulence factors that have been involved in vaccine development, including human trials. The enzyme urease, which catalyses the conversion of urea to CO2 and ammonia, thus neutralizing acidic environments, is a key feature that allows H. pylori, as well as other gastric helicobacters, to survive in the acidic gastric juices. Urease consists of two moieties, UreA (27 kDa) and UreB (62 kDa). It is released by bacteria through

437

438

20 Helicobacter pylori

autolysis and represents 5 %–10 % of the total bacterial protein content. The need of urease for bacterial colonization is proven by the finding that isogenic urease-negative strains cannot colonize the stomach of gnotobiotic piglets [60]. Urease seems to be involved also in the activation and adhesion of inflammatory cells at the site of gastric lesions [61] and to stimulate macrophage-inducible nitric oxide synthase [62], thus contributing to mucosal damage and, possibly, to the development of gastric pathology. H. pylori produces neutrophil-activating protein (HP-NAP), a 17-kDa protein that assembles to form dodecamers [63, 64]. HP-NAP induces chemotaxis and direct activation of neutrophils and monocytes and stimulates production of reactive oxygen intermediates [65]. The contribution of HP-NAP to the recruitment of neutrophils and monocytes is also indirect, through stimulation of mast cells and consequent IL-6 production. All these effects can induce local gastric inflammation and are potentiated by IFN-g and TNF-a. HP-NAP has iron-binding capacity, suggesting its role in iron uptake; however, its expression is not regulated by iron, suggesting that its main function could be to maintain an inflammation level that causes nutrient release from the tissue, thus promoting H. pylori growth [64]. As mentioned above, H. pylori isolates have been divided into two large categories: type I strains, associated with the most severe complications of the infection, and type II strains, more frequently isolated from individuals with mild forms of gastritis. Type I, but not type II strains, have acquired during their evolution a 40-kb genome region named cag, which is a pathogenicity island (PAI) similar to those found in other pathogens [66]. Among the genes included in this region, one of the most characterized is cagA, which encodes the cytotoxin-associated protein (CagA) [46]. The majority of clinical isolates are CagA-positive. CagA is highly immunogenic at both antibody and cellular levels; this immune response has been considered a marker of severe infection. Importantly, the cag PAI encodes proteins that constitute a type IV secretion system, able to translocate CagA into the eukaryotic cell, where CagA is phosphorylated [67]. The translocation and phosphorylation of CagA are followed by induction of IL-8 production by epithelial cells, activation of NF-kB, remodeling of the cytoskeleton, and formation of cellular pedestals [45]; in vitro, cellular shape and motility dramatically change following coculture with H. pylori strains, strictly depending on CagA expression and phosphorylation [68]. CagA activity may explain the association between infection with CagA-positive strains and the development of severe gastric pathology [69]. In agreement with epidemiological observations of infected humans, in Mongolian gerbils H. pylori strains containing an intact cag PAI cause more severe gastric pathology than strains in which cag PAI is absent or incomplete [70, 41]. Active inoculation of CagA into the eukaryotic cell may also account for the high immunogencity of CagA observed in infected individuals. Notably, some cag-negative H. pylori strains still can induce IL-8 production: this ability has been correlated with the presence of the outer inflammatory protein ( oipA) gene, suggesting that it is an important virulence factor in relation to the risk of clinically significant outcomes of H. pylori infection [71]. H. pylori produces a cytotoxin (vacuolating toxin,VacA) that induces vacuolation of cells in vitro and considerable rearrangements of late endosomes and lysosomes, interfering with their functions. Thus,VacA could support the H. pylori strategy of survival

20.6 Current Therapies against H. pylori: Efficacy and Limits

by inhibiting antigen processing and presentation, as shown in vitro [72]. Moreover, the in vitro observation that VacA favors the intracellular survival of H. pylori within AGS cells [73] suggests its role in vivo in maintaining a reservoir of live bacteria in a compartment protected from immune response and antibiotic action. The mature protein contains a 37-kDa moiety essential for toxic activity and a 58-kDa portion that binds to target cells; VacA monomers oligomerize to form esa- and heptameric flowerlike structures [74]. VacA sequence is well conserved among different isolates, except for the mid-region of the 58-kDa moiety, which expresses allelic variation. Clinical and experimental data clearly show that both alleles are equally toxic [75]; they could well represent the evolutionary expression at the bacterial level of a genetic polymorphism at the level of the specific host cell receptor for this toxin. VacA seems to play a role in the first steps of colonization, because the isogenic vacA null mutation compromises H. pylori's ability to initially establish infection in a mouse model; however, if an infection by a vacA mutant is established, the bacterial load and degree of inflammation are similar to those associated with an isogenic wild-type strain [76].

20.5 Eradication of H. pylori: the Pros and Cons

Once the relationship between H. pylori and severe gastric pathologies was proven, evidence was obtained that diseases such as peptic ulcer regress upon eradication of H. pylori infection [44, 77–80]. Even from an economic point of view, it is clear that appropriate H. pylori eradication can produce important health benefits at a reasonable cost, preventing mortality from gastric cancer and peptic ulcer disease [81–83]. Eradicating H. pylori has been evaluated to be cost-effective not only with respect to gastric ulcer but also for non-ulcer dyspepsia [84]. Some have hypothesized that H. pylori infection may protect against gastroesophageal reflux disease (GERD), Barrett's esophagus, and esophageal adenocarcinoma [85–87]. Nevertheless, with GERD, controlled clinical trials have not confirmed this hypothesis so far [88–90], and H. pylori eradication, although it cannot cure GERD, has been reported to prolong the disease-free interval in comparison with anti-secretory therapy alone [89]. Also, no evidence has been found that H. pylori infection reduces the risk of esophageal adenocarcinoma [90]. Thus, the advantages of eradicating H. pylori are evident, and also encouraged by ethical considerations, especially considering that untreated H. pylori-associated gastritis can evolve into cancer [92].

20.6 Current Therapies against H. pylori: Efficacy and Limits

Current therapies against H. pylori are based on the use of a proton pump inhibitor (PPI) plus two or more antibiotics and/or antibacterials, generally clarithromycin

439

440

20 Helicobacter pylori

and amoxycillin or metronidazole [93]. The duration of the therapy generally ranges from one to two weeks, although shorter regimens (3–5 days) have also been proposed [94, 95]. At present, no validated therapies exist as alternatives to current therapies. Many plant-derived substances have been found to exert anti-H. pylori activities, suggesting their possible inclusion in future therapies: among them, flavonoids seem to be of particular interest [96–98]. However, work on these substances is still at the research level, most often limited to in vitro results. The current therapies against H. pylori are generally effective, eradicating the bacterium from the infected individual in 80 %–90 % of the cases. The real efficacy at the level of general practitioners is not well known and could be significantly lower that that reported in controlled studies. Moreover, since only symptomatic patients are treated, patients without symptoms remain at risk of developing severe complications of H. pylori infection. The main reason for therapy failure is lack of compliance due to the side effects of the treatment, such as nausea and general discomfort, which can lead the patient to discontinue treatment. Another relevant reason for failure of the first-line therapy is antibiotic resistance. Within the United States population, antibiotic resistance for metronidazole has reached 35 %–40 % of patients, about 10 % for clarithromycin, and > 1% for amoxycillin [99, 100]. In different areas, similar or higher resistance rates have been reported, up to 80 % for metronidazole [101–103]. Even amoxycillin resistance can reach significant rates in particular geographic areas [104]. This is an intrinsic limitation of antibiotics, in that, as their use increases, phenomena of resistance commonly arise, even in bacterial species different from those targeted. Recrudescence or reinfection after successful therapy against H. pylori is rare in developed countries, but can reach worrying levels in developing countries, varying according to the geographic area considered [105–107]. It is impossible to distinguish between recrudescence and reinfection, except by isolating and genetically characterizing the H. pylori strain from the patient before starting treatment [108]. Finally, we should note that sometimes dyspepsia may persist after eradication therapy [109].

20.7 Why Develop a Vaccine against H. pylori

Vaccines represent the most cost-effective and successful approach to preventing infectious diseases. Mortality and morbidity due to several infectious diseases have been profoundly affected by the widespread use of vaccination. With H. pylori, the drawbacks of antibacterial therapy would be overcome by the use of an efficacious vaccine, which would be cost-effective [110], preventing the insurgence of peptic ulcer, gastric cancer, and other H. pylori-related pathologies. The vaccine, either prophylactic or therapeutic, should be administered to infants and children, i. e., at the age when the infection is acquired. Based on a mathematical model

20.8 Animal Models of H. pylori Infection

that compartmentalizes a population according to age, infection status, and clinical state, it has been reported that vaccination of infants with a prophylactic vaccine lasting only 10 years would be cost-effective in developed countries such as United States or Japan, even if it had an efficacy as low as 50 % [111], also taking into account the progressive, natural decrease of the incidence of infection. The same model indicates that in developing countries, due to the higher incidence of infection, the vaccination effort should be more prolonged to eliminate the pathogen and its associated disease. However, the cost-effectiveness of a vaccination against H. pylori in developing countries would increase considerably when taking into account other clinical consequences of the infection with H. pylori, which are much more evident in developing countries. For example, studies in Africa, Asia, and South America have reported that early acquisition of H. pylori may cause growth retardation [112, 113] and that this infection, by causing hypochlorhydria, favors an increase of diarrheal diseases [114] and enteric infections such as cholera [115] and typhoid fever [116].

20.8 Animal Models of H. pylori Infection

Most of the knowledge on the infection in humans comes from the first investigations in patients with chronic infection, in which, however, the initial colonization of the stomach by the microorganism had occurred several years before the symptoms. Therefore, the early phases of infection remain largely unknown, except for some data obtained in a few studies of self-infection [117, 118] and of accidental infections for professional reasons [119] and by examining volunteers experimentally infected with CagA-negative H. pylori strain [120]. The limited possibility of following all aspects of the pathogenesis of H. pylori infection in humans necessitates the use of animal models to understand the kinetics of the interaction between the bacterium and the host and to study the mechanisms of immune response during infection or after vaccination. Although so far we do not have an ideal animal model reproducing all the numerous aspects of infection and disease observed in humans, the available models represent a precious tool for the development of vaccination strategies, including the selection of bacterial molecules as potential candidates for vaccine development. 20.8.1 Mice and Other Rodents

The first colonization of the stomach of mice by Helicobacter species was described in 1990 using germ-free mice infected with H. felis [121]. This model has been widely used in immunization studies, in which animals were immunized, for example, with various antigens, such as urease [122] or heat shock proteins [123], and then challenged with H. felis. The biology of H. felis, however, is quite different from that of H. pylori; for example, H. felis does not adhere to gastric epithelial cells and does not contain vacA or cag PAI genes [124]. In 1991, the establishment of infections in

441

442

20 Helicobacter pylori

athymic (nude) mice and euthymic germ-free mice by H. pylori strains isolated from patients was reported [125]. The infected mice developed gastritis and ulcerations closely resembling those observed in humans. However, nude and germ-free mice are not suitable for vaccination studies, because of their particular immune status and also because they require sophisticated housing facilities. Subsequently an improved H. pylori model was reported, showing that infection of Balb/c mice with fresh isolates could persist for at least 4 weeks [27]. Then stable and reproducible models of infection in immunocompetent mice with H. pylori were developed [126, 127]. The mouse model reproduces several aspects of human infection. For example, type I (cag+) strains induce more severe lesions than type II (cag–) strains [126]. This model has been extensively used to investigate the role of some virulence factors, such as VacA, CagA, and urease, in gastric colonization and inflammation [128]. The infection persists chronically for at least one year, with the appearance of several lymphocytic infiltrates organized in very well structured lymphoid follicles [129]. In other mouse strains, experimental H. pylori infection gave different levels of gastric pathology, i. e., much more severe in C57BL76 than in BALB/c mice [130], suggesting an important role of host immunity in the outcome of local gastric pathology. Successful colonization with H. pylori has been also described in rats [131], guinea pigs [132], and Mongolian gerbils [133], but these models have not been extensively employed in research studies for H. pylori vaccines, because they are probably less convenient than the mouse model and also due to the limitation of specific reagents. However, as previously mentioned, Mongolian gerbils are of special interest because, upon H. pylori infection, they develop gastric atrophy and intestinal metaplasia, with eventual development of gastric adenocarcinoma [41, 42]. 20.8.2 Ferrets

Ferrets are naturally colonized by H. mustelae. The relevance of this model is that the attachment of H. mustelae to gastric epithelial cells, as well the colonization pattern, strictly resembles that of H. pylori in humans. Also, ferrets develop gastric ulceration upon H. mustelae infection [134]. 20.8.3 Gnotobiotic Piglets

Gnotobiotic piglets were used to demonstrate for the first time that H. pylori urease is a virulent factor in vivo [60]. They have been useful for studies on mixed infections with type I and type II H. pylori strains [135]. However, this model shows some disadvantages: first, the histological damages of the gastric mucosa of infected animals are significantly different from those observed in humans; in addition, these animals require very sophisticated housing facilities.

20.9 The feasibility of Vaccination in Animal Models

20.8.4 Monkeys

H. pylori can spontaneously infect nonhuman primates. In some colonies, in fact, about 60 % of rhesus monkeys are infected by the age of 2 years; the frequency increases to more than 90 % by the time the animals are 11 years old [136], with a gastric pathology that is almost indistinguishable from that observed in humans [137]. Major limits to the use of this model, however, are the sophisticated facilities required for animal housing as well as their very high cost of maintenance. More importantly, because of the susceptibility of monkey species to natural infection, it is very difficult to find an appreciable number of individuals that are not naturally infected. Using this model, therapeutic vaccination protocols have been carried out with varying success [138]. 20.8.5 Dogs

Experimental infection of gnotobiotic beagles was reported early in 1990 [139]. Subsequently, conventional beagles were experimentally infected with a mouse-adapted strain of H. pylori [141]. This model allows following the infected animals without the need of necropsy, as, for example, is needed for mice. Early after infection, the gastric mucosa of these animals was found to be infiltrated with many neutrophils (resulting in increased production of IL-8) and then with mononuclear cells. Four weeks after the initial colonization, at the antral region of the stomach, several follicular structures appeared, mainly composed of peripheral CD4+ cells surrounding a germinal center rich in CD21+ B cells. Interestingly, in the acute phase of infection these dogs showed clinical symptoms, such as diarrhea and vomiting, similar to those reported in acute infections in humans [117, 142]. Vaccine formulations based on purified antigens have been now tested in such a model for both prophylactic and therapeutic vaccinations (unpublished).

20.9 The feasibility of Vaccination in Animal Models

A very large body of evidence exists showing that protection against H. pylori infection can be achieved both prophylactically and therapeutically in animal models [143]. Because the microorganism is localized extracellularly at the mucosal level, particular emphasis has been given to oral immunization, although other mucosal routes of immunization [144], as well as the parenteral route [143] and prime–boost regimens [145, 146] have been considered. Mucosal immunization requires the concomitant use of strong mucosal adjuvants, because proteins are poor immunogens when given mucosally. The strongest mucosal adjuvants are bacterial toxins, such as cholera toxin (CT) and the Escherichia coli heat-labile enterotoxin (LT); however, they in-

443

444

20 Helicobacter pylori

duce severe diarrhea in humans, seriously limiting their use. This is why nontoxic mutants of these molecules are being generated and tested as mucosal adjuvants [147]. The feasibility of mucosal immunization was first demonstrated in mice immunized orally with bacterial lysates or chemically inactivated whole-cell bacteria together with CT, E. coli heat-labile enterotoxin LT, or their nontoxic mutants [143]. When the immunized animals were challenged with H. pylori, a high rate of protection was observed. However, at present, the use of crude antigen preparations can be proposed for humans with difficulty, due to quality-control and regulatory problems related to the quality and reproducibility of lot preparations. Furthermore, whole-cell preparations contain antigens such as LPS and those of the Lewis blood groups shared with the host, i. e., exposed on the surface of the majority of human cells, including gastric epithelial cells [34]. The animal models, and mice in particular, that can be considered valid for screening antigens for human vaccination [148] have greatly helped in selecting antigens suitable for a vaccine. Generally speaking, antigens to be included in a vaccine should be well conserved among the different virulent strains, should be exposed on the bacterial surface or, more generally, accessible to immune response effectors, should contain immunogenic epitopes, and should be relevant to bacterial survival and/or in the pathogenesis of the infection. Moreover, they should be easily produced in large amounts and at acceptable costs. Once these requirements are met, a crucial step is to test the protective efficacy of the antigen under investigation. The efficacy of prophylactic and therapeutic immunization against H. pylori has now been demonstrated for a variety of native and recombinant antigens, such as urease, heat shock proteins, native and recombinant VacA, CagA, HP-NAP, catalase, and others (for an overview, see [143]). Although immunization usually resulted in a strong reduction in bacterial colonization rather than a sterilizing immunity, all the data obtained in animal models indicate the feasibility of vaccination against H. pylori and contribute to the development of an efficacious vaccine. The information derived from knowledge of the H. pylori genome will probably lead to identifying antigen candidates for a vaccine in addition to those already identified [149, 150].

20.10 The Mechanisms of Protective Immunity against H. pylori

H. pylori infection elicits a strong immune response, at both B and T cell levels, as well as substantial cytokine and chemokine responses; nevertheless, the infection is seldom cleared. At present it is not well understood how mucosal or systemic immunization can induce protection against H. pylori. Specific IgA [151] or IgG [152] antibodies produced locally in the gastric compartment were originally hypothesized to mediate protection by favoring killing by neutrophils or monocytes through bacterial opsonization [153] or by neutralizing the activity of bacterial toxin VacA [154]. A potential role of specific antibodies in the effec-

20.10 The Mechanisms of Protective Immunity against H. pylori

tor mechanisms against H. pylori was seriously questioned when it was observed that humans with congenital IgA deficiency do not suffer a H. pylori gastric pathology more severe than that observed in normal individuals [155], and it was proven that protection against either H. pylori or H. felis was attainable by vaccinating immunoglobulin-deficient mice [156–158]. Protection against H. pylori was also achieved in MHC class I knockout mice, indicating that MHC class I-restricted CD8+ T lymphocytes do not play a major role in such protection. In contrast, unsuccessful vaccination of MHC class II knockout mice demonstrated a crucial role of MHC class IIrestricted CD4+ T cells in achieving protection against H. pylori [157, 159]. A working hypothesis of the past few years has concerned the preferential association of proinflammatory Th1-type responses with H. pylori infection and the association of Th2-type responses with protective response after vaccination [160]. This assumption was supported, for example, by the finding that oral immunization failed to protect IL-4 knockout mice [161]. In addition, after therapeutic immunization with urease B subunit plus CT as adjuvant, the levels of IL-4 were found to increase after each immunization, while those of IFN-g decreased [162]. Furthermore, systemic vaccination with H. pylori lysate and aluminum hydroxide conferred protection against H. pylori challenge [163]. Finally, helminth infection, which elicits strong Th2-type immune responses, was shown to reduce gastric atrophy in H. pylori-infected mice [164]; this also suggests a possible explanation of the low prevalence of peptic ulcers in African people, in spite of the high rate of H. pylori infection, which could be due to endemic helminthic infection and the consequent Th2-dominated immune response [165]. On the other hand, more recent observations indicate that the regulatory roles of Th1 and Th2 cells in protective immunity against H. pylori are still to be clarified, because the crucial role of IL-12 and Th1 responses in achieving protection has been demonstrated [166–168]. After H. pylori infection, a long-lasting Th1-type response can be established, contributing to a worsening of the disease and eventually leading to peptic ulcer. In a subset of infected people, the infection can affect the development or the expression in gastric T cells of regulatory cytotoxic mechanisms on B-cell proliferation, facilitating the possibility of neoplastic transformation [169]. As already mentioned, the host's genetic factors can also be relevant in determining the outcome of H. pylori-associated pathologies [49, 51]. It appears now that a Th1-type response can be effective against H. pylori infection, under the conditions that it is not prolonged and that a fine tuning of protective immunity is exerted by Th2 cells. Thus, one can reasonably conclude that a protective immunization should produce a properly balanced Th1/ Th2 response [169–171]. The difficulty of understanding what the protective immune response to H. pylori is and why the natural response seems to be ineffective also resides in the incomplete knowledge of the mechanisms by which H. pylori escapes a protective immune response. For example, H. pylori can either impair phagocytosis or survive in the phagosome after phagocytosis [172, 173]. However, efficient killing by phagocytes have been shown in vitro in the presence of specific antibodies and in the absence of complement [174]. A powerful feature by which H. pylori could become protected from the immune response is its ability, demonstrated in vitro, to penetrate epithelial

445

446

20 Helicobacter pylori

cells and survive within them [175]; if this mechanism is efficient in vivo, it would create a reservoir of live bacteria in the gastric epithelium, which could explain, at least in part, the difficulties in eradicating H. pylori infections. There are some indications that protective immunity can produce a transient enhancement of gastric inflammation, as for example was observed in animals vaccinated and then challenged with H. pylori, leading to the hypothesis that post-immunization gastritis may be part of the protective response, being involved in bacterial clearance [170, 171, 176, 177]. It is clear that a deeper knowledge of the immunological parameters of protection against H. pylori following immunization are of critical importance to interpreting and evaluating the results obtained with vaccines presently under clinical trials and for developing future vaccines. Based on the numerous studies of vaccination in both animal models and human volunteers, it appears that the route of administration, as well as the adjuvant used, can play a crucial role in the achievement of protective immune response. Conceivably, as with other bacterial vaccines, a mixture of different putative protective antigens should be included in an efficacious vaccine. Finally, it has been demonstrated that it is possible to induce strong immune responses by vaccination in H. pylori-infected mucosa; thus, a therapeutic vaccine would probably have a chance of success, because the previous H. pylori-induced inflammation may have efficiently primed the immune responses against bacterial antigens [178].

20.11 Vaccination against H. pylori in Humans

Despite the large body of information that has been acquired on H. pylori vaccination in animals, few clinical studies have been carried out so far. Several of the trials conducted have focused on the use of the most abundant H. pylori antigen, i. e., urease. In addition, with one exception, all trials have been done with the mucosal route of immunization. The need for strong and safe mucosal adjuvants and the issues inherent to the formulation of vaccines to be given mucosally may have limited the number of studies with these vaccines. 20.11.1 Vaccination with Purified Recombinant Urease

A detailed study was conducted in H. pylori-infected volunteers, which were orally immunized with high doses of recombinant urease (20, 60, or 180 mg once weekly for 4 weeks) together with 5 mg of E. coli heat-labile enterotoxin (LT). Although the urease was well tolerated, 16 out 24 of the vaccinees had diarrhea, conceivably due to LT toxicity, the numbers of episodes being uninfluenced by the dose of antigen. Volunteers receiving the highest doses of urease (60 or 180 mg) showed high levels of anti-urease IgA serum antibodies, but the titers did not correlate with reduction of bacterial burden in the stomach. Eradication was in fact never observed, and the im-

20.11 Vaccination against H. pylori in Humans

munization did not contribute to decreasing the gastric inflammation [179]. The reasons for the partial results of this trial on both the immunogenicity and efficacy may be linked to the vaccination regimen and to the liquid formulation of the vaccine, to the urease antigen, to the low dose of the mucosal adjuvant (higher doses, such as 10 mg, induced too-severe diarrhea and forced discontinuation of this dosage), or to difficulties inherent in the therapeutic vaccination itself that are not understood yet. Indeed, despite all efforts, so far no therapeutic vaccines are available on the market. Later, the same researcher group attempted to improve the safety profile of this vaccine by reducing the amount of LT [180]. In a randomized, double blind, placebo-controlled study, 42 healthy H. pylori-negative subjects were immunized orally with 60 mg of recombinant urease in either soluble or acid-resistant, encapsulated form together with 2.5, 0.5, or 0.1 mg of LT. The vaccine was given on days 1, 8, 28, and 57. In this study, diarrhea was evident in 50 % of individuals receiving the highest dose of LT (2.5 mg), but was absent in those who received the lower doses of LT. A slightly better urease-specific antibody response was detectable in the subjects who received the highest dose of LT. However, only one of the volunteers developed IgG against LT. Finally, only volunteers who received the highest dose of LTexperienced an increase of CD4+, CD45RO+, and CD69+ cells, but only after a fifth oral administration of the vaccine. These data confirm, as already known from in vitro assays and animal studies, that LT toxicity, immunogenicity, and adjuvanticity are dose-dependent and that a fine tuning must be found in order to induce protective immune responses against the vaccine without causing unacceptable side effects such as diarrhea. Another attempt, made to circumvent the safety issues inherent in oral administration of wild type LT, has been to replace the oral route with the rectal route of vaccination, which was previously successful in mice [181]. Also in this study, recombinant urease was used at the dose of 60 mg, administered as a rectal enema to 18 healthy, H. pylori-negative adults, together with either 5 or 25 mg of LT, given three times on days 0, 14, and 28 [182]. A strong antibody response to LT was detectable systemically in the majority of the vaccinees, mainly in the group receiving the lowest dose of LT (5 mg). Only a small minority of subjects developed systemic anti-urease IgG or IgA antibody responses. However, no anti-urease or anti-LT IgA antibody was detectable in stool or in salivary samples. Finally, the urease-driven proliferative response and IFN- g production were negligible. All these studies clearly show that oral administration of recombinant urease in particular, and likely of other antigens, requires the use strong and safe mucosal adjuvants to be given at doses sufficiently high to exert their adjuvant effects, but still unable to induce unwanted effects, such as diarrhea. Both the oral and the rectal routes require the development of appropriate formulations able to induce adequate protective immune responses to H. pylori. 20.11.2 Salmonella-vectored Urease

If the attempts made to develop a H. pylori vaccine based on the use of purified recombinant urease have so far given poor results, the attempts to develop vaccines

447

448

20 Helicobacter pylori

based on the administration of live recombinant Salmonella strains expressing urease have given even poorer immunogenicity results, despite the fact that good immunogenicity and efficacy were previously observed in mice with these bacterial constructs. In one study, one or two oral administrations of 1010 CFU or more of a Salmonella enterica serovar Typhi strain, attenuated by deletion of the phoP/phoQ virulence regulon and expressing H. pylori urease, induced serum antibody responses to Salmonella antigens (such as flagella and LPS), but was totally ineffective in inducing any detectable immune response to urease, even after a booster dose of recombinant urease plus wild type LT [183]. Slightly better results were reported in a subsequent study in which six volunteers were immunized orally (5 to 8 × 107 CFU) with S. enterica serovar Typhimurium harboring the same phoP/phoQ deletion [184]. Only one of the six volunteers had detectable urease-specific IgA antibody secreting cells; two others had slight amounts of urease-specific antibodies produced in vitro by cultured peripheral blood mononuclear cells; two subjects had some specific serum IgA antibodies detectable by ELISA but not by western blotting. A further study was carried out in volunteers immunized orally with S. enterica serovar Typhi Ty21 a expressing H. pylori urease. Also in this study, none of the 9 vaccinated volunteers developed any detectable antibody response against urease, and only 3 subjects showed a very weak antigen-specific T-cell response, despite three doses of > 109 CFU received on days 0, 2, and 4 [185]. It is clear that the bacterial vectors for H. pylori antigens still require quite a lot of optimization work to enhance the degree of intestinal colonization by the attenuated Salmonella, to enhance the stability of the plasmid expressing the foreign gene(s), and to ameliorate the safety issues not yet resolved by these constructs. 20.11.3 Inactivated Whole-cell Vaccines

The use of whole-cell vaccines against H. pylori inactivated via various means (sonication, formalin-treatment, etc.) has been successfully demonstrated in a large number of studies carried out in animals immunized either mucosally or parenterally [143]. Whole-cell vaccines offer the advantage of eliciting immune responses against a wide variety of antigens, although it has the major disadvantage of containing potentially dangerous components of the bacterium, such as those, like LPS, which share homologies with self antigens, and are thus able to induce immune responses that cross-react with epitopes of the host [35]. A formalin-inactivated whole-cell H. pylori vaccine was evaluated in a phase I trial in both H. pylori-negative and H. pylori-positive subjects [186]. The vaccine, containing various amounts of bacterial cells, was given orally three times, on days 0, 14, and 28, together with 25 mg of the LTR192G mutant, which contains a glycine instead of an arginine residue in the A1 subunit of the LT, which is supposed to reduce its sensitivity to trypsin. The first part of the trial was an open-label dose-response study in which H. pylori-infected or -uninfected individuals received 2.5 × 106 to

20.11 Vaccination against H. pylori in Humans

2.5 × 1010 bacterial cells together with the LT mutant. Vaccination elicited H. pylorispecific antibody responses only in subjects receiving the highest dose of the vaccine. The increase in IgA and IgG titers was marginal and were seen only in H. pylori-infected patients. The number of antibody-secreting cells induced by the vaccine remained negligible. However, some detectable responses were observed at the duodenal level in H. pylori-negative subjects [187]. The significance of this finding remains, however, unclear. Although some antibody response was induced only in H. pyloriinfected patients, proliferative responses of peripheral blood mononuclear cells and production of IFN-g were observed only in uninfected volunteers (5 and 7 volunteers out of 10, respectively) who had received the highest dose of the vaccine, following in vitro restimulation with a bacterial sonicate (not with a purified antigen such as catalase). The second part of the trial was a randomized double-blind study in which H. pylori-infected individuals received either 2.5 × 1010 bacteria plus 25 mg of LTR192G or placebo plus 25 mg of LTR192G. Vaccinated subjects had significantly higher IgA antibody titers in their stools than subjects receiving the placebo. However, coadministration of the vaccine with the adjuvant only marginally affected the serum antigen-specific IgA antibody response. Vaccination of H. pylori-infected patients did not achieve bacterial eradication, because, in both parts of the trial, the [13C]urea breath test remained positive 2, 6, and 7.5 months after vaccination [38]. It is not known, however, whether vaccination affected the degree of H. pylori colonization of the stomach, because no microbiological data were reported in this study. Finally, diarrhea occurred in 5 subjects out of 18 (28 %) vaccinated with the highest dose of bacteria plus the LTR192G mutant, and in 1 out of 3 (33 %) who received the LTR192G mutant. It is very unlike that the diarrhea was due to residual VacA activity in the vaccine preparation, since VacA activity is very sensitive to formaldehyde treatment. Instead, it is very likely that diarrhea was due to the LT mutant, which retains most of its toxic activities in vitro and in vivo in animals [147]. 20.11.4 Parenteral Multi-component Vaccines

Parenteral vaccination can confer protective immunity against mucosal infection [188]. This has been demonstrated by several research groups, including ours, also in experimental H. pylori infections in various animal models [143]. In most studies, however, the experimental vaccine consisted of an uncharacterized bacterial lysate, rather than well-defined recombinant antigens. Previous experience with the acellular pertussis vaccine had shown that effective immunity against pertussis is achieved by a combination of different antigens participating in different aspects of the pathogenesis of the infection [189]. Based on this knowledge, we decided to pursue the development of a vaccine against H. pylori consisting of various proteins, all involved in the virulence of the bacterium. Previous work on mice had shown that immunization with VacA, CagA, or HP-NAP protected animals against challenge with H. pylori [143, 190]. We tested the effects of immunization with the association of these three antigens in an experimental beagle model of infection with H. pylori, which reproduces various aspects of the infection in humans [140]. We found that the best pro-

449

450

20 Helicobacter pylori

phylactic protection against H. pylori was obtained after parenteral immunization with the three antigens formulated with aluminum hydroxide, the adjuvant most widely utilized in human vaccines (unpublished). These observations prompted us to evaluate the safety and immunogenicity of an aluminum hydroxide-adjuvanted multicomponent vaccine in human volunteers. H. pylori-uninfected individuals were immunized intramuscularly three times, following three different immunization regimes, with a vaccine consisting of either 10 or 25 mg each of CagA,VacA, and HP-NAP, plus aluminum hydroxide [191]. This vaccine was extremely safe, causing only some mild and transient effects at the site of injection no different in aspect or degree from those induced by any aluminum hydroxide-adjuvanted vaccine. The vaccine was highly immunogenic, inducing antibody responses to the three antigens in almost all individuals. Months after the last immunization, most of the subjects still had detectable antibody responses to each of the three antigens. Interestingly, vaccination induced very strong and sustained vaccine antigen-driven cellular proliferative responses and IFN-g production [90]. Several lines of evidence from this study suggest that parenteral vaccination with VacA, CagA, and HP-NAP induces strong, long-lasting immunological memory. Preliminary data show that this vaccine is equally safe and highly immunogenic also in H. pylori-infected subjects (unpublished).

20.12 Conclusions

Since the discovery of H. pylori in the human stomach, the approach to some gastroduodenal diseases related to H. pylori infection has been revolutionized by the concept that the eradication of infection would eventually defeat pathologies such as gastric and duodenal ulcers. The current management of H. pylori infection involves a diagnosis of infection, then an appropriate therapy, based on antacids and antibiotics, that is effective in 80 %–90 % of patients. The therapy may be discontinued by a noncompliant patient or it can fail, mainly due to antibiotic resistance. Furthermore, recrudescence or reinfection can occur. The limits of current therapies can be overcome by introducing an effective vaccine, also from the point of view of cost-effectiveness [110, 111]. Indeed, vaccination of the entire population would rapidly decrease the costs of diagnosis and treatment. Studies carried out in recent decades on H. pylori physiology and on the mechanisms of its virulence and pathogenesis have allowed the identification of several bacterial antigens as potential vaccine candidates. Work on animal models of H. pylori infection has allowed a selection of the more promising vaccines. Most experimental vaccinations against H. pylori in animal models did not achieve eradication of the bacterium, but a strong reduction in bacterial burden was observed, in some cases accompanied by amelioration of gastric pathology. This suggests that further investigation is required on the antigens, routes of immunization, and adjuvants needed to achieve sterilizing protection. However, the real target of vaccination against H. py-

References

lori should be reconsidered: a vaccine able to counteract the development of H. pylori-related pathologies could be considered efficacious even in the absence of complete eradication of H. pylori. Conceivably, such a vaccine should act against at least the virulence factors that are already known to be linked to the most severe outcomes of H. pylori infection. Some vaccines have undergone early-phase clinical trials, giving encouraging data about safety and immunogenicity. However, due to the lack of immunological correlates of protection, we have to await the results of large phase III clinical trials to evaluate the efficacy of these vaccines, i. e., to assess the evidence of protection against infection.

References 1. A. Covacci, J.L. Telford, G. Del Giudice, J. Parsonnet, R. Rappuoli. H. pylori virulence and genetic geography. Science 1999, 284, 1328–1333. 2. D. Falush, T. Wirth, B. Linz, J.K. Pritchard, M. Stephens, M. Kidd, M.J. Blaser, D.Y. Graham, S. Vacher, G.I. Perez-Perez,Y. Yamaoka, F. Megraud, K. Otto, U. Reichard, E. Katzowitsch, X. Wang, M. Achtman, S. Suerbaum. Traces of human migrations in Helicobacter pylori populations. Science 2003, 299, 1582–1585. 3. C. Ghose, G.I. Perez-Perez, M.G. Dominguez-Bello, D.T. Pride, C.M. Bravi, M.J. Blaser. East Asian genotypes of Helicobacter pylori strains in Amerindians provide evidence for its ancient human carriage. Proc. Natl. Acad. Sci. USA 2002, 99, 15107–15111. 4. B. Marshall, ed. Helicobacter Pioneers: Firsthand Accounts from the Scientists Who Discovered Helicobacters, 1892– 1982. 2002, Blackwell Science Ltd., Carlton, Australia. 5. B.J. Marshall, J.R. Warren. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1(8390), 1311–1315. 6. C.S. Goodwin, J.A. Armstrong, B.J.Marshall. Campylobacter pyloridis, gastritis, and peptic ulceration. J. Clin. Pathol. 1986, 39, 353–365. 7. C.S. Goodwin, J.A. Armstrong, T. Chilvers, M. Peters, M.D. Collins, L. Sly, W. McConnel,W.E.S. Harper. Transfer of Campylobacter pylori and

8.

9.

10.

11.

12.

13.

Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelea comb. nov., respectively. Int. J. Syst. Bacteriol . 1989, 39, 397–405. J.G. Fox. The non-H.pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut 2002, 50, 273–283. International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In: Schistosome s, Liver Flukes and Helicobacter pylori. Lyon: IARC, Monogr. Eval. Carcinog. Risks Hum. 1994, 60, 177–240. H.M. Malaty, A. El-Kasabany, D.Y. Graham, C.C. Miller, S.G. Reddy, S.R. Srinivasan,Y. Yamaoka, G.S. Berenson, Age at acquisition of Helicobacter pylori infection: a follow up study from infancy to adulthood. Lancet 2002 359, 931–935. S.K. Sinha, B. Martin, M. Sargent, J.P. McConnell, C.N. Bernstein. Age at acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter 2002, 7, 76–85. J. Tindberg, C. Bengtsson, F. Granath, M. Blennow, O. Nyrén, M. Grandström. Helicobacter pylori infection in a Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology 2001,121, 310–316. D. Rothebacher, M. Winkler, T. Gonser, G. Adler, H. Brenner. Role of infected parents in transmission of Heli-

451

452

20 Helicobacter pylori

14.

15.

16.

17.

18.

19.

20.

21.

22.

cobacter pylori to their children. Pediatr. Infect. Dis. J. 2002, 21, 674–679. H.M. Malaty, D.Y. Graham,W.A. Wattigney, S.R. Srinivasan, M. Osato, G.S. Berenson. Natural history of Helicobacte pylori infection in childhood: 12year follow-up cohort study in a biracial community. Clin. Infect. Dis. 1999, 28, 279–282. T. Kumagai, H.M. Malaty, D.Y. Graham, S. Hosogaya, K. Misawa, K. Furihata, H. Ota, C. Sei, E. Tanaka, T. Akamatsu, T. Shimizu,K. Kiyosawa, T. Katsuyama. Acquisition versus loss of Helicobacter pylori infection in Japan: results from an 8-year birth cohort study. J. Infect.Dis . 1998, 178, 717–721. J. Parsonnet, H. Shmuely, T. Haggerty. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999, 282, 2240–2245. H. Mitchell, F. Megraud. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2002, 7(suppl. 1), 8–12. S.A. Dowsett, L. Archila,V.A. Segreto, C.R. Gonzalez, A. Silva, K.A. Vastola, R.D. Bartizek, M.J. Kowolik. Helicobacter pylori infection in indigenous families of Central America: serostatus and oral and fingernail carriage. J. Clin. Microbiol. 1999, 37, 2456–2460. Y. Lu, T.E. Redlinger, R. Avitia, A. Galindo, K. Goodman. Isolation and genotyping of Helicobacter pylori from untreated municipal wastewater. Appl. Environ. Microbiol. 2002, 68, 1436–1439. P.D. Klein, D.Y. Graham, A. Gaillour, A.R. Opekun, E.O. Smith. Gastrointestinal Physiology Working Group. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Lancet 1991, 337, 1503–1506. F.A.K. El-Zaatari, J.S. Woo, A. Badr, M.S. Osato, H. Serna, L.M. Lichtenberger, R.M. Genta, D.Y. Graham. Failure to isolate Helicobacter pylori from stray cats indicates that H. pylori in cats may be an anthroponosis: an animal infection with a human pathogen. J. Med. Microbiol. 1997, 46, 372–376. G. Bode, D. Rothenbacher, H. Brenner, G. Adler. Pets are no risk factor for H. pylori infection in young chil-

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

dren: results of a population based study in Southern Germany. Pediatr. Infect.Dis. J. 1998, 17, 909–912. L.M. Brown, T.L. Thomas, J.L. Ma,Y.S. Chang,W.C. You, W.D. Liu, L. Zhang, M.H. Gail. Helicobacter pylori infection in rural China: exposure to domestic animals during childhood and adulthood. Scand. J. Infect.Dis. 2001, 33, 686–691. P. Grubel, L. Huang, N. Masubuchi, F.J. Stutzenberger, D.R. Cave. Detection of Helicobacter pylori DNA in houseflies (Musca domestica) on three continents. Lancet 1998, 352, 788–789. M.S. Osato, K. Ayub, H.H. Le, R. Reddy, D.Y. Graham. Houseflies are an unlikely reservoir or vector for Helicobacter pylori. J. Clin. Microbiol. 1998, 36, 2786–2788. L.P. Andersen, A. Dorland, H. Karacan, H. Colding, H.-O. Nilsson, T. Waldströ m, J. Blom. Possible clinical importance of the transformation of Helicobacter pylori into coccoid forms. Scand. J. Gastroenterol. 2000, 9, 898– 903. L. Cellini, N. Allocati, D. Angelucci, T. Iezzi, E. Di Campli, L. Marzio, B. Dainelli. Coccoid H. pylori not culturable in vitro reverts in mice. Microbiol. Immunol. 1994, 38, 843–850. D. Rothenbacher, H. Brenner. Burden of Helicobacter pylori and H. pylorirelated diseases in developed countries: recent development and future implications. Microbes Infect. 2003, in press. R.W. Frenck, J. Clemens. Helicobacter in the developing world. Microbes Infect. 2003, in press. H.H. Xia, N.J. Talley. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am. J. Gastroenterol. 2001, 96, 16–26. C. Montecucco, R. Rappuoli. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat. Rev. Mol.Cell. Biol. 2001, 2, 457–66. M.P. Dore, D.Y. Graham. Pathogenesis of duodenal ulcer disease: the rest of the story. Baillieres Best Pract. Res. Clin. Gastroenterol. 2000, 14, 97–107. P.B. Ernst, B.D. Gold. The disease

References

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

spectrum of Helicobacter pylori : the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 2000, 54, 615–640. B.J. Appelmelk, R. Negrini, A.P. Moran, E.J. Kuipers. Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol. 1997, 5, 70–73. A.P. Moran, M.M. Prendergast. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J. Autoimmun. 2001, 16, 241–256. S.J. Sontag. Guilty as charged: bugs and drugs in gastric ulcer. Am. J. Gastroenterol. 1997, 92, 1255–1261. M.Q. Du, P.G. Isaccson. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. 2002, 3, 97–104. A.C. Wotherspoon, C. Ortiz-Hidalgo, M.R. Falzon, P.G. Isaacson. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991, 338, 1175–1176. N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, M. Yamakido, K. Taniyama, N. Sasaki, R.J. Schlemper. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345, 784– 789. D. Forman, P. Webb, J. Parsonnet. Helicobacter pylori and gastric cancer. Lancet 1994, 343, 243–244. K. Ogura, S. Maeda, M. Nakao, T. Watanabe, M. Tada, T. Kyutoku, H. Yoshida,Y. Shiratori, M. Omata. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J. Exp. Med. 2000, 192, 1601–1609. T. Watanabe, M. Tada, H. Nagai, S. Sasaki, M. Nakao. Helicobacter pylori induces gastric cancer in Mongolian gerbils. Gastroenterology 1998, 115, 642– 648. S.U. Han,Y.B. Kim, H.J. Joo, K.B. Hahm, W.H. Lee,Y.K. Cho, D.Y. Kim, M.W. Kim. Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. J. Gastroenterol. Hepatol. 2002, 17, 253–261. C. Bariol, A. Field, C.R. Vickers,

45.

46.

47.

48.

49.

50.

51.

52.

R. Ward. Regression of gastric T cell lymphoma with eradication of Helicobacter pylori. Gut 2001, 48, 269–271. A. Covacci, R. Rappuoli. Tyrosinephosphorylated bacterial proteins: Trojan horses for the host cell. J. Exp. Med. 2000, 191, 587–592. S. Censini, C. Lange, Z. Xiang, J.E. Crabtree, P. Ghiara, M. Borodovsky, R. Rappuoli, A. Covacci. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA 1996, 93, 14648–14653. J. Parsonnet, G.D. Friedman, N. Orentreich, H. Vogelman. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 40, 297–301. A.M. Nomura, J. Lee, G.N. Stemmermann, R.Y. Nomura, G.I. Perez-Perez, M.J. Blaser. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J. Infect. Dis. 2002, 186, 1138– 1144. E.M. El-Omar, M. Carrington,W.H. Chow, K.E. McColl, J.H. Bream, H.A. Young, J. Herrera, J. Lissowska, C.C. Yuan, N. Rothman, G. Lanyon, M. Martin, J.F. Fraumeni Jr., C.S. Rabkin. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404, 398–402. I.R. Hwang, T. Kodama, S. Kikuchi, K. Sakai, L.E. Peterson, D.Y. Graham, Y. Yamaoka. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002, 123, 1793–1803. C. Figueiredo, J.C. Machado, P. Pharoah, R. Seruca, S. Sousa, R. Carvalho, A.F. Capelinha, W. Quint, C. Caldas, L.J. Van Doorn, F. Carneiro, M. Sobrinho-Simoes. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Canc. Inst. 2002, 94, 1680–1687. L.E. Hansson, O. Nyren, A.W. Hsing, R. Bergstrom, S. Josefsson, W.H. Chow, J.F. Fraumeni Jr., H.O. Adami.

453

454

20 Helicobacter pylori

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 1996, 335, 242–249. S.J. Konturek, P.C. Konturek, P. Pieniazek,W. Bielanski. Role of Helicobacter pylori infection in extragastroduodenal disorders: introductory remarks. J. Physiol. Pharmacol. 1999, 50, 683– 694. A. Gasbarrini, F. Franceschi, A. Armuzzi,V. Ometti, M. Candelli, E.S. Torre, A. De Lorenzo, M. Anti, S. Pretolani, G. Gasbarrini. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut 1999, 4(Suppl. 1), I9–I12. L. Davydov, J.W. Cheng. The association of infection and coronary artery disease: an update. Expert Opin. Investig. Drugs. 2000, 9, 2505–2517. B. Wedi, A. Kapp. Helicobacter pylori infection in skin diseases: a critical appraisal. Am. J. Clin. Dermatol. 2002, 3, 273–282. M. Mayr, S. Kiechl, M.A. Mendall, J. Willeit, G. Wick, Q. Xu. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pyloristrains: prospective results from the Bruneck study. Stroke 2003, 34, 610–615. K.A. Eaton, D.R. Morgan, S. Krakowka. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori. J. Med. Microbiol. 1992, 37, 123–127. T.L. Testerman, D.J. McGee, H.L.T. Mobley. Adherence and colonization. In: Helicobacter pylori Physiology and Genetics. H.L.T. Mobley, G.L. Mendz, S.L. Hazell eds, 2001, ASM Press, Washington DC, USA. K.A. Eaton, C.L. Brooks, D.R. Morgan, S. Krakowka. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect. Immun. 1991, 59, 2470–2475. P.R. Harris, H.L. Mobley, G.I. PerezPerez, M.J. Blaser, P.D. Smith. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology, 1996, 111, 419–425. A.P. Gobert, B.D. Mersey,Y. Cheng,

63.

64.

65.

66.

67.

68.

69.

70.

D.R. Blumberg, J.C. Newton, K.T. Wilson. Urease release by Helicobacter pylori stimulates macrophage inducible nitric oxide synthase. J. Immunol. 2002, 168, 6002–6006. F. Tonello,W.G. Dundon, B. Satin, M. Molinari, G. Tognon, G. Grandi, G. Del Giudice, R. Rappuoli, C. Montecucco. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Mol. Microbiol. 1999, 34, 238–246. C. Montecucco, M. De Bernard. Molecular and cellular mechanisms of action of the VacA and HP-NAP virulence factors of Helicobacter pylori. Microbes Infect. 2003, in press. B. Satin, G. Del Giudice,V. Della Bianca, S. Dusi, C. Laudanna, F. Tonello, D. Kelleher, R. Rappuoli, C. Montecucco, F. Rossi. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J. Exp. Med. 2000, 191, 1467–1476. J. Hacker, E. Carniel. Ecological fitness, genomic islands and bacterial pathogenicity: a Darwinian view of the evolution of microbes. EMBO Rep. 2001, 2, 376–381. M. Stein, R. Rappuoli, A. Covacci. Tyrosin phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc. Natl. Acad. Sci. USA 2000, 97, 1263–1268. M. Stein, F. Bagnoli, R. Halenbeck, R. Rappuoli,W.J. Fantl, A. Covacci. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol. Microbiol. 2002, 43, 971–980. S. Yamazaki, A. Yamakawa,Y. Ito, M. Ohtani, H. Higashi, M. Hatakeyama, T. Azuma. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J. Infect. Dis. 2003, 187, 334–337. M. Akanuma, S. Maeda, K. Ogura, Y. Mitsuno,Y. Hirata, T. Ikenoue, M. Otsuka, T. Watanabe,Y. Yamaji, H. Yoshida, T. Kawabe,Y. Shiratori, M. Omata. The evaluation of putative virulence factors of Helicobacter pylori

References

71.

72.

73.

74.

75.

76.

77.

78.

79.

for gastroduodenal disease by use of a short-term Mongolian gerbil infection model. J. Infect. Dis. 2002, 185, 341– 347. Y. Yamaoka, D.H. Kwon, D.Y. Graham. A Mr 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc. Natl. Acad. Sci. USA 2000, 97, 7533–7538. M. Molinari, M. Salio, C. Galli, N. Norais, R. Rappuoli, A. Lanzavecchia, C. Montecucco. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J. Exp. Med. 1998, 187, 135–140. A.M. Petersen, K. Sorensen, J. Blom, K.A. Krogfelt. Reduced intracellular survival of Helicobacter pylori vacA mutants in comparison with their wildtypes indicates the role of VacA in pathogenesis. FEMS Immunol. Med. Microbiol. 2001, 30, 103–108. P. Lupetti, J.E. Heuser, R. Manetti, P. Massari, S. Lanzavecchia, P.L. Bellon, R. Dallai, R. Rappuoli, J.L. Telford. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin. J. Cell. Biol. 1996, 133, 801–807. J.M. Reyrat,V. Pelicic, E. Papini, C. Montecucco, R. Rappuoli, J.L. Telford. Towards deciphering the Helicobacter pylori cytotoxin. Mol. Microbiol. 1999, 34, 197–204. N.R. Salama, G. Otto, L. Tompkins, S. Falkow. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect. Immun. 2001, 69, 730–736. J.J. Sung, S.R. Lin, J.Y. Ching, L.Y. Zhou, K.F. To, R.T. Wang. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000, 119, 7–14. A. Papa, G. Cammarota, A. Tursi, A. Gasbarrini, G. Gasbarrini. Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: a longterm follow-up study. J. Clin. Gastroenterol. 2000, 31, 169–171. T. Sugiyama, N. Sakaki, H. Kozawa, R. Sato, T. Fujioka, K. Satoh, K. Sugano, H. Sekine, A. Takagi,Y. Ajioka,

80.

81.

82.

83.

84.

85.

86.

87.

T. Takizawa. H. pylori Forum Gastritis Study Group. Sensitivity of biopsy site in evaluating regression of gastric atrophy after H. pylori eradication treatment. Aliment. Pharmacol. Ther. 2002, 16(Suppl. 2), 187–190. N. Kim, S.H. Lim, K.H. Lee, S.E. Choi, H.C. Jung, I.S. Song, C.Y. Kim. Longterm effects of H. pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig. Dis. Sci. 2000, 45, 1754–1762. A.M. Frendrick, M.E. Chernew, R.A. Hirt, B.S. Bloom, R.R. Bandekar, J.M. Scheiman. Clinical and economic effects of population-based H. pylori screening to prevent gastric cancer. Arch. Intern. Med. 1999, 159, 142–148. J. Mason, A.T. Axon, D. Forman, S. Duffett, M. Drummond,W. Crocombe, R. Feltbower, S. Mason, J. Brown, P. Moayyedi. Leeds HELP Study Group. The cost-effectiveness of population H. pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment. Pharmaco l. Ther . 2002, 16, 559–568. S. Ikeda, T. Tamamuro, C. Hamashima, M. Asaka. Evaluation of the cost-effectiveness of H. pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. Aliment. Pharmacol. Ther. 2001, 15, 1777–1785. P. Moayyedi, S. Soo, J. Deeks, D. Forman, J. Mason, M. Innes, B. Delaney. Dyspepsia Review Group. Systematic review and economic evaluation of H. pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000, 321, 659–664. M.J. Blaser. In a world of black and white, Helicobacter pylori is gray. Ann. Intern. Med. 1999, 130, 695–697. M.J. Blaser. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J. Infect. Dis. 1999, 179, 1523– 1530. A.D. Jones, K.D. Bacon, B.A. Jobe, B.C. Sheppard, C.W. Deveney, M.J. Rutten. Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells. J. Gastrointest. Surg. 2003, 7, 68–76.

455

456

20 Helicobacter pylori 88. P. Moayyedi, C. Bardhan, L. Young, M.F. Dixon, L. Brown, A.T. Axon. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001, 121, 1120–1126. 89. W. Schwizer, M. Thumshirn, J. Dent, I. Guldenschuh, D. Menne, G. Cathomas, M. Fried. H. pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001, 357, 1738–1742. 90. P. Malfertheiner, J. Dent, L. Zeijlon, P. Sipponen, S.J. Veldhuyzen Van Zanten, C.F. Burman, T. Lind, M. Wrangstadh, E. Bayerdorffer, J. Lonovics. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease: results from a randomized trial programme. Aliment. Pharmaco l. Ther. 2002, 16, 1431–1442. 91. A.H. Wu, J.E. Crabtree, L. Bernstein, P. Hawtin, M. Cockburn, C.C. Tseng, D. Forman. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int. J. Cancer. 2003, 103, 815–821. 92. R.M. Genta. A year in the life of the gastric mucosa. Gastroenterology 2000, 119, 252–254. 93. P. Malfertheiner, F. Megraud, C. O'Morain, A.P. Hungin, R. Jones, A. Axon, D.Y. Graham, G. Tytgat. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of H. pylori infection: the Maastricht 2–2000 Consensus Report. Aliment. Pharmaco l. Ther. 2002, 16, 167–180. 94. J.P. Gisbert, S. Marcos, J.L. Gisbert, J.M. Pajares. High efficacy of ranitidine bismuth citrate, amoxycillin, clarithromycin and metronidazole twice daily for only five days in H. pylori eradication. Helicobacter 2001, 6, 81–83. 95. Y.H. Hsieh, H.J. Lin, G.Y. Tseng, C.L. Perng, F.Y. Chang, S.D. Lee. A 3-day anti-H. pylori therapy is a good alternative for bleeding peptic ulcer patients with H. pylori infection. Hepatogastroenterology 2001, 48, 1078–1081. 96. T. Yoshida, T. Hatano, H. Ito. Chemistry and function of vegetable polyphe-

97.

98.

99.

100.

101.

102.

103.

104.

105.

nols with high molecular weights. Biofactors 2000, 13, 121–125. E.A. Bae, M.J. Han, D.H. Kim. In vitro anti-H. pylori activity of some flavonoids and their metabolites. Planta Med. 1999, 65, 442–443. F. Tombola, S. Campello, L. De Luca, P. Ruggiero, G. Del Giudice, E. Papini, M. Zoratti. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen Helicobacter pylori. FEBS Letters 2003, 543, 184–189. J.M. Meyer, N.P. Silliman,W. Wang, N.Y. Siepman, J.E. Sugg, D. Morris, J. Zhang, H. Bhattacharyya, E.C. King, R.J. Hopkins. Risk factors for H. pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann. Intern.Med . 2002, 136, 13–24. M.S. Osato, R. Reddy, S.G. Reddy, R.L. Penland, H.M. Malaty, D.Y. Graham. Pattern of primary resistance of H. pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. 2001, 161, 1217–1220. J. Torres, M. Camorlinga-Ponce, G. Perez-Perez, A. Madrazo De La Garza, M. Dehesa, G. Gonzalez-Valencia, O. Munoz. Increasing multidrug resistance in H. pylori strains isolated from children and adults in Mexico. J. Clin. Microbiol. 2001, 39, 2677–2680. J. Yakoob, X. Fan, G. Hu, L. Liu, Z. Zhang. Antibiotic susceptibility of H. pylori in the Chinese population. J. Gastroenterol. Hepatol. 2001, 16, 981– 985. N. Kalach, M. Bergeret, P.H. Benhamou, C. Dupont, J. Raymond. High levels of resistance to metronidazole and clarithromycin in H. pylori strains in children. J. Clin. Microbiol. 2001, 39, 394–397. M.P. Dore, D.K. Kwon, A.R. Sepulveda, D.Y. Graham, G, Realdi. Stable amoxycillin resistance in H. pylori. Helicobacter 2001, 6, 79. P. Hildebrand, P. Bardhan, L. Rossi, S. Parvin, A. Rahman, M.S. Arefin, M. Hasan, M.M. Ahmad, K. GlatzKrieger, L. Terracciano, P. Bauer-

References

106.

107.

108.

109.

110.

111.

112.

113.

feind, C. Beglinger, N. Gyr, A.K. Khan. Recrudescence and reinfection with H. pylori after eradication therapy in Bangladeshi adults. Gastroenterology 2001, 121, 792–798. E. Della Libera, M.R. Rohr, M. Moraes, E.S. Siqueira, A.P. Ferrari Jr. Eradication of H. pylori infection in patient with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates. Braz. J. Med. Biol. Res. 2001, 34, 753–757. A. Ramirez-Ramos, R.H. Gilman, R. Leon-Barua, S. Recavarren-Arce, J. Watanabe, G. Salazar, W. Checkley, J. McDonald,Y. Valdez, L. Cordero, J. Carrazco. Rapid recurrence of Helicobacterpylori infection in Peruvian patients after successful eradication. Clin. Infect.Dis . 1997, 25, 1027–1031. Y.T. Jeen, S.W. Lee, S.I. Kwon, H.J. Chun, H.S. Lee, C.W. Song, S.H. Um, J.H. Choi, C.D. Kim, H.S. Ryu, J.H. Hyun. Differentiation between reinfection and recrudescence of H. pylori strains using PCR-based restriction fragment length polymorphism analysis. Yonsei Med. J. 2001, 42, 41–45. M. Tavakoli, A.T. Prach, M. Malek, D. Hopwood, B.W. Senior, F.E. Murray. Decision analysis of histamine H2receptor antagonist maintenance versus Helicobacter pylori eradication therapy. Pharmacoeconomics 1999, 16, 355–365. M.F. Rupnow, D.K. Owens, R. Shachter, J. Parsonnet. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. Helicobacter 1999, 4, 272–280. M.F.T. Rupnow, R.D. Shachter, K.O. Douglas, J. Parsonnet. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2002, 20, 879–885. P.B. Sullivan, J.E. Thomas, D.G. Wight, G. Neale, E.J. Eastham, T. Corrah, N. Lloyd-Evans, B.M. Greenwood. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch. Dis. Child. 1990, 65, 189–191. A. Dale, J.E. Thomas, M.K. Darboe, W.A. Coward, M. Harding, L.T. Wea-

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

ver. Helicobacter pylori infection, gastric acid secretion, and infant growth. J Pedriatr. Gastroenterol. Nutr. 1998, 26, 393– 397. D.J. Passaro, D.N. Taylor, R. Meza, L. Cabrera, R.H. Gilman, J. Parsonnet. Acute Helicobacter pylori infection is followed by an increase in diarrhoeal disease among Peruvian children. Pediatrics 2001, 108, E87. M.L. Shahinian, D.J. Passaro, D.L. Swerdlow, E.D. Mintz, M. Rodriguez, J. Parsonnet. Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet 2000, 355, 377–378. M.K. Bhan, R. Bahl, S. Sazawal, A. Sinha, R. Kumar, D. Mahalanabis, J.D. Clemens. Association between Helicobacterpylori infection and increased risk of typhoid fever. J. Infect. Dis. 2002, 186, 1857–1860. B.J. Marshall, J.A. Amstrong, D.B. McGechie, R.J. Glancy. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med. J. Austr. 1985, 142, 436– 439. A. Morris, G. Nicholson. Ingestion of Campylobacter pyloridis causes gastritis and raised resting gastric pH. Am. J. Gastroenterol. 1987, 82, 192–199. G.M. Sobala, J.E. Crabtree, M.F. Dixon, C.J. Schorah, J.D. Taylor. Acute H. pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991, 32, 1415–1418. D.Y. Graham, A.R. Opekun, M.S. Osato, H.M.T. El Zimaity, M. Cadoz. H. pylori vaccine development in humans: challenge model. Third Annual Winter H. pyloriWorkshop, Orlando, FL, USA 1999, Poster no. 54. A. Lee, J.G. Fox, G. Otto, J. Murphy. A small animal model of human H. pylori active chronic gastritis. Gastroenterology 1990, 99, 1315–1323. R.L. Ferrero, A. Labigne. Cloning, expression, and sequencing of H. felis urease gene. Mol. Microbiol. 1993, 9, 323– 333. G. Macchia, A. Massone, D. Burroni, A. Covacci, S. Censini, R. Rappuoli. The Hsp 60 of H. pylori: structure and

457

458

20 Helicobacter pylori

124.

125.

126.

127.

128.

129.

130.

131.

immune response in patients with gastroduodenal disease. Mol. Microbiol. 1993, 9, 645–652. Z.Y. Xiang, S. Censini, P.F. Bayeli, J.L. Telford, N. Figura. Analysis and expression of VacA and CagA virulence factors in 43 strains of H. pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Immun. 1995, 63, 94–98. M. Karita, T. Kouchiyama, K. Okita, T. Nakazawa. New small animal model for human gastric H. pylori infection: success in both nude and euthymic mice. Am. J. Gastroenterol. 1991, 86, 1596–1603. M. Marchetti, B. Aricò, D. Burroni, N. Figura, R. Rappuoli, P. Ghiara. Development of a mouse model of H. pylori infection that mimics human disease. Science 1995, 267, 1655–1658. A. Lee, J. O'Rourke, M.C. De Ungria, B. Robertson, G. Daskalopoulos, M.F. Dixon. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997, 112, 1386–1397. P. Ghiara, M. Marchetti, B.J. Blaser, M.K.R. Tummuru, T.L. Cover. Role of the H. pylori virulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease. Infect. Immun. 1995, 63, 4154–4160. P. Ghiara, M. Rossi, M. Marchetti, A. Di Tommaso, C. Vindigni, F. Ciampolini, A. Covacci, J.L. Telford, M.T. De Magistris, M. Pizza, R. Rappuoli, G. Del Giudice. Therapeutic intragastric vaccination against H. pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 1997, 65, 4996–5002. P. Ghiara, A. Covacci, J.L. Telford, R. Rappuoli. H. pylori: pathogenic determinants and strategies for vaccine design. In: Concept in Vaccine Development. S.H.E. Kaufmann ed., de Gruyter, Berlin/New York 1996, 459–496. H. Li, I. Kalies, B. Mellgard, H.F. Helander. A rat model of chronic H. pylori infection: studies of epithelial cell

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

turnover and gastric ulcer healing. Scand. J. Gastroenterol. 1998, 33, 370– 378. N.H. Shomer, C.A. Dangler, M.T. Whary, J.G. Fox. Experimental H. pylori infection induces antral gastritis and gastric mucosa-associated lymphoid tissue in guinea pigs. Infect. Immun. 1998, 66, 2614–2618. F. Hirayama, S. Takagi, H. Kusuhara, E. Iwao,Y. Yokoyama,Y. Ikeda. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with H. pylori. J. Gastroente rol. 1996, 31, 755–757. J.C. Fox, G. Otto, J.C. Murphy, N.S. Taylor, A. Lee. Gastric colonization of the ferret with Helicobacter species: natural and experimental infections. Rev Infect Dis 1991, 13, S671-S680 N.S. Akopyants, K.A. Eaton, D.E. Berg. Adaptive mutation and cocolonization during Helicobacter pylori infection of gnotobiotic piglets. Infect. Immun. 1995, 63, 116–121. A. Dubois, D.E. Berg. The nonhuman primate model for H. pylori infection. In: Methods in Molecular Medicine, H. pylori Protocols. C.L. Clayton and H.T.L. Mobley eds., Humana Press, Totowa, NJ, USA 1997. A. Dubois, N. Fiala, L.M. HamanAckah, E.S. Drazek, A. Tarnawaski. Natural gastric infection with H. pylori in monkeys. Gastroenterology 1994, 106, 1405–1417. C.K. Lee. Vaccination against Helicobacter pylori in non-human primate models and humans. Scand. J. Immunol. 2001, 53, 437–442. M.J. Radin, K.A. Eaton, S. Krakowka, D.R. Morgan, A. Lee. H. pylori gastric infection in gnotobiotic beagle dogs. Infect. Immun. 1990, 58, 2606–2612. G. Rossi, M. Rossi, C.G. Vitali, D. Fortuna, D. Burroni, L. Pancotto, S. Capecchi, S. Sozzi, G. Renzoni, G. Braca, G. Del Giudice, R. Rappuoli, P. Ghiara, E. Taccini. A conventional beagle dog model for acute and chronic infection with Helicobacter pylori. Infect. Immun. 1999, 67, 3112–3120. G. Rossi, D. Fortuna, L. Pancotto, G. Renzoni, E. Taccini, P. Ghiara,

References

142.

143.

144.

145.

146.

147.

148.

R. Rappuoli, G. Del Giudice. Immunohistochemical study of the lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with H. pylori. Infect. Immun. 2000, 68, 4769–4772. A. Morris, G. Nicholson. Ingestion of Campylobacter pyloridis causes gastritis and raised resting gastric pH. Am. J. Gastroenterol. 1987, 82, 192–199. G. Del Giudice, A. Covacci, J.L. Telford, C. Montecucco, R. Rappuoli. The design of vaccines against Helicobacter pylori and their development Annu. Rev. Immunol . 2001, 19, 523–563. A.M. Svennerholm. Prospects for a mucosally-administered vaccine against Helicobacter pylori. Vaccine 2003, 21, 347–353. P. Londono-Arcila, D. Freeman, H. Kleanthous, A.M. O’Dowd, S. Lewis, A.K. Turner, E.L. Rees, T.J. Tibbitts, J. Greenwood, T.P. Monath, M.J. Darsley. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect. Immun. 2002, 70, 5096–5106. M. Vajdy, M. Singh, M. Ugozzoli, M. Briones, E. Soenawan, L. Cuadra, J. Kazzaz, P. Ruggiero, S. Peppoloni, F. Norelli, G. Del Giudice, D. O'Hagan. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal followed by systemic immunizations. Immunology 2003, 110, 86–94. M. Pizza, M.M. Giuliani, M.R. Fontana, E. Monaci, G. Douce, G. Dougan, K.H. Mills, R. Rappuoli, G. Del Giudice. Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19, 2534–2541. D. Bumann, P. Holland, F. Siejak, J. Koesling, N. Sabarth, S. Lamer, U. Zimny-Arndt, P.R. Jungblut, T.F. Meyer. A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening. Infect. Immun. 2002, 70, 6494–6498.

149. D. Bumann, S. Aksu, M. Wendland, K. Janek, U. Zimny-Arndt, N. Sabarth, T.F. Meyer, P.R. Jungblut. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect. Immun. 2002, 70, 3396–3403. 150. N. Sabarth, R. Hurwitz, T.F. Meyer, D. Bumann. Multiparameter selection of Helicobacter pylori antigens identifies two novel antigens with high protective efficacy. Infect. Immun . 2002, 70, 6499– 6503. 151. C.K. Lee, R. Weltzin,W.D. Thomas Jr., H. Kleanthous, T.H. Ermak. Oral immunization with recombinant H. pylori urease induces secretory IgA antibodies and protects mice from challenge with H. felis. J. Infect. Dis. 1995, 172, 161– 162. 152. R.L. Ferrero, J.M. Thieberge, A. Labigne. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterolog y1997, 113, 185–194. 153. M.F. Tosi, S.J. Czinn. Opsonic activity of specific IgG against H. pylori. J. Infect. Dis. 1990, 162, 156–166. 154. T.L. Cover, P. Cao, U.K. Murphy, M.S. Sipple, M.J. Blaser. Serum neutralizing antibody response to the vacuolating cytotoxin of H. pylori. J. Clin. Invest. 1992, 90, 913–918. 155. A.K. Bogstedt, S. Nava, T. Wadstrom, L. Hammarstrom. H. pylori infection in IgA deficiency: lack of role for the secretory immune system. Clin. Exp. Immunol. 1996, 105, 202–204. 156. J. Nedrud, T. Blanchard, S. Czinn, G. Harriman. Orally-immunized deficient mice are protected against H. felis infection. Gut 1996, 39(Suppl. 2), A45. 157. T.H. Ermak, P.J. Giannasca, R. Nichols, G.A. Myers, J. Nedrud, R. Weltzin, C.K. Lee, H. Kleanthous, T.P. Monath. Immunization of mice with urease vaccine affords protection against Helicobacter pyloriinfection in the absence of antibodies and is mediated by MHC Class II-restricted responses. J. Exp. Med. 1998, 188, 2277– 2288. 158. T.G. Blanchard, S.J. Czinn, R.W. Redline, N. Sigmund, G. Harriman, J.G.

459

460

20 Helicobacter pylori

159.

160.

161.

162.

163.

164.

165.

166.

Nedrud. Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cell Immunol. 1999, 191, 74–80. J. Pappo, D. Torrey, L. Castriotta, A. Savinainen, Z. Kabok, A. Ibraghimov. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect. Immun. 1999, 67, 337–341. M. Mohammadi, J. Nedrud, R. Redline, N. Lycke, S.J. Czinn. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 1997, 113, 1848–1857. F.J. Radcliff, A.J. Ramsay, A. Lee. Failure of immunization against Helicobacter infection in IL-4 deficient mice: evidence for a Th2 immune response as the bias for protective immunity. Gastroenterology 1996, 110, A-997. P.F. Saldinger, N. Porta, P. Launois, J.A. Louis, G.A. Waanders, H. Bouzourene, P. Michetti, A.L. Blum, I.E. Corthesy-Theulaz. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 1998, 115, 891–897. J.M. Gottwein, T.G. Blanchard, O.S. Targoni, J.C. Eisenberg, B.M. Zagorski, R.W. Redline, J.G. Nedrud, M. Tary-Lehmann, P.V. Lehmann, S.J. Czinn. Protective anti-Helicobacter immunity is induced with aluminium hydroxide or complete Freund's adjuvant by systemic immunization. J. Infect. Dis. 2001, 184, 308–314. J.G. Fox, P. Beck, C.A. Dangler, M.T. Whary, T.C. Wang, H.N. Shi, C. Nagler-Anderson. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat. Med. 2000, 6, 536–542. M.M. D'Elios, L.P. Andersen, G. Del Prete. Inflammation and host response: the year in Helicobacterpylori. Curr. Opin. Gatsroenterol.1998, 14, 15–19. A.A. Akhiani, J. Pappo, Z. Kabok, K. Schoen,W. Gao, L.E. Franzén, N. Lycke. Protection against Helicobac-

167.

168.

169.

170.

171.

172.

173.

174.

ter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J. Immunol. 2002, 169, 6977–6984. C.A. Garhart, F.P. Heinzel, S.J. Czinn, J.G. Nedrud. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect. Immun. 2003, 71, 910–921. K. Maeda, T. Yamashiro, T. Minoura, T. Fujioka, M. Nasu, A. Nishizono. Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol. Immunol. 2002, 46, 613–620. M.M. D'Elios, A. Amedei, G. Del Prete. Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade MALT lymphoma. Microbes Infect. 2003, in press. C.A. Garhart, R.W. Redline, J.G. Nedrud, S.J. Czinn. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 2002, 70, 3529– 3538. S. Raghavan, A.M. Svennerholm, J. Holmgren. Effects of oral vaccination and immunomodulation by cholera toxin on experimental H. pylori infection, reinfection, and gastritis. Infect. Immun. 2002, 70, 4621–4627. N. Ramarao, T.F. Meyer. Helicobacter resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence-activated cell sorting. Infect. Immun. 2001, 69, 2604– 2611. L.A. Allen, L.S. Schlesinger, B. Kang. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. J. Exp. Med. 2000, 191, 115–128. S. Peppoloni, S. Mancianti, G. Volpini, S. Nuti, P. Ruggiero, R. Rappuoli, E. Blasi, G. Del Giudice. Antibody-dependent macrophage-mediated activity against Helicobacter pylori in the

References

175.

176.

177.

178.

179.

180.

181.

182.

absence of complement. Eur. J. Immunol. 2002, 32, 2721–2715. M.R. Amieva, N.R. Salama, L.S. Tompkins, S. Falkow. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell. Microbiol. 2002, 4, 677–690. S. Raghavan, M. Hjulstrom, J. Holmgren, A.M. Svennerholm. Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect. Immun. 2002, 70, 6383–6388. J.G. Nedrud, S.S. Blanchard, S.J. Czinn. Helicobacter pyloriinflammation and immunity. Helicobacter 2002, 7(Suppl. 1), 24–29. A.-M. Svennerholm, M. Quiding-Jårbrink. Priming and expression of immune responses in the gastric mucosa. Microbes Infect. 2003, in press. P. Michetti, C. Kreiss, K. Kotloff, N. Porta, J.L. Blanco, D. Bachmann, M. Herranz, P.F. Saldinger, I. Corthésy-Theulaz, G. Losonsky, R. Nichols, J. Simon, M. Stolte, S. Ackerman, T.P. Monath, A.L. Blum. Oral immunization with urease and Escherichia coli heat- labile enterotoxin is safe and immunogenic in H. pylori-infected adults. Gastroenterology 1999, 116, 804– 812. S. Banerjee, A. Medina-Fatimi, R. Nichols, D. Tendler, M. Michetti, J. Simon, C.P. Kelly, T.P. Monath, P. Michetti. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002, 51, 634–640. H. Kleanthous, G.A. Myers, K.M. Georgakopoulos, T.J. Tibbitts, J.W. Ingrassia, H.L. Gray, R. Ding, Z.Z. Zhang, W. Lei, R. Nichols, C.K. Lee, T.H. Ermak, T.P. Monath. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 1998, 66, 2879– 2886. S. Sougioultzis, C.K. Lee, M. Alsahli, S. Banerjee, M. Cadoz, R. Schrader, B. Guy, P. Bedofrd, T.P. Monath, C.P.

183.

184.

185.

186.

187.

188.

189. 190.

Kelly, P. Michetti. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002, 21, 194–201. M.D. Di Petrillo, T. Tibbetts, H. Kleanthous, K.P. Killeen, E.L. Hohmann. Safety and immunogenicity of the phoP/phoQ-deleted Salmonella typhi expressing H. pylori urease in adult volunteers. Vaccine 2000, 18, 449–459. H. Angelakopoulos, E.L. Hohmann. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 2000, 68, 2135–2141. D. Bumann,W.G. Metzger, E. Mansouri, O. Palme, M. Wendland, R. Hurwitz. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21 a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001, 20, 845–852. K.L. Kotloff, M.B. Sztein, S.S. Wasserman, G.A. Losonsky, S.C. Di Lorenzo, R.I. Walker. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 2001, 69, 3581–3590. G. Losonsky, K.L. Kotloff, R.I. Walker. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LTR192 G in H. pylori seronegative individuals. Vaccine 2003, 21, 562– 565. R.W. Setter, S.L. Cochi, J.L. Melnick. Live attenuated poliovirus vaccines. In: Vaccines, third edition, S.A. Plotkin and W.A. Orenstein eds, W.B. Saunders, Philadelphia, PA, USA, 1999. R. Rappuoli. Rational design of vaccines. Nat. Med. 1997, 3, 374–376. M. Marchetti, M. Rossi,V. Giannelli, M.M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J.L. Telford, G. Douce, G. Dougan, R. Rappuoli, P. Ghiara. Protection against Helicobacter pylori infection in mice by intragastric vaccina-

461

462

20 Helicobacter pylori tion with H. pylori antigens is achieved using a non-toxic mutant of E. coli heatlabile enterotoxin (LT) as adjuvant. Vaccine 1998, 16, 33–37. 191. P. Malfertheiner,V. Schultze, G. Del Giudice, B. Rosenkranz, S.H.E. Kaufmann, F. Winau, T. Ulrichs, E. Theophil, C.P. Jue, D. Novicki,

F. Norelli, M. Contorni, D. Berti, J.S. Lin, C. Schwenke, M. Goldman, D. Tornese, J. Ganju, E. Palla, R. Rappuoli, B. Scharschmidt. Phase I safety and immunogenicity of a threecomponent H. pylori vaccine. Gastroenterology 2002, 122 (Suppl. 1), A585.

463

21 Novel Vaccination Strategies against Tuberculosis Stefan H. E. Kaufmann

21.1 Introduction

Whenever they work, vaccines are the most cost-efficient measures in medicine. This holds true even for the current vaccine against tuberculosis, Bacille Calmette– Guérin (BCG). This vaccine can prevent miliary tuberculosis in newborn and toddlers at a very low price. For less than $50 US, BCG can prevent loss of a year of life due to disease, disability, or premature death caused by tuberculosis [1]. Not surprisingly, BCG therefore is the most widely used viable vaccine, with more than 3 billion doses administered thus far and more than 100 million doses given each year. Unfortunately, the vaccine is not satisfactory for control of the most prevalent disease, pulmonary tuberculosis in adults. Results on protective efficacy of BCG in various clinical trials range from zero (^0 %) to high (80 %) protection, with an artificial average of 50 % protective efficacy [2, 3]. Consistent with this, different species of nonhuman primates show different protection levels against tuberculosis after BCG vaccination [4]. This average value, however, needs to be viewed with great caution, because in different parts of the world different needs for vaccines exist. Thus, in Southeast Asia and sub-Saharan Africa, with their high incidences of tuberculosis, there is greatest need for the vaccine; whereas in highly industrialized countries, including the US and Western Europe, vaccines are less urgently needed. Hence, comparison of high protective efficacy of BCG in the United Kingdom and no protection in South India is difficult to combine and interpret. Despite the availability of a vaccine against miliary tuberculosis in newborns and the availability of efficacious chemotherapy, tuberculosis remains a major health threat. The DOTS strategy (directly observed treatment, short course), which is promoted worldwide by the World Health Organization (WHO), is highly efficacious where fully implemented [5]. However, DOTS – like every effective chemotherapeutic regime for tuberculosis – depends on at least three drugs given daily over a period of 6 months. Because of the major side effects, the risk of noncompliance is high if administration is not enforced by health workers on a day-to-day basis. Whenever compliance is incomplete, the risk is high that resistant strains arise. In fact, incidences of multi-drug-resistant (MDR) strains are increasing globally, and in several

464

21 Novel Vaccination Strategies against Tuberculosis

countries, including Estonia and Latvia and several parts of Russia and China, MDR cases exceed 10 % of all tuberculosis cases [1, 5]. Globally, more than 50 million people are infected with MDR M. tuberculosis strains. A second factor is the dangerous liaison between the etiologic agents of tuberculosis and acquired immunodeficiency syndrome (AIDS), Mycobacterium tuberculosis and the human immunodeficiency virus (HIV), respectively [6]. More than 40 million individuals are coinfected with M. tuberculosis and HIV, increasing their risk of developing tuberculosis in the year of infection dramatically.

21.2 Mechanisms underlying Infection and Immunity

Mycobacterium tuberculosis is an acid-fast bacillus that preferentially lives within host cells. Antigen-presenting cells (APC), notably mononuclear phagocytes, but to some degree also dendritic cells (DC), represent the major cellular habitat [1, 7]. These APC are programmed for phagocytosis of invading microorganisms and hence possess a broad variety of surface receptors that facilitate uptake of foreign particles. Thus, M. tuberculosis does not need to develop specific invasion strategies to reach its preferred habitat within a cell. In addition, APC express various pattern recognition receptors (PRR), notably the Toll-like receptors (TLR) [8]. In this way, APC sense an encounter with invading pathogens and mobilize appropriate defense mechanisms. With M. tuberculosis, the TLR2 are of particular importance, because they recognize mycobacterial lipoproteins [9]. In addition, the TLR4 and TLR9 participate in sensing the entry of M. tuberculosis into the host. Together, signals mediated by these TLR activate secretion of Th1-promoting cytokines, including interleukin (IL)-12 and IL-18, and surface expression of costimulatory molecules such as CD40 and B7. As a consequence, a potent Th1 response is induced by mycobacteria [1]. Recent evidence, however, suggests that counteracting mechanisms are also induced. DC express the surface receptor DC-SIGN (DC-specific ICAM-3-grabbing nonintegrin). This molecule serves as a receptor for ICAM-2 and ICAM-3 and hence is involved in migration of DC to sites of infection and in T cell stimulation by DC [10]. DC-SIGN, however, also recognizes lipoarabinomannan (LAM) of M. tuberculosis, and this interaction causes secretion of IL-10. IL-10 is an immunosuppressive cytokine, which counteracts Th1cell stimulation. DC-SIGN has also been identified on alveolar macrophages. In addition, the mannose receptor (MR) on macrophages shares mannose specificity with DC-SIGN and apparently induces similar suppressive mechanisms in macrophages upon recognition of LAM [10]. Once engulfed by macrophages, M. tuberculosis ends up in the early phagosome and arrests its maturation at this early stage [9]. Hence, phagosome acidification and fusion with lysosomes are prevented, making the early phagosome a less hostile environment, where M. tuberculosis can replicate or at least persist. Yet, some mycobacterial antigens become accessible to antigen processing, and T cell stimulation takes place. This results in the generation of interferon-g (IFN-g) which partially overcomes the arrest of phagosome maturation. Reactive oxygen intermediates (ROI) and reactive ni-

21.2 Mechanisms underlying Infection and Immunity

trogen intermediates (RNI) are produced, which attack intracellular M. tuberculosis [11]. Current evidence suggests a minor role of ROI and a major role of RNI in control of M. tuberculosis (Figure 21.1). However, the contribution of RNI to controlling mycobacterial growth appears less profound in humans than in mice, and other thus-farunknown mechanisms have to be implied. Even the IFN-g activated macrophage, however, fails to fully eradicate M. tuberculosis organisms that develop into a stage of dormancy. Often, these dormant bacteria persist without producing disease and thus cause a state of latency in the host. More than 90 % of all infected individuals are in a stage of latency, with fewer than 10 % developing disease at a later time [12]. Reactivation of dormant mycobacteria persisting in granulomatous foci represents a predominant form of tuberculosis in adults, although disease can also be activated by reinfection [1, 12]. Only in immunocompromised hosts, including newborns, will infection rapidly develop into active disease. In HIV-infected individuals, the risk of developing tuberculosis is dramatically increased to 1 in 10 during the year after infection, from 1 in 10 during a lifetime in immunocompetent persons. Although we cannot formally exclude the possibility that some individuals eradicate M. tuberculosis rapidly after infection, this possibility seems to be rare to nonexistent (Figure 21.1). The lung represents the major port of entry for M. tuberculosis, as well as the main site of disease manifestation. Fewer than 10 % of all patients develop extrapulmonary tuberculosis. This chapter therefore focuses on the pulmonary disease. The pathogen is normally inhaled within small droplets discharged by patients suffering from active pulmonary tuberculosis. Only droplets containning minute numbers of bacilli reach the alveolar space, where they are engulfed by alveolar macrophages. It is likely that lung DC also engulf some of the bacteria. Macrophages and DC transport their microbial cargo to draining lymph nodes. The site of inflammation and the draining lymph node are called the Ghon-complex. In the lymph nodes, T cell stimulation takes place (Figure 21.1). Because T lymphocytes represent the mediators of acquired immunity, any vaccination strategy has to focus on this lymphocyte population. Importantly, several T cell populations contribute to the protective immune response (Figure 21.1). The conventional CD4 and CD8 T cells are of central importance [1]. The CD4 T cells are specific for antigenic epitopes presented by products of the major histocompatibility complex (MHC) class II. Because of the mycobacterial residence in phagosomes, the antigens have access to the MHC class II processing machinery. These CD4 T cells are of Th1 type, i. e., they are potent IFN-g producers. CD4 T cells of Th2 type are rarely induced, although they may contribute to susceptibility to M. tuberculosis. General agreement exists that these CD4 Th1 cells are the most important mediators of protection against tuberculosis. However, CD8 T cells, which recognize antigenic peptides presented by MHC class I molecules, have been identified both in mice and humans, and convincing evidence has been gathered that these T cells also contribute to protection [1, 7]. It is not fully understood how mycobacterial antigens are introduced to MHC class I molecules. Despite earlier claims that M. tuberculosis forms pores in the phagosomal membrane, allowing antigen translocation into the cytosol [13], this possibility seems unlikely on the basis of more recent findings (Schaible et al., unpublished). M. tuberculosis induces apoptosis in host cells, resulting in the

465

466

21 Novel Vaccination Strategies against Tuberculosis

Fig. 21.1 Schematic depiction of mechanisms underlying immunity to tuberculosis. Upper left and middle: major steps from infection to induction of immune response ; middle and lower left: granuloma formation and breakdown; right: major T cell populations involved in protective immunity; upper right: effector mechanisms in activated macrophages (see colour plates page XL).

formation of apoptotic blebs carrying antigenic cargo. Apoptotic blebs from infected macrophages can be taken up by bystander DC and then presented via the MHC class I pathway (Schaible et al., unpublished). This cross-priming takes advantage of the high phagocytic activity of macrophages and the more efficacious antigen presentation by DC (Figure 21.2). Moreover, infection with M. tuberculosis impairs antigen presentation, and transfer of antigen within apoptotic blebs from infected macrophages to DC could bypass this obstacle. It is therefore likely that cross-priming promotes antigen presentation of all kinds, including MHC class II presentation to CD4 T cells, MHC class I presentation to CD8 T cells, as well as CD1 and MHC class Ib presentation to unconventional T cells (see below). M. tuberculosis-specific CD8 T cells are of Th1 type, i. e., they are potent IFN-g producers. Moreover, they express potent cytolytic activity. By lysing incapacitated macrophages, CD8 T cells could promote translocation of M. tuberculosis to more proficient effector cells. Moreover, CD8 T cells coexpress granulysin and perforin, which together allow for killing of M. tuberculosis hidden within host cells [14, 15]. In addition to these conventional T cells, unconventional T cells appear to play a role in tuberculosis [1, 16–19]. First, M. tuberculosis-reactive CD8 T cells restricted by

21.2 Mechanisms underlying Infection and Immunity

Fig. 21.2 Cross-priming as a major pathway of antigen presentation in tuberculosis (see colour plates page XLI).

nonclassical MHC class Ib molecules have been identified both in mice and in humans. In mice, the H2-M3 molecule presents N-formylated peptides [20, 21]. In humans, HLA-E-restricted CD8 T cells could fulfil a similar function [22]. In addition, the MHC I-like molecules of the CD1 family participate in the immune response against tuberculosis [23]. The CD1 molecules present glycolipids, which are abundant components of the mycobacterial cell wall [23]. The group 1 CD1 molecules are present in humans but absent in mice. They present mycobacterial glycolipids, such as LAM and mycolic acids. The group 2 CD1 molecules, as well as the T cell receptor (TCR) on the homologous NKT cells, are highly conserved in mice and humans. Recently, the first mycobacterial glycolipid antigen presented by group 2 CD1 molecules was identified: phosphatidylinositol tetramannoside (Fischer et al., unpublished). Because of the conserved structure of group 2 CD1 molecules, both human and mouse NKT cells recognize this antigen. Yet, current evidence argues against a critical role of a group 2 CD1-restricted T cell response in tuberculosis [24]. Finally, g/d T-lymphocytes, which recognize phospholigands in the absence of any known presentation molecule, contribute to immunity against M. tuberculosis [17]. These phospholigand-specific g/d T cells do not exist in mice but only in primates. Recent experiments in nonhuman primates provide strong evidence for a role of these g/d T cells in protection against tuberculosis [19]. The unconventional T cells are also typically of Th1 type, and some also possess the killer molecules present in CD8 T cells. Hence, the spectrum of functional activities of these different T cell populations markedly overlaps. It appears that the de-

467

468

21 Novel Vaccination Strategies against Tuberculosis

pendency on differential T cell populations for optimum protection against tuberculosis is due less to different functions than to other biological activities. These include differential activation requirements, different antigen specificities, and different kinetics of appearance. Both the g/d T cells and the group 2 CD1-restricted T cells express a highly biased T cell receptor. Therefore, they recognize only a limited number of antigens. Moreover, these T cells are rapidly activated. Hence, the group 2 CD1-restricted T cells and the g/d T cells most likely perform an early protective function, filling a gap between innate immunity and the classical acquired immune response. The identification of unconventional T cells that recognize nonproteinaceous antigens not only mitigates the classical dogma of peptide recognition by T cells – it also implies that rational vaccine strategies should consider nonproteinaceous antigens as targets in addition to protein antigens.

21.3 Rational Vaccine Design: Basic Considerations

With regard to vaccine development, the following lessons can be learned from natural infection: On the one hand, the immune response against M. tuberculosis in the immunocompetent individual is capable of containing the pathogen and preventing disease activation. Hence, rational vaccine design can benefit from a deep understanding of the mechanisms participating in immunological control of tuberculosis. On the other hand, the immune response fails to achieve sterile eradication of the pathogen and allows for disease progression in a considerable number of cases. In this context it is worth remembering that previous infection with M. tuberculosis fails to mount an efficient protective immune response against secondary encounter with M. tuberculosis, thus allowing for reinfection [25]. The proportion of infected individuals, in whom reinfection occurs, remains to be determined. So far, we do not completely understand the stage of infection at which the decision is made as to whether infection progresses into disease or remains controlled lifelong. Similarly, the mechanisms defining susceptibility or resistance against tuberculosis remain to be elucidated. Obviously, infection with HIV causes general susceptibility to tuberculosis [6, 7]. However, in the absence of exogenous insult, host genetic factors must also exist that determine the fate of infection [26]. In this context, dominant genetic deficiencies, such as deficiencies in IFN-g and IL-12 signaling, which are critical for controlling M. tuberculosis infection from the beginning, are less interesting. Rather, subtle genetic deficiencies that do not impair initial control of M. tuberculosis but become operative at later stages of infection and then contribute to disease outbreak are of central interest. Identifying the factors responsible for resistance and protection on the one hand, and for susceptibility on the other, is critical for rational vaccine design, because susceptible individuals represent the main target for any novel vaccine. In conclusion, in-depth understanding of the mechanisms operative during infection will provide essential information for the design of novel vaccination strategies,

21.4 Protective Antigens and Knockout Targets

which have to aim at stimulating an immune response that is superior to that induced during natural infection in susceptible individuals and which should be at least equal to that operative in resistant individuals. Ideally of course, a novel vaccine would induce mechanisms that eradicate M. tuberculosis. Experience from other successful vaccination strategies, however, suggests that this option is too optimistic and that a vaccine that induces stable containment of M. tuberculosis, that is, it permits contained infection without disease, would represent a more realistic option. Before discussing novel vaccination strategies, we need to address the question of the urgency of the need for a new vaccine. After all, a vaccine is already in use, namely BCG, which was developed in the early 1900s. The French scientists Calmette and Guérin attenuated a Mycobacterium bovis strain by serial passage in bilecontaining medium. This vaccine has been used more often than any other live vaccine, and it is still recommended in numerous countries worldwide. BCG has a good record for low side-effects and of protection against childhood tuberculosis [2]. It protects toddlers and newborns from disseminated tuberculosis (typically miliary tuberculosis) and tuberculous meningitis. However, it fails to achieve satisfactory protection against the most prevalent form of disease – pulmonary tuberculosis in adults. This is the reason for global attempts to produce a more efficient vaccine. BCG is quite efficacious in various experimental animal models, including mice and guinea pigs, as well as in certain nonhuman primates. In these animal species, profound protection, although not sterile eradication of the pathogen, can be achieved by BCG vaccination. Thus, BCG provides a kind of gold standard for measuring efficacy of novel vaccine candidates, which need to be better than BCG. ‘Better’ means, first, superior protection in susceptible individuals, an issue that cannot be definitely determined in animal models; and second, safer. My view, however, is that satisfactory efficacy is the most important issue, which should not be compromised.

21.4 Protective Antigens and Knockout Targets

The elucidation of the complete genome of M. tuberculosis has provided the blueprint for the search of genes of potential value for diagnosis and vaccination [27]. We thus have a means of identifying the virulence genes, which will promote rational attenuation of vaccine strains by targeting defined virulence and persistence factors. Knowledge of the complete genome will be equally important for identifying putative vaccine antigens. However, we should bear in mind that definite rules that define protective antigens do not exist for tuberculosis. Factors that have been proposed as characteristic features of protective antigens include:

. .

Specific antigens: One could argue that antigens that are specific for M. tuberculosis, as opposed to other mycobacteria, including BCG, are particularly potent inducers of protective immune responses. Secreted antigens: Because secreted antigens are more readily accessible to processing than cell-bound antigens, they are considered of particular value.

469

470

21 Novel Vaccination Strategies against Tuberculosis

. . . .

Antigens with unique functions: We can assume that certain functions render a protein particularly adequate for antigen processing. Abundant antigens: The higher the concentration of a protein within the antigenpresenting cell, the more readily it should be processed. In-vivo expressed antigens: Proteins that are expressed only in vitro would be of little help for in vivo immunization, and hence one could argue that in vivo expressed antigens are particularly valuable. Early versus late antigens: Amongst antigens expressed in vivo, a further classification is conceivable: Antigens most relevant to a preventive vaccine should be expressed by M. tuberculosis during the early stages of infection, ideally from the stage of invasion on. In contrast, a therapeutic vaccine for both infected and diseased vaccinees should comprise antigens that are expressed by dormant M. tuberculosis during latency. Early antigens are probably also expressed in the environment, whereas late antigens are probably induced in response to host defense.

None of these features by itself represents an exclusive prerequisite for the definition of a protective antigen. Rather, an unequivocal definition of protective antigens appears impossible at present. However, a combination of such criteria can provide helpful guidelines for the search of protective antigens, as well as for knockout or knockin targets for viable vaccine strains. As a corollary, predictions on the basis of theoretical assumptions and computer searches require experimental verification. The search for candidate proteins by rational vaccine design will benefit from global analysis on the transcriptome and proteome level [28, 29]. Subsequently identified candidates need to be evaluated in protection assays. Most conveniently, antigens can be screened in the form of naked DNA constructs in small animal models, preferably mice and guinea pigs. An alternative approach would be expression library immunization strategies, which allow screening of the entire genome for putative protective antigens [30]. Once antigens have been defined that induce an appreciable degree of protection, further refinements can be pursued, such as construction of fusion proteins, formulation with appropriate adjuvants, etc. Ultimately, however, vaccine efficacy has to be assessed in experimental animal models. The importance of animal experiments is emphasized by the highly controversial results obtained with some vaccine candidates, ranging from beneficial to detrimental outcomes [31, 32]. Searching for knockout and knockin targets requires assessment of attenuation in small animals as well. With regard to rational attenuation, care should be taken to consider not only classical virulence factors, but also ill-defined factors that impair protective immune responses. Whenever nonproteinaceous components, such as sulfatides and glycolipids, are responsible for these effects, the picture becomes even more complicated. In these situations, it will be essential to delete the appropriate key enzymes in the metabolic pathways involved.

21.5 The Major Strategies: Subunit, Attenuated, and Combination Vaccines

21.5 The Major Strategies : Subunit, Attenuated, and Combination Vaccines

Two major strategies are possible: subunit vaccines and viable attenuated vaccines. Table 21.1 shows an overview of the current vaccine candidates [1]. According to what is stated above, different T cell populations with specificity for proteinaceous and nonproteinaceous antigens contribute to protection. Subunit vaccines are aimed at one or a few antigens, raising the question of whether the whole spectrum of T cell populations can be induced. Live vaccines, in contrast, comprise all types of antigens and thus, in principle, are able to stimulate the complete T cell armamentarium. On the other hand, environmental mycobacteria share some antigens with M. tuberculosis, and evidence exists that these environmental mycobacteria can impair the protective immune response through cross-reactivity [33, 34]. Moreover, M. tuberculosis has been shown to impair the immune response and actively suppress it [35, 36]. Hence, attenuation of viable vaccines includes not only deletion of classical virulence factors, but also of immunosuppressive components. Thus, both types of vaccines have their pros and cons. 21.5.1 Subunit Vaccines

The typical subunit vaccine is a vaccine composed of one or a few protective antigens in combination with a potent adjutant. Several antigens have been identified that induce protective immune responses comparable to those stimulated by BCG. These include ESAT-6, antigen 85, and a fusion protein of antigen 85 and ESAT-6 [37–39]. Clearly, more potent adjuvants inducing both CD4 and CD8 T cells are required, and addition of glycolipids and phospholigands to stimulate CD1-restricted T cells and g/d T cells, respectively, need to be considered. Naked DNA vaccines – composed of genes encoding protective protein antigens – are also considered in this group [30, 40, 41]. The promising results obtained in mouse experiments could not be translated to the human system. Hence, adjuvants are needed to reduce the amount of naked DNA required for inducing a protective immune response in humans. Should it be necessary to include nonproteinaceous antigens, these should be added as such. Finally, recombinant microbes expressing protective antigens are considered under subunit vaccines. Although viable vaccine carriers of bacterial or viral origin are used in these subunit vaccines, the specific protective immune response is directed against one or a few antigens expressed by these recombinant carriers. Heterologous carriers for mycobacterial antigens include attenuated Salmonella enterica serotypes and canary pox virus as examples of bacterial and viral carriers, respectively [42, 43].

471

472

21 Novel Vaccination Strategies against Tuberculosis

21.5.2 Attenuated Vaccines

Viable attenuated vaccine strains come in two flavors. First, targeted deletion of virulence factors and immunosuppressive factors result in M. tuberculosis strains that can no longer cause disease but do induce a more efficacious immune response. Reciprocally, recombinant BCG can be constructed. It is known that BCG lacks 129 open reading frames that are present in M. tuberculosis [44]. Moreover, some genes may not be expressed in sufficiently high abundance. First, we could assume that BCG lacks important protective antigens. Recombinant BCG over-expressing antigen 85, which is produced in wild-type BCG at low abundance, induces better protecTab. 21.1 TB vaccine candidates i Vaccine candidate

Potential advantage

Potential disadvantage Examples

1. Subunit Vaccine Antigen in adjuvant

mild side effects

restricted number of T-cell clones, primarily CD4+ T cells; immunogenicity depends on adjuvant type

culture filtrate (ill-defined antigen mixture) [49] defined antigen: ESAT-6 [37] Ag85 [38] Mtb 8.4 [50] fusion protein: Ag85-ESAT-6 [39]

Naked DNA

CD4 and CD8 T cells

restricted number of T-cell clones, conventional T cells, safety concerns

Hsp60 [40] Ag85 [41] Mtb 8.4 [50] therapeutic vaccination [32]

Recombinant carrier expressing antigen

CD4 and/or CD8 T cells

restricted number of T-cell clones, safety concerns

r-vaccinia expressing Ag85 [42] r- Salmonella expressing Ag85 [43]

2. Viable Mycobacterial Vaccine M. tuberculosis deletion CD4 plus CD8 T cells, safety concerns, mutant unconventional T cells immunosuppressive

Auxotrophic mutants

Erpii-M. tuberculosis [51] Acriii- M. tuberculosis [52] Icliv- M. tuberculosis [53] PcaAv-M. tuberculosis [54] Pdimvi- M. tuberculosis [55] SigHvii – M. tuberculosis [56]

improved safety (BCG) reduced immunogeni- Met, Leu, ILVviii – BCG [57] MetB-, ProC-, TrpD-ix M. tuberculosis [58] city, safety concerns Panx – M. tuberculosis [59] (M. tuberculosis)

tion than the parental strain [38]. Similarly, recombinant BCG expressing the RD1 region comprising ESAT-6 and CFP-10 induced better protection than wild-type [45]. Second, we can assume that BCG fails to induce the appropriate combination of T cells required for protection. Indeed, BCG stimulates CD4 T cells efficaciously but is a poor stimulator of CD8 T cells [1]. Recombinant BCG expressing listeriolysin have been constructed [46]. Listeriolysin is capable of forming pores in the phagosomal membrane, thus allowing improved antigen presentation via MHC class I to CD8 T

21.5 The Major Strategies: Subunit, Attenuated, and Combination Vaccines

473

cells. Although this vaccine strain induces better protection than wild-type BCG, further improvements have been achieved recently. Listeriolysin has an optimum pH of 5.5. Normally, the phagosomal pH is in this range. However, BCG neutralizes the phagosomal compartment and, hence, a less acidic pH is generated. Construction of BCG with a deleted urease gene and expressing listeriolysin overcame this obstacle (Grode et al., unpublished). This BCG strain is no longer able to neutralize the phagosomal pH, thus allowing for an optimal pH of listeriolysin. Indeed, this recombinant BCG strain induces a remarkable degree of protection, superior not only to wild-type BCG but also to recombinant BCG expressing listeriolysin only. Finally, a recombinant BCG strain expressing Th1 cell-promoting cytokines could improve the efficiency of the ensuing immune response [60]. Tab. 21.1 (continued) Vaccine candidate

Potential advantage

Potential disadvantage Examples

r-BCG expressing cytolysin

CD4 plus CD8 T cells, devoid of TB-specific unconventional T cells antigens, safety concerns

r-BCG -listeriolysin [46] D urease r-BCG -listeriolysin {Grode et al. unpublished}

r-BCG expressing cytokine

improved immunogenicity

primarily CD4 T cells, devoid of TB-specific antigens, safety concerns

r-BCG – IL-2, IFN-g [60]

r-BCG overexpressing antigen

improved immunogenicity

primarily CD4 T cells, safety concerns

r-BCG-Ag85 [38] r-BCG-RDI [45]

r-BCG coexpressing immunomodulator plus antigen

improved immunogenicity, protective antigens

safety concerns

not done

r-M. tuberculosis deletion mutant expressing immunomoduator

improved immunogenicity

safety concerns

not done

Prime–boost

improved immunogenicity

safety concerns

BCG-protein (Ag85) [48] naked DNA-protein (Ag85) [61] naked DNA-Vaccinia (Ag85) [42] naked DNA-BCG [47] BCG-naked DNA (Rv 3407) {Grode et al. in preparation}

3. Combination Vaccine

i ii iii iv v vi vii viii ix x

adapted from [1] Erb is a secreted protein of M. tuberculosis Acr is a cognate of the a -crystallin family of low molecular weight Hsp Icl is isocitrate lyase PcaA is mycolic acid cyclopropane synthase Pdim is phthiocerol dimycocerosate SigH is alternative s factor MetB is methionine, Leu is leucine, ILV is either isoleucine, leucine or valine MetB is methionine, ProC is proline, TrpD is tryptophane Pan is pantothenate

474

21 Novel Vaccination Strategies against Tuberculosis

21.5.3 Combination Vaccines

Combination-vaccine protocols need to be considered, such as prime–boost experiments using a combination of a prime with naked DNA and a boost with a viral carrier or a protein subunit vaccine. Promising results were obtained with various heterologous prime–boost vaccination schedules in animal experiments [42, 47, 48]. Major emphasis, however, should be given to heterologous prime–boost experiments starting with BCG prime. This is preferable not only for scientific reasons: because BCG has some protective value, notably in newborns, it cannot be given up prematurely. Hence, it would be best to recruit vaccinees for clinical trials amongst those who had already received BCG earlier in life. In these BCG primed individuals, the vaccine candidates could be given as boosters.

21.6 Concluding Remarks

Rational design of an efficacious vaccine against tuberculosis remains a challenging task. First, all successful vaccines currently in use depend on antibodies as mediators of protection. It is, however, most likely that antibodies will not suffice as mediators of protection against tuberculosis and that T lymphocytes are required. Second, in the vast majority of infected individuals, infection with M. tuberculosis results in a protective immune response that can keep the pathogen at bay. For those individuals who maintain protection throughout their lifetime, a vaccine is not essential. It is, however, required for those who will develop disease at a later time. In other words, a vaccine against tuberculosis is needed for those in whom natural infection failed to evoke sufficient immunity. Similarly, BCG induces an immune response that prevents miliary tuberculosis in newborns, but fails to confer protection that can prevent outbreak of disease in adults through reactivation or reinfection. Again, this immune response, although being able to contain the bacteria, ultimately fails to control them over a lifetime. Thus, in both scenarios, a novel vaccine needs to perform better. Although there is reason to hope that a vaccine can be constructed that induces a superior immune response, definite proof for achieving this courageous goal is still missing.

Acknowledgements

I am grateful to Souraya Sibaei and Yvonne Bennett for excellent secretarial help and to Diane Schad for the graphics. My current work on tuberculosis is supported by grants from the DFG (Priority Programme Novel Vaccination Strategies, KA573/4-1), EC (TB Vaccine Cluster), and BMBF (Competence Network Pathogenomics, Competence Network Bacterial Proteomics, Competence Network Structural Genomics of M. tuberculosis, Competence Network Proteomics of Membrane-Bound Proteins).

References

References [1] Kaufmann, S. H. E. Nature Rev Immunol 2001, 1, 20–30. [2] Fine, P. E. M. Rev Infec Dis 1989, 11, S353–S359. [3] Collins, H.; Kaufmann, S. H. E. Lancet Infect Dis 2001, 1, 21–28. [4] Langermans, J. A. M.; Andersen, P.; van Soolingen, D.; Vervenne, R. A. W.; Frost, P. A.; van der Laan, T.; van Pinxteren, L. A. H.; van den Hombergh, J.; Kroon, S.; Peekel, I.; Florquin, S.; Thomas, A. W. Proc Natl Acad Sci USA 2001, 98, 11497–11502. [5] Kaufmann, S. H. E. Nat Med 2000, 6, 955–960. [6] Corbett, E. L.; Steketee, R. W.; ter Kuile, F. O.; Latif, A. S.; Kamali, A.; Hayes, R. J. Lancet 2002, 359, 2177– 2187. [7] Schaible, U.; Collins, H.; Kaufmann, S. H. E. Adv Immunol 1999, 71, 267–377. [8] Janeway, C. A.; Medzhitov, Jr.; Medzhitov, R. Annu Rev Immunol 2002, 20, 197–216. [9] Brightbill, H. D.; Libraty, D. H.; Krutzik, S. R.; Yang, R. B.; Belisle, J. T.; Bleharski, J. R.; Maitland, M.; Norgard, M. V.; Plevy, S. E.; Smale, S. T.; Brennan, P. J.; Bloom, B. R.; Godowski, P. J.; Modlin, R. L. Science 1999, 285, 732–736. [10] Kaufmann, S. H. E.; Schaible, U. E. J Exp Med 2003, 197, 1–5. [11] Raupach, B.; Kaufmann, S. H. E. Curr Opin Immunol 2001, 13, 417–428. [12] Ulrichs, T.; Kaufmann, S. H. E. Mycobacteria and TB; Karger: Basel, 2002, pp. 112–127. [13] Teitelbaum, R.; Cammer, M.; Maitland, M. L.; Freitag, N. E.; Condeelis, J.; Bloom, B. R. Proc Natl Acad Sci USA 1999, 96, 15190–15195. [14] Stenger, S.; Mazzaccaro, R. J.; Uyemura, K.; Cho, S.; Barnes, P. F.; Rosat, J. P.; Sette, A.; Brenner, M. B.; Porcelli, S. A.; Bloom, B. R.; Modlin, R. L. Science 1997, 276, 1684–1687. [15] Stenger, S.; Hanson, D. A.; Teitelbaum, R.; Dewan, P.; Niazi, K. R.; Froelich, C. J.; Ganz, T.; Thoma-

[16]

[17] [18]

[19]

[20]

[21]

[22]

[23] [24]

[25]

[26] [27]

Uszynski, S.; Melian, A.; Bogdan, C.; Porcelli, S. A.; Bloom, B. R.; Krensky, A. M.; Modlin, R. L. Science 1998, 282, 121–125. Sousa, A. O.; Mazzaccaro, R. J.; Russell, R. G.; Lee, F. K.; Turner, O. C.; Hong, S.; Van Kaer, L.; Bloom, B. R. Proc Natl Acad Sci USA 2000, 97, 4204– 4208. Kaufmann, S. H. E. Proc Natl Acad Sci USA 1996, 93, 2272–2279. Rolph, M. S.; Raupach, B.; Kobernick, H. H. C.; Collins, H. L.; Perarnau, B.; Lemonnier, F. A.; Kaufmann, S. H. E. Eur J Immunol 2001, 31, 1944– 1949. Shen,Y.; Zhou, D. J.; Qiu, L. Y.; Lai, X. M.; Simon, M.; Shen, L.; Kou, Z. C.; Wang, Q. F.; Jiang, J. M.; Estep, J.; Hunt, R.; Clagett, M.; Sehgal, P. K.; Li,Y. Y.; Zeng, X. J.; Morita, C. T.; Brenner, M. B.; Letvin, N. L.; Chen, Z. W. Science 2002, 295, 2255–2258. Chun, T.; Serbina, N. V.; Nolt, D.; Wang, B.; Chiu, N. M.; Flynn, J. L.; Wang, C. R. J Exp Med 2001, 193, 1213–1220. Dow, S. W.; Roberts, A.; Vyas, J.; Rodgers, J.; Rich, R. R.; Orme, I.; Potter, T. A. Tubercle Lung Dis 2000, 80, 5–13. Lewinsohn, D. M.; Alderson, M. R.; Briden, A. L.; Riddell, S. R.; Reed, S. G.; Grabstein, K. H. J Exp Med 1998, 187, 1633–1640. Schaible, U. E.; Kaufmann, S. H. E. Trends Microbiol 2000, 8, 419–425. Behar, S. M.; Dascher, C. C.; Grusby, M. J.; Wang, C. R.; Brenner, M. B. J Exp Med 1999, 189, 1973–1980. Van Rie, A.; Warren, R.; Richardson, M.; Victor, T. C.; Gie, R. P.; Enarson, D. A.; Beyers, N.; van Helden, P. D. N Engl J Med 1999, 341, 1174–1179. Casanova, J.-L.; Abel, L. Annu Rev Immunol 2002, 20, 581–620. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Conner, R.; Davies, R.;

475

476

21 Novel Vaccination Strategies against Tuberculosis

[28]

[29] [30]

[31]

[32]

[33] [34] [35]

[36] [37]

[38]

[39]

[40]

Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G. Nature 1998, 396, 190–198. Jungblut, P. R.; Schaible, U. E.; Mollenkopf, H. J.; Zimny-Arndt, U.; Raupach, B.; Mattow, J.; Halada, P.; Lamer, S.; Hagens, K.; Kaufmann, S. H. E. Mol Microbiol 1999, 33, 1103–1117. Domenech, P.; Barry, C. E.; Cole, S. T. Curr Opin Microbiol 2001, 4, 28–34. Skeiky,Y. A. W.; Ovendale, P. J.; Jen, S.; Alderson, M. R.; Dillon, D. C.; Smith, S.; Wilson, C. B.; Orme, I. M.; Reed, S. G.; Campos-Neto, A. J Immunol 2000, 165, 7140–7149. Turner, O. C.; Roberts, A. D.; Frank, A. A.; Phalen, S. W.; McMurray, D. M.; Content, J.; Denis, O.; D'Souza, S.; Tanghe, A.; Huygen, K.; Orme, I. M. Infect Immun 2000, 68, 3674– 3679. Lowrie, D. B.; Tascon, R. E.; Bonato, V. L. D.; Lima,V. M. F.; Faccioli, L. H.; Stavropoulos, E.; Colston, M. J.; Hewinson, R. G.; Moelling, K.; Silva, C. L. Nature 1999, 400, 269–271. Stanford, J. L.; Shield, M. J.; Rook, G. A. W. Tubercle 1981, 62, 55–62. Palmer, C. E.; Long, M. W. Amer Rev Resp Dis 1966, 94, 553. Pancholi, P.; Mirza, A.; Bhardwaj, N.; Steinman, R. M. Science 1993, 260, 984–986. Stenger, S.; Niazi, K. R.; Modlin, R. L. J Immunol 1998, 161, 3582–3588. Brandt, L.; Elhay, M.; Rosenkrands, I.; Lindblad, E. B.; Andersen, P. Infect Immun 2000, 68, 791–795. Horwitz, M. A.; Harth, G.; Dillon, B. J.; Maslesa-Galic, S. Proc Natl Acad Sci USA 2000, 97, 13853–13858. Olsen, A. W.; van Pinxteren, L. A. H.; Okkels, L. M.; Rasmussen, P. B.; Andersen, P. Infect Immun 2001, 69, 2773–2778. Tascon, R. E.; Colston, M. J.; Ragno, S.; Stavropoulos, E.; Gregory, D.;

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

Lowrie, D. B. Nat Med 1996, 2, 888– 892. Huygen, K.; Content, J.; Denis, O.; Montgomery, D. L.; Yawman, A. M.; Deck, R. R.; DeWitt, C. M.; Orme, I. M.; Baldwin, S.; DSouza, C.; Drowart, A.; Lozes, E.; Vandenbussche, P.; VanVooren, J. P.; Liu, M. A.; Ulmer, J. B. Nat Med 1996, 2, 893–898. McShane, H.; Brookes, R.; Gilbert, S. C.; Hill, A. V. S. Infect Immun 2001, 69, 681–686. Hess, J.; Grode, L.; Hellwig, J.; Conradt, P.; Gentschev, I.; Goebel, W.; Ladel, C.; Kaufmann, S. H. E. FEMS Immunol Med Microbiol 2000, 27, 283– 289. Behr, M. A.; Wilson, M. A.; Gill,W. P.; Salamon, H.; Schoolnik, G. K.; Rane, S.; Small, P. M. Science 1999, 284, 1520–1523. Pym, S. A.; Brodin, P.; Majlessi, L.; Brosch, R.; Demangel, C.; Williams, A.; Griffiths, K. E.; Marchal, G.; Leclerc, C.; Cole, S. T. Nat Med 2003, 9, 533–539. Hess, J.; Miko, D.; Catic, A.; Lehmensiek,V.; Russell, D. G.; Kaufmann, S. H. E. Proc Natl Acad Sci USA 1998, 95, 5299–5304. Feng, C. G.; Palendira, U.; Demangel, C.; Spratt, J. M.; Malin, A. S.; Britton,W. J. Infect Immun 2001, 69, 4174–4176. Brooks, J. V.; Frank, A. A.; Keen, M. A.; Bellisle, J. T.; Orme, I. M. Infect Immun 2001, 69, 2714–2717. Horwitz, M. A.; Lee, B. W. E.; Dillon, B. J.; Harth, G. Proc Natl Acad Sci USA 1995, 92, 1530–1534. R. N. Coler, A. Campos-Neto, P. Ovendale, F. H. Day, S. P. Fling, L. Q. Zhu, N. Serbina, J. L. Flynn, S. G. Reed, and M. R. Alderson. J Immunol 2001, 166, 6227–6235. Berthet, F. X.; Lagranderie, M.; Gounon, P.; Laurent-Winter, C.; Ensergueix, D.; Chavarot, P.; Thouron, F.; Maranghi, E.; Pelicic,V.; Portnoi, D.; Marchal, G.; Gicquel, B. Science 1998, 282, 759–762. Yuan,Y.; Crane, D. D.; Simpson, R. M.; Zhu,Y. Q.; Hickey, M. J.; Sher-

References

[53]

[54] [55] [56]

[57]

man, D. R.; Barry, C. E. Proc Natl Acad Sci USA 1998, 95, 9578–9583. McKinney, J. D.; zu Bentrup, K. H.; Munoz-Elias, E. J.; Miczak, A.; Chen, B.; Chan,W. T.; Swenson, D.; Sacchettini, J. C.; Jacobs, W. R.; Russell, D. G. Nature 2000, 406, 735–738. Glickman, M. S.; Cox, J. S.; Jacobs, W. R. Mol Cell 2000, 5, 717–727. Cox, J. S.; Chen, B.; McNeil, M.; Jacobs,W. R. Nature 1999, 402, 79–83. Kaushal, D.; Schroeder, B. G.; Tyagi, S.; Yoshimatsu, T.; Scott, C.; Ko, C.; Carpenter, L.; Mehrotra, J.; Manabe, Y. C.; Fleischmann, R. D.; Bishai,W. R. Proc Natl Acad Sci USA 2002, 99, 8330–8335. Guleria, I.; Teitelbaum, R.; McAdam,

[58]

[59]

[60]

[61]

R. A.; Kalpana, G.; Jacobs,W. R.; Bloom, B. R. Nat Med 1996, 2, 334– 337. Smith, D. A.; Parish, T.; Stoker, N. G.; Bancroft, G. J. Infect Immun 2001, 69, 1142–1150. Sambandamurthy,V. K.; Wang, X. J.; Chen, B.; Russell, R. G.; Derrick, S.; Collins, F. M.; Morris, S. L.; Jacobs, W. R. Nat Med 2002, 8, 1171–1174. Murray, P. J.; Aldovini, A.; Young, R. A. Proc Natl Acad Sci USA 1996, 93, 934–939. Tanghe, A.; D’'Souza, S.; Rosseels,V.; Denis, O.; Ottenhoff, T. H. M.; Dalemans,W.; Wheeler, C.; Huygen, K. Infect Immun 2001, 69, 3041–3047.

477

479

22 Rationale for Malaria Vaccine Development Allan Saul,Victor Nussenzweig, and Ruth S. Nussenzweig

22.1 Introduction

Malaria remains one of the most serious and globally prevalent of human diseases. During the 20th century, malaria was eliminated from the countries of temperate climate that enjoyed striking economic development. The disease prevalence also decreased in some tropical areas following massive applications of insecticides and intense chemotherapy. More recently, however, due to the occurrence and rapid spread of drug resistance, insecticide resistance, wars and revolutions that have caused population dislocations and economic deterioration, the prevalence of malaria (and other infectious diseases) has increased greatly. Malaria parasites (Plasmodia) have a complex life cycle, and, as occurs in many microbial and viral diseases, control by the host requires both humoral and cellmediated immune responses (Figure 22.1). Four species of malaria parasites infect humans: Plasmodium falciparum, P. vivax (the two most prevalent species), P. malariae, and P. ovale. However, most pathology and mortality is due to P. falciparum. It is estimated that in Africa alone, 2 million or more children die of falciparum malaria every year. In other tropical areas of Asia, the Pacific Islands, Papua New Guinea, Central and South America, in addition to infections with P. falciparum, many individuals are infected with P. vivax. P. vivax infections can be severe, relapses are frequent, and chloroquine resistance has already been detected in some areas. Sporozoites, the infective initial stages present in infected Anopheles mosquitoes’ salivary glands and ducts, are injected into the skin and underlying tissues during the mosquito's probing for a blood meal. From the skin, most (> 90 %) rapidly make their way to the liver and enter hepatocytes, where they undergo further development into exoerythrocytic stages or EEF. Prior to reaching their final destination, sporozoites traverse many cells, including hepatocytes [1]. After maturation of the EEFs (> 5 days for P. falciparum, longer for the other three species), each sporozoiteinfected hepatocyte releases tens of thousands of individual parasites (merozoites), which invade erythrocytes. In the erythrocyte, the merozoites undergo differentiation followed by schizogony to produce, after 2–3 days, a new generation of mero-

480

22 Rationale for Malaria Vaccine Development

Fig. 22.1 Life cycle of the malaria parasite. Major targets of vaccines are identified.

zoites. These merozoites invade other erythrocytes, setting up a rapidly progressive infection cycle that can be lethal (particularly with P. falciparum) unless parasitemia is controlled by the host's immune system or by treatment. In some erythrocytes, the merozoites transform into gametocytes by unknown mechanisms. The sexual stages are taken up by mosquitoes and form a zygote that becomes motile (ookinete) and invades the wall of the mosquito stomach (midgut). This is where the ookinete transforms into oocysts, the site of development of thousands of sporozoites. After some time the oocysts rupture, and the sporozoites are released in the hemocoel, where they have access to and invade the salivary gland. The different localizations of the developing parasite stages coincide with the expression of stage-specific antigens. In the infected human host, the parasites are first found in the skin, then within hepatocytes, and later in red blood cells. Therefore, effective vaccines should prevent the progression of the cycle, i. e., inhibit parasite development and/or the severity of the disease and prevent transmission. Is an effective vaccine feasible? This question was answered in the mid-1960s, when in animal models, repeated exposure to gamma-irradiated sporozoites led to

22.2 Preerythrocytic Vaccines

complete protection against sporozoite challenge [2]. Human volunteers were then immunized in the mid 1970s by bites of P. falciparum- or P. vivax-infected, irradiated mosquitoes. After a multiple series of ‘bite vaccinations’, complete protection was achieved [3]. This immunity was directed against sporozoites but was ineffective against blood stages. Importantly, these vaccinees were not only protected against challenge with the parasite strains used for their respective vaccinations, but also against different geographical isolates of P. falciparum and P. vivax. In other words, possible variations in preerythrocytic antigens did not thwart protection. These finding marked the beginning of intensive research efforts aimed towards the development of a malaria vaccine. Because the various developmental stages of these parasites do not replicate in vitro (the only exception being the blood stages of P. falciparum), subunit vaccines needed to be developed. Such subunit vaccines required, not only identification and characterization of the protective antigens, but also determination of how best to present them to the immune system for maximal effectiveness. These requirements turned out to be distinct for different developmental stages. We attempt to summarize what is presently known regarding the various ‘protective’ antigens, the corresponding immune mechanisms, and the current vaccine candidates. Much of this information is based on findings obtained in animal models, but is supported by limited data obtained in a small number of human trials.

22.2 Preerythrocytic Vaccines

Sporozoites and EEFs precede blood stage infection and are therefore designated preerythrocytic stages. Most important from the standpoint of vaccine development, these parasite stages produce no symptoms. Disease occurs only upon red blood cell invasion by the parasites. Thus, an effective anti-preerythrocytic vaccine could be truly prophylactic. Although EEFs, particularly during their early development, share some antigens with sporozoites, the effector mechanisms that must be elicited to inhibit them are distinct. The infectivity of extracellular sporozoites can be neutralized only by antibodies against surface-exposed molecules, and the EEFs are destroyed by cell-mediated immune mechanisms. It is well documented that immunization with irradiated sporozoites elicits not only neutralizing antibodies, but also cell-mediated immune mechanisms that inhibit EEF development [4]. In rodents, the effector mechanism consists mainly of CD8+ T lymphocytes and the released lymphokines, in particular interferon-g [5]. However, CD4+ T cell-mediated protection has been also obtained in mice that lack b2m and are MHC class I deficient [6]. 22.2.1 Rationale for Vaccines that Elicit Antibody-mediated Protection

Neutralizing antibodies against sporozoite surface molecules have been detected in all mammalian and even avian malaria species. The antibodies are primarily directed

481

482

22 Rationale for Malaria Vaccine Development

against a very abundant sporozoite surface antigen, the circumsporozoite (CS) protein [2]. The CS protein has a similar structure in all vertebrate plasmodial species and plays an essential role in sporozoite development in oocysts and in the initial stages of hepatocyte invasion. A conserved C-terminal region of CS contains a thrombospondin type I repeat that is found in several host proteins. It binds to heparan sulfate proteoglycans in the liver, thus arresting the parasites during their passage through the sinusoids [7]. Mice are naturally tolerant to the thrombospondin motif, and therefore antibodies to this region of CS are very difficult to elicit in rodents. Even if this problem were circumvented, the antibodies to the thrombospondin CS motif might be harmful because of possible cross-reaction with host antigens. The middle third of CS consists of tandem, species-specific repeats, which represent the immunodominant B cell epitope. In P. falciparum this B epitope ((NANP) 3) is found in all isolates from different regions of the world. Monoclonal antibodies (or Fab fragments) to the repeats inhibit sporozoite cell invasion [2] and motility [8]. To date, the repeat domain of CS has been the main target of vaccines that aim at eliciting neutralizing antibodies to sporozoites. The possibility that antibodies to TRAP (thrombospondin-related anonymous protein), another sporozoite antigen, might also be effective was raised when it was shown that TRAP is present on the parasite plasma membrane and that TRAP is required for cell invasion [9, 10]. However, most TRAP molecules are released in a burst from the secretory organelles (micronemes) when the parasite establishes contact with the hepatocytes. At this stage a tight junction is established between the extracellular domain of TRAP and the cellular receptors, and the antibodies to TRAP are ineffective in sporozoite neutralization [11]. Because sporozoites enter the hepatocytes within minutes of the infective bite, high levels of antibodies to CS are required to neutralize all sporozoites. It has been commonly argued that an antibody-mediated preerythrocytic vaccine can be effective only if 100 % of sporozoites are neutralized. However, very small numbers of sporozoites are injected by mosquitoes. If the average number is 10, even a vaccine that eliminated 90 % of sporozoites would protect 40 % of naïve individuals. Moreover, in semi-immune individuals who have acquired some degree of resistance to blood stages, the diminution of the inoculum should have the same effect as bed nets and should moderate pathology and reduce mortality [12]. 22.2.2 Rationale for Vaccines that Elicit Cell-mediated Immunity

In human malaria infections, the EEF are particularly attractive targets, because they remain in the liver for about 1 week or longer, and infection is clinically silent during this stage. There may therefore be enough time for a recall of cell-mediated responses elicited by prior vaccination and production of effector T cells that inhibit EEF development. Nevertheless, in humans living in endemic areas, it has been difficult to demonstrate the participation of cell-mediated immunity in protection. It has also been rather disappointing that the peripheral blood lymphocytes from volunteers exposed to irradiated sporozoites or from individuals from endemic areas generally contain little or no cytotoxic T cells (CTL). Even in areas of very high trans-

22.2 Preerythrocytic Vaccines

mission, the frequencies of circulating CD8+ cells that recognize preerythrocytic antigens are low [13, 14]. How do we explain these findings? We should keep in mind that results of T-cell assays in endemic areas may be spurious. All assays have been performed with cells isolated from the peripheral blood, and they may not reflect the numbers of CTL in lymphoid tissues, and in particular, within the enlarged, heavily parasitized livers and spleens of malaria patients. Another problem is that only a very limited numbers of CTL targets are known, thus severely limiting the scope of the studies (see below). However, it is possible that specific mechanisms prevent the expansion of the T cells in malaria endemic areas. For example, CD8+ T cells may become refractory to further antigenic stimulation after the primary clonal burst is established [15]. Because the amount of sporozoite antigen delivered by a mosquito bite is very small, a limited number of memory cell are elicited during the primary immunization. The implication of these observations is that vaccination of children in endemic areas should start early. Moreover, since the level of response and of memory T cells appear to depend on the initial vaccine dose, the maximum well-tolerated amounts of antigen should be used. Another explanation for the weak T cell responses to malaria antigens in endemic areas is that red blood cell infection inhibits the development of dendritic cells and leads secondarily to suppression of the CD8+ T cell responses to EEF antigens [16]. It remains to be established whether the results obtained in rodents with high levels of parasitemia are applicable and relevant to human immune responses. If so, it would provide a very strong rationale for combining preerythrocytic and blood stage vaccines. Even if CTL have little or no role in protection against the preerythrocytic stages of malaria in endemic areas, this does not imply that vaccines that target EEF cannot be very effective. Several lines of evidence demonstrate that, in rodent malaria models, EEF are destroyed by cell-mediated effector mechanisms. Immunity obtained by vaccination with irradiated sporozoites can be reversed, at least in part, by elimination of CD8+ lymphocytes [5]. Cloned CD8+ CTL against defined CS epitopes kill EEF of Plasmodium berghei and P. yoelii in vivo and in vitro and prevent subsequent infection of red blood cells [17, 18]. Low concentrations of interferon-g effectively inhibit EEF development of rodent and human malaria parasites [19]. During the initial stages of immunization with irradiated sporozoites, interferon-g is the main effector mechanism [20]. The destruction of EEF is via production of nitric oxide by infected liver cells and is independent of Fas or perforin-mediated cytotoxicity [21]. In rodent models, there is direct evidence that T cells can control the preerythrocytic stages of malaria infection in the absence of antibodies. Isolated liver cells containing EEF (derived from irradiated sporozoites) are very good immunogens. Intrasplenic injection of naïve mice with the infected liver cells elicits sterile immunity to sporozoites in the absence of antibody [22]. Oral immunization of mice with Salmonella typhimurium expressing P. berghei CS elicits CTL (but not antibodies) and protects 50 %–75 % of mice against challenge with sporozoites [23]. Administration of recombinant Sindbis virus expressing a defined CTL epitope of P. yoelii CS induces potent CD8+ T cell responses and protective immunity in mice [24]. The strategy of priming strong CD8+ responses with one viral vector and boosting with a different

483

484

22 Rationale for Malaria Vaccine Development

vector expressing the same antigens has been particularly effective in eliciting protective cell-mediated immunity in rodent malaria models [25]. Notwithstanding the prominent role of CD8+ cells, CD4+ T cells play an important role in protection, as highlighted in studies performed in b2m knockout mice. After immunization with irradiated sporozoites, these mice were protected from sporozoite challenge, and the protection was abolished after depletion of CD4+ T-cells [6]. Cytotoxic CD4+ T-cells from a human immunized with irradiated sporozoites recognize an epitope of CS. It is well established that CD4+ effector T cells can also destroy EEF [26], but the mechanisms are not known. CD4+ T cells can control viral replication by releasing interferon-g close to the infected cell (see below), and it is conceivable that the same mechanism operates in malaria [27]. The antigens or epitopes that should be included in an EEF vaccine need to be selected preferentially from molecules that can enter the cytoplasm of the infected hepatocyte and that can be processed for presentation at its surface at the time of challenge. At this time, it is also possible that antigen presentation occurs in neighboring cells other than infected hepatocytes. This is because before entering hepatocytes, sporozoites glide and traverse many cells, including Kupffer cells [28] and perhaps endothelial cells and dendritic cells. During their migration, they leave behind a trail of CS and TRAP. Therefore, recognition of processed trail peptides by CTL and the subsequent release of lymphokines may play a role in protective immunity. Notably, Kupffer cells and dendritic cells express class II molecules, thus allowing for the participation of CD4+ effector cells. We argue that the main efforts should be directed to the identification of early EEF antigens in liver-stage libraries (see below), because early EEFs are highly sensitive to inhibition by interferon-g [19]. Late EEF molecules may not be useful for vaccination, even if they elicit large numbers of CTL. It is conceivable that fragments of sporozoites, or of hepatocytes containing late EEFs, are ingested by antigen-presenting cells and elicit CTL responses. However, these CTL will be ineffectual unless they recognize epitopes of EEFs that are starting to develop in the liver at the time of challenge. Thus, the choice of CTL epitopes for malaria vaccines on the basis of HLAbinding motifs alone will not guarantee effectiveness. One vexing problem for the development of EEF vaccines is that very few liverstage antigens that are highly expressed fulfill the conditions above. Two of them, CS and TRAP, have been extensively studied. In addition to its presence on the surface of sporozoites, CS continues to be synthesized in large amounts during early stages of development of EEFs; it is located on their plasma membranes (unpublished observations). CS is GPI-anchored and is released into the cytoplasm of hepatocytes [29]. In addition, CS is found in the trails left behind by sporozoites during their migration among cells, most likely also in the liver itself. As mentioned, TRAP is released in large amounts from micronemes during sporozoite entry into hepatocytes [11]. Although TRAP mRNA is undetectable by PCR in early rodent EEFs (unpublished observations), it is carried into the hepatocytes. TRAP is constitutively secreted during sporozoite gliding and is present in the sporozoite trails together with CS. Successful immunization with TRAP has been documented in rodents, but no T cell epitope has been identified so far [30].

22.2 Preerythrocytic Vaccines

A few other liver-stage antigens have been identified in P. falciparum and shown to be immunogenic in individuals residing in endemic areas [31, 32]. Immunization with one of them, called LSA3, protected chimpanzees against sporozoite challenge and is currently undergoing human trials to determine its immunogenicity and toxicity [33]. It is highly desirable that the search for additional EEF antigens proceed, in order to obtain vaccines that overcome MHC restriction and are recognized by most individuals from endemic areas in Africa, Asia, and Latin America. It has been very difficult, however, to generate cDNA libraries of the early EEFs, because they are very scarce and found inside hepatocytes that contain large amounts of mRNA. Two approaches may overcome these problems. One is to find gene products that are present in sporozoites and are carried over into the EEFs. Subtractive libraries between oocyst and salivary gland sporozoites revealed a set of transcripts that most likely function during or after hepatocyte invasion [34]. Another approach is to obtain cDNA libraries from EEFs that develop in vitro in the absence of hepatocytes [35]. 22.2.3 Human Vaccine Trials

A partial list of malaria vaccine trials that are underway is shown in Table 22.1 and has been recently reviewed. The majority of human vaccine trials with preerythrocytic antigens have used CS as the immunogen. Proof of principle that antibodies to CS can protect was obtained in the late 1980s when volunteers were immunized with tetanus toxoid coupled to NANP3 [2]. The levels of antibodies were, however, low in most volunteers. More recently, entirely synthetic, highly immunogenic vaccines that elicit long-lasting high levels of antibodies to NANP3 have been used in human trials [36]. These individuals were not challenged, because mild immediate hypersensitivity reactions occurred in some volunteers who had been boosted rather soon after the primary injections. This encouraging approach to vaccination was not pursued, however, due to the lack of a pharmaceutical industry partner.

Tab. 22.1 Partial listing of malaria vaccines in planned or clinical trials [48]. Antigen

Vaccine form

Pre-erythrocytic CS protein RTS,S RTS,S ICC-1132 CS long synthetic peptide (P. falciparum) CS long synthetic peptide (P. vivax) MAPs (synthetic peptide)

Stage

Trial country

Major groups involved 1)

Phase 2 Phase 2 Phase 1 Phase 1

Gambia Mozambique USA Switzerland

Phase 1

Colombia

Phase 1

USA

MRC, GSK Bio, MVI CISM, GSK Bio, MVI Apovia, MVI, NIH University of Lausanne, Dictagen (Switzerland) University of Lausanne, Dictagen, University of Cali NYU, CVD (continued overleaf )

485

486

22 Rationale for Malaria Vaccine Development Tab. 22.1 (continued) Antigen

Vaccine form

Stage

Multiple antigens

ME-TRAP (fowl pox, Phase 2 MVA) (epitopes from multiple antigens including CS, LSA1, LSA3 fused to TRAP) MuSt-DO5.1 (DNA) Phase 1 (CS, SSP2, TRAP, LSA1, LSA3, EXP1)

Trial country

Major groups involved 1)

Gambia

University of Oxford, MRC

USA

U.S. Naval Medical Research Institute,Vical, U.S. AID

Asexual blood stage MSP1 MSP142-3D7

Phase 1

Kenya

MSP142-3D7

Phase 1

Mali

MSP142-FVO +MSP142-3D7 AMA1–3D7 AMA1–3D7 AMA1–3D7 +AMA1-FVO AMA1(domain3) – MSP119 chimeric MSP3 (long synthetic peptide) GLURP (long synthetic peptide)

Phase 1

USA

WRAIR, U.S. AID, MVI, GSK Bio WRAIR, U.S. AID, MVI, GSK Bio, NIH, University of Mali MVDU, MVI

Phase 1 Phase 1 Phase 1

USA Netherlands USA

WRAIR, U.S. AID, GSK Bio BMPRC, EMVI MVDU, MVI

Phase 1

China

SMMU,WHO

Phase 1, 2

Switzerland

Phase 1

Netherlands

Institut Pasteur, University of Lausanne, Dictagen, EMVI University of Lausanne, University of Nijmegen, EMVI

Mosquito stage transmission-blocking vaccines Pfs25 (P. falciparum) Phase 1 Pvs25 (P. vivax) Phase 1

Australia USA

MVDU, MVI MVDU

1) Abbreviations BMPRC Biomedical Primate Research Center, Rijswick, The Netherlands CISM Centro de Investigaçao em Saude de Manhiça CVD Center for Vaccine Development, University of Maryland EMVI European Malaria Vaccine Initiative GSK Bio GlaxoSmithKline Biologicals MRC UK Medical Research Council MVDU Malaria Vaccine Development Unit, NIH MVI Malaria Vaccine Initiative at PATH NIH National Institutes of Health USA NYU New York University SMMU Second Military Medical University, Shanghai, China WHO World Health Organization WRAIR Walter Reed Army Institute of Research

22.2 Preerythrocytic Vaccines

Recombinant CS vaccines have been extensively used by investigators from the Walter Reed Army Institute of Research and SmithKlineBeecham. The antigen (named RTS,S) consisted of the hepatitis B surface antigen fused with a large part of the CS protein of P. falciparum (most of its repeats and its C-terminal region). When used with a combination of three adjuvants, it consistently protected between 30 % and 50 % of volunteers for a short time [37]. In a follow-up trial with Gambian semi-immune individuals, the vaccine protected about 70 % of individuals for two months, but there were no differences in levels of parasitemia or protection after 2 months [38]. The same vaccine is currently being used in a trial in African children. In another trial, the RTS,S vaccine was combined with a TRAP recombinant vaccine. In contrast with the previous results, there was no evidence for protection (antigenic competition, perhaps?). CD8+ T cells specific for CS have not been detected in the RTS,S-vaccinated individuals. In all trials there was a positive correlation between antibodies to CS repeat and protection. The participation of cell-mediated immunity cannot, however, be excluded. Uncertainties about mechanisms of protection persist also in trials in which the volunteers were immunized by multiple bites of irradiated, infected mosquitoes. One vexing problem is that, to date, antibody measurements were made by ELISA or, less frequently, by immunofluorescence of P. falciparum sporozoites. Until recently there were no practical functional assays to measure the neutralizing ability of the antibodies in sera from vaccinated individuals. This is because P. falciparum sporozoites are not infectious to common laboratory animals, and they also do not develop fully in vitro except in primary cultures of human hepatocytes. Moreover, it is not possible to evaluate the ability of candidate P. falciparum vaccines to evoke CTL that destroy EEF in humans. An initial step toward solving this problem was taken by generating a hybrid P. berghei (rodent) sporozoite that bears CS protein containing the repeats of P. falciparum. These parasites are fully infective to mice and to hepatocyte cell lines. Monoclonal antibodies against P. falciparum repeats neutralize the infectivity of the hybrid parasites in vitro and in vivo. Remarkably, mice immunized with a P. falciparum vaccine containing CS repeats were protected when challenged with the hybrid rodent sporozoites [39]. Hopefully, this hybrid parasite can be used to monitor the role of humoral mechanisms of protection in humans vaccinated with CS. U.S. Navy investigators focused extensively in DNA malaria vaccines after the demonstration of protection in mice immunized with a plasmid expressing CS [40]. The immunogenicity improved when GM-CSF was encoded in another plasmid. However, the results of human trials of similar vaccines encoding the P. falciparum CS and other EEF antigens were not encouraging. It is nevertheless notable that the CTL response to the DNA CS vaccine was observed in individuals with multiple HLA alleles, suggesting that genetic restriction may not be as great an obstacle for vaccine development as feared. The Oxford laboratory of A. Hill is planning to utilize the powerful prime–boost approach in developing a malaria CTL vaccine. This approach is based on a study made in 1993 by Li et al. [41], who found that recombinant vaccinia virus provides a very powerful booster for CD8+ T cells primed with influenza virus expressing the same epitope. Li et al. noted, however, that the reverse protocol, using influenza as a

487

488

22 Rationale for Malaria Vaccine Development

booster, failed to elicit strong secondary responses. Since then, many groups have confirmed and extended this observation. Although various vectors have been used for priming, boosting has been most effective with vaccinia or with modified vaccinia virus Ankara (MVA), which has a better safety profile. The Oxford group primed individuals with a DNA vaccine encoding multiple immunogens: TRAP followed in tandem by a string of CTL and B epitopes from various EEF proteins selected for their immunogenicity in individuals from endemic areas. Booster injections were done with vaccinia expressing the same series of antigens [42]. Clinical trials of this DNA vaccine are ongoing, as well as of other prime–boost regimens using other viral vectors containing the same TRAP/multiepitope construct. A modified hepatitis B core particle containing epitopes of CS is also undergoing phase I human trials. The core protein of the hepatitis virus consists of 180–240 monomers of about 20 000 daltons. These particles are potent immunogens in individuals infected with hepatitis B, and the immune response is not restricted. The B epitope of falciparum, NANP3, was inserted in the immunodominant region (spike) of each subunit of the core. In addition, a universal T-helper cell epitope of CS was ligated to the C-terminal of each subunit. This antigen (named ICC1132) was very immunogenic in mice and monkeys and elicited very high levels of antisporozoite antibodies. Malaria-specific T cells were induced in ICC1132-immunized mice. Importantly, anamnestic responses were observed in mice primed with P. falciparum sporozoites, suggesting that this vaccine may also boost the immune responses to CS in endemic areas [43]. ICC1132 is now undergoing phase 1 human trials in the USA and Europe using alum or Montanide as adjuvant. One important unsolved issue for malaria vaccines is selection of an adjuvant. Although alum is generally used in human vaccines, it may not be adequate for obtaining the required sustained protective immunity. In a mouse model, natural immunity mediated by NK T cells plays an important role in protection against sporozoite challenge and can be enhanced by administration of a-Gal ceramide [44]. It will be important to verify if these findings are applicable to human vaccines. Another problem that needs urgent attention is the need for booster injections, which are difficult, if not impossible, to achieve in many endemic areas. One attractive approach to solving this predicament is to use the yellow fever virus as a vector for protective epitopes of P. falciparum antigens [45]. Indeed, a single injection of a yellow fever vaccine lasts 10 or more years.

22.3 Asexual Stage Vaccines

Multiple potential modes of actions have been proposed for vaccines that target blood-stage parasites. Such vaccines may:

.

Reduce the rate at which parasites multiply to the point at which they prevent infection, resulting in sterile immunity. In a naïve person, > 90 % killing of parasites in each cycle would be required to prevent infection.

. .

22.3 Asexual Stage Vaccines

Reduce the rate at which parasites multiply, but not to the point of sterile immunity. This would reduce the peak parasite load and the disease associated with the infection. It may also decrease the duration of infection. A substantial reduction in acute disease and a modest impact on growth rates may occur, because chronic infections would not be sustained when killing per cycle is approximately 75 % [46]. Target the disease process without affecting the growth of the parasite [47].

These aims might be met by antibody that targets parasite antigens exposed on the surface of the merozoite or on the surface of infected red cells or soluble toxins secreted by parasites, by antigen–antibody complexes activating monocytes and other cells to destroy parasites in infected red cells, or by activating T cells to destroy parasites. Neither the parasites nor their host erythrocytes express HLA molecules, so killing could not be mediated by conventional CTL responses. However, data from animal models show T cell lines can kill parasites independent of antibody production. A vaccine that induces long-lived sterile immunity would be ideal, but malaria does not naturally induce such immunity, so a vaccine giving long-term sterile immunity against blood-stage malaria parasites would be unprecedented. A vaccine that gives transient sterile protection against infection with blood-stage vaccines may be possible and may be important in areas of epidemic malaria and for travelers. However, the prime aim of vaccines against blood-stage parasites is to prevent disease and death in children in highly endemic areas of malaria. For these, a vaccine that reduces disease without giving sterile immunity and whose effectiveness is sustained by boosting from reinfection may be ideal. In the development of vaccines aimed at the asexual blood stages, most attention has been given to antigens exposed in the form of the parasite between red blood cells, the merozoite. Merozoite antigens under development are either initially expressed on the surface of the merozoite (e. g., MSP1 and MSP2) or are present in organelles at the apical end of the merozoite, which are involved in invasion of erythrocytes. These include RAP1 and RAP2, antigens in the rhoptry organelle associated with membrane, which are discharged during penetration of the red cell or are discharged from micronemes and secreted onto the surface of the merozoite prior to or during invasion (AMA1, EBA175). With the exception of EBA175 and related proteins, which bind erythrocyte surface antigens, the functions of other merozoite surface antigens are unknown. For the most developed antigens, antibody directed against these proteins blocks red cell invasion in vitro. Steady progress has been made towards a vaccine directed against merozoite surface antigens. This endeavor was extensively reviewed in a series of recent publication; please refer to them for more details [48–51]. This chapter emphasizes novel approaches for developing blood-stage vaccines. A major challenge for antibody-based anti-merozoite vaccines is the need to generate high antibody levels. Merozoites attach to uninfected red cells within seconds of release and are internalized in approximately a minute. This places major constraints on the rate at which antibodies can block parasite binding to red cells or other processes involved in invasion. At the microgram-per-milliliter level of specific antibody that is typically achieved after vaccination, the half time with which antigen

489

490

22 Rationale for Malaria Vaccine Development

on a cell surface is complexed by antibody is several minutes [52]. The levels of antibody required in vitro for inhibiting invasion in vitro reflect this theoretical constraint. Typically, milligram-per-milliliter levels of purified antibody are required to obtain significant inhibition. Four approaches to anti-parasite blood-stage vaccines are being investigated, which may obviate the need to achieve such high antibody concentrations. 22.3.1 Red Cell Surface Antigens

Parasite-encoded proteins are inserted into the membrane of infected erythrocytes. In P. falciparum, the PfEMP1 protein mediates adhesion of mature infected cells to the walls of blood vessels and to other blood cells. Because sequestration of infected cells in blood vessels is thought to be a critical factor in severe malaria, e. g., sequestration in brain capillaries in cerebral malaria [53] or in the placenta in pregnancy [54], this function has attracted the most attention. All species of malaria parasites insert novel variant antigens on the surface of their host infected red cells, regardless of whether they sequester or not. These may be essential for maintaining the chronic infection essential for efficient transmission via mosquitoes to other hosts [55]. These antigens are exposed on the surface of infected cells for approximately 24 h; thus killing should not be constrained by the kinetics of binding. Antibodies directed against these antigens are highly effective at killing parasites in a monkey model [56], and their presence in humans predicts the likelihood of subsequent infection with parasites expressing the same antigen serotype [57]. PfEMP1 is a large protein with multiple copies of two related cysteine-rich domains, the DBL and CIDR domains. These domains have multiple binding specificities, but two of them seem critical: binding to CD36 by the second domain (CIDR1a) in parasites causing severe malaria in children and naïve adults [53] and binding by a DBL domain (DBLg) to partially sulfated chondroitin sulfate A (CSA) in parasites that sequester in the placenta in pregnant women [54]. These two domains have been targeted for vaccine development. Because both are cysteine rich, correct folding and disulfide bond formation will be critical. Thus, generation of recombinant proteins as vaccine candidates will not be straightforward. On the other hand, expression of these domains on the surface of CHO or COS cells has been routinely used for mapping domain binding specificity; thus viral delivery systems or DNA vaccines should lead to expression of biologically active molecules and, potentially, correct immunogenicity. The major challenge is the extensive antigenic diversity. It is widely believed that there is almost no commonality between the var gene repertoire expressed between different parasites. Although the diversity is considerable, several lines of evidence suggest that the diversity perhaps not as great as it appears. In Kenya, human antibodies that agglutinate isolates taken from other patients are frequently found in children who were infected at the time that serum was collected, at the end of the low malaria-transmission season, suggesting that variants expressed during a current infection gave rise to antibodies that recognized other parasites at relatively high fre-

22.3 Asexual Stage Vaccines

quency [58]. Infected patients from a low-transmission area and a hyperendemic area both had antibodies that could form mixed agglutinates with two isolates, again suggesting that there was a level of cross-reactive antibody [59]. Monkeys immunized with a minimal binding domain of a single CIDR-a domain from the Malayan camp parasite, surprisingly, not only were protected against Malayan camp parasites expressing that PfEMP1 but also did not experience high parasitemia from Malayan camp parasites expressing other PfEMP1 types; however, they were not protected from subsequent challenge with another isolate [56]. Within a single CIDR or DBL domain, there are short (20 to 80 amino acids), relatively conserved segments interspersed with regions that vary in both length and sequence [60]. An approach to making vaccines directed against CD36 binding PfEMP1 molecules being undertaken as a U.S.AID-funded collaboration between Maxygen and the NIH Malaria Vaccine Development Unit is to develop recombinant proteins that elicit antibodies against these conserved core regions. Development of vaccines that target the CSA binding DBL-g3 domain may be less complicated than CIDR-based vaccines. Genes encoding CSA binding PfEMP1 molecules are relatively rare, with at most only a few per parasite genome. These genes seem to be surprisingly conserved among different parasites, with most CSA binding PfEMP1 types falling into two subclasses [54]. 22.3.2 Antigens Eliciting Antibody-dependent Cellular Inhibition

Passive transfer of IgG from sera of adults living in hyperendemic areas to children results in rapid clearance of parasites in infected children, even though these antibodies do not inhibit the grown of parasites in vitro. Incubation of this antibody preparation with infected erythrocytes and human monocytes from a naïve donor resulted in intra-erythrocytic death of parasites. This phenomenon was called antibody-dependent cellular inhibition (ADCI). Subsequent investigation showed that the killing required cytophilic antibodies (IgG1 and IgG3 in humans) and was mediated by soluble factor(s) that blocked the division of intraerythrocytic parasites at the one-nucleus stage. TNF production by monocytes was implicated, but was not sufficient by itself to kill parasites [61]. The factor(s) that cause the inhibition of parasite growth appear relatively stable. If monocytes are stimulated with merozoites and antibody, the supernatant from these cultures subsequently kills parasites when transferred to new cultures [62]. Antigens associated with merozoites are implicated in ADCI. Specifically, antibodies that recognize three P. falciparum proteins (MSP3 [63], SERA [64], and GLURP [65]) correlated with the ability of those sera to elicit ADCI reactions in vitro and in a SCID mouse model [66]. These three antigens are not anchored to the merozoite membrane, but are present in the parasitophorous vacuole surrounding the maturing parasite and bind to the merozoite surface. Immunization with MSP3 was effective in protecting Aotus monkeys [67], and the level of protection was weakly correlated with levels of anti-MSP3 antibody. Two of these proteins, MSP3 and GLURP, are in vaccine trials as long synthetic peptides.

491

492

22 Rationale for Malaria Vaccine Development

Because the ADCI reaction is not constrained by the time it takes a merozoite to invade an erythrocyte, the concentration of specific antibody required to elicit the response should be correspondingly lower than that required to inhibit invasion. Substantial ADCI occurs at microgram-per-milliliter concentrations of affinity-purified antibodies to MSP3 [63] or GLURP [65]; similar ADCI occurs with non-affinity purified antibodies when they are tested at 5 % of the in vivo level [64]. 22.3.3 Antitoxin Vaccines

Golgi, observing that paroxysms were associated with rupture of schizonts, proposed that a pyrogenic toxin was released. Not only is malaria fever due to the release of a toxin, but other aspects for malaria pathology can also be accounted for by the cytokines released as a result of exposure to a malaria toxin [68]. Recent work has identified the parasite glycophosphatidylinistol glycolipid (GPI) as the dominant toxin and has elucidated, at least in part, the proinflammatory response that results from release of this molecule [47]. A synthetic GPI conjugate generated anti-GPI antibodies in mice, and vaccination gave protection against early death in mice challenged with a lethal line of P. berghei [69]. This experiment shows that an antitoxin vaccine is feasible and raises a broader question: Would such a vaccine, on balance, be useful in field situations? Superficially, it would seem that a vaccine that prevents the disease malaria would be of benefit to malaria patients. However, several observations caution against the use of such vaccines without further study. First, the great majority of malaria infections do not lead to severe disease and death, even if untreated. Observations of volunteers and of neurosyphilis patients treated with malaria therapy show that the initial exponential increase in parasite density abruptly slows at the onset of malaria symptoms [70]. In these patients, had the growth rate continued unchecked, they would have inevitably died of overwhelming parasitemia within a week, before parasites could be transmitted by mosquitoes. It is plausible that the immune response to the malaria ‘toxin’ not only makes people sick, but is also involved in regulation of parasite multiplication, which has been selected by evolution to ensure the host's survival and thus the survival of the parasite. Second, attempts to intervene later in the pathway initiated by malaria toxins have not proved successful. Monoclonal antibodies to TNF, thought to be the major cytokine released, can reduce fever, but in a double-blind trial did not reduce the death rate. In fact, although the reasons are unclear, survivors treated with anti-TNF monoclonal antibodies had a higher probability of residual neurological sequelae [71]. Third, people seek treatment because they are sick, in part due to the symptoms induced by ‘malaria toxins’. Thus, there is a risk that a vaccine that suppresses symptoms, but does not reduce parasite loads, will result in individuals presenting for treatment later in the infection and, in areas with active malaria control, in more asymptomatic parasite reservoirs in the population. Neither of these consequences is likely to benefit individuals or populations.

22.3 Asexual Stage Vaccines

22.3.4 Antibody-independent Mechanisms

Most efforts at developing vaccines against asexual stage parasites have, implicitly or explicitly, sought to generate antibody-dependent killing, e. g., by targeting antigens on the surface of merozoites or infected cells. However, evidence from rodent studies [72] shows that CD4+ T cells can control parasite growth in an antibody-independent fashion, possibly through activation of macrophages and production of nitric oxide and other small reactive molecules. Even when antibody clearly plays a role in limiting growth, e. g., in mice immunized actively with recombinant P. yoelii MSP119 or passively with anti-MSP119, the presence of CD4+ T cells is required for complete parasite clearance [72]. In humans, there is indirect evidence that antibody-independent T cell responses may be important in natural immunity and be a potential target of vaccines. CD4+ and CD8+ T cells can generate anti-parasite activity against P. falciparum in vitro [73]. In a human trial in which volunteers were repeatedly infected with blood-stage parasites and drug-cured at parasitemias too low to cause symptoms, three of four volunteers who had received three infection–cure cycles could not be infected on the fourth challenge. In the fourth volunteer, parasite growth was substantially slower than in the earlier infections. No antibodies were detected against the parasites or red cell surface, although there were proliferative T cell responses involving both CD4 and CD8 T cells, induction of an in vitro interferon-g response, and significantly increased levels of nitric oxide synthase activity in circulating monocytes [74]. These experimental findings on the role of cellular immunity in blood-stage infections contrast with the observation that HIV infection in malaria endemic areas has little impact on the prevalence or severity of malaria. Other than a clear impact on malaria in pregnant women, HIV infection may lead to a modest increase in parasite density and frequency of clinical attack, but these effects are small and not consistently found in field studies [75]. Thus, a blood-stage vaccine targeting cellular immunity is unlikely to closely mimic naturally occurring immunity. Development of a T cell-mediated vaccine has both practical and theoretical difficulties. It is not clear how antigens could be efficiently selected for use as the basis of a T cell vaccine. Antigen location is probably not helpful, and differences in antigen processing and T cell specificities may limit the use of animal models for antigen selection. Suitable antigens may be among the more abundant cellular proteins. This is true of T cell immunity to P. yoelii, in which hypoxanthine guanine xanthine phosphoribosyl transferase, an abundant intracellular enzyme, is one of the dominant antigens mediating cellular immunity [76]. On the positive side, because T cell vaccines may not require correct conformation of the antigen, a variety of immunization routes may be effective, including DNA vaccines, viral vectors, recombinant proteins, and even short synthetic peptides. The T cell vaccine approach also bears a serious theoretical question: Will induction of immunity exacerbate disease? In many ways, the T cell vaccine is the antithesis of the antitoxin–antidisease vaccine. (In the trial discussed above, the authors speculate that one of the reasons for the increased level of nitric oxide synthase that

493

494

22 Rationale for Malaria Vaccine Development

correlated with protection was GPI activation of the Toll-like receptor TLR2 [74].) There is evidence in rodent models that active T cells result in disease. Indeed, nude mice transfected with P. berghei-specific T cells died after challenge earlier and at much lower parasitemia than controls [77].

22.4 Mosquito-stage Vaccines

Vaccines against all stages of malaria potentially block transmission. However, in this review, ‘transmission-blocking vaccines (TBVs)’ is used for vaccines designed to directly block the transmission of malaria parasites. Several recent reviews detail the rationale for TBVs [49, 78–80], the mechanisms of transmission-blocking immunity, and details of the antigens under consideration for TBV [80]. Within this definition of transmission-blocking vaccines, two general targets are being considered: mosquito antigens present in the midgut, salivary glands, or other mosquito organs (‘anti-mosquito vaccines’) and Plasmodium antigens expressed in mosquito stage parasites (‘mosquito-stage vaccines’). Malaria transmission is highly localized, so a successful transmission-blocking vaccine would result in considerable indirect benefits to the individual vaccinated, through decreased malaria infection rates in other family members and neighbors [81]. Currently planned malaria TBVs involve several unusual concepts. Malaria TBVs are designed to work outside the person or animal vaccinated, primarily through antibody ingested with the mosquito's blood meal [80]. Mosquitostage antigens are exposed to antibody for hours, so transmission-blocking immunity (TBI) is unlikely to require the high antibody levels required to block merozoite invasion [52]. Ideally, once vaccinated, protective antibody would last for several years. However, for areas with seasonal or epidemic malaria, protection that lasted a minimum of one transmission season would be useful in the context of integrated control programs. Anti-mosquito vaccines are intended to prevent infection of mosquitoes following a blood meal on an infectious, but vaccinated, human. In addition, they may kill already-infected mosquitoes when they take subsequent meals on vaccinated people and may have an indirect effect on transmission by reducing the number of viable eggs laid. Most of the attention in developing malaria vaccines is targeted to P. falciparum, because it is the dominant parasite causing death and severe morbidity in highly endemic areas in Africa. However, in the low-to-mesoendemic areas seen as the primary target of TBV, P. vivax is often as important as P. falciparum in the impact of malaria. Antigens from both are being developed in parallel. Beside protecting the vaccinated individual, most infectious disease vaccines have a herd immunity effect, protecting people not immunized by reducing the human reservoir of infection. TBV are designed to protect communities only though a herd immunity effect and will not immediately protect the person vaccinated against disease. This raises a whole set of novel testing and regulatory issues: there is no prece-

22.4 Mosquito-stage Vaccines

dent for the phase 2 and phase 3 testing of human vaccines intended purely for inducing herd immunity. Four distinct uses of TBVs are anticipated [78, 79]:

. . . .

As a component of integrated control programs to eliminate endemic malaria in low-tomesoendemic areas. A TBV alone may be sufficient in some areas, but, if coupled with other measures such as the use of insecticide-treated bed nets and better early detection and treatment of infections, could eliminate malaria from much of the world at risk from low-to-mesoendemic malaria. To protect populations against epidemics of malaria in low-endemic areas. Epidemics of malaria usually occur as a result of unseasonable weather conditions or accompany natural or man-made disasters in tropical areas. Although a high proportion of the population can be infected in an epidemic, the biology of the parasite limits the rate at which such epidemics can build up. For P. falciparum, there is a minimum of 32 days from one person receiving an infectious bite, before that infection can result in a secondary infectious mosquito bite. Computer modeling shows that relatively modest reductions (3 ×) in the transmission rate achieved by TBVs alone could have a major impact on the total number of cases of malaria that occur before seasonal or other factors limit an epidemic [82]. To decrease disease in high-endemic areas. Recent studies show a correlation between transmission and disease [83, 84]. The latter study found that a 10 fold reduction in transmission in high-endemic regions ought to result in a decrease of about 20 deaths per 1000 infants per year. The reduction of malaria due to insecticide-treated nets also suggests that TBV use will lead to a substantial reduction of malaria deaths in high-endemic areas [85]. To slow the spread of drug- or vaccine-resistant mutant parasites. A tragedy of malaria control has been the loss of safe, inexpensive, and effective antimalarial drugs through the development of drug resistance. Unfortunately, the spread of drug-resistant malaria may be mimicked by the spread of vaccine-resistant parasites as effective preerythrocytic or blood-stage vaccines are developed. Incorporation of a TBV with vaccines targeting these stages may be an important strategy for preserving their effective life.

22.4.1 Targets of Transmission-blocking Vaccines 22.4.1.1 The 6-Cys Malaria Gamete Surface Antigens Antibodies to two P. falciparum antigens found on the surface of gametes, Pfs230 and Pfs48, can be demonstrated in populations living in highly endemic areas, and these antibodies are able to block transmission of malaria, although they rarely reach levels that give complete transmission-blocking activity [80]. However, MAbs directed against these proteins, when ingested by a mosquito with an infectious blood meal, are potent inhibitors of transmission. Pfs230 and Pfs48 are synthesized in gametocytes within the human host. After release of the gametes from their red cells, these proteins are on the surface of gametes. Both belong to the same superfamily of pro-

495

496

22 Rationale for Malaria Vaccine Development

teins characterized by domains with up to 6 cysteines. Genes encoding at least 7 proteins in this family are now known in the P. falciparum genome. The repeating motif in these proteins has not been found outside the genus Plasmodium (reviewed in [80]). Pfs48 is a compact protein containing 3 copies of the 6-Cys motif. Pfs230, in contrast, is a very large protein. Its gene encodes a 360-kDa protein consisting of a signal peptide, a 260-amino-acid N-terminal domain, a stretch of 25 glutamic acids, 16 copies of a tetrapeptide EEGV repeat, and then 14 copies of the 6-Cys motif. These 14 motifs are arranged in 7 pairs, with the odd-numbered motifs containing only 1 or 2 of the consensus 3 disulfides. Gene-knockout experiments confirm the essential role of Pfs48 and its P. berghei orthologs. Knockout mutants form gametocytes and gametes but have greatly reduced zygote formation. [86]. The occurrence of naturally occurring human transmission-blocking antibodies, the efficient transmission blocking by panels of MAbs, and the possibility of boosting vaccine-induced antibody by subsequent natural infection make Pfs48 and Pfs230 attractive vaccine candidates. However, the number of cysteines and the requirement for correct folding makes the expression of Pfs48 and Pfs230 a daunting task. Material suitable for vaccine use has not yet been achieved [80]. 22.4.1.2 The P25 and P28 EGF Domain Zygote, Ookinete, and Oocyst Antigens A 25-kDa protein was identified on the surface of P. falciparum ookinetes as the target of transmission-blocking antibody. The corresponding gene encodes a protein with a signal peptide followed by 4 tandem EGF-like domains and a hydrophobic C-terminal region replaced by a GPI anchor in the mature protein. A closely related protein, Pfs28, is found on ookinetes but differs in the last EGF domain, which is truncated and ends with a short repeat region. Monoclonal and polyclonal antibodies directed against these proteins are potent inhibitors of transmission [80]. High-level synthesis of Pfs25 occurs after induction of gametes, and Pfs25 is found on mosquito-stage parasites up to and including the oocyst stage. Immunofluorescence techniques enable Pfs28 to be observed first on retort stages, the transitional stage between a zygote and an ookinete. Studies of the P25 and P28 proteins suggest that they are essential, but functionally redundant [87]. Because the P25 and P28 proteins are not expressed at significant levels in the vertebrate host, there is probably no immune selection driving antigenic diversity. Indeed, very limited diversity has been found by direct sequencing of the genes. The low substitution frequencies, the conservative nature of the substitutions, and the likelihood that these have not been selected as a result of immune pressure [88, 89] suggest that antigenic diversity will not be a major issue for P25 and P28 based vaccines. Not surprising in view of the 10 or 11 disulfides present in the mature proteins, initial studies with Pfs25 and Pbs21 showed that antigen produced in E. coli was effective at eliciting antibodies, but these had poor transmission-blocking activities [90, 91]. Three approaches have been taken to circumvent this obstacle.

..

Search for linear epitopes that induce transmission-blocking immunity. Use of live viral vectors and DNA vaccines to generate folded antigen in situ.

.

22.4 Mosquito-stage Vaccines

Use of eukaryotic expression systems to produce correctly folded antigen: expression in baculovirus-infected insect cells [92], in Saccharomyces cerevisiae [93], or Pichia pastoris [94].

Clinical-grade Pfs25 (from P. pastoris) and the P. vivax ortholog, Pvs25 (from S. cerevisiae), have been produced. Human phase I trials with Pvs25 are under way, and trials with Pfs25 are expected to commence soon. In preclinical studies using adjuvants that are suitable for human vaccines, Pvs25 and Pfs25 elicited antibodies that efficiently blocked transmission of malaria to mosquitoes. For example, sera from Rhesus monkeys immunized with Pvs25 emulsified in Montanide ISA720 adjuvant, when mixed with chimpanzee blood infected with P. vivax and fed to mosquitoes in a membrane feeding apparatus, gave near total transmission blockage [80]. At least for Phase 1/2 trials, a satisfactory method of producing antigen appears to have been achieved. The next challenge, which can be addressed only in human trials, will be to find a formulation that is well tolerated and elicits long-lasting, potent antibodies. 22.4.1.3 Chitinase Mosquitoes secrete an acellular chitin-containing membrane, the peritrophic membrane, which separates the blood meal from the endothelial cells of the midgut, which malaria ookinetes must cross before they can invade the actual gut wall. Ookinetes secrete a chitinase that facilitates passage of the ookinete through the peritrophic membrane. Ingestion of allosamidin, a chitinase inhibitor, with the blood meal prevented oocyst formation (reviewed in [80]). For both P. falciparum [95] and P. berghei [96], knockout of the identified chitinase gene reduces infectivity of ookinetes. Recombinant parasite chitinases will now make it possible to test whether this enzyme has potential as a vaccine candidate.

22.5 Conclusion

In conclusion, through the efforts of a large number of investigators, several malaria vaccine candidates are now undergoing human trials that, in many instances, are supported by the Bill and Melinda Gates Foundation. This support is essential in view of the reluctance of most large pharmaceutical companies to invest in vaccine development for diseases that affect the underdeveloped world. As mentioned, in the case of pre-erythrocytic vaccines, proof of efficacy has already been obtained in trials performed in endemic areas. Therefore, notwithstanding the obstacles ahead, there is reason to believe that effective immunoprophylaxis of malaria can be achieved by a combination of vaccines that target several development stages of the parasite. Furthermore, the availability of Plasmodium genome sequences, proteomic analysis and oligonucleotide arrays for expression profiling will most likely reveal new facets of the biology of the parasite relevant to vaccine development.

497

498

22 Rationale for Malaria Vaccine Development

References 1. Mota MM, Pradel G,Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, Nussenzweig V, Rodriguez A. Migration of Plasmodium sporozoites through cells before infection. Science 2001, 291, 141–144. 2. Nussenzweig V, Nussenzweig RS. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989, 45, 283–334. 3. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, De l,V, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185, 1155–1164. 4. Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993, 11, 687–727. 5. Schofield L,Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330, 664–666. 6. Oliveira GA, Nardin EH. Sporozoite induced protective immunity in mice lacking CD8+ T cells. Am J Trop Med Hyg 1997, 57(Suppl 3), 107. 7. Sinnis P, Sim BK. Cell invasion by the vertebrate stages of Plasmodium. Trends Microbiol 1997, 5, 52–58. 8. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun 1986, 51, 859–864. 9. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 1997, 90, 511–522. 10. Sultan AA, Thathy V, Koning-Ward TF, Nussenzweig V. Complementation

11.

12.

13.

14.

15.

16.

17.

18.

of Plasmodium berghei TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker. Mol Biochem Parasitol 2001, 113, 151– 156. Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infect Immun 2000, 68, 3667–3673. Greenwood B. What can be expected from malaria vaccines. In: Hoffman SL, (ed) Malaria Vaccine Development: A Multi-immune Approach. Washington DC: Amer Soc Microbiol; 1996, p. 277. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR, McMichael J, Whittle HC. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992, 360, 434–439. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Lal AA, Gordon DM, Oloo A, Sette A. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997, 7, 97–112. Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F. Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci USA 2002, 99, 11819–11824. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003, 197, 143–151. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341, 323–326. Weiss WR, Berzofsky JA, Houghten RA, Sedegah M, Hollindale M, Hoffman SL. A T cell clone directed at

References

19.

20.

21.

22.

23.

24.

25.

26.

the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol 1992, 149, 2103–2109. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, Nussenzweig RS, Nussenzweig V. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986, 232, 881–884. Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M, Reichel M, Zavala F. Development of antimalaria immunity in mice lacking IFN-g receptor. J Immunol 1995, 154, 5338–5344. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol 1997, 19, 145–148. Renia L, Rodrigues MM, Nussenzweig V. Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage. Immunology 1994, 82, 164–168. Sadoff JC, Ballou WR, Baron LS, Majarian WR, Brey RN, Hockmeyer WT,Young JF, Cryz SJ, Ou J, Lowell GH, Chulay JI. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988, 240, 336–338. Tsuji M, Bergmann CC, Takita SY, Murata K, Rodrigues EG, Nussenzweig RS, Zavala F. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 1998, 72, 6907– 6910. Zavala F, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 2001, 280, 155–159. Renia L, Grillot D, Marussig M, Corradin G, Miltgen F, Lambert PH, Mazier D, Del Giudice G. Effector functions of circumsporozoite pep-

27.

28.

29.

30.

31.

32.

33.

34.

tide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 1993, 150, 1471–1478. Christensen JP, Cardin RD, Branum KC, Doherty PC. CD4(+) T cellmediated control of a g-herpesvirus in B cell-deficient mice is mediated by IFN-g. Proc Natl Acad Sci USA 1999, 96, 5135–5140. Pradel G, Frevert U. Malaria sporozoites actively enter and pass through rat Kupffer cells prior to hepatocyte invasion. Hepatology 2001, 33, 1154–1165. Hugel FU, Pradel G, Frevert U. Release of malaria circumsporozoite protein into the host cell cytoplasm and interaction with ribosomes. Mol Biochem Parasitol 1996, 81, 151–170. Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 1994, 62, 2979–2983. Aidoo M, Lalvani A, Allsopp CE, Plebanski M, Meisner SJ, Krausa P, Browning M, Morris JS, Gotch F, Fidock DA, Druilhe P, Takiguchi M. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995, 345, 1003–1007. Gruner AC, Snounou G, Brahimi K, Letourneur F, Renia L, Druilhe P. Pre-erythrocytic antigens of Plasmodium falciparum: from rags to riches? Trends Parasitol 2003, 19, 74–78. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, Mohamed LB, Slierendregt B, Eling W,Van Belkum A, Dubreuil G, Meis JF, Guerin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000, 6, 1258–1263. Matuschewski K, Ross J, Brown SM, Kaiser K, Nussenzweig V, Kappe SH. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J Biol Chem 2002, 277, 41948–41953.

499

500

22 Rationale for Malaria Vaccine Development 35. Kaiser K, Camargo N, Kappe SH. Transformation of sporozoites into early exoerythrocytic malaria parasites does not require host cells. J Exp Med 2003, 197, 1045–1050. 36. Nardin EH, Oliveira GA, CalvoCalle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, Hall BF, Diggs C, Bodison S, Edelman R. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 2000, 182, 1486–1496. 37. Kester KE, McKinney DA,Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001, 183, 640–647. 38. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P,Yamuah L, Delchambre M,Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358, 1927–1934. 39. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 2002, 169, 6681– 6685. 40. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, Richie TL, Stoltz EL, Trespalacios F, Nerges J, Ng J, Fallarme-Majam V, Abot E, Goh L, Parker S, Kumar S, Hedstrom RC, Norman J, Stout R, Hoffman SL. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intra-

41.

42.

43.

44.

45.

46.

47. 48.

dermal routes. Hum Gene Ther 2002, 13, 1551–1560. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993, 90, 5214–5218. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998, 4, 397–402. Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 2002, 70, 6860–6870. Gonzalez-Aseguinolaza G,Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. Natural killer T cell ligand agalactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002, 195, 617–624. Bonaldo MC, Garratt RC, Caufour PS, Freire MS, Rodrigues MM, Nussenzweig RS, Galler R. Surface expression of an immunodominant malaria protein B cell epitope by Yellow Fever virus. J Mol Biol 2002, 315, 873–885. Paget-McNicol S, Gatton M, Hastings I, Saul A. The Plasmodium falciparum var gene switching rate, switching mechanism and patterns of parasite recrudescence described by mathematical modelling. Parasitology 2002, 124, 225–235. Schofield L. Antidisease vaccines. Chem Immunol 2002, 80, 322–342. Ballou WR, Dubovsky F, Kester KE,

References

49.

50.

51.

52.

53.

54.

55.

56.

57.

58.

59.

Lyon J, Lanar DE, Saul A, Giersing B, Druihle P, Carucci D, Richie TL, Corradin G, Hall BF, Hill AVS, Diggs C, Cohen JD. Update on the clinical development of malaria vaccines. Am J Trop Med Hyg 2003, (in press). Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature 2002, 415, 694–701. Berzins K. Merozoite antigens involved in invasion. Chem Immunol 2002, 80, 125–143. Genton B, Corradin G. Malaria vaccines: from the laboratory to the field. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2, 255–267. Saul A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 1987, 9, 1–9. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002, 415, 673–679. Andrews KT, Lanzer M. Maternal malaria: Plasmodium falciparum sequestration in the placenta. Parasitol Res 2002, 88, 715–723. Saul A. The role of variant surface antigens on malaria-infected red blood cells. Parasitol Today 1999, 15, 455–457. Baruch DI, Gamain B, Barnwell JW, Sullivan JS, Stowers A, Galland GG, Miller LH, Collins WE. Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc Natl Acad Sci USA 2002, 99, 3860– 3865. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998, 4, 358–360. Bull PC, Lowe BS, Kaleli N, Njuga F, Kortok M, Ross A, Ndungu F, Snow RW, Marsh K. Plasmodium falciparum infections are associated with agglutinating antibodies to parasite-infected erythrocyte surface antigens among healthy Kenyan children. J Infect Dis 2002, 185, 1688–1691. Chattopadhyay R, Sharma A, Srivas-

60.

61.

62.

63.

64.

65.

66.

tava VK, Pati SS, Sharma SK, Das BS, Chitnis CE. Plasmodium falciparum infection elicits both variant-specific and cross-reactive antibodies against variant surface antigens. Infect Immun 2003, 71, 597–604. Smith JD, Subramanian G, Gamain B, Baruch DI, Miller LH. Classification of adhesive domains in the Plasmodium falciparum erythrocyte membrane protein 1 family. Mol Biochem Parasitol 2000, 110, 293–310. Bouharoun-Tayoun H., Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182, 409–418. Druilhe P, Bouharoun-Tayoun H. Antibody-dependent cellular inhibition assay. Methods Mol Med 2002, 72, 529– 534. Oeuvray C, Bouharoun TH, Gras MH, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84, 1594–1602. Aoki S, Li J, Itagaki S, Okech BA, Egwang TG, Matsuoka H, Palacpac NM, Mitamura T, Horii T. Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J Biol Chem 2002, 277, 47533– 17540. Theisen M, Dodoo D, Toure-Balde A, Soe S, Corradin G, Koram KK, Kurtzhals JA, Hviid L, Theander T, Akanmori B, Ndiaye M, Druilhe P. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 2001, 69, 5223– 5229. Badell E, Oeuvray C, Moreno A, Soe S, van Rooijen N, Bouzidi A, Druilhe P. Human malaria in immunocompromised mice: an in vivo model

501

502

22 Rationale for Malaria Vaccine Development

67.

68.

69.

70.

71.

72.

73.

74.

to study defense mechanisms against Plasmodium falciparum. J Exp Med 2000, 192, 1653–1660. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002, 185, 657–664. Kwiatkowski D, Bate CA, Scragg IG, Beattie P, Udalova I, Knight JC. The malarial fever response: pathogenesis, polymorphism and prospects for intervention. Ann Trop Med Parasitol 1997, 91, 533–542. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418, 785–789. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am J Trop Med Hyg 1999, 61(1 Suppl), 4–19. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, Memming H, Frenkel J, Enwere G, Bennett S, Kwiatkowski D, Greenwood B. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996, 174, 1091– 1097. Good MF. Towards a blood-stage vaccine for malaria: Are we following all the leads? Nat Rev Immunol 2001, 1, 117–125. Fell AH, Currier J, Good MF. Inhibition of Plasmodium falciparum growth in vitro by CD4+ and CD8+ T cells from non-exposed donors. Parasite Immunol 1994, 16, 579–586. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin LB,Wilson D, Elliott S, Elliott S, Eisen DP, Weinberg JB, Saul A, Good MF. Immunity to malaria after administration of ultralow doses of red cells infected with Plas-

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

modium falciparum. Lancet 2002, 360, 610–617. Rowland-Jones SL, Lohman B. Interactions between malaria and HIV infection: an emerging public health problem? Microbes Infect 2002, 4, 1265– 1270. Makobongo MO, Riding G, Xu H, Hirunpetcharat C, Keough D, De Jersey J, Willadsen P, Good MF. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cellmediated immunity to malaria. Proc Natl Acad Sci USA 2003, 100, 2628– 2633. Hirunpetcharat C, Finkelman F, Clark IA, Good MF. Malaria parasitespecific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol 1999, 21, 319– 329. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria transmission-blocking vaccines: How can their development be supported? Nat Med 2000, 6, 241–244. Carter R. Transmission blocking malaria vaccines. Vaccine 2001, 19, 2309– 2314. Saul A. Transmission blocking vaccines for malaria. In Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF (eds) New Generation Vaccines. 3rd ed. New York: Marcel Dekker; 2003. Carter R. Spatial simulation of malaria transmission and its control by malaria transmission blocking vaccination. Int J Parasitol 2002, 32, 1617–1624. Saul A. Minimal efficacy requirements for malarial vaccines to significantly lower transmission in epidemic or seasonal malaria. Acta Trop 1993, 52, 283– 296. Snow RW, Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 2002, 52, 235–264. Smith TA, Leuenberger R, Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol 2001, 17, 145–149. Lengeler C. Insecticide-treated bed nets and curtains for preventing ma-

References

86.

87.

88.

89.

90.

91.

laria. The Cochrane Library. Issue 4. 2001. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JAM, Dodemont HJ, Stunnenberg HG, van Gemert GJ, Sauerwein RW, Eling W. A central role for P48/45 in malaria parasite male gamete fertility. Cell 2001, 104, 153– 164. Tomas AM, Margos G, Dimopoulos G, van Lin LHM, de Koning-Ward TF, Sinha R, Lupetti P, Beetsma AL, Rodriguez MC, Karras M, Hager A, Mendoza J, Butcher GA, Kafatos F, Janse CJ,Waters AP, Sinden RE. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 2001, 20, 3975–3983. Taylor D, Cloonan N, Mann V, Cheng Q, Saul A. Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs. Mol Biochem Parasitol 2000, 110, 429–434. Tsuboi T, Tachibana M, Kaneko O, Torii M. Transmission-blocking vaccine of Plasmodium vivax malaria. Int J Parasitol 2003, 52, 1–11. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 1994, 62, 5576–5580. Matsuoka H, Paton MG, Barker GC, Alejo Blanco AR, Sinden RE. Studies

92.

93.

94.

95.

96.

on the immunogenicity of a recombinant ookinete surface antigen Pbs21 from Plasmodium berghei expressed in Escherichia coli. Parasite Immunol 1994, 16, 27–34. Martinez AP, Margos G, Barker G, Sinden RE. The roles of the glycosylphosphatidylinositol anchor on the production and immunogenicity of recombinant ookinete surface antigen Pbs21 of Plasmodium berghei when prepared in a baculovirus expression system. Parasite Immunol 2000, 22, 493–500. Hisaeda H, Collins WE, Saul A, Stowers AW. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine 2001, 20, 763–770. Zou L, Miles AP,Wang J, Stowers AW. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003, 21, 1650–1657. Tsai YL, Hayward RE, Langer RC, Fidock DA,Vinetz JM. Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut. Infect Immun 2001, 69, 4048–4054. Dessens JT, Mendoza J, Claudianos C, Vinetz JM, Khater E, Hassard S, Ranawaka GR, Sinden RE. Knockout of the rodent malaria parasite chitinase pbcht1 reduces infectivity to mosquitoes. Infect Immun 2001, 69, 4041–4047.

503

505

23 Vaccine for Specific Targets : HIV R. Kay, E. G.-T. Wee, and A. J. McMichael

23.1 Introduction

The spread of the human immunodeficiency virus (HIV), the causal agent of acquired immunodeficiency syndrome (AIDS), is unrelenting, especially in developing countries. This has implications, not just for healthcare, but also for the economies of areas most severely affected by the virus. In these countries, the option of using the highly effective anti-retroviral drugs, usually in a triple combination regimen, is not economically possible. This has made the development of an effective HIV vaccine of highest priority. However, although efforts to this end have been in progress for 20 years, there is still no HIV vaccine of proven efficacy available. The aims of this chapter are three-fold: to investigate why traditional approaches to vaccine development have not worked for HIV, to discuss novel strategies that have been developed as a result, and to examine the preliminary findings of the clinical trials that have been conducted or are currently in progress. HIV is a single-stranded RNA virus belonging to the lentivirus subfamily of retroviruses. The RNA genome is flanked by long terminal repeats that have roles in nucleic acid integration into the host genome and in regulation of gene expression. Between these, there are nine genes: three major structural genes gag, pol, and env, which code for viral core structural proteins, viral replication, integration enzymes and the viral envelope glycoproteins, gp120 and gp41, respectively, and six smaller regulatory or accessory genes, nef, rev, tat, vif, vpu, and vpr, which play roles in viral infectivity and replication. All these genes are enclosed within a nucleocapsid. HIV has cellular tropism for CD4+ T cells, dendritic cells and macrophages. These three groups of cells have surface CD4, which functions as a receptor for HIV attachment, and the chemokine receptors CCR5 or CXCR4, which serve as coreceptors for gp120. Once binding of these receptors has occurred, gp41 mediates membrane fusion between the invading virus and the cell. This results in transmission of the viral genome and reverse transcriptase into the cell. There, transcription of the viral genome results in viral cDNA being produced. This integrates into the host cell genome to form a provirus that can be immediately activated and expressed or can remain dormant in latent infection (reviewed in [1]). Progression to clinical

506

23 Vaccine for Specific Targets: HIV

AIDS does not immediately follow infection with the virus, but can take between 2 and 15 years.

23.2 Antibody Vaccines

The classical approach to developing a vaccine against a virus is to induce neutralizing antibodies (nAbs). However, whether this is possible for HIV remains unclear. In active HIV infection, the antibody response is ineffective. The primary peak of viremia declines before nAbs, directed against envelope glycoproteins, are detectable [2] (Figure 23.1). Furthermore, HIV-infected individuals have been shown to make nAb responses to their autologous isolates, but these responses take a long time to mature and lack broad reactivity [3]. Recent work has shown that individuals with primary HIV infection generate significant neutralizing antibody responses, but these are quickly made ineffective by the continually mutating virus [4]. Further understanding of why this immune response fails is paramount to eliciting antibodies by vaccination. Work in this area has centered around the only gene product of HIV known to be relevant to protective humoral immunity, namely the virus envelope proteins (gp120–gp41). The only AIDS vaccine trial to complete phase 3 studies was based on eliciting gp120 neutralizing antibodies (see Vaxgen website, http://www.vaxgen.com/). The

Fig. 23.1 The immune response to HIV. The initial viral burst is followed by a rise in CD8+ cells. As the viral load is controlled, the level of CD8+ cells plateaus, and the CD4+ cell count gradually declines. Neutralizing antibody response occurs late and appears to have less of an effect on disease progression.

23.2 Antibody Vaccines

Fig. 23.2 On the surface of the HIV virion, env forms a trimeric complex of gp120–gp41 dimers. The conserved surfaces facilitate the formation of a trimer. The binding of gp120 to CD4 on the T cell induces a conformational change, which exposes the coreceptor binding site. Schematic diagram reproduced with kind permission of Dr. Sattentau [8] (see colour plates page XLI).

results were disappointing – the vaccine was tested on 5000 at-risk volunteers and showed no protective effect. This result was not unexpected, as phase 2 results had hinted at the lack of effectiveness of the nAbs produced [5]. This was in part due to the lack of structural knowledge available when the vaccine was designed. The structure of the env glycoprotein is now well described [6]. It consists of a trimeric complex of gp120–gp41 dimers. The trimer is held together by interactions of conserved gp120 surfaces, which are not exposed on the virion surface, but upon gp120 shedding act as a decoy, stimulating largely irrelevant antibodies. To elicit neutralizing antibodies to gp120, several features of its structure must be overcome. First, the critical CD4 binding site is deeply recessed within the trimer. Second, the conserved elements of the chemokine binding site are exposed only after the sequential binding of two co-receptors, which induces a conformational change in the trimer (Figure 23.2). At this point, antibody binding is probably sterically limited, due to the proximity of the chemokine receptor binding site to the cell membrane. The humoral response is further impeded by a dense array of carbohydrates coating the outer surface of gp120 which, along with the capacity for variation in the hypervariable loops, protects against an antibody response (Figure 23.3). This may not be the full story, however, because one neutralizing antibody has been described, with a particularly large recognition surface resulting from an unusual arrangement of the paired heavy and light chains, that is specific for the carbohydrates on gp120 [7]. Sera from HIV-infected people have been extensively analyzed for the presence of neutralizing antibodies. Five human monoclonal antibodies have been identified that are capable of neutralizing a broad range of isolates [9]. Two of the antibody types that were isolated require CD4 to alter the conformation of gp120, and the other three have been well characterized. One binds to the CD4 binding site in the

507

508

23 Vaccine for Specific Targets: HIV Fig. 23.3 Schematic diagram of the likely arrangement of the HIV-1 gp120 glycoproteins in a trimeric complex. The view is from the target cell membrane. The CD4 binding pockets are indicated by black arrows, the approximate locations of the 2G12 epitopes are indicated by blue spots, and the conserved chemokine-receptor-binding regions are in red. Areas in green indicate the more variable glycosylated surfaces of gp120. Reproduced with kind permission of Prof. Sodroski [6] (see colour plates page XLII).

gp120 domain but requires a particularly long complementarity-determining region 3 (CDR 3) loop to access this site. The second antibody, 2G12, binds to a complex polymannose epitope, and a third binds to a site on gp41 that is usually hidden prior to CD4 binding. These elicit sterilizing immunity in animal models. Gaudain et al. [10] showed that passive administration of IgG1b12 to huSCID mice results in sterilizing immunity to an HIV challenge. Similarly, antibodies administered in the SHIV/macaque model prevent HIV infection [11]. The main caveat from these studies is that the level of antibody required to reach sterilizing immunity was very high and is unlikely to be achieved by active vaccination [12]. The hunt for neutralizing antibodies continues, and several approaches have been tested. These include construction of stabilized gp120–gp41 subunits [13], gp140 oligomers [14], and gp41 peptides and envelope on a carrier that facilitates trimer formation [15]. Further work has focused on the fact that the exposed surface of gp120 is covered with asparagine-linked carbohydrates. One approach was to delete the hypervariable loops of the envelope glycoproteins to expose the conserved polypeptide region [16]. This resulted in formation of a protein with altered immunogenicity compared to the full-length protein. Polyclonal immune sera raised in rats against this protein as an immunogen recognized HIV envelope glycoproteins from a broad range of clade subtypes [17, 18]. Similarly, when the env glycosylation sites of gp120 were mutated, this enabled the core regions to be exposed. However, after infection of macaques, the virus was able to rapidly repair these defects by mutation [19]. Another method of exposing the elusive binding site of gp120 is to induce a conformational change with a combination of monoclonal antibodies (mAbs). In these studies infusion of several antibodies neutralized a primary HIV from different clades in vitro [20]. It is postulated that the antibodies may act sequentially or synergistically to expose the binding site of gp120. Further evidence for this lies in reports that neutralization of SHIV89.6P with two mAbs is further potentialted by the addition of a third mAb that is unable to neutralize the virus by itself, even at high doses [21].

23.3 The T Cell Response

Active immunization strategies to induce nAbs in animal models and clinical trials have involved many of the constructs described above. The main problems from these trials were that only low levels of nAbs were achievable with the immungens used (reviewed in [22]). Second, the nAb response was specific for the vaccine strain but ineffective against primary HIV isolates. There is also concern that the concept of ‘original antigenic sin’ could interfere with this method of controlling infection. This idea postulates that, once antibody responses have been generated against a given virus by vaccination, the host’s ability to generate new responses to related viruses is impaired [23]. This is especially relevant, because there is a growing body of evidence that suggests that individuals chronically exposed to HIV are often exposed to diverse viral strains and substrains. Against this hypothesis is evidence from Rasmussen et al. [24], who vaccinated macaques primed with DNA vectors and boosted with recombinant gp160. Although some of the animals were vaccinated sequentially with two different strains of SHIV, the animals were still able to mount potent nAb responses against the second virus. In other words, the initial B cells response did not block the second response. In a further attempt to expose areas normally hidden on the virion, fusion-competent antigens of gp41 have been formed [25]. Other structural methods of exposing the binding sites of gp120 involve the use of cross-linked CD4–env complexes in which the env conformation is altered. This approach has induced neutralizing antibodies in macaques that are broadly cross reactive [26]. Despite these advances in the understanding of humoral immunity to HIV, the role of antibody in combating HIV infection remains unclear. Certainly, a significant degree of virus transfer is through direct cell-to-cell spread, thereby rendering the virus invisible to this arm of the immune system. The efficacy of the antibody response is further questioned when monitoring the course of HIV infection. After infection, partial containment of replicating HIV usually occurs during the first few weeks. This precedes the formation of virus-specific antibodies, which suggests that the humoral response is not critical at this stage. However, virus-specific CD8+ T cells appear before the partial containment of HIV. These observations and experiments in which CD8+ T cell-depleted macaques could no longer control SIV infection [27, 28] led to studies addressing the role of cell-mediated immunity as a means of controlling early HIV infection.

23.3 The T Cell Response

When naïve CD8+ T cells are activated to differentiate into cytotoxic T lymphocytes (CTL), they produce effector molecules. These include cytokines such as interferon-g (IFN-g), tumor necrosis factor-a (TNF), and chemokines such as RANTES, MIP-1a, and b , all of which play a role in the elimination of infected cells. These molecules are pleiotropic in their action and act both locally and at a distance from their site of production. IFN-g is the main cytokine produced by CD8+ T cells and, as such, its quantity is used to assess the presence of CTL induced by candidate vaccines in clinical trials.

509

510

23 Vaccine for Specific Targets: HIV

Besides cytokines, activated effector cells also produce cytotoxins, which are stored within lytic granules of CTLs. When the CTL recognizes a virally infected cell, cytotoxins are released. There are two main groups of cytotoxins, as reviewed in Lieberman [29]. The first group consists of membrane-perturbing proteins and include perforin and granulysin. Perforin forms transmembrane pores in the target cell membrane. This facilitates the entry of other cytotoxins into the infected cell. The second group of cytotoxins is the family of granzymes. There are ten different granzymes; of these, granzyme B, an aspase, is the most important in inducing apoptosis of the infected cell by activating caspases. This results in destruction of the cell and its contents, including the cellular and viral DNA. 23.3.1 CTL-inducing Vaccines

Because of the difficulties in stimulating neutralizing antibodies, the focus of HIV vaccine development has turned toward inducing cellular immunity in the form of CTLs. These CD8+ T cells recognize virus-infected cells through MHC TCR interactions. Naïve and precursor memory CTLs are then stimulated to proliferate and assume effector roles. These CTLs are capable of secreting cytokines and chemokines and of ultimately inducing the killing of infected cells by apoptosis or otherwise. Evidence strongly implying that CTLs play a critical antiviral role in retroviral infections comes from studies in both animals and humans. The role of CTLs in protection against SIV infection is well documented in animal studies. Control of acute infection during the primary infection stage correlated with the occurrence of CTLs and not of neutralizing antibody [30]. Also, chronically-infected animals that have had their CD8+ T cells depleted by antibody had substantially higher viral loads than those which had intact CD8+ T cells [27]. Barouch et al. demonstrated that DNA vaccines expressing SIVmac239 Gag and HIV-1 89.6P Env, augmented by the administration of the purified fusion protein IL-2/Ig (consisting of interleukin-2 (IL-2) and the Fc portion of immunoglobulin G (IgG) or a plasmid encoding IL-2/Ig) were able to confer protective immunity in rhesus monkeys against a particularly pathogenic SIV–HIV hybrid virus, SHIV-89.6P. After challenge, sham-vaccinated monkeys developed weak CTL responses, rapid loss of CD4+ T cells, high viral loads, significant clinical disease progression, and death in half of the animals by day 140 after challenge. Macaques given the vaccine, although infected, demonstrated potent secondary CTL responses, stable CD4+ T cell counts, low-to-undetectable viral loads, and no evidence of clinical disease or mortality by day 140 after challenge [31–33]. Similar results were obtained when a recombinant poxvirus vaccine was used in place of the DNA vaccine. [34]. However, in one macaque the vaccine eventually failed to protect against eventual infection, due to CTL escape [35]. The work of Shiver et al. [36] showed that a replication-incompetent adenovirus type 5 (Ad5) vector expressing the SIV gag protein can elicit an effective CTL response to the virus. Furthermore, after subsequent challenge with SHIV, animals immunized with the Ad5 vector exhibited the most pronounced attenuation of the

23.3 The T Cell Response

virus infection [36]. Also, Amara et al. [37] reported that a multi-immunodeficiency virus DNA (SIV Gag, Pol, Vif, Vpx, Vpr, and human HIV Env, Tat, Rev from a single transcript) and MVA (SIV Gag, Pol, and HIV-1 Env) vaccine administered in a heterologous DNA-prime and MVA-boost regimen had the potential to raise high levels of immune responses, which controlled SHIV-89.6P intrarectal mucosal challenge in the rhesus macaque model. Using a similar approach but using a different virus vector, Rose et al. [38] developed an SIV vaccine based on attenuated VSV vectors expressing env and gag genes and boosting with vectors having glycoproteins from different VSV serotypes. The vaccinated animals were again challenged with SHIV89.6P. Although control monkeys showed a severe loss of CD4+ T cells and high viral loads, and 7/8 of them progressed to AIDS with an average time of 148 days, all seven vaccinees were initially infected with SHIV89.6P but remained healthy for up to 14 months after challenge, with low or undetectable viral loads [38]. Its important to note that the challenge virus used in these studies was SHIV 89.6P. It has proved harder to protect against other strains of retrovirus, such as SIVmac239, with these types of vaccines [39]. 23.3.2 Studies in Humans

Evidence that CD8+ T cells are important in human HIV infection come from many sources. HIV stimulates a strong CD8+ cytotoxic T cell (CTL) response during acute viremia, which usually persists through the chronic phase of infection [40]. In some asymptomatic HIV+ patients, CTL activity is also detected [41, 42]. Furthermore, the level of circulating CTLs varies inversely with plasma RNA virus load in untreated HIV+ patients [43], although this was not seen in all studies [44]. Another subset of interest are people infected with HIV-1 who do not progress to AIDS. These people have HIV-specific CD4+ T cell proliferative responses [45] and strong CD8+ CTL activity against multiple epitopes [46]. These studies strongly suggest that CTLs have a role in protection against HIV infection. Support for the potential success of this strategy comes from the study of sex workers in Nairobi and Gambia, who are highly exposed to HIV. A small group of these women remain uninfected by the virus. Neutralizing antibodies were not detected in their serum, but they do have detectable HIV-specific CD8+ T cells [47–49]. Also, people who remain uninfected despite occupational exposure to HIV through needle-stick injuries have been shown to have HIV-specific CTL [50]. Discordant couples, in which one partner was infected and the other was not, despite well-documented multiple exposures, have also been observed. Studies on these discordant couples showed that the uninfected partner had detectable HIV-specific CD8+ T cell responses and also HIV-specific CD4+ T cell responses (Pinheiro and RowlandJones, unpublished). In another cohort consisting of HIV+ mothers, it was found that 85 % of children who may have been exposed in utero or perinatally to HIV-1 did not become infected. There was transient appearance of HIV-specific cytotoxic T-lymphocyte activity in a baby born to these HIV-infected parents [51] (reviewed in [52]). These studies strongly suggest that CTLs have a role in protection against HIV infec-

511

512

23 Vaccine for Specific Targets: HIV

tion. Therefore, attempts are being made to emulate this by designing candidate vaccines that induce high levels of virus-specific T cells. Recently, Altfeld et al. [53] reported that a sudden breakthrough of plasma viremia occurred after prolonged immune containment in an individual infected with HIV-1 at a time when 25 distinct CD8+ T-cell epitopes in the viral proteins Gag, RT, Integrase, Env, Nef, Vpr, Vif, and Rev were being targeted. Superinfection with a second clade-B virus was coincident with the loss of immune control. Although HIV-1 superinfection occurred despite a strong virus-specific CD8+ T-cell response, there were differences in about half the epitopes, so that the new virus could have evaded immune control [53]. This finding does not necessarily argue against a vaccine that elicits CTLs. First, the reported case may not necessarily be representative, because superinfection is rare. Secondly, when a healthy individual is vaccinated to produce CTLs, the immune activity is qualitatively distinct from that of an HIV-infected individual whose immune system is impaired due to living with the virus, as exemplified by the weakened CD4+ helper T cells. This could in turn affect the effectiveness of CD8+ T cells to produce cytotoxins even if they still had the ability to recognize epitopes derived from a new virus. It is possible that the superinfection might have occurred in the context of a very different immune response than that produced by vaccination of an uninfected person, specifically in terms of T-cell specificity, the competence of CD8+ T cells, and the strength of CD4+ helper T cells [54]. 23.3.3 CD4+ T Cell Help

CD4+ helper T cells are important in maintaining effective CTL function. For example, containment of LCMV viremia, which is normally associated with a strong CTL response, was lost in CD4+ T cell-depleted mice [55]. Tetramer studies have since helped in identifying the phenotype of these cells. Although present, the CD8+ T cell population that lacked CD4+ T cell help were essentially ‘silenced’ effector cells – positive to stains for epitope specificity but unable to secrete IFN-g [56]. The lack of virusspecific CD4+ helper T cell function in persons with chronic HIV infection [45, 57] suggests that a similar picture of a silenced CTL phenotype could occur in humans. There has been some dispute as to how important CD4+ T cells are for a CD8+ cytotoxic T cell immune response. It is generally agreed that the CD8+ response to acute infections with live virus can be CD4+ T helper cell-independent [58]. Although immunization with an antigen from a noninflammatory source requires CD4+ T cell help to activate antigen-presenting cells (APCs) through CD40 signaling [59–61], infectious agents carry a plethora of immunostimulatory molecules that can activate APCs directly [58, 62]. However, this does not take into account the quality of the memory CD8+ T cells that are produced. It was recently shown that CD4+ T cell help is critical for priming the CD8+ T cell memory response. In CD4+ T cell-deficient mice, pathogen exposure generates normal numbers of effector CD8+ T cells, but the memory T cells had poor replicative capacity upon re-exposure to the antigen [63, 64]. Overall therefore, it is likely that stimulation of an optimal CD8+ T cell response requires coactivation of CD4+ T cells.

23.4 Innate Immunity

Control of HIV and stable clinical status in humans is associated with high levels of virus-specific CD4+ T cell help [45]. This has implications in vaccine development, because an effective HIV vaccine should elicit virus-specific CD4+ T cell help as well as cytotoxic CD8+ T cells. However, one could argue that priming CD4+ T cells may be hazardous, because extra targets for the virus, which has a propensity to infect HIV-specific CD4+ T cells, are generated [57]. 23.3.4 The Dynamics of the CD8+ T Cell Response

Priming of CD8+ T cells is normally achieved by dendritic cells (DCs). In natural viral infections, this form of priming is highly efficient. For example, in acute Epstein–Barr virus (EBV) infection, 40 % of blood CD8+ T cells can be specific for one dominant epitope within weeks of first virus contact [65]. In HIV infection, the CD8+ T cell response is smaller, forming 1%–10 % of peripheral blood CD8+ T cells, which can be detected with epitope-specific tetramers. Many of the tetramer-stained T cells die rapidly ex vivo, and in most studies, only about 10 % can be cloned [66]. Therefore, it is thought that antigen-stimulated T cells, even within the same clone, can be divided into two types: apoptosing effector cells (in large numbers but unlikely to survive) and long-term-memory cells (in low numbers but able to grow). There may be a continuum between these two extremes, in various stages of differentiation. Further work on memory CD8+ T cell development has focused on gene expression in these cells during viral infection [67]. Interestingly, gene expression continues to evolve after viral clearance, resulting in progressive differentiation into memory cells after antigen exposure. In chronic HIV infection (untreated HIV with a high viral load), the expanded CD8+ T cells are maintained at a high level but, in the absence of further antigen, these cells tend to die by apoptosis. The population of T cells that is capable of dividing further maintains long-term memory and is likely to continually generate effector CD8+ T cells. This model is summarized in Figure 23.4. CTL HIV vaccines are being developed in the hope of stimulating this long-term CD8+ T cell memory response, which could be harnessed at the first sign of HIV infection to prevent dissemination. If the HIV antigen persists, such as arguably in Nairobi sex workers, the level of the effector CTLs remains high. There is a danger, therefore, that, should the antigen level decline, this CTL-mediated protection will fall. This is supported by the observation that, when the level of exposure to the virus declined in the Nairobi cohort, such as when the women stopped working for a period of time, protection from HIV was lost [68]. Thus, effective immunization against HIV may require regular boosting.

23.4 Innate Immunity

Innate immunity is the first line of defense against invading pathogens. This response is mounted quickly but is nonspecific. Its potential role in controlling HIV

513

514

23 Vaccine for Specific Targets: HIV

Fig. 23.4 Proposed dynamics of the T cell response to virus-specific T cells. Rare antigen-specific naïve CD8+ T cells are stimulated to divide rapidly. The frequency of effector cells (light blue) is much higher than that of those that can divide in vitro (dark blue). Persisting HIV antigen maintains the expanded T cells at a high level ; without antigen these cells die by apoptosis. The population of T cells that is capable of dividing further (dark blue) maintains long-term memory and is likely to continually generate the expanded effectors (see colour plates page XLII).

infection would be to provide time for the adaptive immune system to become effective, such as in allowing memory CTLs to expand in numbers. The cell types involved in this type of immune response include macrophages and natural killer cells (NKs). Activated macrophages are capable of secreting cytokines including IL-12 which, together with interferons, activate NKs and also induce CD4+ T cells to differentiate into TH1 cells. NKs, like CTLs, release cytotoxins to induce apoptosis of infected cells, which NKs recognize due to changes in cell-surface glycoprotein expression and down-regulation of MHC-1 proteins. Cohen et al. [69] showed that HIV-1 selectively down-regulates HLA-A and HLA-B but not HLA-C or HLA-E. The latter can inhibit NK cells efficiently, so the virus may evade this attack. Exploitation of innate immunity in HIV vaccines is still undeveloped, but is in principle worthy of further research. However, it is unlikely that sustained activation of NK cells would be achievable or safe. The ten mammalian Toll-like receptors (TLRs) recognize and distinguish the molecular patterns of different groups of pathogens and then trigger expression of costimulatory molecules and effector cytokines. These in turn are important in the development of adaptive immune responses. Bacterial DNA, such as that in DNA vaccines, which is characterized by the presence of unmethylated CpG dinucleotides, is distinguished from mammalian DNA and is superior in activation of DCs and in induction of TH1 cytokines such as IL-12 and IL-18. These CpGs are ligands for TLR9. CpG DNA or synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG,

23.5 Mucosal Immunity

which can be synthesized with high purity and sequence fidelity, can become an important agent for TH1 instruction and are included as an adjuvant component during vaccination [70]. There is supporting data to suggest that TLRs recognize, not just bacterial and fungal pathogens, but also viruses [71]. As reviewed elsewhere [72], several TLRs recognize viral products or endogenous molecules produced during viral infection. The stimulation of these particular TLRs may be valuable in an HIV vaccine.

23.5 Mucosal Immunity

Although many people have been infected with HIV intravenously or vertically, the most common form of HIV transmission is mucosal. This has led to work determining whether the mucosal response to HIV could be manipulated to prevent infection. After its transmission, HIV-1 establishes a persistent infection in lymphatic tissues, including mucosal-associated lymphoid tissue (MALT) [73]. HIV-1 replicates most efficiently in activated CD4+ T cells, and there is a greater proportion of activated memory CD4+ T cells in the intestinal lamina propria than in peripheral blood or lymph nodes. There is evidence that a proportion of activated HIV-infected cells home to MALT early in infection [74]. Interestingly, this homing is not restricted to orally transmitted HIV infections (such as during breast feeding). In fact, within days of intravenous infection in macaques, SIV-specific CD4+ memory T cells [74] and CD8+ T cells expressing the mucosal homing receptors [75] are found in the intestine. Therefore, there is interest in whether a mucosal site could be used for vaccination. Certainly, a mucosal immune response can be achieved by administration of immunogens at mucosal inductive sites, where lymphoepithelial follicular structures exist. Both oral and intranasal immunization can stimulate immune system responses locally, in the draining lymph nodes, and at distant effector sites [76]. In HIV there may be a role for direct rectal, vaginal, or paramucosal (draining lymph nodes of the pelvic region) immunization. Genital immunity within MALT has been documented by oral and nasal immunization, which generates antibodies in the genital tract in mice [77] and, more recently, in a proposed HIV vaccine in macaques [78]. These vaccines not only induce humoral response but also effector CD8+ T cells. It may be that T cells in the genital epithelial region may be the first line of defense against HIV. Notably, HIV-1-specific CD8+ T lymphocyte responses have been identified, not only in the in the bloodstream, but also in the cervical mucosa of a highly exposed seronegative group in Kenya [79]. Adjuvants to promote the mucosal response have been used with varying success. The best-defined mucosal adjuvant has been cholera toxin, which binds to the GM-1 receptors expressed on epithelial cells [80]. E. coli heat-labile toxin (LT) is also a potent mucosal adjuvant and binds GM-1 [81]. LT may induce Th1 and Th2 responses, as opposed to cholera toxin, which induces only Th2 [82]. HSP-70 appears to be a par-

515

516

23 Vaccine for Specific Targets: HIV

ticularly encouraging adjuvant for this type of immunization. It functions by engaging the costimulatory molecule CD40 as well as in translocating particles from outside the cell into the HLA class I processing pathway [83]. This adjuvant also stimulates production of chemokines [84].

23.6 Vaccine Design 23.6.1 Attenuated and Killed Vaccines

Some of the most successful vaccines are formed from attenuated viral strains. Nearer the beginning of HIV vaccine research, this method was investigated. Preliminary studies in the SIV/macaque model suggested that viruses can be altered by deletion of a limited amount of genetic material. These viruses remained infectious but were pathogenically inert. Furthermore, when challenged with the wild-type virus, macaques remained immune [85]. The initial enthusiasm for this form of vaccination waned as further work showed that neonatal macaques and macaques chronically infected with attenuated viral strains eventually developed AIDS [86]. Similarly, small cohorts of human infections have occurred with attenuated strains having deletions in the nef gene, notably one from the Sydney blood bank [87], but as with the macaque studies, the attenuated virus eventually regained its pathogenicity, probably through recombination and mutation [88], and the patients developed AIDS-defining illnesses. Because of safety concerns, there is no enthusiasm for pursuing live attenuated virus strategies for an HIV vaccine. Whole killed viruses are noninfectious and nonreplicating, and their use as vaccines is a safer alternative, and they have been used in other infectious diseases. However, there is a theoretical risk that HIV might not be totally inactivated. It is also clear that such killed vaccines do not generate a good CTL response [89]. Ten years ago, there were claims that formalin-fixed SIV could protect against SIV challenge in macaques [90, 91]. However the initial enthusiasm waned as it was shown that this protection was not virus specific [92]. Protection was seen only when the vaccine virus and the challenge virus were grown in human T cell lines. It was postulated that the virus was acquiring other surface proteins, in particular MHC molecules, as it was budding from these cells. The protective immune response therefore may have been due to xenoimmune responses. This has led to further work to see if protection may occur when the virus is grown in cells of different MHC type, but the results have been inconclusive. Because of the high levels of protection initially seen this approach to vaccination may still deserve attention in the future.

23.6 Vaccine Design

23.6.2 Subunit Vaccines 23.6.2.1 DNA Subunit vaccines do not use live attenuated or whole killed virus but consist of genes or epitopes derived from the HIV genome. They are assembled into an immunogen and administered via a vaccine vehicle. There are currently three approaches: as plasmid DNA-based vaccines, in a live bacterial vector, or in a live viral vector. Of the three approaches, naked plasmid DNA-based vaccines are the easiest to produce, because they merely require assembly of the immunogens into an appropriate plasmid vector by standard molecular cloning methods. Mass production of such vaccines is not a difficult procedure, because plasmid DNA can be grown to potentially large quantities in bacteria such as E. coli. This approach was first demonstrated in the murine influenza model [93] but has now been used in vaccines against paramyxoviruses (respiratory syncytial virus and measles virus) [94], malaria [95, 96], and HIV/SHIV [31], among other infectious diseases. DNA-based vaccines have the advantage of being easy to mass produce; however, the levels of CTLs induced are not sufficient to protect against pathogenic challenge [97–96]. 23.6.2.2 Viral and Bacterial Vectors Recombinant viruses have been engineered that lack virulence genes and have the vaccine immunogen inserted into their genome. Examples of such vectors include the attenuated poxvirus vectors fowlpox (FPV) and canarypox (ALVAC), attenuated vaccinia virus, NYVAC, modified vaccinia Ankara (MVA), and adenovirus. Other vectors in development include Semliki Forest Virus and Blue Tongue virus (reviewed in Nkolola and Hanke, in press). These viruses are attenuated and/or replication-deficient in humans and are thus not expected to be pathogenic in vaccines. Recombinant bacterial vectors are also in development, such as Bacille Calmette– Guerin (BCG) and Salmonella typhi. The former has potential for use in children, including neonates. Shata et al. [100] demonstrated that a gp160 DNA vaccine administered orally to mice via a Salmonella vector is capable of eliciting env-specific T cells [99]. Furthermore, a gp120 DNA vaccine in a Shigella vector was able to induce gp120-specific CD8+ T cells in vaccinated mice [100]. 23.6.2.3 Delivery: Prime – Boost Regimen Priming the immune response with one vector followed by boosting with another leads to better T cell responses [101]. A heterologous regimen, in which the prime and the boost vaccines contain identical immunogens but different vaccine vectors, is preferable over a homologous regimen, in which the same vaccine is administered twice [102]. This may be because immune responses generated against the vector-derived proteins are minimized. The efficacy of heterologous prime–boost regimens in animal models is illustrated by a study that used a DNA multigene construct priming followed by a recombinant MVA multiprotein booster [37]. The two DNA inoculations at weeks zero and eight and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered seven months after the booster. The

517

518

23 Vaccine for Specific Targets: HIV

first vaccination with naked DNA probably focuses T-cell responses to the epitopes expressed by the DNA expression vector. The second vaccination with a recombinant attenuated virus expands this response. The major advantage of DNA and recombinant virus or bacterial vaccines is that they can be precisely designed for a specific geographical region based on the predominant viral genetic strain or genetic type and the common HLA types of the population. 23.6.2.4 Whole Protein-based or Epitope-based Vaccines As mentioned above, the HIV RNA genome has nine genes. The proteins encoded by each of these genes have multiple CTL-inducing epitopes. The first step in developing a CTL-based vaccine is to decide whether to adopt a whole-protein vaccine approach or an epitope-based approach, or a combination of the two. The first approach uses the full-length protein or long sequences of it, and the latter approach uses a string of characterized epitopes. Each has its pros and cons. Full-length proteins may have to be inactivated to minimize any risks of their being detrimental to the vaccine recipient, but must retain the potential to elicit immune responses. Although epitope-based vaccines can be specially designed for specific geographical regions by taking into consideration the dominant HLA type of the population and the prevalent circulating clade, the number of epitopes that will be needed is enormous and probably precludes using this approach exclusively. The choice of which proteins or epitopes to include is informed by the temporal expression of the protein relative to the whole life cycle of the virus and knowledge of the processing and hence immunodominance of the peptides. In practice, the majority of vaccines in current clinical trials have used Gag, Pol, Nef, and Tat gene sequences or CTL peptides derived from them. CD8+ T cells respond to all viral protein peptides, but gag and nef are most immunogenic in HIV-infected people [44, 103]. Gag also encodes useful helper epitopes [44]. It is important that if nef, tat, reverse transcriptase, and integrase are used in the vaccine, they are inactivated to reduce any risk of functional protein being made (Nkolola et al., unpublished). It is debatable whether the viral envelope protein, env, should be included in a CTL-based vaccine design. It may be better to reserve this until we are able to elicit effective neutralizing antibodies. As can be seen from the various candidate vaccines, various laboratories have different ideas as to which genes should be included in the immunogen (Table 23.1). 23.6.2.5 Clades The next consideration in immunogen assembly of a CTL-inducing HIV vaccine is the clade sequence to use (reviewed in [104–106]). HIV isolates are genetically diverse. There are six major different clades of HIV, the distributions of which are clustered globally in distinct geographical regions. Each endemic region in the world has a dominant clade, with other clades at a lower incidence. The predominant clade in central and eastern Africa is clade A [107], in North America and Europe it is clade B, and in southern Africa and west and east Asia, it is clade C. The sequence difference between clades varies from 10 %–35 % among the different proteins. For a particular CTL epitope nine amino acids long, a 10 % difference in sequence translates to

23.6 Vaccine Design Tab. 23.1 Prophylactic HIV vaccines in clinical trials (source: [106], as adapted from http :// www.iavi.org/) Abbreviations: VRC: Vaccine Research Center; IAVI: International AIDS Vaccine Initiative ; MRC UK: Medical Research Council of United Kingdom; NIAID: National Institute for Allergy and Infectious Diseases; WRAIR: Walter Reed Army Institute of Research. Vaccine

Immunogen

ALVAC vCP1452 AIDSVAX B/B

Sponsor

Country

Phase

Env-Gag-Pol-CTL epitopes B gp120 B

NIAID

USA

2b

ALVAC vCP1452 AIDSVAX B/B

Env-Gag-Pol-CTL epitopes B gp120 B

NIAID

Brazil, 2b Haiti, Peru, Trinidad & Tobago

DNA.HIVA

Gag CTL epitopes

A

IAVI/MRC UK UK

MVA.HIVA

Gag CTL epitopes

A

ALVAC vCP205 or vCP1452

Env-Gag-Pol CTL epitopes B

AIDSVAX B/B

gp120

ALVAC vCP205

Env-Gag-Pol CTL epitopes B

WRAIR

USA

1

ALVAC vCP1452

Env-Gag-Pol CTL epitopes B

NIAID

USA

1

DNA.HIVA

Gag CTL epitopes

A

IAVI/MRC UK Kenya

1

MVA.HIVA

Gag CTL epitopes

A

MRKAd5 adenovirus

Gag

B

Merck

USA

1

PolyEnv1 vaccinia

Env

A, B, C, St. Jude’s D, E

USA

1

A, B, C NIAID

USA

1

FIT Biotech

Finland

1 1

VCR-HIVDNA009–99-VP Env + GTU-Nef DNA

Clade

2a

Uganda NIAID

USA

2a

B

Gag-Pol-Nef

B

Nef

B

VCR 4302 DNA

Gag-Pol

B

NIAID/VRC

USA

Gag DNA

Gag

B

Merck

USA

1

PGA2/JS2 DNA

Gag, RT, Env, Tat, Rev,Vpu B

NIAID

USA

1

NefTat fusion/gp120

Nef-Tat, gp120

B

NIAID

USA

1

LIPO-4T lipopeptide

Gag-Pol-Nef-TT CD4+ epitopes

B

ANRS

France

1

ALVAC vCP1452

Env-Gag-Pol CTL epitopes B

ANRS

France

1

LIPO-4T lipopeptide

Gag-Pol-Nef-TT CD4+ epitopes

B

519

520

23 Vaccine for Specific Targets: HIV

an average of about one changed amino acid. Even if this epitope is loaded onto MHC-1 and presented, the MHC-1–peptide complex may not be recognizable by the corresponding vaccine-stimulated CTL. However, in some studies, cross-clade CD8+ T cell responses have been detected [40, 108–111]. Some data also hint of some cross-clade immunity – notably a Ugandan study (007), which used a clade B vaccine in a predominantly clade A region [112]. Even so, ideally, the vaccine should match the predominant clade. Without this the vaccine would, at best, deliver suboptimal protection to the population. One consequence of mismatching vaccine and virus would be to narrow the effective response. An outcome is that escape mutants could be easily selected. This has been observed in macaques vaccinated with DNA for SIV gag and then challenged with SHIV89.6P [35]. This is a potentially formidable problem for T cell-inducing vaccines even if clades are matched, because of variability within clades. It is possible that adding additional genes to the vaccine may help, but this approach may be more effective if it is done with separate constructs rather than by linking several genes together in a large open-reading frame [54]. 23.6.3 Measurement of CTL Responses

The IFN-g ELISPOT assay is currently the standard for measuring T cell responses in vaccine trials [113, 114]. This is a relatively simple assay that is also particularly sensitive, allowing small numbers of activated, IFN-g-secreting cells to be identified. However, this assay merely indicates reactivity to synthetic antigen and does not necessarily reflect the activity of CTLs against HIV-1. It is possible that IFN-g may not be the best cytokine to measure, given that it has relatively little anti-HIV effect [115]. Furthermore, there may be limitations in the assay when it is used to measure relatively weak T cell responses. Although it is straightforward to validate the ELISPOT assay on robust immune responses to EBV, CMV, influenza, or HIV in chronically infected people, vaccine responses are smaller and more fragile. Variations in the ELISPOT protocol, such as the use of different developing agents or the length of time to develop each plate, can significantly affect the number and size of the spots and the level of background response (Hanke, unpublished). The use of flow cytometry to measure intracellular cytokine production in peptideor antigen-stimulated T cells is an alternative method to detect responses to vaccine peptides in trials [116, 117]. It also provides additional data on the phenotype of the cells involved. As in the ELISPOT assay, background responses can be a problem. A persistent fluctuating population of spontaneously activated CMV-specific T cells can occur in the bloodstream of CMV-positive healthy donors [118]. Thus, some level of background responses may have to be accepted. These assays measure the ability of circulating T cells to rapidly respond to antigen in vitro. This behavior may not reflect the nature of true memory T cells, which can protect against infection some time after vaccination. There is a need for more assays, including measurement of proliferative capacity and ability to differentiate into multifunctional effector cells, that can accurately quantify responses months after immunization.

23.6 Vaccine Design

23.6.4 Phase 1 and 2 Trials

Currently, more than 10 000 individuals worldwide have received immunizations with HIV-preventive vaccine constructs. Several HIV vaccines have now completed phase 1 and 2 trials in the USA, Europe, Uganda, and Kenya. These trials are regularly updated on the Internet (http://www.iavi.org/science/trials.htm; http://hivinsite. ucsf.edu/InSite) and are summarized in Table 23.1. HIV vaccines currently in phase 1 and 2 trials take several forms. Some groups have used HIV-derived antigens as adjuvanted peptides and proteins or DNA in plasmid form [119, 120]. The approaches using single vaccines have been generally disappointing, although this could be due to the use of less-than-optimal methods for detecting antigen-specific cells. The other form of vaccine currently being tested are those inserted into a vector such as recombinant canarypox [112], MVA (Mwau et al., unpublished), or adenovirus [121]. Combinations of these vaccines, such as priming with DNA and boosting with MVA or adenovirus, are completing phase 2 trials. The safety data are good, with very few serious adverse events. The first phase 1 trial of a DNA vaccine with MVA boost was encouraging, with most volunteers showing an induced CD8+ T cell response to the HIVA peptides (Mwau et al., unpublished). From all of these trials, the immune response in humans is much lower than in macaque studies. This may be due to lower doses used in humans or may be because the assays used differ slightly. However, in each of the studies the constructs have been shown to be immunogenic, suggesting that there is room for improvement. Alterations will include increasing the dose (of MVA, DNA, or both) and optimizing the time between the prime and the boost vaccine. The best route of vaccination also remains to be confirmed. Current practices include intramuscular, subcutaneous, and intradermal – especially for the boosting vector vaccines. The regime must remain acceptable to the volunteer as well as be achievable if it is to succeed in large phase 3 trials. Data are being gathered on how long the immune response to these vaccines lasts. Interestingly, responses were still detectable in some volunteers who had received an HIVA vaccination two years previously (Mwau et al., unpublished). This may be a consequence of the relatively low doses of DNA, which may gradually build up the immune response with repeated exposure and increase in T cell avidity [122]. 23.6.5 Phase 3 Trials

Phase 3 trials of an HIV vaccine will primarily assess whether HIV infection can be prevented. Alternatively, it may be that the vaccine may not prevent infection but may be able to suppress viral load without the use of antiretrovirals. Phase 2 b trials in high-risk subjects will help to decide what will be a realistic measure of success. Phase 3 trials can be carried out only in areas of high endemicity – notably the developing countries. Ideally, vaccines should be tested in phase 3 only if it will be possible to manufacture them in quantities sufficient to immunize millions of people.

521

522

23 Vaccine for Specific Targets: HIV

This requires tremendous global commitment and international collaboration. Furthermore, commitment to the population tested must include accountability for their health. This will inevitably include treatment of patients who seroconvert during phase 3 trails. This is a highly debated area and predominantly affects the motivation of the countries’ governments. The hunt for an HIV vaccine continues to gain momentum. With each study, progress is made either in nearing the ultimate goal of an effective vaccine or in furthering our understanding of the immune system. The next few years should prove the most exciting, with phase 3 trials of promising vaccines to be held in the countries that need them the most.

23.7 Conclusion

Twenty years after the identification of HIV, there is still no vaccine of proven efficacy. The failure to generate a neutralizing antibody-based vaccine has shifted the emphasis to developing CTL-based vaccines, of which there are 17 currently being assessed (Table 23.1). We do not yet know if the CTL-based approach will prove to be the breakthrough in HIV vaccine development. We are cautiously encouraged by preliminary data from ongoing clinical trials. Whether these vaccines are able to stimulate a long-term memory response that is broad enough to cope with virus variability within clades is unclear. Indeed, it may be that induction of CTLs will be one arm of a HIV vaccine. Work may turn toward inducing humoral, mucosal, and innate immune responses as well. Such a multipronged approach may be the only way to effectively compete with a virus that has so far evaded our control.

Acknowledgements

We gratefully acknowledge support from the International AIDS Vaccine Initiative (IAVI), the Medical Research Council (MRC), and the European Vaccine Initiative (Eurovac). References 1. Blankson, J.N., D. Persaud, R.F. Siliciano, The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med, 2002, 53, 557–593. 2. Koup, R.A., J.T. Safrit,Y. Cao, et al., Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol, 1994, 68, 4650–4655.

3. Moog, C., H.J. Fleury, I. Pellegrin, et al., Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol, 1997, 71, 3734– 3741. 4. Richman, D.D., T. Wrin, S.J. Little, C.J. Petropoulos, Rapid evolution of the neutralizing antibody response to

References

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

HIV type 1 infection. Proc Natl Acad Sci USA, 2003, 100, 4144–4149. Connor, R.I., B.T. Korber, B.S. Graham, et al., Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol, 1998, 72, 1552–1576. Wyatt, R., P.D. Kwong, E. Desjardins, et al.,The antigenic structure of the HIV gp120 envelope glycoprotein. Nature, 1998, 393, 705–711. Calarese DA, C.N. Scanlan, M.B. Zwick, et al., Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science, 2003, 300, 2065–2071. Poignard, P., P.J. Klasse, Q.J. Sattentau, Antibody neutralization of HIV-1. Immunol Today, 1996, 17, 239–246. Moore, J.P., P.W. Parren, D.R. Burton, Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol, 2001, 75, 5721–5729. Gauduin, M.C., P.W. Parren, R. Weir, et al., Passive immunization with a human monoclonal antibody protects huPBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med, 1997, 3, 1389–1393. Mascola, J.R., G. Stiegler, T.C. VanCott, et al., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med, 2000, 6, 207–210. Moore, J.P., D.R. Burton, HIV-1 neutralizing antibodies: how full is the bottle? Nat Med, 1999, 5, 142–144. Binley, J.M., R.W. Sanders, B. Clas, et al., A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol, 2000, 74, 627– 643. Earl, P., Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol, 2001, 75, 645–653.

15. Rossio, J.L., M.T. Esser, K. Suryanarayana, et al., Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol, 1998, 72, 7992– 8001. 16. Wyatt R, S.N., Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J., Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol, 1993, 67, 4557– 4565. 17. Jeffs, S.A., J. McKeating, S. Lewis, et al., Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol, 1996, 77, 1403–1410. 18. Barnett, S.W., S. Lu, I. Srivastava, et al., The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol, 2001, 75, 5526– 5540. 19. Reitter, J.N., R.E. Means, R.C. Desrosiers, A role for carbohydrates in immune evasion in AIDS. Nat Med, 1998, 4, 679–684. 20. Xu,W., Smith-Framklin B.A., Li P.L., Wood C., He J., Du Q., Bhat G.J., Kankasa C., Katinger H., Cavacini L., Potent neutralisation of primary human immunodeficiency monoclonal antibodies raised against clade B. J Hum Virol, 2001, 4, 55–61. 21. Hofmann-Lehmann, R., R.A. Rasmussen, J. Vlasak, et al., Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol, 2001, 30, 190–196. 22. Ferrantelli, F., R.M. Ruprecht, Neutralizing antibodies against HIV: back in the major leagues? Curr Opin Immunol, 2002, 14, 495–502. 23. Fazekas de St Groth, W.R., Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med, 1966, 124, 331–345.

523

524

23 Vaccine for Specific Targets: HIV 24. Rasmussen, R.A., D.C. Montefiori, H.L. Robinson, et al., Heterologous neutralizing antibody induction in a simian–human immunodeficiency virus primate model: lack of original antigenic sin. J Infect Dis, 2001, 184, 1603– 1607. 25. LaCasse, R.A., K.E. Follis, M. Trahey, et al., Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science, 1999, 283, 357–362. 26. Fouts, T., K. Godfrey, K. Bobb, et al., Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA, 2002, 99, 11842–11847. 27. Schmitz, J.E., M.J. Kuroda, S. Santra, et al., Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science, 1999, 283, 857–860. 28. Jin, X., D.E. Bauer, S.E. Tuttleton, et al., Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med, 1999, 189, 991–998. 29. Lieberman, J., The ABCs of granulemediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol, 2003, 3, 361–370. 30. Kent, S.J., Woodward, A., Zhao, A., Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with the control of acute HIV-1 infection in macaques. J Infect Dis, 1997, 176, 1188–1197. 31. Barouch, D.H., S. Santra, J.E. Schmitz, et al., Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science, 2000, 290, 486–492. 32. Barouch, D.H., A. Craiu, S. Santra, et al., Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian–human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol, 2001, 75, 2462–2467. 33. Barouch, D.H., T.M. Fu, D.C. Montefiori, et al.,Vaccine-elicited immune responses prevent clinical AIDS in

34.

35.

36.

37.

38.

39.

40.

41.

42.

SHIV(89.6P)-infected rhesus monkeys. Immunol Lett, 2001, 79, 57–61. Barouch, D.H., S. Santra, M.J. Kuroda, et al., Reduction of simian–human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol, 2001, 75, 5151–5158. Barouch, D.H., K.J. Kunstmann, M.J. Kuroda, et al., Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature, 2002, 415, 335–339. Shiver, J.W., T.M. Fu, L. Chen, et al., Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 2002, 415, 331–335. Amara, R.R., F. Villinger, J.D. Altman, et al., Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science, 2001, 292, 69–74. Rose, N.F., P.A. Marx, A. Luckay, et al., An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell, 2001, 106, 539–549. Horton, H., T.U. Vogel, D.K. Carter, et al., Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol, 2002, 76, 7187–7202. Walker, B.D., B.T. Korber, Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol, 2001, 2, 473–475. Walker, B.D., Chakrabarti, S., Moss, B., et al., HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature, 1987, 328, 345–348. Harrer, T., Harrer, E., Kalams, S.A., Elbeik, T., Staprans, S.I., Feinberg, M.B., Cao,Y., Ho, D.D.,Yilma, T., Caliendo, A.M., Johnson, R.P., Buchbinder, S.P., Walker, B.D., Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1

References

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

infection. AIDS Res Hum Retroviruses, 1996, 12, 585–592. Ogg, G.S., J. Xin, S. Bonhoeffer, et al., Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA load. Science, 1998, 279, 2103–2106. Betts, M.R., D.R. Ambrozak, D.C. Douek, et al., Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol, 2001, 75, 11983– 11991. Rosenberg, E.S., J. M. Billingsley, A.M. Caliendo, et al.,Vigorous HIV-1specific CD4+ T cell responses associated with control of viremia. Science, 1997, 278, 1447–1450. Ortiz, G.M., D.F. Nixon, A. Trkola, et al., HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest, 1999, 104, R13–18. Rowland-Jones, S., J. Sutton, K. Ariyoshi, et al., HIV-specific cytotoxic Tcells in HIV-exposed but uninfected Gambian women. Nat Med, 1995, 1, 59–64. Fowke, K.R., N.J. Nagelkerke, J. Kimani, et al., Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet, 1996, 348, 1347–1351. Rowland-Jones, S.L., T. Dong, K.R. Fowke, et al., Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest, 1998, 102, 1758–1765. Pinto, L.A., J. Sullivan, J.A. Berzofsky, et al., ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest, 1995, 96, 867–876. Rowland-Jones, S.L., D.F. Nixon, M.C. Aldhous, et al., HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet, 1993, 341, 860–861. Shearer, G.M., M. Clerici, Protective immunity against HIV infection: Has nature done the experiment for us? Immunol Today, 1996, 17, 21–24.

53. Altfeld, M., T.M. Allen, X.G. Yu, et al., HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature, 2002, 420, 434–439. 54. McMichael, A., M. Mwau, T. Hanke, HIV T cell vaccines, the importance of clades. Vaccine, 2002, 20, 1918–1921. 55. Matloubian, M., R.J. Concepcion, R. Ahmed, CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol, 1994, 68, 8056–8063. 56. Zajac, A.J., J.N. Blattman, K. MuraliKrishna, et al.,Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med, 1998, 188, 2205–2213. 57. Douek, D.C., J.M. Brenchley, M.R. Betts, et al., HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002, 417, 95–98. 58. Gordon, S., Pattern recognition receptors: doubling up for the innate immune response. Cell, 2002, 111, 927–930. 59. Bennett, S.R., F.R. Carbone, F. Karamalis, et al., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 1998, 393, 478–480. 60. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature, 1998, 393, 480–483. 61. Ridge, J.P., F. Di Rosa, P. Matzinger, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 1998, 393, 474–478. 62. Janeway, C.A., Jr., R. Medzhitov, Innate immune recognition. Annu Rev Immunol, 2002, 20, 197–216. 63. Sun, J.C., M.J. Bevan, Defective CD8 T cell memory following acute infection without CD4 T cell help. Science, 2003, 300, 339–342. 64. Shedlock, D.J., H. Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003, 300, 337–339. 65. Callan, M.F., L. Tan, N. Annels, et al., Direct visualization of antigen-specific CD8+ T cells during the primary im-

525

526

23 Vaccine for Specific Targets: HIV

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

76.

mune response to Epstein–Barr virus in vivo. J Exp Med, 1998, 187, 1395–1402. Appay,V., L. Papagno, C.A. Spina, et al., Dynamics of T cell responses in HIV infection. J Immunol, 2002, 168, 3660– 3666. Kaech, S.M., S. Hemby, E. Kersh, R. Ahmed, Molecular and functional profiling of memory CD8 T cell differentiation. Cell, 2002, 111, 837–851. Kaul, R., S.L. Rowland-Jones, J. Kimani, et al., Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest, 2001, 107, 341– 349. Cohen, G.B., R.T. Gandhi, D.M. Davis, et al., The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity, 1999, 10, 661–671. Dalpke, A., S. Zimmermann, K. Heeg, CpG DNA in the prevention and treatment of infections. BioDrugs, 2002, 16, 419–431. Haynes, L.M., Moore, D.D., KurtJones, E.A., Finberg, R.W., Anderson, L.J., Tripp, R.A., Involvement of Tolllike receptor 4 in innate immunity to respiratory syncytial virus. J Virol, 2001, 75, 10730–10737. Akira, S., Mammalian Toll-like receptors. Curr Opin Immunol, 2003, 15, 5– 11. Haase, A.T., Population biology of HIV1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol, 1999, 17, 625–656. Veazey, R.S., M. DeMaria, L.V. Chalifoux, et al., Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science, 1998, 280, 427–431. Cromwell, M.A., R.S. Veazey, J.D. Altman, et al., Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus. J Virol, 2000, 74, 8762– 8766. Ogra, P.L., H. Faden, R.C. Welliver, Vaccination strategies for mucosal im-

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

mune responses. Clin Microbiol Rev, 2001, 14, 430–445. McDermott, M.R., J. Bienenstock, Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol, 1979, 122, 1892–1898. Lehner, T., L. Tao, C. Panagiotidi, et al., Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen. J Virol, 1994, 68, 1624–1632. Kaul, R., F.A. Plummer, J. Kimani, et al., HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol, 2000, 164, 1602–1611. Heyningen, S.V., Cholera toxin: interaction of subunits with ganglioside GM1. Science, 1974, 183, 656–657. Clements, J.D., N.M. Hartzog, F.L. Lyon, Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine, 1988, 6, 269–277. Takahashi, I., M. Marinaro, H. Kiyono, et al., Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis, 1996, 173, 627–635. Castellino, F., P.E. Boucher, K. Eichelberg, et al., Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med, 2000, 191, 1957–1964. Lehner, T., L.A. Bergmeier,Y. Wang, et al., Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol, 2000, 30, 594– 603. Daniel, M.D., F. Kirchhoff, S.C. Czajak, et al., Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science, 1992, 258, 1938– 1941. Baba,T.W., Y.S. Jeong, D. Pennick, et al., Pathogenicity of live, attenuated

References

87.

88.

89.

90.

91.

92. 93.

94.

95.

96.

SIV after mucosal infection of neonatal macaques. Science, 1995, 267, 1820–1825. Learmont, J.C., A.F. Geczy, J. Mills, et al., Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney blood bank cohort. N Engl J Med, 1999, 340, 1715–1722. Jekle, A., B. Schramm, P. Jayakumar, et al., Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol, 2002, 76, 6966–6973. Kahn, J.O., Cherng, D.W., Mayer, K., Murray, H., Lagakos, S., Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549e6 CD4 cell counts: a randomized controlled trial. J Am Med Assoc, 2000, 284, 2193–2202. Murphey-Corb, M., L.N. Martin, B. Davison-Fairburn, et al., A formalin-inactivated whole SIV vaccine confers protection in macaques. Science, 1989, 246, 1293–1297. Putkonen, P., R. Thorstensson, M. Cranage, et al., A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge. J Med Primatol, 1992, 21, 108–112. Stott, E.J., Anti-cell antibody in macaques. Nature, 1991, 353, 393. Ulmer, J.B., J.J. Donnelly, S.E. Parker, et al., Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993, 259, 1745–1749. Hsu, S.C., O.E. Obeid, M. Collins, et al., Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma. Int Immunol, 1998, 10, 1441–1447. Hill, A.V.,W. Reece, P. Gothard, et al., DNA-based vaccines for malaria: a heterologous prime–boost immunisation strategy. Dev Biol (Basel), 2000, 104, 171–179. Wang, R., D.L. Doolan, T.P. Le, et al., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria

97.

98.

99.

100.

101.

102.

103.

104.

105.

DNA vaccine. Science, 1998, 282, 476– 480. Degano, P., J. Schneider, C.M. Hannan, et al., Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine, 1999, 18, 623–632. Robinson, H.L., Montefiori, D.C., Johnson, R.P., Manson, K.H., Kalish, M.L., Lifson, J.D., Rizvi, T.A., Lu, S., Hu, S.L., Mazzara, G.P., et al., Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med, 1999, 5, 526–534. Shata, M.T., M.S. Reitz, Jr., A.L. DeVico, et al., Mucosal and systemic HIV1 Env-specific CD8(+) T cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine, 2001, 20, 623–629. Shata, M.T., D.M. Hone,Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J Virol, 2001, 75, 9665–9670. Hanke, T., T.J. Blanchard, J. Schneider, et al., Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine, 1998, 16, 439– 445. Schneider, J., S.C. Gilbert, T.J. Blanchard, et al., Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med, 1998, 4, 397–402. Rosenberg, E.S., M. Altfeld, S.H. Poon, et al., Immune control of HIV-1 after early treatment of acute infection. Nature, 2000, 407, 523–526. Gaschen, B., J. Taylor, K. Yusim, et al., Diversity considerations in HIV-1 vaccine selection. Science, 2002, 296, 2354– 2360. Nabel, G.,W. Makgoba, J. Esparza, HIV-1 diversity and vaccine development. Science, 2002, 296, 2335.

527

528

23 Vaccine for Specific Targets: HIV 106. McMichael, A., T. Hanke, HIV vaccines 1983–2003. Nat Med, 2003 (May). 107. Neilson, J.R., G.C. John, J.K. Carr, et al., Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol, 1999, 73, 4393–4403. 108. Cao, H., Kanki, P., Sankale, J.L., Dieng-Sarr, A., Mazzara, G.P., Kalams, S.A., Kober, B., Mboup, S., Walker, B.D., Cytotoxic T lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol, 1997, 71, 8615–8623. 109. Ferrari, G., Berend, C., Ottinger, J., Dodge, R., Bartlett, J., Toso, J., Moody, D., Tartaglia, J., Cox,W.I., Paoletti, E.,Weinhold, K.J., Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood, 1997, 90, 2406–2416. 110. Dorrell, L., T. Dong, G.S. Ogg, et al., Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol, 1999, 73, 1708–1714. 111. Rowland-Jones, S.L.,T. Dong, L. Dorrell, et al., Broadly cross-reactive HIVspecific cytotoxic T lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett, 1999, 66, 9–14. 112. Cao, H., P. Kaleebu, D. Hom, et al., Immunogenicity of a recombinant human immunodeficiency virus (HIV)– canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis, 2003, 187, 887– 895. 113. Lalvani, A., R. Brookes, S. Hambleton, et al., Rapid effector function in CD8+ memory T cells. J Exp Med, 1997, 186, 859–865. 114. Mwau, M., A.J. McMichael, T. Hanke, Design and validation of an ELISPOT

115.

116.

117.

118.

119.

120.

121. 122.

123.

124.

assay for use in clinical trials of candidate HIV vaccines. AIDS Res Human Retroviruses, 2002, 18, 611–618. Coccia, E.M., B. Krust, A.G. Hovanessian, Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem, 1994, 269, 23087–23094. Picker, L.J., M.K. Singh, Z. Zdraveski, et al., Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood, 1995, 86, 1408–1419. Sun,Y., E. Iglesias, A. Samri, et al., A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods, 2003, 272, 23–34. Dunn, H.S., D.J. Haney, S.A. Ghanekar, et al., Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis, 2002, 186, 15–22. Boyer, J.D., M. Chattergoon, A. Shah, et al., HIV-1 DNA based vaccine induces a CD8 mediated crossclade CTL response. Dev Biol Stand, 1998, 95, 147–153. Boyer, J.D., A.D. Cohen, S. Vogt, et al., Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis, 2000, 181, 476–483. Emini, E.A., http://63.126. 3. 84/2002/ prelim.htm 2002. Estcourt, M.J., A.J. Ramsay, A. Brooks, et al., Prime–boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol, 2002, 14, 31–37. Lu,W., X. Wu,Y. Lu, et al., Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med, 2003, 9, 27–32. Tryniszewska, E., J. Nacsa, M.G. Lewis, et al.,Vaccination of macaques with longstanding SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol, 2002, 169, 5347–5357.

529

24 Vaccines against Bioterror Agents Karen L. Elkins, Drusilla L. Burns, Michael P. Schmitt, and Jerry P. Weir

24.1 Introduction and Overview

The designation of a human pathogen as a bioterror agent is the result of several considerations, many (if not most) of them not scientific or medical in nature. These include intelligence information, historical examples, ease of production or dissemination, and/or a judgement about the likelihood that a particular pathogen could really harm, or at least frighten, large numbers of people. Distinctions have also been made between pathogens that might be used in a military setting, because they could kill or incapacitate large numbers of troops, and those that might be used against civilian populations, because they could cause panic and consume resources in response even though actual casualties may be relatively few. However they may be defined, pathogens placed in the broad category of bioterror agents are now often being considered separately from other infectious disease agents. It is, of course, debatable as to whether such a differentiation is useful or appropriate; some of these pathogens have historically been of enormous public health importance (smallpox and plague), some are obscure (tularemia), and some might also now be considered emerging diseases (some viral hemorrhagic fevers). Similarly, each has separate vaccination histories and current vaccination issues, covering the gamut from the most successful vaccine in history to those for which vaccination has not even been attempted. What pathogens in this category do have in common is that most of them now rarely or only sporadically cause human disease in nature, and thus few people are either naturally exposed to or deliberately vaccinated against them. This characteristic is part of what may make them attractive to terrorists. It also means that little recent effort has been expended in understanding their pathogenesis and immunology nor in developing diagnostics, treatments, or vaccines. Further, because of low incidence now, testing treatments or vaccines may be logistically difficult. Large amounts of resources are now being devoted to filling gaps in knowledge at both the basic science and product levels, particularly for the so-called Category A high priority pathogens (Table 24.1). In this chapter, the status and prospects for vaccination against the Category A microbes are considered in some detail, with a view toward il-

530

24 Vaccines against Bioterror Agents

Tab. 24.1 Category A bioterror pathogens: status of treatments, vaccination, animal models, and correlates. Category A pathogen (US CDC list*)

Treatments?

Licensed vaccines (US)?

Investigational vaccines (US)?

NHP+ model?

Correlate?

Smallpox (Variola)

Limited; antivirals, supportive

Yes; vaccinia

Yes (e. g., modified vaccinia Ankara)

+

No

Viral hemorrhagic fevers, e. g., Ebola, Marburg, Lassa

Limited; antivirals, supportive

No

No; research level only (e. g., Ebola, Rift Valley fever)

Varies No (some Yes)

Anthrax (Bacillus anthracis)

Antibiotics and supportive

Yes; anthrax vaccine adsorbed (AVA)

Yes (e. g., recombinant protective antigen)

+

Antibodies?

Plague (Yersinia pestis)

Antibiotics and supportive

No

Yes (e. g., F1-V antigens)

+

Antibodies?

Tularemia (Francisella tularensis)

Antibiotics and supportive

No

Yes (live vaccine strain, LVS)

+

No

Botulinum toxin

Antitoxin and supportive

No

Yes (e. g., pentavalent Bot tox)

+

Yes

*

+

The list of Category A pathogens is taken from that designated by the U.S. CDC (found at www.bt.cdc.gov/Agent/agentlist.asp) and is similar but not identical to that developed by the U.S. National Institutes of Health (found at www.niaid.nih.gov/dmid/biodefense/bandc_priority.htm). The CDC defines Category A agents as high priority due to potential for high mortality, major public health impact, and ready dissemination; Category B as second priority due to potential for lower mortality but moderate morbidity and moderate potential for dissemination; and Category C as third priority due to potential as emerging diseases and future engineering potential. The CDC and NIH Category A lists appear to differ somewhat in the particular viral hemorrhagic fevers listed (e. g., bunyaviruses such as hantavirus and flaviviruses such as dengue fever are listed by NIH, but not by CDC). Both Category B lists include brucellosis, Q fever, ricin toxin, staphylococcal enterotoxin B, C. perfringens epsilon toxin, typhus, Burkholderia spp., and viral encephalitis agents; they both also include food-safety and watersafety threats, but differ in some of the specific pathogens mentioned. The NIH Category C list, also described as emerging diseases, includes pathogens such as influenza, yellow fever, multi-drug-resistant tuberculosis, rabies, tickborne hemorrhagic fever viruses, encephalitis viruses, and rickettsias that are not mentioned explicitly in the CDC Category C list, which includes Nipah virus and hantaviruses. NHP = nonhuman primate. + = studies in nonhuman primates have been performed, but no well accepted model has been developed to date.

lustrating the kinds of issues associated with developing vaccines against these organisms. Because knowledge of disease progression, pathogenesis, and immunology of each infection is integrally linked with development of vaccines, these topics are briefly considered as well. A brief mention of the situation for the Category B and C pathogens is also included. More generally, we discuss some of the challenges and strategies now being considered by the U.S. Food and Drug Administration (FDA) to test and regulate vaccines for bioterror pathogens as well as others for which field trials are unrealistic.

24.2 Vaccination against Smallpox

24.2 Vaccination against Smallpox

In a perverse twist of fate, the only human disease ever eradicated from the earth has become one of the most feared diseases of the early 21st century [1]. The world was declared free of smallpox by the World Health Organization in 1980, following a monumental global public health effort of vaccination and surveillance. Although the last natural case of endemic smallpox occurred in Somalia in 1977, the last known case of smallpox was a fatality resulting from a laboratory accident in Birmingham, United Kingdom, in 1978. At the time of that accident, 76 countries were identified as possessing stocks of variola virus, the causative agent of smallpox. That number was officially reduced to two by 1984: the Centers for Disease Control and Prevention in the United States, and the Research Institute of Viral Preparation in the Soviet Union. Nevertheless, there has been recent speculation and increasing concern that stocks of variola virus exist outside these officially sanctioned repositories, and could, in the wrong hands, become an especially lethal and frightening bioterror agent [2]. Although very few currently practicing physicians have actually ever seen or treated a case of smallpox [3], the clinical manifestations of later disease are, nevertheless, fairly unique [4]. Following typical infection via the respiratory tract, there is an incubation period of 7–17 days before the patient enters the prodromal phase, experiencing fever and severe aching pains. In 2–3 days, a papular rash begins to develop on the face and extremities, but soon covers the entire body. The lesions progress to vesicles and then to pustules over the course of 4–7 days, followed by crusting and separation. Death occurs approximately 2 weeks after the appearance of symptoms in up to 30 % of cases and is thought to be due to toxemia. Survivors usually exhibit extensive pitting and scarring that is a permanent, unmistakable sign of their ordeal. There is no known effective treatment for smallpox after symptoms become obvious. Some studies have indicated that cidofovir has antiviral activity against other poxviruses such as vaccinia virus, cowpox, and monkeypox, suggesting the possibility of its use against smallpox in an emergency, but obviously its effectiveness in humans cannot be readily studied [5]. In spite of this present bleak picture of antiviral treatment, it is well known that vaccination after exposure, if performed within 2–3 days, can prevent or mitigate the course of the disease. Smallpox vaccine is spectacularly successful in prophylactically protecting against the disease, as evidenced by its success in eradication. The smallpox vaccine is a live vaccinia virus, a related poxvirus of unknown origin. Although several strains of vaccinia virus were used worldwide in the eradication campaign, four were most widely used: the EM-63, Lister, Temple of Heaven, and New York City Board of Health (NYCBH) strains. In the United States, the only currently licensed vaccine for smallpox is Wyeth's Dryvax, a derivative of the NYCBH virus. The vaccine is a lyophilized preparation prepared by scarification of live calves. Although stable in its lyophilized form, the vaccine has not been manufactured in decades, and the remaining stockpile is limited. Current efforts are underway to produce new stocks of vaccine that are also derived from the NYCBH strain of vaccine,

531

532

24 Vaccines against Bioterror Agents

but made in tissue culture. As noted previously, licensing of new smallpox vaccines will require adequate safety data, as determined in clinical trials, and demonstration of a protective immune response in humans [6]. For NYCBH-derived strains of the vaccine, determination of vaccine efficacy during licensure will likely involve a direct comparison of the new vaccine with the licensed vaccine for the ability to elicit a classic Jennerian vesicle (a ‘take’), a typical indication of a successful vaccination, as well as supporting analyses of vaccinia virus-specific immune responses. Smallpox vaccination with live vaccinia virus is associated with several well documented adverse reactions, including serious and sometimes fatal reactions such as postvaccinal encephalitis and progressive vaccinia. Vaccinia immunoglobulin is available for treating certain smallpox vaccination complications, but efforts are already under way to develop new-generation smallpox vaccines that would be safer than historical vaccines. Evaluation of such new-generation vaccines, however, is extraordinarily complex, due to our incomplete understanding of the protective mechanisms of smallpox vaccination. The actual immune correlates of protection remain unclear, the relative roles of vaccine-induced humoral and cellular response are undefined, and the duration of immunity is unknown. Development of treatments and new vaccines for smallpox is hindered by the nature of the disease and the success of its eradication. The virus has no natural animal host other than humans, a trait that was favorable for eradication but extremely inconvenient for basic studies of virus pathogenesis and viral immunity that would facilitate the development and evaluation of antivirals and vaccines. Recent reports have indicated some success in infecting cynomologous macaques with high doses of variola, although this nonhuman primate model is still being developed [7]. Several other poxvirus models of pathogenesis and immunity exist, including mousepox, cowpox, monkeypox, and vaccinia virus. Although none of these animal models of infection are perfect substitutes for studying variola, they each provide useful information about poxvirus pathogenesis; particularly in combination, they provide valuable models for the evaluation of antivirals and vaccines against smallpox.

24.3 Vaccination against Viral Hemorrhagic Fevers

In contrast to the extremely effective vaccine against smallpox, no vaccines are available for protection against other viruses considered to be credible category A bioterror agents. These viruses include the filoviruses, Marburg and Ebola, and the arenaviruses, Lassa, Junin, and related viruses. All are capable of causing a hemorrhagic fever syndrome with extremely high mortality rates, from 15 % for the arenaviruses up to 90 % for the filoviruses [8]. Unlike smallpox, all these viruses have natural animal hosts (for the filoviruses, the hosts are unknown) and are transmitted to humans only sporadically, presumably through close contact; person-to-person transmission is known to occur. The clinical course of disease varies somewhat among the viruses [9], and not all patients develop the hemorrhagic fever syndrome (e. g., only about 15 %–20 % after Lassa fever infection). Disease progression is fairly rapid

24.4 Vaccination against Anthrax

(e. g., death from Ebola often occurs within 5–7 days after the appearance of symptoms). Treatment is, for the most part, supportive. There is some evidence that the nucleoside analog ribavirin has antiviral activity against arenaviruses such as Lassa and Junin. However, the drug is not approved for treatment of hemorrhagic fevers caused by these viruses, and there is no evidence of antiviral activity against the filoviruses. Because of the sporadic nature of outbreaks, as well as the difficulty of working with such dangerous pathogens, many aspects of virus pathogenesis are poorly understood. Nevertheless, some common features in the diseases caused by this group of viruses include the targeting of dendritic cells and macrophages. During the course of infection, tropism extends to hepatic and endothelial cells, resulting in liver failure and hemostatic disorders, and an enhanced host inflammatory response. Further studies of viral pathogenesis are necessary to understand the nature of the immune response to virus infection and to identify the protective immune responses necessary for an effective vaccine. Although some small animal models exist (e. g., mice and guinea pigs for Ebola), nonhuman primate models are expected to be the most appropriate for basic studies of pathogenesis and for antiviral drug and vaccine evaluation [10]. In spite of the lack of licensed vaccines against hemorrhagic fever-causing viruses and our poor understanding of their basic immunology and pathogenesis, recent progress has been made in vaccine development. For example, a live attenuated Junin virus vaccine has shown promise in trials in Argentina, where the disease is endemic [11]. Furthermore, there is evidence that survivors of Lassa fever infection have lifelong immunity against the disease, an indication that protective immune responses can indeed be generated. Interestingly, however, inactivated Lassa fever vaccines have not worked in nonhuman primate models [12]. Recently, a combination DNA vaccine–adenovirus vector vaccine expressing Ebola virus glycoprotein was shown to protect monkeys against lethal challenge [13]. Although more work needs to be done to extend these findings, the results suggest that successful vaccination may indeed be feasible. As noted above, large gaps remain in our knowledge of the hemorrhagic fevercausing viruses. There are no effective treatments, and no rapid diagnostic methods available that are capable of distinguishing these agents from one another. Studies of pathogenesis and immunology are difficult, for the most part requiring nonhuman primates and BSL-4 facilities. The sheer number of viruses in this general group, especially if category B and C agents are considered, is daunting. Further progress in development of antivirals and vaccines will clearly be challenging.

24.4 Vaccination against Anthrax

Bacillus anthracis is an effective bioterrorism agent, as proven by the events of the autumn of 2001 in the United States, when letters containing anthrax spores were intentionally sent through the postal system, resulting in the exposure of many individuals. Ultimately, 22 people contracted anthrax, and 5 of 11 individuals who had in-

533

534

24 Vaccines against Bioterror Agents

halational anthrax died. Millions of dollars were spent to test contaminated areas and clean up the resulting contamination, and fear was spread throughout a large population. Perhaps no other bioterrorism agent is as easily disseminated as anthrax spores, and thus, efforts to develop and produce new anthrax vaccines are a high priority in several countries. In a natural setting, anthrax is primarily a disease of herbivores. Animals grazing on land contaminated with spores can become infected; once ingested by animals, the spores germinate and cause disease, ultimately killing the host. Bacilli shed by the dying or dead animal then sporulate upon contact with the air and settle in the soil, completing the infectious cycle [14]. Naturally occurring human disease is, in general, limited to individuals who handle infected animals or contaminated animal products such as wool or leather [15]. Depending on the mode of exposure, human anthrax disease manifests itself as inhalational anthrax, gastrointestinal anthrax, or cutaneous anthrax. During a bioterrorism event, the most likely form of the disease would be inhalation anthrax, an extremely lethal form. Inhaled B. anthracis spores are taken up by alveolar macrophages in the lung, which travel to draining lymph nodes, where the spores germinate intracellularly. The vegetative form of the organism escapes the macrophage and ultimately proliferates to high levels in the bloodstream [14]. The bacteria release a tripartite toxin, known as anthrax toxin, that is thought to be responsible for many of the manifestations of the disease. Anthrax toxin is composed of three proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF), which are believed to act together to produce disease symptoms (reviewed in [16]). A schematic diagram of the mechanism of action of anthrax toxin is shown in Figure 24.1. PA released from the bacterium binds its target eukaryotic cell; a portion of the PA protein is cleaved by a eukaryotic protease, allowing PA to oligomerize into a heptamer and to bind to LF and/or EF proteins. A conformational change is believed to take place as the complex is internalized by the cell, which allows PA to deliver LF and EF to the cytoplasm of the cell. These proteins have catalytic activities that alter critical cellular processes. LF is a metalloprotease that cleaves mitogen-activated protein kinase kinases; other, as yet to be discovered substrates, may also play a role in LF action. EF is a potent adenylate cyclase that raises cAMP to supraphysiologic levels within eukaryotic cells. Mechanisms of immunity against this organism have not been clearly defined. However, the key role of anthrax toxin in the disease process would suggest that antitoxin antibodies might play a role in protection. This hypothesis is supported by the finding that anti-PA antiserum provides passive protection against B. anthracis challenge in mice and guinea pigs [17–19]. Although antibiotics are clearly effective against non-engineered strains of B. anthracis when given early [20], anthrax vaccines can provide prophylaxis against the disease, including (in theory) antibiotic-resistant strains. Anthrax vaccines have a long history, beginning with Louis Pasteur in 1881, who protected sheep against anthrax by injecting them with heat-attenuated B. anthracis cultures. The spore form of the Sterne strain, an attenuated strain that has lost one of the two plasmids necessary for virulence, has been in use as a veterinary vaccine since the 1930s [21]. Although live at-

24.4 Vaccination against Anthrax

y n od t i o tib z a an t r a l i u ne

PA

LF or EF

proteolysis

oligomerization

association

receptor

endocytosis

Mammalian cell

LF

EF

Fig. 24.1 Anthrax toxin and protective immunity. PA binds to the target eukaryotic cell and then oligomerizesafter proteolysis. LF and/or EF can then bind to the PA heptamer. The complex undergoes endocytosis, resulting in a conformational change that allows introduction of LF and EF into the cytoplasm of the cell, where their catalytic activities are expressed. New-generation anthrax vaccines target PA. Antibodies to PA are capable of neutralizing its activity, thereby blocking the toxic process.

tenuated spore vaccines have been used for anthrax prophylaxis in humans in Russia [22], both the US and UK human vaccines consist of aluminum adjuvant-adsorbed culture supernatant from a toxigenic, nonencapsulated strain. Both these vaccines contain PA as a major component [23, 24]. A similar vaccine was tested in a field trial in the 1950s and was shown to protect against anthrax disease [25]. New-generation anthrax vaccines will likely be based on PA, although other antigens, such as spore-associated antigens, might provide additional protection [26]. Novel anthrax vaccine candidates include purified recombinant PA, live-attenuated vectors capable of producing PA [23], and DNA vaccines based on PA [27]. The U.S. government is putting forth considerable money and effort to rapidly develop a nextgeneration anthrax vaccine. For example, in October 2002, the National Institutes of Health awarded contracts to two companies to develop vaccines based on purified recombinant PA in an expedited manner (http://www.niaid.nih.gov/newsroom/releases/anthraxvacc.htm).

535

536

24 Vaccines against Bioterror Agents

Progress has been made in understanding the disease and immunity to the organism, but knowledge is still incomplete. Of particular importance is the elucidation of immune mechanisms, which will require the development and refinement of an appropriate animal model. The model of inhalation anthrax that best approximates the human disease is generally believed to be the rhesus macaque, in that the pathology is similar to that seen in humans [28]. However, because of the limited availability of these nonhuman primates, additional animal models will need to be utilized. The rabbit may be a useful model for certain purposes, since the pathology of the disease in the rabbit is similar to that in humans and rhesus macaques [29]. Less reflective of the human disease, but perhaps still useful for certain purposes, are guinea pig and mouse models.

24.5 Vaccination against Plague

The bacterium responsible for the Black Death, Yersinia pestis or plague, caused human pandemics in the 6th, 14th, and 19th centuries that resulted in the deaths of at least 30 million people. The virulence of this organism, and the social fear associated with plague for hundreds of years, have long suggested its use as a biological weapon. Indeed, there are several historical examples of such use, ranging from catapulting plague victims over city walls in the Middle Ages to dropping plague-infected fleas on civilian populations during World War II [30, 31]. Changes in living conditions and resulting decreased contact with animals bearing infected fleas have led to dramatic declines in bubonic plague infection, but Y. pestis remains a zoonotic disease that is endemic in some areas [32]. This gram-negative coccobacillus can infect people via either flea bites or by person-to-person aerosol exposure. Infection via flea bite causes a sudden onset in about 2–8 days of nonspecific systemic symptoms including fever, chills, and fatigue, characteristic formation of ‘bubos‘, and eventually, gangrene and pneumonia. Y. pestis infection acquired by aerosol results in the development of severe pneumonia and sepsis very quickly, within 2 to 4 days. Plague can be successfully treated with antibiotics if diagnosed promptly, but the prognosis for the pneumonic form of the disease, which progresses rapidly, is particularly poor. A successful outcome depends heavily on diagnosis and/or empirical initiation of therapy within about 18 h of the appearance of symptoms. Much attention is therefore now being directed at development of improved rapid diagnosis. The pathogenesis of plague infection is complex, with several virulence factors that are the subject of ongoing study. Indeed, it was through the study of Yersinia that the importance of Type III secretion systems was first recognized. Virulence factors include the LPS of the bacterium, as well as proteins, including the capsule antigen (F1),V antigen, a surface plasminogen activator protease (Pla), the Yersinia outer proteins (Yops), and the Ybt and Yfe iron-acquisition mechanisms. All collectively contribute to pathogenesis by permitting bacterial acquisition of nutrients necessary for survival and replication, by inflicting damage on host cells, and by allowing avoidance of phagocytosis and macrophage-mediated killing [33]. The immunology

24.5 Vaccination against Plague

of plague infection has been studied in animal models such as mice, rats, and guinea pigs, and to a much lesser degree in primates. Although Yersinia pestis can invade macrophages, it is predominantly an extracellular bacterium, with antibodies being much more important in protective immune responses than cell-mediated effector functions [34]. Nonetheless, a role for cell-mediated immunity has been suggested in several experimental circumstances. As might be expected for a disease that has long figured so prominently in causing human deaths, vaccination for protection against Yersinia pestis infection has a long history. Both live attenuated and killed whole-cell vaccines have been used, but neither has been subjected to controlled clinical trials [35]. In the USSR, and now in Russia and other republics of the former Soviet Union, a live attenuated vaccine designated EV76 was used for most of the 1900s and is still produced. This pgm mutant of virulent Y. pestis is clearly greatly reduced in virulence compared to the parent bacterium and likely affords at least some protection against both systemic and pneumonic infection; however, the vaccine has notable reactogenicity, and safety concerns remain. In the early 1900’s, a formalin-killed whole-cell vaccine was developed from virulent Y. pestis, and the U.S. Army developed a similar vaccine for use in World War II [36]. This vaccine was administered as three doses over six months, and circumstantial evidence suggested efficacy against systemic bubonic plague infection [37]. However, little protection was observed in mice following aerosol plague exposure [38], and persons immunized with this killed vaccine have presented later with pneumonic plague infection [35]. Manufacture of this vaccine in the U.S. was discontinued in 1998; a similar vaccine is still produced in the United Kingdom. Although antibodies to the various virulence factors and to the LPS have been observed after both infection and immunization with purified antigens, only antibodies to the F1 and V antigens have been associated with protection against systemic (bubonic) and aerosol challenge [35]. Despite the observations that transfer of antibodies to F1 and/or V antigen to naive animals provides protection against Y. pestis challenge in several experimental models, efforts to establish clear antibody-based correlates of protection after active vaccination are ongoing, and results are not entirely straightforward. Nonetheless, F1 and V proteins, either in combination or expressed as a fusion protein, are under active study as components of new-generation subunit vaccines both in the U.S. and in U.K., and two such candidates are nearing human clinical trials [39]. Other approaches to further develop subunit plague vaccines that include additional antigens, other adjuvants, and other delivery methods are at the research level. Additional information on pathogenesis and virulence factors and on immune correlates of protection will be helpful. Enhancements of the subunit vaccines are clearly needed to ensure robust protection against a Y. pestis strain that lacks the capsule F1 antigen. Although several well characterized animal models of plague infection exist, none is ideal, and further refinements, particularly of Yersinia infection in nonhuman primates, will also continue to be of interest.

537

538

24 Vaccines against Bioterror Agents

24.6 Vaccination against Tularemia

Francisella tularensis is unfamiliar even to many microbiologists, despite its ability to infect and causes disease in a wide variety of mammals. Francisella can also be harbored by insect vectors such as ticks. People contract tularemia by contact with these infected vector animals; in contrast to agents such as smallpox or plague, there are no known cases of person-to-person transmission. Although this may not be the ideal scenario for a bioterror weapon, exposure to small numbers of one of the two major biotypes of F. tularensis, Type A or subspecies tularensis, results in a severe acute disease that is often fatal [40]. The virulence of Type A, coupled with the fact that tularemia can be acquired by inhalation, is presumably the attraction in the bioweapon arena. Indeed, it has been reported that tularemia has been developed as a biological weapon in both Japan and the USSR [41]. Although the nonspecific symptoms such as fever, lymphadenopathy, and fatigue caused by F. tularensis infection often delay prompt diagnosis, tularemia can be successfully treated by antibiotics when diagnosis is timely. Immunotherapeutic approaches and therapeutic vaccination have not been studied. Tularemia was a clinical problem of modest prevalence, in the U.S. as well as in other parts of the world such as Scandinavia and the former Soviet Union, for the first half of the 20th century. After World War II, rates of the disease declined steadily, and thus neither the disease nor the bacterium has received much recent attention. Most of what is known about F. tularensis today derives from older literature or from study of a live attenuated vaccine strain (LVS) in animals as a model intracellular pathogen. F. tularensis is the only intracellular Category A microbe, and because it is an intracellular bacterium, it presents special problems in developing vaccines. To date, relatively little is understood about the pathogenesis of Francisella infection. The capsule remains the only classically identified virulence factor [42]. No secreted toxins or other protein virulence factors of F. tularensis have been identified, and although all strains have an LPS, the molecule for all practical purposes lacks traditional endotoxic activity [43]. Several genes that contribute directly or indirectly to the ability of Francisella to grow in macrophages and thereby to virulence have been identified, including a two-cistron operon, mglAB [44], and a 23-kDa protein of unknown function [45, 46]. However, it is likely that a number of the disease manifestations result from collateral damage from the host immune response to infection. Rather more is known about the immunology of Francisella infection [40, 47]. F. tularensis appears to be a classic intracellular bacterium that provokes a strong innate immune response followed by activation of specific effector T cells, which appear to be largely responsible for long-term and memory responses to the bacterium (Figure 24.2). The specific effector functions provided by T cells are the subject of ongoing study, and include at least elaboration of interferon gamma for activation of macrophages with resulting control of the macrophages‘ intracellular burden. However, a variety of experimental approaches indicate that, although interferon gamma is likely to be necessary for protective immune responses, it is unlikely to be sufficient [48, 49], and thus its utility as a correlate (at least by itself) is doubtful.

24.6 Vaccination against Tularemia

Innate

Specific

MyD88 TNF Other?

Mac IFN

NK?

PMN

CD4, CD8 T cells: IFN, TNF, ?

IL12 p40

B-1 B cells: Natural Ab?

B-2 B cells: Anti-LPS Abs

Fig. 24.2 Elements of immunity to Francisella tularensis. In animal models (most of which use the Live Vaccine Strain of F. tularensis), Francisella infection elicits a strong innate immune response. Macrophages and neutrophils are required for initial responses, but the role of dendritic cells has not been directly examined to date. The role of natural killer cells has not been well studied, but there is some evidence that neither conventional NK cells nor NK T cells are major contributors to innate immunity to Francisella. Both interferon gamma (IFN) and tumor necrosis factor alpha (TNF) are required for initial survival, but the exact cellular sources of these mediators remain to be determined (‘ other’). IL12 p70 is produced by Francisella-infected macrophages, but in animal models only IL12 p40 is required for bacterial clearance. Several relatively minor roles for B cells are likely, including B cell-dependent production of both ‘ natural‘ and specific antibodies (the majority of which are directed against the LPS of the bacterium), as well as antibody-independent functions of B cells such as chemokine production. The majority of longterm control of Francisella clearly depends on ab+ T cells,with roles for both CD4 + and CD8+ T cells being important. T cell production of IFN appears necessary but not sufficient for protection, and current research is directed at elucidating other correlates, such as T cell-derived TNF.

As for many other intracellular pathogens, animal and human studies have strongly indicated that killed whole cell Francisella vaccines do not provide appreciable protection against tularemia [40, 50]. In contrast, the Soviet Union derived and has long used a variety of live attenuated strains of F. tularensis as human vaccines, with apparent success, as evidenced by significant impact on the epidemiology of disease [51]. In the U.S., the Live Vaccine Strain or LVS was derived from a mixture of live attenuated Russian strains by further passage through mice [52]. LVS has been used in the U.S. as an investigational vaccine, but it is not licensed for general use, and its specific efficacy and safety profiles have not been well established. Although the appeal of LVS is currently limited by lack of understanding of the genetic basis of its attenuation and lack of well defined correlates of protection, in the U.S. it remains the only realistic current vaccine candidate. As may be evident from the above discussion, pathogenic mechanisms of Francisella infection remain poorly understood, and progress on this point is hampered

539

540

24 Vaccines against Bioterror Agents

by the paucity of tools for efficient genetic manipulation of F. tularensis. Although rather more has been learned about the immunology of Francisella infection, no clear correlates of protection have been identified, and it is fairly clear that specific antibody responses are not useful correlates [40, 50, 53]. Studies in rhesus macaques and cynomolgous monkeys have been described [54, 55], indicating that these nonhuman primates are susceptible and suffer a disease process that appears similar to that in humans. However, these efforts have not risen to the level of providing a well characterized nonhuman primate model of Francisella infection. Further progress in vaccine development will require stronger basic knowledge on all of these fronts.

24.7 Vaccination against Botulinum Toxin

The botulinum toxins are the most poisonous compounds known to humans and can be lethal at concentrations estimated to be as low as one nanogram per kilogram of body weight. Because of their extreme toxicity and the relative ease with which they can be produced, the toxins are considered likely candidates for use as biological weapons [56, 57]. The botulinum toxins, of which there are seven serotypes designated A–G, are elaborated by various strains of Clostridium botulinum, a gram-positive, spore-forming, anaerobic bacterium that can contaminate improperly processed food. Botulism is now rare, with only 25–30 cases of foodborne disease reported annually in the United States. Although foodborne botulism is perhaps the best known form of the disease, the incidence of two other less familiar forms, wound botulism and infant botulism, has recently increased in the United States. The initial clinical signs of botulism include general fatigue, blurred vision, and difficulty in speaking and swallowing. These may be followed by a symmetric descending flaccid paralysis, and in severe untreated cases death ensues due to asphyxiation caused by paralysis of muscles required for respiration. The mortality associated with botulism has declined dramatically in recent years, from a rate of 25 % in the 1950s to approximately 5 % by the late 1990s. This reduction is due to improved therapy for botulism, which primarily involves supportive care and prompt administration of a botulinum equine antitoxin. Botulinum toxin serotypes A, B, E and F are associated with human disease, and types C and D primarily cause botulism in animals. Recent studies have demonstrated that primates are sensitive to all the botulinum toxins, which strongly suggests that humans are also susceptible to all seven antigenic types [57]. The toxins are synthesized as 150 kDa single-chain polypeptides. The polypeptides are subsequently nicked to produce an enzymatically active 50-kDa N-terminal domain that is linked by a disulfide bond to the 100-kDa C-terminal region, which is required for binding to neuronal cells and for intracellular translocation (Figure 24.3). The Nterminal region has a Zn-dependent protease activity that cleaves presynaptic vesicle proteins at the neuromuscular junction; release of the neurotransmitter acetylcholine is subsequently inhibited, resulting in paralysis.

24.7 Vaccination against Botulinum Toxin

S

S

Hc

NH3

COOH Protease activity

50-kDa Light Chain

Translocation domain

Binding domain

100-kDa Heavy Chain

Fig. 24.3 Botulinum toxin structure. The toxins are synthesized as 150-kDa single-chain polypeptides that are subsequently nicked into a heavy chain and a light chain, which remain linked by a disulfide bond. The light chain contains a Zn-dependent protease activity, and the 100-kDa heavy chain is required for translocation and receptor binding. The 50-kDa Hc receptor-binding region is the focus of future vaccine development. Immunization of animals with the Hc domain results in production of toxin-neutralizing antibodies and confers protection against neurotoxin challenge.

The Pentavalent Botulinum Toxoid vaccine (PBT), composed of formalin-inactivated and partially purified botulinum toxin serotypes A–E, is the only candidate currently being studied for protection against botulism in the U.S. PBT has been administered to almost 6000 laboratory workers and military personnel over the past 30 years in studies conducted under Investigational New Drug Applications [58]. Efficacy trials for the vaccine have not been done and are not considered practical, due to the rare occurrence of botulism, and human challenge studies are unethical due to the extreme toxicity of the toxins. Nevertheless, animal immunization studies have indicated that the vaccine is protective against challenge with the five toxin serotypes, and anti-botulinum toxin antibodies alone are sufficient to provide protection against the disease [57, 58]. A 1996 FDA advisory committee addressed the issue of efficacy for the PBT vaccine and considered it reasonable to conduct surrogate efficacy studies in animals in lieu of human clinical trials. The PBT vaccine is not currently manufactured, and there is significant interest in producing a second-generation vaccine. Research into the development of new vaccines against botulism has focused on several areas, including the construction and testing of recombinant nontoxic fragments that contain only the 50-kDa C-terminal receptor-binding region (Figure 24.3), known as the Hc fragment [59, 60]. Mice immunized with the Hc fragment are protected against challenge with high levels of the neurotoxins [59]. Current efforts involve over-expression and purification of the Hc region from several toxin serotypes in the Pichia pastoris yeast expression system [58, 61]. Other studies for development of new botulism vaccines have examined the effectiveness of inactive holotoxin [62], antigenic peptides from the Hc domain [63], and DNA vaccines [64].

541

542

24 Vaccines against Bioterror Agents

24.8 Vaccination against Category B and C Pathogens

The pathogens belonging to Categories B and C comprise wildly diverse groups, and a thorough treatment of the vaccination status for each is beyond the scope this chapter. The only vaccine licensed in the U.S. for any of these pathogens is Ty21A, for protection against Salmonella infection. Vaccines for Shigella, Q fever, staphylococcal enterotoxin B, and cholera are under active investigation. Brucella vaccines have been developed and used widely in animals, but only in China for humans. Vaccines for others, such as Burkholderia or Clostridium perfringens toxin, have not seriously advanced beyond the research level.

24.9 Vaccine Development and Regulation for ‘Low-incidence’ Pathogens, including Bioterror Pathogens and Emerging Diseases

Current development of new licensed vaccines, particularly in societies such as the United States, is notably more complex than even a decade or two ago. The historical model amounted to finding vaccine candidates by empirically testing killed virulent organisms or deriving attenuated strains, without a corresponding basic understanding of the disease pathogenesis or the nature of a relevant protective immune response. This approach is rapidly being replaced by taking advantage of better basic science knowledge combined with genetic engineering. Issues of high quality and consistent manufacture, ever-increasing public expectations of vaccine safety, profitability, and liability compound the process. In the U.S., vaccine testing now proceeds through carefully defined investigational phases in specific patient populations (the well known Phase 1 and 2 clinical trials to evaluate safety and immunogenicity and Phase 3 trials to evaluate effectiveness). Issuance of a license, which permits distribution of and access to a vaccine by the public through health care practitioners, follows FDA scrutiny, not only of clinical trial data, but also of the quality and appropriateness of manufacturing methods, of quality control testing, of facilities and equipment used, and of consistency of manufacture [65]. The decision to license a vaccine in the U.S. ultimately rests on overall demonstration of a clear expectation of benefits to the vaccinated individual, compared to any associated risks. All these considerations continue to be of interest, and necessary, for development of vaccines against those pathogens that might rarely cause disease in nature. Expectations for extensive clinical trial testing to evaluate human safety in particular will no doubt remain high. It is obvious, however, that the low incidence of natural disease greatly limits the ability to design an appropriate Phase 3 efficacy trial. One possible solution to this difficulty may be human challenge studies, which have been considered ethical in some circumstances; for example, cholera vaccines have been tested using controlled human challenge with Vibrio cholera, because cholera can be reliably treated with appropriate rehydration and antibiotic therapies [66]. There are many circumstances in which human challenge studies (for instance, with viral

24.10 Perspectives

pathogens for which no treatment is available) are not applicable, however. This reality was recently addressed in the U.S. by the promulgation of new regulations, colloquially known as the ‘Animal Rule’ (21 CFR part 314, subpart I, and part 601, subpart H). These regulations were designed to facilitate evaluation of new drugs, including vaccine-induced protection, in animal models rather than in human subjects. Because such an evaluation can never be ideal, several important considerations must be addressed and conditions satisfied. Thus, when field trials are not possible or human challenge studies are not ethical, the FDA may rely on animal data when (1) there is a reasonably well understood mechanism of disease pathogenesis and mechanism of disease prevention; (2) a vaccine candidate can prevent disease in animal species that are relevant to human disease; (3) an animal study can be designed with an endpoint that is obviously related to the expected benefit in humans, such as prevention of death or major morbidity; and (4) the animal model(s) permit selection and extrapolation of a dose to be used in humans. These requirements obviously place a high premium on a strong knowledge base and on the availability of relevant animal models (usually including nonhuman primates) for each pathogen under consideration. Of particular note is the value of correlates of protection in the animal model that could be invoked to evaluate the likelihood of protection in humans. This knowledge is currently often lacking for the low-incidence pathogens; indeed, among the Category A pathogens discussed here, only the mechanism of protection against botulinum toxin is well established. In contrast, even after years of positive experience with vaccinia, no real understanding of its mechanism of protection has been developed.

24.10 Perspectives

As suggested by the discussion above, there remains a strong need for basic research that illuminates the pathogenesis and immunology of these, and many other, infectious disease agents. The dread invoked by the prospect of someone inflicting deliberate harm on other people by using microbial pathogens, although clearly a source of fear, has a possible silver lining. Many of the suggested pathogens, including the ones discussed here, continue to cause disease the old-fashioned way, via natural exposure. Globally, human suffering caused by infectious diseases such as tuberculosis and malaria remains an enormous public health challenge. The increased scientific understanding that comes with the heightened awareness of the bioweapon pathogens will hopefully yield completely new strategies, such as nonspecific immunomodulation, that leapfrog traditional vaccination or treatment approaches. Such strategies will no doubt have more broadly applicable utility than as responses to bioterror events per se. Even more generally, the increased attention and resources should yield new insights on global pathogenic and host response mechanisms. The associated scientific disciplines of microbial pathogenesis and immunology were already poised to make great interrelated strides. Development of tools for manipulating bacteria, animals, and components of the mammalian immune system have matured suffi-

543

544

24 Vaccines against Bioterror Agents

ciently to be directly applicable to the study of infectious diseases and to permit elegant experimentation. Given the potential for development of synthetic pathogens that may be even more difficult to control than the ones nature provided, good science, and the application of good scientific judgement, will be as important in the future as it has been to date.

Acknowledgements

We are grateful to our CBER colleagues, Dr. Karen Goldenthal and Dr. Norman Baylor, and to Dr. Susan Straley (University of Kentucky, Lexington, KY, USA) for their careful and thoughtful critique of the manuscript and many valuable suggestions for its improvement. References 1. F. Fenner, D. Henderson, I. Arita, et al., Smallpox and Its Eradication, World Health Organization, Geneva, 1988. 2. D. A. Henderson, Science, 1999, 283, 1279–1282. 3. D. A. Henderson, Emerg Infect Dis, 1998, 4, 488–492. 4. J. G. Breman, D. A. Henderson, N Engl J Med, 2002, 346, 1300–1308. 5. D. A. Henderson, T. Inglesby,V, J. G. Bartlett, et al., JAMA, 1999, 281, 2127–2137. 6. S. R. Rosenthal, M. Merchlinsky, C. Kleppinger, et al., Emerg Infect Dis, 2001, 7, 920–926. 7. M. Enserink, R. Stone, Science, 2002, 295, 2001–2005. 8. L. Borio, T. Inglesby, C. J. Peters, et al., JAMA, 2002, 287, 2391–2405. 9. S. Baize, P. Marianneau, M. C. Georges-Courbot, et al., Curr Opin Infect Dis, 2001, 14, 513–518. 10. J. A. Wilson, C. M. Bosio, M. K. Hart, Cell Mol Life Sci, 2001, 58, 1826–1841. 11. J. I. Maiztegui, K. T. McKee Jr., J. G. Barrera Oro, et al., J Infect Dis, 1998, 177, 277–283. 12. S. P. Fisher-Hoch, J. B. McCormick, Rev Med Virol, 2001, 11, 331–341. 13. N. J. Sullivan, A. Sanchez, P. E. Rollin, et al., Nature, 2000, 408, 605– 609. 14. M. Mock, A. Fouet, Annu Rev Microbiol, 2001, 55, 647–671.

15. P. S. Brachman, A. F. Kaufman, F. G. Dalldorf, Bacteriol Rev, 1966, 30, 646– 659. 16. M. Mourez, D. B. Lacy, K. Cunningham, et al., Trends Microbiol, 2002, 10, 287–293. 17. S. F. Little, B. E. Ivins, P. F. Fellows, et al., Infect Immun, 1997, 65, 5171– 5175. 18. D. Kobiler,Y. Gozes, H. Rosenberg, et al., Infect Immun, 2002, 70, 544–560. 19. R. J. Beedham, P. C. Turnbull, E. D. Williamson,Vaccine, 2001, 19, 4409– 4416. 20. V. P. Hsu, S. L. Lukacs, T. Handzel, et al., Emerg Infect Dis, 2002, 8, 1039– 1043. 21. S. H. Leppla, J. B. Robbins, R. Schneerson, et al., J Clin Invest, 2002, 110, 141–144. 22. A. V. Stepanov, L. I. Marinin, A. P. Pomerantsev, et al., J Biotechnol, 1996, 44, 155–160. 23. L. Baillie, J Appl Microbiol, 2001, 91, 609–613. 24. A. M. Friedlander, P. R. Pittman, G. W. Parker, JAMA, 1999, 282, 2104– 2106. 25. P. S. Brachman, H. Gold, S. A. Plotkin, et al., Am J Public Health, 1962, 52, 632–645. 26. S. Cohen, I. Mendelson, Z. Altboum, et al., Infect Immun, 2000, 68, 4549– 4558.

References 27. M.-L. Gu, S. H. Leppla, D. M. Klinman,Vaccine, 1999, 17, 340–344. 28. D. L. Fritz, N. K. Jaax,W. B. Lawrence, et al., Lab Invest, 1995, 73, 691–702. 29. G. M. Zaucha, L. M. Pitt, J. Estep, et al., Arch Pathol Lab Med, 1998, 122, 982–992. 30. G. W. Christopher, T. J. Cieslak, J. A. Pavlin, et al., JAMA, 1997, 278, 412– 417. 31. T. Inglesby,V, D. T. Dennis, D. A. Henderson, et al., JAMA, 2000, 283, 2281– 2290. 32. R. D. Perry, J. D. Fetherston, Clin Microbiol Rev, 1997, 10, 35–66. 33. G. R. Cornelis, Proc Natl Acad Sci USA, 2000, 97, 8778–8783. 34. A. M. Friedlander, S. L. Welkos, P. L. Worsham, et al., Clin Infect Dis, 1995, 21 Suppl 2, S178–181. 35. R. W. Titball, E. D. Williamson, Vaccine, 2001, 19, 4175–4184. 36. K. F. Meyer, D. C. Cavanaugh, P. J. Bartelloni, et al., J Infect Dis, 1974, 129, Suppl, S13–18. 37. D. C. Cavanaugh, B. L. Elisberg, C. H. Llewellyn, et al., J Infect Dis, 1974, 129, Suppl, S37–40. 38. P. Russell, S. M. Eley, S. E. Hibbs, et al.,Vaccine, 1995, 13, 1551–1556. 39. E. D. Williamson, J Appl Microbiol, 2001, 91, 606–608. 40. A. Tarnvik, Rev Infec Dis, 1989, 11, 440–451. 41. D. T. Dennis, T. V. Inglesby, D. A. Henderson, et al., JAMA, 2001, 285, 2763–2773. 42. A. M. Hood, J Hygiene, 1977, 79, 47–65. 43. P. Ancuta, R. Pedron, R. Girard, et al., Infect Immun, 1996, 64, 2041–2046. 44. G. S. Baron, F. E. Nano, Molecr Microbiol, 1998, 29, 247–259. 45. C. Gray, S. Cowley, K. Cheung, et al., FEMS Microbiol Lett, 2002, 215, 53–56. 46. M. Telepnev, I. Golovliov, T. Grundstrom, et al., Cell Microbiol, 2003, 5, 41– 51. 47. K. L. Elkins, S. C. Cowley, C. M. Bosio, Microbes Infect, 2003, 5, 135–142.

48. K. L. Elkins, A. Cooper, S. M. Colombini, et al., Infect Immun, 2002, 70, 1936–1948. 49. A. Sjostedt, R. J. North, J. W. Conlan, Microbiology, 1996, 142, 1369– 1374. 50. L. Foshay, Annu Rev Microbiol, 1950, 4, 313–330. 51. G. Sandstrom, J Chem Techn Biotechnol, 1994, 59, 315–320. 52. H. T. Eigelsbach, C. M. Downs, J Immunol, 1961, 87, 415–425. 53. K. L. Elkins, C. M. Bosio, T. R. Rhinehart-Jones, Infect Immun, 1999, 67, 6002–6007. 54. R. L. Schricker, H. T. Eigelsbach, J. Q. Mitten, et al., Infect Immun, 1972, 5, 734–744. 55. J. D. White, J. R. Rooney, P. A. Prickett, et al., J Infect Dis, 1964, 114, 277– 283. 56. J. L. Middlebrook, D. R. Franz, Botulinum Toxins, Office of the Surgeon General, Washington, DC, 1997. 57. S. S. Arnon, R. Schechter, T. Inglesby, et al., JAMA, 2001, 285, 1059– 1070. 58. M. P. Byrne, L. A. Smith, Biochimie, 2000, 82, 955–966. 59. M. A. Clayton, J. M. Clayton, D. R. Brown, et al., Infect Immun, 1995, 63, 2738–2742. 60. C. Montecucco, G. Schiavo, O. Rossetto, Arch Toxicol Suppl, 1996, 18, 342–354. 61. M. P. Byrne, T. J. Smith,V. A. Montgomery, et al., Infect Immun, 1998, 66, 4817–4822. 62. N. Kiyatkin, A. B. Maksymowych, L. L. Simpson, Infect Immun, 1997, 65, 4586–4591. 63. S. Bavari, D. D. Pless, E. R. Torres, et al.,Vaccine, 1998, 16, 1850–1856. 64. J. Clayton, J. L. Middlebrook,Vaccine, 2000, 18, 1855–1862. 65. L. A. Falk, L. K. Ball,Vaccine, 2001, 19, 1567–1572. 66. M. M. Levine, F. Noriega, P N G Med J, 1995, 38, 325–331.

545

Part VI Vaccines in the Real World: Safety, Cost Efficiency and Impact of Vaccination

549

25 Imperfect Vaccines and the Evolution of Pathogen Virulence Paul W. Ewald

25.1 Introduction

Throughout the past century, vaccination programs have been formulated to protect individuals and populations primarily by protecting people from infection. It is increasingly being recognized that the focus on protection from infection is misplaced, for two related reasons. The first is that vaccines, even successful ones, often are imperfect; that is, they may protect people from disease but not from infection. If so, measurements of infection are not as relevant as measures of morbidity and mortality. The second reason is that vaccination programs may influence the evolution of the pathogen’s virulence, that is, the inherent harmfulness of the disease organism. When a pathogen is eradicated globally, distinction between the incidence and the harmfulness of infection is a moot point – when no pathogens remain to be transmitted, it does not matter whether the pathogen was more harmful or less harmful prior to eradication. When the target organism is not eradicated, however, the distinction is important, because the vaccination program itself may cause an evolutionary change in the target organism, making it more or less harmful than it was at the inception of the vaccine program. When an antigen is used in a vaccine, any variant that is immunologically distinct from the antigen or that does not express the antigen at all will be controlled less well by the vaccination program than those pathogens that express that vaccine antigen. This process can lead to vaccine escape, whereby the variant that is less well controlled by the vaccine increases in frequency during the course of the vaccine program. This evolutionary consideration is important, because vaccination programs generally do not eradicate target pathogens. At the global level, only the smallpox vaccine has eradicated the target organism. Failure to eradicate pathogens occurs because vaccines are imperfect and vaccine coverage of the population is inadequate. The potential for substantial evolution over a time scale of years results largely from the ability of pathogen populations to multiply and evolve rapidly. Rapid multiplication allows pathogens to spread from small numbers of infected individuals throughout groups in which control efforts are weak. Rapid growth, along with rapid generation of genetic variation by mutation and genetic recombination, may allow pathogens to

550

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

evolve around vaccine-acquired immunity and spread through vaccinated or previously infected populations. Vaccination programs therefore need to consider the genetic malleability of target pathogens at the outset to adequately evaluate alternative strategies for controlling the pathogens. When the target pathogen is prone to genetic variation, control strategies especially need to consider the evolutionary effects of vaccination on the target organism. When eradication does not occur, a thorough assessment of the effectiveness of the vaccine program must consider not only the frequency but also the virulence of the pathogens that are left in the wake of the vaccination program. If the vaccination causes an evolutionary reduction in the virulence of the target, the program will tend to be considered particularly successful, for several reasons. The most obvious reason is that mild variants cause less damage to those who are not vaccinated or who develop insufficient immunity in response to vaccination. Even in countries with good vaccination programs, a substantial number of people may remain unvaccinated because of personal choice or reduced investments in vaccination programs. In the United States, for example, standard vaccination coverage of children varied between 70 % and 98 % during the late 1970s and early 1980s [89]. Vaccination programs may also be curtailed as a result of changing public opinion or sociopolitical turmoil. Whatever the cause of incomplete coverage, evolutionary reductions in the virulence in response to vaccination will increase the chances that the infections that continue to occur will be mild. An indirect benefit is that circulating mild variants may act as free live vaccines by stimulating immunity that protects against virulent variants that arise by mutation or enter from other areas. The circulating benign strains may therefore protect the population as a whole against the spread of more harmful strains. Recent theory about the evolutionary effects of vaccination suggests that the imperfect nature of vaccines could favor increased or decreased virulence [31, 32]. This theory, however, treats pathogen virulence as though it could be turned up or down to accommodate vaccine-induced suppression of virulence. This may be true for some pathogens, but it is perhaps more likely that pathogens may not have the option to elevate expression of molecules sufficiently to overcome an immune response that has already honed in on it. If so, targeting the virulence antigens places the pathogens that encode them at a selective disadvantage relative to pathogen variants that do not encode them. The evolutionary result would be a reduction in pathogen virulence [26, 27]. This process can be incorporated into a virulence-antigen strategy for the generation of vaccines. This strategy dictates that vaccines should be based on virulence antigens, that is, those antigens that make mild but transmissible organisms harmful (Figure 25.1, right). In contrast, the traditional approach to vaccine development selects antigens on the basis of the protection conferred to study subjects, regardless of whether the antigens are virulence antigens (Figure 25.1, left). By selectively suppressing the virulent variants, virulence-antigen vaccines force the target pathogens to evolve toward benignity. The corollary of the virulence-antigen strategy is that antigens should be excluded from vaccines if they do not directly contribute to virulence and if they are present on both avirulent and virulent strains. The exclusion of such antigens improves the tendency of avirulent strains circulating

25.2 Virulence-antigen Vaccines against Bacteria Traditional strategy

Virulence antigen strategy

Safe Use antigens that broaden the spectrum of protection

Long-lasting immunity Inexpensive

Use virulence antigens

Fig. 25.1 Criteria for development of vaccines according to traditional strategies and the virulence-antigen strategy. Non-overlapping criteria occur because virulence-antigen criteria are based on evolutionary effects of the vaccine on the target organisms.

in the population to protect against virulent strains by favoring those benign strains that bear cross-reactive antigens, that is, just the strains that give the virulence antigen strategy its strength. Virulence antigens are often excellent candidates for vaccines according to traditional criteria; they have therefore occasionally been selected for vaccination programs without any consideration of their likely evolutionary effects. The programs that have used such vaccines provide inadvertent experiments, the first steps in assessing whether the virulence-antigen strategy does in fact cause evolutionary reduction in virulence as suggested above.

25.2 Virulence-antigen Vaccines against Bacteria 25.2.1 Corynebacterium diphtheriae

The best illustration of the virulence-antigen strategy is the diphtheria toxoid vaccine, which is based on a modified diphtheria toxin. The diphtheria toxin is encoded by a viral tox gene, which is repressed by a DNA-binding protein (DtxR) when iron is available. When iron is scarce, dissociation of iron and DtxR allows transcription of the tox gene. The toxin blocks protein synthesis elongation factor 2, causing host cell death [66, 67], which apparently liberates nutrients for C. diphtheriae’s use. By this mechanism, C. diphtheriae may generate resources for itself when resource are scarce [78, 79]. Accordingly, symptomatic C. diphtheriae infections are more contagious than asymptomatic infections [53]. In unimmunized people, the toxin therefore seems to provide its C. diphtheriae with a competitive benefit relative to C. diphtheriae that do not produce toxin. The immunological responses to the toxoid vaccine neutralize the toxin activity and thereby cause the toxin to be a net drain on the bacterium's nutrient budget. C. diphtheriae without the tox gene can still infect and be transmitted from both vac-

551

552

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

cinated and unvaccinated hosts [53]. The tox gene therefore meets the definition of a virulence antigen, namely, that it makes viable benign pathogens harmful. When vaccination prevents the negative effects of the toxin, the toxinless strains should have a competitive advantage over the toxigenic strains because the toxinless strains do not waste valuable resources producing an ineffective toxin. According to the evolutionary logic on which the virulence antigen strategy is based, the population of toxinless strains should increase relative to toxigenic strains wherever toxoid vaccines have been extensively administered. This transition is confirmed by the data [14, 67, 68, 87]. The most detailed data set came from the vaccination program administered in Romania from 1958 through 1972 (Figure 25.2). As the acquired immunity rose to 97 %, the percentage of isolates that were toxigenic dropped from 86 % to 3 %, and diphtheria vanished (Figure 25.2). If all of the costs of vaccine development and administration could be tallied and health benefits per dollar spent calculated, the control of diphtheria by the toxoid vaccine would surely be one of the most cost-effective vaccine programs ever conducted. Only the smallpox program would rank higher, that higher rank being attributable to global eradication, which allowed for abandonment of continuous vaccination. A comparison of the incidences of diphtheria and pertussis during the vaccination programs of the 20th century gives a sense of the cost effectiveness of the diphtheria program. In the United States, pertussis and diphtheria each affected about two people per 1000 during the 1920s, before vaccines were used [13, 13 a]. Vaccines for both pathogens had become generally available during the second quarter of the century and were incorporated into a single vaccination during this period. Vaccine coverage has therefore been virtually the same for these two diseases for most of the period during which vaccination programs against these two diseases have been in place. During the last quarter of the 20th century, the incidence of pertussis had declined in well-vaccinated populations to a level that was 100-fold less than the pre-vaccine

Fig. 25.2 Frequencies of diphtheria, toxigenic strains and immunity in the study population during the diphtheria immunization program in Romania. Morbidity percentages use the number of cases in 1958 as the denominator. Data are from Pappenheimer (1982).

25.2 Virulence-antigen Vaccines against Bacteria

incidence; but this incidence was still about 100-fold greater than the incidence of diphtheria [13, 13 a, 14, 16]. The few outbreaks of diphtheria that still occur in wellvaccinated regions are typically attributable to foreign travel or to limited circulation among small groups of people who have compromised states of health or live in poor, densely populated, urban areas [35, 44, 69]. This extraordinary success at longterm control of diphtheria is as expected from virulence-antigen strategy, because the disease is controlled, not just by the direct effects of the toxoid vaccine, but also indirectly through serological cross-reactivity between the benign, toxinless C. diphtheriae and toxigenic strains. The experience with diphtheria also illustrates the stability of control by a virulence-antigen vaccine in the face of temporary reductions in vaccine coverage. In the United States during the last quarter of the 20th century, about three-quarters of children and one-quarter of adults had protective immunity against diphtheria [14]. Yet, unlike the resurgence of pertussis when vaccination coverage has diminished [40, 56, 61, 72], a resurgence of diphtheria did not occur. The virtual eradication of diphtheria that occurs when vaccine coverage rises above 95 % (Figure 25.2) persists at substantially lower levels of coverage. Diphtheria has reoccurred only where vaccination has been dramatically reduced. In the Republic of Georgia, for example, diphtheria vaccination declined from 68 % in 1989 to 37 % in 1992; epidemic diphtheria returned in 1993 [77]. 25.2.2 Bordetella pertussis

For most of the 20th century, the standard vaccine against pertussis has been a suspension of killed Bordetella pertussis. The occasional negative effects associated with the vaccine [42] have led to the development of safer acellular vaccines. The pertussis toxin (PT) is largely responsible for protective immune responses and was therefore used as the basis for the first acellular vaccines. Because the severe effects of pertussis are largely attributable to this toxin, vaccines generated from deactivated toxin should control pertussis by the same evolutionary process described above for diphtheria. Virulent B. pertussis should be replaced with benign B. pertussis, which will naturally immunize people against any remaining virulent strains. The different vaccines control different strains of B. pertussis to different degrees [8 a]. This variation in the effects of different vaccines underscores the importance of a vaccine that selectively disfavors more-virulent variants of B. pertussis. Unfortunately, data from the literature do not allow for evaluation of whether the pertussis toxoid vaccine causes an evolutionary decline in the virulence of B. pertussis, because vaccination programs soon switched to acellular vaccines to which other antigens were added. B. pertussis produces an array of antigens that can be included in acellular vaccines. Besides PT, the major candidates are filamentous hemagglutinin (FHA), adenylate cyclase toxin (ACT), tracheal cytotoxin, dermonecrotic toxin, lippooligosaccharide endotoxins, agglutinogens, and pertactin [16]. Numerous studies have investigated various combinations and concentrations of these antigens in acellular vaccines, which often generated responses as good as or better than whole-cell vaccines

553

554

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

with fewer dangerous side effects [3, 28, 50, 71–73, 80, 83, 88]. The virulence-antigen strategy emphasizes, however, that the candidate antigens should be carefully evaluated, not just according to their contributions to short-term protection, but also on the basis of their contributions to virulence. FHA, for example, contributes to the infectious process by facilitating adherence to cells and by allowing entry and internal survival in macrophages [48, 89 a]. Although these characteristics foster infections by virulent B. pertussis, the characteristics themselves are apparently not harmful if the molecules that directly cause pathology (such as PT) are absent. FHA therefore probably does not qualify as a candidate for a virulence-antigen vaccine. It may even interfere with selective control of virulent strains when incorporated into a vaccine, because it can reduce the serological response to PT [3]. Studies of immunological responses to FHA, however, suggest that it could generate cross-protective immunity when present on benign strains. Respiratory IgG and IgA responses to FHA are long-lived following B. pertussis infection [2]; continued exposure to natural infections keeps anti-FHA IgG from waning [86]; and antibodies to FHA are particularly apparent in subclinical reinfections [49]. These findings indicate that long-lived resistance to pertussis is substantially maintained by infection-induced immunity. FHA immunity from mild infections appears to make an important contribution, but adding FHA to acellular vaccines may provide little if any extra short-term protection in the human population. In the context of the virulence-antigen strategy, this evidence suggests that pertussis may be better controlled if the FHA in acellular vaccines is replaced by a virulence antigen that provides similar short-term protection. Such a replacement would disfavor virulent B. pertussis in the population. The benign variants would thus be favored, and immune response to their FHA would protect against virulent B. pertussis. It is still unclear whether acellular vaccines that contain FHA or other components besides PT toxoid actually increase the protection against pertussis in human populations [85]. Long-term field trials comparing the different acellular vaccines are therefore warranted. Direct assessments of inherent virulence of different strains, such as measurements of PT production, are needed to determine whether B. pertussis becomes less virulent when PT vaccines are used than when whole-cell vaccines are used or when acellular vaccines incorporate antigens other than virulence antigens. The other B. pertussis antigens under consideration include several candidates for virulence-antigen vaccines. Adenylate cyclase toxin contributes to virulence by inhibiting phagocytes [16]. The major biochemical mechanism apparently results from cAMP accumulation in the host cell, resulting from catalysis of the breakdown of ATP [22]. Like diphtheria toxin, ACT is not essential for bacterial growth, but ACT – mutants grew to lower densities in a mouse model [22], suggesting that ACT may confer a competitive benefit when not neutralized by an immune response. ACT therefore is a good candidate for inclusion in virulence-antigen vaccine. The promise of the other antigens is unclear, but some contribute directly to virulence, at least in experimental settings. Pertactin may contribute to invasiveness and can trigger strong IgG responses in adults [23, 48]. Tracheal cytotoxin may inhibit ci-

25.2 Virulence-antigen Vaccines against Bacteria

lia movement, which probably helps the bacteria avoid being cleared from the respiratory tract; it also damages epithelial cells, apparently by inhibiting DNA synthesis [16, 89 a]. Dermonecrotic toxin causes skin necrosis in laboratory animals [16]. An evolutionary approach is particularly applicable to pertussis, because pertussis vaccines tend to prohibit disease but not infection [37, 49]. Even with high levels of vaccine coverage, B. pertussis continues to circulate [39]. Moreover, most damage by B. pertussis occurs in third-world countries [15], where intensive vaccination campaigns would be difficult. These factors indicate that chances for global eradication of B. pertussis by vaccination are remote. Virtual eradication of pertussis by virulenceantigen vaccines, however, should require less complete coverage (as with diphtheria) and is therefore a more realistic goal. The changes that occur during individual B. pertussis infections lend credence to the possibility of driving B. pertussis to a milder state by using vaccine-induced protection against virulence antigens. As infections proceed, avirulent mutants tend to increase in frequency. This tendency indicates that mutations leading to mild infections occur readily and can be selected for on the basis of immune responses against the virulence antigens [89 a]. Avirulent strains generated by this process revert back to virulent strains at a low frequency, apparently because sets of genes related to infections are controlled by a positive inducer locus (bvg), which experiences both deactivating and then restorative mutations [89 a]. This reversion to virulence, along with the tendency for both subclinical infection in the immunized and prolonged infection after clinical recovery, emphasize the need for a virulence-antigen strategy. Even a low frequency of reversion can represent a substantial input of virulent variants. A virulence-antigen strategy should present a more formidable barrier to spread of reverted strains by increasing the probability that unimmunized people will have developed a partial immunity due to colonization with mild strains. If the virulence antigens are selected against strongly, one would expect evolution of reduced tendencies to reversion, perhaps even evolutionary loss of the reversion mechanism. An analogous reduction in reversion to virulence has occurred in C. diphtheriae; it has become more refractory to the phage that encodes diphtheria toxin where toxoid vaccination has been maintained [51]. 25.2.3 Hemophilus influenzae

Like the diphtheria toxoid vaccine, the Hemophilus influenzae type b (Hib) vaccines have inadvertently conformed to the virulence-antigen criteria, and they too appear to have a disproportionately high effectiveness in suppressing severe disease. During the course of Hib vaccination, H. influenzae shifted from being an important cause of life threatening illness, particularly of bacterial meningitis, to a rare cause [1, 7, 9, 10, 21, 25, 60, 81]. During vaccine development, the polysaccharide antigen that comprises the type b capsule (polyribosyl ribotol phosphate, abbreviated PRP) was identified as a promising vaccine component, because type b H. influenzae has been responsible for the vast majority of invasive disease due to H. influenzae; it typically caused more than

555

556

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

95 % of invasive disease and 99 % of the disease caused by the six typeable strains [4, 8, 20, 33, 57, 90]. Simple PRP vaccines were introduced in the mid-1980s and were replaced with polysaccharide conjugate vaccines during the late 1980s and early 1990s. During this period, rates of invasive disease dropped precipitously, often even more so than expected as a direct result of protection by the vaccine [9 , 12, 25, 58, 59 70, 81]. Any direct effects of the vaccine would be enhanced by suppression due to competition between type b and other H. influenzae. Because Hib cross-reacts serologically with nontypeable H. influenzae [47], this competition may not be limited to simultaneous coinfection with competing strains. These interpretations are based on the idea that the Hib vaccines favored evolution toward less virulent H. influenzae variants. The available evidence supports this assumption. A multi-state study by the U.S. Centers for Disease Control [90] showed that the absolute frequency of invasive disease caused by type b strains declined between 1986 and 1989 as PRP vaccines were being introduced, but the frequency of disease caused by other capsular serotypes and nontypeable strains did not. A study of school children showed that use of conjugate vaccine reduced the frequency of Hib carriage, confirming that fewer sources of Hib were present after vaccination [59]. These findings indicate that the Hib vaccination program caused H. influenzae to evolve toward benignity through a disproportionate loss of type b genotypes.

25.3 Virulence-antigen Vaccines against Viruses

Although the above examples involve bacterial diseases, the virulence-antigen strategy is potentially applicable to any vaccination program. The most important step is discovery of virulence antigens. Viruses present a challenge, because their virulence is so intertwined with host characteristics that it can be difficult to distinguish virulence antigens from other antigens. Yet even among viruses, possibilities for control through virulence-antigen vaccines are apparent. Consider the human papillomavirus (HPV). The HPV serotypes that cause cervical cancer have two proteins that contribute to virulence by neutralizing the host biochemical defenses against cancer [29]. HPV's E6 protein binds to the cell's p53 protein, which guards against cancer by arresting cell division. It also interferes with cellular apoptosis [21 a] and therefore hampers the ability of the cell to protect the rest of the body by killing itself and the HPV that it contains. E7 blocks a second biochemical defense against cancer, the retinoblastoma protein. The lethality of cancer is as devastating to the virus as it is to the person, but the path leading to cancer is beneficial for the virus. It allows the papillomavirus to keep the cell multiplying. The more the cell divides, the more the integrated virus can replicate itself with little exposure to surveillance by the immune system. Because E6 and E7 are presented by MHC molecules, infected cells can be recognized and destroyed by the immune system. E6 and E7 are therefore vaccine candidates. Because E6 and E7 are virulence antigens, a vaccine derived from them would be a virulence-antigen vaccine that could favor the papillomaviruses that do not have

25.3 Virulence-antigen Vaccines against Viruses

the damaging form of these proteins. Experimental vaccines derived from E6 and E7 do stimulate cellular immunity and may therefore offer another opportunity to evaluate the effectiveness of virulence-antigen vaccines [6, 38, 52]. As with other opportunities, though, capitalizing on them depends on using them instead of antigens that do not meet the virulence-antigen criterion. Currently, they are being considered more as therapeutic vaccines than as prophylactic vaccines [6]. The logic is that humoral immunity to the viral coat will be useful in preventing infection, whereas cellular immunity to E6 or E7 is more important in controlling established infections. Although E6 and E7 could still have an evolutionary effect if they are used only in therapeutic vaccines, the evolutionary effect would be greater if they were used prophylactically as well. A hybrid strategy for prophylactic vaccines involves conjugating portions of these proteins with coat protein [11, 64]. From an evolutionary perspective, this strategy is better than using the coat protein alone, because the conjugate preserves at least some of evolutionary favoring of benign strains. One caveat is that E6 and E7 vary substantially within HPV serotypes [65, 91, 93]. Evolutionary changes can therefore be expected within as well as between serotypes. Research is needed to determine whether any of the E6 or E7 variants within the oncogenic HPV serotypes contribute differently to the virulence of HPV infections. If benign variants exist, the virulence-antigen strategy dictates that they should not be used in vaccines. As with vaccination against HPV, efforts to control the human immunodeficiency virus (HIV) have increasingly considered therapeutic vaccines (e. g., [30]). HIV, however, has a greater potential for within-host evolution than HPV. This potential poses both problems and opportunities for use of the virulence-antigen strategy. A problem is that the virus may readily evolve a new virulence mechanism in response to the inhibition of one virulence mechanism by a virulence-antigen vaccine; however, the long period of within-host evolution per infection offers a greater opportunity for a therapeutic virulence-antigen vaccine. The most damaging variants of HIV's proteins need to be identified and used in a vaccine that is administered early during infection while the immune system is still functional and before the virulent variants have been generated. Then, when the variants arise by mutation in the vaccinated person, they may be quickly suppressed by the immune system before they have a chance to gain a toehold. Protein variants responsible for syncytium induction, for example, arise regularly during HIV infections and lead predictably to rapid downfall of the immune system. Antigens variants that are unique to syncytium-inducing phenotypes could be used in therapeutic vaccines that are administered early during an HIV infection. The immunity thus generated should therefore slow the progression of HIV infections to AIDS, because the syncytium-inducing phenotype would be inhibited.

557

558

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

25.4 Circumventing Social Barriers to Vaccination

The successes of vaccination programs against the most dangerous pathogens leaves behind pathogens that cause serious disease in ever smaller percentages of the population. For such pathogens, slight negative effects of vaccines may be sufficient to offset the positive effects, because of the small probability of a serious infection in an unvaccinated individual. In such situations the willingness of individuals to accept vaccination and institutional support for vaccination programs may be low. The overall result may be lower vaccine coverage and more infections. The substantial incidence of childhood respiratory diseases during stable vaccination programs has led researchers to recommend revaccination in older age groups to boost waning immunity [15, 51, 74]. Without revaccination, people in older age groups can act as reservoirs. But if adults risk only asymptomatic or mildly symptomatic infection they may be unmotivated to become vaccinated, leading to low coverage. The diphtheria vaccination experience in China illustrates the contribution of adult infections to childhood illness. Vaccination coverage of infants in the Hubei province during the 1970s and 1980s rose above 80 %, an adequate level for controlling diphtheria if maintained across generations [92]. Adults, however, were not targeted because diphtheria does not affect adults as severely as children. The low vaccination levels among adults were insufficient to prevent an outbreak of toxigenic C. diphtheriae, which was controlled within a few weeks by targeting adults [92]. This study draws attention to the two options for using virulence-antigen vaccines. If the public and governmental attitudes toward vaccinations allow for extensive vaccination among adults, the option used in the Hubei province can be enacted. If, however, attitudes do not allow for much vaccination among adults, increasing the coverage among children should favor increased evolution toward benignity. This evolution should indirectly reduce the danger posed by adult infections, because the pathogens infecting adults often come from children and will therefore tend to be more benign under such programs. Enactment of both options would obviously provide the best control, but partial enactment of one could provide an effective solution to the problem. More generally, the virulence-antigen strategy is especially appropriate for dealing with social resistance to vaccination, because it is amenable to low vaccine coverage. Individuals who are not vaccinated will obtain protection from infections with the circulating benign strains. In such situations, traditional vaccines can lead to increased disease in older age groups, because immunity among older children may depend on repeated subclinical infections [1, 81]. The virulence-antigen strategy, however, should ameliorate this problem by leaving mild variants to circulate in the community, which can then cause repeated subclinical infections. Age differences in immune responses to particular antigens can also be used to control pathogens with multiple virulence antigens. An acellular pertussis vaccine containing the virulence antigen pertactin, for example, stimulated a strong immune response in adults but not in children when administered as part of an acellular

25.5 A Call for Field Experiments

DPT vaccine [73, 23]. If the adult response is protective, an adult booster using pertactin could be an effective part of a virulence-antigen strategy.

25.5 A Call for Field Experiments

The possibilities for controlling the evolution of virulence by using the virulenceantigen strategy was recently questioned by Andrew Read with reference to a mathematical model of the process [94]. Read contends that the costs of virulence are not sufficiently high to offset the benefits of virulence [94]. The mathematical model that served as the basis for Read’s criticism [31, 32], however, is at best only suggestive on this issue, because values for the competitive advantage of the more-virulent variants are only guesses. With diphtheria, for example, the costs of virulence can be estimated on the basis of the costs of toxin production, which amount to approximately 5 % of the bacterium’s protein budget. The advantage associated with toxin production, however, cannot be quantified with existing evidence. Moreover, the model treats within-host growth rate as a variable influenced by vaccination, whereas the virulence-antigen strategy focuses on the particular biochemical attributes that distinguish virulent from benign strains. Blocking the virulence-enhancing attributes will suppress the particular variants that posses them. If new variants arise with similar or greater virulence, the process of virulence-antigen vaccine development needs to be iterated to control them. A priori, one could argue that the need for this iteration might occur rapidly or slowly. The evidence from the two examples of virulence-antigen vaccines that have been enacted, however, suggests that this need arises slowly. The diphtheria vaccination program is still extremely effective at controlling diphtheria after three-quarters of a century, and the Hib program is still effective after more than a decade. Read proposes that mild strains would not be able to increase at the expense of virulent strains in response to virulence-antigen vaccines [94]. This proposal can be evaluated indirectly by assessing whether mild strains can persist in populations even without virulence-antigen vaccines. Such persistence would suggest that mild strains are to some extent holding their own in competition with virulent strains. The evidence from C. diphtheriae accords with this idea, because mild strains have been present in substantial frequencies even before the onset of vaccination programs. In Romania, for example, toxinless C. diphtheriae comprised about 14 % of the isolates prior the vaccination program (Figure 25.2). Mild and harmful strains of H. influenzae also coexisted prior to vaccination. Introducing a virulence-antigen vaccine would simply nudge this competitive balance by disfavoring harmful strains, thus allowing them to be partially or entirely displaced by benign strains. Pathogenby-pathogen assessment of whether mild strains coexist with virulent strains would provide a sense of whether the situation with diphtheria and H. influenzae can be generalized to other potential targets of virulence-antigen vaccines. Models and discussions alone, however, will not resolve the ambiguities and disagreements over the general value of the virulence-antigen strategy. Field experi-

559

560

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

ments are needed. At a minimum, the relative frequencies of virulent and benign strains need to be quantified during vaccination programs that use virulence-antigen vaccines, as was done with diphtheria in Romania (Figure 25.2). Ideally, the results of such intervention should be compared with results from similar populations in which vaccines provided the same level of short-term protection but were not virulence-antigen vaccines. Such a design is ethically acceptable so long as the nonevolutionary efficacies of the two vaccines are indistinguishable. The need to rigorously evaluate the virulence-antigen strategy has been heightened by increasing evidence that vaccine escape is occurring for a variety of pathogens, such as measles, mumps, pertussis, and hepatitis B [19, 34, 36, 43, 46, 62, 84]. The virulence-antigen strategy not only offers a way to cope with vaccine escape, but it capitalizes on vaccine escape. It simply controls the process so benign variants rather than virulent variants escape. C. diphtheriae, for example, readily escaped control by the toxoid diphtheria vaccine, but the escape worked in favor of public health, because it was the benign toxinless variants that escaped. There is increasing recognition that vaccine-induced immunity often prevents disease but not infection. When children are vaccinated against pertussis, for example, the disease is generally prevented, but the organism is still present and transmissible [37]. Prospects for eradication are indeed dim if the vaccines used to control target pathogens do not prevent infection. Rather than accepting nonsterilizing immunity and vaccine escape as inherent problems of vaccine programs, the virulence-antigen strategy uses these characteristics as parts of the solution. References 1. Adams, W. G., Deaver, K. A., Cochi, S. L., Plikaytis, B. D., Zell, E. R., Broome, C. V., Wenger, J. D. 1993, Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era, J. Amer. Med. Assoc. 269, 221– 226. 2. Amsbaugh, D. F., Li, Z. M., Shahin, R. D. 1993, Long-lived respiratory immune response to filamentous hemagglutinin following Bordetella pertussis infection, Infect. Immun. 61, 1447–1452. 3. Anderson, E. L., Mink, C. M., Berlin, B. S., Shih, C. N., Tung, F. F., Belshe, R. B. 1994, Acellular pertussis vaccines in infants: evaluation of single-component and two-component products, Vaccine 12, 28–31. 4. Anonymous 1992, Hib, Hib, hooray, Lancet 340, 845. 5. Barkin, R. M. 1975, Measles mortality: analysis of the primary cause of death, Am. J. Dis.Children 129, 307–309.

6. Berry, A. M., Paton, J. C., Hansman, D. 1992, Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type3, Microb.Pathog. 12, 87–93. 7. Bijlmer, H. A. 1991, World wide epidemiology of Haemophilus influenzae meningitis: industrialized versus non-industrialized countries,Vaccine 9, S5–S9. 8. Bijlmer, H. A., van Alphen, L., Geelen-van den Broek, L., Greenwood, B. M.,Valkenburg, H. A., Dankert, J. 1992, Molecular epidemiology of Haemophilus influenzae type b in The Gambia, J. Clin. Microbiol. 30, 386–390. 8a. Blumberg, B. M., Epstein, L. G., Saito,Y., Chen, D., Sharer, L. R., Anand R. 1992, Human immunodeficiency virus type-1 nef quasispecies in pathological tissue. J. Virol. 66, 5256– 5264. 9. Booy, R., Moxon, E. R., Macfarlane,

References

10.

11.

12.

13.

13a.

14.

15.

16.

17.

18.

19.

J. A., Mayonwhite, R. T., Slack, M. P. E. 1992, Efficacy of Haemophilus influenzae type b conjugate vaccine in Oxford region, Lancet 340, 847. Booy, R., Hodgson, S., Carpenter, L., Mayonwhite, R. T., Slack, M. P. E., Macfarlane, J. A., Haworth, E. A., Kiddle, M., Shribman, S., Roberts, J. S. C., Moxon, E. R. 1994, Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T, Lancet 344, 362– 366. Breitburd F, Coursaget P. 1999, Human papillomavirus vaccines. Semin. Cancer Biol. 9, 431–444. Broadhurst, L. E., Erickson, R. L., Kelley, P. W. 1993, Decreases in invasive Haemophilus influenzae diseases in US army children, 1984 through 1991, J. Amer. Med.Assoc. 269, 227–231. Brooks, G. F. 1969, Recent trends in diphtheria in the United States, J. Infect. Dis. 120, 500–502. Brooks, G. F., Buchanan, T. M. 1970, Pertussis in the United States, J. Infect. Dis. 122, 123–125. Chen, R. T., Broome, C. V., Weinstein, R. A.,Weaver, R., Tsai, T. F. 1985, Diphtheria in the United States, 1971– 81, Am. J. Public Hlth. 75, 1393–1397. Cherry, J. D. 1992, Pertussis: the trials and tribulations of old and new pertussis vaccines,Vaccine 10, 1033–1038. Cherry, J. D., Brunell, P. A., Golden, G. S., Karzon, D. T. 1988, Report of the task force on pertussis and pertussis immunization, 1988, Pediatrics 82, S939–S984. Christodoulides, M. 1990, Pertussis vaccines: present status, In A. Mizrahi (ed). Bacterial Vaccines. Advances in Biotechnological Processes, Wiley-Liss, New York, pp. 169–199. Clemens, J. D., Sack, D. A., Rao, M. R., Chakraborty, J., Khan, M. R., Kay, B., Ahmed, F., Banik, A. K., van Loon, F. P. L.,Yunus, M., Harris, J. R. 1992, Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area, J. Infect. Dis. 166, 1029–1034. Cooreman MP, Leroux-Roels G, Paulij WP. 2001,Vaccine- and hepatitis

20.

21.

22.

23.

24.

25.

26.

27.

28.

B immune globulin – induced escape mutations of hepatitis B virus surface antigen. J. Biomed. Sci. 8, 237–247. Dajani, A. S., Asmar, B. I., Thirumoorthi, M. C. 1979, Systemic Haemophilus influenzae disease: an overview, J. Pediatrics 94, 355–364. Duclos, P. 1992, Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children, Can. Med. J. Assoc. 146, 1363–1366. NOTE#Q10# Ehrmann, I. E., Weiss, A. A., Goodwin, M. S., Gray, M. C., Barry, E., Hewlett, E. L. 1992, Enzymatic activity of adenylate cyclase toxin from Bordetella pertussis is not required for hemolysis, FEBS Lett. 304, 51–56. Englund, J. A., Glezen,W. P., Barreto, L. 1992, Controlled study of a new five-component acellular pertussis vaccine in adults and young children, J. Infect. Dis. 166, 1436–1441. Englund, J. A., Decker, M. D., Edwards, K. M., Pichichero, M. E., Steinhoff, M. C., Anderson, E. L. 1994, Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study, Pediatrics 93, 37–43. Eskola, J., Peltola, H., Kayhty, H., Takala, A. K., Makela, P. H. 1992, Finnish efficacy trials with Haemophilus influenzae type b vaccines, J. Infect. Dis. 165, S137–S138. Ewald, P. W. 1994, Evolution of Infectious Disease, Oxford University Press, New York. Ewald, P. W. 1996,Vaccines as evolutionary tools: the virulence antigen strategy. In: Concepts in Vaccine Develop ment. S. H. E. Kaufmann (ed). de Gruyter: Berlin, pp. 1–25. Feldman, S., Perry, C. S., Andrew, M., Jones, L., Moffitt, J. E., Abney, R., Carlyle, W., Freeman, E. E., Hendrick, J., Hopper, S., Ray, M., Sistrunk,W., Smith,W. H., Stone, L., Welch, P.,Womack, N., Miller, J., Thompson, R. H., Simmons, L., Sherwood, J. A., Denney, S. J., Shaak, C., Cooke, D. T., Mccaslin, L. 1992, Comparison of acellular (B type) and wholecell pertussis-component diphtheria–tetanus–pertussis vaccines as the first

561

562

25 Imperfect Vaccines and the Evolution of Pathogen Virulence

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

booster immunization in 15- to 24month-old children, J. Pediatrics 121, 857–861. Furumoto H, Irahara M. 2002, Human papilloma virus (HPV) and cervical cancer. J Med Invest. 49, 124–133. Gallo RC, Burny A, Zagury D. 2002, Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine. DNA Cell Biol. 21, 611–618. Gandon S, Mackinnon MJ, Nee S, Read AF. 2001, Imperfect vaccines and the evolution of pathogen virulence. Nature 414, 751–756. Gandon S, Mackinnon M, Nee S, Read A. 2003, Imperfect vaccination: some epidemiological and evolutionary consequences. Proc R Soc Lond B Biol Sci. 270, 1129–1136 Granoff, D. M., Basden, M. 1980, Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease, J. Infect. Dis. 141, 40–46. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J. 2001, Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20, 299–303. Harnisch, J. P., Tronca, E., Nolan, C. M., Turck, M., Holmes, K. K. 1989, Diphtheria among alcoholic urban adults, Ann. Intern. Med. 111, 71–72. He C, Nomura F, Itoga S, Isobe K, Nakai T. 2001, Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol. 16, 1373–1377. He Q, Arvilommi H,Viljanen MK, Mertsola J. 1999, Outcomes of Bordetella infections in vaccinated children: effects of bacterial number in the nasopharynx and patient age. Clin Diagn Lab Immunol. 6, 534–536. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC. 2000,Viral recombinant vaccines to the E6 and E7 antigens of HPV16. Virology 270, 146–161. Herwaldt, L. A. 1993, Pertussis and

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

pertussis vaccines in adults, J. Amer. Med. Assoc. 269, 93–94. Hewlett, E. L. 1990, Bordetella species, In G. L. Mandell, R. G. Douglas, J. E. Bennett (eds). Principles and Practice of Infectious Disease, Wiley, New York, pp. 1757–1762. Holmgren, J., Svennerholm, A. M., Jertborn, M., Clemens, J., Sack, D. A., Salenstedt, R.,Wigzell, H. 1992, An oral b subunit whole cell vaccine against cholera,Vaccine 10, 911–914. Howson, C. P., Fineberg, H. V. 1992, Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine, J. Amer. Med. Assoc. 267, 392–396. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. 1999, Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30, 1312– 1317. Kallick, C. A., Brooks, G. F., Dover, A. S., Brown, M. C., Brolnitsky, O. 1970, A diphtheria outbreak in Chicago, Ill. Med. J. 137, 505–512. Kamiya, H., Nii, R., Matsuda, T., Yasuda, N., Christenson, P. D., Cherry, J. D. 1992, Immunogenicity and reactogenicity of Takeda acellular pertussiscomponent diphtheria–tetanus–pertussis vaccine in 2- and 3-month-old children in Japan, Am. J. Dis.Child. 146, 1141–1147. Lim CS, Chan KP, Goh KT, Chow VT. 2003, Hemagglutinin–neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore. J Med Virol. 70, 287–292. Liu,V. C., and Smith, A. L. 1992, Molecular Mechanism of Haemophilus influenzae Pathogenicity, H. Schonfeld, and H. Helwig, eds. Bacterial Meningitis, Vol 45, Karger: Basel, Switzerland, pp. 30– 51. Locht, C., Bertin, P., Menozzi, F. D., Renauld, G. 1993, The filamentous haemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp, Mol. Microbiol 9, 653–660. Long, S. S., Welkon, C. J., Clark, J. L. 1990, Widespread silent transmission of

References

50.

51.

52.

53.

54.

55.

56.

57.

58.

pertussis in families: antibody correlates of infection and symptomatology, J. Infect. Dis. 161, 480–486. Marcinak, J. F., Ward, M., Frank, A. L., Boyer, K. M., Froeschle, J. E., Hosbach, P. H. 1993, Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children, Am. J. Dis. Child. 147, 290–294. Mencarelli, M., Zanchi, A., Cellesi, C., Rossolini, A., Rappuoli, R., Rossolini, G. M. 1992, Molecular epidemiology of nasopharyngeal corynebacteria in healthy adults from an area where diphtheria vaccination has been extensively practiced, Eur. J. Epidemiol. 8, 560–567. Meneguzzi G, Cerni C, Kieny MP, Lathe R 1991, Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181, 62– 69. Miller, L. W., Older, J. J., Drake, J., Zimmerman, S. 1972, Diphtheria immunization: effect upon carriers and the control of outbreaks, Am. J. Dis Child 123, 197–199. Mills, K. H. G., Redhead, K. 1993, Cellular immunity in pertussis, J. Med. Entomol. 39, 163–164. Minami, A., Hashimoto, S., Abe, H., Arita, M., Taniguchi, T., Honda, T., Miwatani, T., Nishibuchi, M. 1991, Cholera enterotoxin production in Vibrio cholerae-O1 strains isolated from the environment and from humans in Japan, Appl. Environ. Microbiol. 57, 2152–2157. Munoz FM, Keitel WA. 2003, Progress in the diagnosis, prevention, and treatment of pertussis. Curr Infect Dis Rep. 5, 213–219 Murphy, T. V., Osterholm, M. T. 1987, Prospective surveillance of Haemophilus influenza type b disease in Dallas County, Texas, and in Minnesota, Pediatrics 79, 173–180. Murphy, T. V., Pastor, P., Medley, F., Osterholm, M. T., Granoff, D. M. 1993a, Decreased Haemophilus colonization in children vaccinated with Hae-

59.

60.

61.

62.

63.

64.

65.

66. 67.

68.

mophilus influenzae type b conjugate vaccine, J. Pediatrics 122, 517–523. Murphy, T. V., White, K. E., Pastor, P., Gabriel, L., Medley, F., Granoff, D. M., Osterholm, M. T. 1993b, Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination, J. Amer. Med. Assoc. 269, 246–248. Musser, J. M., Kroll, J. S., Granoff, D. N., Moxon, E. R., Brodeur, B. R., Campos, J., Dabernat, H., Frederiksen,W., Hamel, J., Hammond, G., Hoiby, E. A., Jonsdottir, K. E., Kabeer, N., Kallings, I., Khan,W. N., Kilian, N., Knowles, K., Koornhof, H. J., Law, B., Li, K. I., Montgomery, J., Pattison, P. E., Piffaretti, J. C.,Takala, A. K., Thong, M. L.,Wall, R. A.,Ward, J. I., Selander, R. K. 1990, Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae, Rev. Infect. Dis. 12, 75–111. Ntezayabo B, De Serres G, Duval B. 2003, Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 22, 22–27. Oon CJ, Chen WN. 1998, Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat. 5, S17–23. Osek, J., Svennerholm, A. M., Holmgren, J. 1992, Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili, Infect. Immun. 60, 4961–4964. Osen W, Jochmus I, Muller M, Gissmann L. 2000, Immunization against human papillomavirus infection and associated neoplasia. J Clin Virol. 19, 75–78. Pang T, Hu X, Mazurenko N, Kisseljov F, Ponten J 2002, Multiple variants of HPV16 E6 gene in cervical invasive squamous cell carcinoma. Anticance r Res. 22, 1011–1016. Pappenheimer, A. M. 1977, Diphtheria toxin, Annu. Rev. Biochem. 46, 69–94. Pappenheimer, A. M. 1982, Diphtheria: studies on the biology of an infectious disease, Harvey Lectures 76, 45–73. Pappenheimer, A. M., Gill, D. M. 1973, Diphtheria, Science 182, 353–358.

563

564

25 Imperfect Vaccines and the Evolution of Pathogen Virulence 69. Pappenheimer, A. M., Murphy, J. R. 1983, Studies on the molecular epidemiology of diphtheria, Lancet 322, 923– 926. 70. Peltola, H., Kilpi,T., Anttila, M. 1992, Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines, Lancet 340, 592–594. 71. Petersen, J. W., Ibsen, P. H., Bentzon, M. W., Capiau, C., Heron, I. 1991, The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans, FEMS Microbiol. Immunol. 76, 279–287. 72. Pichichero, M. E., Francis, A. B., Blatter, M. M., Reisinger, K. S., Green, J. L., Marsocci, S. M., Disney, F. A. 1992, Acellular pertussis vaccination of 2-month-old infants in the United States, Pediatrics 89, 882–887. 73. Podda, A., Nencioni, L., Marsili, I., Peppoloni, S.,Volpini, G., Donati, D., Ditommaso, A., Demagistris, M. T., Rappuoli, R. 1991, Phase-I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69-kDa, Vaccine 9, 741–745. 74. Poland, G. A., Jacobson, R. M. 1994, Failure to reach the goal of measles elimination: apparent paradox of measles infections in immunized persons, Arch. Intern. Med. 154, 1815–1820. 75. Rubins, J. B., Duane, P. G., Charboneau, D., Janoff, E. N. 1992, Toxicity of pneumolysin to pulmonary endothelial cells in vitro, Infect. Immun. 60, 1740– 1746. 76. Sack, D. A., Clemens, J. D., Huda, S., Harris, J. R., Khan, M. R., Chakraborty, J.,Yunus, M., Gomes, J., Siddique, O., Ahmed, F., Kay, B. A., Vanloon, F. P. L., Rao, M. R., Svennerholm, A. M., Holmgren, J. 1991, Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh, J. Infect. Dis. 164, 407–411. 77. Sasse, A., Malfait, P., Padrón, T., Erikashvili, M., Freixa, E., Moren, A. 1994, Outbreak of diphtheria in Republic of Georgia, Lancet 343, 1358–1359.

78. Schmitt, M. P., Holmes, R. K. 1991, Characterization of a defective diphtheria toxin repressor (dtxR) allele and analysis of dtxR transcription in wild-type and mutant strains of Corynebacterium diphtheriae, Infect. Immun. 59, 3903–3908. 79. Schmitt, M. P., Twiddy, E. M., Holmes, R. K. 1992, Purification and characterization of the diphtheria toxin repressor, Proc. Natl. Acad. Sci. USA 89, 7576–7580. 80. Seachrist, L. 1995, New pertussis vaccines safer, more effective, Science News 148, 54. 81. Shapiro, E. D. 1993, Infections caused by Haemophilus influenzae type b: the beginning of the end? J. Amer. Med. Assoc. 269, 264–266. 82. St.Geme, J. W., Falkow, S. 1992, Capsule loss by Haemophilus influenzae type b results in enhanced adherence to and entry into human cells, J. Infect. Dis. 165, S117–S118. 83. Storsaeter, J., Olin, P. 1992, Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance,Vaccine 10, 142–144. 84. Tamin, A., Rota, P. A., Wang, Z. D., Heath, J. L., Anderson, L. J., Bellini, W. J. 1994, Antigenic analysis of current wild type and vaccine strains of measles virus, J. Infect. Dis. 170, 795–801. 85. Taranger J, Trollfors B, Bergfors E, Knutsson N, Lagergard T, Schneerson R, Robbins J.B. 2001, Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 108, E115. 86. Tomoda, T., Ogura, H., Kurashige, T. 1992, The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community, J. Infect. Dis. 166, 908–910. 87. Uchida, T., Gill, D. M., Pappenheimer, A. M. 1971, Mutation in the structural gene for diphtheria toxin carried by temperate phage b, Nature New Biol. 233, 8–11. 88. Vanura, H., Just, M., Ambrosch, F., Berger, R. M., Bogaerts, H.,Wynen, J., Vandevoorde, D.,Wiedermann, G.

References

89.

89a.

90.

91.

1994, Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 µg of FHA and either 25 or 8 µg of PT with response to whole-cell pertussis DTP vaccine,Vaccine 12, 210–214. Warren, K. S. 1986, New scientific opportunities and old obstacles in vaccine development, Proc. Natl. Acad. Sci. USA 83, 9275–9277. Weiss, A. A., Hewlett, E. L. 1986, Virulene factors of Bordetella pertussis. Ann. Rev. Microbiol. 40. Wenger, J. D., Pierce, R., Deaver, K., Franklin, R., Bosley, G., Pigott, N., Broome, C. V. 1992, Invasive Haemophilus influenzae disease: a populationbased evaluation of the role of capsular polysaccharide serotype, J. Infect. Dis. 165, S34–S35. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. 1995, Human papillomavirus type 16 variant lineages in United States po-

92.

93.

94.

95.

pulations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 69, 7743– 7753. Youwang,Y., Jianming, D.,Yong, X., Pong, Z. 1992, Epidemiological features of an outbreak of diphtheria and its control with diphtheria toxoid immunization, Int. J. Epidemiol. 21, 807– 811. Zehbe I, Wilander E, Delius H, Tommasino M. 1998, Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58, 829–833. Zimmer C. 2003, Infectious diseases. Taming pathogens: an elegant idea, but does it work? Science 300, 1362–1364. Zuber, P. L. F., Gruner, E., Altwegg, M., von Graevenitz, A. 1992, Invasive infection with non-toxigenic Corynebacterium diphtheriae among drug users, Lancet 339, 1359.

565

567

26 Cost-Effectiveness of Vaccinations Thomas D. Szucs

26.1 Introduction

Vaccines are the most popular preventive intervention worldwide. Since the beginning of the 20th century, the wide use of vaccination in children and in selected populations at high risk has produced substantial achievements in the control of vaccine-preventable diseases (Table 26.1). The economic importance of vaccines lies partly in the burden of disease that can be avoided and partly in the competition for resources between vaccines and other interventions [1]. Until the 1980s, few economic evaluations had been carried out. Since then, the confrontation of most countries with escalating health-care costs and tighter budgets has awakened the interest in pharmacoeconomic analysis. In a literature search in Medline and HEED (economic database, University of York, UK), I could identify 200 pharmacoeconomic evaluations of vaccines, 156 had been published in peer-reviewed journals. Interventions that produce both a health benefit and cost savings are inherently cost-effective. For the early vaccines such as diphtheria, tetanus, pertussis (DTP), polio, and measles vaccines, for example, economic evaluation consisted of comparing the costs of vaccination with the savings in treatment costs. For all these vaccination strategies, monetary savings are attained together with improved health status, and the decision to vaccinate is straightforward. However, other vaccines that do not save costs produce health benefits. The decision to vaccinate depends now on the willingness of society to pay for increased health benefits. An instrument to assess the relative value of different immunization strategies is the economic evaluation, in which different vaccination strategies are calculated and compared with a reference strategy, which is often the nonintervention strategy, i. e., no vaccination. Costs can be divided into medical costs related to the disease (medication, laboratory tests, consultations, hospitalizations) or the vaccination (purchase price of the vaccine, costs for administering the vaccine, treatment of side effects). Societal costs are indirectly related to the treatments and vaccination and are mainly costs of lost productivity due to disease [2].

United States

newborns

newborns

Diphtheria, tetanus, pertussis

Rotavirus

Australia France Spain

infants < 18 months old

children < 5 y old

children < 1 y old

healthy working adults

Haemophilus influenzae type b

Haemophilus influenzae type b

Haemophilus influenzae type b

Influenza

United States

Switzerland

children 0–5

Finland

Rotavirus

Pneumococcus

Australia

Rotavirus

United States

Country applicable

Population

Agent

societal perspective

societal perspective

French national health insurance system

societal perspective

society and thirdparty payer

society

society and health care system

society and health care system

society and health care system

Perspective

Tab. 26.1 Cost-effectiveness of selected immunization programs. Year a

Randomized control trial: when vaccine not well 2000 matched with circulating virus, net cost US$ 65.59 per person; when well matched, net cost US$ 11.17

1999

1996

Cost-effectiveness FRF 54 084 (A 8245) per LYS or FRF 34 050 (A 5191) per QALY gained Vaccination of infants under 1 y would be similar in magnitude to its expenses

1994

2003

1998

1999

1998

Cost-effectiveness of 3 doses (given with DTP) US$ 6930 per QALY gained

CHF 33 740 (approximately US$ 19 300) per QALY from the societal perspective and CHF 38 240 (US$ 21 300) per QALY from the third-party payer (sickness funds) perspective

Cost-saving if vaccine price < US$ 20

Cost-neutral at a vaccine price of US$ 26 from a societal viewpoint, US$ 19 from healthcare system perspective

Cost-saving from societal perspective and CE ratio of US$ 103 per case prevented from the healthcare system perspective, at a vaccine price of US$ 20

For both net savings. Benefit–cost ratios 27 : 1 and 2000 9 : 1 from the society and from the healthcare system perspective for DTaP

Results

33

32

31

30

29

28

27

5

26

Reference

568

26 Cost-Effectiveness of Vaccinations

adults > 50 y old

adolescents

Hepatitis A

Hepatitis A

a

United States

healthy working adults

Influenza societal perspective

societal perspective

Perspective

From healthcare perspective US$ 7902 per LYS

Testing for antibodies and vaccination of those without antibodies US$ 230 000 per LYS

Model: influenza vaccination cost saving. Mean savings of US$ 13.66 per person

Results

2000

1999

2001

Year a

35

6

34

Reference

Year of publication; DTaP: diphtheria and tetanus toxoids and acellular pertussis vaccine; DTwP: diphtheria and tetanus toxoids and whole-cell pertussis vaccine; RRV-TV: tetravalent rhesus rotavirus vaccine; CE: cost-effectiveness ratio; LYS: life year saved; QALY: quality adjusted life year

United States: health care system the 10 states with the highest rates

United States

Country applicable

Population

Agent

Tab. 26.1 (continued)

26.1 Introduction 569

570

26 Cost-Effectiveness of Vaccinations

There is no single criterion of a cost–effectiveness ratio, below which an intervention should be adopted. A threshold value of US$ 50 000 per life-year saved is often quoted in the medical literature. Laupacis et al. [3] found in 1992 that technologies that cost less than US$ 20 000 per quality-adjusted life-year (QALY) were almost universally accepted as appropriate; technologies that cost between US$ 20 000 and US$ 100 000 were provided routinely, but there might be no consensus about their appropriateness; and technologies that cost over US$ 100 000 per QALY were generally deemed inappropriate. Similarly, the Committee to Study Priorities for Vaccine Development [4] placed candidate vaccines into four groups or levels: Level I: Level II: Level III: Level IV:

most favorable, saves money and QALYs more favorable, costs < US$ 10000 per QALY favorable, costs > US$ 10 000 and < US$ 100 000 per QALY less favorable, costs > US$ 100 000 per QALY

26.2 Differences between Vaccines and Medicines

Vaccines differ from classical medicines in at least three ways: first, there is a longer tradition of economic evaluations for vaccines than for medicines. Some of the earliest economic studies were carried out in the field of vaccines in the public health arena. Second, comparatively fewer central decision-makers need to be convinced, as compared to drugs. The reason for this is a more centralized process of recommending vaccines and vaccination policies. Third, externalities are more relevant in the field of vaccines. Such externalities may be positive or negative. Positive externalities are present when herd immunity prevents the spread of the disease in the community.

26.3 Analytic Methods 26.3.1 Elements of an Economic Evaluation

All economic studies investigate the balance between inputs (the consumption of resources) and outcomes (improvements in the state of health of individuals and/or society). 26.3.2 The Input

Although the unit price of a drug is often a prime factor in decision-making, research on economic outcomes provides a more comprehensive interpretation of cost. This is accomplished by determining the overall cost of a given diagnostic or

26.3 Analytic Methods

therapeutic process from the initiation of diagnosis until a final outcome is achieved. The various types of costs can be grouped under the following categories:

.. .

direct medical costs direct nonmedical costs indirect costs

26.3.3 Direct Medical Costs

Interpretation of what belongs in each of these categories varies. Direct medical costs are defined as those resources used by the provider in the delivery of medical care. As an example, direct medical costs for a hospital include:

.. .. . .

vaccines, drugs laboratory tests medical supplies use of diagnostic equipment: e. g., magnetic resonance imaging, CAT scans, and x-ray imaging medical staff time for personnel such as physicians, nurses, pharmacists, physical therapists, and laboratory technicians room and board: the cost of supplies, equipment, and personnel required for routine patient-related services such as food, laundry, and housekeeping.

These costs can be directly related to the care of patients. Other costs of operating a hospital include plant maintenance and repair, utilities, telephone, accounting, legal fees, insurance, taxes, real estate costs, and interest expense. In general, most economic studies do not factor general operating costs into the dollar value assigned to the cost of resources expended for a given medicine. With respect to direct medical expenses, it is easy to see why length of stay is an important cost factor to hospitals, especially when payment is determined by prospective payment schemes, e. g., diagnosis-related groups (DRGs). Costs such as room and board are directly tied to the length of stay, regardless of the reason. The cost of laboratory tests, supplies, and medical staff time vary with the medical condition being treated, but are multiplied by the length of stay. 26.3.4 Direct Nonmedical Costs

The economic literature generally defines direct nonmedical costs as out-of-pocket expenses paid by the patient for items outside the healthcare sector. This category includes such costs as:

..

travel to and from the hospital, clinic, or doctor’s office travel and lodging for family members who live elsewhere

571

572

26 Cost-Effectiveness of Vaccinations

.. .

domestic help or home nursing services insurance copayments and premiums treatment not covered by third-party payers

Although these costs are generally classified as ‘nonmedical’, to the patient they are real and often substantial costs of medical care. What makes them nonmedical is that they are not costs incurred by the healthcare provider and are somewhat difficult to measure. For example:

. . .

A patient's inability to afford competent follow-up care at home may result in poor compliance with drug therapies and eventual treatment failure. This may lead to additional hospital stays or office visits, which affect the provider's bottom line. A patient's inability to bear the unreimbursed costs of medications may also lead to poor compliance and costly complications. High transportation costs may lead to missed appointments for necessary followup visits, which can result in deterioration of a patient’s medical condition and increased treatment costs for the provider.

Even though these costs may not be directly incurred by the provider, they can be used in selling situations by making the provider aware of their potential economic impact. It may also be possible to use these costs to encourage payers (e. g., employers, insurance companies) to discuss the use of a more cost-effective test with the healthcare provider. This has certainly been true for influenza vaccines and vaccines to contain occupational hazards in healthcare workers (e. g., hepatitis B). 26.3.5 Indirect Costs

One definition of indirect costs is the overall economic impact of illness on the patient's life. These include:

.. .

loss of earnings due to temporary, partial, or permanent disability unpaid assistance by family members in providing home healthcare loss of income to family members who forfeit paid employment to remain at home and care for the patient

Like direct nonmedical costs, indirect costs are real to the patient, but abstract to the provider – but may affect the provider's direct medical costs. For example, patients who cannot earn income may not be able to pay their bills – including medical bills. Economic hardship may result in poor compliance with drug therapies as patients reduce doses or fail to refill prescriptions to save money. The medical provider may have to bear the additional costs of managing complications. Economic hardship may also result in missed follow-up appointments, leading to the same types of problems for providers as described above for direct nonmedical costs.

26.3 Analytic Methods

The issue of economic productivity losses has been extensively discussed in the field of influenza. A large body of evidence has demonstrated that influenza vaccination is cost-effective in healthy working adults [5] and very effective in healthcare workers [6, 7]. In the future, economic benefits should be assessed for every individual organization or company, taking into account all individual criteria. Using this information, employers can judge for themselves whether they are willing to offer an influenza shot to their employees. Because most European healthcare systems are financed directly or indirectly on the basis of paid labor income, a positive effect of influenza vaccination on productivity will also be highly important on a societal level. 26.3.6 The Output: Consequences and Outcomes

Final states or outcomes can be negative (sometimes referred to as the five D’s):

.. .. . .. ..

death disability (patient is permanently disabled and unable to return to work or school, perform household chores, etc.) discomfort (patient is in constant state of moderate to high levels of pain) dissatisfaction (patient is not satisfied with the course of treatment or services provided) disease (patient's condition is not being controlled, resulting in frequent relapses, rehospitalization, and expenditure of additional resources) There are also positive outcomes: patient is cured patient is able to resume normal functions patient has an improved or satisfactory quality of life patient’s medical condition is successfully managed or stabilized by continued drug therapy

The use of outcomes research represents an important advance in medical economic analysis because of the relationship between the final state, or result, of diagnosis and therapy and overall cost-effectiveness. If one can demonstrate that a product will achieve cost-effective positive outcomes, one will increase the chances of making the sale. 26.3.7 Economic Evaluation Methodology

The most common methods employed by health economists are classical research designs such as cost of illness, cost–benefit, cost-effectiveness, cost–utility, cost-minimization, and cost-of-illness analyses [8–9]. An overview of these methodologies is given in Table 26.2.

573

574

26 Cost-Effectiveness of Vaccinations Tab. 26.2 Overview of types of pharmacoeconomic evaluations. Type of study

Intervention Consequences costs

Measurement of consequences

Compares alternatives

Assumes equivalent effectiveness

Cost–benefit analysis

monetary value of resources consumed

monetary value of outcomes

economic

not necessarily, no although comparisons are implicit

Cost–utility analysis

monetary value of resources consumed

utility of health effects

quality-adjusted yes life-years QALYs)

no

lives saved

no

indirect costs economic

Costeffectiveness analysis

subsequent use of resources

economic

monetary value of resources consumed

effects on health

yes

years of life saved indirect costs

cases treated

subsequent use economic of resources

An example of an economic analysis of a vaccination program is given in the appendix of this chapter for illustration and teaching purposes.

26.4 Cost-of-Illness Studies

In the economic literature one finds references to cost of illness. Definitions vary, but generally ‘cost of illness’ refers to all the costs as they are borne by society. The cost of illness to society is reflected by such factors as loss of productivity in the work force and loss of income by the patient, which results in the loss of tax revenues and inability to purchase the goods and services that drive the economy. The important point is that everyone in society bears the cost: healthcare providers, patients, thirdparty payers, and business and industry. 26.4.1 Cost-minimization Analyses

Cost-minimization analysis (CMA) is concerned with comparing the costs of different treatment modes that produce the same result. For example, this form of analysis could be used to compare the cost of two programs that involve minor surgery for adults.

26.4 Cost-of-Illness Studies

Both have the same outcome in terms of the surgical procedure, but the first program might require the patient to stay overnight at the hospital, and the second might be done through day surgery without requiring hospitalization. Given these two alternatives, the search would be for the least costly treatment. Although we might be interested in the extent to which day surgery shifts costs from the institution to the patient, the main efficiency comparison would be on a cost-per-surgical-procedure basis. As far as vaccines are concerned, this type of study is used most frequently when a new vaccine is introduced into a therapeutic class, which includes close competitors and no measurable therapeutic effect between them has been documented. When the cost of two interventions is being compared, cost-minimization analysis often assumes that they lead to identical health outcomes. Studies of this nature should report evidence to support the contention that outcome differences are nonexistent or trivial. In most instances, however, the issues are more than solely cost. It rarely happens that two therapies having the same indication produce identical health outcomes in every respect. 26.4.2 Cost–Benefit Analyses

As applied to healthcare, cost–benefit analysis (CBA) measures all costs and benefits of competing therapies in terms of monetary units. Generally, a ratio of the discounted value of benefits to costs (the present value of both) is calculated for each competing therapy. The ratios for each of the competing therapies and for competing programs (e. g., intensive care unit versus new diagnostic equipment) can be readily compared. CBA has the shortcoming of requiring the assignment of a dollar value to life and to health improvements, including quality-of-life variables. This presents equal benefit issues as well as substantial measurement problems. CBA, for these reasons, has not been widely used in recent years for evaluating drug therapies. 26.4.3 Cost-effectiveness Analyses

Cost-effectiveness analyses (CEA) measure changes in the cost of all relevant treatment alternatives, but measure the differences in outcomes in some ‘natural’ unit such as actual lives saved, years of lives saved, or children immunized. CEA can also be applied equally to instances where the outcome is in terms of quality of life. Costeffectiveness analysis is useful in comparing alternative therapies that have the same outcome units (e. g., years of life expectancy, or of lives saved), but the treatments do not have the same effectiveness (i. e., one drug may lead to greater life expectancy). The measure compared is the cost of therapy divided by the units of effectiveness, and hence, a lower number signifies a more cost-effective outcome. This type of study has the advantage that it does not require the conversion of health outcomes to monetary units and thereby avoids equal benefit and other difficult issues in the valuation of benefits. It has the disadvantage of not permitting comparison across programs that have different endpoints. In other words, a vaccine

575

576

26 Cost-Effectiveness of Vaccinations

whose function is aimed at reducing infant mortality rates cannot be compared with a vaccine designed to improve the functional status of senior citizens. Moreover, it cannot compare outcomes measured in clinical units with quality-of-life measures. 26.4.4 Cost–Utility Analyses

Cost–utility analysis (CUA) compares the added costs of therapy with the number of quality-adjusted life-years gained. The quality adjustment weight is a utility value, which can be measured as part of clinical trials or independently. The advantage of cost–utility analysis is that therapies that produce different or multiple results can be compared. As explained in the previous section, the QALY, which has been the standard measure of benefit thus far, is achieved in each instance by adjusting the length of time affected through the health outcome by the utility value (on a scale of 0 to 1) of the resulting health status. Many analysts are more comfortable with this measure of the consequences of medical care than with the use of money as the measure of benefits [10]. Cost–utility analysis is an improvement over cost-effectiveness analysis, because it can measure the effects of multiple outcomes (such as the impact of vaccines on both morbidity and mortality or the impact on both pain and physical functional status). Cost–utility analysis is essentially a special type of cost-effectiveness analysis, in which reductions in mortality and morbidity are combined in a single index. The most used is quality-adjusted life-years (QALY). QALYs combine changes in quantity and quality of life (QoL) into one composite measure that is independent of program or disease. This approach makes it possible to compare new vaccines across drastically different forms of illness, ranging from pneumonia to long-term neurologic impairments. The quality adjustment factors (or utilities) are weights ranging from 0 to 1 (1 = optimal health, 0 = health state judged equivalent to death). They should reflect aggregated preferences of individuals for the outcomes. The factors have been measured directly on patients and the general public. This approach is particularly useful for evaluating immunization programs that produce gains not only in mortality but also in morbidity, like vaccination against Haemophilus influenza type b or Streptococcus pneumoniae. 26.4.5 The Importance of the Perspective

The choice of the perspective is the single most important point in the analysis, because it determines which costs should be included and how they should be valued. The answer to the question of whether or not a vaccine is cost-effective may depend on who is asking it. Patients, society in general, or third-party payers may reach different judgments about specific costs. In the comprehensive societal perspective, all costs and benefits should be identified, regardless of who incurs the costs and who receives the benefits. Hospitalization costs, vaccine efficacy, and vaccine prices, as well as incidence of disease, are the main determinants in the cost-effectiveness equation. For a rotavirus

26.4 Cost-of-Illness Studies

immunization program, for example, number and cost of hospitalizations are of paramount importance. With the gradual decline of hospitalization rates associated with rotavirus diarrhea in the United States, the value of a rotavirus vaccine has decreased as well. Furthermore, with the changing health care system, some groups, like health maintenance organizations, may experience even lower rates of hospitalizations as the care of patients with diarrhea is shifted from the inpatient setting to the outpatient setting. Because caregiver loss of earnings accounts for more than 90 % of societal costs, companies contracting health services for their employees may perceive that societal costs are particularly important and may opt to pay for the vaccine themselves to ensure continuity in their workforce [11]. 26.4.6 The Use of Models

Most economic evaluations of immunization programs are based on decision-analytic models. Economic analysis almost always employs mathematical modeling or simulation to some extent. Modeling designs are, however, those in which the model is the primary feature of the analysis. The main advantage of such models is that they offer a flexible and timely framework for analysis. Because incidence rates of infectious diseases may differ substantially from year to year, models may offer the advantage of more stable estimates of incidence rates. Models however have clear limitations. Various pieces of information from different studies and populations are put together in the same model. Moreover, estimates incorporated into the analysis may be inaccurate, and because of the complexity of many models, biases may not be apparent to the readers of the study. Models may be very important in the forefront of developing vaccines, as an aid for research and development planning. As an example, Sandra and Taira [12] evaluated the cost-effectiveness of vaccinating adolescent girls for high-risk HPV infections relative to current practice. They assumed that a vaccine would become available with a 75 % probability of immunity against high-risk HPV infection. This might result in a life expectancy gain of 2.8 days or 4.0 quality-adjusted life-days at a cost of US$ 246 relative to current practice (incremental cost effectiveness of US$ 22 755/quality-adjusted life-year). The authors concluded that if all 12-year-old girls currently living in the United States were vaccinated, >1300 deaths from cervical cancer would be averted during their lifetimes. The vaccination of girls against highrisk HPV is likely to be relatively cost effective even when vaccine efficacy is low. If the vaccine efficacy rate is 35 %, the cost effectiveness increases to US$ 52 398/ QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial. A similar approach was used by Barnato et al. [13] for cocciodidomycosis. They used a decision model to determine that among children, vaccination would save 1.9 quality-adjusted life-days (QALD) and US$ 33 per person. Among adults, screening followed by vaccination would save 0.5 QALD per person and cost US$ 62 000 per quality-adjusted life-year gained over no vaccination. If the birth cohort in highly endemic counties of California and Arizona had been immunized in 2001, 11 deaths

577

578

26 Cost-Effectiveness of Vaccinations

would have been averted and US$ 3 million would have been saved (in net present value) over the lifetime of these infants. Vaccination of adults to prevent disseminated coccidioidomycosis would provide a modest health benefit similar in magnitude to other vaccines, but would increase the net expenditures. Vaccination of children in highly endemic regions would provide a larger health benefit and would reduce total healthcare expenditures. 26.4.7 Why Discounting?

Future cost and benefit streams are usually discounted to reflect the fact that money spent or saved in the future should not weight as heavily in the program decisions as money spent or saved today. This is primarily due to time preferences. That is, individually and as society, we prefer to have money or resources now as opposed to later, because we can benefit from them in the interim. 26.4.8 Dealing with Uncertainty

Economic evaluations of vaccines require the analyst to combine information on the incidence of the disease to be prevented, the probabilities of sequelae, the clinical effectiveness of the vaccine, and the costs incurred both in treatment of the disease and its sequelae as well as in the administration of the vaccine and in treating its adverse effects. Sensitivity analysis is the main method by which analysts allow for uncertainty. This implies changing the value of the variables known to be uncertain or to change over time. A plausible range for variation can be determined by reviewing of the literature or by consulting experts. Another approach is to use scenario analysis. Typically, the scenarios will include a base case (best-guess), the most optimistic scenario (best-case) and the most pessimistic (worst-case) scenario. Finally, another approach is to undertake a threshold analysis. Here, the critical value(s) of a parameter or parameters central to the decision are identified, and the analyst assesses which combination of parameter estimates could cause the threshold to be exceeded, making the program unacceptable. 26.4.9 Target Populations

Cost-effectiveness of immunization is very sensitive to incidence and prevalence rates of disease. Concentrating interventions in those segments of the population at high risk can turn an unfavorable cost-effectiveness ratio into a cost-effective intervention. Hepatitis A vaccination is indicated for persons at high risk of contracting hepatitis A, such as travelers, health workers, and people living in endemic areas. Incidence rates may vary greatly in different geographical locations and in different age cohorts. Because the case-fatality rate of hepatitis A increases with age, O’Connor

26.4 Cost-of-Illness Studies

and colleagues [14] studied the cost-effectiveness of hepatitis A vaccination strategies for adults in the United States. Compared with no intervention, testing for antibodies to hepatitis A and vaccinating those without antibodies saved an additional year of life at a cost of US$ 230 000. Compared with this strategy, vaccination of every adult over 50 years saved an additional year of life at a cost of US$ 20.1 million. Several factors make hepatitis A vaccination in adults prohibitively expensive. Most importantly, hepatitis A continues to remain a relatively uncommon disease in the United States adult population. Although mortality rates in those aged over 50 is relatively high, the number of years saved is relatively small. In addition, the cost of vaccination compared with other vaccines is high (US$ 114 for 2 doses). Moreover, in the United States annual incidence rates vary cyclically over time, with outbreaks occurring approximately every 10 years. The cost-effectiveness of influenza is well established in persons aged 65 years or older, a group that is at increased risk of severe influenza-related complications [15, 16]. However, in healthy adults younger than 65 years the cost-effectiveness is less clear. In a review of cost-effectiveness evaluations of influenza vaccination in healthy, working-age adults, Wood et al. [17] found that estimates varied widely compared with a no-vaccination strategy from a net cost of US$ 106 per infection averted in one study to net savings of US$ 46.85 per vaccinee [18]. Studies differed in design (prospective, retrospective, model-based), in the definition of illness, and in the measurement of costs associated with vaccination or illness. Moreover, influenza illness rates and vaccine efficacy may differ substantially from year to year, limiting their generalizability. 26.4.10 The Timing of Economic Studies

The management of the timing of economic studies follows as critical a pathway as does clinical management of the vaccine. There are various opportunities to perform different types of economic study. Yet, although there are a wide range of available instruments and tools for conducting an economic study, each study must be selected with careful consideration of the intended objective of the research. Cost of illness (or burden of the disease) could be of great value in the Phase 2 period. Generally, clinical trial personnel at this stage are of poor value for economic purposes, because the number of patents included is small and the protocol contract is great. It is possible to undertake prospective economic studies in Phase 3, as soon as the number of patients included is great enough. However, it is in the premarketing period just after the availability of marketing approval, that such a pharmacoeconomic study should be performed, to support the reimbursement and price-negotiation process. Phase 3 b and Phase 4 are the time to undertake pharmacoeconomic studies, provided that they approximate real life as closely as possible. Including economic parameters in study protocol forces one to consider the limits of the protocol itself and to think about the nature and constraints of the protocol.

579

580

26 Cost-Effectiveness of Vaccinations

26.4.11 Collecting Economic Data during a Clinical Trial

As described above, it may be practical and cost-effective to gather certain data during a clinical trial that is otherwise designed to measure the efficacy and adverse effects of a compound under study. However, generating economic data in Phase 3 is not without some controversy. Some researchers point out that clinical trials measure efficacy – the performance of the drug in controlled circumstances. However, as the name suggests, cost-effectiveness studies are aimed at determining the costs and benefits under real conditions. Whereas health authorities like the FDA permit the use of placebos as comparators in trials, this does not provide useful information in economic trials and particularly in the measurement of costs. At the time Phase 3 trials begin, the new drug may be compared against the existing ‘gold standard’. However, by the time the new product gets to market, there may be other products that are more appropriate comparators but which were not on the market when the trials started. This situation is compounded by the economist's view that the comparator product should be the one that is most likely to be replaced in practice. The process of collecting costs during clinical trials merits special attention. There are certain costs incurred on the patient's behalf as a result of procedures that would not normally be given. These costs, called protocol-driven costs, must be isolated and not included in the analysis. In practice this does not cause serious problems, because these same added costs were being incurred in both arms of the trial and hence would cancel each other out. 26.4.12 Post-marketing Studies and Pharmacoeconomics

A pharmacoeconomic evaluation has a different focus than the clinical trial in two respects. First, the economic evaluation is concerned more with extrapolating what happens in real life than what happens under controlled conditions. Second, the economic study attempts to measure different outcomes. Although the clinical trial focuses on medical indicators, the economic study is designed to measure the effects on resource consumption, production, and/or QoL. Therefore, the design aspects of a clinical trial may often introduce a bias in the measurement of the effect. The simple fact of randomizing patients into two groups: the drug to be evaluated and a reference drug or a group of reference drugs invariably differentiates the study from actual medical practice patterns, in which physicians try to prescribe the right drug for the right patient. So, purely observational post-marketing pharmacoeconomic studies (PMS) might be seen as an interesting alternative to randomizing the clinical trial even in naturalistic, realistic, or pragmatic styles. The design of the study is as simple as possible. Different designs of PMS studies are available with or without a case-control group. Through PMS pharmacoeconomic studies, it is also possible to obtain a comparative evaluation of strategy that could not be compared in randomized clinical trials,

26.5 Areas of Controversy

for ethical reasons. The weakness of PMS pharmacoeconomic studies is the relative lack of statistical power compared with randomized clinical trials. Regardless, researchers must be aware in performing PMS pharmacoeconomic studies not to transform them into a naturalistic study and to keep them scientific. This problem could be solved by employing data from physicians using office-based computers to follow their patients. The data obtained from doctors' in-office computers are a very valuable tool in performing pharmacoeconomic studies, because they provide the best representation of real life. Generally, data are collected in real time for each patient consulting for any condition. The data are generally collected first for the physician’s own use, and thus any bias in the collection is kept to a minimum. Furthermore, pharmacoeconomic studies based on doctors’ in-office computer data are superior to those using data collected from a large number of practices, including GPs and specialists, and if the studies are based on a wide variety of outcomes, including health indicators, biological parameters, and medical resources. The great strength of PMS pharmacoeconomic studies is that they provide a description of what is happening in the real world with real patients.

26.5 Areas of Controversy 26.5.1 Measuring Indirect Costs

Health economists have two approaches by which to determine the indirect cost of disease, but both are subject to criticism or potential bias. The human-capital approach is based on the concept that human beings are similar to capital equipment (at least insofar as their working lives are concerned) in the sense that they can be expected to yield a flow of productive activity in future years. If the value of this activity in any period of time is assumed to be equal to the individual's rate of pay, then the benefits of health care can be measured in terms of forgone income due to ill health. Criticisms of this approach include:

.. . .

ethical objections to monetary values being placed on human lives use of rates of pay as a measurement of value, because these are subject to varying labor market conditions ignoring the nonfinancial costs of pain, suffering, and grief that are often associated with illness not based on an individual’s valuation of benefits – a third-party view is taken about a person's ‘worth’ to society in terms of productive potential

Another approach involves the individuals' willingness to pay, which seeks to establish the value that people attach to health care outcomes by asking them how much they would be prepared to pay to obtain the benefits or avoid the costs of illness. This method involves the use of questionnaires containing either open-ended

581

582

26 Cost-Effectiveness of Vaccinations

or discrete-valuation questions. This is the preferred method among health economists, but questionnaires have to be carefully designed to avoid bias [19]. 26.5.2 Externalities

As with most infectious diseases, the inevitable spread of disease, as well as the constitution of herd immunity effects, represents the so-called economic externalities. This means that the economic impact of these events should also be taken in account. Unfortunately, most clinical economic approaches have not specifically valued these externalities. Thus, the economic burden of influenza and the cost-effectiveness of its management interventions might be underestimated in most studies available. 26.5.3 Methodologic Quality

The quality of economic evaluations for interventions against communicable diseases, including vaccines, has been variable [20]. In too many instances, studies have not complied with appropriate techniques recommended in standard textbooks of economic evaluation [21, 22]. Two important responses to this problem have recently been provided. First, in 2002 a consensus statement on appropriate methods for economic evaluation of vaccination programs was published by Beutels et al. [23]. Second, the journal Vaccine very recently published an editorial policy statement on the submission of economic evaluations of vaccines [24]. The editors of Vaccine decided to use the guidelines defined by the British Medical Journal in 1996 for authors and peer reviewers of economic evaluations to ensure clear standards for submission and editorial management [25]. Table 26.3 displays the quality criteria of the British Medical Journal guidelines.

26.6 Challenges of the Future

We are now undoubtedly in an era of assessment and accountability for all new technologies in healthcare. However, sufficient economic data are still lacking to support the formulation of health policy, and a particular challenge for the future is to conduct further health economic research on immunization. Specific areas for such studies include:

. .. ..

effectiveness under field conditions (i. e., not under the conditions of a randomized controlled trial) the real value of economic production losses the conditions for implementing novel immunization programs cost estimates for more ambitious immunization programs the economic benefits of combination vaccines

26.6 Challenges of the Future Tab. 26.3 Checklist for submission of economic evaluations to the British Medical Journal. Recently adopted by the editors of Vaccine. Study design 1. The research question is stated. 2. The economic importance of the research question is stated. 3. The viewpoint(s) of the analysis are clearly stated and justified. 4. The rationale for choosing the alternative programs or interventions compared is stated. 5. The alternatives being compared are clearly described. 6. The form of economic evaluation used is stated. 7. The choice of form of economic evaluation is justified in relation to the questions addressed. Data collection 8. The source(s) of effectiveness estimates used are stated. 9. Details of the design and results of effectiveness study are given (if based on a single study). 10. Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness studies). 11. The primary outcome measure(s) for the economic evaluation are clearly stated. 12. Methods to value health states and other benefits are stated. 13. Details of the subjects from whom valuations were obtained are given. 14. Productivity changes (if included) are reported separately. 15. The relevance of productivity changes to the study question is discussed. 16. Quantities of resources are reported separately from their unit costs. 17. Methods for the estimation of quantities and unit costs are described. 18. Currency and price data are recorded. 19. Details of currency of price adjustments for inflation or currency conversion are given. 20. Details of any model used are given. 21. The choice of model used and the key parameters on which it is based are justified. Analysis and interpretation of results 22. Time horizon of costs and benefits is stated. 23. The discount rate(s) is stated. 24. The choice of rate(s) is justified. 25. An explanation is given if costs or benefits are not discounted. 26. Details of statistical tests and confidence intervals are given for stochastic data. 27. The approach to sensitivity analysis is given. 28. The choice of variables for sensitivity analysis is justified. 29. The ranges over which the variables are varied are stated. 30. Relevant alternatives are compared. 31. Incremental analysis is reported. 32. Major outcomes are presented in dissaggregated as well as aggregated forms. 33. The answer to the study question is given. 34. Conclusions follow from the data reported. 35. Conclusions are accompanied by the appropriate caveats.

From this research, it will be important to disseminate the data and to adapt the findings to other countries. Nevertheless, the source of funding for research and its application in clinical trials programs represents some of the practical problems faced by medical economics today within academia and the industry.

583

584

26 Cost-Effectiveness of Vaccinations

26.6.1 Limitations and Ethical Issues

The general ethics of economic assessment of technologies rests on the fundamental supposition that information is a condition of making good choices and that ‘good’ is what results in the greatest good for the greatest number. Of primary concern from a policy viewpoint is the fact that cost-effectiveness analyses do not usually incorporate the importance of the distribution of the costs and the consequences (health gains) among different patient or population groups into the analysis. Yet, in some cases the identity of the recipient group (e. g., the poor, the elderly, working mothers, or a geographically remote community) may be an important factor in assessing the social desirability of an immunization program. Indeed, it may be the motivation for the program itself. Although it is sometimes suggested that differential weights be attached to the value of outcomes accruing to special recipient groups, this is seldom done. Rather, an equitable distribution of costs and consequences across socioeconomic or other defined groups in society is viewed as a competing dimension upon which decisions are made, in addition to that of efficient deployment of resources. Another point of controversy is when we should allow an aggregation of modest benefits to larger numbers of people to outweigh more significant benefits to fewer people. Within the model, all QALYs are considered equal without regard to the nature of the health benefit that they measure. Thus, the number of QALYs gained through many people receiving a small health benefit as a result of a reduction of a minor form of illness can be the same as the number of QALYs gained by averting a very small number of deaths. And finally, economic evaluation techniques assume that resources freed or saved by preferred programs will be employed in alternative worthwhile programs. This assumption warrants careful scrutiny, for if the freed resources are consumed by other ineffective or unevaluated programs, then not only is there no savings, but overall healthcare system costs will actually increase without any assurance of additional improvements in the health status of the populations. 26.6.2 Strategic Outlook for the Vaccine Industry

Health economics will become one of the most significant strategic success factors for the biotech industry in an era of cost-containment. The challenge will not only be to meet the requirements of government agencies and payers who are increasingly asking for economic assessments of commercial products, but also to address the value of medical economics to clinicians. In the future, it will certainly be necessary for clinicians to apply the tools of economic analyses both in research and in practice. Instead of waiting for policy analysts, third-party payers, or governmental agencies to hand down decisions about which services are deemed worth the cost, physicians

26.7 Case Study ... : Economic Evaluation of Vaccination ...

might also become practicing clinical economists. Another approach is to explore ways in which clinical decisions are both influenced by and also influence the cost of care. Clinicians need to integrate economic thinking into their decision-making if medical care is to be rational but not rationed. Biotech/vaccine and pharmaceutical companies can contribute significantly to this process by expanding economic research on their products, by providing training and know-how to medical professionals, and by encouraging customers to acknowledge the validity of such research.

26.7 Case Study for Illustration and Education: Economic Evaluation of Vaccination of Children Against Hepatitis A and Hepatitis B in Germany

A short, abstract version of this study was published [2]. 26.7.1 Objective

The purpose of study was to compare three different combined vaccination strategies against hepatitis A (HAV) and hepatitis B (HBV) with nonvaccination in children and youths and to analyze net costs per strategy, cost-effectiveness, and epidemiological development in projection for the next 30 years in Germany. This study also determined the cost-effectiveness of combined vaccination against hepatitis A and B vs. vaccination only against hepatitis B. 26.7.2 Methodology

An overview over a period of 3 times 10 years is given, developing models according to present data on the German population, birth rate development, incidence and course of disease, and costs of treatment. Missing data are replaced with considerate estimates. The evaluation was conducted separately for hepatitis A and hepatitis B, calculating the incidence and cases of infection for each, as well as disease and treatment costs. Then both datasets were brought together, adding vaccination costs, and incrementing them to the nonvaccination scenario. 26.7.2.1 Determination of Costs In general, costs are calculated as price multiplied by quantity. During this study, vaccination and treatment costs were evaluated from a statutory health insurance fund (third-party payer, TPP) perspective. The number of expected infections with or without vaccination and the extrapolated number of avoided infections were determined. Age-adjusted decision trees for calculation of the number of expected manifestations per course with the respective possibilities of occurrence are developed separately for hepatitis A in age groups 0 < 15 years and = 15 years and for hepatitis B

585

586

26 Cost-Effectiveness of Vaccinations

in age groups 0 < 5 years, 5 < 15 years, and = 15 years). Treatment costs per strategy were calculated as numbers of cases and courses multiplied by costs per case and course. Incremental net costs resulted from the total difference in treatment costs for hepatitis A or B (with or without vaccination) plus the costs of combined hepatitis vaccination. Costs per case and course were obtained retrospectively from standardized interviews with pediatricians and from the literature. All costs were discounted at the beginning of each cycle (10 years, discount rate 5 % p. a.). 26.7.2.2 Determination of Effectiveness Effectiveness is defined as the extent to which medical interventions achieve health improvements in real practice settings. In this study, reduction of infection and number of avoided infections represent the parameters of effectiveness. 26.7.2.3 Determination of Cost-effectiveness Cost-effectiveness is assessed as cost per avoided hepatitis A or hepatitis B infection, dividing incremental net costs by the number of avoided hepatitis A or hepatitis B infection accumulated for all three cycles. A result is given for each strategy. Furthermore, the remaining costs of vaccination and of unavoidable treatment were calculated to show the remaining burden for TPP. 26.7.3 Results

It was possible to demonstrate the following for the next 30 years, based on the situation in Germany: 26.7.3.1 Costs The vaccination costs for all three cycles were A 1.02 billion in the vaccination strategy 11–15 years, A 2.35 billion in the vaccination strategy 1–15 years, and A 2.4 billion in the vaccination strategy 0–15 years. Age adjusted decision trees for calculation of the number of expected manifestations per course with the according possibilities of occurence are developed separately for hepatitis A in age groups below and above 15 years and for hepatitis B in age groups 0 < 5 years, 5–14 years and above 15 years. Significant decrease in new infections would lead to savings in treatment costs between A 1.48 billion by vaccination at age 11–15 years and A 2.61 billion by vaccination at age 0–15 years. 26.7.3.2 Effectiveness I determined that a maximum reduction of new infections with HAV of up to 59 500 would be obtained by vaccination of all 0–15-year-old children, with 5700 new infections over 30 years remaining. A maximum reduction of new infections with HBV of up to 46 700 by vaccination of all 0–15-year-old children, with 6700 new infections in 30 years remaining may be expected. A signifycant drop in HAV and HAB incidence in the vaccinated age groups should occur (Table 26.4).

26.7 Case Study ... : Economic Evaluation of Vaccination ... Tab. 26.4 Expected number of infections with and without vaccination against HAV and HBV. Vaccination strategy All aged 11–15 years All aged 1–15 years

All aged 0–15 years

HAV Infections without vaccination Reduction Remaining infections

65.151 –19.826 45.325

65.151 –57.596 7.555

65.151 –59.475 5.676

HBV Infections without vaccination Reduction Remaining infections

53.304 –21.905 31.399

53.304 –45.820 7.484

53.304 –46.640 6.664

26.7.3.3 Cost-effectiveness The cost-effectiveness of vaccination ranges from costs of A 46 118 per avoided HAV or HBV infection up to savings of about A 25 564 per avoided HAV or HBV infection, depending on cycle and vaccination strategy. Considering the commonly accepted number of unreported cases of hepatitis A and hepatitis B as 5 times the known incidence, the range of savings per avoided HAV or HBV infection is between A 1329 and A 35 688 (Tables 26.5–26.7). By varying some of the assumptions used in the study, it is possible to see how much impact some of the key parameters have on the overall result. From the mathematical examples given above, we can see how changing the vaccine efficacy and Tab. 26.5 Cost-effectiveness of a combined vaccination against hepatitis A and B (costs discounted over 10, 20, and 30 years, discount factor 5% p. a. Vaccination strategy All aged All aged 11–15 years 1–15 years

All aged 0–15 years

1. Cycle Net cost, discounted in Mio* A Avoided infections Cost per infection avoided (C)

292.913 7,787 37,616

1,077.258 23,375 46,086

1,124.045 24,373 46,119

2. Cycle Net cost, discounted in Mio* A Avoided infections Cost per infection avoided (C)

–152.629 14,767 –10,336

–282.838 35,896 –7,880

–286.070 36,764 –7,781

3. Cycle Net cost, discounted in Mio* A Avoided infections

–184.690 19,177

–333.764 44,145

–336.615 44,978

Cost per infection avoided (C)

–9,631

–7,560

–7,484

Cost per infection avoided (C), cumulative over all 3 cycles (C)

–1,064

4,454

4,725

* Mio = Million

587

588

26 Cost-Effectiveness of Vaccinations Tab. 26.6 Cost-effectiveness of a combined vaccination against HAV and HBV assuming a five-fold increased rate of underreporting. Cost-effectiveness (Cost per avoided infection, discounted, 3 cycles cumulated, in D )

Reported incidence 5-fold incidence *

Vaccination strategy All aged 11–15 years

All aged 1–15 years

All aged 0–15 years

–1.064 –15.953

4.454 –10.010

4.725 –9.728

* Assuming that the underreported rates are similarly distributed for all age groups and virus types.

Tab. 26.7 Remaining costs due to a 5-fold higher rate of underreporting in comparisonto basecase results. Remaining costs of vaccination and treatment (discounted, 3 cycles cumulated, in bn D )

Reported incidence 5-fold incidence *

Without vaccination

Vaccination strategy All aged 11–15 years All aged 1–15 years All aged 0–15 years

1,732 8,658

1,688 5,331

2,193 3,483

2,233 3,498

* Assuming that the underreported rates are similarly distributed for all age groups and virus types.

compliance rates has a direct effect on the number of avoided infections. More subtle variations in the costs of treatment and in the discount rate can have largescale effects on the overall cost-effectiveness of a program. It is good practice in health economic models to test the assumptions made by varying the parameters and determining the revised outcomes. In this study, variation in the protective efficacy and compliance rates were tested, along with changes in treatment costs and discount rates (Table 26.8). Discount rates are essentially equivalent to interest rates. To achieve an investment outcome of A 511.29 after a fixed period, you can either invest a smaller initial sum at a higher interest rate or invest a larger initial sum at a lower interest rate. Hence, a low interest rate (discount rate) requires a greater initial investment – that is, the treatment is more expensive at lower discount rates. The current situation in Germany is that children are vaccinated against hepatitis B as part of the routine childhood immunization schedule, with a catch-up vaccination at 11–15 years if necessary. The comparison of combined vaccination with single hepatitis B vaccination gives a more accurate picture of the potential savings that could be made within the German healthcare system. Although the existing hepatitis B vaccination program is effective at reducing the incidence of hepatitis B, it does not offer any absolute cost savings. The substitution of the combined vaccine improves the cost-effectiveness by reducing the number of hepatitis A infections, while increasing costs only in terms of the difference in price between the combination vaccine vs. the monovaccine.

26.7 Case Study ... : Economic Evaluation of Vaccination ... Tab. 26.8 Sensitivity analysis: changes in cost-effectiveness, cumulative over all cycles.

Variable/value

Cost per avoided infection (in D ) Vaccination strategy All aged 11–15 years All aged 1–15 years All aged 0–15 years

Vaccine effectiveness 99 % (base case) 90 % 85 %

–1.064 796,59 1.994

4.454 6.267 7.431

4.725 6.536 7.698

Compliance < 11 J./= 11 J. 100 %/50 % (base case) 100 %/20 % 80 %/20 %

–1.064 –1.069 –1.069

4.454 5.412 9.523

4.725 5.674 9.790

Treatment costs –20 % –10 % Base case +10 % +20 %

2.871 903,453 –1.064 –3.032 –4.999

7.180 5.817 4.454 3.091 1.729

7.393 6.059 4.725 3.390 2.056

Discount factor 5 % p. a. (base case) 3 % p. a.

–1.064 –4.746

4.454 2.861

4.725 3.230

Costs discounted 10, 20, or 30 years, 5 % p. a. in base-case analysis.

An interesting observation is the increase in cost-effectiveness offered by the addition of hepatitis A vaccination to the existing program. All three age strategies offer significant savings over the only-hepatitis-B strategy (Table 26.9). 26.7.3.4 Which Strategy Saves the Most Money? All the vaccination strategies save money in terms of the treatment cost of avoided infections, but this saving must be offset against the costs of vaccination. The net costs of vaccination are greatest in the 0–15 age group, purely because of the number of individuals vaccinated in the first year of the study period (Table 26.10). 26.7.3.5 Which Strategy is the Most Effective in Terms of Disease Prevention? The greatest number of hepatitis A and B infections are avoided by vaccination of the 0–15 year age group. However, the severity of hepatitis infections increases with age. Only 10 % of children up to the age of 15 y suffer from symptomatic hepatitis A infection compared to 75 % of those aged 15 or more. For the purposes of this study, I assumed that hepatitis A infection caused no complications and had no sequelae. If the most cost-effective strategy is used – vaccination of all 11–15-year-olds – a large proportion of the group at highest risk of HAV infection is left unprotected (incidence 9.9/100 000 at 0–4 years; 11.8/100 000 at 5–14 years). Hepatitis B, although it has a lower incidence, is a more serious infection than hepatitis A. It is likely to be symptomatic in about 30 % of cases occurring in those aged 5–14 years and in about 34 % of cases in those aged 15 years and above. In patients aged 5–14 who suffer a

589

590

26 Cost-Effectiveness of Vaccinations Tab. 26.9 Comparison of vaccination against hepatitis B with a combined vaccination hepatitis B plus A in Germany. Differences are displayed for costs and outcomes over 30 years. Vaccination strategy All aged 11–15 years All aged 1–15 years

All aged 0–15 years

Vaccination costs HBV vaccination HAV–HBV vaccination Incremental vaccination costs

A 0.630 bn A 0.777 bn C 146,74 Mio

A 1,553 bn A 1,870 bn C 317 Mio

A 1,553 bn A 1,917 bn C 365 Mio

Avoided infections HBV vaccination HAV–HBV vaccination Incremental avoided infections

21.905 41.731 19.826

46.640 103.416 56.776

46.640 106.115 59.475

Cost-effectiveness ratio (CER) HBV vaccination HAV–HBV vaccination Change in CER

A 7.276 A –1.064 C 8.340

A 15.306 A 4.454 C 10.851

A 15.305 A 4.725 C 10.580

* Comparison with HBV vaccination of all 0–15-year-old children and adolescents

Tab. 26.10 Vaccination costs and treatment savings. 0–15 year-olds: A 1.92 billion/ 1–15 year-olds: A 1.87 billion/ 11–15 year-olds: A 0.78 billion/

0–15 year-olds: A 1.42 billion 1–15 year-olds: A 1.41 billion 11–15 year-olds: A 0.82 billion

symptomatic infection, 40 % are likely to become carriers of hepatitis B, which has a marked effect on the incidence of liver disease and hepatocellular carcinoma in later life. In terms of preventing the disease, a high number of chronic carriers also presents a significant reservoir of virus persisting in the community. 26.7.4 Discussion

In conclusion, by means of all compared combined immunization strategies against hepatitis A and hepatitis B virus, it is possible to demonstrate a beneficial influence on the epidemiology of both viruses and to obtain a decrease in incidence. Because this regression seems to be stronger the more extensive the immunization is, a vaccination of all 0–15-year-old children should be preferred from an epidemiological point of view. Considering the scenario of a combined HAV/HBV vaccination from 11 to 15 years, a large percentage of the population, at high risk of hepatitis A infection, still remains without protective vaccination. In all three vaccination strategies, savings per avoided infection can be achieved starting at the second cycle of the study. Vaccination between 11–15 years seems to be the preferable strategy from an economic point of view.

26.7 Case Study ... : Economic Evaluation of Vaccination ...

The remaining costs (for vaccination and unavoidable diseases) are only slightly higher for the extensive immunization strategies (none vs. 1–15 years) than for the vaccination from 11 to 15 years, because they avoid more infections and thereby lower resulting treatment costs. By considering the unreported cases of HAV or HBV infections, an improved costeffectiveness can be shown, which ranges between savings of A 1329 and A 35 688 per avoided infection now. According to present calculations, the use of an initially more expensive combined vaccine represents a cost-effective alternative to the sole hepatitis B vaccination and also shows a more beneficial effect from an epidemiological point of view. Simply considering cost-effectiveness, the 11–15 year old vaccination strategy appears to be most economically favorable, because the cost per avoided infection is lowest. However, because this strategy protects the fewest children, it saves the least amount of money, because the remaining number of infections in the 0–11 age group (and therefore the expense of treating these infections) is highest. Also, looking at the wider issue of disease control, neither hepatitis A nor B will be eradicated by the 11–15-year-old strategy. Those aged younger than 11 years remain at risk of hepatitis A infection at the period of highest incidence, and childhood hepatitis B infections with a high likelihood of developing carrier status are not avoided. From an epidemiological standpoint, vaccination of 1–15 or 0–15 year olds will achieve substantially better results. Comparing a combined hepatitis vaccination with sole hepatitis B strategy, the cost-effectiveness of hepatitis B vaccination programs can be improved by substituting the combined vaccine into the existing framework. In summary:

. .

Combined vaccination against hepatitis A and B in 11–15 year-old children is a cost-effective strategy offering financial savings. The vaccination of 11–15 year-olds offers the smallest absolute savings in terms of avoided treatment costs.

In medical terms (i. e., avoided infections), the most effective vaccination strategy against hepatitis A and B is vaccination of all children aged 0–15 years. When the number of unreported cases of hepatitis A and B is taken into consideration, universal vaccination of all children aged 0–15 years is cost-effective. The replacement of the current hepatitis B vaccination program with a combined vaccination program will improve the cost-effectiveness of hepatitis vaccination in all pediatric age groups. These findings take no account of the savings associated with protection against hepatitis A and B in individuals aged more than 15 years. 26.7.4.1 Limitations of the Study Limitation comment birth cohorts were no longer hepatitis A and B infections are both more clinically included in the study population significant in the adult population. Once beyond this age and as they became older than 15, the potential savings from avoided infections in adulthood was not considered. Had just the initial 11–15year-old cohorts been followed over the entire 30-year period (i. e., until the first co-

591

592

26 Cost-Effectiveness of Vaccinations

hort of 15-year-olds was 45), the savings associated with avoided disease in adulthood would be substantial. Varying the compliance rates in all patients leads to higher costs per avoided infections. However, the cost-effectiveness ratio of vaccination all 11–15 year olds remains stable. This is mainly due to a proportionate increase of costs and effectiveness resulting in a constant ratio. That the result of this strategy are affected by changes in compliance is reflected in the amount of remaining costs. The fact that a higher proportion of the population would remain unprotected into adulthood was not considered. The results are not directly applicable to other countries, because they are based on German data and because of potential differences in epidemiology, incidence healthcare models, and healthcare funding.

References 1. Jefferson T. Do vaccines make best use of available resources? Vaccine 1999, 17 (Suppl.3), S69–73. 2. Szucs T. Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 2000, 18, S86–89. 3. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilisation? Can Med Assoc J 1992, 146, 473– 481. 4. Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, D.C.: National Academy Press; 2000. 5. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997, 39, 408–414. 6. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999, 281, 908–913. 7. Carman WF, Elder AG, Wallace LA, McAulay K,Walker A, Murray GD, Stott DJ. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000, 355, 93–97. 8. Luce BR, Elixhauser A. Standards for the Socioeconomic Evaluation of Health Care Services. Berlin: Springer, 1990. 9. Szucs TD, Schramm W: Die sozioökonomische Evaluation. Einführung in

10.

11.

12.

13.

14.

15.

16.

17.

die Methodologie. Hämostaseologie 1994, 14, 84–89. Drummond M: Cost-effectiveness league tables: more harm than good. Soc Sci Med 1993, 37, 33–40. Tucker A, Haddix A, Bresee J, et al. Cost-effectiveness Analysis of a rotavirus immunization program for the United States. JAMA 1998, 279, 1371– 1376. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9, 797–806. Barnato A, Sanders G, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis 2001, 7, 797–806. O’Connor JB, Imperiale TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 1999, 30, 1077–1081. Nichol K, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. PharmacoEconomics 1999, 16(Suppl 1), 63–71. Mullooly J, Bennett M, Hornbrook M, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994, 121, 947–952. Wood S, Nguyen V, Schmidt C. Economic evaluations of influenza vaccination in healthy working-age adults: em-

References

18.

19.

20.

21.

22.

23.

24.

25.

26.

ployer and society perspective. PharmacoEconomics 2000, 18, 173–183. Nichol KL LA, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995, 333, 889–893. Johannesson M, Jonsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 1991, 19, 55–77. Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ. 2000, 9, 681–698. Gold MR, Siegel JE, Russell LB, Weinstein MB. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. Drummond M, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Second edition. New York: Oxford University Press, 1998. Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pechevis M,Van Doorslaer EK, van Hout BA. Economic evaluation of vaccination programs: a consensus statement focusing on viral hepatitis. Pharmacoeconomics. 2002, 20, 1–7. Spier R, Jeffereson T, Demicheli V. An editorial policy statement: submission of economic evaluations of vaccines. Vaccine 2002, 20, 1693–1695. Drummond MF, Jefferson TO. Related articles, links guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996, 313, 275–283. Ekwueme D, Strebel P, Hadler S, et al. Economic evaluation of use of diphtheria, tetanus and acellular pertusis vaccine or diphtheria, tetanus and whole-cell pertusis vaccine in the Uni-

27.

28.

29.

30.

31.

32.

33.

34.

35.

ted States, 1997. Arch Pediatr Adolesc Med 2000, 154, 797–803. Carlin, J, Jackson, T, Lane, L, et al. Cost effectiveness of rotavirus vaccination in Australia. Australian and New Zealand Journal of Public Health 1999, 23, 611–616. Takala, A, Koskenniemi, E, Joensuu, J, et al. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998, 27, 272–282. Ess S, Schaad UB, Gervais A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 2003, 21, 3273–3281. McIntyre, P, Hall, J, Leeder, S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Australian Journal of Public Health 1994, 18, 394–400. Livartowski, A, Boucher, J, Detournay, B, et al. Cost-effectiveness of vaccination against Haemophilus influenzae invasive disease in France. Vaccine 1996, 14, 495–500. Jimenez, F, Guallar-Castillon, P, Rubio Terres, C, et al. Cost–benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. PharmacoEconomics 1999, 15, 75–83. Buxton Bridges, C, Thompson, W, Meltzer, M, et al. Effectiveness and cost–benefit of influenza vaccination of healthy working adults. JAMA 2000, 284, 1655–1663. Nichol, K. Cost–benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001, 161, 749–759. Jacobs, R, Margolis, H, Coleman, P. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 2000, 154, 763–770.

593

595

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations Michel Goldman and Paul-Henri Lambert

27.1 Introduction

The development of new vaccines and novel vaccination strategies will more and more depend on adequate consideration of safety issues. Indeed, despite the remarkable achievements of vaccines in protecting whole populations from major infectious threats, public skepticism about vaccines is rapidly rising in a context of distrust in science and increased attention to safety. Public concern about vaccine safety was already manifest at the time of the first cowpox vaccination trial by Jenner [1]. One would have anticipated that the extraordinary success of this vaccine, which ultimately allowed smallpox eradication, would definitively ensure public acceptance of immunization programs. However, it turned out that the efficacy of vaccines actually exerted the opposite effect on their acceptance. As a matter of fact, concerns about the side effects and risks of vaccines increased when the burden of the targeted diseases decreased. Many vaccine-preventable diseases are currently so rare in developed countries that real or hypothetical side effects of the corresponding vaccines become dominant in the public’s perception [1, 2]. The consequences of decreased vaccine coverage caused by a loss of public confidence in vaccines proved to be dramatic in several circumstances. For example, major pertussis epidemics occurred during the 1970s in countries where antivaccine movements exploited the fear of irreversible brain damages after whole-cell pertussis vaccination, which ultimately proved to be unjustified [1, 3]. More recently, important outbreaks of measles caused by decreased vaccine uptake occurred in the Netherlands, United Kingdom, and Ireland [4, 5] in relation to allegations about side effects of the measles vaccine, especially its putative involvement in the pathogenesis of autism. The restoration of public trust in vaccines should be considered a priority of public health policies. This will depend both on a critical assessment of vaccine safety and on the ability of the scientific community and health authorities to disseminate the available information in a credible manner. Established facts should be recognized, unsubstantiated allegations should be rebutted on a scientific basis, and uncertainties should be acknowledged. Herein, we use this approach to discuss current views

596

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

on vaccine safety, with particular attention to the risk of autoimmunity, which became a major issue in recent years.

27.2 Recognized Adverse Effects of Vaccines: a Brief Overview

The most common side effects of vaccines are related to the transient inflammatory reaction they elicit, and the other adverse reactions are extremely rare (Table 27.1). Some degree of inflammation is required for the efficient induction of acquired immunity, and the adjuvant contained in vaccine formulations acts at least in part by triggering local inflammation. This often results in various degrees of pain and redness at the site of vaccine injection. Occasionally, a transient systemic reaction consisting of fever, myalgias, or headaches might develop. The degree of inflammation, usually qualified as reactogenicity, varies according to the vaccine considered. It is usually more important with live attenuated vaccines (see below) and the whole-cell pertussis vaccine. Indeed, the latter induces local redness and swelling in 30 % of vaccinees and fever in about 40 % of them. Persistent crying, seizures, and hypotonic–hyporesponsive episodes can also occur after whole-cell pertussis vaccination, but with a much lower frequency [6]; however, allegations about the vaccine causing sudden infant death syndrome, infantile spasms, or epilepsy were denied on the basis of appropriate studies [1]. For live attenuated vaccines, the low-grade infection related to the replication of the vaccine agent might result, not only in mild systemic symptoms, but also occasionally in some features of the original infection. With measles–mumps–rubella vaccine, skin rashes occur in about 5 % of vaccinees, and thrombocytopenia in about 1/30 000 individuals (see below). Likewise, about 3 %–4 % of children immunized with a varicella vaccine developed a mild vesicular rash [2]. Paralytic poliomyelitis is an extremely rare complication of the oral polio vaccine (1 in 760.000 vaccinations). Tab. 27.1 Rare severe adverse effects caused by live vaccines. Vaccine

Adverse effect (rate)

Measles–mumps–rubella

thrombocytopenia (1/30 000) encephalitis (1/million) meningitis (2/million)

Oral polio

paralysis (1/million)

Rotavirus *

intussusception (1/10 000)

Smallpox

eczema vaccinatum systemic vaccinia encephalitis myocarditis/pericarditis death (1/million)

i e y (40/million **) e t

* Rotashield vaccine, withdrawn in 1999. ** Global rate of life-threatening reactions expected from past experience.

27.2 Recognized Adverse Effects of Vaccines: a Brief Overview

Allegations about the risk of cancer related to simian virus 40 contamination of some initially used oral polio vaccines were not substantiated. This theoretical risk does not deserve consideration with current vaccines, which are produced by using cells from SV-40-free monkey colonies. Likewise, the hypothesis about a connection between oral polio vaccine and the HIV epidemic was ruled out conclusively [1]. The smallpox vaccine recently reintroduced in the United States is probably the vaccine endowed with the highest degree of reactogenicity. It frequently induces local pain and erythema at the inoculation site, regional lymphadenopathy, and fever, reflecting active replication of vaccinia virus [7]. In a recent study, although these adverse events were not serious, in more than one third of subjects they were causes of missed work, school, sleep, or recreational activities [7]. Moreover, this vaccine is expected to occasionally cause severe reactions, including eczema vaccinatum, systemic vaccinia, and post-vaccinal encephalitis. Eczema vaccinatum preferentially develops in patients with skin diseases, especially atopic dermatitis, whereas systemic vaccinia mainly affects patients with immune deficiency. Smallpox vaccination is therefore contraindicated in these patient populations. Recently, the Centers for Disease Control called attention to cases of myocarditis and pericarditis that developed after smallpox vaccination, so the vaccine is currently not administered to patients with cardiovascular disease. On the basis of past experience, the overall rate of severe side effects and fatalities caused by smallpox vaccination should be around 1000 and 1 per million vaccinees, respecttively. Importantly, vaccinated persons may inadvertently inoculate unvaccinated persons, which might represent a threat to patients in contact with vaccinated personnel in hospital environments. The risks associated with live vaccines are increased in immunodeficient patients, and guidelines regarding contraindications of vaccines in persons with immune deficiency disorders should be strictly followed [2]. Hypersensitivity reactions to vaccine components have also been observed. Although extremely rare, they were occasionally life-threatening. Usually, they cannot be predicted except in patients with egg allergy, for whom influenza and yellow fever vaccines are contraindicated because they might contain residual egg protein. In contrast, the measles–mumps–rubella vaccine can be safely administered to these patients [2]. Intussusception was a unique complication of a rhesus–human reassortant rotavirus vaccine introduced in 1998 [8]. Although this complication was observed in only 15 children after administration of about 1.5 million doses in the United States, it eventually led to withdrawal of the vaccine in 1999. The measure triggered a hot debate because, despite this rare complication, the vaccine could have been of major benefit in developing countries where rotavirus infection is a leading cause of morbidity and mortality [9]. An unexpected and remarkable immunological side effect of an experimental vaccine was the immunopotentiation of disease after RSV infection in children previously immunized with an inactivated RSV vaccine. This enhanced respiratory pathology apparently reflected a Th2-biased response to the vaccine [10]. Another concern that is frequently expressed is the potential risk of ‘overloading’ the immune system by increasing the number of vaccine antigens given to an individual child. This hypothesis has never been substantiated.

597

598

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

27.3 Autoimmunity Triggered by Infection or Immunization : an Increasing Concern

Autoimmune disorders represent a growing burden for health budgets as their incidence has significantly increased in recent years [11, 12]. This is especially well documented for early-onset type-I autoimmune diabetes [13]. Identification of the mechanisms involved in the induction of autoimmunity is therefore of paramount importance. It is generally assumed that autoimmune disorders result from complex interactions between genetic traits and environmental factors. Indeed, the relatively low concordance rate of autoimmune diseases observed among identical twin pairs [14] and the changes in the incidence of type-I diabetes and multiple sclerosis when children from a given population migrate from one region to another [15, 16] strongly suggest a critical role for environmental factors in addition to genetic predisposition. Although there is clinical and experimental evidence for the involvement of infectious agents in the pathogenesis of autoimmunity, in most autoimmune diseases the trigger has not been formally identified, leaving room for hypotheses and allegations, especially on the putative role of vaccines [17]. 27.3.1 Mechanisms of Autoimmunity Induction

Activation and clonal expansion of autoreactive lymphocytes represent critical steps in the pathogenesis of autoimmune diseases. Infections might be responsible for these key events through several non-mutually-exclusive mechanisms, including molecular mimicry, enhanced presentation of self-antigens, bystander activation, polyclonal B cell activation, and impaired T cell regulation [18]. 27.3.1.1 Molecular Mimicry The molecular mimicry hypothesis is based on sequence homologies between microbial peptides and self-antigen epitopes. This concept was initially established in an experimental model in which immunization with a hepatitis B virus polymerase peptide containing a 6 amino acid sequence of rabbit myelin basic protein elicited an autoimmune T cell response leading to autoimmune encephalomyelitis [19]. The demonstration that a viral infection in itself can lead to autoimmune pathology caused by molecular mimicry was established in a murine model of herpes simplex keratitis in which pathogenic autoreactive T clones were shown to cross-react with a peptide from the UL6 protein of the herpes simplex virus [20]. Evidence that a viral infection can induce pathogenic autoreactive T cells was also provided in a model of Theiler's murine encephlomyelitis virus encoding a mimic peptide [21]. Autoimmunity dependent on CD8+ T lymphocytes might also involve molecular mimicry, as shown in the model of inflammatory bowel disease induced in immunodeficient mice by CD8+ T cell clones directed against mycobacterial heat shock protein hsp60 and cross-reacting with the hsp60 self antigen [22]. However suggestive these experimental data are, there is still uncertainty as to whether molecular mimicry is a key mechanism in the pathogenesis of autoimmunity [23]. As a matter of fact, mo-

27.3 Autoimmunity Triggered by Infection or Immunization: an Increasing Concern

lecular mimicry in itself is probably not sufficient to trigger autoimmune pathology. 27.3.1.2 Enhanced Presentation of Self-antigens Infection can promote processing and presentation of self-antigens by several mechanisms. First, cellular damage induced by microbes can result in the release of sequestered self-antigens that stimulate autoreactive T cells, as clearly demonstrated in autoimmune diabetes induced by coxsackievirus B4 infection in mice [24]. Second, the local inflammatory reaction elicited in tissues by microbes promotes dendritic cell maturation, which represents a key step in the induction phase of immune responses. Indeed, microbial products engage Toll-like receptors on dendritic cells, resulting in up-regulation of the membrane expression of major histocompatibility complex and costimulatory molecules and secretion of cytokines promoting T cell activation, including interleukin-12 [25]. Third, a T cell response directed against a single self-peptide can diversify during an inflammatory reaction, by a process of ‘epitope spreading’, which has been well documented in murine models of encephalomyelitis [18]. 27.3.1.3 Bystander Activation The release of cytokines such as interleukin-12 can promote bystander activation of memory T cells and thereby trigger autoimmune reactions. Indeed, Shevach et al. [26, 27] established in murine models of encephalomyelitis that quiescent autoreactive T cells can differentiate into pathogenic Th1 effectors in presence of microbial products or synthetic CpG-containing oliogodeoxynucleotides inducing IL-12 synthesis. Recent data suggest that it is actually IL-23, a cytokine containing the IL-12p40 chain, that might be the pathogenic cytokine in such settings [28]. Likewise, the Fujinami group [29] demonstrated that viral infection can elicit relapses of autoimmune encephalomyelitis in primed animals in a nonantigen-specific manner. 27.3.1.4 Polyclonal B Cell Activation Hypergammaglobulinemia and autoantibody responses can occur as a consequence of the activation of B cells independent of the specificity of their membrane receptor. Recent observations in a model of lymphocytic choriomeningitis virus infection demonstrated that this process might occur as a consequence of B cell receptor-independent antigen uptake, followed by the presentation of viral peptides to CD4+ T cells which, upon activation, provide helper signals to B cells [30]. 27.3.1.5 Antibodies Besides their pathogenic role as direct effectors of autoimmune pathology, antibodies promote or enhance autoreactive T cell responses in several ways. Indeed, antibodies can facilitate capture of self-antigen by antigen-presenting cells and, as a consequence, the activation of autoreactive T cells [31, 32]. Furthermore, they might induce inflammation in the targeted tissue and thereby promote local release of selfantigens, epitope spreading, and recruitment of activated T cells [32]. These and other mechanisms probably explain the impact of maternal antibodies on the devel-

599

600

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

opment of autoimmune pathology in early life, as documented in experimental models of type-1 diabetes and autoimmune ovarian disease [33, 34]. 27.3.1.6 Regulatory T Cells There is growing evidence that regulatory T cells are instrumental in controlling autoreactive T cells both in neonates and adults [35]. Indeed, depletion of regulatory CD4+ CD25+ T cells promotes autoimmunity, although in adult animals this maneuver is not sufficient by itself and requires administration of self-antigen [36]. Infectious agents can influence T cell regulatory circuits in several ways. On one hand, the engagement of Toll-like receptors on dendritic cells by microbial products induces the production of interleukin-6, which inhibits the suppressive effects of regulatory T cells [37], thereby providing an additional mechanism promoting effector T cell responses upon dendritic cell activation. On the other hand, regulatory T cells themselves express Toll-like receptors and respond to bacterial products by increasing their suppressor activity [38]. Elucidation of the factors that determine the net result of these interactions in the course of infections in vivo will certainly represent an area of intense investigation in the near future. 27.3.2 Autoimmune Pathology in the Course of Infectious Diseases

In clinics, rheumatic fever caused by an anti-streptococcal immune response that cross-reacts with cardiac myosin represents the prototype of autoimmune disease of infectious origin [39]. Another well documented example is the Guillain–Barré syndrome occurring in the course of Campylobacter jejuni infection and mediated by antibacterial lipopolysaccharide antibodies cross-reacting with human gangliosides [40]. More recently, antibodies directed against the Tax protein of the human T-lymphotropic virus type 1 (HTLV-1) and cross-reacting with the heterogeneous nuclear ribonucleoprotein-A1 (hnRNP-A1) self-antigen were demonstrated in HTLV-1-associated myelopathy/tropical spastic paraparesis [41]. As far as T cell-mediated autoimmunity is concerned, cross-reactivity between microbial peptides and self-antigens was documented in several disorders, including type-I diabetes, multiple sclerosis, and antibiotic-resistant Lyme arthritis [42, 43]. From a clinical perspective, a clear-cut relation between the onset of autoimmune pathology and viral infection has been firmly established only for type-1 diabetes consecutive to congenital rubella [44, 45]. Infection-associated autoimmunity in humans also occurs in the context of polyclonal B cell activation. This occurs in chronic hepatitis C virus infection and causes mixed cryoglobulinemia [46], and in HIV infection, where it is sometimes associated with autoantibody-induced thrombocytopenia [47]. On the whole, the role of infections as etiological agents of human autoimmune disease has been demonstrated in only a few instances. However, their involvement in the exacerbation of a preexisting autoimmune disorder is rather well established. For example, epidemiological data strongly suggest that relapses of multiple sclerosis can be triggered by bacterial or viral infections [48, 49].

27.3 Autoimmunity Triggered by Infection or Immunization: an Increasing Concern

27.3.3 The Risk of Vaccine-associated Autoimmunity

Isolated case reports and increased attention in the media to possible side effects of vaccines have dramatically modified the perception in the medical community and the public of the risk of autoimmunity elicited by vaccination, despite the lack of epidemiological support for such concern. Indeed, only a few examples of autoimmune pathology could be firmly attributed to vaccination (see below). Interestingly, autoimmune reactions were observed only rarely after administration of vaccines against infections known to be associated with autoimmunity (Table 27.2 and [50]). The case of the vaccine against Lyme disease is especially relevant, because this vaccine contained the self-mimic OspA antigen thought to be involved in arthritis consecutive to infection with Borrelia burgdorfi. This supports the concept that the development of autoimmune pathology most often requires tissue damage and the long-lasting inflammatory reaction that occur during natural infections but not after vaccination. 27.3.3.1 Vaccine-attributable Autoimmune Diseases Guillain–Barré Syndrome and Influenza Vaccine Guillain–Barré syndrome (GBS, polyradiculoneuritis) was associated with the 1976– 1977 vaccination campaign against swine influenza using the A/New Jersey/8/76 swine flu vaccine [51]. The estimated attributable risk of vaccine-related GBS in the adult population was just under one instance per 100 000 vaccinations, and the period of increased risk in swine flu-vaccinated versus nonvaccinated individuals was concentrated primarily within the 5-week period after vaccination (relative risk: 7.60). Although the original Centers for Disease Control study demonstrated a statistical association and suggested a causal relation between the two events, controversy has persisted for several years. The causal relation was reassessed and confirmed in a later study focusing on cases observed in Michigan and Minnesota [52]. The relative risk of developing Guillain–Barré syndrome in the vaccinated population of these two states, as compared to swine flu-nonvaccinated individuals, during the

Tab. 27.2 Autoimmune pathology occurring in the course of natural infections but not after administration of corresponding vaccines .

Congenital rubella Inadvertent administration of rubella vaccine during pregnancy

Diabetes in offspring yes no

Influenza Influenza vaccine

Multiple sclerosis flare yes no

Lyme disease Lyme vaccine

Arthritis yes no

601

602

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

6 weeks after vaccination was 7.10 per million, whereas the excess cases of Guillain– Barré syndrome during the first 6 weeks attributed to the vaccine was 8.6 per million vaccinees in Michigan and 9.7 per million vaccinees in Minnesota. The pathogenic mechanisms involved are still unknown. With subsequent influenza vaccines, no significant increase in the development of Guillain–Barré syndrome was noted [53], and it is currently assumed that the risk of developing Guillain–Barré syndrome after vaccination (one additional case per million persons vaccinated) is substantially less than the risks of severe influenza and influenza-related complications [50]. Measles–Mumps–Rubella Vaccine and Thrombocytopenia Another example of a confirmed autoimmune adverse effect of vaccination is idiopathic thrombocytopenia (ITP), which may occur after measles–mumps–rubella (MMR) vaccination [54–58]. The reported frequency of clinically apparent ITP after this vaccine is about 1 in 30 000 vaccinated children. In one study [54], the relative incidence in the 6-week post-immunization risk period was estimated at 3.27 (95 % CI: 1.49 to 7.16) compared to the control period. In about two thirds of the patients, platelet counts under 20 000 mL–1 have been recorded. The clinical course of MMR-related ITP is usually transient, but it is not infrequently associated with bleeding and, as shown in a study conducted in Finland, it can occasionally be severe [59]. In the latter study, an increase in platelet-associated immunoglobulins occurred in 10 out of 15 patients, whereas circulating anti-platelet autoantibodies specific for platelet glycoprotein IIb/IIIa were detected in 5 out of 15 patients. These findings are compatible with an autoimmune mechanism triggered by the immune response to MMR vaccination. However, the risk for thrombocytopenia after natural rubella (1/3000) or measles (1/6000) infection is much greater than after vaccination [50]. Patients with a history of previous immune thrombocytopenic purpura are prone to develop this complication, and in these individuals the risk of vaccination should be weighed against that of being exposed to the corresponding viral diseases [60]. 27.3.3.2 Vaccine-related Allegations of Autoimmune Adverse Effects Hepatitis B and Multiple Sclerosis The possible association of hepatitis B (HB) vaccination with the development of multiple sclerosis (MS) was primarily questioned in France, following a report of 35 cases of primary demyelinating events occurring at one Paris hospital between 1991 and 1997 within 8 weeks of recombinant HB vaccine injection [61–62]. The neurological manifestations were similar to those observed in MS. Inflammatory changes occurred in the cerebrospinal fluid, and high-signal-intensity lesions were observed in the cerebral white matter on T2-weighted magnetic resonance imaging. After a mean follow-up of three years, half of these patients had progressed to clinically definite MS. These neurological manifestations occurred in individuals considered at higher risk for MS: a preponderance of women, mean age near 30 years, overrepresentation of the DR2 HLA antigen, and a positive family history of MS. These observations rapidly alerted the French pharmacovigilance system and, from 1993 through 1999, several hundred instances with similar demographic and clinical

27.3 Autoimmunity Triggered by Infection or Immunization: an Increasing Concern

characteristics were identified. It is essential to note that this episode occurred in a very special context. In France, nearly 25 million people received the HB vaccine during this period, of whom 18 million were adults, and this represented about 40 % of the population of the country. No cases were reported in children under three years of age. Since these initial reports, at least 10 studies aiming at defining the significance of such observations have now been completed: none of these studies found any significant association between hepatitis B vaccination and the occurrence of demyelinating events or MS. Two recent studies bear particular weight in confirming the lack of a significant association between hepatitis B vaccination and the occurrence of MS. Confavreux et al. [63] conducted a case-crossover study in patients included in the European Database for Multiple Sclerosis who had a relapse between 1993 and 1997. The index relapse was the first relapse confirmed by a visit to a neurologist and preceded by a relapsefree period of at least 12 months. Exposure to vaccination in the two-month risk period immediately preceding the relapse was compared with that in the four previous two-month control periods, for calculation of relative risks. Of 643 patients with relapses of multiple sclerosis, 2.3 % had been vaccinated during the preceding twomonth risk period, compared with 2.8 % to 4.0 % who were vaccinated during one or more of the four control periods. The relative risk of relapse associated with exposure to any vaccination during the previous two months was 0.71 (95 % CI, 0.40 to 1.26). There was no increase in the specific short-term risk of relapse associated with hepatitis B. Another recent study [64] also excluded a possible link between hepatitis B vaccine and multiple sclerosis. These authors conducted a nested case-control study in two large cohorts of nurses in the United States, those in the Nurses’ Health Study (which has followed 121 700 women since 1976) and those in the Nurses’ Health Study II (which has followed 116 671 women since 1989). For each woman with multiple sclerosis, five healthy women and one woman with breast cancer were selected as controls. The analyses included 192 women with multiple sclerosis and 645 matched controls. The multivariate relative risk of multiple sclerosis associated with exposure to hepatitis B vaccine at any time before the onset of the disease was 0.9 (95 % CI, 0.5 to 1.6). The relative risk associated with hepatitis B vaccination within two years before the onset of the disease was 0.7 (95 % CI, 0.3 to 1.8). The results were similar in analyses restricted to women with multiple sclerosis that began after the introduction of the recombinant hepatitis B vaccine. These reassuring data are consistent with the fact that, since the integration of hepatitis B vaccine into national childhood immunization schedules in over 125 countries, it has been used in more than 500 million persons and has proved to be among the safest vaccines yet developed. Vaccination and Diabetes Type-1 diabetes (formerly known as insulin-dependent diabetes mellitus, IDDM, or juvenile diabetes) results from autoimmune destruction of pancreatic b cells in genetically susceptible individuals exposed to environmental risk factors. The incidence is particularly high in some geographic areas, e. g., Finland and Sardinia, where it can reach 40 cases per 100 000. During recent decades, there has been a regular increase in the incidence of type-1 diabetes in most countries of the world. In a

603

604

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

recent European multicenter study covering the period 1989–1994, the annual rate of increase in incidence was found to be 3.4 %, with a particularly rapid rate of increase in children under 4 years of age (6.3%) [65]. In this context, it is not surprising that the potential role of childhood vaccines as triggering event for this disease has been questioned. This possibility has been evaluated in a few epidemiological studies. A case-control study conducted in Sweden in the mid-1980s did not find any significant effect of vaccination against tuberculosis, smallpox, tetanus, pertussis, or rubella on the odd-risk for diabetes [66]. However, some authors [67, 68] have hypothesized that the timing of vaccination may be of importance and that certain vaccines (e. g., Haemophilus influenzae type b, Hib), if given at 2 months of age or later may increase the risk of type-1 diabetes. This was not confirmed by a 10-year followup study of more than 100 000 Finnish children involved in a clinical trial of Hib vaccine [69]. A recent study conducted in four large health maintenance organizations (HMOs) in the U.S. did not find any association between administration of routine childhood vaccines and the risk of type-1 diabetes. The timing of hepatitis B or Hib vaccination had no effect on the risk of diabetes [70]. Therefore, at this stage, there are no serious indications of any significant influence of current childhood vaccines on the occurrence of type-1 diabetes. Overall, the risk of induction or exacerbation of autoimmune disease associated with current vaccines is very low. Because several vaccine-preventable infections are well known to negatively influence the course of autoimmune diseases (e. g., multiple sclerosis or systemic lupus erythematosus), vaccination is strongly recommended for such people (e. g., influenza vaccination in patients with multiple sclerosis). 27.3.3.3 New-generation Vaccines and Autoimmunity : Approaches to Early Risk Assessment Although the available data are reassuring, we must remain vigilant, because the risk of autoimmunity associated with some of the new-generation vaccines might be increased compared to current vaccines. Several new adjuvants that are being developed aim at inducing strong cytotoxic and inflammatory Th1-type immune responses against viruses or other intracellular pathogens. Such agents may occasionally favor the expression of underlying autoimmune diseases or induce autoimmune responses in exceptional cases in which the vaccine antigens contain immunodominant epitopes that cross-react with self-antigens. Indeed, a recent study indicates that inflammatory signals can drive organ-specific autoimmunity to a self-antigen that is tolerogenic under normal conditions [71]. Special attention should certainly be given to adjuvants acting as strong inducers of IL-12 or IL-23 synthesis [26–28]. Cancer vaccines based on dendritic cells pulsed with tumor antigens might result in autoimmunity induction as well [72, 73]. Although autoimmunity features might not be rare after dendritic cell vaccination, the development of clinical autoimmune pathology might depend on the genetic background, as suggested by a recent study comparing lupus-prone and normal mice [73]. The administration of agents targeting regulatory T cells, such as anti-CTLA4 antibody to enhance cancer vaccines, also appears to be associated with a significant risk of autoimmunity induction, as observed in both experimental and clinical settings [74, 75].

27.4 Other Unsubstantiated Allegations

During the course of vaccine development, only a comprehensive and multidisciplinary strategy may help to reduce the theoretical risk that a new vaccine would induce autoimmune manifestations. This may include a search for potential molecular and immunological mimicry between vaccine antigens and host components through an intelligent combination of bioinformatics and immunological studies. One should keep in mind that, by itself, an identified mimicry is of little pathogenic significance. Information should be gathered on the relative ability of such epitopes to bind to human major histocompatibility complex molecules, to be processed by human antigen-presenting cells, and to be recognized by autoreactive T cells. New vaccine formulations and adjuvants should be assessed for their ability to induce or enhance autoimmune pathology in relevant animal models. When the stage of clinical development is reached, appropriate immunological investigations (e. g., autoimmune serology) may be systematically included in phase 1–3 trials. On an ad hoc basis, clinical surveillance of potential autoimmune adverse effects may have to be included in the monitoring protocol. Such surveillance has to be extended through the post-marketing stage if specific rare events must be ruled out.

27.4 Other Unsubstantiated Allegations

There is a long list of unsubstantiated allegations about vaccine-induced disorders (Table 27.3). Allegations regarding autoimmune diseases, neurological damages related to whole-cell pertussis, and adverse effects of polio vaccines were considered previously in this chapter. Among other allegations, the putative relation between the measles–mumps–rubella (MMR) vaccine and autism deserves special attention, because it has influenced vaccine coverage in several regions.

Tab. 27.3 Examples of unsubstantiated allegations about safety of vaccines . Vaccine

Allegation

Hepatitis B vaccine Haemophilus influenzae type b vaccine Diphtheria–pertussis–tetanus vaccine

multiple sclerosis diabetes mellitus sudden infant death syndrome, epilepsy, infantile spasms paralytic poliomyelitis, simian virus 40 infection, AIDS arthritis autism Gulf war syndrome neurodevelopmental disorders macrophagic myofasciitis immune deficiency, allergies

Inactivated polio vaccine Lyme disease vaccine Measles vaccine Anthrax vaccine Thiomersal-containing vaccines Aluminum-containing vaccines Multiple vaccinations

605

606

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

27.4.1 Measles–Mumps–Rubella Vaccine and Autism

The hypothesis of a role of MMR vaccine in the pathogenesis of autism was put forward in 1998 on the basis of a small study of 12 children with autism who were referred to a gastroenterologist for suspicion of bowel disease. The physician then elaborated and publicized in the media a theory implying that persistent infection of the intestine with measles vaccine virus, related to its combined administration with rubella and mumps vaccines, results in inflammatory gut lesions allowing absorption of neurotoxins from the gastrointestinal tract, eventually causing autism. This theory was rather well received by the public, because there was temporal association between MMR vaccination and recognition of autism symptoms. Furthermore, the hypothesis provided a plausible explanation for the increasing frequency of autism diagnosis during the past 20 years. A number of studies, including thorough epidemiological analyses of large cohorts of children, were conducted to explore the different aspects of the hypothesis; the overall conclusion was that there was evidence neither for intestinal inflammation nor for autism as a consequence of MMR vaccination [1, 76]. 27.4.2 Thiomersal and Neurological Disorders

Allegations also target common components of vaccines, including preservatives and adjuvants. Indeed, there has been a major debate on the putative toxic effects of thiomersal, which was used for several years as preservative in many vaccine formulations. This debate was based on the fact that one of the ingredients of thiomersal is ethylmercury, a product known to cause neurological damage when administered in large doses [1]. Although the amounts of ethylmercury received by vaccinated children are well below those shown to induce neurotoxicity [77], and although toxicity guidelines were in fact related to methylmercury (which has a much longer in vivo half-life than ethylmercury), theoretical concerns eventually led to the removal of thiomersal from vaccines used in the United States [1]. 27.4.3 Aluminum and Macrophagic Myofasciitis

A novel potential culprit appeared after publication of reports on a new disease entity named macrophagic myofasciitis (MMF). MMF is a poorly defined syndrome characterized by myalgias, arthralgias, and fatigue [78]. It is claimed to be sometimes associated with central nervous system lesions reminiscent of multiple sclerosis [79]. Muscle biopsies in MMF patients showed infiltration with inflammatory cells, including macrophages loaded with intracytoplasmic inclusions corresponding to aluminum. A causal relation was then proposed between the occurrence of MMF and previous administration of vaccines containing aluminum salt as adjuvant [78]. However, there is no evidence so far of a direct link between the persistence of alu-

References

minum in a tiny (2-mm) muscle lesion and the observation of systemic manifestations [80]. Results of ongoing controlled studies will determine the real significance of these observations. 27.4.4 Multiple Vaccinations and Allergies

Finally, we should also mention unsubstantiated claims about immune disorders putatively attributed to the administration of a large number of vaccines in childhood. Indeed, children are now required to receive 23 or more vaccine doses by the age of 6 in the United States [1]. Whereas the fear of immune deficiency is not supported by a reasonable rationale, the hygiene hypothesis is used to support the theory that excessive immunizations in childhood might favor the development of atopic dermatitis, asthma, and other related allergic disorders [1]. Although this is still a matter of debate, a recent study is reinsuring, because it demonstrates that high vaccination coverage does not favor, but on the contrary transiently suppresses, atopy in early childhood [81].

27.5 Concluding Remarks

All vaccines carry some risk of adverse events, but fortunately, vaccine-related toxicity is usually rare, mild, and transient. Despite their excellent safety record, vaccines will remain the target of unsubstantiated accusations by antivaccine movements developing their activities on the basis of decreased public trust in the medical establishment, vaccine manufacturers, and health authorities. In this context, it is essential to consider safety as a first priority in vaccine development, even in the earliest stages of research. Furthermore, the public’s questions concerning vaccine safety should be taken seriously and addressed properly, even if based on poorly documented allegations. Depending on the issue raised and its potential impact, well designed and well conducted epidemiological investigations might be necessary to gather objective data. Dissemination of the available information by appropriate means is essential to restore the public's trust in vaccines. The long-term challenge is to modify the perception of vaccination-associated risks so that individuals everywhere benefit from the protection provided by carefully developed vaccines.

References 1. Wilson CB, Marcuse EK. Vaccine safety–vaccine benefits: science and the public's perception. Nature Rev Immunol 2001, 1, 160–165. 2. Halsey NA. Vaccine safety: Real and

perceived issues. In The Vaccine Book, ed BR Bloom and P.-H Lambert, Elsevier: Amsterdam, 2003, pp. 371–389. 3. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangaroza RE,

607

608

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

Miller E, Chen RT. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998, 351, 356– 361. van den Hof S, Conyn-van Spaendonck MA, van Steenbergen JE. Measles epidemic in the Netherlands, 1999–2000. J Infect Dis 2002, 186, 1483– 1486. Coughlan S, Connell J, Cohen B, Jin L, Hall WW. Suboptimal measles– mumps–rubella vaccination coverage facilitates an imported measles outbreak in Ireland. Clin Infect Dis 2002, 35, 84–86. Salmaso S. In The Vaccine Book, ed BR Bloom and P.-H Lambert, Elsevier: Amsterdam 2003, pp. 211–224. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, Atmar RL, Edelman R, Nolan CM, Belshe RB, National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346, 1265–1274. Intussusception among recipients of rotavirus vaccine: United States, 1998– 1999. MMWR Morb Mortal Wkly Rep 1999, 48, 577–581. Weijer C. The future of research into rotavirus vaccine. BMJ 2000, 321, 525– 526. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccineenhanced RSV disease. Vaccine 2001, 20, Suppl 1: S20–S31. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84, 223–243. Onkamo P,Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type I diabetes: the analysis of the data on published incidence trends. Diabetologia 1999, 42, 1395– 1403. Rosenbauer J, Herzig P, von Kries R, Neu A, Giani G. Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in children un-

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

der 5 years of age in Germany. Diabetologia 1999, 42, 1055–1059. Salvetti M, Ristori G, Bomprezzi R, Pozzilli P, Leslie RD. Twins: mirrors of the immune system. Immunol Today 2000, 21, 342–347. Noseworthy JH, Lucchinetti C, Rodriguez M,Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343, 938–952. Dahlquist G. The aetiology of type I diabetes: an epidemiological perspective. Acta Paediatr Suppl 1998, 425, 5– 10. Wraith D, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003, 362, 1659–1666. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001, 108, 1097–1104. Fujinami RS and Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985, 230, 1043–1045. Zhao ZS, Granucci F,Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998, 279, 1344–1347. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001, 108, 311–318. Steinhoff U, Brinkmann V, Klemm U, Aichele P, Seiler P, Brandt U, Bland PW, Prinz I, Zugel U, Kaufmann SH. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 1999, 11, 349– 358. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nature Immunol 2001, 2, 797–801. Horwitz MS, Ilic A, Fine C, Rodriguez E, Sarvetnick N. Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virusmediated autoimmune diabetes. J Clin Invest 2002, 109, 79–87.

References 25. Medzhitov R, Janeway CA. Decoding the pattern of self non self by the innate immune system. Science 2002, 296, 298–300. 26. Segal BM, Klinman DM, Shevach EM. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol 1997, 158, 5087– 5090. 27. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000, 164, 5683–5688. 28. Watford WT, O'Shea JJ. Autoimmunity: a case of mistaken identity. Nature 2003, 421, 706–708. 29. Theil DJ, Tsunoda I, Rodriguez F, Whitton JL, Fujinami RS. Viruses can silently prime for and trigger central nervous system autoimmune disease. J Neurovirol 2001, 7, 220–227. 30. Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, Zinkernagel RM. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol 2003, 4, 343–349. 31. Tung KS, Agersborg SS, Alard P, Garza KM, Lou YH. Regulatory T-cell, endogenous antigen and neonatal environment in the prevention and induction of autoimmune disease. Immunol Rev 2001, 182, 135–148. 32. von Herrath JF, Bach JF. Juvenile autoimmune diabetes: a pathogenic role for maternal antibodies? Nat Med 2002, 8, 331–333. 33. Greeley SA, Katsumata M,Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 2002, 8, 399–402. 34. Setiady YY, Samy ET, Tung KS. Maternal autoantibody triggers de novo T cellmediated neonatal autoimmune disease. J Immunol 2003, 170, 4656–4664. 35. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000, 18, 423–449. 36. McHugh RS, Shevach EM. Cutting Edge: Depletion of CD4+CD25+ regula-

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

tory T cells is necessary but not sufficient for induction of organ-specific autoimmune disease. J Immunol 2002, 168, 5979–5983. Psare C, Medzhitov R. Toll pathwaydependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299, 1033–1036. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003, 197, 403–411. Cunningham MW, Antone SM, Smart M, Liu R, Kosanke S. Molecular analysis of human cardiac myosincross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun 1997, 65, 3913–3923. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain–Barré syndrome. N Engl J Med 1995, 333, 1374–1379. Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC Jr, Hasty KA, Callaway JC, Zunt J, Desiderio D, Stuart JM. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 2002, 8, 509–513. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001, 345, 340–350. Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol Life Sci 2000, 57, 542–551. Robles DT, Eisenbarth GS. Type 1A diabetes induced by infection and immunization. J Autoimm 2001, 16, 355– 362. Clarke WL, Shaver KA, Bright GM, Rogol AD, Nance WE. Autoimmunity in congenital rubella syndrome. J Pediatr 1984, 104, 370–373. Casato M, Taliani G, Pucillo LP, Goffredo F, Lagana B, Bonomo L. Cryoglobulinaemia and hepatitis C virus. Lancet 1991, 337, 1047–1048. Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune

609

610

27 Immunological Safety of Vaccines: Facts, Hypotheses and Allegations

48.

49.

50.

51.

52.

53.

54.

55.

56.

thrombocytopenia. Cell 2001, 106, 551– 561. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995, 74, 415–418. Andersen O, Lygner PE, Bergstrom T, Andersson M,Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993, 240, 417–422. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001, 16, 309–318. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain–Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979, 110, 105–123. Safranek TJ, Lawrence DN, Kurland LT, Culver DH,Wiederholt WC, Hayner NS, Osterholm MT, O’Brien P, Hughes JM. Reassessment of the association between Guillain–Barre syndrome and receipt of swine influenza vaccine in 1976–1977: results of a twostate study. Expert Neurology Group. Am J Epidemiol 1991, 133, 940–951. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT. The Guillain–Barre syndrome and the 1992– 1993 and 1993–1994 influenza vaccines. N Engl J Med 1998, 339, 1797– 1802. Miller E,Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84, 227–229. Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles– mumps–rubella vaccination. Pediatrics 1996, 97, 738–739. Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med 1966, 275, 352–356.

57. Jonville-Bera AP, Autret E, GalyEyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur–Merieux Serums et Vaccins. Pediatr Infect Dis J 1996, 15, 44–48. 58. Beeler J,Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996, 15, 88–90. 59. Nieminen U, Peltola H, Syrjala MT, Makipernaa A, Kekomaki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: a report on 23 patients. Acta Paediatr 1993, 82, 267–270. 60. Pool V, Chen R, Rhodes P. Indications for measles–mumps–rubella vaccination in a child with prior thrombocytopenia purpura. Pediatr Infect Dis J 1997, 16, 423–424. 61. Gout O, ThÉodorou I, Liblau R, Lyon-Caen, O. Central nervous system demyelination after recombinant hepatitis B vaccination report of 25 cases. Neurology 1997, 48. 62. Tourbah A, Gout O, Liblau R, LyonCaen O, Bougniot C, Iba-Zizen MT, Cabanis EA. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology 1999, 53, 396–401. 63. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001, 344, 319–326. 64. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001, 344, 327–332. 65. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 2000, 355, 873–876. 66. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study: vaccinations and infections as risk deter-

References

67.

68.

69.

70.

71.

72.

73.

74.

minants for diabetes in childhood. Diabetologia 1991, 34, 176–181. Classen JB, Classen DC. Immunization in the first month of life may explain decline in incidence of IDDM in The Netherlands. Autoimmunity 1999, 31, 43–45. Classen JB, Classen DC. Association between type 1 diabetes and Hib vaccine: causal relation is likely. BMJ 1999, 319, 1133. Karvonen M, Cepaitis Z, Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. BMJ 1999, 318, 1169–1172. DeStefano F, Mullooly JP, Okoro CA, Chen RT, Marcy SM,Ward JI, Vadheim CM, Black SB, Shinefield HR, Davis RL, Bohlke K. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001, 108, E112. Vezys V, LeFrançois L. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing antigen. J Immunol 2002, 169, 6677–6680. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000, 191, 795–804. Bondanza A, Zimmermann VS, Dell’Antonio G, Dal Cin E, Capobianco A, Sabbadini MG, Manfredi AA, Rovere-Querini P. Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J Immunol 2003, 170, 24–27. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J,Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of

75.

76.

77.

78.

79.

80.

81.

prophylaxis and therapy. J Exp Med 2001, 194, 481–489. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100, 4712–4717. Madsen KM, Hviid A,Vestergaard M, Schendel D, Wohlfart J, Thorsen P, Olsen J, Melbye M. A population-based study of measles, mumps and rubella vaccination and autism. N Engl J Med 2002, 347, 1477–1482. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002, 360, 1737–1741. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Macrophagic myofasciitis assess longterm persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124, 1821–1831. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maisonobe T, Coquet M, Degos JD, Gherardi RK. Central nervous system disease in patients with macrophagic fasciitis. Brain 2001, 124, 974–983. Vaccine Safety Advisory Committee. Vaccine safety. Weekly Epidemiological Record 1999, 74, 337–340 and 2003, 78, 17–24. Grüber C, Illi S, Lau S, Nickel R, Forster J, Kamin W, Bauer C-P, Wahn V, Whan U, and the MAS-90 Study Group. Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics 2003, 111, e282–e288.

611

Index

Index

abundant antigens 466 Acanthaceilonema vitae 64 accessory genes 501 ff acellular vaccines 549 acidification 462 acquired immunodeficiency syndrome (AIDS) 459 ff, 501–524 action mechanisms 180, 187 f activation – dendritic cells 63 ff – innate immunity 18 f – microbial adjuvants 115 ff active immunization 243 Ad genomes/vectors vaccines 268 adamantyl dipeptide (AdDP) 201 f adaptive immunity 4 ff, 17–50, 411– 428 adaptive responses 81, 115 ff, 197 adaptor pathway 27 adeno associated virus seroptype2 (AAV-2) 269 adenovirus 266 ff, 342, 352 adenylate cyclase toxin (ACT) 549 adenylate/uridylate-rich elements (AUUUA) 396 adjuvants 113–218 – chemical 36 – HIV 511 ff – host-derived 129 – 145 – hyporesponsiveness 53 – microbial 115 – 128 – mucosal 197 – 217, 349, 352 f – oral 388 ff – Th dominated immune responses 51–72 – tuberculosis 467 f administration 204 ff, 393 admixing, antigen–adjuvants 204 adoptive lymphocyte transfer 344 adoptive vaccination 363 ADP/ATP exchange 132 adverse effects 592 aerosol exposure 532 age-dependent effectiveness 304 Agelas mauritianis 26 agglutinogens 549 agonistic anti-CD40 monoclonal antibodies 77 Agrobacterium tumefaciens 395 allergies 21, 601 f alpha viruses 276 Alum 52 ff aluminum compounds 56 ff aluminum containing vaccines 601

aluminum hydroxide 201 aluminum salts 129, 147 ALVAX virus 272 alveolar macrophages 344, 530 amantadine 201 amino acids 396, 419 aminoalkylglucoaminide phosphates (AGP) 117, 123 f amoxycillin 436 ff amphipathic protein 184 amplicon vectors 273 f animal models 191, 437 ff Anopheles mosquitos 475 anthrax 226, 363 f, 526 ff, 601 anti-apoptotic pathways 102 anti-idiotypes 373 Antibacillus pleuropneumonia 237 antibiotics 435 antibodies 4 ff – agonistic anti CD40 77 – immunological safety 595 – plant-based vaccines 397 – wide-spectrum protective 363 – 383 antibody-dependent cell mediated cytotoxicity (ASDCC) 243 antibody-dependent cellular inhibitions (ADCI) 487 antibody-idiotypic network 369 ff antibody-independent mechanisms 489 antibody-induction 153 antibody-mediated protection 477 antibody responses 90 antibody vaccines 502 ff antidotes 363 – 383 – bacterial vectors 376, 513 – idiotypic networks 369 ff antigen-adjuvants – admixing 204 – carrier combination 183 – direct admixing 204 – covalent linkage 205 antigen binding property 373 antigen degradation 197 antigen dose effect 57 f antigen presenting cells (APC) – adjuvants 53 ff, 64 ff – antigen specific T cells 95 ff – antiviral DNA vaccines 300 – host-derived adjuvants 130, 134 f, 137 – ISCOMs 190

613

614

Index

– liposomes 176, 181 f – microparticle adjuvants 149 ff, 157 ff – mucosal vaccination 198 ff, 344, 347 ff – virus-like particles 413 – tuberculosis 460 f antigen specific T cells – kinetics 95 ff – multimers 92 f antigens 10 ff, 37, 91, 104 – degradation 197 – H. pylori 433 ff – hetrologous 328 ff – maize germ tissue 400 f – malaria 482 – microbial adjuvants 115 ff – plant-based vaccines 393 – receptors 17 ff – tuberculosis 465, 468 antiinflammatory effects 35 Antinobacillus pleuropneumoniae 223 f antitoxin vaccines 488 antiviral activity 527 antiviral DNA vaccines 287–315 apoptosis 267, 509 aprotinin 397 Archaea filum 249 archeosome 175, 179 f arenoviridae 288 ff, 528 arginine residue 281 Argus SC 238 aroA mutations 322 arthritis 597, 601 arthropod invaders 17 AS04 adjuvant 246 asexual blood stage 482 aspartic acid 281 Aspergillus spp. 370 atrophic gastritis 433 attenuated vaccines – bacterial 225 f, 317 ff – HIV 512 f – immunological safety 592 – plague 533 – recombinant viral vectors 304 – tuberculosis 467 ff autism 601 autoimmunity 594 ff auxotrophic mutants 467 average daily weight gain (ADG) 234 avidin 397 avidity 99 ff, 148 Avipoxvirus 271 f

B cell responses 84 ff, 412 f B cell superstimulatory antigen effect 211 B epitope 478 ff, 481 ff B lymphocytes 344 Bacillus anthracis 10 – bacterial vaccines 223 – bioterror agents 526, 529 f Bacillus Calmette-Guerin (BCG) 459 – 473 – adjuvants 65 – bacterial vaccines 230, 317 – expression vectors 347 bacteremias 368 bacteria 5 – meningitis 154 – subunit vaccines 249 – T cell formation 81 – virulence-antigen vaccines 547 bacterial artificial chromosomes 273 bacterial derivatives 53 f bacterial DNA 119, 150 bacterial lipopolysacharide (LPS) 137 bacterial lipoproteins (BLP) 66 bacterial strains 319 bacterial toxins 201, 349 bacterial vaccines 221–242 – live recombinant 317–339, 347 f bacterial vectors, antidotes 376, 513 Bacteroides nodosus 239 Barrett’s esophages 435 beta glucan 374 binding affinity, TCR–MHC 99 f biodegradable polymeric particles 349 biopharmaceutical crops 403 bioterror agents 368, 525–541 blood-borne infections 342 blood stage, asexual 482 ff boost vaccination protocol 105 Bordetella pertussis 10, 36 – bacterial vaccines 232 – expression vectors 348 – microparticle delivery systems 160 – subunit vaccines 245 – virulence-antigen vaccines 549 ff Bordetella spp. 234, 331 Borrelia burgdoferi 247 botulinum toxin 363, 36 ff bovine serum albumin (BSA) 177 Brucella spp. 235, 538 bunyaviruses 287 ff Burgholderia 538 bystander activation 595

Index

cag pathogenicity islands (cagPAI) 433 f, 437 ff, 445 ff calcium phosphate 201 calreticulin 130 ff Campylobacter jejuni 342, 596 Campylobacter pyloridi see: Heliobacter pylori canarypox (ALVAC) 512 cancer 157, 267 Candida albicans 60, 371, 374 canine parovirus (CPV) 393 cap genes 79, 269 capsid proteins 392 capsid virus-like particles 417 ff capsular polysaccharides 265 carbohydrate 3, 10, 116 ff cardiac drugs 363 catalase 440 f cationic lipids 182 cauliflower maosaic virus 35S RNA 394 CCR5 receptors 6 ff, 420, 501 ff CD type cells 9 ff – mucosal vaccination 343 – S. Typhi 325 – tuberculosis 468 ff – virus-like particles 414 ff CD4 T cells 6 ff, 12 ff, 189 CD8+ T cells 75 ff, 98 ff – HIV 502–518 – immunological safety 594 – ISCOMs 189 – malaria 479 – subunit vaccines 266 cell adhesin molecules (CAM) 252 cell-associated enveloped virus (EEV) 271 cell bank systems 283 ff cell differentiation, C/B 31 cell lines 282 f cell mediated immunization (CMI) 56, 155, 341, 369 cell membrane antigens 152 cellular compartments 302 cellular DNA 505 f cellular inhibitions 487 central European encephalitis virus 287 ff ceramides 177 CFP-10 antigen 469 chaperone 130 ff chelating groups 186 chemical adjuvants 201 chemokines 5, 20 – effector cells 29 ff – HIV 501–518 – memory 75, 84

– mucosal vaccination 344, 351 – virus-like particles 420 chicken embryo fibroplast (CEF) 272 chimase 29 chimeric antigens 302 chimeric virus-like particles 420 ff Chinese hamster ovary (CHO) 135 chitinase 493 chitosan 159 Chlamydia pneumoniae 255 Chlamydia psittaci 240 Chlamydia spp. 342 Chlamydia trachomatis 160 chloroform 180 cholate 175 cholera toxin (CT) 11, 52, 73 – adjuvants 117 f, 201, 353 – bacterial vaccines 227 f, 319 f – H. pylori 439 cholesterol 152, 175 ff, 184, 351 chondroitin sulfate 486 chromosomes 256, 273 cidofovir 527 CIDR domains 486 cilia 5 circumsporozoites (CS) protein 478 ff clade sequences 513 clarithromycin 435 f clinical trials – heat shock proteins 140 – HIV 507 ff, 514 ff – immunization cost-effectiveness 576 – ISCOMs 191 – live recombinant vaccines 323 – malaria 481 ff – virosomal technology 213 – virus-like particles 421 ff clones 255, 277 Clostridium botulinum 536 Clostridium difficile 342 Clostridium perfingens 10, 538 Clostridium tetani 10, 349, 386 clotting cascade 5 cochleates 174, 179 f codon usage 396 colchine 363 colizin EZ 223 colonizations 320 f, 433 combination vaccines 467 ff commensal flora 347 common mucosal immune system (CMIS) 201 complement cascade 5 complement receptors 21 ff complementary determining region (CDR) 373

615

616

Index

compositions – ISCOMs 184 – liposomes 176 f congenital rubella 597 conjugates 105, 387 conventional cytomegalovirus (CMV) 278 coreceptors 6, 90 ff, 503 ff coronavirus 342 Corynebacterium diphtheriae 10, 349, 547 ff Corynebacterium parvum 59 cost-effectiveness 563 – 589 coupled epitopes 418 ff coupling agents 186, 369 covalent linkage, antigen–adjuvants 205 cowpea mosaic virus (CPMV) 390 ff CpG 52 – adjuvants 150 – DNA 22, 121 f – oligonucleotides 246, 350 f – virus-like particles 412 crescents 269 f critical micelle concentration (CMC) 180 cross priming 131 Cryptococcus neoformans 26, 33, 370 ctxA negative derivatives 326 culture cells 317 culture protocols 105 CVD strains 319 ff, 326 ff CXR receptors 501 ff cysteine group 419 cytokines 6, 14, 20 ff, 76, 460 ff – adjuvants 53 ff, 57 ff – antigen specific T cells 91 f – antiviral DNA vaccines 299 ff – capture assays 92 – disrupted 61 – effector cells 31 ff – HIV 506 – 518 – host-derived adjuvants 141 ff – microbial adjuvants 115 ff – microparticle adjuvants 147, 151 f – mucosal vaccination 201 f, 351 – oral vaccines 387 – Th2-inducing 35 – tuberculosis 468 – virus-like particles 414 ff cytomegalovirus (CMV) 75, 287 ff, 368 cytometry 91, 516 cytopathic viruses 7 cytosines, unmethylated 150 cytosol 397, 461 cytosolic heat shock proteins 131 cytotoxic activites 4 ff cytotoxic T cells (CTR) 37, 90 ff, 97 ff

– HIV 505–518 – malaria 478 – mucosal vaccination 343 – virus-like particles 411 ff cytotoxic T lymphocytes (CTL) – antiviral DNA vaccines 302 f – HIV 506 – 518 – host-derived adjuvants 136 – ISCOMs 188 – microparticle adjuvants 147 ff, 155 ff – mucosal vaccination 199, 350 ff – virosomal technology 208 – virus-like particles 413 cytotoxin 434 ff

danger signals 117, 137 DBL domains 486 decreasing potential model, T cell formation 81 defecting interfering particles 276 defensins 5, 28 ff degradation, antigens 197 delayed type hypersensitivity (DTH) 56, 300 deletion mutants 467 delivery systems – HIV 513 – maize 398 – microparticle adjuvants 147–172 – mucosal vaccination 205, 345, 347 ff – oral vaccines 388 ff deltavirus 289 f dendritic cells 5, 24 f, 29, 35, 63 ff – adjuvants 54, 57 ff – antigen specific T cells 96 ff – HIV 509 ff – host-derived adjuvants 134 ff – innate immunity 18 – microbial adjuvants 115 ff – microparticle adjuvants 149 ff – mucosal vaccination 198, 344 – subunit vaccines 279 – tuberculosis 460 – virus-like particles 414 f Dengue virus types 287 ff depletion, T cells 100 depot effect 210 dermonecrotic toxin 549 detection phase 18, 91 diabetes 597 ff, 601 diarrhea 399 differentiation patterns, T cells 102 digoxin 363 dimers 503 ff dioleoylphospatidyl ethanolamine (DOPE) 183

Index

dimethyl dioctadecyl ammonium bromide (DDA) 176 diphteria 52, 74, 158, 243, 564 diphteria–pertussis–tetanus vaccine 601 direct admixing, antigen–adjuvants 204 direct conjugation antigens 105 directly-observed treatment strategy (DOTS) 459 ff disabled infectious single cycle (DISC) 273 ff disease agents 364 DNA vaccines 222 ff, 287 – 315 – adenovirus Ebola 529 – binding protein (DtxR) 547 – endonuclease 223 – HIV 505 ff, 513 f – microarrays 248, 269 – microparticle delivery systems 155 f – mucosal 348 – plasmid replicons 277 – tuberculosis 466 double-stranded genomes 269 double-stranded RNA (dsRNA) 21 ff, 198, 414 DtaP toxoids 247 DTP triple vaccine 232 dysentery 319

E1 gene region 267 ff E2 proteins (HCV) 303 E6 protein 552 Ebola virus 267, 526 ff economic evaluation 563, 569 EcSf2a hybrid 230 eczema vaccinatum 592 edema factor 224, 530 edible vaccines 345 f, 389 ff Edwardsiella ictaluri 240 effectiveness 103 – antidotes 368 – antiviral DNA vaccines 304 – hepatitis trials 582 effectors 28, 75–101 – mucosal vaccination 344 – virus-like particles 412 Ehrlichia risticii 239 El TOR strains 326 electrostatic interactions 208 elicit cell meadiated immunity 477 f EM-63 strains 527 encapsulation 180 encephalitis 592 endocytosis 182 endogenouos adjuvants 63 f, 139

endonuclease 223 endosperm 400 endothelial cells 480 Engerix 421 enhanced liposome processing 182 enhanced T cell responses 76 enterobacteria 21, 319 enterotoxigenic E. coli (ETEC) 228, 320, 388–400 env genes 275, 501 ff enveloped DNA viruses 269 enzyme-linked immunosorbent assays (ELISA) 92, 254, 400 enzyme-linked immunospot assay (ELISPOT) 91 ff, 516 enzymes 5 eosinophil granulocytes 29 eosinophilia 14, 387 Epaxyl 183 epidermis 177 epilepsy 601 epithelium 198 epitopes 8 ff, 51 ff, 99 f – adjuvants 57 ff, 136 – antidotes 368 ff – antiviral DNA vaccines 289 f, 301 f – HIV 514 – malaria 478 ff – mucosal vaccination 350, 416 ff – subunit vaccines 252 – virus-like particles 425 ff Epstein – Barr virus (EBV) 75, 509 ER lumen 130 ff erythrocytes 13, 476, 485 ff ESAT-6 antigen 468 Escherichia coli 23, 52 f – adjuvants 60, 117 – bacterial vaccines 223 ff – enterotoxin 439, 442 – HIV 511 – ISCOMs 189 – mucosal vaccination 342, 346 – oral vaccines 387 ff, 399 f – subunit vaccines 251 – virosomal technology 201 esophagal adenocarcinoma 435 eukaryotic cells – anthrax 530 – antigen encoding 222 – liposomes 182 – plant-based vaccines 398 – subunit vaccines 277 European encephalitis virus 287 ff EV76 Yersinia pestis strain 229

617

618

Index

ex-vivo detection 91 EX492 strain 319 ff, 324 exoerythrocytic stages 475 ff exotoxins 10, 231, 349 extracellular bacteria 9 ff

Fab molecules 363 ff Fc receptors 5 ferrets, H. mustelae 431 FG glycoprotein, mucosal vaccination 353 FhuA outer membran proteins 254 filamentous hemagglutin (FHA) 247, 348, 549 filoviruses 528 fimbrial protein (FimH) 21 ff flagellin 21 ff, 117 ff flaviviruses 287 ff flu-virosome 183 follicles 84 foot and mouth disease virus (FMDV) 391 ff formaldehyde 223 formalin 279, 444, 512 fowl pox virus (FPV) 272, 303 f, 512 fowl taphoid strain 9R 238 Franciscella tulariensis 232, 526, 534 ff freeze drying 176 Freund’s complete adjuvant (FCA) 56–64, 129 ff, 153, 177 fucose residues 21 f full length infectious clones 277 functional avidity 99 functional heterogeneity 101 fungal infections 370 f fused epitopes 416 f fusion competent antigens 505 Fusobacterium necrophorum 239 fusogenic capacity 211 fusogenic liposomes 182

G protein 281 gag genes 256, 275, 501 ff gag-pol DNA 304 galE mutation 231, 323 gamete surface antigen 6-cys 491 gametocytes 13, 476 gastroesophageal reflux disease (GERD) gastrointestinal infections 342 gene expression, stability 398 gene silencing, transcriptional 394 genes 268 ff genetic adjuvants 300 ff genetic recombination 545 genomic approach 248, 255 f

433 ff

germinal centers 84 glomerular filtration 367 glucan 374 GLURP, malaria 487 glutamic acid (E333) 281 glutaraldehyde 223 glycans 14, 24 ff glycosphingolipids 26 glycoproteins (gp) 6 ff, 21, 157, 346 – antiviral DNA vaccines 299 – HIV 501–524 – plant-based vaccines 393 – virosomal technology 211, 256 glycosides 150, 351 glycosylphosphatidylinoistol (GPI) 23, 480, 487 GNA antigens 252 ff gnobiotic piglets 438 Gram-negative bacteria 119, 223 – adjuvants 150, 201 – H. pylori 431 – plague 532 granulocyte macrophage colony stimulating factor (GM-CSF) 34, 141, 300 granzyme A 75 growth factor 5 Guillain–Barré syndrome 597 Gulf war syndrome 601 gus marker gene 395 gut associated lymphoid tissue (GALT) 344

H-10407 E.coli strain 228 H6 ScFv strains 377 Haemophilus paragallinarum 239 Hansenula anomala 372 f hantavirus 287 ff haplotypes 7 heat labile enterotoxin (LT) – bacterial vaccines 228 – H. pylori 439, 442 – HIV 511 ff – ISCOMs 189 – microbial adjuvants 117 ff – microparticle delivery systems 160 – mucosal vaccination 201, 346, 349 – oral vaccines 388, 394 ff, 399 ff heat shock proteins (HSP) 23 ff, 140, 594 – H. pylori 437 – host-derived adjuvants 129–138 Helicobacter felis 437 Helicobacter mustelae 438 Helicobacter pylori 11, 437, 431– 458 – mucosal vaccination 342, 347 – subunit vaccines 246

Index

helper cells 9, 17 ff – adjuvants 53 ff – HIV 508 – 518 – subunit vaccines 268 – virus-like particles 411 ff hemagglutin (HA) 6, 175, 208 ff – microparticle delivery systems 161 – mucosal vaccination 352 ff – subunit vaccines 281 hemolytic activity 186 hemolytic uremic syndrome 229 Hemophilus influenza 10, 244, 601 – antidotes 363 ff – b type 564 – HMW1 252 – virulence-antigen vaccines 551 hemorrhagic fevers 526 ff hepadnaviridae 290 heparin-binding cytokines 30 hepatitic necrosis 267 hepatitis A 210, 368, 565, 581 hepatitis B 5, 23, 368 – clinical trials 421 f, 581 – immunological safety 598, 601 f – liposomes 176, 183 – mucosal vaccination 342 – plant-based vaccines 393 hepatitis B surface antigen (HbsAg) – microparticle delivery systems 159 – subunit vaccines 246 – virus-like particles 412, 416 ff hepatitis B vaccine 152, 246, 290 hepatitis C 5, 75 – antidotes 364 – virus-like particles 416 f hepatitis D 287 ff hepatocytes 475, 480 f herbivores 530 herpes simplex virus (HSV) 5, 594 – DNA vaccines 287, 291 – microparticle adjuvants 150 – mucosal vaccination 342 – subunit vaccines 272 ff heterogeneity, T cells 101 heterologous antigens 328 ff heterologous prime-boost vaccination 282 heterologous proteins 377, 397 Hib conjugates 10 highly attenuated poxvirus (NYVAC) 272 HLA expressions 247, 463, 485 host cellular sensors 24 f host defense system 244, 341 host-derived adjuvants 129 – 145, 201 – self-nonself model 137 ff

host genes, heterologouos 330 f host–vector systems 377 HtrA gene 324 human bacterial diseases 226 ff human embryonic kidney (HEK) 267 human immunodeficiency virus (HIV) 3–16, 23, 459 ff, 501–524 – adjuvants 56, 65 – antidotes 364 – antiviral DNA vaccines 295 ff – expression vectors 347 – gag sequences 425 – ISCOMs 188 – liposomes 176 – macaque model 504 ff – memory 75 – mucosal vaccination 342, 346 – nef genes 501 ff – neutralizing antibodies (nAbs) 502 ff – original antigenic sin model 505 – prophylactic vaccines 514 – rev genes 501 ff – subunit vaccines 265 ff – T cells 89 – viral vaccines 256 – virus-like particles 412 human Lewis blood antigens 432 human metapneumovirus 342 human neutrophil derived α defensins (HNP1) 28 human papilloma virus (HPV) 150, 422, 552 human pathogens – subunit vaccines 249, 393 see also: pathogens human recombinant subunit vaccines 282 human retinal cell 911 267 human T lymphotropic virus type 1 (HTLV-1) 596 human Th1/2 vaccines 65 hyaluronic acid 159 hypersensitivity reactions 363 f, 593 hyporesponsiveness, adjuvants 53 hystamine 29 ff

idiopathic thrombocytopenia (ITP) 598 idiotypic network, antidotes 369 ff Ig/FcεR crosslinks 21 IgA 7 – antigen specific 341 – H. pylori 440 – oral vaccines 386 IgE 14 – adjuvants 56 – antibody responses 148

619

620

Index

IgG – adjuvants 56 – H. pylori 440 – HIV 504 – live recombinant vaccines 325 – malaria 487 ff – oral vaccines 386 – subunit vaccines 244 IgM 244, 412 IL series 52 ff, 75 – adjuvants 58 ff – ISCOMs 189 – microparticle adjuvants 148, 151 f – mucosal vaccination 343 – oral vaccines 387 IL1 receptor associated protein kinase (IRAK) 138 imidazoquinolines 21, 117, 124 f Imidiquod 124 immun deficiency 601 immune responses 17 – 78, 187, 393, 502 f immune stimulating complexes (ISCOM) 52, 152, 173, 184 – 196 – adjuvants 116 f, 149 ff – mucosal vaccination 351 immune systems 4 ff, 478, 509 ff immunization 243, 564 ff immunoglobulin 5, 363 immunological memory 73 – 88 immunological safety 591 – 607 immunopotential 131, 197, 209 f immunopotentiating reconstituted influenza virosomes (IRIV) 177 immunostimulatory adjuvants 150 ff immunotoxicotheraphy 363 ff imperfect vaccines 545 – 561 in-vivo expression technology (IVET) 248, 466 in-vivo kinetics, antigen specific T cells 95 ff inactivated poliovirus vaccine (IPV) 279, 386 inactivated vaccines 222 ff, 386, 444 incorporation 205 ff infection mechanisms 4, 460 f, 527 Infexal 183 inflammatory processes 26 ff, 80, 592 ff inflammatory protein 1beta (MIP1beta) 301 influenza 4, 7, 10, 23 – adjuvants 60 ff – antiviral DNA vaccines 292 f – immunization cost-effectiveness 564 – immunological safety 596 f, 601 – liposomes 178 – mucosal vaccination 342 – virosomal technology 208 ff – virulence-antigen vaccines 551

inherent immunogenicity 204 innate immunity 4 ff, 17 – 50 – combined autoadaptive 411 – 428 – HIV 509 f – microbial adjuvants 115 ff – T cell formation 81 – mucosal adjuvants 197 in-silico analysis 255 instructive T cell formation 81 insulin CT conjugate 387 insulin dependent diabetes mellitus (IDDM) 599 ff integrin 5 interferon (IFN) 5, 32, 76, 387 – HIV 505–518 – mucosal vaccination 343 – tuberculosis 460 ff interleukins 32 ff, 460 intestinal colonization 320 f intestine epithelia 329 intracellular bacteria 1 ff intracellular cytokine staining (ICS) 91 ff, 98 ff intracellular enveloped virus (IEV) 271 intracellular mature virus (IMV) 271 intraepithelial lymphocytes 344 intramuscular injections 368 intranasal delivery 352 introns 395 intussusception 592 inverted terminal repeats (ITR) 268 ff iron restriction 238, 462 ISCOMATRIX 184 ff, 352 ISCOREP 185 ff, 193

Japanese encephalitis virus 287 ff JBK70 strains 326 Junin fever 528

KANAPOX 272 Kazak translation initiation sequence 290 Kb restricted CTL epitope SIIFEKL 136 keratin 177 killed vaccines 245, 386, 512 f see also: inactivated vaccines killer antibodies 364, 369, 371 ff, 379 kinetics, antigen specific T cells 95 ff KT-ScFv strain 379 Kupffer cells 480

Index

La Crosse virus 287 ff labile enterotoxin see: heat labile Lactococcus lactis 347 LamB outermembrane proteins 254 Langerhans cells 33 Lassa fever 526 ff LCMV 288 ff lectin-like oxidized lipoprotein (LOX) 135 lectins 21, 24 ff Legionella 364 Leishmania major 12, 23, 59 ff, 64 ff Leishmanial Ag(LeIF) 52 lentivirus subfamily 501 Leptospirosa ssp. 22, 117, 239 letal factor 227, 530 leucocytes 5 life years saved (LYS) 572 ligand–receptor interactions 115 ligands 21 – host-derived adjuvants 134 f – lymphpocytes 51 ff – microbial 117 – T cells 99 – TLRs 27 limited dilution assay (LDA) 91 ff linear differentiation model, T cell formation 79 lipid A derivatives 52 lipid-based particles 152 lipoarabinomannans (LAM) 23, 460 lipooligosaccharide endotoxins 549 lipopeptides 37, 21 ff, 116 ff lipopolysaccharides (LPS) 21 ff, 175, 178 – adjuvants 117 ff, 147, 201 lipoproteins 21 f, 116 ff, 201 liposomes 75, 173 – 196 – microparticle adjuvants 149, 152 – mucosal vaccination 352 lipoteichoic acids (LTA) 21 ff, 119 Lister, smallpox 527 live attenuated vaccines 355, 533, 592 live bacterial vectors 347, 376 f live carriers 222, 224 ff live cholera vaccines 326 ff live polio vaccine 346 live recombinant bacterial vaccines 317–339 live Shigella vaccines 327 live vaccinia virus 527 liver cell schizont 13 livestock pathogens 393 long-term memory T cells 80 long-terminal repeats (LTR) 275 low-molecular weight TLR agonists 124 lyme disease 245 ff, 597, 601

lymph nodes 55 ff, 148, 530 lymphocyte antigen receptors 51 ff lymphocytes 5, 17 ff, 28, 147 ff – adjuvants 115 ff, 199 – malaria 479 – tuberculosis 461 see also: cytotoxic T lymphocytes (CTL) lymphocytic choriomeningitis virus (LCMV) 76 lymphoma epitopes 29 lymphotoxin 84 Lysteria monocytogenes 76, 95, 100 f, 331

M. bovis 230 M cells 344 M. smegmatis 23 M. tuberculosis 22, 62, 371 macaque model, HIV 504 ff macroglobulin 134 macrophages 4 ff, 11 ff, 29, 35 – adjuvants 134 ff, 153 – anthrax 530 – mannose receptors 21 – mucosal vaccination 198, 343 f – oral vaccines 388 – plague 532 macrophagic myofascitis (MMF) 601 magnetically activated cell sorting (MACS) 100, 254 maize delivery system 394 ff, 398 major (cytotoxic) histocompatibility complex (MHC) 6 ff, 90 ff, 208 – epitope complexes 93, 98 ff – haplotypes 131 – liposomes 182 ff – mucosal adjuvants 199 major (cytotoxic) histocompatibility complex (MHC) class I – HIV 512 – malaria 477 – receptors 26 ff – subunit vaccines 266 – tuberculosis 461 – virus-like particles 413 major (cytotoxic) histocompatibility complex (MHC) class II 35, 441 – adjuvants 53 ff – ISCOMs 190 major immunodominant region (MIR) 418 malaria 3, 12, 475–500 – adjuvants 56, 150 – antidotes 364 – GLURP 487 – liposomes 178

621

622

Index

– PEGF domains 492 – T cells 89 mammalian immune system 4 ff mammalian poxviruses 271 f mannose 21 ff, 460 Marburg virus 526 ff mast cells (MC) 5, 18, 24 ff, 387 matrix poteins 281 measles 294, 363, 601 measles–mumps–rubella (MMR) 592, 598 f membrane integration 208 memory 73 – 88, 101 MenB example 248 f meningococcal proteosomes 178 meningitis 154, 363 merozoite 13, 475 ff, 485 ff mesenteric lymph node (MLN) 344 metabolite production 385 metal chelating groups 186 metastases 131 metronidazole 436 ff MF59 adjuvant 52, 246, 353 mice models – DNA vaccines 287 ff – H. pylori 437 ff – HIV 504 f – ISCOMs 187 microbial adjuvants 115 – 128 microbial genome sequences 249 microbicidal IdAb 375 microparticles 52 f, 147 – 172 migration 102 minerals 53, 201 mitogen activated protein (MAP) 76, 138 modified vaccina Ankara (MVA) – mucosal vaccination 346 – DNA vaccines 303 f – HIV 512 – malaria 484 – subunit vaccines 272 molecular mimicry, autoimmunity 594 monkey model – H. pylori 439 – HIV 506 f – ISCOMs 191 monoclonal antibodies 368, 503 ff monocytes 5 monocyte chemotactic protein1 (MCP1) 301 monophosphoryl lipid A (MPL) 118, 150, 176, 202 mosquito stage transmission blocking vaccines 482, 490 ff MPL + aluminum hydroxide (AS04) 246 mRNA stability 395

mucopeptides 52, 201 mucosa associated lymphoid tissue (MALT) 160, 344, , 432, 511 f mucosal adjuvants 197 – 217 mucosal adressin cell adhesion molecule 1 (MAdCAM1) 344 mucosal IgA antibody responses 159 mucosal immunity 221 f – HIV 511 f – ISCOMs 189 – microparticles 148 f, 159 – plant-based vaccines 385 mucosal infections 7, 326 mucosal live bacterial vectors 376 f mucosal vaccination 341 – 361 multicomponent vaccines 445 multidrug resistant (MDR) strains 459 multilamellar vesicles (MLV) 180 multimers, antigen specific T cells 92 multiple antigens 482 multiple sclerosis 597 ff, 601 multiple vaccinations 601 mumps 363 muramyl dipeptide (MDP) 152, 157, 178, 202 Murray valley encephalitis virus 287 ff mutants 317 ff – HIV 504 f – imperfect vaccines 545 – tuberculosis 467 Mycobacteria 331, 342, 461 Mycobacterium avium 12, 28 Mycobacterium bovis 37, 465 Mycobacterium leprae 388 Mycobacterium tuberculosis 230, 364, 459–473 Mycoplasma pneunomiae 342 Mycoplasma spp. 119, 237 myocarditis 592

naïve effectors 75, 102 naïve T cells 57 ff, 82 f nasal associated lymphoid tissue (NALT) 344 nasal vaccination 353 natural killer cells (NK) 5, 24 ff – DNA vaccines 300 – HIV 509 ff – mucosal vaccination 198, 343 ff, 351 necrosis 267 nef genes, HIV 501 ff negative stranded RNA virus 281 Neisseria gonnorrhoeae 342 Neisseria meningitis 3, 11, 248 – liposomes 178

Index

– microparticle adjuvants 154 – subunit vaccines 244 neisserial surface protein (NspA) 251 nerve growth factor (NGF) 85 neuraminidase 6 neurodevelopmental disorders 601 neutralizing antibodies (nAbs), HIV 502 ff neutrophil activating protein (NAP) 434, 440 f, 445 f New York City Board of Health (NYCBH) strains 527 nicotine derivatives 417 niosome 175 ff Nippostrongylus brasiliensis 61 nonionic surfactant vesicles (NISV) 52, 177 nonionic surfactants 175 ff Norwalk virus – mucosal vaccination 346 – oral vaccines 387, 392 ff – virus-like particles 416 ff novasomes 177 nuclear factor of activated T cells (NFAT) 58 ff nucleic microbial structural proteins 116 nucleocapsid proteins 281

O antigen, Shigella spp. 230 O1/O139 cholera serogroups 227 oil-in-water adjuvants 152 oligodeoxynucleotides (ODN) 21, 201, 350 ff, 510 oligomannose epitopes 8 f oligosaccharides 14 oncolytic adenoviruses 267 ff Oncophage 140 ookinete/ oozyst 476, 492 opsonins 5 oral poliovirus vaccine (OPV) 279, 592 oral vaccines 355, 385 – 410 ORF termed genomes 254, 275 original antigenic sin model, HIV 505 orthomyxo viridae 292 Orthopoxvirus 271 outer membrane vesicles (OMV) 175, 178, 251 ovalbumin (OVA) 52 ff, 95, 153, 205

PEGF domains, malaria 492 p53 protein 552 pancreatic islets 387 papilloma virus 416 f, 422 f parainfluenza 345 paralysis 592, 601

paramyxo viridae 294 f parasite-derived glycans 24 parasite vaccines 255 ff parasitic pathogens 5, 12 ff parenteral delivery 342 parenteral immunization 187, 387, 445 particle-based replicons 279 parvovirus B19 associated chronic fatigue syndrome 368 passive vaccination 243, 363 – 383 Pasteurella spp. 234 pathogen associated molecular patterns (PAMP) 20 ff, 29, 37 – adjuvants 54 ff – host-derived adjuvants 137 – microbial adjuvants 116 ff – microparticle adjuvants 149 f – mucosal adjuvants 198 pathogenicity islands, cag (cagPAI) 433 f pathogens 4, 17 – 50 – bioterror agents 525 – expression vectors 347 – H. pylori 433 ff – HIV 509 ff – live recombinant bacterial 319 ff – mucosal adjuvants 200 – plant-based vaccines 393 – toxoids 243 ff pattern recognition receptors (PRR) 21, 54, 116 ff, 460 PCR based assays 257 pentavalent botulinum toxoid (PBT) 537 peptic ulcer 433 peptides 6, 11, 36, 52 ff – antibodies 378 – defensins 28 – host-derived adjuvants 130 ff, 133 ff – innate immunity 21 – MHC complexes 99 – mucosal vaccination 352 – plant-based vaccines 397 – synthetic 147 ff peptidoglycan (PG) 22, 117 ff peptin antigen 90 perforin 75 pericanditis 592 pertactin 247, 549 pertussis – acellular vaccine 246 – adjuvants 65 – antidotes 363 – immunization cost-effectiveness 564 – virulence-antigen vaccines 549 ff Peyer’s patches 182, 344

623

624

Index

pgm mutant, plague 533 pH sensitivity 176, 183 phagocytes 17 ff, 21 ff, 147 ff phagocytic uptake 244 phagocytosis 4 ff phagolysosome fusion 462 phagosome–lysosome system 11 pharmaeconomics 576 ff phenol 223 phenotype generation 5 ff, 83 phoP/phoQ virulence 444 phospatyl serine (PS) 179 phosphatidylcholine (PC) 177 phosphoinositide residues (PILAM) 23 phospholigand specific δγ T cells 463 phospholipids 152, 175 – 184, 351 phosphoprotein 281 phosphorothioate (PTO) 121 phosphatidyl ethanolamin (PE) 179 Pichia anomala 371, 374 Picornaviridae 279 pivotal role 210 plague 363, 229, 526, 532 ff – pgm mutant 533 plant-based oral vaccines 385 – 410 plasmid DNA – HIV 513 f – microparticle adjuvants 147 ff – mucosal vaccination 352 – replicons 277 – subunit vaccines 274 plasmid PXO1 227 Plasmodium berhei 26, 479, 488 Plasmodium falciparum 13, 23, 33, 475–500 – expression vectors 347 – host-derived adjuvants 134 – parasite vaccines 255 Plasmodium malariae 475–500 Plasmodium ovale 475–500 Plasmodium pastoris 493 Plasmodium spp. 13, 265 Plasmodium vivax 475–500 Plasmodium yoelii 26, 347, 479, 489 Pneumocystis carinii 370 pneumonia 363, 564 pol genes 275, 501 ff polioviruses – antidotes 363 – immunological safety 592, 601 – live 346 – oral vaccines 386 – subunit vaccines 265, 279 f – virus-like particles 412 poloxamers 159

polylactide-co-glycolides (PLG) 153 f, 158 f, 349 polyadenylation 395 polyanhydrides 159 polyanionic ligands 21 polyclonal B cell activation 595 polyethylene glycol (PEG) 176 polymerases 271 polymorphism 11 polyorthoesters 159 polypeptides 536 polyphomorphonuclear cells (PMN) 198 polyphosphazenes 159 polyradiculoneuritis 597 polyribosyl ribotol phosphate (PRP) 551 polysaccharide vaccines 244 ff porcine pleuropneumonia 237 porcine respiratory syndrome virus (PRRSV) 387 Porphyromonas 117 Porphyromonas gingivalis 254 Porphyromonas gingivitidis 22 potential mechanisms, memory 76 ff poxviruses 512, 269 ff precursors, mucosal 344 preerythrocytic vaccines 477, 481 f preexisting antibodies 189 preexisting immunity 346 preexisting influenza virus 211 prevention infection 4 ff primates immunization 187 prime-boost 282, 303 – DNA vaccines 289 f, 300 ff – HIV 509 ff – mucosal adjuvants 205 – tuberculosis 468 prion diseases 368 prodomal phase, smallpox 527 progenomes 275 prokaryotic proteins 398 promoters 394 prophylactic vaccines, HIV 514 protease complexes 133 f protection mechanisms 3–16, 181 protein aluminate precipitates (alum) 52 f, 56 protein-based vaccines 514 protein disulfide isomerase (PDI) 133 protein polysaccharide conjugates 147 ff proteins 36 – amphipathic 184 – mucosal vaccination 351 f – nucleic microbial 116 – plant-based vaccines 390, 398 – subunit vaccines 147, 246, 281

Index

proteosome 175, 178 f proton pump inhibitor (PPI) 435 protozea 364 Pseudomonas aeruginosa exotoxin A (rEPA) 231 pur E mutations 322 purified recombinant urease 442

QS21, microparticle adjuvants 150 QTP motif, subunit vaccines 252 quality adjusted life days (QALD) 574 quality adjusted life years (QALY) 564 quality control systems 283 quality of life (QOL) 572 Quil A 351 quillaic acid residue 187 Quillaja saponaria 151 ff, 173, 184 f, 203

Rabies virus – antidotes 363, 368 – antiviral DNA vaccines 299 – mucosal vaccination 346 – subunit vaccines 281 radiotoxic compounds 369 RANK ligands 414 RANTES molecules 76, 420, 505 RAP antigens 485 reactive nitrogen intermediates (RNI) 461 ff reactive oxygen intermediates (ROI) 460 ff reactive oxygen species (ROS) 121 receptor–ligand pairs 97 receptors 4 ff – endocytosis 182 – HIV 501 ff – killer toxins 371 – lymphocyte 51 ff – mucosal vaccination 344 ff – T cells 99 – tuberculosis 460 recombinant adenoviral vectors (rAds) 266 recombinant antibodies 397 recombinant bacterial vectors 512 recombinant carriers 467 recombinant DNA technology 245, 416 recombinant herpes simplex viruses 273 recombinant protein subunits 147 ff recombinant strains, Streptococcus gordonii 377 recombinant urease 442 recombinant vaccines 266, 282, 317–339 recombinant viral vectors 304 red-cell surface antigens 486 f

regulatory T cells 98 f, 596 reinfection 4 f rep/cap genes 269 repair mechanisms 5 replication mechanism 5, 266 f, 276 f respiratory syncytial virus (RSV) – DNA vaccines 295 – immunological safety 593 – mucosal vaccination 342, 345, 353 – oral vaccines 386 respiratory tract 7, 353, 527 retention signals 397 reticular bodies 255 retroviridae 275 f, 295, 501 rev genes, HIV 501 ff revers vaccinology 248 rhabsoviridae 281 ff, 299 rhesus human reassortant rotavirus vaccine Rhesus macaques 188, 191 rhinovirus 342 rimantadine 201 RNA – double-stranded 414 – polymerases 271 – replicons 277 – single stranded positive sense 276 rotavirus 564 – immunological safety 592 – mucosal vaccination 342 – oral vaccines 386, 393 – virus-like particles 412, 416 rubella 597 Russian spring/summer encephalitis virus 287 ff

593

Saccharomyces cerevisiae 159, 423, 493 safety, immunological 591 – 607 Salmonella enterica 23, 320 f Salmonella enterica seovar Typhi 231, 444 Salmonella minnesota 150 salmonella pathogenicity islands (SPI) 320 Salmonella spp. 33 – antiviral DNA vaccines 301 – bacterial vaccines 223 ff, 319–326 – bioterror agents 538 – expression vectors 347 – live recombinant vaccines 323 ff Salmonella typhi 11 – HIV 512 – malaria 479 – microparticle delivery systems 159 f – subunit vaccines 244 Salmonella vectors 330, 443 f

625

626

Index

salmonellosis 73, 238 saponins – ISCOMs 184 – microparticle adjuvants 150 f – mucosal vaccination 201, 351 scavenger receptors 5, 21 ff, 116 ff, 135 ScFv strains, Streptococcus gordonii 377 schistomiasis 12 Schistosoma haematobium 347 Schistosoma mansoni 14, 24 f, 348 – adjuvants 59 f, 64 Schistosoma species 14, 35 SEKDEL amino acids 398 selectin 75, 84 selfantigens 595 self-nonself model, host-derived adjuvants 137 selfreplicating RNA (replicon) 276 f selo molecules targeting 420 f Semliki Forest virus (SFV) 276 Sendai virus virosomes 182 serines 30, 130 serogroup B (MenB), N. meningitis 248 serogroup O1/O139, cholera 227 seroprotection 212 serum antibody 9, 154 serum thickness 363 serum transfer 74 shaping adaptive immunity 17–50 Shigella flexneri 319 ff, 328 Shigella spp. – antigen 230 – bacterial vaccines 229 – bioterror agents 538 – expression vectors 347, 512 – heterologous antigens 331 side effects 591 signal peptides 397 signaling cascades, TLR-initiated 27 signaling lymphocyte activation molecule (SLAM) associated protein (SAP) 85 signature tagged mutagenesis 248 simian immunodeficiency virus (SIV) 8, 504 ff – fusion epitopes 302 – HIV hybrid virus 506 f – ISCOMs 188 – microparticle delivery systems 160 Sindbis virus (SIN) 276 single-chain variable fragment antibodies 376 ff single-dose vaccines 157 single-stranded positive sense RNA genome 276 single-stranded RNA virus 501 ff

skin penetration properties, liposomes 177 smallpox 73 ff, 89 ff, 526 ff, 592 social barriers, vaccination strategies 554 ff specific secretory IgA (S-IgA) 343 specific target vaccines 429–607 splenocytes 95, 100 f, 301 sporozoites 13, 475 ff squalene 152 stabilization, liposomes 181 stable systems, plant-based vaccines 390 staphylococcal enteroxin B 160 Staphylococcus aureus 10, 22 ff, 253 Staphylococcus carnosus 347 starch 159, 400 stimulation, CTL 148 stratum corneum 177 streptamers 92, 98 f Streptococcus agalactiae 254 Streptococcus gordonii 347, 376 f Streptococcus pneumoniae 10 – immunization cost-effectiveness 572 – microparticle delivery systems 160 – subunit vaccines 244, 253 Streptococcus pyrogenes 202 Streptococcus spp. 239 – antidotes 363 ff – virus-like particles 412 structures – HIV genes 501 ff – T cells avidity 99 – virosomes 209 subunit vaccines 222 f, 243–263 – bacterial 226 f – HIV 513 – human pathogens 249, 393 – oral 386 – QTP motif 252 – tuberculosis 467 ff – virus vectors 265 – 286 severe acute respiratory syndrome (SARS) 257, 387 sudden infant death syndrome 601 sulfo MBS linkers 419 superdomination, T cells 100 f surface antigens 482 f, 491 surface charge 176 surfactants 53, 175 synapses 101 Syntex adjuvant fomulation (SAF) 152 ff synthetic particle adjuvants 153 synthetic peptides 147 synthetic TLR compounds 120 syphilis 73 systemic vaccinia 592

Index

T cell-based vaccines 89 – 111 T cell dependent antigens 244 T cell epitopes 57 ff T cell formation – decreasing potential model 81 – linear differentiation model 79 T cell independent B cell antigens 412 T cell population 291 ff T cell receptors (TCR) 26 ff, 79, 90 ff, 463 T cell responses 36 – adjuvant induced 51–72 – HIV 505–518 – virus-like particles 411 ff T cells 3, 17 ff, 90 ff – adjuvants 53 ff, 61 f – antiviral DNA vaccines 300 – depletion 100 – differentiation patterns 102 – heterogeneity 101 – immunological safety 596 – ISCOMs 188 – microparticle adjuvants 147, 151 ff – mucosal vaccination 343, 350 f – oral vaccines 387 – superdomination 100 f – tuberculosis 461 – type γδ 24, 62, 463 – virus-like particles 411 ff targeting – antiviral DNA vaccines 302 – liposomes 181 – mutagenesis 317 f – plant-based vaccines 397 – population 574 – transmission-blocking malaria vaccines 491 ff – tuberculosis 465 – virus-like self molecules 420 f telomeres, memory 79 Temple of heaven strains smallpox 527 terminal repeats 501 terminators 395 tetanus 52, 243 – antidotes 368 – immunization cost-effectiveness 564 – microparticle adjuvants 158 – mucosal vaccination 350 tetramers 508 ff therapeutic vaccines 162 thiomersal containing vaccines 601 three-signal model, adjuvants 58 ff thrombocytopenia 592, 598 thymic lymphocytes see: T cells 74 thymidine kinase (TK) 271 tick borne encephalitis 290

tobacco mosaic virus (TMV) 390 ff Togaviridae 276, 287 ff Toll like receptors (TLR) 4 ff, 21 ff, 26 ff, 36 – adjuvants 54 ff, 58 ff – HIV 510 – host-derived adjuvants 138 – microbial adjuvants 116 ff – microparticle adjuvants 150 – mucosal vaccination 198, 206, 343 – T cells 103 – tuberculosis 460 toral aqueous extrable protein (TAP) 135, 400 tox gene 547 toxemia 527 toxins 117 ff toxoids 243 – 263 Toxoplasma gondii 30 ff, 347 tracheal cytotoxin 549 transactivators 77 transcription 60 f, 76 – adenoviral genes 268 ff – plant-based vaccines 394 – RNA replicons 278 transcriptional gene silencing (TGS) 394 f transferrin binding protein B (TbpB) 251 transfersomes 175 ff transforming growth factor (TGF)-β family 36, 343 transgene transmission 395, 398 transgenic maize kernel virus 401 transgenomes 275 transient systems 390 translation enhancer 396 transmembranes 30, 223, 281 transmissible gastroenteritis virus (TGEV) 393, 399 f, 402 transmission blocking vaccines (TBV) 482, 490 ff transmission phase 18 Treponema pallidum 342 trimers 503 ff triple vaccine DTP 232 triterpenoid glycosides 150 Trypanosoma cuzi 23 tryptase 29 tuberculosis 3, 11 f, 52, 459 – 473 – adjuvants 56 – bacterial vaccines 230 – memory 73 – T cells 89 tularemia – antidotes 363 f – bacterial vaccines 232 – bioterror agents 526, 534 ff

627

628

Index

tumor necrosis factor (TNF) 5, 76, 505 ff tumors 52, 131 two-cistron operon mglAB tuleremia 534 two-signal model, adjuvants 53 ff typhoid fever, bacterial vaccines 231 typhoid strains 319 ff, 324 typhoid strains Ty21 strain 11, 231 typhoid strains TyLPs(p24-VLP) epitopes 425 tyrosine phosphatase 75

unilamellar vesicles (SUV) 180 unmethylated CpG motifs 350 unmethylated cytosines 150 untranslated region (UTR) 395 uptake – antigens 199 – microparticles in APC 153 – mucosal vaccination 344 – receptor-mediated 133 – subunit vaccines 244 urease 433 f, 437 ff, 442 ff urogenital tract infections 342

vaccine resistant mutant parasites 489 vaculating toxin (VacA) 434 ff, 440 ff, 445 ff valent vaccines 10 variable fragment antibodies 376 varicella antidotes 368 varicella zoster virus 287 ff Variola 526 Vaxgen, HIV 503 vectors, live bacterial 328 Venezuelan equine encephalitis virus (VEE) 276 vesicles 175 ff – microparticle adjuvants 152 – nonionic surfactant 177 – subunit vaccines 251 vesicular stomatitis virus (VSV) 281 veterinary bacterial vaccines 233 ff viable mycobacterial vaccine 467 Vibrio cholerae 11 – bacterial vaccines 223, 227 f, 319 ff – delivery systems 159 f – mucosal vaccination 342, 346, 349 – oral vaccines 386 ff, 393 f viral agents 363 viral DNA 505 f viral hemorrhagic fevers 526 ff

viral membrane proteins 175 viral pathogens 5 viral proteins 351, 398 viral tox gene 547 viral vaccines 256, 415 f viral vectors 513 virions 270, 280, 503 ff virosomal technology 197–217 virosomes 174 f, 177 f – microparticle adjuvants 151 – mucosal vaccination 208 f, 348 virulence 11, 545–561 – bacterial vaccines 223 f, 317 – H. pylori 433 ff – plague 532 – toxoids 243 virus-like particles (VLP) 411– 428 virus vectors 265–286 VL/R chains 372 vpr/vpu genes 501 ff VSV vectors 507

Water Reed formulation 183 West Nile virus 290 Western blotting 255 whole cell vaccines 245 – H. pylori 444 – pertussis 549 f – plague 534 whooping cough 232 wide-spectrum protective antibodies 363–383 Williopsis saturnus var mraki 371, 374 f WT05, gene 325 Wyeth’s Dryvax 527

xenoimmune responses 512

yeast killer toxins (YKT) 371 ff yellow fever 265 Yersinia enteroclitica 36 Yersinia outer proteins (Yops) 532 Yersinia pestis 229, 526, 532 ff

ZH9 strain 319 ff zygotes, malaria 476, 491 f zymosan 21, 134